

Draft for consultation

Pressure ulcer management

The prevention and management of pressure ulcers in primary and secondary care

Clinical Guideline TBC

Methods, evidence and recommendations

November 2013

Draft for Consultation

*Commissioned by the National Institute for
Health and Clinical Excellence*

Disclaimer

Healthcare professionals are expected to take NICE clinical guidelines fully into account when exercising their clinical judgement. However, the guidance does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and/or their guardian or carer.

Copyright

National Clinical Guideline Centre 2013.

Funding

National Institute for Health and Care Excellence 2013.

Contents

Acknowledgements, GDG membership and methods	8
1 Guideline summary	9
1.1 Algorithms.....	9
1.2 Key priorities for implementation.....	12
1.3 Full list of recommendations	13
1.4 Key research recommendations	17
2 Pressure ulcer treatment	18
2.1 Introduction	18
2.1.1 Extrapolating adults recommendations to neonates, infants, children and young people.....	18
2.1.2 Pressure ulcers caused by devices	19
2.1.3 Accounting for individuals' comfort.....	19
3 Pressure ulcer measurement	20
3.1 Introduction	20
3.2 Review question: What are the most reliable techniques/tools to measure the dimensions of a pressure ulcer?	20
3.2.1 Clinical evidence for intra-rater reliability	25
3.2.2 Economic evidence (adults)	41
3.2.3 Clinical evidence (neonates, infants, children and young people)	41
3.2.4 Economic evidence (neonates, infants, children and young people)	41
3.2.5 Evidence statements	41
3.3 Recommendations and link to evidence.....	45
3.3.1 Adults	45
3.3.2 Neonates, infants, children and young people	47
4 Categorisation of pressure ulcers	49
4.1 Introduction	49
4.2 Review question: What is the best method of categorising different types of pressure ulcers?	49
4.2.1 Clinical evidence (adults).....	49
4.2.2 Clinical evidence for studies assessing more than 1 tool.....	56
4.2.3 Economic evidence (adults)	75
4.2.4 Clinical evidence (neonates, infants, children and young people)	75
4.2.5 Economic (neonants, infants, children and young people).....	75
4.2.6 Evidence statements	75
4.3 Recommendations and link to evidence.....	76
4.3.1 Adults	76
4.3.2 Neonates, infants, children and young people	77

5	Nutrition and hydration	79
5.1	Introduction	79
5.2	Review question: What are the most clinically and cost-effective nutritional interventions for the treatment of pressure ulcers?	79
5.2.1	Clinical evidence (adults).....	79
5.2.2	Economic evidence (adults)	117
5.2.3	Clinical evidence (neonates, infants, children and young people)	119
5.2.4	Economic evidence (neonates, infants, children and young people)	119
5.2.5	Evidence statements	119
5.3	Recommendations and link to evidence.....	127
5.3.1	Adults	127
5.3.2	Neonates, infants, children and young people	130
6	Pressure redistributing devices	134
6.1	Introduction	134
6.2	Review question: What are the most clinically and cost effective pressure redistributing devices for the management of pressure ulcers?.....	134
6.2.1	Clinical evidence (adults).....	134
6.2.1	Economic evidence (adults)	181
6.2.2	Clinical evidence (neonates, infants, children and young people)	183
6.2.3	Economic evidence (neonates, infants, children and young people)	183
6.2.4	Evidence statements	184
6.3	Recommendations and link to evidence.....	194
6.3.1	Adults	194
6.3.2	Neonates, infants, children and young people	196
7	Adjunctive therapies.....	201
7.1	Negative pressure wound therapy (NPWT) - introduction.....	201
7.2	Review question: What is the clinical and cost effectiveness of negative pressure wound therapy for the treatment of pressure ulcers?.....	201
7.2.1	Clinical evidence (adults).....	201
7.2.2	Economic evidence (adults)	209
7.2.3	Clinical evidence (neonates, infants, children and young people)	215
7.2.4	Economic evidence (neonates, infants, children and young people)	215
7.2.5	Evidence statements	215
7.3	Hyperbaric oxygen therapy.....	217
7.4	Review question: What is the clinical and cost-effectiveness of hyperbaric oxygen therapy for the treatment of pressure ulcers?	217
7.4.1	Clinical evidence (adults).....	217
7.4.2	Economic evidence (adults)	217
7.4.3	Clinical evidence (neonates, infants, children and young people)	218

7.4.4	Economic evidence (neonates, infants, children and young people)	218
7.5	Electrotherapy.....	218
7.6	Review question: What is the clinical and cost effectiveness of electrotherapy for the treatment of pressure ulcers?	218
7.6.1	Clinical evidence (adults).....	218
7.6.1	Economic evidence (adults)	245
7.6.2	Clinical evidence (neonates, infants, children and young people)	247
7.6.3	Economic evidence (neonates, infants, children and young people)	247
7.6.4	Evidence statements	247
7.7	Recommendations and link to evidence.....	250
8	Debridement	255
8.1	Review question: What are the most clinically and cost effective methods of debridement of non-viable tissue for the treatment of pressure ulcers?	255
8.1.1	Clinical evidence (adults).....	255
8.1.1	Economic evidence (adults)	283
8.1.2	Clinical evidence (neonates, infants, children and young people)	285
8.1.3	Economic (neonates, infants, children and young people).....	285
8.1.4	Evidence statements	285
8.2	Maggot (larval) therapy	290
8.3	Review question: What are the most clinically and cost effective methods of maggot debridement of non-viable tissue for treatment of pressure ulcers?	291
8.3.1	Clinical evidence (adults).....	291
8.3.2	Economic evidence (adults)	296
8.3.3	Clinical evidence (neonates, infants, children and young people)	296
8.3.4	Economic evidence (neonates, infants, children and young people)	296
8.3.5	Evidence statements	296
8.4	Recommendations and link to evidence.....	297
8.4.1	Adults	297
8.4.2	Neonates, infants, children and young people	301
9	Systemic antibiotics	304
9.1	Review question: What are the most clinically and cost effective systemic agents for the treatment of pressure ulcers?	304
9.1.1	Clinical evidence (adults).....	304
9.1.2	Economic evidence (adults)	304
9.1.3	Clinical evidence (neonates, infants, children and young people)	304
9.1.4	Economic evidence (neonates, infants, children and young people)	304
9.1.5	Evidence statements	304
9.1.6	Recommendations and link to evidence.....	305
10	Topical antimicrobials and antiseptics	309
10.1	Review question: What are the most clinically and cost effective topical agents for	

the treatment of pressure ulcers?	309
10.1.1 Clinical evidence (adults).....	309
10.1.2 Economic evidence (adults)	442
10.1.3 Clinical evidence (neonates, infants, children and young people)	444
10.1.4 Economic evidence (neonates, infants, children and young people)	444
10.1.5 Evidence statements	444
10.2 Recommendations and link to evidence.....	477
10.2.1 Adults	477
10.2.2 Neonates, infants, children and young people	480
11 Dressings	482
11.1 Review question: What are the most clinically and cost effective dressings for the treatment of pressure ulcers?	482
11.1.1 Clinical evidence (adults).....	482
11.1.2 Economic evidence (adults)	618
11.1.3 Clinical evidence (neonates, infants, children and young people)	625
11.1.4 Economic evidence (neonates, infants, children and young people)	625
11.1.5 Evidence statements	625
11.1.6 Recommendations and link to evidence.....	655
12 Management of heel pressure ulcers.....	663
12.1 Review question: What is the most clinically and cost-effective method for management of pressure ulcers of the heel?	663
12.1.1 Clinical evidence (adults).....	663
12.1.2 Economic evidence (adults)	672
12.1.3 Clinical evidence (neonates, infants, children and young people)	674
12.1.4 Economic evidence (neonates, infants, children and young people)	674
12.1.5 Evidence statements	674
12.2 Recommendations and link to evidence.....	676
12.2.1 Adults	676
12.2.2 Neonates, infants, children and young people	677
13 References	679
14 Acronyms and abbreviations	694
15 Glossary	696
Appendices.....	707
Appendices A-O can be found in separate documents.....	707

1 **Acknowledgements, GDG membership and**

2 **methods**


3 Further details on acknowledgements, GDG membership and methods used to develop this guideline
4 can be found in part 1 of the guideline, 'Prevention of pressure ulcers'.


5

1 Guideline summary

1.1 Algorithms

- 3 For algorithms on identifying pressure ulcer risk and the prevention of pressure ulcers, please see
- 4 part 1, 'Prevention of pressure ulcers'.
- 5





1.2 Key priorities for implementation

- 2 From the full set of recommendations, the GDG selected 10 key priorities for implementation. The
3 criteria used for selecting these recommendations are listed in detail in The guidelines manual.¹³¹ The
4 reasons that each of these recommendations was chosen are shown in the table linking the evidence
5 to the recommendation in the relevant chapter.
- 6
- 7 • Carry out and document an assessment of pressure ulcer risk on initial contact for adults receiving
8 NHS care which does not involve admission to secondary care or a care home (for example, care
9 received at a GP surgery or an accident and emergency department) only if they have a risk factor,
10 for example:
- 11 o significantly limited mobility (for example, people with a spinal cord injury)
12 o a previous pressure ulcer
13 o the risk of nutritional deficiency
14 o the inability to reposition themselves
15 o a neurological condition
16 o significant cognitive impairment.[1.1.2]
- 17
- 18 • Offer adults who have been assessed as being at elevated risk of developing a pressure ulcer a
19 skin assessment by a trained healthcare professional (see recommendation 1.3.4). The
20 assessment should take into account any pain or discomfort reported by the patient and the skin
21 should be checked for:
- 22 o skin integrity in areas of pressure
23 o colour changes or discoloration
24 o variations in heat, firmness and moisture (for example, because of incontinence, oedema, dry
25 or inflamed skin).[1.1.5]
- 26
- 27 • Develop and document an individualised care plan for adults at elevated risk of developing a
28 pressure ulcer, taking into account:
- 29 o • the outcome of risk and skin assessment
30 o • the need for additional pressure relief at specific at-risk sites
31 o • their mobility and ability to reposition themselves
32 o • other comorbidities
33 o • patient preference.[1.1.8]
- 34
- 35 • Encourage adults, who have been assessed as being at risk of developing a pressure ulcer, to
36 change their position frequently and at least every 6 hours. If they are unable to reposition
37 themselves, offer help to do so, using appropriate equipment if needed. Document the frequency
38 of repositioning required.[1.1.9]
- 39
- 40 • Use a high-specification foam mattress for adults who are:
- 41 o • admitted to secondary care

- 1 o • at elevated risk of developing a pressure ulcer in primary and community care settings (as
2 identified by the risk and skin assessment).[1.1.14]
- 3
- 4 • Carry out and document an assessment of pressure ulcer risk in neonates, infants, children and
5 young people, using a scale validated for this population (for example, the Braden Q scale for
6 children), to support clinical judgement.[1.2.1]
- 7
- 8 • Provide training to healthcare professionals on preventing a pressure ulcer, including:
9 o who is most likely to be at risk of developing a pressure ulcer
10 o how to identify pressure damage
11 o what steps to take to prevent new or further pressure damage
12 o who to contact for further information and for further action.[1.3.3]
- 13
- 14 • Provide further training to healthcare professionals who have contact with anyone at elevated
15 risk of developing a pressure ulcer. Training should include:
16 o how to carry out a risk and skin assessment
17 o how to reposition
18 o information on pressure redistributing devices
19 o discussion of pressure ulcer prevention with patients and their carers
20 o details of sources of advice and support.[1.3.4]
- 21
- 22 • Discuss with adults with a heel pressure ulcer a strategy to offload heel pressure as part of their
23 individualised care plan.[1.4.24]

1.3 Full list of recommendations

- 25 1. Record and document the surface area of all pressure ulcers in adults. If possible, use a
26 validated measurement technique (for example, transparency tracing or a photograph).
- 27 2. Document an estimate of the depth of all pressure ulcers and the presence of undermining,
28 but do not routinely measure the volume of a pressure ulcer.
- 29 3. Record and document the surface area of all pressure ulcers in neonates, infants, children
30 and young people, preferably using a validated measurement technique (for example, transparency
31 tracing or a photograph).
- 32 4. Document an estimate of the depth of a pressure ulcer and the presence of undermining, but
33 do not routinely measure the volume of a pressure ulcer in neonates, infants, children and young
34 people.
- 35 5. Categorise each pressure ulcer in adults using a validated classification tool (such as the
36 International NPUAP-EPUAP (2009) Pressure Ulcer Classification System). Use this to guide ongoing
37 preventative strategies and management. Repeat and document each time the ulcer is assessed.
- 38 6. Categorise each pressure ulcer in neonates, infants, children and young people at onset using
39 a validated classification tool (such as the International EPUAP-NPUAP (2009) Pressure Ulcer
40 Classification System) to guide ongoing preventative and management options. Repeat and
41 document each time the ulcer is assessed.

- 1 7. Offer adults with a pressure ulcer a nutritional assessment by a dietitian or other healthcare
2 professional with the necessary skills and competencies.
- 3 8. Offer nutritional supplements to adults with a pressure ulcer who have a nutritional
4 deficiency.
- 5 9. Do not offer nutritional supplements to treat a pressure ulcer in adults whose nutritional
6 intake is adequate.
- 7 10. Provide information and advice to adults with a pressure ulcer on how to follow a balanced
8 diet to maintain an adequate nutritional status, taking into account energy, protein and
9 micronutrient requirements.
- 10 11. Do not offer subcutaneous or intravenous fluids to treat a pressure ulcer in adults whose
11 hydration status is adequate.
- 12 12. Offer an age-related nutritional assessment to neonates, infants, children and young people
13 with a pressure ulcer. This should be performed by a paediatric dietitian or other healthcare
14 professional with the necessary skills and competencies.
- 15 13. Discuss with a paediatric dietitian (or other healthcare professional with the necessary skills
16 and competencies) whether to offer nutritional supplements specifically to treat a pressure ulcer in
17 neonates, infants, children and young people whose nutritional intake is adequate.
- 18 14. Offer advice on a diet that provides adequate nutrition for growth and healing in neonates,
19 infants, children and young people with a pressure ulcer.
- 20 15. Discuss with a paediatric dietitian whether to offer nutritional supplements to correct
21 nutritional deficiency in neonates, infants, children and young people with a pressure ulcer.
- 22 16. Assess fluid balance in neonates, infants, children and young people with a pressure ulcer.
- 23 17. Ensure there is adequate hydration for age, growth and healing in neonates, infants, children
24 and young people. If there is any doubt, seek further medical advice.
- 25 18. Use high-specification foam mattresses for adults with a pressure ulcer. If this is not
26 sufficient to redistribute pressure, consider the use of a dynamic support surface.
- 27 19. Do not use standard-specification foam mattresses for adults with a pressure ulcer.
- 28 20. Use a high-specification cot or bed mattress or overlay for all neonates, infants, children and
29 young people with a pressure ulcer.
- 30 21. If pressure on the affected area cannot be relieved by other means (such as repositioning),
31 consider a dynamic support surface, appropriate to the size and weight of the child or young person
32 with a pressure ulcer, if this can be tolerated.
- 33 22. Consider using specialist support surfaces (including dynamic support surfaces where
34 appropriate) for neonates, infants, children and young people with a pressure ulcer, taking into
35 account their current pressure ulcer risk and mobility.
- 36 23. Tailor the support surface to the location and cause of the pressure ulcer for neonates,
37 infants, children and young people.
- 38 24. Do not routinely offer adults negative pressure wound therapy to treat a pressure ulcer,
39 unless it is necessary to reduce the number of dressing changes (for example, in a wound with a large
40 amount of exudate).
- 41 25. Do not offer the following to adults to treat a pressure ulcer:

- 1 • electrotherapy
- 2 • hyperbaric oxygen therapy.
- 3 26. Do not routinely use negative pressure wound therapy to treat a pressure ulcer in neonates,
4 infants, children and young people.
- 5 27. Do not use the following to treat a pressure ulcer in neonates, infants, children and young
6 people:
 - 7 • electrotherapy
 - 8 • hyperbaric oxygen therapy.
- 9 28. Assess the need to debride a pressure ulcer in adults, taking into consideration:
 - 10 • the amount of necrotic tissue
 - 11 • the grade, size and extent of the pressure ulcer
 - 12 • patient tolerance
 - 13 • any comorbidities
- 14 29. Offer debridement to adults if identified as needed in the assessment:
 - 15 • use autolytic debridement, using an appropriate dressing to support it
 - 16 • consider using sharp debridement if autolytic debridement is likely to take longer and
17 prolong healing time.
- 18 30. Do not routinely offer adults with a pressure ulcer:
 - 19 • larval (maggot) therapy
 - 20 • enzymatic debridement.
- 21 Consider larval therapy if sharp debridement is contraindicated or if there is associated vascular
22 insufficiency.
- 23 31. Consider autolytic debridement with appropriate dressings for dead tissue in neonates,
24 infants, children and young people. Consider sharp and surgical debridement by trained staff if
25 autolytic debridement is unsuccessful.
- 26 32. Do not offer systemic antibiotics specifically to heal a pressure ulcer in adults.
- 27 33. After a skin assessment, offer systemic antibiotics to adults with a pressure ulcer if there are
28 any of the following:
 - 29 • signs and symptoms of systemic sepsis
 - 30 • spreading cellulitis
 - 31 • underlying osteomyelitis.
- 32 34. Discuss with the local hospital microbiology department which antibiotic to offer adults with
33 infection to ensure that the systemic antibiotic is effective against local strains of infection.
- 34 35. Do not offer systemic antibiotics to adults based only on positive wound cultures without
35 clinical evidence of infection.

- 1 36. Consider systemic antibiotics for neonates, infants, children and young people with a
2 pressure ulcer with signs of local or systemic infection.
- 3 37. Discuss with a local hospital microbiology department which antibiotic to offer neonates,
4 infants, children and young people with infection to ensure that t systemic antibiotic is effective
5 against local strains of bacteria.
- 6 38. Do not routinely use topical antiseptics and antimicrobials to treat a pressure ulcer in adults.
- 7 39. Do not routinely use topical antiseptics and antimicrobials to treat a pressure ulcer in
8 neonates, infants, children and young people.
- 9 40. Consider using a dressing for adults that promotes a warm, moist wound healing
10 environment to treat grade 2, 3 and 4 pressure ulcers.
- 11 41. Discuss with the adult what type of dressing should be used, taking into account:
- 12 • pain and tolerance
- 13 • position of the ulcer
- 14 • amount of exudate
- 15 • frequency of dressing change.
- 16 42. Do not offer gauze dressings to treat a pressure ulcer in adults.
- 17 43. Do not use iodine dressings to treat a pressure ulcer in neonates.
- 18 44. Consider using a dressing which promotes a warm, moist healing environment to treat grade
19 2, 3 and 4 pressure ulcers in neonates, infants, children and young people.
- 20 45. Consider using topical antimicrobial dressings to treat a pressure ulcer where clinically
21 indicated in neonates, infants, children and young people, for example, where there is spreading
22 cellulitis.
- 23 46. Do not offer gauze dressings to treat a pressure ulcer in neonates, infants, children and
24 young people.
- 25 47. Discuss with adults with a heel pressure ulcer a strategy to offload heel pressure as part of
26 their individualised care plan.
- 27 48. Discuss with parents or carers of neonates and infants and with children and young people, a
28 strategy to offload heel pressure as part of their individualised care plan, taking into account
29 differences in size, mobility, pain and tolerance.
- 30
- 31

1.4 Key research recommendations

- 2 **1. What is the effect of enzymatic debridement of non-viable tissue compared with sharp**
3 **debridement on the rate of healing of pressure ulcers in adults?**
- 4 **2. Does negative pressure wound therapy (with appropriate dressing) improve the healing of**
5 **pressure ulcers, compared with use of dressing alone in adults with pressure ulcers?**
- 6 **3. Do pressure redistributing devices reduce the development of pressure ulcers for those who are**
7 **at risk of developing a pressure ulcer?**
- 8 **4. When repositioning a person who is at risk of developing a pressure ulcer, what is the most**
9 **effective position – and optimum frequency of repositioning – to prevent a pressure ulcer**
10 **developing?**
- 11 **5. Which pressure ulcer tools are most effective for predicting pressure ulcer risk in children?**
- 12 **6. In neonates, infants, children, young people and adults who have adequate nutritional status**
13 **and who have a pressure ulcer, does providing further nutritional supplements improve healing**
14 **of the pressure ulcer?**

2 Pressure ulcer treatment

2.1 Introduction

3 Many pressure ulcers can be prevented but if a pressure ulcer does develop then it is imperative that
4 it is treated promptly and effectively. Although potentially very serious, most pressure ulcers can be
5 cured. Stage 1 pressure ulcers are usually reversible if identified promptly and most stage 2 and 3
6 pressure ulcers can be healed with appropriate care. Stage 4 pressure ulcers can heal but are often
7 more problematic, with some requiring surgery to achieve healing. This guideline considers a wide
8 range of areas such as support surfaces and adjunctive therapies, for the management of pressure
9 ulcers.

10 The management of pressure ulcers requires a multidisciplinary approach for optimum management
11 to be achieved. Usually the first requirement when a pressure ulcer develops is to remove the causal
12 process by introducing pressure relieving strategies such as repositioning and the use of appropriate
13 support surfaces. 'Repositioning' refers to the movement of the individual to relieve pressure, which
14 may require assistance (sometimes with special equipment such as a hoist or turning bed) or can be
15 done by the individual. The term 'support surfaces' refers to things such as mattresses or cushions on
16 which the person is positioned. Once relief from pressure has been provided, healing needs to be
17 stimulated which is done by debridement that is the removal of dead tissue. This can be achieved by
18 various techniques including the use of various dressings or more manual removal. Any other casual
19 factors will also ideally be corrected such as nutritional deficiencies or poor blood supply and the
20 wound will need to be cleaned and dressed to allow healing. The evidence for these factors and
21 other therapies, including electrotherapy, negative pressure wound therapy and hyperbaric oxygen
22 therapy are reviewed in this guideline. Consideration of ulceration caused by ischemia or
23 neuropathy, venous leg ulcers, pressure ulcers caused by devices and Kennedy terminal ulcers have
24 been excluded. Treatment strategies for pressure ulcers can potentially be both costly and complex.
25 A multitude of devices including different mattresses systems and pressure ulcer wound care
26 products are currently used within the NHS although few have been evaluated in randomised trials
27 (RCTs). There is therefore a need to evaluate the evidence to decide which of the many available
28 treatments promote the most cost-effective healing of pressure ulcers.

29 The management of pressure ulcers is provided in a wide range of settings such as in the community,
30 in hospital or in residential care. Thus a range of staff are involved in patient care and providing
31 patient support. In addition, it should also be recognised that the management of pressure ulcers is
32 challenging for patients, family members and caregivers.

2.1.31 Extrapolating adults recommendations to neonates, infants, children and young people

34 For ease of use, the guideline and its recommendations have been divided into two sections, part 1
35 (prevention) and part 2 (management). Part 1 and part 2 both contain recommendations for adults
36 and neonates, infants, children and young people, using methods outlined in Chapter 3 and 4,
37 respectively.

38 It is acknowledged that there are differences in the recommendations for adults and those for
39 neonates, infants, children and young people. However, due to the significant differences in the
40 means and sites by which younger populations may develop pressure ulcers, the GDG chose to use
41 the results of the Delphi consensus to develop the recommendations, rather than extrapolating from
42 evidence in adult populations.

43 However, the GDG acknowledges that some of those recommendations developed for adults may be
44 applicable to neonates, infants, children and young people and that healthcare professionals may
45 wish to consider the principles of these recommendations when treating these populations.

- 1 In each 'Linking evidence to Recommendations' section, recommendations for adults can be found in
- 2 yellow boxes and recommendations for neonates, infants, children and young people in pink boxes.
- 3 Recommendations which are applicable for all ages can be found in blue boxes.

2.1.2 Pressure ulcers caused by devices

- 5 The GDG wished to highlight that the prevention and management of pressure ulcers caused by
- 6 devices is outside the scope of the current guideline (see Appendix A).

2.1.3 Accounting for individuals' comfort

- 8 Throughout the guideline, when developing recommendations for the prevention and management
- 9 of pressure ulcers, the GDG have taken consideration of the individuals' concurrent needs for sleep,
- 10 pain relief, meal times and rehabilitation. The GDG felt that it was important to highlight that a
- 11 balance needs to be achieved between all of these factors for each individual who is at risk of or who
- 12 has developed a pressure ulcer.

3 Pressure ulcer measurement

3.1 Introduction

3 The measurement of pressure ulcer size can be used by healthcare professionals for recording and
4 monitoring the progression and healing of a pressure ulcer. Recording this accurately can allow an
5 assessment to be made as to whether a treatment is effective in promoting healing, by reducing the
6 size of the pressure ulcer.

7 It is important for healthcare professionals to understand that a pressure ulcer does not only affect
8 the visible skin but that it also has a cavity underneath it with depth and volume. As well as the
9 visible cavity, a cavity under the skin that cannot be directly observed (undermining) may be present.
10 This would need to be considered in addition to any measurement of visible damage.

11 A variety of methods and tools are available for measuring different aspects of a pressure ulcer, for
12 example, planimetry or photography. To be useful, the method used must be both accurate and
13 reliable, without causing damage to the tissue, or undue pain or discomfort to the individual.

14 Given the potential benefits of measuring a pressure ulcer in identifying its progression to assess
15 healing and progression the GDG were interested in investigating which tools were both reliable and
16 accurate for measuring pressure ulcers.

3.2 Review question: What are the most reliable techniques/tools to measure the dimensions of a pressure ulcer?

18
19 One systematic review¹⁴¹ looked at the performance of instruments designed for measuring the
20 dimensions of pressure ulcers. This systematic review was included in the current evidence review
21 and it was subsequently updated to include 1 other study (Terris 2011)¹⁸⁵. Overall 13 studies were
22 included in the evidence review.^{11,26,34,48,66,70,77,107,168,169,182,185,188} Evidence from these is summarised in
23 the clinical GRADE evidence profile below. The quality of these studies is outlined in Table 5-Table 7.

24 The O'Meara review¹⁴¹ looked at studies of any design which reported an evaluation of a pressure
25 ulcer measurement instrument as the main focus of the investigation. The authors did not include
26 assessment checklists where the focus was the performance of the tool overall rather than the
27 measurement of pressure ulcer dimensions.

28

Summary of included studies

Study	Population	Instruments	Outcomes (for definitions, see Table 1)
Griffin 1993 ⁷⁰	Mean age 31 years in a spinal cord injury rehabilitation centre with stage 2 to 5 pressure ulcers.	Tracing from photo, digital table, and computerised planimetry; direct transparency tracing, digital tablet and computerised planimetry.	<ul style="list-style-type: none"> • Intra-rater reliability; agreement
Anthony 1985 ¹¹	Minimal details of participant characteristics and settings.	Slide photo digitiser, and computerised planimetry; acetate tracing and square count.	<ul style="list-style-type: none"> • Intra-rater reliability; inter-rater reliability.
Schubert 1996 ¹⁶⁹	People from a geriatric clinic, with stage 3 pressure ulcers.	Transparency tracing and digital planimetry.	<ul style="list-style-type: none"> • Intra-rater reliability; inter-rater reliability.
Lucas 2002 ¹⁰⁷	Older adults in long-term care settings, Netherlands with stage 3 pressure ulcers.	Photo, transparent grid, whole and partial square count.	<ul style="list-style-type: none"> • Intra-rater reliability; inter-rater reliability.
Sugama 2007 ¹⁸²	Older adults in long-term care settings.	Portable digital device consisting of 3 layer sterile tracing grid and digital pad (VISITRAK).	<ul style="list-style-type: none"> • Intra-rater reliability; inter-rater reliability • Accuracy
Frantz 1992 ⁶⁶	Minimal details of participant characteristics and settings.	Stereophotogrammetry and computerised image analysis; scanned photographic images and computerised planimetry (reference standard).	<ul style="list-style-type: none"> • Inter-rater reliability
Buntinx 1996 ³⁴	Older adults in geriatric department of hospital. Study included other wounds but did not separate by wound type. Pressure ulcers were the predominant wound type (21/27).	Transparent grid.	<ul style="list-style-type: none"> • Inter-rater reliability
Schubert 1997 ¹⁶⁸	Minimal details of participant characteristics and settings	Transparency tracing plus: <ul style="list-style-type: none"> • digital planimetry (reference standard) • diameter product • whole square count • whole and partial square count • whole and residual square count. 	<ul style="list-style-type: none"> • Accuracy.
Thomas 1990 ¹⁸⁸	Inpatients and outpatients at a large metropolitan county hospital. Study	Slide photography, digitising tablet, and computerised planimetry; transparency tracing and digital planimetry;	<ul style="list-style-type: none"> • Agreement.

Study	Population	Instruments	Outcomes (for definitions, see Table 1)
	included other wounds but wound stratified by type of ulcer.	kundin device and mathematical formula.	
Cutler 1993 ⁴⁸	Older adults in long-term care settings, LA, USA.	Elliptical area (direct diameter measurement); elliptical area (diameters from tracing); elliptical area (diameters from photos); tracing and computerised planimetry; photo and computerised planimetry.	<ul style="list-style-type: none"> • Agreement
Schubert 1996 ¹⁶⁹	Older adults in a geriatric clinic.	Saline-gel injection into wound cavity; subsequent measurement of volume required to fill cavity.	<ul style="list-style-type: none"> • Intra-rater reliability; inter-rater reliability.
Berg 1990 ²⁶	Minimal details of participant characteristics and settings.	Sterile fluid injection into cavity; subsequent measurement of volume required to fill cavity.	<ul style="list-style-type: none"> • Inter-rater reliability.
Hayward 1993 ⁷⁷	People with pressure ulcers in an inpatient service.	Alginate mould of wound cavity with application of: water displacement (reference standard) and NMR spectroscopy.	<ul style="list-style-type: none"> • Accuracy
Terris 2011 ¹⁸⁵	People with stage 3 and 4 pressure ulcers with spinal cord injuries.	14 cm disposable ruler placed adjacent to pressure ulcer to measure length and width of wound. Digital photographs taken with camera.	<ul style="list-style-type: none"> • Intra-rater reliability; inter-rater reliability

Table 1: Definitions of outcome measures used in this review

Outcome	Definition
Intra-rater reliability	Do 2 assessments performed by the same investigator produce the same result?
Inter-rater reliability	Do 2 or more different investigators achieve the same result?
Accuracy	The closeness of computations or estimates to the exact or true values.
Agreement	The degree to which scores or ratings are identical

Table 2: Details of statistical measures used in this review

Heading	Definition
Correlation	Extent to which 2 or more variables are associated with each other.
Co-efficients of variation	The ratio of the standard deviation of the measurements on a subject to the mean of these measurements.
Intraclass correlation coefficient	A measure of the inter-rater reliability for 2 or more raters. May also be used to assess test-retest reliability. Conceptualised as ratio of between-groups variance to total variance.
Kappa coefficient	A measure of non-random agreement between observers or measurements of the same categorical variable.
Pearson's correlation coefficient	A measure of the linear relationship between 2 variables in a sample and used as an estimate of the correlation in the whole population.

Table 3: Glossary of instruments for measuring dimensions of pressure ulcers

Instrument	Details
Tracing from photograph	Making a slide of the pressure ulcer using a camera with a macrolens and then outlining pressure ulcer margins from the projected slide image (photographic method).
Transparency tracing	Transparency method. A transparent plastic film (for example, acetate) is placed directly over the pressure ulcer and the margins are traced usually with an indelible pen.
Transparent grid	An adhesive transparent plastic film is placed over the wound (see transparency tracing) and a pre-printed transparent square grid is used along with this so the tracing can be traced onto this grid sheet with an indelible pen. The grid squares can then be counted (see square count).
Computerised/ digital planimetry/ digital tablet/slide photo digitiser	A planimeter or digitising tablet can be used to calculate the ulcer surface area from the photographs taken using slide film and a camera. An enlarged slide is then scanned by a digitiser connected to a microcomputer, the pressure ulcer is compared to the known frame and an area calculated.
Square count	After a tracing of the pressure ulcer has been made it is then laid over squared graph paper of known dimensions and the squares inside the sore boundary are counted to give an absolute value of area.
Whole square count	The number of whole squares which lie inside the tracing.
Partial square count	Each partial square was assumed to contribute on average half (50%) the area of a whole square.
Residual square count	Residual square count for each such partial square a visual estimate was made of the proportion that was inside the tracing. The sum of all proportions gave the equivalent number of whole squares.
Stereophotogrammetry	A method of applying optical triangulation to produce 3-dimensional measurements from 2 separate 2-dimensional photographs.
Kundin device and mathematical formula	A disposable, 3-dimensional, plastic-coated paper wound gauge.

Instrument	Details
NMR spectroscopy of a mould	Nuclear magnetic resonance spectrometer is a research technique that exploits the magnetic properties of certain atomic nuclei to determine physical and chemical properties of atoms or the molecules in which they are contained. It relies on the phenomenon of nuclear magnetic resonance and can provide detailed information about the structure, dynamics, reaction state, and chemical environment of molecules. It was used to make cross sectional images of the moulds which then could be made and processed with software.

Table 4: Categorisation of values into levels of acceptability^a

Acceptability of values	Very good/excellent		Fair/good		Poor	
Correlation	Excellent		Good	Fair	Poor	
Intra class coefficient (ICC) ^b	0.75+		0.60 to 0.74	0.40 to 0.59	<0.40	
Kappa coefficient ^c	0.75+		0.60 to 0.74	0.40 to 0.59	<0.40	
Correlation	Perfect	High	Moderate		Low	No correlation
Pearson's correlation coefficient ^d	1.00	0.75+	0.25 and 0.75		<0.25	0
Intra-rater reliability % variation	Adequate		Acceptable		Poor	
Coefficient of variation ^e	<10%		10-20%		>20%	
Inter-rater reliability % variation	Adequate		Acceptable		Poor	
Coefficient of variation ^f	<20%		20-30%		>30%	

(a) These have been categorised into excellent/good/poor to provide a general idea of what the values mean in the evidence tables below.

(b) Fleiss, J. L. (1981) *Statistical methods for rates and proportions*. 2nd ed. (New York: John Wiley) pp. 38–46

(c) Orwin RG. *Evaluating coding decisions*. In: Cooper H, Hedges LV (editors). *The Handbook of Research Synthesis*. New York (NY): Russell Sage Foundation, 1994.

(d) As per NCGC guidance 2012.

(e) As per NCGC guidance 2012.

(f) As per NCGC guidance 2012.

3.211 Clinical evidence for intra-rater reliability

2 **Table 5: Clinical evidence profile: measurement of wound diameter**

Study	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	n	Tool	Statistical methods	Evaluation	Acceptability of values	Quality
Intra-rater reliability – minimal details of participant characteristics – no details of pressure ulcer site provided.											
Anthony 1985 ¹¹	Very serious limitations ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	N/A	4 subjects with 4 pressure ulcers	Longest diameter assessed with tape measure Shortest diameter assessed with tape measure.	Mean (range) of coefficients of variation (SD/mean %) for 3 nurses' assessment of 2 wounds x10	4.2% (2.1 – 6.8%) 7.0% (4.1-11%)	Very good/excellent Very good/excellent	Very low
Intra-rater reliability - People with spinal cord injuries with a stage 3 or 4 pressure ulcer – no details of pressure ulcer sites for the 10 pressure ulcers provided but the 15 people in the whole study pressure ulcer sites were n=2 ankle, n=8 foot and heel, n=8 ischium, n=1 knee, n=8 sacrum and buttock, n=1 thigh, n=3 trochanter.											
Terris 2011 ¹⁸⁵	Very serious limitations ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^c	10 pressure ulcers (randomly selected) study included 15 participants with 31 pressure ulcers	Length assessed with ruler Width assessed with ruler Digital photographs taken	Kappa coefficient; 2 wound care nurses and a 3 rd study team member for in-person assessments and to take digital photos	0.072 (p=0.02) 0.110 (p=0.009)	Poor Poor	Very low
Inter-rater reliability - minimal details of participant characteristics – no details of pressure ulcer site provided.											
Anthony 1985 ¹¹	Very serious	No serious inconsistency	No serious indirectness	Serious imprecision ^b	N/A	4 subjects with 4	Longest diameter	Difference between	Means (cm): 1 st wound	Poor	Very low

Study	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	n	Tool	Statistical methods	Evaluation	Acceptability of values	Quality
	limitations ^a					pressure ulcers; 3 observers	assessed with tape measure Shortest diameter assessed with tape measure	means for 3 nurses' assessment of 2 wounds tested using ANOVA	2.19, 7.75, 6.87 (p<0.001); 2 nd wound 1.93, 1.76, 1.53 (p<0.01) Means (cm): 1 st wound 1.45, 1.94, 1.82 (p<0.001); 2 nd wound 1.30, 1.45, 1.63 (p<0.01)	Poor	
Inter-rater reliability – elderly adults in geriatric department of hospital – no details of pressure ulcer site provided.											
Buntinx 1996 ³⁴	Very serious limitations ^a	No serious inconsistency	No serious indirectness	Serious ^b	Serious ^c	20 subjects, 27 wound (21 pressure ulcers, 2 leg ulcers, 3 venous leg ulcers and an amputation wound)	Longest diameter (instrument not stated) Longest diameter perpendicular to the above	Correlation coefficients (exact analysis not stated) between six raters assessing 27 wounds. Difference between means of the six raters.	Range of correlation coefficients 0.72 -0.98 p=0.93 for overall difference between means p=0.88 for overall difference	Very good/excellent	Very low

Study	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	n	Tool	Statistical methods	Evaluation	Acceptability of values	Quality
							(instrument not stated)	Correlation coefficients not reported for this wound dimension. Difference between means of six raters reported as above.	between means		
Inter-rater reliability - People with spinal cord injuries with a stage 3 or 4 pressure ulcer– pressure ulcer sites were n=2 ankle, n=8 foot and heel, n=8 ischium, n=1 knee, n=8 sacrum and buttock, n=1 thigh, n=3 trochanter.											
Terris 2011 ¹⁸⁵	Very serious limitations ^a	No serious inconsistency	No serious indirectness	Serious limitations ^b	Serious ^c	15 subjects with 31 pressure ulcers	Length assessed with ruler Width assessed with ruler Digital photographs taken	Kappa coefficient	0.075 (p=0.003) 0.103 (<0.001)	Poor Poor	Very low

- 1 (a) The study was of low methodological quality (see table below). Anthony and Buntinx used ANOVA for inter-rater reliability but did not give full account of the methods used and they did
- 2 not give estimate of all potential sources of variability. There were a small number of assessors.
- 3 (b) There were a limited number of observations.
- 4 (c) No confidence interval was given so cannot comment on imprecision.
- 5 Inter-rater reliability results were mixed. It is not possible to comment on the acceptability of the methods of analysis as there was not enough detail
- 6 given.

1 **Table 6: Clinical evidence profile: measurement of pressure ulcer depth**

Study	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	n	Tool	Statistical methods	Evaluation	Acceptability of values	Quality
Intra-rater reliability – elderly participants with stage 3 pressure ulcers at geriatric clinic – pressure ulcer site n=8 sacral, n=2 trochanter, n=1 forefoot.											
Schubert 1996 ¹⁶⁹	Very serious limitations ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^c	11 participants with 11 pressure ulcers	Depth at wound centre assessed with probe	Coefficient of variation generated from repeated measures ANOVA for assessment of 11 wounds (unclear whether 1 or 2 nurses involve in assessment)	Coefficient of variation 26%	Poor	Very low
Inter-rater reliability – elderly participants with stage 3 pressure ulcers at geriatric clinic – pressure ulcer site n=8 sacral, n=2 trochanter, n=1 forefoot.											
Schubert 1996 ¹⁶⁹	Very serious limitations ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^c	11 participants with 11 pressure ulcers	Depth at wound center assessed with probe	Coefficient of variation generated from repeated measures ANOVA; 11 wounds measured on four separate occasions 2 nurses involved	Coefficient of variation 48%	Poor	Very low
Inter-rater reliability - minimal details of participant characteristics 5 stage 2 ulcers, 18 stage 3 ulcer and 13 stage 4 ulcer (NPUAP) – pressure ulcer site n=10 coccyx, n=10 malleolus, n=6 heel; n=4 ischial tuberosity, n=3 trochanter, n=2 lateral foot.											
Frantz 1992 ⁶⁶	Serious limitations ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^c	36 pressure	Depth measur	Pearson's correlation	Pearson's correlation	Very good/excellent	Very low

Study	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	n	Tool	Statistical methods	Evaluation	Acceptability of values	Quality
						ulcers	ed using stereophotogrammetry and computerised image analysis	used for 2 raters assessing 144 steroslides (four photos of 36 ulcers taken at 2-week intervals)	0.96		
Accuracy - elderly adults with stage 3 pressure ulcers at geriatric clinic– pressure ulcer site n=8 sacral, n=2 trochanter, n=1 forefoot.											
Schubert 1996 ¹⁶⁹	Very serious limitations ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^c	11 patients with 11 pressure ulcers	Probe assessed against ratio between wound volume and area (reference standard)	Difference between normalised (that is relative to baseline) means for the 2 methods derived from time series data for each participant.	Group mean 55% (highest value 144%)	Poor	Very low
Accuracy – minimal details of patient characteristics 5 stage 2 ulcers, 18 stage 3 ulcer and 13 stage 4 ulcers (NPUAP) – pressure ulcer site n=10 coccyx, n=10 malleolus, n=6 heel; n=4 ischial tuberosity, n=3 trochanter, n=2 lateral foot.											
Frantz 1992 ⁶⁶	Serious limitations ^a	No serious inconsistency	No serious inconsistency	Serious imprecision ^b	Serious ^c	36 pressure ulcers	Depth measured using stereophotogrammetry and	Pearson’s correlation used for 2 raters assessing 144 steroslides	Pearson’s correlation 0.96	Very good/excellent	Very low

Study	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	n	Tool	Statistical methods	Evaluation	Acceptability of values	Quality
							computerised image analysis	(four photos of 36 ulcers taken at 2-week intervals)			

1 (a) The study was of low/very low methodological quality (see table below).

2 (b) There were a limited number of observations.

3 (c) No confidence interval was given so cannot comment on imprecision.

4

5 Central pressure ulcer depth with a probe was not valid when it was compared to a reference standard. It is to be noted that the reference standard used
6 may not be valid due to the assumption that pressure ulcer depth would not vary over the base of the pressure ulcer and that the walls of the pressure
7 ulcer were steep. Intra and inter-rater reliability was more variable for the depth probe compared to measurements of other wound dimensions.
8 Stereophotogrammetry with computerised image analysis was highly correlated for inter-rater reliability. However the Pearson's correlation coefficient
9 does not measure association repeatability. Therefore it does not estimate any bias that may occur in measurements of 1 assessor to another.

10 **Table 7: Clinical evidence profile: measurement of pressure ulcer surface area**

Study	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	N	Tool	Statistical methods	Evaluation	Acceptability of values	Quality
Intra-rater reliability - mean age 31 years in a spinal cord injury rehabilitation centre with grade 2 to 5 ulcers, USA – pressure ulcer sites n=8 gluteal/ischial, n=12 sacral/coccygeal, n=2 trochanteric, various size 688+/-228mm²											
Griffin 1993 ⁷⁰	No serious limitations	No serious	No serious	Very serious ^{b,d}	N/A	20 people with 22 pressure ulcers	Tracing from photo, digital table, and computerised planimetry; Direct transparency tracing, digital tablet and computerised planimetry	ICC generated from 1-way random-effects ANOVA. One physiotherapist assessed five wounds twice with 1 hour	ICC (SE) SEM for mean of 3 measurements per wound: Instrument 1: 0.999 (0.577) 18.8mm ² Instrument 2: 0.999 (0.577)	Instrument 1: Very good/excellent Instrument 2: Very good/excellent	Low

Study	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	N	Tool	Statistical methods	Evaluation	Acceptability of values	Quality
								between measurements	25.1mm ² Mean (SE) surface area estimated from mean of 3 measurements per wound (mm ²) Instrument 1: 1,188.9 (626.4) Instrument 2: 18.1% (10.0-42.6%)		
Intra-rater reliability – minimal details of participant characteristics– no details of pressure ulcer site											
Anthony 1985 ¹¹	Very serious limitations ^a	No serious inconsistency	No serious indirectness	Very serious ^{b,d}	N/A	4 subjects with 4 pressure ulcers	Slide photo digitiser, and computerised planimetry; Acetate tracing and square count	Mean (range) of coefficients of variation (SD/mean %) for 3 nurses' assessment of four wounds x10 on the same day	Instrument 1: 11.0% (2.8-28.2%) Instrument 2: 18.1% (10.0-42.6%)	Fair/good	Very low
Intra-rater reliability – elderly adults with stage 3 pressure ulcers– pressure ulcer site n=8 sacral, n=2 trochanter, n=1 forefoot.											
Schubert 1996 ¹⁶⁹	Very serious limitations ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^c	11 people with 11 pressure ulcers	Transparency tracing and digital planimetry	Coefficient of variation generated from repeated	Coefficient of variation 2%	Very good/excellent	Very low

Study	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	N	Tool	Statistical methods	Evaluation	Acceptability of values	Quality
								measures ANOVA; 11 wounds measured on four separate occasions (number of assessors unclear)			
Intra-rater reliability - older adults in long-term care with stage 3 pressure ulcers, pressure ulcer sites were n=7 gluteal, n=7 sacrum/coccyx, n=1 greater trochanter, n=2 medial femoral epicondyle, n=3 lateral malleolus, n=10 calcaneus.											
Lucas 2002 ¹⁰⁷	No serious limitations	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^c	26 people, 30 wounds	Photo, transparent grid, and whole plus partial square count	ICC from 2-way random effects ANOVA. Two physiotherapists assessed 30 wound x2 on 2 occasions, 2 weeks apart.	ICC 0.99 for both assessors	Very good/excellent	Low
Intra-rater reliability - older adults in long-term care – pressure ulcer site n=5 sacral, n=3 trochanteric, n=1 iliac, n=1 calcaneal.											
Sugama 2007 ¹⁸²	No serious limitations	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^c	10 ulcers	Portable digital device consisting of 3-layer sterile tracing grid and digital pad (VISITRAK)	ICC derived from ANOVA. Four nurses assessed 10 wounds from 10 people..	ICC 0.99	Very good/excellent	Low
Inter-rater reliability – minimal details of participant characteristics– no details of pressure ulcer site provided.											
Anthony	Very serious	No serious	No serious	Serious	Serious	4	Slide photo	Difference	Statistically	Poor	Very low

Study	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	N	Tool	Statistical methods	Evaluation	Acceptability of values	Quality
1985 ¹¹	limitations ^a	inconsistency	indirectness	imprecision ^b	s ^c	subjects with 4 pressure ulcers	digitiser, and computerised planimetry; Acetate tracing and square count	between means for 3 nurses' assessment of 4 wounds tested using ANOVA	significant differences observed between assessors for 2 out of four ulcers for instrument 1 and for 3 out of four ulcers for instrument 2 (p< 0.01 for all comparisons)		
Inter-rater reliability – elderly participants with stage 3 pressure ulcers at a geriatric clinic– pressure ulcer site n=8 sacral, n=2 trochanter, n=1 forefoot.											
Schubert 1996 ¹⁶⁹	Very serious limitations ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^c	11 people with 11 pressure ulcers	Transparency tracing and digital planimetry	Coefficient of variation from repeated measures ANOVA for assessment of 11 wounds by 2 nurses	Coefficient of variation 3%	Very good/excellent	Very low
Inter-rater reliability – older adults in long-term care with stage 3 pressure ulcers pressure ulcer sites were n=7 gluteal, n=7 sacrum/coccyx, n=1 greater trochanter, n=2 medial femoral epicondyle, n=3 lateral malleolus, n=10 calcaneus.											
Lucas 2002 ¹⁰⁷	No serious limitations	No serious inconsistency	No serious inconsistency	Serious imprecision ^b	Serious ^c	26 people, 30 wounds	Photo, transparent grid, and whole plus partial square count	ICC from 2-way random effects ANOVA. Two physiothera	ICC 0.99	Very good/excellent	Low

Study	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	N	Tool	Statistical methods	Evaluation	Acceptability of values	Quality
								pists assessed 30 wounds x2 on 2 occasions, 2 weeks apart			
Inter-rater reliability – older adults in long-term care– pressure ulcer site n=5 sacral, n=3 trochanteric, n=1 iliac, n=1 calcaneal.											
Sugama 2007 ¹⁸²	No serious limitations	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^c	10	Portable digital device consisting of 3-layer sterile tracing grid and digital pad (VISITRAK)	ICC derived from ANOVA. Four nurses assessed 10 wounds from 10 people.	ICC 0.99	Very good/excellent	Low
Inter-rater reliability –details of participant characteristics 5 stage 2 ulcers, 18 stage 3 ulcer and 13 stage 4 ulcer (NPUAP) – pressure ulcer site n=10 coccyx, n=10 malleolus, n=6 heel; n=4 ischial tuberosity, n=3 trochanter, n=2 lateral foot.											
Frantz 1992 ⁶⁶	Serious limitations ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^c	36 pressure ulcers	Stereophotogrammetry and computerised image analysis;	Peasons’s correlation for 2 raters assessing 144 steroslides (four photos of 36 ulcers taken at 2-week intervals	Pearson’s correlation coefficient 0.98	Very good/excellent	Very low
Inter-rater reliability – elderly adults at a geriatric department of a hospital– no details of pressure ulcer site provided.											
Buntinx 1996 ³⁴	Very serious limitations ^a	No serious inconsistency	No serious inconsistency	Serious imprecision ^b	Serious ^c	27 pressure ulcers	Transparent grid	Correlation coefficients (exact method not stated) between 6 raters	Range of correlation coefficients 0.94-0.98	Very good/excellent	Very low

Study	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	N	Tool	Statistical methods	Evaluation	Acceptability of values	Quality
								(3physicians , 3 nurses) assessing 27 wounds (20 people)			
Accuracy - minimal details of participant characteristics – no details of pressure ulcer site provided.											
Schubert 1997 ¹⁶⁸	Very serious limitations ^a	No serious inconsistency	No serious inconsistency	No serious	Serious ^c	373 ulcers	Transparency tracing plus: Digital planimetry (reference standard) Diameter product Whole square count Whole plus partial square count Whole plus residual square count	Regression with reference area as independent variable and index measurements as dependent variables. Regression coefficients were compared with the null hypothesis using Student's t-test. One assessor measured 373 wounds	Instrument 2: average value significantly higher than reference standard (31% p<0.001 for difference between instruments) Instrument 3: significantly lower than reference standard (-13%, p<0.001) Instrument 4: mean value around 1% greater than reference standard Instrument 5: mean	N/A	Very low

Study	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	N	Tool	Statistical methods	Evaluation	Acceptability of values	Quality
									value around 1% less than reference standard		
Accuracy - older adults in long-term care – pressure ulcer sites were n=12 sacral, n=12 trochanteric, n=4 calcaneal, n=1 iliac and n=1 toe.											
Sugama 2007 ¹⁸²	Serious limitations ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^c	30 people with 30 pressure ulcers	Portable digital device consisting of 3-layer sterile tracing grid and digital pad; Scanned photographic images and computerised planimetry (reference standard)	Correlation coefficient (exact method not stated) calculated from average of 3 measurements. Four nurses assessed 30 people with 1 wound each.	Correlation coefficient 0.99 (p<0.001)	Very good/excellent	Very low
Agreement - mean age 31 years in a spinal cord injury rehabilitation centre with grade 2 to 5 ulcers– pressure ulcer sites n=8 gluteal/ischial, n=12 sacral/coccygeal, n=2 trochanteric, various size 688+/-228mm².											
Griffin 1993 ⁷⁰	Serious limitations ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^c	20 people with 22 ulcers	Tracing from photo, digital table, and computerised planimetry; Direct transparency tracing, digital tablet and computerised planimetry	Pearson's correlation 2 way mixed model ANOVA with patients and methods as main effects; 3-way mixed model ANOVA with patients,	Pearson's correlation 0.98 (p<0.0001). Two –way ANOVA: significant difference between patients (p=0.0001) but not between	Very good/excellent	Very low

Study	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	N	Tool	Statistical methods	Evaluation	Acceptability of values	Quality
								methods and days as main effects. One physiotherapist assessed 20 people with 22 wounds	methods (p=0.88) Three-way ANOVA: no significant differences between methods over time.		
Agreement - inpatients and outpatients – size ranged 15.83mm² to 35740mm² – no details of pressure ulcer site provided.											
Thomas 1990 ¹⁸⁸	Very serious limitations ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^c	37 pressure ulcers	Slide photography, digitising tablet, and computerised planimetry; Transparency tracing and digital planimetry; Kundin device and mathematical formula	Assessed using Pearson's correlation and repeated measures ANOVA. Thirty-seven pressure ulcers assessed. No information about assessors.	Pearson's correlation between instruments : 1&2, 0.996; 1&3, 0.934; 2&3, 0.936; p</=0.0001 for all correlations . p=0.0001 for difference between means (instruments).	Very good/excellent	Very low
Agreement - older patients in long-term care with stage 3 or 4 pressure ulcers - size ranged from 1.2cm² to 61.6cm² – pressure ulcer sites were n=8 sacrum, n=4 coccyx, n=4 hip, n=3 heel, n=1 buttock.											
Cutler 1993 ⁴⁸	Very serious limitations ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^c	20 people with 20 pressure ulcers	Elliptical area (direct diameter measurement); Elliptical area	Assessed using Pearson's correlation coefficient and	Pearson's correlation: between instruments : 1 & 4, 0.979; 1& 5,	Very good/excellent	Very low

Study	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	N	Tool	Statistical methods	Evaluation	Acceptability of values	Quality
							(diameters from tracing) Elliptical area (diameters from photos); Tracing and computerised planimetry; Photo and computerised planimetry.	variance components model assessing effects of people, sample (refers to duplicate tracing or photograph) and replication (refers to multiple measurements obtained from computerised planimetry).	0.971; 1& 2, 0.982; 4& 5, 0.963; 2&4, 0.991; 3&5, 0.989; p< 0.001 for all correlations except 4& 5, which was not reported. Estimates from the variance components model suggested that most of the observed variation came from participants rather than samples or replication (that is the instruments).		

- 1 (a) The study was of low/very low methodological quality (see table below).
- 2 (b) There were a limited number of observations.
- 3 (c) No confidence interval was given so cannot comment on imprecision.
- 4 (d) The confidence interval was wide.
- 5

O'Meara (2012)¹⁴¹ summarised the findings by reliability, accuracy and agreement:

3.2.1.1 Reliability

Intra-rater reliability for transparency tracing from a Polaroid photo and whole plus partial square count from a grid was satisfactory. The intra-class correlation coefficient was good. Intra-rater reliability of tracing from slide photography versus direct contact transparency tracing (both with computerised planimetry) was high and showed no difference between the instruments but there were a small number of pressure ulcers assessed. A portable digital system showed that the intra-rater and inter-rater reliability was good. A transparency tracing with whole plus partial square count was adequate for inter-rater reliability. Another study assessed stereophotogrammetry and computerised image analysis and had a good Pearson's correlation coefficient.

3.2.1.2 Accuracy

One study analysed the accuracy of 4 interventions in addition to tracing onto a grid compared to a reference standard (transparency tracing and digital planimetry). Whole square count and whole plus residual square count were found to have accuracy. It was a large study but there was an inappropriate use of regression analysis to estimate accuracy. Another study compared a portable digital device to a scanned photographic image combined with computerised planimetry (reference standard). This was highly correlated but the exact statistical method was not reported so the suitability of the analysis cannot be assessed.

3.2.1.3 Agreement

Photography combined with digital planimetry, transparency tracing combined with digital planimetry and the Kundin device with a mathematical adjustment showed statistically significant differences. Another study showed that photographic tracing and direct acetate tracing (both combined with a digitising table and computerised planimetry) had no statistically significant differences. There were methodological and statistical problems in the agreement studies.

Intra-rater reliability of sterile saline gel mixture to fill the pressure ulcer cavity was found to be good and inter-rater reliability fair or good in 1 study. Another study showed no statistically significant difference in the variation for inter-rater reliability for a sterile saline gel to fill the pressure ulcer cavity. An additional study reported a high Pearson's correlation for stereophotogrammetry combined with computerised image analysis by 2 assessors independently. There was a high Pearson's correlation for nuclear magnetic resonance spectroscopy of alginate mold and water displacement of the mold (reference standard) for agreement. Pearson's correlation coefficient is not appropriate for inter-rater reliability, accuracy or agreement as it only looks at association rather than bias and can give misleading results.

3.2.1.4 Overall findings

O'Meara (2012)¹⁴¹ reported that most of the evaluations had methodological and/or statistical problems. The methods that may be reliable are: measuring surface area with grid tracings from photographs combined with whole plus partial square count; a portable digital pad and stereophotogrammetry combined with computerised image analysis. There may be agreement between photographic tracing and direct transparency tracing (both combined with computerised planimetry). No conclusions could be made for studies of diameter or depth and evaluations of volume measurement were of poor quality. There was little data on feasibility.

Table 8: Quality of reliability studies

Study	Are the participants representative?	Selection criteria clear?	Assessors representative?	Assessor selection criteria clear?	Time period short enough between measurements short enough?	Did all receive scheduled repetitions of measurements?	Description of execution of measurements adequate for replication?	Description of sequence of repeated measurements adequate?	Inter-rater reliability: was measurement performed without knowledge of other rater's values?	Was order of measurements random?	Were withdrawals explained?
Anthony 1985 ¹¹	Unclear	No	Unclear	No	Yes	No	Yes	Yes	Unclear	No	No ^a
Berg 1990 ²⁶	Unclear	No	Unclear	No	Yes	Yes	Yes	No	Yes	No	N/A
Buntinx 1996 ³⁴	Yes	Yes	Yes	No	Unclear	Unclear	No	No	Unclear	No	No ^a
Frantz 1992 ⁶⁶	Yes	Yes	Unclear	No	Yes	Yes	Yes	Yes	Yes	No	N/A
Griffin 1993 ⁷⁰	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	N/A	Yes	Yes
Lucas 2002 ¹⁰⁷	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	n/a
Schubert 1996 ¹⁶⁹	Yes	Yes	Unclear	No	Unclear	Unclear	Yes	No	Yes	No	Yes
Sugama 2007 ¹⁸²	Yes	No	Yes	No	Yes	Yes	Yes	Yes	Unclear	Yes	n/a
Terris 2011 ¹⁸⁵	Yes	Yes	Yes	No	Yes	Unclear	Yes	Unclear	Unclear	Unclear	N/A

(a) No, not explained, but there may not have been any withdrawals.

N/A, not applicable (no withdrawals or inter-rater reliability not assessed)

3.2.12 Economic evidence (adults)

- 2 No relevant economic evaluations comparing ulcer measurement techniques were identified.

3.2.23 Clinical evidence (neonates, infants, children and young people)

- 4 No RCTs or cohort studies were identified. Recommendations were developed using a modified
5 Delphi consensus technique. Further details can be found in Appendix N.

3.2.64 Economic evidence (neonates, infants, children and young people)

- 7 No relevant economic evaluations comparing ulcer measurement techniques were identified.

3.2.85 Evidence statements

3.2.591 Clinical (adults)

3.2.5.101 *Measurement of pressure wound diameter*

- 11 • One study (n=4) reported that measuring the longest diameter with a tape measure had
12 potentially very good/excellent intra-rater reliability for measurement of pressure ulcer diameter
13 (very low quality).
- 14 • One study (n= 4) reported that measuring the shortest diameter with a tape measure had
15 potentially very good/excellent intra-rater reliability for measurement of pressure ulcer diameter
16 (very low quality).
- 17 • One study (n= 15) reported that measuring the length with a ruler and using digital photographs
18 had potentially poor intra-rater reliability for measurement of pressure ulcer diameter (very low
19 quality).
- 20 • One study (n= 15) reported that measuring the width with a ruler and using digital photographs
21 had potentially poor intra-rater reliability for measurement of pressure ulcer diameter (very low
22 quality).
- 23 • One study (n=4) reported that measuring the longest diameter with a tape measure had
24 potentially poor inter-rater reliability for measurement of pressure ulcer diameter (very low
25 quality).
- 26 • One study (n= 4) reported that measuring the shortest diameter with a tape measure had
27 potentially poor inter-rater reliability for measurement of pressure ulcer diameter (very low
28 quality).
- 29 • One study (n= 15) reported that measuring the length with a ruler and using digital photographs
30 had potentially poor inter-rater reliability for measurement of pressure ulcer diameter (very low
31 quality).
- 32 • One study (n= 15) reported that measuring the width with a ruler and using digital photographs
33 had potentially poor inter-rater reliability for measurement of pressure ulcer diameter (very low
34 quality).
- 35 • One study (n=20) reported that measuring the longest diameter with an instrument that was not
36 stated had potentially very good/excellent inter-rater reliability for measurement of pressure
37 ulcer diameter (very low quality).
- 38 • One study (n=20) reported that measuring the longest diameter perpendicular with an instrument
39 that was not stated had potentially very good/excellent inter-rater reliability for measurement of
40 pressure ulcer diameter (very low quality).
- 41

3.2.5.112 Measurement of pressure ulcer depth

- 2 • One study (n=11) reported that measuring the depth at the center of the pressure ulcer with a
3 probe had potentially poor intra-rater reliability for measurement of pressure ulcer depth (very
4 low quality).
- 5 • One study (n=11) reported that measuring the depth at the center of the pressure ulcer with a
6 probe had potentially poor inter-rater reliability for measurement of pressure ulcer depth (very
7 low quality).
- 8 • One study (n=unknown, 36 pressure ulcers included) reported that measuring the depth using
9 stereophotogrammetry and computerised image analysis had potentially very good/excellent inter-
10 rater reliability for measurement of pressure ulcer depth (very low quality).
- 11 • One study (n=11) reported that measuring the depth using a probe assessed against a ratio
12 between pressure ulcer volume and area had potentially poor accuracy for measurement of
13 pressure ulcer depth (very low quality).
- 14 • One study (n= unknown, 36 pressure ulcers included) reported that measuring the depth using
15 stereophotogrammetry had potentially very good/excellent accuracy for measurement of pressure
16 ulcer depth (very low quality).
- 17

3.2.5.113 Measurement of wound surface area

- 19 • One study (n=20) reported that measuring the pressure ulcer surface area using tracing from
20 photo, digital table and computerised planimetry may have had very good or excellent intra-rater
21 reliability for measurement of pressure ulcer surface area (very low quality).
- 22 • One study (n=20) reported that measuring the pressure ulcer surface area using direct
23 transparency tracing, digital tablet and computerised planimetry may have had very good or
24 excellent intra-rater reliability for measurement of pressure ulcer surface area (very low quality).
- 25 • One study (n=4) reported that measuring the pressure ulcer surface area using slide photo
26 digitiser and computerised planimetry may have had fair or good intra-rater reliability for
27 measurement of pressure ulcer surface area (very low quality).
- 28 • One study (n=4) reported that measuring the pressure ulcer surface area using acetate tracing
29 and square count may have had fair or good intra-rater reliability for measurement of pressure
30 ulcer surface area (very low quality).
- 31 • One study (n=11) reported that measuring the pressure ulcer surface area using transparency
32 tracing and digital planimetry potentially had very good or excellent intra-rater reliability for
33 measurement of pressure ulcer surface area (very low quality).
- 34 • One study (n=26) reported that measuring the pressure ulcer surface area using photo,
35 transparent grid and whole and partial square count potentially had very good or excellent intra-
36 rater reliability for measurement of pressure ulcer surface area (very low quality).
- 37 • One study (n=10) reported that measuring the pressure ulcer surface area using a portable digital
38 device consisting of 3-layer sterile tracing grid and digital pad potentially had very good/excellent
39 intra-rater reliability for measurement of pressure ulcer surface area (very low quality).
- 40 • One study (n=4) reported that measuring the pressure ulcer surface area using slide photo
41 digitiser and computerised planimetry potentially had poor inter-rater reliability for measurement
42 of pressure ulcer surface area (very low quality).
- 43 • One study (n=4) reported that measuring the pressure ulcer surface area using acetate tracing
44 and square count potentially had poor inter-rater reliability for measurement of pressure ulcer
45 surface area (very low quality).
- 46 • One study (n=11) reported that measuring the pressure ulcer surface area using transparency
47 tracing and digital planimetry potentially had very good or excellent inter-rater reliability for
48 measurement of pressure ulcer surface area (very low quality).

- 1 • One study (n=26) reported that measuring the pressure ulcer surface area using photo,
2 transparent grid and whole and partial square count potentially had very good or excellent inter-
3 rater reliability for measurement of pressure ulcer surface area (very low quality).
- 4 • One study (n=10) reported that measuring the pressure ulcer surface area using a portable digital
5 device consisting of 3-layer sterile tracing grid and digital pad potentially had very good/excellent
6 inter-rater reliability for measurement of pressure ulcer surface area (very low quality).
- 7 • One study (n= unknown, 36 pressure ulcers included) reported that measuring the pressure ulcer
8 surface area using a stereophotogrammetry and computerised image analysis potentially has very
9 good or excellent inter-rater reliability for measurement of pressure ulcer surface area (very low
10 quality).
- 11 • One study (n= unknown, 27 pressure ulcers included) reported that measuring the pressure ulcer
12 surface area using a transparent grid potentially had very good or excellent inter-rater reliability
13 for measurement of pressure ulcer surface area.
- 14 • One study (n= unknown, 373 pressure ulcers included) reported that measuring the pressure ulcer
15 surface area using transparency tracing plus diameter product compared to reference standard
16 potentially had unknown accuracy for measurement of pressure ulcer surface area (very low
17 quality).
- 18 • One study (n=30) reported that measuring the pressure ulcer surface area using transparency
19 tracing plus whole square count compared to reference standard potentially had unknown
20 accuracy for measurement of pressure ulcer surface area (very low quality).
- 21 • One study (n=30) reported that measuring the pressure ulcer surface area using transparency
22 tracing plus whole and partial square count compared to reference standard potentially had
23 unknown accuracy for measurement of pressure ulcer surface area (very low quality).
- 24 • One study (n= 30) reported that measuring the pressure ulcer surface area using transparency
25 tracing plus whole and residual square count compared to a reference standard potentially had
26 unknown accuracy for measurement of pressure ulcer surface area (very low quality).
- 27 • One study (n=30) reported that measuring the pressure ulcer surface area using a portable digital
28 devices (3-layer sterile tracing grid and digital pad compared to scanned photographic images and
29 computerised planimetry (reference standard) potentially had very good or excellent accuracy for
30 measurement of pressure ulcer surface area (very low quality).
- 31 • One study (n=20) reported that measuring the pressure ulcer surface area using tracing from
32 photo, digital table and computerised planimetry compared to direct transparency tracing, digital
33 table and computerised planimetry potentially had very good or excellent agreement for
34 measurement of pressure ulcer surface area (very low quality).
- 35 • One study (n= unknown, 37 pressure ulcers included) reported that measuring the pressure ulcer
36 surface area using slide photography, digitising tablet and computerised planimetry compared to
37 transparency tracing and digital planimetry potentially had very good or excellent agreement for
38 measurement of pressure ulcer surface area (very low quality).
- 39 • One study (n= unknown, 37 pressure ulcers included) reported that measuring the pressure ulcer
40 surface area using transparency tracing and digital planimetry compared to a Kundin device and
41 mathematical formula potentially had very good or excellent agreement for measurement of
42 pressure ulcer surface area (very low quality).
- 43 • One study (n= unknown, 37 pressure ulcers included) reported that measuring the pressure ulcer
44 surface area using tracing from slide photography, digitising tablet and computerised planimetry
45 compared to a Kundin device and mathematical formula potentially had very good or excellent
46 agreement for measurement of pressure ulcer surface area (very low quality).
- 47 • One study (n=20) reported that measuring the pressure ulcer surface area using elliptical area
48 (direct diameter measurement) compared to tracing and computerised planimetry potentially had

- 1 very good or excellent agreement for measurement of pressure ulcer surface area (very low
2 quality).
- 3 • One study (n=20) reported that measuring the pressure ulcer surface area using elliptical area
4 (direct diameter measurement) compared to photo and computerised planimetry potentially had
5 very good or excellent agreement for measurement of pressure ulcer surface area (very low
6 quality).
- 7 • One study (n=20) reported that measuring the pressure ulcer surface area using elliptical area
8 (direct diameter measurement) compared to elliptical area (diameters from tracing) and
9 mathematical formula potentially had very good or excellent agreement for measurement of
10 pressure ulcer surface area.
- 11 • One study (n=20) reported that measuring the pressure ulcer surface area using tracing and
12 computerised planimetry compared to elliptical area (diameters from tracing) potentially had very
13 good/excellent agreement for measurement of pressure ulcer surface area (very low quality).
- 14 • One study (n=20) reported that measuring the pressure ulcer surface area using elliptical area
15 (diameters from tracing) compared to tracing and computerised planimetry potentially had very
16 good or excellent agreement for measurement of pressure ulcer surface area (very low quality).
- 17 • One study (n=20) reported that measuring the pressure ulcer surface area using elliptical area
18 (diameters from photos) compared to photo and computerised planimetry potentially had very
19 good or excellent agreement for measurement of pressure ulcer surface area (very low quality).
- 20 • One study (n=11) reported that measuring the pressure ulcer volume using saline-gel injection
21 into wound cavity and subsequent measurement of volume required to fill cavity potentially had
22 very good or excellent intra-rater reliability of measurement of pressure ulcer volume (very low
23 quality).
- 24 • One study (n=11) reported that measuring the pressure ulcer volume using saline-gel injection
25 into wound cavity and subsequent measurement of volume required to fill cavity potentially had
26 fair or good inter-rater reliability of measurement of pressure ulcer volume (very low quality).
- 27 • One study (n=5) reported that measuring the pressure ulcer volume using sterile fluid injection
28 into wound cavity and subsequent measurement of volume required to fill cavity potentially had
29 very good or excellent inter-rater reliability of measurement of pressure ulcer volume (very low
30 quality).
- 31 • One study (n= unknown, 36 pressure ulcers included) reported that measuring the pressure ulcer
32 volume using stereophotogrammetry and computerised image analysis potentially had very good
33 or excellent inter-rater reliability of measurement of pressure ulcer volume (very low quality).
- 34 • One study (n=4) reported that measuring the pressure ulcer volume using alginate mold of wound
35 cavity with application of water displacement (reference standard) compared to NMR
36 spectroscopy potentially had very good or excellent accuracy of measurement of pressure ulcer
37 volume (very low quality).
- 38 • One study (n=20) reported that measuring the pressure ulcer volume using mathematical
39 adjustment applied to weight of alginate mold compared to spheroid volume from measuring
40 wound dimensions potentially had very good or excellent accuracy of measurement of pressure
41 ulcer volume (very low quality).

3.2.52 Economic (adults)

43 No relevant economic evaluations were identified.

3.2.53 Clinical (neonates, infants, children and young people)

45 No evidence was identified.

3.2.514 Economic (neonates, infants, children and young people)

2 No relevant economic evaluations were identified.

3.3 Recommendations and link to evidence

3.3.1 Adults

Recommendations	<ol style="list-style-type: none"> 1. Record and document the surface area of all pressure ulcers in adults. If possible, use a validated measurement technique (for example, transparency tracing or a photograph). 2. Document an estimate of the depth of all pressure ulcers and the presence of undermining, but do not routinely measure the volume of a pressure ulcer.
Relative values of different outcomes	<p>The GDG considered reliability and accuracy to be the most critical outcomes to inform decision-making on measuring the dimensions of a pressure ulcer..</p> <p>Other important outcomes included impact linked to healing/delayed healing, complications and severity. No data was identified on these outcomes.</p>
Trade-off between clinical benefits and harms	<p>The methods of pressure ulcer measurement that may be reliable included; measuring surface area with grid tracings from photographs combined with whole plus partial square count or a portable digital pad and stereophotogrammetry combined with computerised image analysis. There may be agreement between photographic tracing and direct transparency tracing (both combined with computerised planimetry). There were no conclusions made for diameter or depth. Evaluations of volume measurement were of poor quality and there was little data on feasibility. Most of the studies had problems in regards to methodology and/or statistical evaluation and thus it was hard to draw a conclusion on the best technique.</p> <p>It was agreed by the GDG that it was important to measure the surface area of a pressure ulcer, as this would allow the healthcare professional to confirm the progress of healing and reduction in the size of the pressure ulcer. It was felt that this was of particular importance to grade 3 to 4 pressure ulcers.</p> <p>The GDG therefore agreed that the surface area of all pressure ulcers should be measured, given that it was considered possible to obtain an accurate measurement, using straightforward and cost effective techniques (for example, transparent tracing or photographic planimetry). The GDG felt that obtaining and recording a quantitative assessment of healing and reduction in size was particularly important where care was being provided by multiple healthcare professionals, as this would allow for consistent reporting of changes in pressure ulcer size, and thus a reduction in healthcare professional subjectivity.</p> <p>Additionally, the GDG considered that the subsequent management approach offered may depend upon the results of surface area measurement. For example, additional management strategies may be needed for a person with a pressure ulcer that has increased in size.</p> <p>The group agreed that the technique chosen to measure the surface area should be carefully considered by the healthcare professional and may depend upon the site of the ulcer.</p>

	<p>The GDG did not consider the measurement of volume to be as relevant to the subsequent care provided and therefore, formal measurement of this was not recommended routinely. It was acknowledged that there were more difficulties in obtaining an accurate measurement of volume and the availability of equipment would mean that this would be difficult to achieve consistently across the NHS. However, the group felt that there were some circumstances in which the measurement of volume may be important (for example, where the presence of undermining is suspected) and therefore, a qualitative assessment of the volume of the wound to confirm healing and ulcer improvement may be useful to identify cases where formal measurement would be beneficial.</p> <p>The measurement of depth was not considered by the GDG to be helpful, given that the depth of a wound can vary considerably across a pressure ulcer and measurement of ulcer volume should be conducted in situations where this is considered necessary.</p> <p>The GDG did not consider there to be an advantage of a particular measurement technique, though it was acknowledged that there was some potential harms relating to the use of some methods of measurement. The group agreed that there may be infection control issues relating to the use of saline to obtain a measurement of pressure ulcer volume. The GDG also highlighted possible issues with patient tolerability in using a probe to ascertain pressure ulcer depth.</p> <p>Photographic techniques were considered to provide a method of measurement which did not require contact with the wound which may be more tolerable for the individual, although it was acknowledged that there were limitations to this technique as it was not possible to identify any undermining.</p>
<p>Economic considerations</p>	<p>No economic studies were identified that answered the review question.</p> <p>It was acknowledged that there may be economic implications of documenting the surface area of pressure ulcers, especially if photographic techniques are used. However the GDG felt that doing so was an important part of pressure ulcer management, and would lead to a more efficient allocation of resources, as the progress of a pressure ulcer could be accurately monitored, and management strategies allocated accordingly. The GDG therefore agreed that, when taking into account future savings and improvements in quality of life due to improved healing, the initial cost would be justified, provided that a straightforward technique could be used. Such documentation is considered current best practice, and as such, this recommendation is not expected to have a large impact on resource. In some studies highly specialised measurements were used. These were likely to be costly and unavailable within routine practise except within the research field and so are not recommended.</p> <p>Finally, the GDG did not think it would be cost-effective to routinely measure the volume of a pressure ulcer. The group agreed that this would have a larger impact on resources and would provide little benefit over a qualitative assessment undertaken at the time of surface area measurement.</p>
<p>Quality of evidence</p>	<p>Overall, the quality of the evidence was very low. Only the outcomes accuracy and reliability were reported.</p> <p>The GDG did not feel that the study by Buntinx used appropriate statistical analysis and therefore the results of this study should not be considered.</p> <p>The group also noted that it was not always appropriate to use the Pearson's</p>

	correlation as a measure of accuracy.
Other considerations	Photographic techniques for the measurement of pressure ulcers may present data confidentiality considerations relating to the production and storage of digital images.

3.3.12 Neonates, infants, children and young people

Recommendations	<p>3. Record and document the surface area of all pressure ulcers in neonates, infants, children and young people, preferably using a validated measurement technique (for example, transparency tracing or a photograph).</p> <p>4. Document an estimate of the depth of a pressure ulcer and the presence of undermining, but do not routinely measure the volume of a pressure ulcer in neonates, infants, children and young people.</p>
Relative values of different outcomes	<p>The GDG considered reliability and accuracy to be the most critical outcomes for making a decision on the most reliable and accurate tool to measure the dimension of a pressure ulcers.</p> <p>Other important outcomes included impact linked to healing/delayed healing, complications and severity. No data was identified on these outcomes.</p>
Trade-off between clinical benefits and harms	<p>The GDG used 3 statements from the Delphi consensus survey to develop the recommendations: 'Healthcare professionals should formally document the surface area of a pressure ulcer in neonates, infants, children and young people, using a validated quantitative technique such as planimetry.', 'Healthcare professionals should undertake a qualitative assessment of the depth and volume of pressure ulcers in neonates, infants, children and young people' and 'Healthcare professionals should not formally measure the depth and volume of a pressure ulcer in neonates, infants, children and young people.' The 2 former statements were agreed in Round 1 of the Delphi consensus survey and a recommendation was subsequently agreed to highlight the need to document surface area of the pressure ulcer, using validated techniques. The GDG felt that transparency tracing and photography were the methods of measuring the surface area of a pressure ulcer that were likely to be readily available to the greatest number of healthcare professionals and were not likely to be overly time consuming. The GDG emphasised the need to ensure that the results were documented so that the progress of the pressure ulcer could be easily assessed, particularly where care was being delivered by a team.</p> <p>The latter statement was amended and included in Round 2. The GDG discussed the statements on formal measurement and qualitative assessment of pressure ulcer depth and volume. Comments received during Round 1 suggested that there were benefits to the healthcare professional in knowing the depth and volume of a pressure ulcer. However there was disagreement as to which was the best method to do so. The GDG therefore agreed that the 2 statements would be merged into a single statement to reflect that an estimate of depth and volume was likely to be the most appropriate means of measuring a pressure ulcer. The statement 'Healthcare professionals should document an estimate of the depth and volume of a pressure ulcer in neonates, infants, children and young people.' was therefore included in Round 2, where it was agreed at the pre-defined consensus agreement level.</p> <p>The GDG discussed this statement and agreed that the volume of a pressure ulcer should not be routinely measured using formal methods, as the resource implications of carrying out this measurement were likely to be significant. Additionally, the GDG were not aware of any benefits to formally measure the</p>

	<p>volume of a pressure ulcer that could not be gained from an estimate. Additionally, the GDG noted that some methods used for measuring volume may be harmful to the person who has a pressure ulcer and can cause pain and discomfort, particularly in neonates, infants, children and young people. However, in line with the statement included in Round 2 of the survey, it was agreed that an estimate of volume may be useful information to note and that this should be documented in the notes. The GDG highlighted that it was also important to note the presence of any undermining, as this would not be information documented in formal measurement of ulcer surface area.</p>
Economic considerations	<p>It was acknowledged that there may be economic implications of documenting the surface area of pressure ulcers, especially if photographic techniques are used. However, the GDG felt that doing so was an important aspect of pressure ulcer management, and would lead to a more efficient allocation of resources, as the progress of a pressure ulcer could be accurately monitored, and management strategies allocated accordingly. The GDG therefore agreed that, when taking into account future savings and improvements in quality of life due to improved healing, the initial cost would be justified, provided that a straightforward technique could be used. Such documentation is considered current best practice, and as such, this recommendation is not expected to have a large impact on resource.</p> <p>Finally, the GDG did not think it would be cost-effective to routinely measure the volume of a pressure ulcer. The group agreed that this would have a larger impact on resources and would provide little benefit over a qualitative assessment undertaken at the time of surface area measurement.</p>
Quality of evidence	<p>No RCTs or cohort studies were identified for neonates, infants, children or young people. Formal consensus using a modified Delphi was therefore used to develop the recommendation.</p> <p>To inform the recommendation, the GDG used 3 statements which were included in Round 1 of the Delphi consensus survey and reached 75%, 71% and 16% consensus agreement. The latter statement was therefore included in Round 2 of the survey, where it reached 86% consensus agreement.</p> <p>Further details can be found in Appendix N.</p>
Other considerations	<p>The GDG noted that other validated methods of measuring pressure ulcers were available, for example, planimetry.</p> <p>The GDG highlighted that it was possible for an ulcer to increase in size during the course of healing.</p>

4 Categorisation of pressure ulcers

4.1 Introduction

3 Several classification systems for categorising the severity of pressure ulcers have been proposed
4 over the years. Early systems were for generally developed for research or audit purposes but
5 present systems are now used within normal clinical practice as part of the provision of care, local
6 and national prevention policies and clinical audit. Systems used a variety of terms to classify the
7 pressure ulcer, most commonly 'category', 'stage' or 'grade'. Generally, the higher the grade of ulcer,
8 the more severe it is considered. Although systems were originally developed to help healthcare
9 professionals to identify the depth of tissue damage in each pressure ulcer but their use has allowed
10 for healthcare professionals to communicate and plan the care of an individual.

11 As part of producing a consistent system, the NPUAP and EPUAP developed a common international
12 definition and classification system for pressure ulcers (European Pressure Ulcer Advisory Panel and
13 National Pressure Ulcer Advisory Panel. Treatment of pressure ulcers: Quick Reference Guide.
14 Washington DC: National Pressure Ulcer Advisory Panel; 2009¹³²) and this is embedded within clinical
15 practice for by many healthcare professionals.

16 The GDG were therefore interested in identifying the most effective method means of categorising
17 different types of pressure ulcers, using a variety of tools.

4.2 Review question: What is the best method of categorising different types of pressure ulcers?

19
20 For full details see review protocol in Appendix C.

4.2.1 Clinical evidence (adults)

22 Twenty three studies were included that met the protocol criteria for this clinical question. Nineteen
23 studies^{9,20-22,33,34,52,53,60,88,97,109,137,139,164,167,201,203 76} evaluated only 1 tool per study, but 4^{78,150,163,210}
24 evaluated 2 or more tools. The studies evaluating multiple tools provide the most valid comparison
25 between different tools, as confounding is more likely if different tools are compared across the
26 different contexts of different studies. However results from studies evaluating only 1 tool have also
27 been included, as a crude comparison of different tools between studies is still possible. Twelve
28 studies used photographs of pressure ulcers, and 11 used real participants (Table 9) for
29 measurement of reliability and accuracy. Results for these have been presented together, but the
30 use of photographs or real participants is clearly indicated, as this may have influenced results. These
31 articles, and important definitions, are summarised in Table 9 to Table 13. Quality of outcomes is
32 summarised in tables Table 22 and Table 23.

33

Summary of included studies

Table 9: Summary of studies included in the review

Study	Photographs (n)/patients (n)	Evaluators	Instruments	Outcomes
Pedley 2004 ¹⁵⁰	Patients (n=30)	2 nurses from UK	EPAP and 2 digit Stirling	• Inter-rater reliability
Schoonhaven 2007 ¹⁶⁷	Patients (n=128)	2 nurses from Holland	EPUAP	• Inter-rater reliability
Feuchtinger 2006 ⁶⁰	Patients (n=90)	Clinical staff and research nurses (n unclear)	EPUAP	• Inter-rater reliability
Vanderwee 2007A ²⁰³	Patients (n=unclear)	1870 nurses from Belgium	EPUAP	• Inter-rater reliability/accuracy
Kottner 2009 ⁹⁷	Patients from care homes in Holland (n=684)	Number not stated. First evaluation by trained nurses. Second evaluation by specialist wound management nurses	EPUAP	• Inter-rater reliability
Vanderwee 2007 ²⁰¹	Patients (n=225)	'Local co-ordinator' and 'team of nurses'. Number unknown	EPUAP	• Inter-rater reliability
Beeckman 2007 ²¹	Photographs (n=20)	1452 nurses from Belgium, Netherlands, UK, Sweden and Portugal.	EPUAP	• Accuracy
Beeckman 2008 ²⁰	Photographs (n=20)	426 nurses from Belgium	EPUAP	• Accuracy
Beeckman 2010 ²²	Photographs (n=20)	1217 Belgian, Dutch, British and Portuguese nurses	EPUAP	• Accuracy
Kelly 2011 ⁸⁸	Photographs (n=3)	93 nurses in Norfolk	EPUAP	• Accuracy
Sarhan 2010 ¹⁶⁴	Photographs (n=50)	10 nurses at a National Spinal Injury Centre.	EPUAP	• Accuracy

Study	Photographs (n)/patients (n)	Evaluators	Instruments	Outcomes
Defloor 2006 ⁵²	Photographs (n=56)	559 nurses	EPUAP	<ul style="list-style-type: none"> • Sequential intra-rater reliability • Concurrent intra-rater reliability • Accuracy
Defloor and Schoonhaven 2004 ⁵³	Photographs (n=56)	44 pressure ulcer experts from Belgium	EPUAP	<ul style="list-style-type: none"> • Inter-rater reliability • Accuracy
Nixon 2005A ¹³⁹	Patients (n=2646)	120: 1 lead research nurse, 410 research nurse and 109 ward nurses	Modified EPUAP scale	<ul style="list-style-type: none"> • Accuracy
Marrie 2003 ¹⁰⁹	Patients with pressure ulcers (n=46)	Unclear, possibly 2.	NPUAP	<ul style="list-style-type: none"> • Inter-rater agreement
Buckley 2005 ³³	Photographs (n=10)	33 home health nurses	NPUAP	<ul style="list-style-type: none"> • Accuracy
Hart 2010 ⁷⁶	Photographs (n=18)	256 staff nurses and wound/skin care nurses	NPUAP	<ul style="list-style-type: none"> • Inter-rater reliability
Alvey 2012 ⁹	Photographs (n=5)	31 student and qualified nurses	NPUAP, with computerised clinical decision support	<ul style="list-style-type: none"> • Accuracy
Buntinx 1996 ³⁴	Patients (n=20)	3 physicians and 3 nurses from Belgium	Shea	<ul style="list-style-type: none"> • Inter-rater reliability
Russell 2001 ¹⁶³	Photographs (n=12)	97 nurses – 27 clinical nurse specialists, 21 pressure ulcer advisory panel members, 25 acute nurses and 24 community nurses.	Stirling EPUAP	<ul style="list-style-type: none"> • Accuracy • Precision
Healey 1995 ⁷⁸	Photographs (n=10)	109 nurses	Stirling scale Torrance scale Surrey scale	<ul style="list-style-type: none"> • Inter-rater reliability • Ease of use
Nixon 1998 ¹³⁷	Patients (n=unclear)	94 nurses from UK	Torrance	<ul style="list-style-type: none"> • Inter-rater reliability
Yarkony 1990 ²¹⁰	Patients with pressure	10 registered	Yarkony-kirk	<ul style="list-style-type: none"> • Inter-rater 'correlation'

Study	Photographs (n)/patients (n)	Evaluators	Instruments	Outcomes
	ulcers (unclear) (n=10)	rehabilitation nurses	Shea	<ul style="list-style-type: none"> • Inter-rater 'agreement'

Table 10: Definitions of outcome measures used in this review

Outcome	Definition
Concurrent intra-rater reliability	Do 2 assessments performed by the same investigator during the same testing session produce the same result?
Sequential intra-rater reliability	Do 2 assessments performed by the same investigator during 2 testing sessions at different times produce the same result?
Inter-rater reliability	Do 2 or more different investigators achieve the same result?
Accuracy	The closeness of computations or estimates to the exact or true values (decided by an expert panel).

Table 11: Details of statistical measures used in this review

Heading	
Intraclass Correlation Coefficient	A measure of the inter-rater reliability for 2 or more raters. May also be used to assess test-retest reliability. Conceptualised as ratio of between-groups variance to total variance.
Kappa Coefficient	A measure of non-random agreement between observers or measurements of the same categorical variable
Spearman's Correlation Coefficient	A measure of the linear relationship between 2 categorical variables in a sample and used as an estimate of the correlation in the whole population.

Table 12: Glossary of instruments for categorising pressure ulcers

Instrument	Grading/staging details
NPUAP 1989	<p>Grade 1: non-blanchable erythema of intact skin, the heralding lesion of pressure ulceration</p> <p>Grade 2: Partial thickness skin loss involving epidermis, dermis or both. The ulcer is superficial and presents clinically as an abrasion, blister or shallow crater</p> <p>Grade 3: Full thickness skin loss involving damage or necrosis to subcutaneous tissue that may extend down to, but not through, underlying fascia. The ulcer presents clinically as a deep crater, with or without undermining of adjacent tissue</p> <p>Grade 4: Full-thickness skin loss with extensive destruction, tissue necrosis, or damage to muscle bone or supporting structures (for example, joint capsule).</p>
EPUAP 1989	<p>Grade 1: non-blanchable erythema of intact skin. Discolouration of the skin, warmth, oedema, induration or hardness may also be used as indicators, particularly in individuals with darker skin.</p> <p>Grade 2: Partial thickness skin loss involving epidermis, dermis or both. The ulcer is superficial and presents clinically as an abrasion or blister</p> <p>Grade 3: Full thickness skin loss involving damage to or necrosis of subcutaneous tissue that may extend down to, but not through, underlying fascia.</p> <p>Grade 4: Extensive destruction, tissue necrosis, or damage to muscle, bone or supporting structures with or without full thickness skin loss</p>
<p>NPUAP/EPUAP 2009</p> <p>[European Pressure Ulcer Advisory Panel and National Pressure Ulcer Advisory Panel. Treatment of pressure ulcers: Quick Reference Guide. Washington DC: National Pressure Ulcer Advisory Panel; 2009]</p>	<p>Category/Stage 1: Non-blanchable redness of intact skin Intact skin with non-blanchable erythema of a localized area usually over a bony prominence. Discoloration of the skin, warmth, oedema, hardness or pain may also be present. Darkly pigmented skin may not have visible blanching. Further description: The area may be painful, firm, soft, warmer or cooler as compared to adjacent tissue. Category/Stage I may be difficult to detect in individuals with dark skin tones. May indicate “at risk” persons.</p> <p>Category/Stage 2: Partial thickness skin loss or blister Partial thickness loss of dermis presenting as a shallow open ulcer with a red pink wound bed, without slough. May also present as an intact or open/ruptured serum-filled or sero-sanguinous filled blister. Further description: Presents as a shiny or dry shallow ulcer without slough or bruising. This category/stage should not be used to describe skin tears, tape burns, incontinence associated dermatitis, maceration or excoriation.</p> <p>Category/Stage 3: Full thickness skin loss (fat visible) Full thickness tissue loss. Subcutaneous fat may be visible but bone, tendon or muscle are <i>not</i> exposed. Some slough may be present. <i>May</i> include undermining and tunnelling.</p> <p>Further description: The depth of a Category/Stage III pressure ulcer varies by anatomical location. The bridge of the nose, ear, occiput and malleolus do not have (adipose) subcutaneous tissue and Category/Stage III ulcers can be shallow. In contrast, areas of significant adiposity can develop extremely deep Category/Stage III pressure ulcers. Bone/tendon is not visible or</p>

Instrument	Grading/staging details
	<p>directly palpable.</p> <p>Category/Stage 4: Full thickness tissue loss (muscle/bone visible)</p> <p>Full thickness tissue loss with exposed bone, tendon or muscle. Slough or eschar may be present. Often include undermining and tunneling. Further description: The depth of a Category/Stage IV pressure ulcer varies by anatomical location. The bridge of the nose, ear, occiput and malleolus do not have (adipose) subcutaneous tissue and these ulcers can be shallow. Category/Stage IV ulcers can extend into muscle and/or supporting structures (for example, fascia, tendon or joint capsule) making osteomyelitis or osteitis likely to occur. Exposed bone/muscle is visible or directly palpable.</p>
<p>Torrance [Healey F. The reliability and utility of pressure sore grading scales. Journal of Tissue Viability. 1995; 5: 111-114]</p>	<ol style="list-style-type: none"> 1. Blanching hyperaemia 2. Non blanching hyperaemia 3. Ulceration progresses through the dermis only 4. Lesion extends into the subcutaneous fat 5. Infective necrosis penetrates the deep fascia
<p>Stirling [Healey F. The reliability and utility of pressure sore grading scales. Journal of Tissue Viability. 1995; 5: 111-114]</p>	<ol style="list-style-type: none"> 0. Normal appearance, intact skin 0.1 Healed with scarring 0.2 Tissue damage but not assessed as a pressure sore <ol style="list-style-type: none"> 1.1 Non blanchable erythema with increased localised heat 1.2 Blue/purple/black discolouration 2.1 blister 2.2 Abrasion 2.3 shallow ulcer without undermining of adjacent tissue 2.4 Any of these with blue/purple/black discolouration or induration 3.1 Crater, without undermining of adjacent tissue 3.2 Crater, with undermining of adjacent tissue 3.3 Sinus, the full extent of which is uncertain 3.4 Full thickness skin loss, but wound bed is covered with necrotic tissue which masks the true extent of tissue damage 4.1 Visible exposure of bone, tendon or capsule 4.2 Sinus assessed as extending to bone, tendon or capsule
<p>Yakony-Kirk [Yarkony GM et al. Classification of pressure ulcers. Arch Dermatol 1990]</p>	<ol style="list-style-type: none"> 1. Red area. Present longer than 30 minutes, but less than 24 hours OR present longer than 24 hours 2. Epidermis and/or dermis ulcerated with no subcutaneous fat observed

Instrument	Grading/staging details
126; 1218-1219]	<ol style="list-style-type: none"> 3. Subcutaneous fat observed, no muscle observed 4. Muscle/fascia observed, but no bone observed 5. Bone observed, but no involvement of joint space 6. Involvement of joint space
Shea [Shea JD. Pressure sores: classification and management. Clin Orthop. Relat. Res. 1975; 112: 89-100]	<ol style="list-style-type: none"> 1. Limited to epidermis, exposing dermis 2. Full thickness of dermis to junction of subcutaneous fat 3. Fat obliterated, limited by deep fascia undermining of skin 4. Bone at the base of ulceration 5. Closed large cavity through a small sinus

Table 13: Categorisation of values into levels of acceptability

Agreement (reliability and accuracy)	Excellent	Good	Fair	Poor
Intra class coefficient (ICC) ^a	0.75+	0.60 to 0.74	0.40 to 0.59	<0.40
Kappa coefficient ^b	0.75+	0.60 to 0.74	0.40 to 0.59	<0.40

(a) Fleiss, J. L. (1981) *Statistical methods for rates and proportions*. 2nd ed. (New York: John Wiley) pp. 38–46

(b) Orwin RG. *Evaluating coding decisions*. In: Cooper H, Hedges LV (editors). *The Handbook of Research Synthesis*. New York (NY): Russell Sage Foundation, 1994.

4.2.12 Clinical evidence for studies assessing more than 1 tool

- 2 Quality of evidence was generally considered low quality, but where high quality evidence was
3 identified it has been highlighted in the following summary.
- 4 Yarkony²¹⁰ showed the Yarkony-Kirk scale had superior inter-rater reliability to the Shea scale¹⁷³
5 within the samples studied. However, the lack of variance data made it impossible to make
6 inferences to the population (Table 14).
- 7 Healey⁷⁸ showed that the Torrance scale¹⁹⁴ had better inter-rater reliability than the 2 digit Stirling
8 scale in the studied sample, but population inferences were again not possible. Importantly, both
9 tools' kappa readings were classified as 'poor' (Table 15). The Stirling also appeared to be more
10 difficult to use.
- 11 In a study with high quality outcomes, Russell and Reynolds¹⁶³ compared the EPUAP with 2 digit
12 Stirling, using continuous measures for 'accuracy' and 'precision' (Table 16). The former was the
13 absolute mean of all positive and negative deviations from the gold standard, whilst the latter was
14 the absolute mean of all absolute departures from the gold standard. The 2 digit Stirling tool was
15 significantly better for both outcomes (accuracy mean difference: 0.1 better for Stirling (95% CIs 0.04
16 to 0.17); precision mean difference: 0.13 better for Stirling (95% CIs: 0.09 to 0.17); see forest plots in
17 Appendix I).
- 18 In another study with high quality outcomes, Pedley¹⁵⁰ also compared the EPUAP with 2 digit Stirling,
19 in terms of inter-rater reliability (Table 19). Although the EUAP had greater reliability in terms of the
20 sample values, with Stirling classified as 'fair' and EPUAP as 'poor', population inferences were not
21 possible due to the lack of variance data.
- 22 Overall, despite the fact that most evidence only existed as point estimates, the Yarkony-Kirk scale
23 seemed superior to the Shea scale. The Torrance appeared superior to Stirling, whilst the Stirling
24 scale appeared superior to the EPUAP. Note that because of different populations in different
25 studies, it is not possible to use indirect treatment comparisons to conclude that the Torrance scale
26 was also superior to the EPUAP.

4.2.2.1 Evidence summaries

Table 14: Yarkony-kirk versus Shea

Study	Statistical measure	Yarkony-kirk	Shea	n	Comments	Quality
Inter-rater reliability						
Yarkony et al. 1990 ²¹⁰	% agreement of staging. This represented the number of pairwise assessments that agreed on staging level.	85%	68%	Unclear. 10 registered rehabilitation nurses staging 72 pressure ulcers on unknown number of participants. Only 2 pair of raters assessed each pressure ulcer but unclear how the pairs were allocated.	PATIENT STUDY Standard correlation methods unsuitable for assessing reliability, as possible for measures to be perfectly correlated but not agree. Unclear how the 10 nurses made up the testing pairs. Potential for bias as 1 testing technique may have had pairs who were randomly similar and the other tool may have had pairs who were not. Only by ensuring the same pairs were used across tools can we have a useful comparison. Nurses trained and experienced with Shea, but not Yarkony.	Low

Table 15: Torrance versus 2 digit Stirling

Study	Statistical measure	Torrance	2 digit Stirling	n	Comments	Quality
Inter-rater reliability						
Healey 1995 ⁷⁸	Cohen's kappa for inter-rater reliability	0.29	0.15	37 nurses graded 10* photos using Torrance; Another independent sample of 37 nurses graded the same 10* photos using 2 digit Stirling. Agreement across all raters per picture calculated for each scale, and then overall value for all photos derived for each	PHOTOGRAPHIC STUDY Unclear how groups were allocated, so possibility of bias – for example, through 1 group of raters being more homogenous than the other.	Low

Study	Statistical measure	Torrance	2 digit Stirling	n	Comments	Quality
				scale. *due to technical error some raters only graded 6 photos		
Ease of use						
Healey 1995 ⁷⁸	Descriptive	16% found it easy to use, 35% found it difficult to use	11% found it easy to use, 57% found it difficult to use	As above	As above	NA

Table 16: EPUAP versus Stirling

Study	Statistical measure	EPUAP	Stirling	n	Comments	Quality
Accuracy (lower value indicates better accuracy)						
Russell 2001 ¹⁶³	Absolute mean of all interval <u>positive and negative</u> differences from gold standard (decided by expert consensus)	Absolute Mean(sd) [n] 0.15(0.21)[86]	Absolute Mean(sd) [n] 0.045 ^a (0.21)[85]	97 nurses graded 12 photos using both scaling systems.	PHOTOGRAPHIC STUDY Assuming an interval scale for such an ordinal measure may be invalid. Wide range of expertise, including 27 clinical nurse specialists, 21 pressure ulcer advisory panel members, 25 acute nurses and 24 community nurses.	High
Precision (lower value indicates better precision)						
Russell 2001 ¹⁶³	Mean of all interval <u>absolute</u> differences from gold standard (that is all taken as positive) (decided by expert consensus)	Mean(sd) [n] 0.49(0.15)[86]	Mean(sd) [n] 0.36(0.15)[85]	As above	As above	High

Study	Statistical measure	EPUAP	Stirling	n	Comments	Quality
Inter-rater reliability (higher better)						
Pedley 2004 ¹⁵⁰	Cohen's kappa for inter-rater reliability	0.308	0.475	2 nurses evaluated 35 PUs in 30 people.	PATIENT STUDY Both nurses familiar with both testing scales. Low number of included nurses means we cannot be certain these results are representative of all nurses.	High

(a) The reported figure in the paper was -0.045. However, to calculate the mean difference this value was converted to an absolute value. Although it was important to include positive and negative values to derive this accuracy value, which allows for cancellation of positive and negative differences from the gold standard provided there is no systematic bias to negative or positive, the sign of the final mean was not important (and indeed would be misleading as we are simply interested in the absolute discrepancy from zero - just as an archer would be interested in a 1cm distance from the bullseye, not whether it was 1cm north or 1cm south).

4.2.2.2 Clinical evidence for studies assessing 1 tool

4.2.2.2.1 NPUAP

Two studies with low quality outcomes evaluated the inter-rater reliability of the NPUAP(1989) scale, with Marrie¹⁰⁹ demonstrating excellent reliability and Hart⁷⁶ showing fair reliability (Table 17).

In terms of accuracy, Buckley³³ showed a moderate agreement of 67.8% for home health nurses compared to a gold standard (Table 17), using a high quality methodology.

4.2.2.2.2 EPUAP

The EPUAP(1989) has been extensively studied (Table 18). Defloor⁵² showed 'poor' concurrent and 'fair' sequential intra-rater reliability, but inter-rater reliability appears to be in the 'excellent' category^{53,60,167,201,203}. However all these reliability studies were of low quality.

Accuracy appears to range from 'poor' in terms of kappa values^{20,21} to very high agreement percentages in other studies⁵³. It is difficult to account for these accuracy differences in terms of the characteristics of the assessors, or the use of photographs or patients, but the higher quality of methodology in the 2 former studies compared to the latter suggests this may be an important factor explaining the varying results.

4.2.2.2.3 EPUAP/NPUAP (2009)

The EPUAP/NPUAP (2009) scale has shown good inter-rater reliability in terms of very high % agreement in a low quality study⁹⁷ (Table 19).

However its accuracy appears 'moderate'⁸⁸ in terms of kappa, and % agreement figures appear modest^{9,164}. Of these accuracy studies, only Sarhan¹⁶⁴ was high quality.

4.2.2.2.4 Torrance

A low quality study showed the Torrance scale has good inter-rater reliability in terms of % agreement¹³⁷ (Table 20).

4.2.2.2.5 Shea

A study with high quality methodology³⁴ showed the Shea scale appears to have only 'fair' inter-rater reliability in terms of kappa (Table 21).

4.2.2.3 Summary

In conclusion, inter-rater reliability appears good throughout the various tools that have been studied singly, with perhaps the EPUAP having the most favourable results. Overall, accuracy appears less impressive, and this is uniform across tools.

4.2.2.4 Evidence summaries

Table 17: NPUAP 1989

Study	Statistical measure	NPUAP 1989	n	Comments	Quality (see tables 15 and 16).
Inter-rater reliability					
Marrie 2003 ¹⁰⁹	ICC	0.91 (no variance measure supplied)	Unclear but probably 2 assessors each graded ulcers in 46 participants.	PATIENT STUDY Poor description of assessors.	Low
Inter-rater reliability					
Hart 2006 ⁷⁶	Kappa	0.56 (sd: 0.17)	256 staff nurses and wound/skin care nurses looked at 18 photographs of pressure ulcers and assigned a stage of pressure ulcer to them.	PHOTOGRAPHIC STUDY Highly trained raters, so may lack external validity. Provided photos with and without an accompanying verbal description, but only results pertaining to no verbal description given here. WOC certification was a factor improving inter-rater reliability: kappa was 0.66(SE 0.04) for certified versus 0.54 (SE 0.03) for non-certified nurses.	Low
Accuracy					
Buckley 2005 ³³	% accuracy (percentage of raters agreeing with gold standard)	Mean across all 5 pressure ulcer photos: 67.8% Photo 1 of stage IV: 39%	33 home health nurses looked at the 5 pressure ulcer photos. They then assigned a stage of pressure ulcer to them.	PHOTOGRAPHIC STUDY During viewing nurses were given a brief case history, read aloud. This	High

Study	Statistical measure	NPUAP 1989	n	Comments	Quality (see tables 15 and 16).
	for each photo. Gold standard decided by expert consensus)	Photo 2 if stage IV: 100% Photo of stage II: 82% Photo of PU covered with necrotic tissue: 82% Photo of PU covered with eschar: 88%		may have enhanced accuracy and thus reduced external validity.	

Table 18: EPUAP 1989

Study	Statistical measure	EPUAP 1989	n	Comments	Quality
Concurrent intra-rater reliability					
Defloor 2006 ⁵²	Kappa	0.38 (95% CIs: 0.26-0.50)	473 nurses looked at 65 photos of pressure ulcers in 1 sitting and assigned a stage of pressure ulcer to them. There were 9 pairs of identical photos within the pack of 65, and it was on the agreement of the stage of pressure ulcer across these 9 pairs during the same session from which the concurrent intra-rater reliability measure was derived.	PHOTOGRAPHIC STUDY The 473 nurses were participating in a wound care conference, reducing external validity.	Low
Sequential intra-rater reliability					
Defloor 2006 ⁵²	Kappa	0.52 (95% CIs: 0.50-0.55)	86 different nurses looked at 56 photos (no duplicates) twice with an interval of 1 month and assigned a stage of pressure ulcer to them. Agreement of the stage of	PHOTOGRAPHIC STUDY Expertise of these 86 nurses not clearly described.	Low

Study	Statistical measure	EPUAP 1989	n	Comments	Quality
			pressure ulcer across all 56 photos across both sessions yielded the sequential intra-rater reliability measure.		
Inter-rater reliability					
Schoonhaven 2007 ¹⁶⁷	Kappa for inter-rater reliability	0.96	2 nurses looked at 128 people and assigned a stage of pressure ulcer to them.	PATIENT STUDY These were expert assessors and so results may lack external validity. Very poorly reported.	Low
Inter-rater reliability					
Vanderwee 2007 ²⁰¹	Spearman's rho	0.96 (p<0.001)	Unknown number of nurses and 'local co-ordinator' evaluated 225 people.	PATIENT STUDY Poor reporting of evaluators. Inappropriate measure of reliability.	Low
Inter-rater reliability					
Vanderwee 2007A ²⁰³	Kappa for inter-rater reliability	Researcher against nursing staff: 0.88 (95% CIs: 0.85-0.91) Study nurse against nursing staff: 0.89 (95% CIs: 0.87-0.92)	1868 nursing staff, 1 researcher and 1 study nurse assessed unknown number of people.	PATIENT STUDY The reliability was not between the different nurses but instead between each nurse and the researcher and/or study nurse. Hence this may be more of an accuracy than reliability study.	Low
Inter-rater reliability					
Defloor and Schoonhoven 2004	Linear weighted kappa	Inter-rater reliability linear weighted kappa between all 44	44 nursing staff looked at 56 photos and assigned a stage of	PHOTOGRAPHIC STUDY	Low

Study	Statistical measure	EPUAP 1989	n	Comments	Quality
		experts (<u>excluding</u> grading of incontinence lesions): 0.78-0.79 (researchers 0.79, staff nurses 0.78, pressure ulcer nurses 0.79)	pressure ulcer to them.	Raters described as 'experts' which may reduce external validity.	
Inter-rater reliability					
Feuchtinger 2006 ⁶⁰	% agreement	Overall agreement between raters: 97.7% (767/990)	Unknown number of clinical staff and research nurses carried out 90 pairwise assessments in 90 people (with multiple pressure ulcer sites).	PATIENT STUDY Very unclear reporting of assessors.	Low
Accuracy					
Defloor 2006 ²⁰²	Kappa. Compared to gold standard derived from expert consensus.	0.50 (95% CIs: 0.49-0.52)	473 nurses looked at 56 photographs and assigned a stage of pressure ulcer to them and the agreement with the gold standard was evaluated.	PHOTOGRAPHIC STUDY The 473 nurses were participating in a wound care conference, reducing external validity. Accuracy also measured in the same way with the other cohort of 86 nurses, but results very similar so not reported.	High
Accuracy					
Nixon 2005 ¹³⁹	% agreement on pressure ulcer	Overall: 78.8% (1888/2396 stagings agreed with gold standard)	Number of people not reported. Six research nurses	PATIENT STUDY	High

Study	Statistical measure	EPUAP 1989	n	Comments	Quality
	gradings done by 109 nurses against a gold standard (6 research nurses).	<u>Break down of different sites:</u> Sacrum: 76% Left buttock: 75% Right buttock: 75% Right hip: 94% Left hip: 95% Left heel: 69% Right heel: 71%	each undertook simultaneous (but independent) staging measurements with the same 109 nurses on different patients (looking at up to 4 pressure ulcer sites on each individual).	This was designated an inter-rater reliability analysis by the study authors, but because the 109 nurses are being compared to the 6 research nurses, who, in a previous analysis had excellent agreement (105/107 grade agreed) this analysis has been designated an accuracy analysis in this review.	
Accuracy					
Beeckman 2007 ²¹	Kappa. Compared to gold standard derived from expert consensus (12 trustees from the EPUAP).	Median (IQR) kappa: 0.29 (0.14-0.47).	1452 nurses looked at 20 photographs and assigned a stage of pressure ulcer to them. These were compared to gold standard stagings.	PHOTOGRAPHIC STUDY Accuracy increased by expertise: Chi square 36.2 (p<0.001) Best for 'expert', [kappa 0.47(0.32-0.56)] lowest for 'limited' [kappa 0.25 (0.089-0.38)].	High
Accuracy					
Beeckman 2008 ²⁰	Kappa. Compared to gold standard derived from expert consensus (12 trustees from	Overall median (IQR) kappa: 0.24	426 nurses looked at 20 photographs and assigned a stage of pressure ulcer to them. These were compared to gold standard stagings.	PHOTOGRAPHIC STUDY Analysis included ulcers that were not PUs. Not possible to extricate	High

Study	Statistical measure	EPUAP 1989	n	Comments	Quality
	the PUCLAS workgroup).		<u>Specific grade % agreement</u> Normal skin: 92.9% Blanchable erythema: 68.7% Grade 1: 38.2% Grade 2: 29.1% Grade 3: 24.6% Grade4: 47.9%	them from overall result, but individual pressure ulcer accuracy ratings given. No clear effect for accuracy to depend on qualification: student nurses had kappa of 0.19-0.23* compared to 0.25-0.30* for qualified nurses. *2 values given as these were baseline values in an RCT (post-intervention results not relevant and so not reported).	
Accuracy					
Beeckman 2010 ²²	% agreement. Compared to gold standard derived from expert consensus (12 trustees from the EPUAP).	50.0% (8266/16520 stagings accurate).	1217 nurses looked at 20 photographs and assigned a stage of pressure ulcer to them, which were compared to gold standard stagings.	PHOTOGRAPHIC STUDY Article results included non-pressure ulcers. Results on left are those with these non-pressure ulcer data removed by systematic reviewer. Some nurse attending a wound care conference so this may have reduced external validity.	High

Study	Statistical measure	EPUAP 1989	n	Comments	Quality
Accuracy					
Defloor and Schoonhoven 2004 ⁵³	% agreement with gold standard provided by 9 EPUAP trustees	Accuracy for: normal skin 99.4% blanchable erythema 95.3% non-blanchable erythema 96.1% blister 86.8% superficial pressure ulcers 94.5% deep pressure ulcers 95.2% Overall: 94.55%	44 pressure ulcer 'experts' looked at 56 photographs and assigned a stage of pressure ulcer to them, which were compared to gold standard stagings.	PHOTOGRAPHIC STUDY Raters described as 'experts' which may reduce external validity.	Low

Table 19: EPUAP/NPUAP 2009

Study	Statistical measure	EPUAP/ NPUAP 2009	n	Comments	Quality
Accuracy					
Alvey 2012 ⁹	% agreement with gold standard (WOC nurse)	Overall: 64.2% (79/123) Suspected deep tissue injury: 80% (24/30) Stage I: 74% (23/32) Stage III: 65% (20/31) Unstageable: 39% (12/31)	31 student and qualified nurses looked at 5 photographs and assigned a stage of pressure ulcer to them (but the stage II photograph assessments had to be excluded from analysis due to computer error).	PHOTOGRAPHIC STUDY The tool included computerised clinical decision support, involving drop down menus to facilitate accurate staging. Hence this may have influenced accuracy.	High
Accuracy					
Kelly and Isted 2011 ⁸⁸	Kappa and % agreement compared to an	Overall: 56% (156/279) [Kappa: 0.48] Stage I: 86% Stage II: 56%	93 nurses looked at 3 photographs and assigned a stage of pressure ulcer to them.	PHOTOGRAPHIC STUDY Gold standard unspecified. No effect of	Low

Study	Statistical measure	EPUAP/ NPUAP 2009	n	Comments	Quality
	unspecified gold standard.	Stage III: 43% Stage IV: 89% Unstageable: 6%		seniority on accuracy: band 2-4 nurses had overall accuracy of 57% and band 5-7 nurses had overall accuracy of 55%. Chi square with Yates' correction showed no significant difference.	
Accuracy					
Sarhan 2010 ¹⁶⁴	% agreement compared to gold standard, which was the result recorded in patient notes based on a face to face examination by a trained nursing staff member.	Overall: 85% Sacrum stage 4: 102/150 [68%] Ischium stage 3: 77/80 [96%] Foot stage 1: 20/20 [100%] Foot stage 2: 20/20 [100%] Ankle stage 1: 20/20 [100%] Ankle stage 2: 20/20 [100%] Trochanter stage 3: 35/40 [88%] Trochanter stage 4: 20/30 [67%] Hip stage 3: 34/40 [85%] Hip stage 4: 23/30 [77%] Knee stage 3: 8/10 [80%] Knee stage 4: 15/20 [75%] Back stage 1: 10/10 [100%] Back stage 2: 10/10 [100%]	10 nurses looked at 50 images of pressure ulcers and assigned a stage of pressure ulcer to them from 50 people with spinal cord injury.	PHOTOGRAPHIC STUDY The gold standard is suspect, as the expertise of the nurse carrying out the face to face examination was unclear. Thus this may not be a true accuracy study. If it is not a true accuracy study, it has little relevance to this review, as in this context these results only demonstrate that photographic diagnosis is a reasonable proxy for face to face diagnosis.	Low
Inter-rater reliability					
Kottner 2009 ⁹⁷	%Inter-rater agreement (P ₀)	2007: P ₀ =338/352 = 0.96 (trained nurses) 2008: P ₀ =318/332 = 0.96 (wound management nurses)	Unknown number of trained nurses and wound management nurses assessed 12792 participants from care	PATIENT STUDY Two analyses done over 2 successive years for different rater groups –	Low

Study	Statistical measure	EPUAP/ NPUAP 2009	n	Comments	Quality
			homes. Each person was assessed just once by any single pair of assessors, with a 1-3 day interval.	hence the 2 separate results for different years. The article appeared to report the results wrongly, stating that the P ₀ results on left (0.96 for both years) were for the assessment of pressure ulcer / no pressure ulcer rather than of the 5 different stagings. However the tabular data in article strongly suggested that the results are for the reliability across all 5 different stagings.	

Table 20: Torrance (1983)

Study	Statistical measure	Torrance (1983)	n	Comments	Quality
Inter-rater reliability					
Nixon 1998 ¹³⁷	% agreement	Pre-study: 97.8 (649/664) During study: 91.5 (779/851)	Pre-study: 94 nurses. 133 paired assessments were done on people, generating 664 paired assessments of skin sites. During-study: 171 co-assessments undertaken in recovery area and ward, generating 851 site assessments.	PATIENT STUDY Two reliability studies done (pre- and during-study). Unclear why this was so. Poorly reported methodology. Expertise of nurses unknown.	Low

Table 21: Shea

Study	Statistical measure	Shea	n	Comments	Quality
Inter-rater reliability					
Buntinx 1996 ³⁴	Group kappa	0.42(95% CIs: 10-74)	3 physicians and 3 nurses performed 126 assessments on unknown number of people.	PATIENT STUDY Expertise of nurses unknown.	High

Table 22: Quality of reliability studies.(tThis was modified from QUADAS).

Study	Are the patients representative?	Selection criteria clear?	Assessors representative?	Assessor selection criteria clear?	Time period between measurements short enough?	Did all receive scheduled repetitions of measurements?	Description of execution of measurements adequate for replication?	Description of sequence of repeated measurements adequate?	Inter-rater reliability: was measurement performed without knowledge of other rater's values?	Was order of measurements random?	Were withdrawals explained?	Overall Quality ^a
Kottner 2009 ⁹⁷	Yes	Yes, random	Unclear	No	No (1-3 days)	No	No	Yes	Yes	Unclear	No	Low
Yarkony 1990 ²¹⁰	Unclear	No	Unclear	No	Yes	Yes	No	No	Yes	Unclear	NA	Low
Healey 1995 ⁷⁸	NA - photos	NA - photos	Unclear	Yes	NA	Yes	Yes	Yes	Yes	Unclear	NA	Low
Marrie 2003 ¹⁰⁹	Yes	No	Unclear	No	Unclear	Yes	Yes	Yes	Unclear	Unclear	NA	Low
Defloor 2006 ⁵²	NA - photos	NA - photos	No	Yes	NA	Yes	Yes	Yes	NA (intra-rater)	Yes	NA	Low
Hart 2006 ⁷⁶	NA - photos	NA - photos	No	Yes	NA	Yes	Yes	Yes	Yes	NA	Yes	Low
Vanderwee 2007 ²⁰¹	Yes	Yes	Unclear	No	Unclear	Yes	No	No	Yes	Unclear	NA	Low
Vanderwee 2007A ²⁰³	Unclear	Yes, random	No	No	Unclear	Yes	Yes	Yes	Yes	Unclear	NA	Low
Nixon 1998 ¹³⁷	Unclear	No	Unclear	No	Unclear	Yes	Yes	Yes	Unclear	Unclear	NA	Low
Schoonhoven 2007 ¹⁶⁷	Yes	No	No	Yes	Unclear	Yes	No	No	Unclear	Unclear	NA	Low
Buntinx 1996 ³⁴	Yes	Yes, convenience	Unclear	Yes	Unclear	Yes	Yes	Yes	Yes	Unclear	NA	High
Pedley 2004 ¹⁵⁰	Yes	Yes, convenience	No	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	NA	High
Defloor	NA -	NA	No	No	NA	Yes	Yes	Yes	Unclear	NA	NA	Low

Study	Are the patients representative?	Selection criteria clear?	Assessors representative?	Assessor selection criteria clear?	Time period between measurements short enough?	Did all receive scheduled repetitions of measurements?	Description of execution of measurements adequate for replication?	Description of sequence of repeated measurements adequate?	Inter-rater reliability: was measurement performed without knowledge of other rater's values?	Was order of measurements random?	Were withdrawals explained?	Overall Quality ^a
and Schoonhoven 2004 ⁵³	photos											
Feuchtinger 2006 ⁶⁰	Yes	No	Unclear	No	Unclear	Yes	No	No	Unclear	Unclear	Na	Low

(a) *For most categories, 'yes' responses gained 1 point, but triple weighting was given to 'Inter-rater reliability: was measurement performed without knowledge of other rater's values?', and double weighting to each of 'Are the patients representative?' and 'Time period between measurements short enough?'. For photographic studies, NA was taken as a yes for 'Time period between measurements short enough?'. This was because the use of photographs would avoid any bias from long intervals between ratings. The total score was therefore out of 15. Scores of 10/15 and above were categorised as high quality and scores of 9 and below were categorised as low quality. The weightings are based on an estimate of the relative importance of the quality criteria, and the scores are designed to be roughly in line with the threshold for 'high quality' used by some researchers for the full QUADAS assessment. NA=not applicable

Table 23: Quality of accuracy studies. This was modified from QUADAS.

Study	Are the patients representative?	Selection criteria clear?	Assessors representative?	Assessor selection criteria clear?	If a reference standard is employed, is it likely to generate a valid measurement?	Time period between measurements short enough?	If a reference standard is employed, did the whole sample or a random selection of the sample receive verification using the reference standard?	If a reference standard is employed, did patients receive the same reference standard regardless of the index measurement result?	If a referenced standard is used, was this independent of the index measurement?	Description of execution of measurements adequate for replication?	Results for each measurement method interpreted without knowledge of the results of the other methods used?	Was order of measurements random?	Were withdrawals explained?	Overall grading ^a
Alvey 2012 ⁹	NA - photos	NA - photos	Unclear	Yes	Yes	NA	Whole	Yes	Yes	Yes	Yes	NA	NA	High
Nixon 2005A ¹³⁹	Yes	Yes	Yes	Yes	Yes	Yes	Whole	Yes	Yes	Yes	Unclear	NA	NA	High
Sarhan 2010 ¹⁶⁴	NA - photos	NA - photos	Unclear	No	No	NA	Whole	Yes	Yes	Yes	Yes	NA	NA	Low
Russell 2001 ¹⁶³	NA - photos	NA - photos	Yes	Yes	Yes	NA	Whole	Yes	Yes	Yes	Yes	NA	NA	High
Defloor 2006 ⁵²	NA - photos	NA - photos	No	Yes	Yes	NA	Whole	Yes	Yes	Yes	Yes	Yes	NA	High
Beeckman 2010 ²²	NA - photos	NA - photos	Yes	Yes, convenience	Yes	NA	Whole	Yes	Yes	Yes	Yes	NA	NA	High
Buckley 2005 ³³	NA - photos	NA - photos	Yes	Yes, convenience	Yes	NA	Whole	Yes	Yes	Yes	Yes	NA	NA	High
Kelly 2011 ⁸⁸	NA - photo	NA - photo	Yes	Yes, random	Unclear	NA	Whole	Yes	Yes	Yes	Yes	NA	NA	Low

Study	Are the patients representative?	Selection criteria clear?	Assessors representative?	Assessor selection criteria clear?	If a reference standard is employed, is it likely to generate a valid measurement?	Time period between measurements short enough?	If a reference standard is employed, did the whole sample or a random selection of the sample receive verification using the reference standard?	If a reference standard is employed, did patients receive the same reference standard regardless of the index measurement result?	If a referenced standard is used, was this independent of the index measurement?	Description of execution of measurements adequate for replication?	Results for each measurement method interpreted without knowledge of the results of the other methods used?	Was order of measurements random?	Were withdrawals explained?	Overall grading ^a
	s	s												
Beeckman 2007 ²¹	NA - photos	NA - photos	Yes	Yes, convenience	Yes	NA	Whole	Yes	Yes	Yes	Yes	NA	NA	High
Beeckman 2008 ²⁰	NA - photos	NA - photos	Yes	Yes, convenience	Yes	NA	Whole	Yes	Yes	Yes	Yes	NA	NA	High
Vanderwee 2007A ²⁰³	Unclear	Yes, random	Unclear	No	Unclear	Unclear	Whole	Yes	Yes	Yes	Yes	NA	NA	Low
Defloor and Schoonhoven 2004 ⁵³	NA - photos	NA - photos	No	No	Yes	NA	Whole	Yes	Yes	Yes	Yes	NA	NA	Low

(a) *For most categories, 'yes' responses gained 1 point, but triple weighting was given to 'If a reference standard is employed, is it likely to generate a valid measurement?', and double weighting to each of 'Are the patients representative?' and 'Time period short enough between measurements short enough?'. For photographic studies, NA was taken as a yes for 'Time period short enough between measurements short enough?'. This was because the use of photographs would avoid any bias from long intervals between ratings. The total score was therefore out of 17. Scores of 11/17 and above were categorised as high quality and scores of 10 and below were categorised as low quality. The weightings are based on an estimate of the relative importance of the quality criteria, and the scores are designed to be roughly in line with the threshold for 'high quality' (10/15) used by some researchers for the full QUADAS assessment.

NA=not applicable

4.2.13 Economic evidence (adults)

2 Published literature

3 No relevant economic evaluations comparing ulcer measurement techniques were identified.

4.2.14 Clinical evidence (neonates, infants, children and young people)

5 No RCTs or cohort studies were identified. Recommendations were developed using a modified
6 Delphi consensus technique. Further details can be found in Appendix N.

4.2.15 Economic (neonates, infants, children and young people)

8 No economic evidence was identified.

4.2.16 Evidence statements

4.2.6.1 Clinical (adults)

4.2.6.1.1 Accuracy

12 • Predominantly high quality evidence from 12 studies suggested that the accuracy of pressure
13 ulcer categorisation was adequate in the EPUAP, NPUAP and Stirling categorisation tools. Of the 3
14 tools studied, EPUAP had the greatest weight of high quality evidence supporting its accuracy.

4.2.6.1.2 Intra-rater reliability

16 • Low quality evidence from 1 study suggested that intra-rater reliability of pressure ulcer
17 categorisation was adequate in the EPUAP.

4.2.6.1.3 Inter-rater reliability

19 • Predominantly low quality evidence from 14 studies suggested that inter-rater reliability of
20 pressure ulcer categorisation was adequate in the Yarkony-kirk, Stirling, EPUAP, NPUAP, Torrance
21 and Shea categorisation tools. Of the 6 tools studied, EPUAP had the greatest weight of evidence
22 supporting its inter-rater reliability.

4.2.6.2 Clinical (neonates, infants, children and young people)

24 • No evidence was identified.

4.2.6.3 Economic (neonates, infants, children and young people)

26 • No relevant economic evaluations were identified.

27

4.3 Recommendations and link to evidence

4.3.1 Adults

<p>Recommendations</p>	<p>5. Categorise each pressure ulcer in adults using a validated classification tool (such as the International NPUAP-EPUAP (2009) Pressure Ulcer Classification System). Use this to guide ongoing preventative strategies and management. Repeat and document each time the ulcer is assessed.</p>
<p>Relative values of different outcomes</p>	<p>Accuracy of categorisation tools was regarded as a critical outcome, as it is vital if it is to be used to inform treatment as inaccurate categorisation might lead to inappropriate treatments being used. Accuracy was identified as more important than reliability, as an accurate measurement will be reliable, but it is possible to be reliable but not accurate. Therefore high accuracy encapsulates both accuracy and reliability, but high reliability can exist alongside poor accuracy.</p> <p>However, reliability was still regarded as important, as it is useful for allowing the comparison of pressure ulcer measurement across time. Such charting of progress is essential for making decisions on continuing, adapting or changing treatments. High intra-rater reliability is important for meaningful comparisons between categorisations made by 1 assessor on the same patient across time. High inter-rater reliability is important when comparing measurements undertaken by different assessors on the same patient over time.</p> <p>Ease of use of the tools was also regarded as an important outcome, as this minimises patient and assessor time.</p>
<p>Trade-off between clinical benefits and harms</p>	<p>The GDG did not consider there would be any direct harms from the use of the reviewed tools. Inaccurate or unreliable tools could be regarded as an indirect source of potential harm for the individual with the pressure ulcer. Conversely, clinical benefits are likely to arise from accurate and reliable tools, as this will lead to optimal treatment decisions and affective charting of progress. Hence a discussion of the trade-off between benefits and harms may, in this context, be conducted by discussing the relative reliability and accuracy of the different tools.</p> <p>Accuracy was measured only in the European Pressure Ulcer Advisory Panel (EPUAP), Stirling and National Pressure Ulcer Advisory Panel (NPUAP) categorisation tools. The EPUAP tool appeared to have superior accuracy to the NPUAP categorisation tool. In the only study investigating the accuracy of the NPUAP categorisation tool, agreement was 67.8%, while the 3 EPUAP accuracy studies that used percentage agreement as a measure showed values of 78.8%, 50% and 94.5%. The Stirling and EPUAP tools were measured together in 1 study, with Stirling having superior accuracy. However the parametric analysis measures used were inappropriate and so the validity of these results is unclear. Overall, of the 3 tools, the EPUAP tool had the most evidence suggesting adequate accuracy, thus this may be the tool conferring the most clinical benefits from high accuracy. None of the tools stood out as likely to confer any significant harm upon people as a result of poor accuracy. Intra-rater reliability was measured only in the EPUAP tool, but it was poor to fair. Inter-rater reliability was measured in the Yarkony-kirk, Stirling, EPUAP, NPUAP, Torrance and Shea tools. Again, the EPUAP tool had the most supportive evidence. Although 1 pairwise comparison showed that the Stirling tool was superior to the EPUAP tool, the kappa rating for Stirling was only 'fair'. In stand-alone studies of the EPUAP tool an 'excellent' kappa rating was indicated. The EPUAP may therefore be the tool conferring the most clinical benefits from its high reliability. No tool stood out as likely to confer any significant harm upon people as a result of poor reliability.</p>

	<p>The GDG were in agreement that using a categorisation tool had many benefits, such as standardising practice between healthcare professionals and organisations. The evidence was unclear and did not allow the GDG to recommend the use of a specific categorisation tool yet, they wished to provide an example of a tool to aid healthcare professionals. As the EPUAP categorisation tool is widely used and embedded in clinical practice across the UK the GDG chose to include reference to this tool within the recommendation, acknowledging that other categorisation tools were available.</p>
Economic considerations	<p>Different methods of categorisation are unlikely to have different resource implications. Categorisation of a pressure ulcer is considered best practice, and is essential in order to assess preventative and management efforts effectively. Using a categorisation tool that has high reliability and accuracy could ensure appropriate treatments are implemented efficiently.</p> <p>Categorisation is already embedded in clinical practice therefore, no additional resources are thought to be required.</p>
Quality of evidence	<p>The majority of accuracy outcomes were high quality. Most of these related to studies concerning the EPUAP tool, further strengthening the conclusion that the most convincing evidence indicates it is an accurate form of categorisation. In contrast, the majority of reliability outcomes were low quality. The greater quality of the accuracy studies was partly due to their simpler methodology, as there was less scope for important methodological omissions. It was unclear in some studies which version of EPUAP was used.</p> <p>An important issue concerns the use of either photographs or patients in the different studies. The GDG felt that photographs were not as accurate as directly seeing the patient. However, this was taken into account when assessing the quality criterion for both accuracy and reliability. Hence further consideration of this factor when reviewing the quality of evidence would constitute double-counting.</p>
Other considerations	<p>The GDG felt it was important that the categorisation of pressure ulcers was used to standardise practice as it would help to monitor the severity of pressure ulcers in an environment and help inform treatment.</p> <p>The GDG agreed that modified versions of validated tools should not be used.</p> <p>The GDG highlighted that the use of a classification scale was a static measurement of a dynamic process and thus it was important to continually reassess the category of a pressure ulcer. It was agreed that classification should be repeated each time the pressure ulcer is assessed.</p>

4.3.12 Neonates, infants, children and young people

Recommendations	<p>6. Categorise each pressure ulcer in neonates, infants, children and young people at onset using a validated classification tool (such as the International EPUAP-NPUAP (2009) Pressure Ulcer Classification System) to guide ongoing preventative and management options. Repeat and document each time the ulcer is assessed.</p>
Relative values of different outcomes	<p>Accuracy of categorisation tools was regarded as a critical outcome, as it is vital that categorisation is accurate if it is to be used to inform treatment as inaccurate categorisation might lead to inappropriate treatments being used. Accuracy was regarded as more important than reliability, as an accurate measurement will also be reliable, but it is possible to be reliable but not accurate. Therefore high accuracy encapsulates both accuracy and reliability, but high reliability can exist alongside poor accuracy. However, reliability was still regarded as important, as it is</p>

	<p>useful for allowing the comparison of pressure ulcer measurement across time. Such charting of progress is essential for making decisions on continuing, adapting or changing treatments. High intra-rater reliability is important for meaningful comparisons between categorisations made by 1 assessor on the same patient across time. High inter-rater reliability is important when comparing measurements undertaken by different assessors on the same patient over time.</p> <p>Ease of use of the tools was also regarded as an important outcome, as this will minimise patient and assessor time.</p>
Trade-off between clinical benefits and harms	<p>The GDG used 1 statement from the Delphi consensus survey to inform the recommendation on categorisation of pressure ulcers. The statement was 'Healthcare professionals should classify all pressure ulcers in neonates, infants, children and young people using the EPUAP/NPUAP grading scheme'. The statement was agreed by the Delphi consensus panel. Further detail on the Delphi consensus survey can be found in Appendix N.</p> <p>The statement on categorisation was included in Round 1 of the Delphi consensus survey. Comments from the panel members emphasised that the categorisation of pressure ulcers was essential to ensure consistency and standardisation of practice. The GDG discussed the results of the survey and agreed that categorisation of pressure ulcers was appropriate and a recommendation was therefore developed to support the categorisation of all pressure ulcers. The GDG noted however, that the results of categorisation should help to guide the management of the pressure ulcer, as well as future preventative strategies. The GDG discussed how often categorisation should be repeated and agreed that a pressure ulcer should be categorised at each assessment and the results of categorisation documented.</p> <p>A number of comments from panel members suggested that the EPUAP categorisation tool was in widespread use across the UK and the GDG therefore chose to include reference to this tool within the recommendation, acknowledging that other categorisation tools were available.</p>
Economic considerations	<p>Different methods of categorisation are unlikely to have different resource implications. Categorisation of a pressure ulcer is considered best practice, and is essential in order to assess preventative and management efforts effectively in neonates, infants, children and young people.</p>
Quality of evidence	<p>No RCTs or cohort studies were identified for neonates, infants, children or young people. Formal consensus using a modified Delphi was therefore used to develop the recommendation.</p> <p>To inform the recommendation, the GDG used 1 statement which was included in Round 1 of the Delphi consensus survey and reached 84% consensus agreement.</p> <p>Further details can be found in Appendix N.</p>
Other considerations	<p>There were no other considerations.</p>

5 Nutrition and hydration

5.1 Introduction

3 Nutritional factors are important in the healing process of pressure ulcers, in conjunction with other
4 management strategies, as various nutrients have been associated with promoting pressure ulcer
5 repair through their role in collagen formation and development of connective tissue. For example,
6 nutrients such as protein, vitamin C and zinc have historically been considered important, due to
7 their role in collagen formation. Other nutritional supplements considered to be potentially
8 important are arginine, an amino acid that stimulates insulin secretion and protein formation,
9 collagen protein and hydrolysate, which provide protein in a hydrolysed form. Adjusting intake of
10 these components can be achieved by varying amounts in the diet but also by the use of specific
11 supplements. Supplementation can be achieved by the use of single tablets or in combination, often
12 as a drink. Due to the numerous compositions of nutrient drinks, they are notoriously difficult to
13 compare with each other. One of the major factors frequently considered to impact on pressure
14 ulcer healing is baseline nutritional status, as a poor nutritional state is generally considered to
15 inhibit pressure ulcer healing. It is therefore important to identify those at risk of malnutrition and
16 start treatment to improve nutritional state as well as contemplating any further needs associated
17 with pressure ulcer repair. NICE clinical guideline 32 'Nutrition support in adults'¹³⁰ provides
18 recommendations on screening the nutritional status of people in hospital and in the community.
19 The GDG were therefore interested in whether recommendations for nutritional interventions would
20 be different depending on the presence or absence of malnutrition.

21 The GDG were also interested in whether there was any guidance on hydration interventions that
22 would aid the treatment of pressure ulcers.

5.2 Review question: What are the most clinically and cost-effective nutritional interventions for the treatment of pressure ulcers?

24 For full details see review protocol in Appendix C.

5.2.1 Clinical evidence (adults)

27 No randomised trials of interventions for hydration to treat pressure ulcers were found. For
28 nutritional interventions to treat pressure ulcers, 1 Cochrane review was identified¹⁰² which included
29 4 randomised trials (Taylor, 1974¹⁸³, Ter Riet, 1995¹⁸⁴, Chernoff, 1990⁴², and Norris, 1971¹⁴⁰). These
30 randomised trials have been included in the evidence review and the Cochrane Review was updated.
31 Ten further randomised trials were found (Desneves, 2005⁵⁴, Lee, 2006¹⁰⁴, Cereda, 2009⁴⁰, Van
32 Anholt, 2010¹⁹⁸, Brewer, 1967³⁰, Benati, 2001²⁵ and Ohura, 2011¹⁴², Meaume, 2009¹¹⁴, Leigh, 2012¹⁰⁵
33 and Theilla, 2012^{186,187}). One study (Meaume, 2009)¹¹⁴ only included people with heel pressure
34 ulcers. Benati (2001)²⁵ met the inclusion criteria for the review but it had incomplete outcome
35 reporting and so it was not possible to extract any results from this paper.

36

37 The evidence from these studies is summarised in the clinical GRADE evidence profile below (Table
38 4). See also the study selection flow chart in Appendix D, forest plots in Appendix I, study evidence
39 tables in Appendix G and exclusion list in Appendix J.

40

41 Most of the studies identified looked at different forms of nutritional supplementation, in addition to
42 the standard hospital diet, versus the standard hospital diet alone. The supplements differed in their
43 composition therefore it was not possible to meta-analyse them. Two studies were identified which

- 1 compared ascorbic acid against placebo. Although the populations differed (people in a nursing
- 2 home and people who had undergone surgery) they were meta-analysed.
- 3
- 4 Studies which included pressure ulcers of all stages were analysed separately from those which
- 5 included people with pressure ulcers of stages 2 and above (the classification system used is
- 6 reported, where provided by the authors). Studies including participants who had an adequate
- 7 nutritional status were separated from those who had a nutritional deficiency.
- 8

Summary of included studies

Study	Intervention/comparator	Population	Outcomes	Study length
Benati 2001 ²⁵	Normal hospital diet plus an oral supplementation with an iso-calorie and iso-protein solution enriched with arginine, vitamins and trace elements with antioxidant effect versus normal hospital diet plus oral supplementation with high protein calorie solution versus normal hospital diet.	People with severe cognitive impairment and pressure ulcers. Reduced oral food intake.	<ul style="list-style-type: none"> • Pressure ulcer status tool (PSST) 	2 weeks
Brewer 1967 ³⁰	Oral zinc sulphate 220mgs (50mg zinc) 3 times per day versus inert substance (lactose).	People with spinal cord injuries and poorly healing pressure ulcers of various sizes, types, locations and duration (5 months to 2 years).	<ul style="list-style-type: none"> • Proportion of people completely healed; side effects 	2-3 months
Cereda 2009 ⁴⁰	Disease-specific nutritional treatment - standard hospital diet plus 400ml oral supplement (500kcal, 34g protein, 6g arginine, 500mg vitamin C, 18mg zinc) or tube fed 100ml high protein formula (20% energy from protein, enriched with arginine, zinc and vitamin C) versus standard protocol - hospital diet (16% energy from protein) without any additional supplement or tube fed standard formula energy and the infusion of appropriate volumes of a standard formula satisfied protein requirements.	Elderly residents in long-term facilities with stage 2, 3 or 4 pressure ulcers (NPUAP 2007) who were orally or tube fed.	<ul style="list-style-type: none"> • Reduction in pressure ulcer area reduction in Pressure Ulcer Scale for Healing (PUSH) tool score at week 12; proportion of people with complete healing; % reduction in pressure ulcer area at 12 weeks; all-cause mortality. 	12 weeks
Chernoff 1990 ⁴²	Very high protein (25% of calories) formula versus high protein (16% of calories) formula.	Long-term tube fed institutionalised people with pressure ulcers.	<ul style="list-style-type: none"> • Proportion of people with complete healing; % reduction in ulcer surface area. 	8 weeks
Desneves 2005 ⁵⁴	Standard hospital diet plus 2 tetrapaks of a	Inpatients with stage 2,3	<ul style="list-style-type: none"> • Reduction in PUSH tool scores. 	3 weeks

Study	Intervention/comparator	Population	Outcomes	Study length
	defined arginine-containing supplement (500kcal, 21g protein, 0g fat, 500mg vitamin C, 30mg zinc and 9g arginine) versus standard hospital diet plus 2 tetrapaks of high protein, high energy supplement (providing additional 500kcal, 18g protein, 0g fat, 72mg vitamin C and 7.5mg zinc) versus standard hospital diet.	or 4 pressure ulcer. Diagnosis: dementia (n=1), cerebrovasulcar accident (n=6), spinal cord injury (n=2), parkinson's disease (n=1), chronic cardiac failure (n=2), fractured bones (n=3), pressure ulcers (alone) (n=1).		
Lee 2006 ¹⁰⁴	Standard diet plus concentrated, fortified, collagen protein hydrolysate supplement versus standard diet plus placebo.	Residents of long-term care facilities with pressure ulcers stage 2, 3 or 4.	<ul style="list-style-type: none"> Reduction in mean PUSH tool score; % reduction in PUSH tool score. 	8 weeks
Leigh 2012 ¹⁰⁵	Hospital diet plus 4.5g arginine supplement versus hospital diet plus 9g arginine supplement.	Inpatients with category 2, 3 or 4 pressure ulcers.	<ul style="list-style-type: none"> Reduction in mean PUSH tool score; Reduction in mean PUSH tool score by nutritional status; concordance. 	3 weeks
Norris 1971 ¹⁴⁰	Oral zinc sulphate (200mg) capsules 3 times per day versus placebo.	People in a hospital with chronic disease and geriatric problems with non-superficial pressure ulcers. Diagnosis: brain damage after head injury (n=1), senile dementia n=1), subdural hematoma (n=1), paraplegia (n=4), multiple sclerosis (n=2), cerebral thrombosis (n=1), poliomyelitis (n=1), quadriplegia (n=1), brain damage after cardiac	<ul style="list-style-type: none"> Mean reduction in pressure ulcer volume. 	12 weeks treatment then crossed over for another 12 weeks.

Study	Intervention/comparator	Population	Outcomes	Study length
		arrest (n=1), rheumatoid arthritis, amputee (n=1).		
Ohura 2011 ¹⁴²	Protein, fat, carbohydrate versus same nutrition as before trial.	Tube fed people with stage 3 to 4 pressure ulcers. The majority of participants were older adults.	<ul style="list-style-type: none"> Proportion of people with complete healing within 12 weeks; reduction in pressure ulcers at 12 weeks; study-related adverse events. 	12 weeks
Taylor 1974 ¹⁸³	Basic hospital diet plus 500mg ascorbic acid twice daily versus basic hospital diet plus placebo.	People undergoing surgery with pressure ulcers. Diagnosis fractured neck of femur (n=9), rheumatoid arthritis (n=2), cerebrovascular accident (n=2), fractured pelvis (n=1), peripheral vascular disease (n=1), paraplegia (n=1), gastric ulcer (n=1), benign prostatic hypertrophy (n=1), diverticular disease (n=1), aortic aneurysm (n=1).	<ul style="list-style-type: none"> % surface reduction at 1month; completely healed pressure sores; mean rates of healing (cm² per week); all-cause mortality. 	1 month
Ter Riet 1995 ¹⁸⁴	Ascorbic acid supplementation (500mg twice daily) as effervescent tablets versus identical placebo which contained 10mg of ascorbic acid.	People from 11 nursing homes and 1 hospital with pressure ulcers (partial thickness skin loss or worse). Most people had nutritional deficiency on admission.	<ul style="list-style-type: none"> Time to complete healing; mean surface area reduction (cm²/week and %/week); proportion of people with complete healing at 84 days; mean volume reduction (ml/week/%/week); mean healing velocity (cm/week); all-cause mortality. 	12 weeks
Theilla 2012 ^{186,187}	Enteral nutritional formula enriched in fish oil and antioxidants versus isonitrogenous	People in an intensive care unit with grade 2 or	<ul style="list-style-type: none"> Increase in PUSH tool mean score. 	28 days

Study	Intervention/comparator	Population	Outcomes	Study length
Van Anholt 2010A ¹⁹⁸	Oral nutritional supplement 250kcal, 28.4g carbohydrates (45% energy), 20g protein (30% energy), 3g arginine, 7g fat (25% energy), 238mg vitamin A, 250mg vitamin C, 38mg vitamin E, 1.5mg carotenoids, 9mg zinc, 64ug selenium, 1.35mg copper, 200ug folic acid versus non-caloric, flavoured placebo.	Non-malnourished people at health care centres, hospitals and long-term care facilities, aged 18 to 90 years with stage 3 to 4 pressure ulcers (EPUAP).	<ul style="list-style-type: none"> Reduction in pressure ulcer size per week; reduction in mean PUSH tool scores; incidence of diarrhoea, nausea and vomiting; all-cause mortality. 	Maximum 8 weeks
Meaume 2009 ¹¹⁴	10g sachet of ornithine alpha-ketoglutarate versus 1 sachet of placebo.	Elderly people (geriatric, internal medicine, physical medicine and rehabilitation, trauma, plastic surgery, cardiology, neurology and dermatology settings) who had pressure ulcers of the heel of stage 2 or 3 (NPUAP classification).	<ul style="list-style-type: none"> % reduction in pressure ulcer surface area; greater than 90% reduction by week 6; rate of complete healing (cm²/day); all-cause mortality. 	6 weeks.

Table 24: Minimal important difference for continuous outcomes – baseline values

Study	Treatment	Control
Pressure ulcer surface area - mean cm² baseline values and standard deviations		
Cereda 2009 ⁴⁰ – protein, arginine, zinc	20.15 (11.13)	20.7 (14.7)
Van Anholt 2010 ¹⁹⁹ – protein, arginine	10.5 (2.3)	11.5 (2.5)
Meaume 2009 ¹¹⁴ – alpha ketoglutarate	8.7 (6.7)	8.2 (8.9)
Median standard deviation: 7.8 x 0.5 = 3.9 MID for pressure ulcer surface area		
Pressure ulcer scale for healing (PUSH) score - mean baseline values and standard deviations		
Cereda 2009 ⁴⁰ – protein, arginine, zinc	13.5 (2.2)	14.0 (2.6)
Lee 2006 ¹⁰⁴ - protein	9.11 (4.15)	6.07 (2.65)
Desneves 2005 ⁵⁴ – arginine	9.4 (1.2)	8.7 (1.0)
Desneves 2005 ⁵⁴ – protein, vitamin C, zinc	8.0 (0.5)	8.7 (1.0)
Van Anholt 2010 ¹⁹⁹ – protein, arginine	11.5 (0.7)	11.4 (0.7)
Median standard deviation: 1.1 x 0.5 = 0.55 MID for pressure ulcer surface area		

Table 25: Clinical evidence profile: 500kcal, 34g protein, 6g arginine, 500mg vitamin C, 18mg zinc and standard hospital diet versus standard hospital diet

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Supplement and standard hospital diet	Standard hospital diet	Relative (95% CI)	Absolute		
Proportion with complete healing – elderly adults in long term care with stage 2, 3, 4 ulcersⁱ (unclear if nutritionally deficient)⁴⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	1/13 (7.7%)	0/15 (0%)	Peto OR 8.62 (0.17 to 438.7) ^f	80 more per 1000 (from 110 fewer to 260 more)	Very low	Critical
							-	0%		80 more per 1000 (from 110 fewer to 260 more)		
Mean % reduction in ulcer size (change scores) – elderly adults in long term care with stage 2, 3, 4 ulcersⁱ (unclear if nutritionally deficient)⁴⁰												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^e	None	72% n=13	45% n=15	-	MD 27% p=0.05	Very low	Critical
Mean reduction in ulcer size (cm²) (change scores) – elderly adults in long term care with stage 2, 3, 4 ulcersⁱ (unclear if nutritionally deficient)⁴⁰												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	Serious ^g	14.5 (s.d 8.03) n=13	8.41 (s.d 5.59) n=15	-	MD 6.09 higher (0.89 to 11.29 higher)	Very low	Critical
Mean reduction in PUSH scores (change scores) (0= complete healing, 17=greatest severity) (change scores) – elderly adults in long term care with stage 2, 3, 4 ulcers (unclear if nutritionally deficient)⁴⁰												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious ^d	Serious ^h	-6.1 (s.d 2.7) n=13	-3.3 (s.d 2.4) n=15	-	MD 2.8 lower (4.71 to 0.89 lower)	Very low	Critical
All-cause mortality - elderly long term care adults with stage 2, 3, 4 ulcersⁱ (unclear if nutritionally deficient)⁴⁰												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Supplement and standard hospital diet	Standard hospital diet	Relative (95% CI)	Absolute		
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/15 (13.3%)	0/15 (0%)	Peto OR 7.94 (0.47 to 133.26) ^f	130 more (from 60 fewer to 330 more)	Very low	Important
							-	0%		-		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability of supplements												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects (nausea, vomiting, diarrhoea)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Cereda (2009)⁴⁰ used a computer-generated randomisation list used but no details of allocation concealment were provided. The drop-out rate was higher than the event rate for the outcome 'proportion with complete healing'.

(b) The confidence interval crossed both MID points (0.75 to 1.25 for dichotomous data and 0.5 x SD for continuous data). Limited number of events.

(c) The confidence interval crossed both MID points (0.75 to 1.25 for dichotomous data and 0.5 x SD for continuous data).

(d) The confidence interval crossed 1 MID point (0.75 to 1.25 for dichotomous data and 0.5 x SD for continuous data).

(e) No standard deviations were given. The study used a very small sample size.

(f) Peto-odds ratio was used as 1 arm had zero events.

(g) The Mann-Whitney U-test was used for non-homogenous distribution of variance, but log transformation was not conducted.

(h) The data was analysed using ANOVA for repeated measures but log transformation was not conducted.

(i) NPUAP 2007 classification of pressure ulcers.

Table 26: Clinical evidence profile: 250kcal, 28.4g carbohydrates, 20g protein, 3g arginine, 7g fat, vitamins, minerals and standard hospital diet versus standard hospital diet and placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Nutritional supplement and standard hospital diet	Standard hospital diet and placebo	Relative (95% CI)	Absolute		
Reduction in mean PUSH scores (change scores) – elderly adults with stage 3-4 ulcers (non-malnourished)¹⁹⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^e	None ^f	6 n=22	5.4 n=21	-	MD 0.6 p=0.011g	Very low	Critical
Rate of mean reduction in ulcer size (cm²/week) (change scores)– elderly adults with stage 3-4 ulcers (non-malnourished)¹⁹⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^e	None ^f	8.4cm ² /week i n=22	8.75cm ² /week ki n=21 0.15cm ² /day after week 8	-	MD =0.35cm ² /weekj p=0.006g	Very low	Critical
Adverse events related to the product– elderly adults with stage 3-4 ulcers (non-malnourished)¹⁹⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	9/22 (40.9%)	4/21 (19%)	RR 2.15 (0.78 to 5.92)	219 more per 1000 (from 42 fewer to 937 more)	Very low	Important
							-	19.1%		220 more per 1000 (from 42 fewer to 940 more)		
Incidence of diarrhoea– elderly adults with stage 3-4 ulcers (non-malnourished)¹⁹⁸												
1	Randomised	Very	No serious	No serious	Very	None	6/22	2/21	RR	177 more	Very	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Nutritional supplement and standard hospital diet	Standard hospital diet and placebo	Relative (95% CI)	Absolute		
	trial	serious ^a	inconsistency	indirectness	serious ^c		(27.3%)	(9.5%)	2.86 (0.65 to 12.64)	per 1000 (from 33 fewer to 1000 more)	low	
							-	9.5%		177 more per 1000 (from 33 fewer to 1000 more)		
Incidence of nausea– elderly adults with stage 3-4 ulcers (non-malnourished)¹⁹⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	1/22 (4.5%)	1/21 (4.8%)	RR 0.95 (0.06 to 14.3)	2 fewer per 1000 (from 45 fewer to 633 more)	Very low	Important
							-	4.8%		2 fewer per 1000 (from 45 fewer to 638 more)		
Incidence of vomiting– elderly adults with stage 3-4 ulcers (non-malnourished)¹⁹⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/22 (0%)	1/21 (4.8%)	Peto OR 0.13 (0 to	41 fewer per 1000 (from 48 fewer to 198	Very low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Nutritional supplement and standard hospital diet	Standard hospital diet and placebo	Relative (95% CI)	Absolute		
							-	4.8%	6.51)	more) 41 fewer per 1000 (from 48 fewer to 199 more)		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability of supplements												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Van Anholt (2010)¹⁹⁸ did not provide details of allocation concealment or sequence generation, or details of the blinding of outcome assessors. Recruitment stopped early due to lack of patients fulfilling inclusion criteria. High drop-out.

(b) The confidence interval crossed 1 MID point (0.75 to 1.25 for dichotomous data and 0.5 x SD for continuous data).

- (c) The confidence interval crossed both MID points (0.75 to 1.25 for dichotomous data and 0.5 x SD for continuous data). There were a limited number of events.
- (d) The confidence interval crossed both MID points (0.75 to 1.25 for dichotomous data and 0.5 x SD for continuous data).
- (e) No standard deviations were provided by the author. The study had a small sample size.
- (f) If data did not meet the assumption of normal distribution, they were log-transformed to enhance normality before statistical analysis (for pressure ulcer size).
- (g) The study reported the p value for treatment by time. The p value for treatment by time² (curve fits: p</=0.016 for ulcer size (cm²/week) and p</=0.033 for PUSH scores/week. A repeated-measures mixed model was used and data was adjusted for centre.
- (h) EPUAP and NPUAP 2009 classification of pressure ulcers.
- (i) Data estimated from graph.
- (j) The mean difference was calculated from estimated graph values.

Table 27: Clinical evidence profile: 500kcal, 18g protein, 0g fat, 72mg vitamin C and 7.5mg zinc and standard hospital diet versus standard hospital diet for treating pressure ulcers

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Nutritional supplement and standard hospital diet	Standard hospital diet	Relative (95% CI)	Absolute		
PUSH scores at week 3 (0=complete healing, 17=greatest severity) (final scores) – elderly adults or people with a spinal injury, stage 2, 3 or 4 ulcers ^d (unclear if nutritionally deficient) 54												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	Serious ^c	6 (s.d 1.2) n= 5	7 (s.d 1.5) n= 6	-	MD 1 lower to 0.6 higher)	Very low	Critical
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Nutritional supplement and standard hospital diet	Standard hospital diet	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects (nausea, vomiting, diarrhoea)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) Desneves (2005)⁵⁴: did not provide details of allocation concealment or details of blinding of participants or those administering treatment. However, outcome assessors were blinded.
- (b) The confidence interval crossed both MID points (0.75 to 1.25 for dichotomous data and 0.5 x SD for continuous data).
- (c) The between-group comparisons were evaluated using the Mann-Whitney U-test but no log transformations conducted.
- (d) Australian Wound Management Association Clinical Practice Guidelines classification of pressure ulcers.

Table 28: Clinical evidence profile: 500kcal, 21g protein, 0g fat 500mg vitamin C, 30mg zinc and 9g arginine and standard hospital diet versus standard hospital diet

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Nutritional supplement and standard hospital diet	Standard hospital diet	Relative (95% CI)	Absolute		
PUSH scores at week 3 (0=complete healing, 17=greatest severity) (final scores) – elderly adults or people with a spinal injury, stage 2, 3 or 4 ulcers^d(unclear if nutritionally deficient)⁵⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	Serious ^b	2.6 (s.d 0.6) n= 5	7 (s.d 1.5) n= 6	-	MD 4.4 lower (5.71 to 3.09 lower)	Very low	Critical
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability of supplements												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects (nausea, vomiting, diarrhoea)												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Nutritional supplement and standard hospital diet	Standard hospital diet	Relative (95% CI)	Absolute		
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Desneves (2005) did not provide details of allocation concealment or details of blinding of participants or those administering treatment. However outcome assessors were blinded.

(b) The between-group comparisons were evaluated using the Mann-Whitney U-test but no log transformations conducted.

(c) Australian Wound Management Association Clinical Practice Guidelines classification of pressure ulcers.

Table 29: Clinical evidence profile: 500kcal 21g protein, 0g fat, 500mg vitamin C, 30mg zinc, 9g of arginine and standard hospital diet versus 500kcal 18g protein, 0g fat, 72mg vitamin C and 7.5mg zinc and standard hospital diet

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	500kcal 21g protein, 0g fat, 500mg vitamin C, 30mg zinc, 9g of arginine and standard hospital diet	500kcal 18g protein, 0g fat, 72mg vitamin C and 7.5mg zinc and standard hospital diet	Relative (95% CI)	Absolute		
PUSH scores at week 3 (0=complete healing, 17=greatest severity) (final scores) – elderly adults or people with a spinal injury, stage 2, 3 or 4 ulcers^c(unclear if nutritionally deficient)⁵⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	Serious ^b	2.6 (s.d 0.6) n= 5	6 (s.d 1.2) n= 5	-	MD 3.4 lower (4.58 to	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	500kcal 21g protein, 0g fat, 500mg vitamin C, 30mg zinc, 9g of arginine and standard hospital diet	500kcal 18g protein, 0g fat, 72mg vitamin C and 7.5mg zinc and standard hospital diet	Relative (95% CI)	Absolute		
										2.22 (lower)		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability of supplements												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects (nausea, vomiting, diarrhoea)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	500kcal 21g protein, 0g fat, 500mg vitamin C, 30mg zinc, 9g of arginine and standard hospital diet	500kcal 18g protein, 0g fat, 72mg vitamin C and 7.5mg zinc and standard hospital diet	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Desneves (2005) did not provide details of allocation concealment or blinding of participants or those administering treatment. However outcome assessors were blinded.

(b) The between-group comparisons were evaluated using the Mann-Whitney U-test but no log transformations conducted.

(c) Australian Wound Management Association Clinical Practice Guidelines classification of pressure ulcers.

Table 30: Clinical evidence profile: 4.38g protein, 2.23g fat, 15.62g carbohydrate, minerals and vitamins (per 100ml) and standard hospital diet versus standard hospital diet

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Nutritional supplement and standard hospital diet	Standard hospital diet	Relative (95% CI)	Absolute		
Proportion with complete healing- majority elderly, tube-fed adults with stage 3 to 4 pressure ulcers (unclear if nutritionally deficient) ¹⁴²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	7/21 (33.3%)	4/29 (13.8%)	RR 2.42 (0.81 to 7.21)	196 more per 1000 (from 26 fewer to	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Nutritional supplement and standard hospital diet	Standard hospital diet	Relative (95% CI)	Absolute		
							-	13.8%		857 more) 196 more per 1000 (from 26 fewer to 857 more)		
Mean reduction in ulcer size (cm²)(change scores)-majority elderly, tube-fed adults with stage 3 to 4 pressure ulcers (unclear if nutritionally deficient)¹⁴²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None ^d	1.31 (s.d 0.24) n= 21	0.32 (s.d 0.2) n= 29	-	MD 0.99 higher (0.86 to 1.12 higher)e	Low	Critical
Study-related adverse events –majority elderly, tube-fed adults with stage 3 to 4 pressure ulcers (unclear if nutritionally deficient)¹⁴²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	8/29 (27.6%)	5/30 (16.7%)	RR 1.66 (0.61 to 4.47)	110 more per 1000 (from 65 fewer to 578 more)	Very low	Important
							-	16.7%		110 more per 1000 (from 65 fewer to 579)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Nutritional supplement and standard hospital diet	Standard hospital diet	Relative (95% CI)	Absolute (more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability of supplements												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Ohura (2011)¹⁴² was an unblinded study with a high drop-out with a differential of greater than 10% between arms.

(b) The confidence interval crossed 1 MID point (0.75 to 1.25 for dichotomous data and 0.5 x SD for continuous data).

(c) The confidence interval crossed both MID points (0.75 to 1.25 for dichotomous data and 0.5 x SD for continuous data).

(d) For size of pressure ulcer, analyses were performed on log-transformed data, taking into consideration a lognormal distribution observed in the population at each time point.

(e) A graph and confidence intervals were reported in the study (which were assumed to be log-transformed) so the point estimate and 95% confidence intervals were calculated.

(f) NPUAP classification of pressure ulcers.

Table 31: Clinical evidence profile: very high protein dietary formula (92 to 150gms/day) versus high protein dietary formula (57 to 90 gms/day)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Very high protein dietary formula (92 to 150gms/day)	High protein dietary formula (57 to 90 gms/day)	Relative (95% CI)	Absolute		
Proportion with complete healing – long-term tube-fed adults with pressure ulcers (unclear if nutritionally deficient)⁴²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	4/6 (66.7%)	0/6 (0%)	Peto OR 15.64 (1.57 to 155.75)	670 more per 1000 (from 260 more to 1070 more)	Very low	Critical
							-	0%		670 more per 1000 (from 260 more to 1070 more)		
Mean surface area reduction (%) – long-term tube-fed adults with pressure ulcers (unclear if nutritionally deficient)⁴²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	73% n=6	42% n=6	-	MD 31%	Very low	Critical
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Very high protein dietary formula (92 to 150gms/day)	High protein dietary formula (57 to 90 gms/day)	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability of supplements												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects (nausea, vomiting, diarrhoea)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Chernoff (1990)⁴² was an abstract. No details of sequence generation, allocation concealment or blinding were reported by the authors. No details were provided on baseline differences except ulcer size – the very high protein group ranged from 1.6cm² to 46.4cm² and 1.6cm² to 63.8cm² in the high protein group.

(b) A very small sample size was used and there were a limited number of events.

(c) No standard deviations given. The study used a very small sample size.

Table 32: Clinical evidence profile: 1000mg ascorbic acid (500mg twice daily) and standard hospital diet versus standard hospital diet and placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	500mg ascorbic acid and standard hospital diet	Standard hospital diet and placebo	Relative (95% CI)	Absolute		
Proportion with complete healing – people from 11 nursing homes and 1 hospital (most with nutritional deficiencies) with pressure ulcers (partial thickness skin loss or worse) and adults undergoing surgery (unclear if nutritionally deficient)^{k 184}; Taylor (1974)¹⁸³												
2	Randomised trials	Very serious ^a	Serious inconsistency ^d	No serious indirectness	Very serious ^b	None	23/53 (43.4%) ^e	25/55 (45.5%) ^e	RR 0.95 (0.62 to 1.47)	23 fewer per 1000 (from 173 fewer to 214 more)	Very low	Critical
							-	39.4%		20 fewer per 1000 (from 150 fewer to 185 more)		
Time to complete healing (better indicated by lower values) – people from 11 nursing homes and 1 hospital with pressure ulcers (partial thickness skin loss or worse) (most with nutritional deficiencies)¹⁸⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None ^f	n= 43	n= 45	-	HR 0.78 higher (0.39 to 1.54 higher)	Very low	Critical
Mean % surface area reduction – people undergoing surgery (unclear if nutritionally deficient)¹⁸³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	84 (s.d 2.4) n= 10	42.7 (s.d23.43) n= 10	-	MD 41.3 higher (20.51 to	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	500mg ascorbic acid and standard hospital diet	Standard hospital diet and placebo	Relative (95% CI)	Absolute		
										62.09 higher)g		
Rate of mean reduction in ulcer size (cm²/week) – people from 11 nursing homes and 1 hospital with pressure ulcers (partial thickness skin loss or worse) (most with nutritional deficiencies)¹⁸⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	0.21 n=43	0.27 n=45	-	MD -0.06 Adjusted difference: -0.02 (95% CI - 0.20 to 0.16)h	Very low	Critical
Rate of mean reduction in ulcer size (cm²/week) – people undergoing surgery (unclear if nutritionally deficient)¹⁸³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^l	None	2.47 n=10	1.45 n=10	-	MD 1.02	Very low	Critical
Rate of mean reduction in volume (ml/week) – people from 11 nursing homes and 1 hospital with pressure ulcers (partial thickness skin loss or worse) (most with nutritional deficiencies)¹⁸⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	Serious ⁱ	0 n=43	0.20 n=45	-	MD -0.20 Adjusted difference: -0.66 (95% CI - 1.44 to 0.78)f	Very low	Critical
Rate of % reduction in volume (%/week) – people from 11 nursing homes and 1 hospital with pressure ulcers (partial thickness skin loss or worse) (most with nutritional deficiencies)¹⁸⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^{cj}	Serious ⁱ	-3.39 n=43	16.71 n=45	-	-20.10 Adjusted	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	500mg ascorbic acid and standard hospital diet	Standard hospital diet and placebo	Relative (95% CI)	Absolute		
										difference: 35.33 (95% CI - 11.31 to 81.91)		
Rate of mean healing velocity (cm/week) – people from 11 nursing homes and 1 hospital with pressure ulcers (partial thickness skin loss or worse) (most with nutritional deficiencies) ¹⁸⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	Serious ⁱ	0.12 n=43	0.19 n=45	-	-0.08 Adjusted difference -0.05 (95% CI - 0.148 to 0.048)	Very low	Critical
All-cause mortality– people from 11 nursing homes and 1 hospital (most with nutritional deficiencies) with pressure ulcers (partial thickness skin loss or worse) and people undergoing surgery (unclear if nutritionally deficient)¹⁸⁴; Taylor (1974)¹⁸³												
2	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	4/53 (7.5%)	6/55 (10.9%)	RR 0.69 (0.21 to 2.32)	34 fewer per 1000 (from 86 fewer to 144 more)	Very low	Important
							-	10.6%		33 fewer per 1000 (from 84 fewer to 140 more)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	500mg ascorbic acid and standard hospital diet	Standard hospital diet and placebo	Relative (95% CI)	Absolute		
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability of supplements												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) Ter Riet (1994)¹⁸⁴ did not provide details of allocation concealment. The control group had a greater number of large ulcers at baseline. There was a high drop-out rate. Taylor (1974)¹⁸³ was a quasi-randomised study using year of birth. There was inadequate allocation concealment.
- (b) The confidence interval crossed both MID points (0.75 to 1.25 for dichotomous data and 0.5 x SD for continuous data).
- (c) No standard deviations were given.
- (d) I^2 was 56% but p value was 0.13 so this was not significant. The populations differed as 1 study included people in a nursing home and the other included people undergoing surgery.
- (e) Data was extracted from graphs in the Cochrane Review by Langer.
- (f) Cox proportional hazards analysis in which wound survival ratio was adjusted for differences from baseline. Kaplan-Meier wound survival curves were done for all participants, $p=0.84$ log rank test, 1 tailed.
- (g) The standard deviation was calculated from the standard error.
- (h) The 95% CI were calculated from 90% CI, which was reported by the authors.
- (i) No log transformation of data and non-parametric tests were used.
- (j) There were only 12 people in the intervention group and 13 people in the control group when this was measured.
- (k) Ter Riet (1994)¹⁸⁴ state that most participants had a nutritional deficiency on admission. Taylor (1974)¹⁸³ does not mention whether participants were nutritionally deficient.
- (l) No standard deviations given. The study used a small sample size.

Table 33: Clinical evidence profile: zinc sulfate versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Zinc sulfate	Placebo	Relative (95% CI)	Absolute		
Proportion with complete healing - zinc sulfate 220mg versus placebo (unclear if nutritionally deficient)³⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	Serious ^c	1/6 (16.7%)	2/7 (28.6%)	RR 0.58 (0.07 to 4.95)	120 fewer per 1000 (from 266 fewer to 1000 more)	Very low	Critical
							-	28.6%		120 fewer per 1000 (from 266 fewer to 1000 more)		
Mean reduction in pressure ulcer volume (ml) - zinc sulfate 200mg 3 times per day versus placebo – people in a hospital with chronic disease and geriatric problems with non-superficial pressure ulcers (unclear if nutritionally deficient)¹⁴⁰												
1	Randomised trial	Very serious ^d	No serious inconsistency	No serious indirectness	Very serious ^b	Serious ^c	10.1 (s.d 9) n= 10	6 (s.d 17.5) n= 10	-	MD 4.1 higher (8.1 lower to 16.3 higher)	Very low	Critical
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Zinc sulfate	Placebo	Relative (95% CI)	Absolute		
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability of supplements												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects (nausea, vomiting, diarrhoea)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Brewer (1967)³⁰ did not provide details of sequence generation or unclear allocation concealment. No details of baseline values were provided.

(b) The confidence interval crossed both MID points (0.75 to 1.25 for dichotomous data and 0.5 x SD for continuous data).

(c) No log transformations and no non-parametric tests were used.

(d) Norris (1971)¹⁴⁰ did not provide details of sequence generation. There was a high drop-out rate.

Table 34: Clinical evidence profile: concentrated, fortified, collagen protein hydrolysate versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Concentrated, fortified, collagen protein hydrolysate	Placebo	Relative (95% CI)	Absolute		
Mean reduction in PUSH scores (final scores) – elderly adults or people with a spinal injury, stage 2, 3, or 4 ulcers (unclear if nutritionally deficient but overweight)¹⁰⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	Serious ^e	3.55 (s.d 4.66) n= 44	3.22 (s.d 4.11) n= 27	-	MD 0.33 higher (1.74 lower to 2.4 higher)	Very low	Critical
% reduction in PUSH tool score (change scores) – elderly adults or people with a spinal injury, stage 2, 3, or 4 ulcers (unclear if nutritionally deficient but overweight)¹⁰⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^d	None	60% n=44	48% n=27	-	MD 12% p<0.05	Very low	Critical
All-cause mortality– elderly adults or people with a spinal injury, stage 2, 3, or 4 ulcers (unclear if nutritionally deficient but overweight)¹⁰⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	1/56 (1.8%)	1/33 (3%)	RR 0.59 (0.04 to 9.11)	12 fewer per 1000 (from 29 fewer to 246 more)	Very low	Important
							-	3%		12 fewer per 1000 (from 29 fewer to 243 more)		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Concentrated, fortified, collagen protein hydrolysate	Placebo	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects (nausea, vomiting, diarrhoea)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) There was inadequate sequence generation (the first participant was randomised by a flip of a coin, following participants were alternated between the 2 groups.) There was no allocation concealment. There was a high drop-out rate.
- (b) The confidence interval crossed 1 MID point (0.75 to 1.25 for dichotomous data and 0.5 x SD for continuous data).
- (c) The confidence interval crossed both MID points (0.75 to 1.25 for dichotomous data and 0.5 x SD for continuous data). There were a limited number of events.
- (d) No standard deviations were given.
- (e) ANOVA with repeated measures was used to compare pressure ulcer healing. No log transformation and no non-parametric tests were used.
- (f) NPUAP 2005 classification for pressure ulcers.

Table 35: Clinical evidence profile: ornithine alpha-ketoglutarate versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	10g Ornithine alpha-ketoglutarate	Placebo	Relative (95% CI)	Absolute		
Rate of complete healing (cm²/day) – elderly adults who had pressure ulcers of the heel of stage 2 or 3 (unclear if nutritionally deficient)¹¹⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	0.07 (s.d 0.11) n= 85	0.04 (s.d 0.08) n= 75	-	MD 0.03 higher (0 to 0.06 higher)	Very low	Critical
Mean % reduction in ulcer size – elderly adults who had pressure ulcers of the heel of stage 2 or 3 (unclear if nutritionally deficient) – log transformed data¹¹⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None ^f	59.5 (s.d 71.4) n= 85	54 (s.d 69) n= 75	-	Simple analysis: MD 5.5 higher (16.28 lower to 27.28 higher) Ancova analysis p=0.477	Very low	Critical
Mean surface area reduction (cm²) – elderly adults who had pressure ulcers of the heel of stage 2 or 3(unclear if nutritionally deficient)¹¹⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None ^f	2.3 (s.d 4.2) n= 85	1.7 (s.d 1.7) n= 75	-	MD 0.6 higher (0.37 lower to 1.57 higher)	Very low	Critical
90% reduction by week 6– elderly adults who had pressure ulcers of the heel of stage 2 or 3(unclear if nutritionally deficient)¹¹⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	23.4% n=85	13% n=75	OR 0.49 (CI 0.16 to 14.6)e	-	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	10g Ornithine alpha-ketoglutarate	Placebo	Relative (95% CI)	Absolute		
All-cause mortality – elderly adults who had pressure ulcers of the heel of stage 2 or 3 (unclear if nutritionally deficient)¹¹⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	5/89 (5.6%)	3/76 (3.9%)	RR 1.42 (0.35 to 5.76)	17 more per 1000 (from 26 fewer to 188 more)	Very low	Important
							-	4%		17 more per 1000 (from 26 fewer to 190 more)		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability of supplements												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects (nausea, vomiting, diarrhoea)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) There was a very high drop-out in both arms. Due to problems in recruitment, the study was opened up to other centres so some centres had 2 participants and randomisation was balanced by blocks of 4. There were baseline differences. The missing data higher than event rate.
- (b) The confidence interval crossed 1 MID point.
- (c) The confidence interval crossed both MID points.
- (d) This is the value reported by the study.
- (e) This is the odds ratio reported by study.
- (f) ANCOVA used. Non-parametric tests detected between-group differences ($p=0.044$) which were confirmed by parametric tests after log-transformation to normalise distribution ($p=0.027$ for group comparisons).
- (g) NPUAP classification of pressure ulcers.

Table 36: Clinical evidence profile: arginine 4.5g versus arginine 9g

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Arginine 4.5g	Arginine 9g	Relative (95% CI)	Absolute		
Decrease in PUSH tool scores (better indicated by lower values) – people in hospital with pressure ulcers grade 2, 3 or 4¹⁰⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	3.4 n=12	3.1 n=11	MD 0.30 p=0.991	Not pooled	Very low	Critical
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability of supplements												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Arginine 4.5g	Arginine 9g	Relative (95% CI)	Absolute		
Side effects (nauseas, vomiting, diarrhoea)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No details were provided of blinding of participant or healthcare professional; there was a greater than 10% differential drop-out.

(b) No standard deviations were given for between group differences. No log transformations were provided.

(c) NPUAP classification of pressure ulcers.

Table 37: Clinical evidence profile: arginine 4.5g in malnourished participants versus arginine 9g in malnourished participants

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Arginine 4.5g	Arginine 9g	Relative (95% CI)	Absolute		
Decrease in PUSH tool scores (better indicated by lower values) – people in hospital with pressure ulcers grade 2, 3 or 4¹⁰⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	0.90 n=unclear	2.9 n=unclear	MD 2	Not pooled	Very low	Critical
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Arginine 4.5g	Arginine 9g	Relative (95% CI)	Absolute		
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability of supplements												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects (nausea, vomiting, diarrhoea)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No details of blinding of participant or healthcare professionals were provided. There was a greater than 10% differential drop-out.

(b) No standard deviations given for between group differences were provided and the authors did not report the sample size. No log transformations were provided.

(c) NPUAP classification of pressure ulcers.

Table 38: Clinical evidence profile: arginine 4.5g in well-nourished participants versus arginine 9g in well-nourished participants

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Arginine 4.5g + well nourished	Arginine 9g + well nourished	Relative (95% CI)	Absolute		
Decrease in PUSH tool scores (better indicated by lower values)- people in hospital with pressure ulcers grade 2, 3 or 4¹⁰⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2.7 n= unclear	3 n= unclear	MD 0.30	Not pooled	Very low	Critical
Proportion of people with pressure ulcers completely healed												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Arginine 4.5g + well nourished	Arginine 9g + well nourished	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability of supplements												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No details of blinding of participants or healthcare professionals were provided. There was a greater than 10% differential drop-out.

(b) No standard deviations given for between group differences were provided and the authors did not report sample size. No log transformations were provided.

(c) NPUAP classification of pressure ulcers.

Table 39: Clinical evidence profile: nutritional formula with fish oil and macronutrients versus isocaloric control formula

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Nutritional formula with fish oil and macronutrients	Isocaloric control formula - ICU patients	Relative (95% CI)	Absolute		
Increase in mean PUSH tool score (better indicated by lower values) – people in intensive care with pressure ulcers grade 2 or above^c – unclear if nutritionally deficient^{186,187}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	1.50 n= 20	0.30 n= 20	MD 1.20	Not pooled	Very low	Critical
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) No details of allocation concealment were provided by the authors. There was no blinding of staff in the intensive care unit, participants or the assessor of pressure ulcer severity.*
- (b) No standard deviations were given for between group differences. No log transformations were provided*
- (c) NPUAP classification of pressure ulcers.*

5.2.12 Economic evidence (adults)

5.2.221 Published literature

- 3 One study was included with a relevant comparison.⁸⁰ This is summarised in the economic evidence
- 4 profile below (Table 40). See also the study selection flow chart in Appendix D and study evidence
- 5 table in Appendix H.
- 6

Table 40: Economic evidence profile: Nutritional supplement versus standard hospital diet

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
Hisahige 2012 ⁸⁰ (Japan)	Partially applicable ^a	Potentially serious limitations ^b	Economic evaluation based on single RCT plus post trial extrapolation. Comparison of nutritional supplementation to standard hospital diet in people with pressure ulcers.	-£586	-16.2 pressure ulcer days	The supplement dominates the standard hospital diet (cost saving and fewer pressure ulcer days)	Unclear.

(a) This study is set in Japan; the authors claim to reports a societal perspective, yet this does appear to align with the perspective of a Japanese healthcare provider in this case.

(b) The effectiveness estimates are based on the results of a single RCT set in Japan, rather than a systematic procedure. QALYs are reported but calculation is unclear. It is unclear how the cost-effectiveness ratios have been calculated; many of these are negative. Only these cost-effectiveness ratios are reported from the analysis of uncertainty.

5.2.212 Unit costs

2 In the absence of recent UK cost-effectiveness analysis, relevant unit costs are provided below to aid
3 consideration of cost effectiveness. These costs represent costs per day of various supplements used
4 in the treatment of pressure ulcers. These are the list prices, and the GDG acknowledged that the
5 actual price paid is often much lower than those stated in the table below. The specific supplements
6 included are illustrative only, and should not be interpreted as GDG recommendations.

7 **Table 41: Unit cost estimates per day for nutritional supplements in a community setting**

Item	Cost	Notes
Vitamin C (200mg)	£0.14	£1.31 per packet of 28 tablets. 3 tablets per day.
High protein supplements ^a (200ml)	£3.70	Fortisip extra. £1.85 per 200ml bottle. 2 bottles given per day.

8 (a) Such supplements also contain further potentially beneficial ingredients such as zinc and vitamin C

9 Source: BNF62⁸⁵, dosage based on discussion with GDG member

10 Total costs depend on the duration and quantity of the nutritional supplementation that is required,
11 and will vary greatly amongst participants. Monthly costs of vitamin C and protein supplementation
12 would be £4 and £115 respectively.

5.2.23 Clinical evidence (neonates, infants, children and young people)

14 No RCTs or cohort studies were identified. Recommendations were developed using a modified
15 Delphi consensus technique. Further details can be found in Appendix N.

5.2.24 Economic evidence (neonates, infants, children and young people)

17 No economic evidence was identified.

5.2.25 Evidence statements

5.2.25.1 Clinical (adults)

5.2.25.1.1 Supplement of 500kcal, 34g protein, 6g arginine, 500mg vitamin C, 18mg zinc in addition to a standard hospital diet versus standard hospital diet alone

- 21
- 22 • One study (n=28) showed a supplement of 500kcal, 34g protein, 6g arginine, 500mg vitamin C,
23 18mg zinc in addition to a standard hospital diet may be more clinically effective than standard
24 hospital diet alone for complete healing of pressure ulcers (very low quality).
- 25 • One study (n=28) reported a supplement of 500kcal, 34g protein, 6g arginine, 500mg vitamin C,
26 18mg zinc in addition to a standard hospital diet may be more clinically effective and a standard
27 hospital diet alone for reduction in ulcer size (%). The mean for the supplement was 72% and 45%
28 for the standard hospital diet. No estimate of precision could be derived (very low quality).
- 29 • One study (n=28) showed a supplement of 500kcal, 34g protein, 6g arginine, 500mg vitamin C,
30 18mg zinc in addition to a standard hospital diet may be more clinically effective than standard
31 hospital diet alone for reduction in ulcer size (cm²) (very low quality).
- 32 • One study (n=28) showed a supplement of 500kcal, 34g protein, 6g arginine, 500mg vitamin C,
33 18mg zinc in addition to a standard hospital diet is potentially more clinically effective than
34 standard hospital diet alone for reducing mean PUSH tool scores (very low quality).
- 35 • One study (n=28) showed a standard hospital diet alone may be more clinically beneficial than a
36 supplement of 500kcal, 34g protein, 6g arginine, 500mg vitamin C, 18mg zinc in addition to a
37 standard hospital diet for reducing all-cause mortality (very low quality).

- 1 • No evidence was found for the following outcomes:
- 2 o Time to complete healing (time to event data)
- 3 o Rate of complete healing
- 4 o Rate in change of size of ulcer
- 5 o Pain (wound-related)
- 6 o Time in hospital
- 7 o Patient acceptability of supplements
- 8 o Side effects (nausea, vomiting, diarrhoea)
- 9 o Health-related quality of life

5.2.5.102 Supplement of 250kcal, 28.4g carbohydrates, 20g protein, 3g arginine, 7g fat, vitamins, minerals in addition to a standard hospital diet versus standard hospital diet and placebo

- 12 • One study (n=43) showed there may be no clinical difference between a supplement of 250kcal,
13 28.4g carbohydrates, 20g protein, 3g arginine, 7g fat, vitamins, minerals in addition to a standard
14 hospital diet and a standard hospital diet and placebo for reducing mean PUSH tool score, the
15 direction of the estimate of effect favoured the supplement. Imprecision could not be derived.
16 (very low quality).
- 17 • One study (n=43) showed there may be no clinical difference between a supplement of 250kcal,
18 28.4g carbohydrates, 20g protein, 3g arginine, 7g fat, vitamins, minerals in addition to a standard
19 hospital diet and a standard hospital diet and placebo for rate of reduction in ulcer size
20 (cm²/week). The direction of the estimate of effect favoured the standard hospital diet and
21 placebo. Imprecision could not be derived. (very low quality).
- 22 • One study (n=43) showed a supplement of 250kcal, 28.4g carbohydrates, 20g protein, 3g arginine,
23 7g fat, vitamins, minerals in addition to a standard hospital diet is potentially more clinically
24 harmful than a standard hospital diet and placebo for adverse events related to the product (very
25 low quality).
- 26 • One study (n=43) showed a supplement of 250kcal, 28.4g carbohydrates, 20g protein, 3g arginine,
27 7g fat, vitamins, minerals in addition to a standard hospital diet may be more clinically harmful
28 than a standard hospital diet and placebo for adverse events related to the product (very low
29 quality).
- 30 • One study (n=43) showed a supplement of 250kcal, 28.4g carbohydrates, 20g protein, 3g arginine,
31 7g fat, vitamins, minerals in addition to a standard hospital diet may be more clinically harmful
32 compared to a standard hospital diet and placebo for diarrhoea (very low quality).
- 33 • One study (n=43) showed there may be no clinical difference between a supplement of 250kcal,
34 28.4g carbohydrates, 20g protein, 3g arginine, 7g fat, vitamins, minerals in addition to a standard
35 hospital diet compared to a standard hospital diet and placebo for nausea. The direction of the
36 estimate of effect favoured the supplement (very low quality).
- 37 • One study (n=43) showed there may be no clinical difference between a supplement of 250kcal,
38 28.4g carbohydrates, 20g protein, 3g arginine, 7g fat, vitamins, minerals in addition to a standard
39 hospital diet compared to a standard hospital diet and placebo for vomiting. The direction of the
40 estimate of effect favoured the supplement (very low quality).
- 41 • No evidence was found for the following outcomes:
- 42 o Time to complete healing (time to event data)
- 43 o Rate of complete healing
- 44 o Reduction in size of ulcer and volume of ulcer.
- 45 o Proportion of people completely healed
- 46 o Pain (pressure ulcer related)
- 47 o Time in hospital

- 1 o Patient acceptability of supplements
- 2 o Mortality (all-cause)
- 3 o Health-related quality of life

5.2.5.143 Supplement of 500kcal, 18g protein, 0g fat, 72mg vitamin C and 7.5mg zinc in addition to a standard hospital diet versus standard hospital diet

- 5
- 6 • One study (n=11) showed there may be no clinical difference between a supplement of 500kcal,
7 18g protein, 0g fat, 72mg vitamin C and 7.5mg zinc in addition to a standard hospital diet and a
8 standard hospital diet for reducing PUSH tool scores by week 3. The direction of the estimate of
9 effect favoured the supplement (very low quality).
- 10 • No evidence was found for the following outcomes:
 - 11 o Time to complete healing (time to event data)
 - 12 o Rate of complete healing
 - 13 o Rate in change of size of ulcer
 - 14 o Reduction in size of ulcer and volume of ulcer.
 - 15 o Proportion of people completely healed
 - 16 o Pain (pressure ulcer-related)
 - 17 o Time in hospital
 - 18 o Patient acceptability of supplements
 - 19 o Side effects (nausea, vomiting, diarrhoea)
 - 20 o Mortality (all-cause)
 - 21 o Health-related quality of life

5.2.5.124 Supplement of 500kcal, 21g protein, 0g fat, 500mg vitamin C, 30mg zinc and 9g arginine and standard hospital diet versus standard hospital diet

- 22
- 23
- 24 • One study (n=11) showed a clinical benefit of a supplement of 500kcal, 21g protein, 0g fat, 500mg
25 vitamin C, 30mg zinc and 9g arginine for reducing PUSH tool scores and standard hospital diet
26 compared to a standard hospital diet alone (very low quality).
- 27 • No evidence was found for the following outcomes:
 - 28 o Time to complete healing (time to event data)
 - 29 o Rate of complete healing
 - 30 o Rate in change of size of ulcer
 - 31 o Reduction in size of ulcer and volume of ulcer.
 - 32 o Proportion of people completely healed
 - 33 o Pain (pressure ulcerrelated)
 - 34 o Time in hospital
 - 35 o Patient acceptability of supplements
 - 36 o Side effects (nausea, vomiting, diarrhoea)
 - 37 o Mortality (all-cause)
 - 38 o Health-related quality of life
- 39

5.2.5.105 Supplement of 500kcal, 21g protein, 0g fat, 500mg vitamin C, 30mg zinc and 9g arginine versus supplement of 500kcal, 18g protein, 0g fat, 72mg vitamin C and 7.5mg zinc in addition to standard hospital diet

- 40
- 41
- 42
- 43 • One study (n=11) showed a clinical benefit of a supplement of 500kcal, 21g protein, 0g fat, 500mg
44 vitamin C, 30mg zinc and 9g arginine for reducing PUSH tool scores compared to a supplement of

- 1 500kcal, 18g protein, 0g fat, 72mg vitamin C and 7.5mg zinc in addition to a standard hospital diet
2 (very low quality).
- 3 • No evidence was found for the following outcomes:
- 4 o Time to complete healing (time to event data)
- 5 o Rate of complete healing
- 6 o Rate in change of size of ulcer
- 7 o Reduction in size of ulcer and volume of ulcer.
- 8 o Proportion of people completely healed
- 9 o Pain (pressure ulcer related)
- 10 o Time in hospital
- 11 o Patient acceptability of supplements
- 12 o Side effects (nausea, vomiting, diarrhoea)
- 13 o Mortality (all-cause)
- 14 o Health-related quality of life

5.2.5.156 Supplement of 4.38g protein, 2.23g fat, 15.62g carbohydrate, minerals and vitamins (per 100ml) and standard hospital diet versus standard hospital diet

- 16
- 17 • One study (n=50) showed there is potentially a clinical benefit for a supplement of 4.38g protein,
18 2.23g fat, 15.62g carbohydrate, minerals and vitamins (per 100ml) and standard hospital diet for
19 complete healing of pressure ulcers when compared to a standard hospital diet (very low quality).
- 20 • One study (n=50) showed there is no clinical difference between a supplement of 4.38g protein,
21 2.23g fat, 15.62g carbohydrate, minerals and vitamins (per 100ml) and standard hospital
22 compared to a standard hospital diet for reducing the mean ulcer size (cm²) (low quality).
- 23 • One study (n=50) showed a supplement of 4.38g protein, 2.23g fat, 15.62g carbohydrate, minerals
24 and vitamins (per 100ml) and standard hospital diet may be clinically harmful for study-related
25 adverse events when compared to a standard hospital diet (very low quality).
- 26 • No evidence was found for the following outcomes:
- 27 o Time to complete healing (time to event data)
- 28 o Rate of complete healing
- 29 o Rate in change of size of ulcer
- 30 o Pain (pressure ulcer related)
- 31 o Time in hospital
- 32 o Patient acceptability of supplements
- 33 o Mortality (all-cause)
- 34 o Health-related quality of life

5.2.5.357 Very high protein dietary formula (92 to 150gms/day) versus high protein dietary formula (57 to 90gms/day)

- 36
- 37 • One study (n=12) showed a very high protein dietary formula (92 to 150gms/day) is potentially
38 more clinically effective for complete healing of pressure ulcers when compared to a high protein
39 dietary formula (57 to 90gms/day) in long-term tube-fed people (very low quality).
- 40 • One study (n=12) reported a very high protein dietary formula (92 to 150gms/day) may be more
41 clinically effective for reducing mean surface area (%) of pressure ulcers when compared to a high
42 protein dietary formula (57 to 90gms/day) in long-term tube-fed people. No estimate of precision
43 could be derived (very low quality).
- 44 • No evidence was found for the following outcomes:
- 45 o Time to complete healing (time to event data)

- 1 o Rate of complete healing
- 2 o Rate in change of size of ulcer
- 3 o Pain (pressure ulcer related)
- 4 o Time in hospital
- 5 o Patient acceptability of supplements
- 6 o Side effects (nausea, vomiting, diarrhoea)
- 7 o Mortality (all-cause)
- 8 o Health-related quality of life

5.2.5.198 Supplement of 1000mg ascorbic acid in addition to standard hospital diet versus hospital diet and placebo

- 11 • Two studies (n=108) showed there may be no clinical difference between a supplement of
12 1000mg ascorbic acid in addition to standard hospital diet and hospital diet and placebo for
13 complete healing of pressure ulcers. The direction of estimate of effect favoured the standard
14 hospital diet and placebo group (very low quality).
- 15 • One study (n=85) reported there may be no difference between a supplement of 1000mg ascorbic
16 acid in addition to standard hospital diet and hospital diet and placebo for time to complete
17 healing of pressure ulcers (very low quality).
- 18 • One study (n=20) showed a hospital diet and placebo were more clinically effective than a
19 supplement of 1000mg ascorbic acid in addition to standard hospital diet for reducing mean
20 surface area (%) (very low quality).
- 21 • One study (n=88) reported there is possibly no clinical difference between a supplement of
22 1000mg ascorbic acid in addition to standard hospital diet and hospital diet and placebo for rate
23 of mean reduction in ulcer size (cm²/week). The direction of the estimate of effect favoured
24 either intervention (very low quality).
- 25 • One study (n=88) reported there is possibly no clinical difference between a supplement of
26 1000mg ascorbic acid in addition to standard hospital diet and hospital diet and placebo for rate
27 of mean reduction in ulcer size (%). The direction of the estimate of effect favoured either
28 intervention (very low quality).
- 29 • One study (n=88) reported there may be no clinical difference between a supplement of 1000mg
30 ascorbic acid in addition to standard hospital diet and hospital diet and placebo for rate of mean
31 reduction in ulcer size (cm²/week/%). The direction of the estimate of effect favoured either
32 intervention (very low quality).
- 33 • One study (n=88) reported there is potentially no clinical difference between a supplement of
34 1000mg ascorbic acid in addition to standard hospital diet and hospital diet and placebo for rate
35 of mean reduction in ulcer volume (cm²/week/%). The direction of the estimate of effect favoured
36 the supplement (very low quality).
- 37 • One study (n=88) reported there is potentially no clinical difference between a supplement of
38 1000mg ascorbic acid in addition to standard hospital diet and hospital diet and placebo for rate
39 of mean healing velocity. The direction of the estimate of effect favoured the supplement (very
40 low quality).
- 41 • One study (n=88) showed there may be no clinical difference between a supplement of 1000mg
42 ascorbic acid in addition to standard hospital diet and hospital diet and placebo for mortality. The
43 direction of the estimate of effect favoured the supplement (very low quality).
- 44 • No evidence was found for the following outcomes:
 - 45 o Time to complete healing (time to event data)
 - 46 o Rate of complete healing
 - 47 o Pain (pressure ulcer related)

- 1 o Time in hospital
- 2 o Patient acceptability of supplements
- 3 o Side effects (nausea, vomiting, diarrhoea)
- 4 o Health-related quality of life

5.2.5.159 Zinc sulphate versus placebo

- 6 • One study (n=13) showed zinc sulphate may be more clinically effective for complete healing than
7 placebo (very low quality).
- 8 • One study (n=13) showed there may be no clinical difference between zinc sulphate and placebo
9 for mean reduction in pressure ulcer volume. The direction of the estimate of effect favoured zinc
10 sulphate (very low quality).
- 11 • No evidence was found for the following outcomes:
 - 12 o Time to complete healing (time to event data)
 - 13 o Rate of complete healing
 - 14 o Rate in change of size of ulcer
 - 15 o Pain (pressure ulcer related)
 - 16 o Time in hospital
 - 17 o Patient acceptability of supplements
 - 18 o Side effects (nausea, vomiting, diarrhoea)
 - 19 o Mortality (all-cause)
 - 20 o Health-related quality of life

5.2.5.1210 Supplement of concentrated, fortified, collagen protein hydrolysate versus placebo

- 22 • One study (n=71) showed there is potentially no clinical difference between a supplement of
23 concentrated, fortified, collagen protein hydrolysate when compared to placebo for reducing
24 PUSH tool scores. The direction of the estimate of effect favours placebo (mean) (very low
25 quality).
- 26 • One study (n=71) showed there is potentially no clinical difference between a supplement of
27 concentrated, fortified, collagen protein hydrolysate when compared to placebo for reducing
28 PUSH tool scores (%). The direction of the estimate of effect favours placebo (very low quality).
- 29 • One study (n=89) showed there may be no clinical difference between a supplement of
30 concentrated, fortified, collagen protein hydrolysate when compared to placebo for all-cause
31 mortality. The direction of the estimate of effect favoured the placebo (very low quality).
- 32 • No evidence was found for the following outcomes:
 - 33 o Time to complete healing (time to event data)
 - 34 o Rate of complete healing
 - 35 o Rate in change of size of ulcer
 - 36 o Reduction in size of ulcer and volume of ulcer.
 - 37 o Proportion of people completely healed
 - 38 o Pain (pressure ulcer related)
 - 39 o Time in hospital
 - 40 o Patient acceptability of supplements
 - 41 o Side effects (nausea, vomiting, diarrhoea)
 - 42 o Health-related quality of life
- 43

5.2.5.1.11 Ornithine alpha-ketoglutarate versus placebo

- 2 • One study (n=160) showed there is potentially no clinical difference between ornithine alpha-
3 ketoglutarate and placebo for rate of complete healing of heel pressure ulcers (grade 2 or 3
4 pressure ulcers). The direction of the estimate of effect favoured ornithine alpha-ketoglutarate
5 (very low quality).
- 6 • One study (n=160) showed no clinical difference between ornithine alpha-ketoglutarate and
7 placebo for mean reduction in size (% reduction). The direction of the estimate of effect favoured
8 ornithine alpha-ketoglutarate (very low quality).
- 9 • One study (n=160) showed no clinical difference between ornithine alpha-ketoglutarate and
10 placebo for mean reduction in size (mean surface area reduction). The direction of the estimate of
11 effect favoured ornithine alpha-ketoglutarate (very low quality).
- 12 • One study (n=160) showed no clinical difference between ornithine alpha-ketoglutarate and
13 placebo for 90% reduction in heel pressure ulcers. The direction of the estimate of effect favoured
14 ornithine alpha-ketoglutarate (low quality).
- 15 • One study (n=165) showed there may be no clinical difference between ornithine alpha-
16 ketoglutarate and placebo for mortality. The direction of the estimate of effect favoured the
17 placebo (very low quality).
- 18 • No evidence was found for the following outcomes:
 - 19 o Time to complete healing (time to event data)
 - 20 o Rate in change of size of ulcer
 - 21 o Proportion of people completely healed
 - 22 o Pain (pressure ulcer related)
 - 23 o Time in hospital
 - 24 o Patient acceptability of supplements
 - 25 o Side effects (nausea, vomiting, diarrhoea)
 - 26 o Health-related quality of life

5.2.5.12 Arginine 4.5g and Arginine 9g

- 28 • One study (n=23) reported there may be no difference between arginine 4.5g and arginine 9g for
29 reducing PUSH tool scores. The direction of estimate of effect favoured arginine 4.5g. The clinical
30 importance is unknown (very low quality).
- 31 • One study (n=unclear) reported there may be no difference between arginine 4.5g in
32 malnourished patient and arginine 9g in malnourished people for reducing PUSH tool scores. The
33 direction of estimate of effect favoured arginine 9g. The clinical importance is unknown (very low
34 quality).
- 35 • One study (n=unclear) reported there may be no difference between arginine 4.5g in non-
36 malnourished patient and arginine 9g in non-malnourished people for reducing PUSH tool scores.
37 The direction of estimate of effect favoured arginine 9g. The clinical importance is unknown (very
38 low quality).
- 39 • No evidence was found for the following outcomes:
 - 40 o Time to complete healing (time to event data)
 - 41 o Rate of complete healing
 - 42 o Rate in change of size of ulcer
 - 43 o Reduction in size of ulcer and volume of ulcer.
 - 44 o Proportion of people completely healed
 - 45 o Pain (pressure ulcer related)
 - 46 o Time in hospital

- 1 o Patient acceptability of supplements
- 2 o Side effects (nausea, vomiting, diarrhoea)
- 3 o Mortality (all-cause)
- 4 o Health-related quality of life

5.2.5.1.13 Nutritional formula with fish oil versus macronutrients and an isocaloric control formula

- 6 • One study (n=40) reported there may be no difference between a nutritional formula with fish oil
7 and macronutrients and an isocaloric control formula for increasing mean PUSH tool scores. The
8 direction of estimate of effect favoured the isocaloric control formula. The clinical importance is
9 unknown (very low quality).
- 10 • No evidence was found for the following outcomes:
 - 11 o Time to complete healing (time to event data)
 - 12 o Rate of complete healing
 - 13 o Rate in change of size of ulcer
 - 14 o Reduction in size of ulcer and volume of ulcer.
 - 15 o Proportion of people completely healed
 - 16 o Pain (pressure ulcer related)
 - 17 o Time in hospital
 - 18 o Patient acceptability of supplements
 - 19 o Side effects (nausea, vomiting, diarrhoea)
 - 20 o Mortality (all-cause)
 - 21 o Health-related quality of life

5.2.322 Economic (adults)

- 23 • One cost-effectiveness analysis from Japan found that nutritional supplementation dominates
24 standard hospital diet in the treatment of pressure ulcers (reduced costs and fewer pressure ulcer
25 days). This study was deemed to be partially applicable and had potentially serious limitations.

5.2.363 Clinical (neonates, infants, children and young people)

27 No evidence was identified.

5.2.384 Economic (neonates, infants, children and young people)

29 No evidence was identified.

30

5.3 Recommendations and link to evidence

5.3.1 Adults

Recommendations	<p>7. Offer adults with a pressure ulcer a nutritional assessment by a dietitian or other healthcare professional with the necessary skills and competencies.</p> <p>8. Offer nutritional supplements to adults with a pressure ulcer who have a nutritional deficiency.</p> <p>9. Do not offer nutritional supplements to treat a pressure ulcer in adults whose nutritional intake is adequate</p> <p>10. Provide information and advice to adults with a pressure ulcer on how to follow a balanced diet to maintain an adequate nutritional status, taking into account energy, protein and micronutrient requirements</p>
Relative values of different outcomes	<p>The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.</p> <p>The following were considered to be important outcomes; side effects, health related quality of life, time in hospital, mortality and acceptability of treatment.</p>
Trade-off between clinical benefits and harms	<p>The evidence was limited. Thirteen studies were identified but each of these looked at different supplement mixes. There was no strong evidence of a change in critical or important outcomes associated with the use of nutritional supplementation.</p> <p>A nutritional supplement of 500 calories, 34g protein, 6g arginine, 500mg vitamin C, 18mg zinc showed some benefit for complete healing, a higher mean reduction in the size of pressure ulcer and lower mortality rate. It was unclear if the population of this study had any nutritional deficiency.</p> <p>A nutritional supplement of 250 calories, 28.4g carbohydrates, 20g protein, 3g arginine, 7g fat, vitamins and minerals showed no benefits, showed a clinical harm from adverse events, including a higher incidence of diarrhoea, in a non-malnourished population.</p> <p>A nutritional supplement of 500 calories, 18g protein, 0g fat, 72mg vitamin C and 7.5mg zinc showed no benefit in PUSH tool scores. The PUSH tool monitors the length, width, amount of exudate and tissue type of a pressure ulcer, and is a method of predicting pressure ulcer healing in an elderly or spinal injured population. It was not clear if the population of this study had any nutritional deficiency.</p> <p>A nutritional supplement including 500 calories, 21g protein, 0g fat, 500mg vitamin C, 30mg zinc and 9g arginine showed a lower PUSH score (with lower being more beneficial). These supplements were all in addition to the standard hospital diet and compared to the standard hospital diet. When the 2 supplements were compared there to each other there was a clinical benefit of the supplement which included 500 calories, 21g protein, 0g fat, 500mg vitamin C, 30mg zinc and 9g arginine for reduction in PUSH tool scores.</p>

	<p>A study of tube fed people who received 4.38g protein, 2.23g fat, 15.6g carbohydrate, minerals and vitamins per 100ml in addition to the standard hospital diet showed a higher incidence of complete healing in the supplement group. However, the group also had a higher incidence of adverse events.</p> <p>A very high protein formula (92 to 150gm/day) given in addition to the standard hospital diet was clinically beneficial compared to an additional high protein formula (57g to 90 g per day) in long-term tube-fed people. However, it was unclear if the population of this study had any nutritional deficiency and the GDG were concerned that the clinical benefits were dependant on the protein content of the hospital diet. The study also had a very small sample size.</p> <p>Two studies were meta-analysed for 1000mg ascorbic acid supplementation in addition to the standard hospital diet in a population of people whom mostly had nutritional deficiencies. No difference was found except for a higher reduction in the surface area of the pressure ulcer in the group who received nutritional supplementation.</p> <p>When zinc sulphate 220mg was compared to placebo in a population of people with spinal cord injuries, in whom it was unclear if there was any nutritional deficiency, there was less complete healing of pressure ulcers in the zinc sulphate group. Yet, another study of zinc sulphate 200mg 3 times per day compared to placebo (lactose) showed a higher mean reduction in pressure ulcer volume. The GDG were uncertain of the clinical benefit of this outcome, particularly as these studies had very small sample sizes.</p> <p>There were no differences between a concentrated, fortified, collagen protein hydrolysate nutritional supplement compared to placebo, in an overweight population with no indication of nutritional deficiency. There were no differences for ornithine alpha-ketoglutarate compared to placebo and it was unclear if the population were nutritionally deficient. There were no differences reported between arginine 4.5g and arginine 9g for reducing PUSH tool scores.</p> <p>The GDG considered there to be insufficient evidence to support the use of nutritional supplements for people with press</p> <p>The GDG developed a corresponding recommendation to highlight that people who have a pressure ulcer should receive an assessment to identify the presence of any nutritional deficiency.</p> <p>The GDG considered that all people who have a pressure ulcer would benefit from maintaining an adequate nutritional status and information should be provided to these groups to help encourage this.</p>
<p>Economic considerations</p>	<p>The GDG considered 1 economic analysis from Japan which found that nutritional supplementation dominated a standard hospital diet amongst tube-fed, bed-ridden people with stage 3 to 4 pressure ulcers. However it was unclear whether the patients were nutritionally deficient. The applicability of this study is limited as the study was conducted in Japan.</p> <p>The GDG discussed that the correction of nutritional deficiency is best practice and is an issue of patient safety. The GDG agreed that it was important for people to be provided with adequate nutrition, as the correction of nutritional deficiency has benefits which extend far beyond the treatment of pressure ulcers. The GDG considered the UK costs of nutritional supplements and agreed that whilst the list prices documented were not negligible, the actual prices paid for nutritional supplements were very low especially in hospitals, and the correction of nutritional</p>

	<p>deficiency can be achieved at low cost particularly with a 'food first' approach.</p> <p>The GDG felt there was limited additional benefit to providing extra nutritional supplementation where nutritional status was adequate and intake was meeting any additional losses. It was felt that, given the (albeit small) costs, it would not be cost-effective to do so.</p> <p>The GDG discussed the resource implications of nutritional assessment by a dietician or healthcare professional with the necessary skills and competencies. It was recognised that there is an economic implication associated with healthcare professional time, but that this was necessary in order to promote the efficient use of resources; that is, it is necessary to establish an individual's nutritional status in order to plan treatment accordingly. The GDG agreed that the cost of assessing the patient would be offset by efficiencies gained through appropriate treatment strategies, leading to reduced treatment costs overall, and improvements in quality of life.</p> <p>The additional costs of providing information are thought to be small, and justified by potentially large gains.</p>
Quality of evidence	<p>Overall, the quality of evidence for the effects of nutritional supplements for the management of pressure ulcers was of low quality because of study limitations. The GDG acknowledged that evidence was often difficult to interpret as nutritional interventions are rarely used in isolation and in clinical practice, are used with appropriate dressings, repositioning and pressure redistributing devices. There was also limited information about liquid losses from the pressure ulcer that would need replacing such as levels of exudative loss.</p> <p>The GDG highlighted that studies of nutritional supplementation do not always consider the consumption of supplements and overall calorie intake.</p> <p>These recommendations were based on GDG informal consensus after reviewing the evidence for nutritional supplements.</p>
Other considerations	<p>The GDG clearly stated that it was important people were provided with adequate nutrition, regardless of the effectiveness of nutritional supplementation in treating pressure ulcers. However, if people did not have a nutritional deficiency then there was limited evidence for additional nutritional supplementation as long as ongoing losses in energy and protein from exudate are also met. The GDG felt that people should be offered a nutritional assessment from a qualified practitioner so that a person's nutritional status can be determined. They also noted the importance of giving people and carers information and advice regarding nutrition so that they can ensure they are meeting their nutritional requirements and replacing any losses from the pressure ulcer.</p> <p>The GDG highlighted the importance of ensuring that people who are nutritionally deficient should be provided with appropriate nutritional supplementation to provide the correct level of nutrition, in line with NICE clinical guideline 32 'Nutrition support in adults: Oral nutrition support, enteral tube feeding and parenteral nutrition'¹³⁰.</p> <p>Recommendations on the provision of information to patients and carers can be found in NICE clinical guideline 138 'Patient experience in adult NHS services: improving the experience of care for people using adult NHS services.'</p>

1

Recommendations	11. Do not offer subcutaneous or intravenous fluids to treat pressure ulcers
------------------------	---

	in adults whose hydration status is adequate.
Relative values of different outcomes	<p>The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.</p> <p>Side effects, health related quality of life, time in hospital, mortality and acceptability of treatment were considered important outcomes.</p>
Trade off between clinical benefits and harms	<p>No evidence was found for hydration for the treatment of pressure ulcers. The GDG felt that if a person's hydration is adequate then they would not require a hydration strategy to alter how they are being hydrated. The GDG also considered that it was unlikely that there would be any benefits to the provision of additional fluids in people with an adequate hydration status and that it was possible that the provision of additional fluids could result in harms to the individual.</p> <p>The GDG noted that medical opinion should be sought by any healthcare professional that has identified a person has less than adequate hydration status.</p>
Economic considerations	<p>Extra resources would be required to provide additional hydration strategies to individuals with adequate hydration. Given that the GDG felt that such additional strategies were not required, it would not be cost-effective to offer these.</p>
Quality of evidence	<p>This recommendation was based on GDG consensus as there was no evidence found.</p>
Other considerations	<p>There were no other considerations.</p>

5.3.12 Neonates, infants, children and young people

Recommendations	<p>12. Offer an age-related nutritional assessment to neonates, infants, children and young people with a pressure ulcer. This should be performed by a paediatric dietitian or other healthcare professional with the necessary skills and competencies.</p>
Relative values of different outcomes	<p>The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.</p>
Trade-off between clinical benefits and harms	<p>The GDG developed the statement that 'Healthcare professionals should offer neonates, infants, children and young people with pressure ulcers a suitable age related nutritional assessment' which was accepted during round 1 of the Delphi consensus survey at a consensus level of 100%.</p> <p>The GDG therefore used the statement to develop a recommendation that all neonates, infants, children and young people who have developed a pressure ulcer should have a suitable age related nutritional assessment. The GDG considered that it was important for healthcare professionals to identify whether any child who has had a pressure ulcer has an adequate nutritional intake, as correction of nutritional deficiency may improve the ability of the body to heal.</p> <p>The GDG considered that there is likely to be significant benefits to providing a nutritional assessment to this population, in the subsequent ability to heal, as well as other related improvements associated with identifying nutritional deficiencies. The GDG felt that any resource implications of providing an assessment would be outweighed by the subsequent benefits of identifying deficiency, in terms of both pressure ulcer treatment and other related health outcomes.</p> <p>Comments received from the Delphi consensus panel provided further support for</p>

	the provision of a nutritional assessment for all people who have developed a pressure ulces, highlighting that the loss of protein from the wound may result in a decreased ability to heal and suboptimal nutritional status.
Economic considerations	There may be cost-implications of offering a nutritional assessment to neonates, infants, children and young people with pressure ulcers. However, such assessment will promote efficient allocation of resources, as it will allow nutritional supplementation to be targeted towards those who require it most. The GDG agreed that the cost of assessing the patient would be offset by efficiencies gained through appropriate treatment strategies, leading to reduced treatment costs overall, and improvements in quality of life. The GDG noted that nutritional status was a crucial issue of patient safety, and would have potentially large quality of life gains which would extend far beyond the treatment of pressure ulcers.
Quality of evidence	No evidence was identified on the use of nutritional interventions or hydration strategies for the treatment of pressure ulcers (randomised trials or cohort studies) in neonates, infants, children or young people. The GDG therefore used formal consensus methods (modified Delphi consensus) to develop statements to help inform the recommendation. One statement was included in Round 1 of the Delphi consensus survey, where it reached 100% consensus agreement.
Other considerations	Members of the Delphi consensus panel highlighted that healthcare professionals should take into account weight and ethnicity when assessing nutritional status.

1

Recommendations	<p>13. Discuss with a paediatric dietitian (or other healthcare professional with the necessary skills and competencies) whether to offer nutritional supplements specifically to treat pressure ulcers in neonates, infants, children and young people whose nutritional intake is adequate.</p> <p>14. Offer advice on a diet that provides adequate nutrition for growth and healing in neonates, infants, children and young people with pressure ulcers.</p> <p>15. Discuss with a paediatric dietitian whether to offer nutritional supplements to correct nutritional deficiency in neonates, infants, children and young people with pressure ulcers.</p>
Relative values of different outcomes	The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.
Trade-off between clinical benefits and harms	The GDG developed 2 statements for inclusion in the Delphi consensus survey: 'Healthcare professionals should offer neonates, infants, children and young people with pressure ulcers, who are nutritionally deficient, correction of their nutritional deficiency' and 'Healthcare professionals should ensure that neonates, infants, children and young people with pressure ulcers have a diet that maintains adequate nutritional status, including that required for growth and wound healing'. The former statement was agreed in Round 1 of the Delphi consensus, at a consensus agreement level of 94%. The latter was also agreed in Round 1 of the Delphi consensus, at a level of 99%. The GDG agreed that for neonates, infants, children and young people who have pressure ulcers and who received a nutritional assessment identifying a nutritional deficiency, healthcare professionals should aim to correct the deficiency. The GDG

	<p>considered that there were benefits in terms of pressure ulcer treatment and other health related outcomes to the correction of nutritional deficiency and that any harms, for example possible resource implications, were likely to be outweighed. A recommendation was therefore developed to highlight that any neonate, infant, child or young person who has a pressure ulcer should be provided with a diet which provides suitable nutrition to allow for growth and healing, as these requirements may be increased in these individuals.</p> <p>Qualitative responses gathered during Round 1 of the survey highlighted the importance of correcting a nutritional deficiency in conjunction with someone with appropriate expertise, namely a dietitian, with experience of working with the relevant population (either a paediatric dietitian or a dietitian with appropriate experience of working with neonates, infants, children or young people). The GDG felt that this was appropriate and that involving a paediatric dietitian was likely to be necessary as many healthcare professionals would not have relevant expertise to provide suitable nutritional supplementation. A recommendation was therefore developed to highlight that before offering correction of a nutritional deficiency in neonates, infants, children and young people with pressure ulcers, there should be a discussion with a dietitian with suitable experience of working with these populations.</p> <p>The GDG also discussed whether neonates, infants, children and young people with an adequate nutritional status, but who have developed a pressure ulcer, should be offered further nutritional supplementation, specifically for treatment of the pressure ulcer. The GDG felt that there should be discussed with a dietitian before providing further supplementation in this situation. A recommendation was therefore developed to reflect this.</p>
Economic considerations	<p>The GDG considered the UK costs of nutritional supplements and agreed that whilst the list prices documented were not negligible, the actual prices paid for nutritional supplements were very low, and correction of nutritional deficiency can be achieved at low cost. Discussion with a suitable dietician will allow the correct nutrients to be provided, and is expected to promote clinically and cost-effective treatment.</p> <p>The GDG discussed that ensuring neonates, infants, children and young people are offered a diet adequate nutrition for growth and healing is best practice and is an issue of patient safety. The GDG highlighted that provision of adequate nutrition has benefits which extend far beyond treatment of pressure ulcers.</p>
Quality of evidence	<p>No evidence was identified on the use of nutritional interventions or hydration strategies for the treatment of pressure ulcers (randomised trials or cohort studies) in neonates, infants, children or young people.</p> <p>The GDG therefore used formal consensus methods (modified Delphi consensus) to develop statements to help inform the recommendation. Two statements were included in Round 1 of the survey, where they reached 94% and 99% consensus agreement.</p>
Other considerations	<p>Panel members highlighted that some clinical conditions or situations (for example, those entering end of life care) may not benefit from the correction of nutritional deficiency and in these situations, care should be considered on a case by case basis.</p>

1

	<p>16. Assess fluid balance in neonates, infants, children and young people with pressure ulcers.</p>
Recommendations	<p>17. Ensure there is adequate hydration for age, growth and healing in</p>

	neonates, infants, children and young people. If there is any doubt, seek further medical advice.
Relative values of different outcomes	The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.
Trade-off between clinical benefits and harms	<p>The GDG developed 1 statement for inclusion in the Delphi consensus survey: ‘Healthcare professionals should not offer hydrational supplementation to neonates, infants, children or young people at risk of developing pressure ulcers, where hydrational intake is adequate for developmental age and associated fluid losses. The statement was not agreed in Round 1 of the Delphi consensus. The GDG discussed the qualitative responses received during Round 1 and identified that there was general agreement on the principles underlying the statement. The GDG therefore amended the statement to clarify that the statement refers to any supplementation specifically for pressure ulcer prevention in those neonates, infants, children and young people who have sufficient hydration. The statement was therefore amended to ‘Healthcare professionals should ensure that neonates, infants, children and young people have adequate hydration for age, growth and healing. Where there is any doubt, seek medical advice.’ The statement was included in Round 2 of the Delphi consensus and was accepted by the panel.</p> <p>Qualitative responses received during Round 2 of the survey generally agreed that the statement highlighted that over-hydration was often considered to be a problem. Comments also noted that any assessment of fluid balance should account for any additional fluid requirements needed for wound healing. As such, the GDG discussed these issues and felt that 2 recommendations were needed, to ensure that neonates, infants, children and young people who have developed pressure ulcers are offered an assessment of fluid balance and to highlighted that anyone who has a pressure ulcer is provided with adequate hydration to account for their age, growth and healing.</p> <p>The GDG felt that where inadequate hydration was identified in an assessment, all healthcare professionals should seek further advice from a suitable healthcare professional, likely to be a medical doctor. The GDG therefore amended the recommendation to reflect this and did not feel that it was appropriate to develop a recommendation on the correction of any fluid deficiency.</p>
Economic considerations	There may be cost-implications of assessing fluid balance and ensuring adequate hydration in those with pressure ulcers. However, such assessment will promote efficient allocation of resources, as it will allow hydration strategies to be targeted towards those who require them. In addition, the GDG discussed that ensuring adequate hydration for growth and healing is best practice and is an issue of patient safety, and would have potentially large quality of life gains which would extend far beyond the treatment of pressure ulcers.
Quality of evidence	<p>No evidence was identified on the use of nutritional interventions or hydration strategies for the treatment of pressure ulcers (randomised trials or cohort studies) in neonates, infants, children or young people.</p> <p>The GDG therefore used formal consensus methods (modified Delphi consensus) to develop statements to help inform the recommendation.</p> <p>1 statement was included in Round 1 of the Delphi consensus survey that reached 47% consensus agreement. The statement was amended and included in Round 2 of the survey, where it was agreed at a consensus level of 97%.</p>
Other considerations	Recommendations on the use of intravenous fluids in neonates, infants, children and young people will be included in the NICE clinical guideline ‘Intravenous fluids in children’, currently in development.

6 Pressure redistributing devices

6.1 Introduction

3 Pressure relieving and redistributing devices are widely accepted methods of both preventing and
4 treating pressure ulcers. A vast range of devices, including different types of mattresses, overlays,
5 cushions and seating, are available which vary considerably in both cost and mechanism. Generally,
6 these devices work by reducing pressure, friction or shearing forces and may be unpowered and
7 considered 'low-tech' or 'static', or powered devices which are 'high-tech'.

8 The selection of device by the healthcare professional is likely to depend upon the person's mobility,
9 the result of skin assessment, the severity and site of the pressure ulcer, weight, staff availability and
10 skill. The choice of a pressure redistributing device by a healthcare professional should also account
11 for a person's wishes and tolerability of the device.

12 It is generally accepted that these devices should be used in conjunction with other treatment
13 strategies such as repositioning and management of the pressure ulcer (for example, by use of an
14 appropriate dressing).

15 The GDG were interested in what the most clinically and cost effective pressure redistributing
16 devices are for the management of pressure ulcers.

17 Recommendations on the use of pressure redistributing devices for the prevention of pressure ulcers
18 can be found in part 1 of the guideline.

6.2 Review question: What are the most clinically and cost effective pressure redistributing devices for the management of pressure ulcers?

20 For full details see review protocol in Appendix D.

6.2.1 Clinical evidence (adults)

24 A Cochrane Review looking at support surfaces for treating pressure ulcers was retrieved from the
25 search and this was used as the basis for our review. It included 17 randomised trials<sup>6,29,44,51,55-
26 57,59,73,89,123,126,136,145,161,162,180</sup>. Two additional randomised trials were found via systematic searches and
27 were used to update the Cochrane review.^{39,108} Evidence from the RCTs are summarised in the
28 clinical GRADE evidence profile below. See also the study selection flow chart in Appendix D, forest
29 plots in Appendix I, study evidence tables in Appendix G and exclusion list in Appendix J.

30 Various types of devices were used to redistribute pressure, and for the purposes of the Cochrane
31 review, these were categorised as 'low-tech' (non-powered), constant low pressure (CLP), high-tech
32 and other devices.

33 The 'low-tech' CLP devices included:

- 34 • Standard foam mattresses
- 35 • Alternative foam mattresses or overlays
- 36 • Gel-filled mattresses or overlays
- 37 • Fibre-filled mattresses or overlays
- 38 • Air-filled mattresses or overlays
- 39 • Water-filled mattresses or overlays

- 1 • Bead-filled mattresses or overlays
- 2 • Sheepskins
- 3
- 4 The high-tech support surfaces included:
- 5 • Alternating-pressure mattresses or overlays
- 6 • Air-fluidised beds
- 7 • Low-air-loss beds
- 8
- 9 The other support surfaces included:
- 10 • Turning beds or frames
- 11 • Operating table overlays
- 12 • Wheelchair cushions
- 13 The Cochrane Review notes that this classification has since been updated by the National Pressure
- 14 Ulcer Advisory Panel (EPUAP & NPUAP 2009) and will be considered in future updates of their
- 15 review.

Summary of included studies

Study	Intervention/comparison	Population	Outcomes	Length of study
Allman 1987 ⁶	Air-fluidised therapy (CLINITRON) repositioned every 4 hours versus conventional treatment (including 2-hourly turns, heel and elbow protectors, alternating-pressure mattresses).	People undergoing surgery aged 18 or over with pressure ulcers of all stages. Graded using the Shea staging system.	<ul style="list-style-type: none"> • Median change in total surface area of ulcers; improvement in condition of pressure ulcer; pain response. 	Mean 13 days follow-up (range 4-77 days).
Branom 2001 ²⁹	PressureGuard CFT (constant force therapy) (non-powered mattress) versus LAL mattress.	People in hospital from long term and sub-acute care centre specialising in ventilator-dependent adults and those with extensive wound care needs. Bedridden adults with a pressure ulcer at grade 3 or 4 on trunk or pelvis (classification system not reported).	<ul style="list-style-type: none"> • Meeting the goals of pressure ulcer treatment as determined by medical team (including wound closure, maintenance of condition and preparation for flap). • The rate of pressure ulcer healing over 8 weeks. 	8-week follow-up.
Caley 1994 ³⁸	LAL bed (Monarch, Mediscus) versus LAL overlay.	People in acute care with existing pressure ulcers.	<ul style="list-style-type: none"> • Median change in pressure ulcer area 	Average 24-day follow-up.
Cassino 2013 ³⁹	Three-dimensional overlay (AIARTEX), made of 3-D macro-porous material vs dry viscoelastic polyurethane polymer overlay (AKTON)	Long-term care patients	<ul style="list-style-type: none"> • Complete healing; improved; unchanged/worsened; suspension due to worsening; suspension due to intolerance; mortality; comfort 	12 weeks
Clark 1998 ⁴⁴	ProActive 2 cushion (Pegasus) (cushion for day chairs and wheelchairs, seating automatically adjusts to an individual's weight) versus ROHO cushion (dry flotation system). All individuals had a Pegasus Airwave System in bed.	Elderly adults in 2 acute care hospitals and 2 nursing homes. Grade 2 pressure ulcers or above, classification system not reported.	<ul style="list-style-type: none"> • Number of pressure ulcers healed completely; rate of healing (cm²/day); rate of healing (cm³/day). 	Average 58.6 days (ProActive) and 43.73 days (ROHO).

Study	Intervention/comparison	Population	Outcomes	Length of study
Day 1993 ⁵¹	Air suspension bed (Therapulse, Kinetic concepts); foam mattress overlay (Geomatt, SpanAmerica). Wound care standardised for 2 groups.	Hospitalised adults with existing grade 2-4 pressure ulcers, graded using the NPUAP classification system.	<ul style="list-style-type: none"> • Mean pressure ulcer size (initial minus end) divided into grade 2 and grade 3/4 ulcers; mean comfort scores. 	7-day follow-up.
Devine 1995 ⁵⁵	Alternating-pressure mattress (Nimbus I) (modular, with rows of figure-of-8 shaped cells; 2 sets of cells are inflated and deflated over 10 minute cycle) versus alternating-pressure mattress (Pegasus Airwave) (double layer mattress with a 3-cell alternating cycle lasting 7.5 minutes). All participants were subject to the standard hospital protocol for wound dressing; details of this were not provided.	Elderly adults in hospital with pressure ulcers of grade 2 or above. The classification system used was not specified.	<ul style="list-style-type: none"> • Complete healing at 4 weeks; comfort; median rate of reduction in area (cm²/day); withdrawal rates by group and reasons for withdrawal. 	4-week follow-up.
Evans 2000 ⁵⁶	Alternating-pressure mattress replacement system (APMRS) (Nimbus 3) versus alternating-pressure mattress replacement system (APMRS) for adults in hospital (P.Biwave, P.Airwave.P.Cairwave or AlphaXCell) or alternating-pressure mattress overlay (AlphaXCell or Quattro) for people in a nursing home. Turning and wound care was standardised for 2 groups.	People in a hospital or nursing home, aged over 65 years with either grade 2 or 3 pressure ulcer (classification system not reported), or grade 2 pressure ulcer and difficulty to reposition in bed, unable to tolerate 30 degree tilt, unable to move in bed, in bed for over 20 hours or 24 hours, over 108kg and bed-bound or who have undergone spinal anaesthetic.	<ul style="list-style-type: none"> • Absolute and relative reduction in pressure ulcer surface area; comfort. 	2-week follow-up period.
Ferrell 1993 ⁵⁹	LAL bed (KINAIR) versus 10cm convoluted foam overlay on top of standard foam	Older adults in an elderly nursing home with	<ul style="list-style-type: none"> • Rate of healing; pressure ulcer surface area was traced 	Median follow-up of 33 days (LAL group)

Study	Intervention/comparison	Population	Outcomes	Length of study
	mattress .Both groups had similar co-interventions as per standard care that is mobilisation as much as possible; 2-hourly turning during waking hours; avoidance of head-of-bed elevation; avoidance of dragging people on sheets; nutritional support; infection control.	multiple medical problems, and with trunk or trochanter pressure ulcers. Grade 2 pressure ulcers or above (Shea grading system).	twice/week on plastic film and area measured using planimetry; ulcers completely healed (covered with epithelium).	and 40 days (foam mattress).
Groen 1999 ⁷³	Foam replacement mattress (3 layers of polyurethane foam designated as comfort, load-distributing and support layers) versus Secutex water mattress (placed on top of standard hospital mattress, 3 PVC sections holding 26 litres water each, with heating element).Standard turning protocol (every 2-3 hour) for both groups.	People in a nursing home, aged over 59 years with a pressure ulcer on trunk, grade 3 (superficial cutaneous or subcutaneous necrotic) or grade 4 (deep subcutaneous necrotic). The classification system used was not reported.	<ul style="list-style-type: none"> Proportion with healed pressure ulcers at 4 weeks; mean pressure ulcer severity score at 4 weeks. 	4-week follow-up.
Keogh 2001 ⁸⁹	Profiling bed with a pressure reducing foam mattress or cushion versus flat-based bed with a pressure relieving or redistributing mattress or cushion.	People from 2 surgical and 2 medical wards; over 18 years old; Waterlow score of 15-25; tissue damage no greater than grade 1 (EPUAP grading system).	<ul style="list-style-type: none"> Proportion with healed grade 1 pressure ulcers. 	5-10 days follow-up.
Makhsous 2009 ¹⁰⁸	Wheelchair cushion equipped with an individualised cyclic pressure-relief protocol versus regular wheelchair cushions. Treatment was specific to the individual and a variety of wound care modalities applied when required (topical wound dressings eg wound gel, hydrocolloid, alginate, foam and moisture barrier) also	Wheelchair users with spinal cord injury (paraplegia or tetraplegia) with existing stage 2 or 3 pressure ulcers (classification system not specified) in the sacral and/or ischial area.	<ul style="list-style-type: none"> Healing of pressure ulcers; healing rate of pressure ulcers; PUSH score improvement; % surface area healing; % PUSH score improvement. 	30 days follow-up.

Study	Intervention/comparison	Population	Outcomes	Length of study
	silver antimicrobial dressings and negative pressure wound therapy.			
Mulder 1994 ¹²³	Air suspension bed (Therapulse, Kinetic concepts) (a pulsating air suspension therapy – cushions alternatively inflate and deflate but classed as LAL rather than AP) versus convoluted foam mattress overlay. Wound care and repositioning standardised for both groups.	People in a nursing home with grade 3-4 pressure ulcers (International Association of Enterostomal Therapists staging system).	<ul style="list-style-type: none"> Wound closure; pressure ulcer improvement (pressure ulcer reduced by 1 grade or more, including healed completely). 	Maximum 12-weeks' follow-up or until ulcers healed, whichever came first.
Munro 1989 ¹²⁶	Air-fluidised bed (Clinitron) versus standard care. The bed/mattress in the standard care group was not described. Sheepskins or gel pads were placed beneath ulcer areas. Standard care involved positioning and massage.	Males with grade 2 or 3 pressure ulcers (classification system not specified), expected to remain in hospital for at least 15 days.	<ul style="list-style-type: none"> Change in mean pressure ulcer area (mm²); individuals' perception of pain; patient satisfaction. 	15-day follow-up.
Nixon 2006 ¹³⁶	Alternating-pressure overlay within 24 hours of admission versus alternating-pressure mattress within 24 hours of admission.	Adults over 55 years of age, from vascular, orthopaedic, medical or care of the elderly wards with an expected length of stay at least 7 days and Braden score of 1 or 2, or an existing grade 2 pressure ulcer (grading system not specified).	<ul style="list-style-type: none"> Proportion of people developing a new pressure ulcer of grade 2 or above; time to development of new pressure ulcers; proportion of participants developing a new pressure ulcer within 30 days; healing of existing pressure ulcers; patient acceptability; adverse events. 	30-day follow-up.
Osterbrink 2005 ¹⁴⁵	Repose device versus small cell versus large cell.	Participants recruited from aged care facility, acute care hospitals and home care setting, over 18 years old, with at least 1 grade 2 pressure ulcer at any bony prominence (EPUAP classification). If	<ul style="list-style-type: none"> Pressure ulcer healing success; weekly changes in pressure ulcer (ulcer size, grade, wound bed, edge appearance and local treatment). 	Follow-up time as long as clinical circumstances allowed. Maximum duration 42 days.

Study	Intervention/comparison	Population	Outcomes	Length of study
		recruited from hospital, must have been nursed on care of the elderly, neurological or surgical units.		
Russell 2000 ¹⁶⁰	Two types of alternating cell mattress systems with pressure-relieving cushions: Huntleigh Nimbus 3 with Aura cushion and 4-hourly turning versus Pegasus Cairwave Therapy System with Proactive 2 seating cushion and 8-hourly turning.	Individuals from care of the elderly units with pressure ulcers of grade 2 and above (Torrance classification system). Average age 83.9 and 84.6 years in the 2 groups.	<ul style="list-style-type: none"> Pressure ulcer healing: all types, and divided into heel and sacral pressure ulcers at 12 and 18 months. 	18-month follow-up.
Russell 2003 ¹⁶²	Alternating-pressure, multicell mattress with 10 minute cycle time (Nimbus 3) versus fluid overlay mattress (RIK static). All adults had standard 4-hourly re-positioning, but could have additional turning at the individual's request.	Adults with grade 1 or 2 pressure ulcers (EPUAP classification) admitted to hospital. Mean age 80 years. Baseline Waterlow scores 21.8 and 21.3 in groups 1 and 2 respectively and baseline Burton scores 14.6 and 14.2.	<ul style="list-style-type: none"> Improved pressure ulcer response; length of hospital stay. 	Length of follow-up unclear, but presumably until discharge from enrolment hospital.
Strauss 1991 ¹⁸⁰	Home air-fluidised therapy (CLINITRON) when grade 3 or 4 pressure ulcers present, plus the consultative and technical services of a visiting nurse specialist versus conventional or standard therapy, individual specific and prescribed (n=50), but included alternating –pressure pads, air-filled mattresses, water-filled mattresses, high density foam pads.	People: with at least 1 grade 3 or 4 pressure ulcer (Shea classification); who would probably require future hospitalisation for the pressure ulcer; with severely limited mobility; for who home air-fluidised therapy was a practical option, likely to comply, live at least 1 year; aged	<ul style="list-style-type: none"> Pressure ulcers classified by blinded observers as improved; unchanged; worse; or not accessible; pressure ulcer-related hospitalisations and costs per patient; pressure ulcer-related hospital days per person. 	36-week follow-up

Study	Intervention/comparison	Population	Outcomes	Length of study
		16 years or over.		

6.2.1.1 Low tech constant pressure devices

Table 42: Clinical evidence profile: water mattress overlay versus low-tech mattress

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Water mattress overlay	Low-tech mattress	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed at 4 weeks – grade 3 ulcers (no classification system specified), people in a nursing home, 4-week follow-up⁷³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	27/60 (45%)	29/60 (48.3%)	RR 0.93 (0.63 to 1.37)	34 fewer per 1000 (from 179 fewer to 179 more)	Very low	Critical
							-	48.3%		34 fewer per 1000 (from 179 fewer to 179 more)		
Percentage reduction in pain (change values)– grade 3 ulcers (no classification system specified), people in a nursing home, 4-week follow-up⁷³												
1	Randomised trial	Very serious ^{a, d}	No serious inconsistency	No serious indirectness	Very serious ^c	None	35.9%	16.2%	MD 19.7% higher	-	Very low	Important
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size of pressure ulcers												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Water mattress overlay	Low-tech mattress	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Groen (1999) did not provide details of the randomisation method used. There was unclear allocation concealment and no blinding of outcome assessors was reported. There was insufficient reporting of incomplete outcome data and no details provided of type of analysis used. The authors report selectively and the details of the grading system used are not specified.

(b) The confidence interval crossed both MID points.

(c) There was not enough data to analyse in Revman.

(d) There were baseline differences in pain at start of trial (40% in water mattress overlay group and 20% for low-tech mattress group).–

Table 43: Clinical evidence profile: 3 dimensional macroporous overlay versus gel overlay

Quality assessment	No of patients	Effect	Quality	Importance
--------------------	----------------	--------	---------	------------

No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	3-D microporous overlay	Gel overlay	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – people in long-term care - all grade of ulcers (EPUAP-NPUAP)³⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	3/35 (8.6%)	5/37 (13.5%)	RR 0.63 (0.16 to 2.46)	50 fewer per 1000 (from 114 fewer to 197 more)	Very low	Critical
							-	13.5%		50 fewer per 1000 (from 113 fewer to 197 more)		
Mortality (all-cause) – people in long-term care - all grade of ulcers (EPUAP-NPUAP)³⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	3/35 (8.6%)	7/37 (18.9%)	RR 0.45 (0.13 to 1.62)	104 fewer per 1000 (from 165 fewer to 117 more)	Very low	Important
							-	18.9%		104 fewer per 1000 (from 164 fewer to 117 more)		
Suspension due to worsening of pressure ulcers– people in long-term care - all grade of ulcers (EPUAP-NPUAP)³⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	9/35 (25.7%)	17/37 (45.9%)	RR 0.56 (0.29 to 1.09)	202 fewer per 1000 (from 326 fewer to 41 more)	Very low	Important
							-	46%		202 fewer per 1000 (from 327 fewer to 41 more)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	3-D microporous overlay	Gel overlay	Relative (95% CI)	Absolute		
Suspension due to intolerance– people in long-term care - all grade of ulcers (EPUAP-NPUAP)³⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	5/35 (14.3%)	2/37 (5.4%)	RR 2.64 (0.55 to 12.75)	89 more per 1000 (from 24 fewer to 635 more)	Very low	Important
								5.4%		89 more per 1000 (from 24 fewer to 635 more)		
Unchanged/worsened– people in long-term care - all grade of ulcers (EPUAP-NPUAP)³⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	16/35 (45.7%)	22/37 (59.5%)	RR 0.77 (0.49 to 1.2)	137 fewer per 1000 (from 303 fewer to 119 more)	Very low	Critical
							-	59.5%		137 fewer per 1000 (from 303 fewer to 119 more)		
Improved– people in long-term care - all grade of ulcers (EPUAP-NPUAP)³⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	16/35 (45.7%)	9/37 (24.3%)	RR 1.88 (0.96 to 3.68)	214 more per 1000 (from 10 fewer to 652 more)	Very low	Critical
							-	24.3%		214 more per 1000		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	3-D microporous overlay	Gel overlay	Relative (95% CI)	Absolute		
										(from 10 fewer to 651 more)		
Patient comfort (fair to excellent) – people in long-term care - all grade of ulcers (EPUAP-NPUAP)³⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	27/35 (77.1%)	19/37 (51.4%)	RR 1.5 (1.05 to 2.16)	257 more per 1000 (from 26 more to 596 more)	Very low	Important
								51.4%		257 more per 1000 (from 26 more to 596 more)		
Patient comfort (poor) – people in long-term care - all grade of ulcers (EPUAP-NPUAP)³⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	8/35 (22.9%)	18/37 (48.6%)	RR 0.47 (0.23 to 0.94)	258 fewer per 1000 (from 29 fewer to 375 fewer)	Very low	Important
							-	48.7%		258 fewer per 1000 (from 29 fewer to 375 fewer)		
Time to complete healing (time to event data)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of healing (continuous data)												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	3-D microporous overlay	Gel overlay	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of ulcer (absolute and relative) (continuous data)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size of ulcer and volume of ulcer												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care (continuous data)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life (continuous data)												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The study was unblinded. There were baseline differences for grade of pressure ulcers, but the higher grade were in the intervention group.

(b) The confidence interval crossed both MID points.

(c) The confidence interval crossed 1 MID point.

6.2.1.2 High-tech pressure devices

Table 44: Clinical evidence profile: low-air-loss bed versus low-tech foam mattress overlay

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Low-air-loss bed	Foam mattress overlay	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed - Shea grade 2 ulcers or above, people in an elderly nursing home, mean 36 days follow-up⁸⁵⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	26/43 (60.5%)	19/41 (46.3%)	RR 1.3 (0.87 to 1.96)	139 more per 1000 (from 60 fewer to 445 more)	Very low	Critical
							-	46.3%		139 more per 1000 (from 60 fewer to 444 more)		
Proportion of people with pressure ulcers completely healed - International Association of Enterostomal Therapists (IAET) staging system stage 3 and 4 ulcers, people in a nursing home, 12 weeks follow-up^{g123}												
1	Randomised trial	Very serious ^c	No serious inconsistency	No serious indirectness	Very serious ^d	None	5/31 (16.1%)	3/18 (16.7%)	RR 0.97 (0.26 to 3.58)	5 fewer per 1000 (from 123 fewer to 430 more)	Very low	Critical
							-	16.7%		5 fewer per 1000 (from 124 fewer to 431 more)		
Proportion of people with pressure ulcers completely healed (meta-analysed) – Shea grade 2 ulcers or above and International Association of Enterostomal Therapists staging system stage 3 and 4 ulcers – people in an elderly nursing home^{123, 59}												
2	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	31/74 (41.9%)	22/59 (37.3%)	RR 1.25 (0.84 to	93 more per 1000 (from 60	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Low-air-loss bed	Foam mattress overlay	Relative (95% CI)	Absolute		
		.c					-	31.5%	1.86)	fewer to 321 more)		
										79 more per 1000 (from 50 fewer to 271 more)		
Pressure ulcers reduced by 1 grade or more including healed completely - International Association of Enterostomal Therapists staging system stage 3 and 4 ulcers, people in a nursing home, 12-weeks follow up¹²³												
1	Randomised trial	Very serious ^c	No serious inconsistency	No serious indirectness	Very serious ^d	None	10/31 (32.3%)	5/18 (27.8%)	RR 1.16 (0.47 to 2.86)	44 more per 1000 (from 147 fewer to 517 more)	Very low	Critical
							-	27.8%		44 more per 1000 (from 147 fewer to 517 more)		
Rate of healing (mm²/day) median (25th, 75th percentiles) - Shea grade 2 ulcers or above, people in a nursing home, mean 36 days follow-up⁵⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^f	Serious ⁱ	9.0 (4.0, 19.8)	2.5 (0.5 to 6.5)	p=0.0002	-	Very low	Critical
Mean change in ulcer size (final values)– NPUAP stage 2 ulcers, people in hospital, 7 days follow-up⁵¹												
1	Randomised trial	Very serious ^e	No serious inconsistency	No serious indirectness	Serious ^b	Serious ^h	7.3 (s.d 2.4) n= 25	5.3 (s.d 2.1) n=23	-	MD 2 higher (0.73 to 3.27 higher)	Very low	Critical
Mean change in ulcer size (final values) – NPUAP stage 3 and 4 ulcers, people in hospital, 7 days follow-up⁵¹												
1	Randomised	Very	No serious	No serious	No serious	Serious	37.1 (s.d 8.1)	12.4 (s.d 3.5)	-	MD 24.7	Very	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Low-air-loss bed	Foam mattress overlay	Relative (95% CI)	Absolute		
	trial	serious ^e	inconsistency	indirectness		^h	n=17	n=12		higher (20.37 to 29.03 higher)	low	
Mean comfort scores (perception of comfort) (better indicated by lower values) – NPUAP stage 2 to 4 ulcers, people in hospital, 7 days follow-up⁵¹												
1	Randomised trial	Very serious ^e	No serious inconsistency	No serious indirectness	No serious imprecision	None	4.1 (s.d 1.3) n=20	3.7 (s.d 1.3) n=19	T[37]=0.91 p>0.05	MD 0.4 higher (0.42 lower to 1.22 higher)	Low	Critical
Mortality - Shea grade 2 ulcers or above, people in a nursing home, mean 36 days follow-up⁵⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	11/43 (25.6%)	7/41 (17.1%)	RR 1.5 (0.64 to 3.49)	85 more per 1000 (from 61 fewer to 425 more)	Very low	Important
							-	17.1%		86 more per 1000 (from 62 fewer to 426 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Low-air-loss bed	Foam mattress overlay	Relative (95% CI)	Absolute		
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) Ferrell (1993) terminated at interim analysis as difference much larger than expected. There was unclear sequence generation and blinding, as well as insufficient reporting of incomplete outcome data. There was a higher drop-out than event rate for the 'proportion completely healed' outcome.
- (b) The confidence interval crossed 1 MID point.
- (c) Mulder (1994) did not provide details of the randomisation method and there was unclear allocation concealment and blinding. It was also unclear from which group drop-outs came from; not all of the pre-specified outcomes were reported and ulcer size was not reported at baseline. There was insufficient reporting of incomplete outcome data and a higher drop-out than event rate for 'proportion completely healed' outcome.
- (d) The confidence interval crossed both MID points.
- (e) Day (1993) did not report clear methods of randomisation, allocation concealment or blinding. There was insufficient reporting of incomplete outcome data and not all of the pre-specified outcomes were analysed. The authors did not report initial ulcer sizes.
- (f) There was not enough data to put in Revman.
- (g) The Cochrane review did not conduct meta-analysis as the outcomes were measured in different ways. Ferrell (1993) used tracing of the epithelial border of the ulcer on plastic film and then the are measured using a polar planimeter. The wounds were assessed using the four-point Shea scale and the Sessing scale (similar to Shea scale, but was undergoing development at time of the study), which has 7 verbal descriptions of ulcers including colour, presence of granulation tissue, evidence of infection, drainage, odour and eschar. Mulder (1994) assessed wound surface area by photoplanimetry. Ulcer volume = ulcer length x width x depth (of deepest ulcer point). The pressure ulcers were assessed using the International Association of Enterostomal Therapists staging system. Only stage 3 and 4 ulcers were included in this study.
- (h) The baseline had a larger difference than the difference between the final values therefore the results should be viewed with caution. There was no log transformation of data.
- (i) A non-parametric test (Wilcoxon rank-sum) was used but there was no log transformation of data.

Table 45: Clinical evidence profile: low-air-loss bed versus low-air-loss overlay

Quality assessment							No of patients		Effect		Quality	Importance	
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Low-air-loss bed	Low-air-loss overlay	Relative (95% CI)	Absolute			
Median change in ulcer area (cm²) – people in acute care, mean 24 day follow-up³⁸													
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	3.9 cm ²	1.9 cm ²	p=0.060	-	Very low	Critical	
Mean changes in pressure ulcer surface area– people in acute care, mean 24 day follow-up³⁸													
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	10.2 cm ²	3.8 cm ²	-	-	Very low	Critical	
Proportion of people with pressure ulcers completely healed													
-	-	-	-	-	-	-	-	-	-	-	-	-	
Time to complete healing of pressure ulcers													
-	-	-	-	-	-	-	-	-	-	-	-	-	
Rate of change in size of ulcer													
-	-	-	-	-	-	-	-	-	-	-	-	-	
Pain (wound-related)													
-	-	-	-	-	-	-	-	-	-	-	-	-	
Time in hospital or NHS care													
-	-	-	-	-	-	-	-	-	-	-	-	-	
Patient acceptability													
-	-	-	-	-	-	-	-	-	-	-	-	-	
Side effects													
-	-	-	-	-	-	-	-	-	-	-	-	-	
Mortality													
-	-	-	-	-	-	-	-	-	-	-	-	-	
Health-related quality of life													
-	-	-	-	-	-	-	-	-	-	-	-	-	

(a) There was very little data provided (median change in area and range). It was unclear (and unlikely) that the outcome assessment was blind to treatment group. No description of co-interventions except skincare protocol applied to both groups; insufficient reporting of incomplete outcome data; high drop-out.

(b) No data were available to analyse in Revman.

Table 46: Clinical evidence profile: air-fluidised therapy (AFT) versus standard or conventional therapies

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Air-fluidised bed	Standard care	Relative (95% CI)	Absolute		
Proportion with 50% reduction in total surface area – Shea all stages, people in surgery, mean 13 days follow-up⁶												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	9/31 (29%)	8/34 (23.5%)	RR 1.23 (0.54 to 2.8)	54 more per 1000 (from 108 fewer to 424 more)	Very low	Critical
							-	23.5%		54 more per 1000 (from 108 fewer to 423 more)		
Proportion with improvement in pressure ulcers – Shea stage 3 or 4 ulcers, people at home, 36 weeks follow-up¹⁸⁰												
1	Randomised trial	Very serious ^{c,i}	No serious inconsistency	No serious indirectness	Serious ^d	None	19/22 (86.4%) ^o	9/13 (69.2%) ^o	RR 1.25 (0.84 to 1.86)	173 more per 1000 (from 11 fewer to 595 more)	Very low	Critical
							-	69.2%		173 more per 1000 (from 11 fewer to 595 more)		
Proportion with improvement in pressure ulcers – Shea all stages, people in surgery, mean 13 days follow-up⁶												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious ^d	None	22/31 (71%)	16/34 (47.1%)	RR 1.51 (0.99 to	240 more per 1000	Low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Air-fluidised bed	Standard care	Relative (95% CI)	Absolute		
									2.3)	(from 5 fewer to 612 more)		
							-	47.1%		240 more per 1000 (from 5 fewer to 612 more)		
Proportion with improvement in pressure ulcers – Shea all stages (people in surgery and people at home) – meta-analysed^{6,180}												
2	Randomised trials	Serious ^{a,c}	No serious inconsistency	No serious indirectness	Serious ^d	None	41/53 (77.4%) ^o	25/47 (53.2%) ^o	RR 1.4 (1.04 to 1.88)	213 more per 1000 (from 21 more to 468 more)	Low	Critical
							-	58.1%		232 more per 1000 (from 23 more to 511 more)		
Change in mean ulcer area (mm²) – stage 2 or 3 ulcers (not specified which classification system), people in hospital, 15 days follow-up (final values)¹²⁶												
1	Randomised trial	Very serious ^e	No serious inconsistency	No serious indirectness	Very serious ^k	Serious ^l	1158mm ²	2051mm ²	-	p=0.05	Very low	Critical
Change in total surface area (median, range) cm²– Shea all stages, people in surgery, mean 13 days follow-up⁶												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^f	Serious ^m	-1.2 (-38.0 to +15.5)	+0.5 (-55.1 to +94.7)	-	Difference (median): -1.7cm ² (95% CI -9.2cm ² to -0.6cm ²)	Very low	Critical
Reduction in pain^g– Shea all stages, people in surgery, mean 13 days follow-up⁶												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Air-fluidised bed	Standard care	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^{a,h}	No serious inconsistency	No serious indirectness	Serious ^d	None	8/13 (61.5%)	4/14 (28.6%)	RR 2.15 (0.85 to 5.48)	329 more per 1000 (from 43 fewer to 1000 more)	Very low	Important
Increase in pain^e– Shea all stages, people in surgery, mean 13 days follow-up⁶												
1	Randomised trial	Very serious ^{a,h}	No serious inconsistency	No serious indirectness	Very serious ^b	None	0/13 (0%)	3/14 (21.4%)	Peto OR 0.12 (0.01 to 1.31)	183 fewer per 1000 (from 212 fewer to 49 more)	Very low	Important
							21.4%	182 fewer per 1000 (from 212 fewer to 49 more)				
Time in hospital (better indicated by lower values) – Shea stage 3 or 4 ulcers, people at home, 36 weeks follow-up¹⁸⁰												
1	Randomised trial	Very serious ^c	No serious inconsistency	No serious indirectness	Very serious ^b	None	11.5 (s.d 8.8) days n= 47	21.5 (s.d 23.8) days n= 50	-	MD 10 lower (161.64 lower to 141.64 higher)	Very low	Important
Median length of stay in hospital after randomisation– Shea all stages, people in surgery, mean 13 days follow-up⁶												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^f	None	16 days	15 days	-	-	Very low	Important
Patient satisfaction (better indicated by higher values) – stage 2 or 3 ulcers (not specified which classification system), people in hospital, 15 days follow-up¹²⁶												
1	Randomised trial	Very serious ^{e,h}	No serious inconsistency	No serious indirectness	No serious imprecision	None	57.5 (s.d 6.1) n= 8	48.6 (s.d 12.3) n=10	-	MD 8.9 higher (0.18 to 17.62)	Low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Air-fluidised bed	Standard care	Relative (95% CI)	Absolute (higher)		
Increase in comfort– Shea all stages, people in surgery, mean 13 days follow-up⁶												
1	Randomised trial	Very serious ^{a,h}	No serious inconsistency	No serious indirectness	Serious ^d	None	8/13 (61.5%)	3/14 (21.4%)	RR 2.87 (0.96 to 8.55)	401 more per 1000 (from 9 fewer to 1000 more)	Very low	Critical
Reduction in comfort– Shea all stages, people in surgery, mean 13 days follow-up⁶												
1	Randomised trial	Very serious ^{a,h}	No serious inconsistency	No serious indirectness	Very serious ^b	None	1/13 (7.7%)	6/14 (42.9%)	RR 0.18 (0.02 to 1.30)	351 fewer per 1000 (from 420 fewer to 129 more)	Very low	Critical
Mortality – Shea all stages, people in surgery and at home^{6, 180}												
2	Randomised trials	Serious ^{a,c}	No serious inconsistency	No serious indirectness	Very serious ^b	None	22/89 (24.7%)	26/88 (29.5%)	RR 0.83 (0.51 to 1.34)	50 fewer per 1000 (from 145 fewer to 100 more)	Very low	Important
							-	27.9%				
Proportion of patients with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of ulcer												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Air-fluidised bed	Standard care	Relative (95% CI)	Absolute		
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) Allman (1987) did not report clear allocation concealment and there were baseline differences. The size of ulcer at baseline was not reported.
- (b) The confidence interval crossed both MID points.
- (c) Strauss (1991) did not report clear allocation concealment and there was insufficient reporting of incomplete outcome data. The size of ulcer at baseline was not reported. There was also a high drop-out rate.
- (d) The confidence interval crossed 1 MID point.
- (e) Munro (1989) did not report clear allocation concealment and no information regarding sample size calculations, randomisation method, blinding, baseline characteristics or extent of follow-up were reported. No raw data was presented in the paper and there was insufficient reporting of incomplete outcome data.
- (f) It was not possible to analyse data in Revman.
- (g) There was a change in pain intensity from baseline (from asking participants to score 0 to 5 on words to describe pain (none, mild, discomforting, distressing, horrible or excruciating)).
- (h) The participant self-reported outcomes.
- (i) Improvement was assessed by an independent nurse reviewer's assessment of the participants' pressure ulcers. There was no definition of improvement.
- (j) Improvement was defined as those pressure ulcers that had healed, much improved, or a little improved. Non-improvement included those that were unchanged, a little worse, or much worse. This was assessed by an investigator and a plastic surgeon independently from photographs.
- (k) The change scores were given by study but it was not possible to analyse data in Revman as no standard deviations were given.
- (l) The ulcer size (diameter) at day 1 had a larger difference between the groups than the difference between the ulcer sizes at day 15. There was no log transformation of data.
- (m) Non-parametric tests were used but there was no log transformation of data.
- (n) Less than half the participants completed the questionnaire.
- (o) Strauss used an independent nurse reviewer's assessment of the participants' pressure ulcer, the data was given for both reviewers and then for the purposes of this review, the results were amalgamated for the 35 participants who were assessed.

Table 47: Clinical evidence profile: alternating-pressure mattress versus alternating-pressure mattress

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alternating-pressure mattress	Alternating-pressure mattress	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – grade 2 and above (grading system not specified), elderly adults, 4-week follow-up – alternating-pressure mattress (Nimbus 1) versus alternating-pressure mattress (Pegasus Airwave)⁵⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	10/16 (62.5%)	5/14 (35.7%)	RR 1.75 (0.79 to 3.89)	268 more per 1000 (from 75 fewer to 1000 more)	Very low	Critical
							-	35.7%		268 more per 1000 (from 75 fewer to 1000 more)		
Proportion of pressure ulcers completely healed – grade 2 and above (Torrance classification system), elderly adults, 18 months follow-up – alternating pressure mattress (Nimbus 3) with Aura cushion and 4-hourly turning versus alternating pressure mattress (Pegasus Cairwave Therapy System) with Proactive 2 seating cushion and 8-hourly turning¹⁶¹												
1	Randomised trial	Serious ^c	No serious inconsistency	No serious indirectness	No serious imprecision	None	65/71 (91.5%)	65/70 (92.9%)	RR 0.99 (0.9 to 1.09)	9 fewer per 1000 (from 93 fewer to 84 more)	Moderate	Critical
							-	92.9%		9 fewer per 1000 (from 93 fewer to 84 more)		
Proportion of people with decrease in pressure ulcer size – grade 2 and above (grading system not specified), elderly adults, 4-week follow-up – alternating pressure mattress (Nimbus 1) versus alternating pressure mattress (Pegasus Airwave)⁵⁵												
1	Randomised	Very	No serious	No serious	Very	None	4/16	6/14	RR 0.58 (0.21 to	180 fewer per 1000	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alternating-pressure mattress	Alternating-pressure mattress	Relative (95% CI)	Absolute		
	trial	serious ^a	inconsistency	indirectness	serious ^d		(25%)	(42.9%)	1.65)	(from 339 fewer to 279 more)		
							-	42.9%		180 fewer per 1000 (from 339 fewer to 279 more)		
Proportion of people with increase in pressure ulcer size– grade 2 and above (grading system not specified), elderly adults, 4-week follow-up– alternating pressure mattress (Nimbus 1) versus alternating pressure mattress (Pegasus Airwave)⁵⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	2/16 (12.5%)	3/14 (21.4%)	RR 0.58 (0.11 to 3.00)	90 fewer per 1000 (from 191 fewer to 429 more)	Very low	Critical
							-	21.4%		90 fewer per 1000 (from 190 fewer to 428 more)		
Median rate of reduction in surface area (cm/day) – grade 2 and above (grading system not specified), elderly adults, 4-week follow-up– alternating pressure mattress (Nimbus 1) versus alternating pressure mattress (Pegasus Airwave)⁵⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^e	Serious ^h	0.089cm2/day	0.107cm2/day	Difference 0.018 cm ² (95% CI 0.179 to 0.143) p=0.92	-	Very low	Critical
Median absolute reduction in wound surface area per day – grade 2 and above (grading system not specified), elderly adults in hospital and nursing homes, 2 week follow-up – alternating pressure mattress (Nimbus 3) versus alternating pressure mattress (P.Biwave, P.Airwave, P. Cairwave or AlphaXCell) or alternating-pressure mattress overlay (AlphaXCell or Quattro)⁵⁶												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alternating-pressure mattress	Alternating-pressure mattress	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^f	No serious inconsistency	No serious indirectness	Very serious ^e	Serious ^h	0.12cm ² (range 0 to 0.21cm ²)	0.08cm ² (range 0.04 to 0.33cm ²)	p=0.570	-	Very low	Critical
Median relative reduction in wounds surface area– grade 2 and above (grading system not specified), elderly adults in hospital and nursing homes, 2 week follow-up– alternating pressure mattress (Nimbus 3) versus alternating pressure mattress (P.Biwave, P.Airwave, P. Cairwave or AlphaXCell) or alternating-pressure mattress overlay (AlphaXCell or Quattro)⁵⁶												
1	Randomised trial	Very serious ^f	No serious inconsistency	No serious indirectness	Very serious ^e	Serious ^h	2.44% (range 0-7.14%)	1.34% (range 1.11-2.88%)	p=0.570	-	Very low	Critical
Median absolute reduction in wound surface are per day– grade 2 and above (grading system not specified), elderly adults in hospital and nursing homes, 2 week follow-up– alternating pressure mattress (Nimbus 3) versus alternating pressure mattress (P.Biwave, P.Airwave, P. Cairwave or AlphaXCell) or alternating-pressure mattress overlay (AlphaXCell or Quattro)⁵⁶												
1	Randomised trial	Very serious ^f	No serious inconsistency	No serious indirectness	Very serious ^e	Serious ^h	0.11cm ² (range 0.04 to 0.41cm ²)	0.05cm ² (range 0-0.48cm ²)	p=0.570	-	Very low	Critical
Median relative reduction in wounds surface area – grade 2 and above (grading system not specified), elderly adults in hospital and nursing homes, 2 week follow-up– alternating pressure mattress (Nimbus 3) versus alternating pressure mattress (P.Biwave, P.Airwave, P. Cairwave or AlphaXCell) or alternating-pressure mattress overlay (AlphaXCell or Quattro)⁵⁶												
1	Randomised trial	Very serious ^f	No serious inconsistency	No serious indirectness	Very serious ^e	Serious ^h	1.57% (range 0.45-5%)	0.99% (range 0-2.54%)	p=0.570	-	Very low	Critical
Mean time in hospital (for those who completed the trial) – grade 2 and above (Torrance classification system), elderly adults in hospital and nursing homes, 18 months follow-up– alternating pressure mattress (Nimbus 3) with Aura cushion and 4-hourly turning versus alternating pressure mattress (Pegasus Cairwave Therapy System) with Proactive 2 seating cushion and 8-hourly turning¹⁶¹												
1	Randomised trial	Serious ^c	No serious inconsistency	No serious indirectness	Very serious ^e	None	21.6 days n=57	21.7 days n=55	-	-	Very low	Important
Comfort (people in hospital)– grade 2 and above (grading system not specified), elderly adults in hospital and nursing homes, 2 week follow-up– alternating pressure mattress (Nimbus 3) versus alternating pressure mattress (P.Biwave, P.Airwave, P. Cairwave or AlphaXCell) or alternating-pressure mattress overlay (AlphaXCell or Quattro)⁵⁶												
1	Randomised	Very	No serious	No serious	Very	None	5 (very comfortable)	4	p=0.006	-	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alternating-pressure mattress	Alternating-pressure mattress	Relative (95% CI)	Absolute		
	trial	serious ^{f,g}	inconsistency	indirectness	serious ^e)	(comfortable)				
Comfort (people in nursing homes)– grade 2 and above (grading system not specified), elderly adults in hospital and nursing homes, 2 week follow-up– Nimbus 3 versus P.Biwave, P.Airwave, P. Cairwave or AlphaXCell) or alternating-pressure mattress overlay (AlphaXCell or Quattro)⁵⁶												
1	Randomised trial	Very serious ^{f,g}	No serious inconsistency	No serious indirectness	Very serious ^e	None	5 (very comfortable)	4 (comfortable)	p=0.002	-	Very low	Critical
Comfort – grade 2 and above (grading system not specified), elderly adults, 4-week follow-up– alternating pressure mattress (Nimbus 1) versus alternating pressure mattress (Pegasus Airwave)⁵⁵												
1	Randomised trial	Very serious ^{a,g}	No serious inconsistency	No serious indirectness	Very serious ^e	None	Median 8/10	Median 8/10	-	-	Very low	Critical
Mortality – grade 2 and above (grading system not specified), elderly adults, 4-week follow-up– alternating pressure mattress (Nimbus 1) versus alternating pressure mattress (Pegasus Airwave)⁵⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	6/22 (27.3%)	5/19 (26.3%)	RR 1.04 (0.38 to 2.86)	11 more per 1000 (from 163 fewer to 489 more)	Very low	Important
							-	26.3%		11 more per 1000 (from 163 fewer to 489 more)		
Mortality – grade 2 and above (Torrance classification system), elderly adults, 18 months follow-up– alternating pressure mattress (Nimbus 3) with Aura cushion and 4-hourly turning versus alternating pressure mattress (Pegasus Cairwave Therapy System) with Proactive 2 seating cushion and 8-hourly turning¹⁶¹												
1	Randomised trial	Serious ^c	No serious inconsistency	No serious indirectness	Serious ^c	None	16/71 (22.5%)	10/70 (14.3%)	RR 1.58 (0.77 to 3.23)	83 more per 1000 (from 33 fewer to 319 more)	Low	Important
							-	14.3%		83 more per 1000		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alternating-pressure mattress	Alternating-pressure mattress	Relative (95% CI)	Absolute		
										(from 33 fewer to 319 more)		
Mortality – grade 2 and above (grading system not specified), elderly adults in hospital and nursing homes, 2 week follow-up– alternating pressure mattress (Nimbus 3) versus alternating pressure mattress (P.Biwave, P.Airwave, P. Cairwave or AlphaXCell) or alternating-pressure mattress overlay (AlphaXCell or Quattro)⁵⁶												
1	Randomised trial	Very serious ^f	No serious inconsistency	No serious indirectness	Very serious ^d	None	7/17 (41.2%)	3/15 (20%)	RR 2.06 (0.64 to 6.57)	212 more per 1000 (from 72 fewer to 1000 more)	Very low	Important
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Devine (1995) did not report whether there was blinding of outcome assessors and there was baseline differences in the groups (more people incontinent of urine in alternating pressure mattress (Nimbus) group, more people catheterised in alternating pressure mattress (Airwave) group). Baseline pressure ulcer size was not reported and there was drop-out higher than event rate. The study used a very small sample size.

(b) The confidence interval crossed 1 MID point.

(c) Russell (2000) did not provide details of the randomisation method and there was unclear allocation concealment.

(d) The confidence interval crossed both MID points.

(e) There was not enough data available to analyse in Revman.

(f) Evans (2000) did not report a method of randomisation and there was unclear allocation concealment. A large proportion of participants did not complete follow-up (11/20 in nursing home group and 75% of hospital group). The study used a very small sample size.

(g) The participants self-reported outcomes.

(h) There was no log transformation of data.

Table 48: Clinical evidence profile: alternating-pressure mattress overlay versus alternating-pressure mattress

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alternating-pressure mattress overlay	Alternating-pressure mattress	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – grade 2 and above (classification system not specified), elderly adults, 30 day follow-up^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	20/59 (33.9%)	19/54 (35.2%)	RR 0.96 (0.58 to 1.6)	14 fewer per 1000 (from 148 fewer to 211 more)	Very low	Critical
							-	35.2%		14 fewer per 1000 (from 148 fewer to 211 more)		
Time to healing (median days)^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^e	None	20 days (12 to not estimable)	20 days (10 to not estimable)	-	p=0.86 log-rank test	Very low	Important
Absolute change in surface area (cm²) - change values (better indicated by higher values) – grade 2 and above (classification system not specified), elderly adults, 30 day follow-up^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	1 (SD 2.3) n=33	2 (SD 6.1) n=36	-	MD 1 lower (3.14 lower to 1.14 higher)	Very low	Critical
% change in surface area (change values) (better indicated by higher values) – grade 2 and above (classification system not specified), elderly adults, 30 day follow-up^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	-35 (SD 605.5) n=33	34.4 (SD 108.6) n=36	-	MD 69.4 lower (279.01 lower to	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alternating-pressure mattress overlay	Alternating-pressure mattress	Relative (95% CI)	Absolute		
										140.21 higher)		
Pressure ulcer improvement– grade 1 or 2 pressure ulcers (EPUAP classification system), elderly adults, follow-up period not specified¹⁶²												
1	Randomised trial	Very serious ^d	No serious inconsistency	No serious indirectness	No serious imprecision	None	56/75 (74.7%)	60/83 (72.3%)	RR 1.03 (0.86 to 1.25)	22 more per 1000 (from 101 fewer to 181 more)	Low	Critical
							-	72.3%		22 more per 1000 (from 101 fewer to 181 more)		
Worsening of pressure ulcers– grade 1 or 2 pressure ulcers (EPUAP classification system), elderly adults, follow-up period not specified¹⁶²												
1	Randomised trial	Very serious ^d	No serious inconsistency	No serious indirectness	Very serious ^b	None	16/75 (21.3%)	22/83 (26.5%)	RR 0.8 (0.46 to 1.41)	53 fewer per 1000 (from 143 fewer to 109 more)	Very low	Critical
							-	26.5%		53 fewer per 1000 (from 143 fewer to 109 more)		
Time in hospital (mean) – grade 1 or 2 pressure ulcers (EPUAP classification system), elderly adults, follow-up period not specified¹⁶²												
1	Randomised trial	Very serious ^d	No serious inconsistency	No serious indirectness	Very serious ^e	None	22.17 days	20.05 days	-	p=0.23	Very low	Important
Patient acceptability (requested changes for comfort or other device-related reasons) – grade 2 and above (classification system not specified), elderly adults, 30 day follow-up^{136,138}												
1	Randomised	Serious ^a	No serious	No serious	Serious ^c	None	230/989	186/982	RR 1.23	44 more	Low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alternating-pressure mattress overlay	Alternating-pressure mattress	Relative (95% CI)	Absolute		
	trial		inconsistency	indirectness			(23.3%)	(18.9%)	(1.03 to 1.46)	per 1000 (from 6 more to 87 more)		
							-	18.9%		43 more per 1000 (from 6 more to 87 more)		
Proportion of participants with negative comments on mattress motion– grade 2 and above (classification system not specified), elderly adults, 30 day follow-up^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	328/929 (35.3%)	285/891 (32%)	RR 1.1 (0.97 to 1.26)	32 more per 1000 (from 10 fewer to 83 more)	Very low	Important
							-	32%		32 more per 1000 (from 10 fewer to 83 more)		
Proportion of participants with positive comments for mattress motion– grade 2 and above (classification system not specified), elderly adults, 30 day follow-up^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None	272/929 (29.3%)	263/891 (29.5%)	RR 0.99 (0.86 to 1.14)	3 fewer per 1000 (from 41 fewer to 41 more)	Low	Important
							-	29.5%		3 fewer per 1000 (from 41 fewer to		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alternating-pressure mattress overlay	Alternating-pressure mattress	Relative (95% CI)	Absolute		
										41 more)		
Proportion of participants commenting negatively on getting into or out of bed– grade 2 and above (classification system not specified), elderly adults, 30 day follow-up^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	124/929 (13.3%)	127/891 (14.3%)	RR 0.94 (0.74 to 1.18)	9 fewer per 1000 (from 37 fewer to 26 more)	Low	Important
								14.3%		9 fewer per 1000 (from 37 fewer to 26 more)		
Participants commenting negatively on movement in bed– grade 2 and above (classification system not specified), elderly adults, 30 day follow-up^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	290/929 (31.2%)	260/891 (29.2%)	RR 1.07 (0.93 to 1.23)	20 more per 1000 (from 20 fewer to 67 more)	Low	Important
							-	29.2%		20 more per 1000 (from 20 fewer to 67 more)		
Proportion of participants commenting positively on movement in bed– grade 2 and above (classification system not specified), elderly adults, 30 day follow-up^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	25/929 (2.7%)	27/891 (3%)	RR 0.89 (0.52 to 1.52)	3 fewer per 1000 (from 15 fewer to 16 more)	Very low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alternating-pressure mattress overlay	Alternating-pressure mattress	Relative (95% CI)	Absolute		
							-	3%		3 fewer per 1000 (from 14 fewer to 16 more)		
Proportion of participants commenting on temperature as hot or warm— grade 2 and above (classification system not specified), elderly adults, 30 day follow-up^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	67/929 (7.2%)	50/891 (5.6%)	RR 1.29 (0.9 to 1.83)	16 more per 1000 (from 6 fewer to 47 more)	Very low	Important
							-	5.6%		16 more per 1000 (from 6 fewer to 46 more)		
Proportion of participants commenting on sweaty or sticky temperature— grade 2 and above (classification system not specified), elderly adults, 30 day follow-up^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	32/929 (3.4%)	23/891 (2.6%)	RR 1.33 (0.79 to 2.26)	9 more per 1000 (from 5 fewer to 33 more)	Very low	Important
							-	2.6%		9 more per 1000 (from 5 fewer to 33 more)		
Proportion of participants commenting on cold or cool temperature— grade 2 and above (classification system not specified), elderly adults, 30 day follow-up^{136,138}												
1	Randomised	Very	No serious	No serious	Very	None	11/929	11/891	RR 0.96	0 fewer	Very	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alternating-pressure mattress overlay	Alternating-pressure mattress	Relative (95% CI)	Absolute		
	trial	serious ^a	inconsistency	indirectness	serious ^b		(1.2%)	(1.2%)	(0.42 to 2.2)	per 1000 (from 7 fewer to 15 more)	low	
							-	1.2%		0 fewer per 1000 (from 7 fewer to 14 more)		
Mattress not working or not working properly– grade 2 and above (classification system not specified), elderly adults, 30 day follow-up^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	16/929 (1.7%)	18/891 (2%)	RR 0.85 (0.44 to 1.66)	3 fewer per 1000 (from 11 fewer to 13 more)	Very low	Important
							-	2%		3 fewer per 1000 (from 11 fewer to 13 more)		
Hard to tuck sheet under or sheets come off or gather or mattress cover slips– grade 2 and above (classification system not specified), elderly adults, 30 day follow-up^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	19/929 (2%)	6/891 (0.7%)	RR 3.04 (1.22 to 7.57)	14 more per 1000 (from 1 more to 44 more)	Very low	Important
							-	0.7%		14 more per 1000 (from 2 more to		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alternating-pressure mattress overlay	Alternating-pressure mattress	Relative (95% CI)	Absolute		
											46 more)	
Mattress or bed too high– grade 2 and above (classification system not specified), elderly adults, 30 day follow-up^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	72/929 (7.8%)	48/891 (5.4%)	RR 1.44 (1.01 to 2.05)	24 more per 1000 (from 1 more to 57 more)	Very low	Important
							-	5.4%		24 more per 1000 (from 1 more to 57 more)		
Mattress slippy– grade 2 and above (classification system not specified), elderly adults, 30 day follow-up^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	9/929 (1%)	4/891 (0.4%)	RR 2.16 (0.67 to 6.98)	5 more per 1000 (from 1 fewer to 27 more)	Very low	Important
							-	0.5%		6 more per 1000 (from 2 fewer to 30 more)		
Mattress too soft or edges soft or slope– grade 2 and above (classification system not specified), elderly adults, 30 day follow-up^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	19/929 (2%)	29/891 (3.3%)	RR 0.63 (0.35 to 1.11)	12 fewer per 1000 (from 21 fewer to 4 more)	Very low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alternating-pressure mattress overlay	Alternating-pressure mattress	Relative (95% CI)	Absolute		
							-	3.3%		12 fewer per 1000 (from 21 fewer to 4 more)		
Not able to use backrest– grade 2 and above (classification system not specified), elderly adults, 30 day follow-up ^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	4/929 (0.4%)	2/891 (0.2%)	RR 1.92 (0.35 to 10.45)	2 more per 1000 (from 1 fewer to 21 more)	Very low	Important
							-	0.2%		2 more per 1000 (from 1 fewer to 19 more)		
Mattress-related fall ^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	0/828 (0%)	4/891 (0.4%)	Peto OR 0.14 (0.02 to 1.03)	4 fewer per 1000 (from 4 fewer to 0 more)	Very low	Important
							-	0.5%		4 fewer per 1000 (from 5 fewer to 0 more)		
Mattress-related suspected contact dermatitis– grade 2 and above (classification system not specified), elderly adults, 30 day follow-up ^{136,138}												
1	Randomised	Very	No serious	No serious	Very	None	0/929	1/891	Peto OR	1 fewer	Very	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alternating-pressure mattress overlay	Alternating-pressure mattress	Relative (95% CI)	Absolute		
	trial	serious ^a	inconsistency	indirectness	serious ^b		(0%)	(0.1%)	0.13 (0 to 6.54)	per 1000 (from 1 fewer to 6 more)	low	
							-	0.1%		1 fewer per 1000 (from 1 fewer to 6 more)		
Mattress-related climbed over or fell through cot sides– grade 2 and above (classification system not specified), elderly adults, 30 day follow-up^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/929 (0.2%)	1/891 (0.1%)	RR 1.92 (0.17 to 21.12)	1 more per 1000 (from 1 fewer to 23 more)	Very low	Important
							-	0.1%		1 more per 1000 (from 1 fewer to 20 more)		
Mattress deflation during transfer– grade 2 and above (classification system not specified), elderly adults, 30 day follow-up^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	0/929 (0%)	1/891 (0.1%)	Peto OR 0.13 (0 to 6.54)	1 fewer per 1000 (from 1 fewer to 6 more)	Very low	Important
							-	0.1%		1 fewer per 1000 (from 1 fewer to 6 more)		

Adverse events

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alternating-pressure mattress overlay	Alternating-pressure mattress	Relative (95% CI)	Absolute		
										more)		
Mortality– grade 2 and above (classification system not specified), elderly adults, 30 day follow-up ^{136,138}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	20/59 (33.9%)	12/54 (22.2%)	RR 1.53 (0.83 to 2.82)	118 more per 1000 (from 38 fewer to 404 more)	Very low	Important
							-	22.2%		118 more per 1000 (from 38 fewer to 404 more)		
Rate of change in size of pressure ulcer												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) Nixon (2006) did not report blinding and the drop-out was higher than the event rate. The outcomes of patient acceptability and side effects were for the study as a whole rather than solely those who had pressure ulcers.
- (b) The confidence interval crossed both MID points.
- (c) The confidence interval crossed 1 MID point
- (d) Russell (2003) did not report blinding and there was unclear allocation concealment. There was insufficient reporting of incomplete outcome data.
- (e) There was not enough data to analyse in Revman.
- (f) This was a non-validated assessment of outcome.

Table 49: Clinical evidence profile: air-filled devices versus alternating pressure mattress

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Air-filled devices	Alternating-pressure mattress	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – grade 2 ulcer or above (EPUAP classification system), elderly adults, maximum follow-up 42 days¹⁴⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	7/34 (20.6%)	1/26 (3.8%)	RR 5.35 (0.7 to 40.84)	167 more per 1000 (from 12 fewer to 1000 more)	Very low	Critical
							-	3.9%		170 more per 1000 (from 12 fewer to 1000 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcer												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Air-filled devices	Alternating-pressure mattress	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Osterbrink (2005) did not report the randomisation method, whether there was allocation concealment or blinding and there was insufficient reporting of incomplete outcome data. The authors did not report baseline ulcer size.

(b) The confidence interval crossed both MID points and there were a limited number of events.

Table 50: Clinical evidence profile: alternating-pressure cushion versus dry flotation cushion

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alternating-pressure cushion	Dry flotation cushion	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – grade 2 ulcers or above, elderly adults, mean 51 days follow-up⁴⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	3/14 (21.4%)	5/11 (45.5%)	RR 0.47 (0.14 to 1.56)	241 fewer per 1000 (from 391 fewer to 255 more)	Very low	Critical
							-	45.5%		241 fewer per 1000 (from 391 fewer to 255 more)		
Rate of healing (cm²/day) – grade 2 ulcers or above, elderly adults, mean 51 days follow-up⁴⁴												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alternating-pressure cushion	Dry flotation cushion	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	Serious ^d	0.13 (SD 0.37)	0.27 (SD 0.56)	-	MD 0.14 lower (0.52 lower to 0.24 higher)	Very low	Critical
Rate of healing (cm³/day) – grade 2 ulcers or above, elderly adults, mean 51 days follow-up⁴⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	Serious ^d	0.56 (SD 0.86)	0.49 (SD 0.86)	-	MD 0.07 higher (0.61 lower to 0.75 higher)	Very low	Critical
% change in area per day– grade 2 ulcers or above, elderly adults, mean 51 days follow-up⁴⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	Serious ^d	2.56 (SD 7.86)	5.71 (SD 5.57)	-	MD 3.15 lower (8.42 lower to 2.12 higher)	Very low	Critical
% change in volume per day– grade 2 ulcers or above, elderly adults, mean 51 days follow-up⁴⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	Serious ^d	1.00 (SD 1.83)	0.68 (SD 0.86)	-	MD 0.32 higher (0.76 lower to 1.4 higher)	Very low	Critical
Mortality– grade 2 ulcers or above, elderly adults, mean 51 days follow-up⁴⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^{b,e}	None	3/14 (21.4%)	1/11 (9.1%)	RR 2.36 (0.28 to	124 more per 1000	Very low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alternating-pressure cushion	Dry flotation cushion	Relative (95% CI)	Absolute		
									19.66)	(from 65 fewer to 1000 more)		
							-	9.1%		124 more per 1000 (from 66 fewer to 1000 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcer												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Clark (1998): unclear details of randomisation; unblinded observer; grading system of ulcers not specified. High drop-out.

(b) Confidence interval crossed both MID points.

(c) Confidence interval crossed 1 MID point.

(d) No log transformation of data.

(e) Limited number of events.

Table 51: Clinical evidence profile: profiling bed versus foam mattress

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Profiling bed	Foam mattress	Relative (95% CI)	Absolute		
Proportion of people with completely healed pressure ulcers – any grade of pressure ulcers, surgical or medical adults, grade 1 occurred, 5-10 days follow-up⁸⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	4/4 (100%)	2/10 (20%)	RR 3.96 (1.28 to 12.24)	592 more per 1000 (from 56 more to 1000 more)	Very low	Critical
							-	20%		592 more per 1000 (from 56 more to 1000 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Profiling bed	Foam mattress	Relative (95% CI)	Absolute		
Mortality												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Keogh (2001) did not report clear blinding and not all of the study's pre-specified outcomes were reported. Not all participants had pressure ulcers (only 14 had existing pressure ulcers), so there was a small sample size and uneven distribution, with only 4 in the experimental group. Grade 1 pressure ulcers analysed only. The authors did not address incomplete outcome data. There was a high drop out from study and it is not possible to identify how many of those who dropped-out had existing pressure ulcers at start of the trial.

(b) There were a limited number of events.

Table 52: Clinical evidence profile: constant force mattress versus low-air-loss mattress

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Constant force mattress	LAL mattress	Relative (95% CI)	Absolute		
Mean % rate of closure per week – grade 3 or 4 ulcers (classification system not specified), long-term or subacute people in hospital from wards specialising in ventilator-dependent or extensive wound care needs, at 8 week follow-up²⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	Serious ^c	9 (s.d 4.8) n= 10	5 (s.d 3.7) n= 8	-	MD 4 higher (0.07 to 7.93 higher)	Very low	Critical
Proportion of people with complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size and volume of pressure ulcer												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Constant force mattress	LAL mattress	Relative (95% CI)	Absolute		
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The randomisation reported was inadequate and there was unclear allocation concealment and blinding. No details of incomplete outcome data, type of analysis, pressure ulcer sizes at baseline or classification of pressure ulcers were given. The study used a very small sample size.

(b) The confidence interval crossed 1 MID point.

(c) The data was not log transformed.

Table 53: Clinical evidence profile: wheelchair cushion with equipped with individualised cyclic pressure-relief protocol versus standard wheelchair cushion^b

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Wheelchair cushion with cyclic pressure-relief protocol	Standard wheelchair cushion	Relative (95% CI)	Absolute		
Pressure ulcer closure (cm²)^c – stage 2 or 3 ulcers (classification system not specified), paraplegic or tetraplegic wheelchair users, 30 days follow-up¹⁰⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	78.5 (s.d 74.4) n=22	12.49 (s.d 52.0) n=22	p<0.001	MD 66.01 higher (28.08 to 103.94 higher)	Low	Critical
Pressure ulcer closure rate (cm²/day)^c – stage 2 or 3 ulcers (classification system not specified), paraplegic or tetraplegic wheelchair users, 30 days follow-up¹⁰⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	2.17 (s.d 1.46) n=22	2.3 (s.d 2.04) n=22	p<0.001	MD 1.94 higher (0.89 to 2.99 higher)	Low	Critical
PUSH score improvement^c – stage 2 or 3 ulcers (classification system not specified), paraplegic or tetraplegic wheelchair users, 30 days follow-up¹⁰⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	2.5 (s.d 2.3) n=22	0.7 (s.d 1.1) n=22	p=0.001	MD 1.8 higher (0.73 to 2.87 higher)	Low	Critical
% surface area reduction^c – stage 2 or 3 ulcers (classification system not specified), paraplegic or tetraplegic wheelchair users, 30 days follow-up¹⁰⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	45.0 (s.d 22.0) n=22	10.2 (s.d 34.9) n=22	p<0.001	MD 34.8 higher (17.78 to 51.82 higher)	Low	Critical
% PUSH score improvement^c – stage 2 or 3 ulcers (classification system not specified), paraplegic or tetraplegic wheelchair users, 30 days follow-up¹⁰⁸												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Wheelchair cushion with cyclic pressure-relief protocol	Standard wheelchair cushion	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	21.9 (s.d 24.6) n=22	5.8 (s.d 9.2) n=22	p=0.003	MD 16.1 higher (5.13 to 27.07 higher)	Low	Critical
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Makhsous (2010) did not provide details of sequence generation, allocation concealment or blinding. The study used a small sample size.

(b) The study included people who had a spinal cord injury and so would not be able to reposition themselves.

(c) Change scores were presented in the paper.

6.211 Economic evidence (adults)

2 **Published literature**

3 One study was included with a relevant comparison.⁶¹ This is summarised in the economic evidence
4 profile below (Table 54). See also the study selection flow chart in Appendix D and study evidence
5 tables in Appendix H.

6 One study that met the inclusion criteria was selectively excluded¹⁹⁶ – this is summarised in Appendix
7 H, with reasons for exclusion given.

8 One additional study was found which included devices for the management of pressure ulcers as
9 part of a more complex management strategy.¹⁹³ This study was not included as the cost-
10 effectiveness of the strategy as a whole is evaluated, and does not provide information on the cost-
11 effectiveness of the device alone.

Table 54: Economic evidence profile: alternating pressure overlays verses alternating pressure mattress replacements verses high specification foam mattresses

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
Fleurance 2005 ⁶¹ (UK)	Partially applicable ^a	Potentially serious limitations ^b	A decision analytic model which compared 3 alternatives: alternating pressure overlays (AO), alternating pressure mattress replacements (AR), and high-specification foam mattresses (SC).	<p>Superficial ulcers - 4 week horizon AR-AO = -£20 SC-AR = £100</p> <p>Severe ulcers - 4 week horizon AR-AO = -£11 SC-AR = £56</p>	<p>QALYs</p> <p>Superficial ulcers - 4 week horizon AR-AO = 0.00005 SC-AR = -0.00027</p> <p>Severe ulcers - 4 week horizon AR-AO = 0.00002 SC-AR = -0.00011</p>	<p>Superficial - 4 week horizon AR dominates other options</p> <p>Severe - 4 week horizon AR dominates other options</p>	The probability of AR being the most CE at a threshold of £20,000 was 64% for superficial ulcers at 1 and four weeks, and 61% and 61-62% for severe pressure ulcers at 1 and four weeks respectively.

(a) UK NHS setting; cost year 2003.

(b) Quality of life data is obtained from healthcare professionals rather than from patients, short time horizon may not capture full economic impact of these devices. Estimates of health effect estimated rather than obtained from the literature, baseline health outcomes not based on randomised data.

1 **Unit costs**

2 Unit costs were presented to aid consideration of cost effectiveness (see Table 55).

3 **Table 55: Unit costs**

Device	Purchase cost	Rental cost	Source
High specification foam mattresses			
Softform premiere	£199.00	NA	Correspondence with Invacare
Harvest Reflect 2 Replacement Mattress	£140.00	NA	Correspondence with Harvest healthcare
Harvest Prime Comfort Plus	£120.00	NA	Correspondence with Harvest healthcare
Pentaflex (4 way turn, acute)	£204.14	NA	Huntleigh
Constant low pressure			
Breeze	£3,453.70	£12.85 per day ^a	Huntleigh
Alternating pressure			
Nimbus 3	£3,565.18	£13.56 per day ^a	Huntleigh

4 (a) *Minimum of 10 day rental*

5 Note - these prices have been obtained directly from manufacturers, and represent the list price for
6 the NHS. It is acknowledged that prices vary locally; therefore these prices are illustrative only. The
7 devices included in the table are those identified by GDG members as being commonly used, and
8 should not be interpreted as recommended devices.

6.2.2 Clinical evidence (neonates, infants, children and young people)

10 No RCTs or cohort studies were identified. Recommendations were developed using a modified
11 Delphi consensus technique. Further details can be found in Appendix N.

6.2.3 Economic evidence (neonates, infants, children and young people)

13 **Published literature**

14 No relevant economic evaluations were identified.

15 **Economic considerations**

16 In the absence of economic evidence, the GDG considered relevant UK NHS unit costs of various
17 mattresses and overlays (see Table 56) These were considered alongside clinical evidence obtained
18 from the Delphi consensus panel to inform qualitative judgement about cost-effectiveness.

19 **Table 56: Unit costs**

Device	Cost	Source
High specification foam mattresses and overlays		
Softform incubator pad (high specification foam)	£49.48	NHS supply chain catalogue ¹
Softform cot mattress (high specification foam)	£107.63	NHS supply chain catalogue ¹

Device	Cost	Source
Repose babytherm redistributing overlay (with pump)	£91.55	NHS supply chain catalogue ¹
Repose paediatric mattress Overlay (with pump)	£91.55	NHS supply chain catalogue ¹
Repose mattress overlay (with pump)	£106.11	NHS supply chain catalogue ¹
Softform premiere	£199.00	Correspondence with manufacturer
Dynamic support surfaces		
Nimbus paediatric mattress	£13.56 per day rental (purchase price £3,293)	Correspondence with manufacturer
Nimbus 3 mattress	£13.56 per day rental (purchase price £3,565)	Correspondence with manufacturer

- 1 Note: the costs above are included for illustrative purposes only and should not be interpreted as
 2 recommendations in favour of these particular devices. These are list prices only and local prices may
 3 vary.

6.2.4 Evidence statements

6.2.4.1 Clinical (adults)

6.2.4.161 *Water mattress overlay versus low-tech mattress*

- 7 • One study (n=120) showed there may be no clinical difference between a water mattress overlay
 8 and a low-tech mattress for the proportion of people with pressure ulcers completely healed
 9 within trial period, but the direction of the estimate of effect favoured the low-tech mattress
 10 (very low quality).
- 11 • One study (n=120) showed there may be a clinical benefit for a water mattress overlay compared
 12 to a low tech mattress for reducing reduction in pain. No estimate of precision could be derived
 13 (very low quality).
- 14 • No evidence was found for the following outcomes:
- 15 o Time to complete healing
 - 16 o Rate of reduction in size of ulcers
 - 17 o Reduction in size and/or volume of pressure ulcer
 - 18 o Time in hospital or NHS care
 - 19 o Patient acceptability
 - 20 o Side effects
 - 21 o Mortality (all cause)
 - 22 o Health-related quality of life

6.2.4.132 *3-D macroporous overlay versus gel overlay*

- 24 • One study (n=72) showed there may be no clinical difference between a 3-D macroporous overlay
 25 and a gel overlay for the proportion of people with pressure ulcers completely healed. The
 26 direction of the estimate of effect favoured the gel overlay (very low quality).
- 27 • One study (n=72) showed a 3-D macroporous overlay may be more clinically effective for reducing
 28 mortality (all-cause) when compared to a gel overlay (very low quality).

- 1 • One study (n=72) showed a 3-D macroporous overlay is potentially more clinically effective for
2 reducing suspension due to worsening of pressure ulcers when compared to a gel overlay (very
3 low quality).
- 4 • One study (n=72) showed a 3-D macroporous overlay may be more clinically effective for reducing
5 suspension due to intolerance when compared to a gel overlay (very low quality).
- 6 • One study (n=72) showed a 3-D macroporous overlay is potentially more clinically effective for
7 reducing unchanged/worsened pressure ulcers when compared to a gel overlay (very low quality).
- 8 • One study (n=72) showed a 3-D macroporous overlay is potentially more clinically effective for
9 improving pressure ulcers when compared to a gel overlay (very low quality).
- 10 • One study (n=72) showed a 3-D macroporous overlay may be more clinically effective for
11 increased comfort when compared to a gel overlay (very low quality).
- 12 • One study (n=72) showed a 3-D macroporous overlay is potentially more clinically effective for
13 reducing discomfort when compared to a gel overlay (very low quality).
- 14 • No evidence was found for the following outcomes:
 - 15 o Time to complete healing (time to event data)
 - 16 o Rate of healing (continuous data)
 - 17 o Rate of change in size of ulcer (absolute and relative) (continuous data)
 - 18 o Reduction in size of ulcer and volume of ulcer
 - 19 o Pain (pressure ulcer related)
 - 20 o Time in hospital or NHS care (continuous data)
 - 21 o Side effects
 - 22 o Health-related quality of life (continuous data)
 - 23

6.2.4.243 Low-air loss-bed versus low-tech foam mattress overlay

- 25 • One study (n=84) showed a low-air-loss bed is potentially more clinically effective for the
26 proportion of people with pressure ulcers completely healed within the trial period when
27 compared to a low-tech foam mattress overlay (very low quality).
- 28 • One study (n=49) showed there may be no clinical harm between a low-air-loss bed and a low
29 tech foam mattress overlay for the proportion of people with pressure ulcers completely healed
30 within the trial period, but the direction of the estimate of effect could favour the low-tech foam
31 mattress overlay (very low quality).
- 32 • Two studies (n=133) showed a low-air-loss bed is potentially more clinically effective for the
33 proportion of people with pressure ulcers completely healed within the trial period at when
34 compared to a low-tech foam mattress overlay (very low quality).
- 35 • One study (n=49) showed there may be no clinical difference between a low-air-loss bed and a
36 low-tech foam mattress overlay for pressure ulcers reduced by 1 grade or more, including
37 completely healed (very low quality).
- 38 • One study (n=84) reported there is potentially a clinical benefit for a low-air-loss bed compared
39 to a low-tech foam mattress overlay for rate of ulcer healing. No estimate of precision could be
40 derived (very low quality).
- 41 • One study (n=48) reported a mean difference for change in pressure ulcer size for stage 2
42 pressure ulcers was 2 higher (0.73 to 3.27) in a low-air-loss bed compared with a low-tech foam
43 mattress overlay. The clinical importance is unknown (very low quality).
- 44 • One study (n=29) reported a mean difference for change in pressure ulcer size for stage 3 and
45 stage 4 pressure ulcers was 24.7 higher (20.37 to 29.03) in a low-air-loss bed compared with a low-
46 tech foam mattress overlay. The clinical importance is unknown (very low quality).

- 1 • One study (n=39) showed there is no clinical benefit of a low-air-loss bed for patient acceptability
2 (mean comfort score) when compared with a low-tech foam mattress overlay (low quality).
- 3 • One study (n=84) showed there may be a clinical harm for a low-air-loss bed compared to a low-
4 tech foam mattress overlay for all-cause mortality (very low quality).
- 5 • No evidence was found for the following outcomes:
 - 6 o Time to complete healing
 - 7 o Pain (pressure ulcer related)
 - 8 o Time in hospital or NHS care
 - 9 o Side effects
 - 10 o Health-related quality of life

6.2.4.114 Low-air-loss bed versus low-air-loss overlay

- 12 • One study (n=93) showed there may be a clinical benefit for a low-air-loss bed compared to a
13 low-air-loss overlay for reduction in size of pressure ulcer (median change in pressure ulcer area).
14 No estimate of precision could be derived (very low quality).
- 15 • One study (n=93) showed there may be a clinical benefit for a low-air-loss bed compared to a
16 low-air-loss overlay for reduction in size of pressure ulcer (mean change in pressure ulcer surface
17 area). No estimate of precision could be derived (very low quality).
- 18 • No evidence was found for the following outcomes:
 - 19 o Time to complete healing
 - 20 o Rate of reduction in size of ulcers
 - 21 o Proportion of completely healed within trial period
 - 22 o Pain (pressure ulcer-related)
 - 23 o Time in hospital or NHS care
 - 24 o Patient acceptability
 - 25 o Side effects
 - 26 o Mortality (all cause)
 - 27 o Health-related quality of life

6.2.4.185 Air-fluidised therapy (AFT) versus standard/conventional therapies

- 29 • One study (n=65) showed there may be no clinical difference between an air-fluidised therapy
30 and a standard/conventional therapy for proportion of people with 50% reduction in total surface
31 area (very low quality).
- 32 • One study (n=35) showed air-fluidised therapy is potentially more clinically effective for
33 proportion with improvement in pressure ulcers when compared to standard/conventional
34 therapy (very low quality).
- 35 • One study (n=65) showed air-fluidised therapy is potentially more clinically effective for
36 proportion with improvement in pressure ulcers when compared to standard/conventional
37 therapy (low quality).
- 38 • Two studies (n=100) showed air-fluidised therapy is potentially more clinically effective for
39 proportion with improvement in pressure ulcers when compared to standard/conventional
40 therapy (low quality).
- 41 • One study (n=40) showed there may be a clinical benefit for air-fluidised therapy compared to
42 standard/conventional therapy for change in mean ulcer area (stage 2 or 3 ulcers). No estimate of
43 precision could be derived (very low quality).
- 44 • One study (n=65) showed there may be a clinical benefit for air-fluidised therapy compared to
45 standard/conventional therapy for change in total pressure ulcer surface area (very low quality).

- 1 • One study (n=18) showed air-fluidised therapy is more clinically effective for patient acceptability
2 (patient satisfaction) when compared to standard/conventional therapy (low quality).
- 3 • One study (n=27) showed air-fluidised therapy is potentially more clinically effective for patient
4 acceptability (more people experiencing an increase in comfort) when compared to
5 standard/conventional therapy (very low quality).
- 6 • One study (n=27) showed there may be a clinical benefit for air-fluidised therapy compared to
7 standard/conventional therapy for patient acceptability (fewer people experiencing a reduction in
8 comfort) (very low quality).
- 9 • One study (n=97) showed there may be a clinical benefit for air-fluidised therapy compared to
10 standard/conventional therapy for time in hospital (very low quality).
- 11 • One study (n=27) reported there may be no clinical difference between air-fluidised therapy and
12 standard/conventional therapy length of stay in hospital after randomisation, but the direction of
13 the estimate of effect could favour standard care. No estimate of precision could be derived (very
14 low quality).
- 15 • One study (n=27) showed air-fluidised therapy is potentially more clinically effective for pain
16 (more people experiencing a reduction in pain) when compared to standard or conventional
17 therapy (very low quality).
- 18 • One study (n=27) showed there may be a clinical benefit for air-fluidised therapy compared to
19 standard/conventional therapy for pain (fewer people experiencing an increase in pain) (very low
20 quality).
- 21 • One study (n=112) showed air-fluidised therapy is potentially more clinically effective at reducing
22 all-cause mortality when compared to standard/conventional therapy (very low quality).
- 23 • Two studies (n=177) showed there may be no clinical difference between an air-fluidised therapy
24 and standard/conventional therapy at reducing all-cause mortality, the direction of the estimate
25 of effect favoured air-fluidised therapy (very low quality).
- 26 • No evidence was found for the following outcomes:
 - 27 o Time to complete healing
 - 28 o Rate of reduction in size of pressure ulcers
 - 29 o Proportion of completely healed within trial period
 - 30 o Side effects
 - 31 o Health-related quality of life

6.2.4.326 Alternating-pressure mattress (Nimbus 1) versus alternating-pressure mattress (Pegasus Airwave)

- 33 • One study (n=30) showed an alternating-pressure mattress (Nimbus 1) is potentially more
34 clinically effective for proportion of people with pressure ulcers completely healed (grade 2 and
35 above) when compared to an alternating-pressure mattress (Pegasus Airwave) (very low quality).
- 36 • One study (n=30) showed there may be a clinical harm for a alternating-pressure mattress
37 (Nimbus 1) compared to an alternating-pressure mattress (Pegasus Airwave) for proportion of
38 people with decrease in pressure ulcer size (grade 2 and above) (very low quality).
- 39 • One study (n=30) showed an alternating-pressure mattress (Nimbus 1) may be more clinically
40 effective than an alternating-pressure mattress (Pegasus Airwave) for proportion of people with
41 increase in pressure ulcer size (grade 2 and above) (very low quality).
- 42 • One study (n=41) reported medians an alternating-pressure mattress (Nimbus 1) and an
43 alternating-pressure mattress (Pegasus Airwave) for patient acceptability (comfort). The median
44 for both interventions was 8/10. No estimate of effect or precision could be derived (very low
45 quality).

- 1 • One study (n=41) showed there may be no clinical difference between an alternating-pressure
2 mattress (Nimbus 1) and an alternating-pressure mattress (Pegasus Airwave) for mortality, but the
3 direction of the estimate of effect could favour either intervention (very low quality).
- 4 • One study (n=41) reported there may be no clinical difference between an alternating-pressure
5 mattress (Nimbus 1) and an alternating-pressure mattress (Pegasus Airwave) for rate of reduction
6 in pressure ulcer surface area (grade 2 and above), but the direction of the estimate of effect
7 could favour either intervention (very low quality).
- 8 • No evidence was found for the following outcomes:
 - 9 o Time to complete healing
 - 10 o Pain (pressure ulcer related)
 - 11 o Time in hospital or NHS care
 - 12 o Side effects
 - 13 o Health-related quality of life

**6.2.4.147 Alternating-pressure mattress (Nimbus 3) with cushion (Aura) and 4-hourly turning versus an
15 alternating-pressure mattress (Pegasus Cairwave Therapy System) with seating cushion (Proactive
16 2) and 8-hourly turning**

- 17 • One study (n=141) showed no clinical difference between an alternating-pressure mattress
18 (Nimbus 3) with cushion (Aura) and 4-hourly turning for proportion of people with pressure ulcers
19 completely healed (grade 2 and above) when compared with an alternating-pressure mattress
20 (Pegasus Cairwave Therapy System) with seating cushion (Proactive 2) and 8-hourly turning, the
21 direction of the estimate of effect favours the 4-hourly turning (moderate quality).
- 22 • One study (n=112) reported the mean difference for time in hospital for an alternating-pressure
23 mattress (Nimbus 3) with cushion (Aura) and 4-hourly turning, and an alternating-pressure
24 mattress (Pegasus Cairwave Therapy System) with seating cushion (Proactive 2) and 8-hourly
25 turning. The mean for the alternating-pressure mattress (Nimbus 3) was 21.6 days and 21.7 days
26 for the alternating-pressure mattress (Pegasus Cairwave Therapy System). No estimate of effect
27 or precision could be derived (very low quality).
- 28 • One study (n=141) showed an alternating-pressure mattress (Nimbus 3) with cushion (Aura) and
29 4-hourly turning is potentially more clinically harmful for mortality when compared to an
30 alternating-pressure mattress (Pegasus Cairwave Therapy System) with seating (Proactive
31 2) cushion and 8-hourly turning (low quality).
- 32 • No evidence was found for the following outcomes:
 - 33 o Time to complete healing
 - 34 o Rate of reduction in size of ulcers
 - 35 o Reduction in size and/or volume of ulcer
 - 36 o Pain (pressure ulcer related)
 - 37 o Patient acceptability
 - 38 o Side effects
 - 39 o Health-related quality of life

**6.2.4.108 Alternating-pressure mattress (Nimbus 3) versus alternating-pressure mattress (Pegasus Biwave,
41 Pegasus Airwave, Pegasus Cairwave or AlphaXCell) or alternating-pressure mattress overlay
42 (AlphaXCell or Quattro)**

- 43 • One study (n=32) reported medians for patient acceptability (comfort) for people in hospital for
44 an alternating-pressure mattress (Nimbus 3) and a different alternating-pressure mattress
45 (Pegasus Biwave, Pegasus Airwave, Pegasus Cairwave or AlphaXCell) or alternating-pressure
46 mattress overlay (AlphaXCell or Quattro). The median for the alternating-pressure mattress
47 (Nimbus 3) was 5 (very comfortable) and 4 (comfortable) for alternating-pressure mattress

- 1 (Pegasus Biwave, Pegasus Airwave, Pegasus Cairwave or AlphaXCell) or alternating-pressure
2 mattress overlay (AlphaXCell or Quattro). No estimate of effect or precision could be derived (very
3 low quality).
- 4 • One study (n=32) reported medians for patient acceptability (comfort) for elderly people in a
5 hospital or nursing home for an alternating-pressure mattress (Nimbus 3) and a different
6 alternating-pressure mattress (Pegasus Biwave, Pegasus Airwave, Pegasus Cairwave or
7 AlphaXCell) or alternating-pressure mattress overlay (AlphaXCell or Quattro). The median for the
8 alternating-pressure mattress (Nimbus 3) was 5 (very comfortable) and 4 (comfortable) for
9 alternating-pressure mattress (Pegasus Biwave, Pegasus Airwave, Pegasus Cairwave or
10 AlphaXCell) or alternating-pressure mattress overlay (AlphaXCell or Quattro). No estimate of
11 effect or precision could be derived (very low quality).
- 12 • One study (n=32) showed there may be a clinical harm for an alternating-pressure mattress
13 (Nimbus 3) compared to a different alternating-pressure mattress (Pegasus Biwave, Pegasus
14 Airwave, Pegasus Cairwave or AlphaXCell) or alternating-pressure mattress overlay (AlphaXCell or
15 Quattro) for mortality (very low quality).
- 16 • One study (n=32) reported medians for absolute reduction in wound surface area per day (grade
17 2 and above) for people in hospital for an alternating-pressure mattress (Nimbus 3) and a
18 different alternating-pressure mattress (Pegasus Biwave, Pegasus Airwave, Pegasus Cairwave or
19 AlphaXCell) or alternating-pressure mattress overlay (AlphaXCell or Quattro). The median for the
20 Nimbus 3 alternating-pressure mattress was 0.12cm² (range 0 to 0.21cm²) and 0.08cm² (range
21 0.04 to 0.33cm²) for alternating-pressure mattress (Pegasus Biwave, Pegasus Airwave, Pegasus
22 Cairwave or AlphaXCell) or alternating-pressure mattress overlay (AlphaXCell or Quattro). No
23 estimate of precision could be derived (very low quality).
- 24 • One study (n=32) reported medians for relative reduction in wound surface area (grade 2 and
25 above) for people in hospital for an alternating-pressure mattress (Nimbus 3) and a different
26 alternating-pressure mattress (Pegasus Biwave, Pegasus Airwave, Pegasus Cairwave or
27 AlphaXCell) or alternating-pressure mattress overlay (AlphaXCell or Quattro). The median for the
28 Nimbus 3 alternating-pressure mattress was 2.44% (range 0 to 7.14%) and 1.34% (range 1.11 to
29 2.88%) for alternating-pressure mattress (Pegasus Biwave, Pegasus Airwave, Pegasus Cairwave or
30 AlphaXCell) or alternating-pressure mattress overlay (AlphaXCell or Quattro). No estimate of
31 precision could be derived (very low quality).
- 32 • One study (n=32) reported medians for absolute reduction in wound surface area per day (grade
33 2 and above) for elderly people in hospital or a nursing home for an alternating-pressure mattress
34 (Nimbus 3) and a different alternating-pressure mattress (Pegasus Biwave, Pegasus Airwave,
35 Pegasus Cairwave or AlphaXCell) or alternating-pressure mattress overlay (AlphaXCell or Quattro).
36 The median for the Nimbus 3 alternating-pressure mattress was 0.11cm² (range 0.04 to 0.41cm²)
37 and 0.05cm² (range 0 to 0.48cm²) for alternating-pressure mattress (Pegasus Biwave, Pegasus
38 Airwave, Pegasus Cairwave or AlphaXCell) or alternating-pressure mattress overlay (AlphaXCell or
39 Quattro). No estimate of precision could be derived (very low quality).
- 40 • One study (n=32) reported medians for relative reduction in wound surface area (grade 2 and
41 above) for elderly people in hospital or a nursing home for an alternating-pressure mattress
42 (Nimbus 3) and a different alternating-pressure mattress (Pegasus Biwave, Pegasus Airwave,
43 Pegasus Cairwave or AlphaXCell) or alternating-pressure mattress overlay (AlphaXCell or Quattro).
44 The median for the alternating-pressure mattress (Nimbus 3) was 1.57% (range 0.45 to 5%) and
45 0.99% (range 0 to 2.54%) for alternating-pressure mattress (Pegasus Biwave, Pegasus Airwave,
46 Pegasus Cairwave or AlphaXCell) or alternating-pressure mattress overlay (AlphaXCell or Quattro).
47 No estimate of precision could be derived (very low quality).
- 48 • No evidence was found for the following outcomes:
49 o Time to complete healing
50 o Proportion of completely healed within trial period

- 1 o Pain (pressure ulcer related)
- 2 o Time in hospital or NHS care
- 3 o Side effects
- 4 o Health-related quality of life

6.2.4.159 Alternating-pressure mattress overlay versus alternating-pressure mattress

- 6 • One study (n=113) showed there may be no clinical difference between an alternating-pressure
7 mattress overlay and an alternating-pressure mattress for proportion of people with pressure
8 ulcers completely healed (grade 2 and above), but the direction of the estimate of effect could
9 favour the alternating-pressure mattress (very low quality).
- 10 • One study (n=158) showed there is no clinical benefit of an alternating-pressure mattress overlay
11 for pressure ulcer improvement (grade 1 or 2) when compared with an alternating-pressure
12 mattress (low quality).
- 13 • One study (n=158) showed there may be no clinical difference between an alternating-pressure
14 mattress overlay and an alternating-pressure mattress for worsening of pressure ulcers (grade 1
15 or 2), but the direction of the estimate of effect could favour either intervention (very low
16 quality).
- 17 • One study (n=1971) showed there is potentially no clinical difference between an alternating-
18 pressure mattress overlay and an alternating-pressure mattress for patient acceptability (number
19 requesting changes for comfort or other device-related reason) (low quality).
- 20 • One study (n=158) reported the mean for time in hospital for an alternating-pressure mattress
21 overlay and an alternating-pressure mattress. The mean for an alternating-pressure mattress was
22 22.17 days and 20.02 days for an alternating-pressure mattress. No estimate of precision could be
23 derived (very low quality).
- 24 • One study (n=113) showed an alternating-pressure mattress overlay is potentially more clinically
25 harmful for mortality when compared to an alternating-pressure mattress (very low quality).
- 26 • One study (n=113) reported medians for an alternating-pressure mattress and an alternating-
27 pressure mattress overlay for time to ulcer heading. The median for both interventions was 20
28 days. No estimate of precision could be derived (very low quality).
- 29 • One study (n=69) showed there is potentially no clinical difference between an alternating-
30 pressure mattress and an alternating-pressure mattress overlay for absolute change in pressure
31 ulcer surface area (very low quality).
- 32 • One study (n=1820) showed there is potentially no clinical difference between an alternating-
33 pressure mattress overlay and an alternating-pressure mattress for patient acceptability
34 (proportion of people with negative comments on mattress motion). The direction of the estimate
35 of effect favoured the air-filled devices (very low quality).
- 36 • One study (n=1820) showed there is no clinical difference between an alternating-pressure
37 mattress overlay for patient acceptability (proportion of people with positive comments on
38 mattress motion) when compared with an alternating-pressure mattress the direction of the
39 estimate of effect favoured the alternating-pressure mattress (low quality).
- 40 • One study (n=1820) showed there is potentially no clinical difference between an alternating-
41 pressure mattress overlay and an alternating-pressure mattress for patient acceptability
42 (proportion of people with negative comments on getting into/out of bed). The direction of the
43 estimate of effect favoured the alternating-pressure mattress (low quality).
- 44 • One study (n=1820) showed there is no clinical difference between an alternating-pressure
45 mattress overlay for patient acceptability (proportion of people with negative comments on
46 movement in bed) when compared with an alternating-pressure mattress. The direction of the
47 estimate of effect favoured the alternating-pressure mattress (low quality).

- 1 • One study (n=1820) showed there may be no clinical difference between an alternating-pressure
2 mattress overlay and an alternating-pressure mattress for patient acceptability (proportion of
3 people with positive comments on movement in bed). The direction of the estimate of effect
4 favoured the alternating-pressure mattress (very low quality).
- 5 • One study (n=1820) showed there is potentially no clinical difference between an alternating-
6 pressure mattress overlay and an alternating-pressure mattress for patient acceptability
7 (proportion of people commenting on temperature as hot or warm). The direction of the estimate
8 of effect favoured the alternating-pressure mattress (very low quality).
- 9 • One study (n=1820) showed there is potentially no clinical difference between an alternating-
10 pressure mattress overlay and an alternating-pressure mattress for patient acceptability
11 (proportion of people commenting on temperature as sweaty or sticky). The direction of the
12 estimate of effect favoured the alternating-pressure mattress overlay (very low quality).
- 13 • One study (n=1820) showed there may be no clinical difference between an alternating-pressure
14 mattress overlay and an alternating-pressure mattress for patient acceptability (proportion of
15 people commenting on temperature as cold/cool), but the direction of the estimate of effect
16 favoured either intervention (very low quality).
- 17 • One study (n=1820) showed there may be no clinical difference between an alternating-pressure
18 mattress overlay and an alternating-pressure mattress for patient acceptability (proportion of
19 people reporting the mattress not working or not working properly). The direction of the estimate
20 of effect favoured the alternating-pressure mattress overlay (very low quality).
- 21 • One study (n=1820) showed there is potentially no clinical difference between an alternating-
22 pressure mattress overlay and an alternating-pressure mattress for patient acceptability
23 (proportion of people commenting that it was hard to tuck the sheet under, sheets come off or
24 gather or the mattress cover slips). The direction of the estimate of effect favoured the
25 alternating-pressure mattress overlay (very low quality).
- 26 • One study (n=1820) showed there is potentially no clinical difference between an alternating-
27 pressure mattress overlay and an alternating-pressure mattress for patient acceptability
28 (proportion of people commenting the mattress/bed was too high). The direction of the estimate
29 of effect favoured the alternating-pressure mattress overlay (very low quality).
- 30 • One study (n=1820) showed there may be no clinical difference between an alternating-pressure
31 mattress overlay and an alternating-pressure mattress for patient acceptability (proportion of
32 people reporting the mattress as slippery). The direction of the estimate of effect favoured the
33 alternating-pressure mattress overlay (very low quality).
- 34 • One study (n=1820) showed there is potentially no clinical difference between an alternating-
35 pressure mattress overlay and an alternating-pressure mattress for patient acceptability
36 (proportion of people reporting the mattress as too soft or edges soft or sloping). The direction of
37 the estimate of effect favoured the alternating-pressure mattress overlay (very low quality).
- 38 • One study (n=1820) showed there may be no clinical difference between an alternating-pressure
39 mattress overlay and an alternating-pressure mattress for patient acceptability (proportion of
40 people reporting they were not able to use backrest). The direction of the estimate of effect
41 favoured the alternating-pressure mattress overlay (very low quality).
- 42 • One study (n=1820) showed there is potentially no clinical difference between an alternating-
43 pressure mattress overlay and an alternating-pressure mattress for side effects (mattress related
44 fall). The direction of the estimate of effect favoured the alternating-pressure mattress overlay
45 (very low quality).
- 46 • One study (n=1820) showed there may be no clinical difference between an alternating-pressure
47 mattress overlay and an alternating-pressure mattress for side effects (mattress-related
48 suspected contact dermatitis). The direction of the estimate of effect favoured the alternating-
49 pressure mattress overlay (very low quality).

- 1 • One study (n=1820) showed there may be no clinical difference between an alternating-pressure
2 mattress overlay and an alternating-pressure mattress for side effects (mattress-related climbed
3 over/fell through cot sides). The direction of the estimate of effect favoured the alternating-
4 pressure mattress overlay (very low quality).
- 5 • One study (n=1820) showed there may be no clinical difference between an alternating-pressure
6 mattress overlay and an alternating-pressure mattress for side effects (mattress deflation during
7 transfer). The direction of the estimate of effect favoured the alternating-pressure mattress
8 overlay (very low quality).
- 9 • No evidence was found for the following outcomes:
- 10 o Rate of reduction in size of pressure ulcers
- 11 o Pain (pressure ulcer related)
- 12 o Side effects
- 13 o Health-related quality of life

6.2.4.110 Air-filled devices versus alternating-pressure mattress

- 15 • One study (n=60) showed there may be a clinical benefit for an air filled device compared to an
16 alternating-pressure mattress for the proportion of people with pressure ulcers completely
17 healed (grade 2 and above) (very low quality).
- 18 • No evidence was found for the following outcomes:
- 19 o Time to complete healing
- 20 o Rate of reduction in size of pressure ulcers
- 21 o Reduction in size and/or volume of ulcer
- 22 o Pain (pressure ulcer related)
- 23 o Time in hospital or NHS care
- 24 o Patient acceptability
- 25 o Side effects
- 26 o Mortality (all cause)
- 27 o Health-related quality of life

6.2.4.128 Alternating-pressure cushion versus dry flotation cushion

- 29 • One study (n=25) showed there may be a clinical benefit for a dry flotation cushion for proportion
30 of people with pressure ulcers completely healed (grade 2 and above) compared to an
31 alternating-pressure cushion (very low quality).
- 32 • One study (n=25) showed there may be a clinical benefit for a dry flotation cushion for mortality
33 when compared to an alternating-pressure cushion (very low quality).
- 34 • One study (n=25) showed there may be a clinical benefit for a dry flotation cushion for rate of
35 ulcer healing (area of ulcer) when compared to an alternating-pressure cushion (very low quality).
- 36 • One study (n=25) showed there may be a clinical benefit for an alternating-pressure cushion
37 compared to a dry flotation cushion for rate of ulcer healing (volume of ulcer) (very low quality).
- 38 • One study (n=25) showed an alternating-pressure cushion is potentially more clinically effective
39 for percentage change in pressure ulcer area per day when compared to a dry flotation cushion
40 (very low quality).
- 41 • One study (n=25) showed there may be a clinical benefit for an alternating-pressure cushion
42 compared to a dry flotation cushion for percentage change in volume of pressure ulcer per day
43 (very low quality).
- 44 • No evidence was found for the following outcomes:
- 45 o Time to complete healing

- 1 o Reduction in size and/or volume of pressure ulcer
- 2 o Pain (pressure ulcer related)
- 3 o Time in hospital or NHS care
- 4 o Patient acceptability
- 5 o Side effects
- 6 o Health-related quality of life

6.2.4.1.12 Profiling bed versus foam mattress

- 8 • One study (n=14) showed there is potentially a clinical benefit for a profiling bed compared to a
9 foam mattress for the proportion of people with completely healed pressure ulcers (very low
10 quality).
- 11 • No evidence was found for the following outcomes:
 - 12 o Time to complete healing
 - 13 o Rate of reduction in size of pressure ulcers
 - 14 o Reduction in size and/or volume of pressure ulcer
 - 15 o Pain (pressure ulcer related)
 - 16 o Time in hospital or NHS care
 - 17 o Patient acceptability
 - 18 o Side effects
 - 19 o Mortality (all cause)
 - 20 o Health-related quality of life

6.2.4.1213 Constant force mattress versus low-air-loss mattress

- 22 • One study (n=18) showed a constant force mattress is potentially more clinically effective for the
23 percentage rate of pressure ulcer closure per week when compared to a low-air-loss mattress
24 (very low quality).
- 25 • No evidence was found for the following outcomes:
 - 26 o Time to complete healing
 - 27 o Reduction in size and/or volume of pressure ulcer
 - 28 o Proportion of completely healed within trial period
 - 29 o Pain (pressure ulcer related)
 - 30 o Time in hospital or NHS care
 - 31 o Patient acceptability
 - 32 o Side effects
 - 33 o Mortality (all cause)
 - 34 o Health-related quality of life

**6.2.4.1354 Wheelchair cushion with equipped with individualised cyclic pressure-relief protocol versus
36 standard wheelchair cushion**

- 37 • One study (n=44) showed a wheelchair cushion equipped with individualised cyclic pressure-relief
38 protocol is more clinically effective for pressure ulcer closure rate (area) when compared to a
39 standard wheelchair cushion (low quality).
- 40 • One study (n=44) showed a wheelchair cushion equipped with individualised cyclic pressure-relief
41 protocol is more clinically effective for PUSH score improvement when compared to a standard
42 wheelchair cushion (low quality).

- 1 • One study (n=44) showed a wheelchair cushion equipped with individualised cyclic pressure-relief
2 protocol is more clinically effective for percentage surface area reduction improvement when
3 compared to a standard wheelchair cushion (low quality).
- 4 • One study (n=44) showed a wheelchair cushion equipped with individualised cyclic pressure-relief
5 protocol is more clinically effective for PUSH score improvement when compared to a standard
6 wheelchair cushion (low quality).
- 7 • One study (n=44) showed a wheelchair cushion equipped with individualised cyclic pressure-relief
8 protocol is more clinically effective for percentage PUSH score improvement when compared to a
9 standard wheelchair cushion (low quality).
- 10 • No evidence was found for the following outcomes:
- 11 o Time to complete healing
- 12 o Proportion of completely healed within trial period
- 13 o Pain (pressure ulcer related)
- 14 o Time in hospital or NHS care
- 15 o Patient acceptability
- 16 o Side effects
- 17 o Mortality (all cause)
- 18 o Health-related quality of life

6.2.4.2 Economic (adults)

- 20 • One cost-utility analysis found that alternating pressure mattress replacements dominate
21 alternating pressure overlays and standard care (high specification foam mattresses) in the
22 treatment of pressure ulcers. This study was assessed to be directly applicable with potentially
23 serious limitations.

6.2.4.3 Clinical (neonates, infants, children and young people)

25 No evidence was identified.

6.2.4.4 Economic (neonates, infants, children and young people)

27 No evidence was identified.

6.3 Recommendations and link to evidence

6.3.1 Adults

Recommendations	<p>18. Use high-specification foam mattresses for adults with a pressure ulcer. If this is not sufficient to redistribute pressure, consider the use of a dynamic support surface.</p> <p>19. Do not use standard-specification foam mattresses for adults with a pressure ulcer.</p>
Relative values of different outcomes	The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.
Trade off between	One study showed that a low-air-loss bed was more clinically beneficial than a foam

<p>clinical benefits and harms</p>	<p>mattress overlay for complete healing. Another study showed no difference between a foam mattress overlay and a low-air-loss bed for grade 3 and 4 pressure ulcers. There was higher mortality in the low-air-loss bed group and there was a clinical benefit of low-air-loss bed for rate of ulcer healing, but no clinical difference for patient acceptability or reduction by 1 grade of pressure ulcer. Air-fluidised therapy beds showed some clinical benefit compared to standard or conventional therapies (these varied and included repositioning and massage, use of a sheepskin, gel pad, heel and elbow protector, alternating pressure mattress, alternating pressure pads, air-filled mattresses, water filled mattresses and pads or high density foam pads) for improvement in pressure ulcers. This study also showed a clinical benefit for the reduction in pain, time in hospital, patient satisfaction, and an increase in comfort. There was no clinical benefit for length of stay in hospital or reduction in mortality. There was no clinical difference between a water mattress overlay and a low-tech mattress for pressure ulcers completely healed but there were less people on the water mattress overlay with pain. There were no clinically beneficial results for alternating-pressure mattress overlays compared to alternating-pressure mattresses except for percentage change in surface area. In this study there were more deaths in the mattress group compared to the mattress overlay group. There was a clinical benefit for air-filled devices compared to alternating pressure mattress for proportion of people with pressure ulcers completely healed. There were varying results for 1 alternating-pressure mattress compared to another alternating-pressure mattress. This however was dependant on the exact device in use. There were no clear outcomes for low-air-loss beds compared to low-air-loss overlays. There was an uncertain clinical benefit for a constant force mattress when compared to a low-air-loss mattress. There was a large clinical benefit for a profiling bed when compared to a foam mattress for complete healing of pressure ulcers.</p> <p>An alternating-pressure cushion was more clinically beneficial than a dry flotation cushion for completely healing grade 2 or above pressure ulcers. There was less mortality in the dry flotation cushion group. A 3-D macroporous overlay compared to a gel overlay showed no clinical difference for pressure ulcers completely healed but a benefit of the 3-D macroporous overlay for reducing mortality, discomfort and suspension due to worsening of pressure ulcers or intolerance, and increasing improvement. A wheelchair cushion equipped with an individualised pressure-relief protocol was more clinically beneficial for the reduction in the size of pressure ulcers.</p> <p>Overall, there is no high quality evidence to suggest a benefit in healing for any particular type of device. However people with pressure ulcers are at risk of developing further pressure ulcers, thus the GDG felt it appropriate to recommend the use of high specification mattresses (which are widely used in current clinical practice) for all people as standard. This recommendation is reflective of prevention strategies for pressure ulcers.</p> <p>The GDG highlighted that standard foam mattresses should not be provided to people who have developed pressure ulcers and developed a recommendation to emphasise this.</p>
<p>Economic considerations</p>	<p>High specification foam mattresses are considered to be cost-effective for the prevention of pressure ulcers, compared to standard mattresses. It can therefore be inferred that it is cost-effective for people to remain on these mattresses once a pressure ulcer develops. The mattress will assist with on-going prevention, and will also aid pressure ulcer treatment. High specification foam mattresses are therefore considered to be cost-effective for the treatment of pressure ulcers, compared to standard mattresses.</p> <p>The GDG considered 1 cost-utility analysis which compared alternating pressure mattresses and alternating pressure overlays to high specification foam mattresses</p>

	<p>for the treatment of pressure ulcers. The study found that alternating pressure mattresses dominate alternating pressure overlays and high specification mattresses, with reduced costs and increased QALYs. However this study had potentially serious limitations and was considered to be only partially applicable.</p> <p>The GDG also considered the unit costs of various devices, and acknowledged that dynamic support surfaces are more costly than high specification foam mattresses. The GDG discussed that, although there was no clear clinical evidence, the crucial factor when healing pressure ulcers is pressure relief, and that the dynamic support surfaces do reduce pressure better than high specification foam. Efficient pressure relief will improve quality of life and up front unit costs will be offset, or at least mitigated, by the reduction in further treatment costs.</p> <p>Based on the existing economic evidence, discussion of unit costs and potential benefits of dynamic surfaces, the GDG agreed that where high specification foam was not sufficient for the healing of a pressure ulcer, the use of dynamic support surfaces was likely to be cost effective.</p>
Quality of evidence	<p>The evidence reviewed was of varying populations, interventions, comparisons, and outcomes which made a conclusion of which type of device was preferential very difficult. The evidence was of low to very low quality due to study limitations and most outcomes had serious to very serious imprecision.</p> <p>The GDG discussed the evidence limitations. They further agreed that that none of the studies followed up people for a sufficient amount of time, which is likely to have limited the apparent effectiveness of the mattresses.</p>
Other considerations	<p>The GDG agreed that high specification foam mattresses are commonly used in the NHS for the prevention of pressure ulcers, thus the group considered that it would be unethical to discontinue the use of this device, if it had been started prior to the development of the pressure ulcer.</p>

6.3.2 Neonates, infants, children and young people

Recommendations	20. Use a high-specification cot or bed mattress or overlay for all neonates, infants, children and young people with a pressure ulcer.
Relative values of different outcomes	<p>The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.</p>
Trade-off between clinical benefits and harms	<p>The GDG used 2 statements from the Delphi consensus panel to develop the recommendation, 'Healthcare professionals should use a high specification cot or bed mattress for all neonates, infants and children who have developed pressure ulcers' and 'Healthcare professionals should use a high specification cot or bed overlay for all neonates, infants and children who have developed pressure ulcers'. The former was accepted during Round 1 of the Delphi consensus survey, the latter was not accepted.</p> <p>During Round 1, qualitative comments received on the use of high specification bed mattresses highlighted that the provision of a pressure redistributing device should be tailored to the child and that selection should consider the physical, clinical and environmental situation. Other comments emphasised that the use of any pressure redistributing device should only be used in combination with a repositioning regimen.</p> <p>The GDG subsequently discussed the latter statement on the use of overlays as well as the comments received during Round 1, which focused on the benefits of using an overlay where a mattress is unavailable. In particular, comments noted that the use</p>

	<p>of an overlay would be preferable to delaying pressure relief. However, comments also highlighted that there were potential safety issues in the use of certain overlays, particularly where this raises the height of the child above the bed rails. The statement was therefore amended to highlight that an overlay may be considered where a mattress is unavailable but safety should be considered where this is used. The GDG therefore amended the statement to 'Healthcare professionals should consider the use of a high specification cot or bed overlay for neonates, infants and children who have developed pressure ulcers, where a high specification mattress is not available, taking into account safety' for inclusion in Round 2 of the Delphi consensus survey.</p> <p>The amended statement was included in Round 2 of the survey and was agreed by the panel. Qualitative responses gathered in Round 2 emphasised that any overlay used should be high specification and noted that repositioning should still be considered a mainstay of care, regardless of the use of a pressure redistributing device.</p> <p>The GDG discussed both of the agreed statements. The GDG felt that high specification mattresses should be provided as standard to all neonates, infants, children and young people who have developed a pressure ulcer, as the potential benefits in reducing pressure were likely to outweigh any harms. The GDG discussed further the use of high specification overlays. The GDG noted that it was likely that high specification mattresses would be provided to people admitted to secondary care, as these would be given as standard preventative treatment. The GDG therefore felt that the recommendation should provide the option of providing people with pressure ulcers a high specification bed mattress or overlay. The GDG felt, although the Delphi consensus panel had agreed a statement that overlays used only be used in the absence of a mattress, that recommending the provision of either device would help to ensure that pressure was reduced across different settings in which care was provided (for example, in the operating theatre, where care is provided in the home, or in long term residential settings).</p> <p>The GDG felt that the option to provide an overlay to those who had developed a pressure ulcer should remain as pressure reduction was the most urgent consideration in this situation and, if the use of an overlay was to facilitate the reduction of pressure, this would be important where there is a delay in providing a high specification foam mattress.</p> <p>Furthermore, the GDG noted that some populations (for example, neonates in neonatal intensive care units) were often provided with high specification cot or bed overlays as standard.</p>
Economic considerations	<p>There are costs associated with high specification foam cots and mattresses and overlays. The estimated purchase costs are £50-£199 (typical products identified by GDG members), and the devices can be used over a number of years, therefore the expected cost per patient is low. The GDG considered these costs likely to be offset by the benefits of the intervention in terms of improvement in the person's quality of life, and reduction in future treatment costs through improved healing.</p>
Quality of evidence	<p>No RCTs or cohort studies were identified for neonates, infants, children or young people. Formal consensus using a modified Delphi was therefore used to develop the recommendation.</p> <p>To inform the recommendation, the GDG used 2 statements which were included in Round 1 of the Delphi consensus survey and reached 83% and 64% consensus agreement. The latter statement was therefore included in Round 2 of the survey, where it reached 86% consensus agreement.</p>

	Further details can be found in Appendix N.
Other considerations	The GDG highlighted that healthcare professionals should be aware of potential safety considerations in the use of overlays for neonates, infants, children and young people, where the use of an overlay causes the child to be above the height of the bed rails.

1

Recommendations	21.If pressure on the affected area cannot be relieved by other means (such as repositioning), consider a dynamic support surface, appropriate to the size and weight of the child or young person with a pressure ulcer, if this can be tolerated.
Relative values of different outcomes	The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.
Trade-off between clinical benefits and harms	<p>The GDG used 1 statement from the Delphi consensus panel to develop the recommendation ‘Healthcare professionals should not use dynamic support surface for the treatment of pressure ulcers in neonates, infants and children’. The statement was not accepted during Round 1 of the Delphi consensus survey and was therefore amended for inclusion in Round 2 of the survey.</p> <p>The GDG discussed the use of dynamic support surfaces and the comments received during Round 1, which focused upon considering the appropriateness of a dynamic support surface, taking into account a child’s weight, clinical condition and tolerability. The statement was therefore amended to highlight that a dynamic support surface may be considered however, any decision should account for these factors.</p> <p>Additionally, the GDG identified that dynamic support surfaces may be appropriate for both children and young people, depending upon individual factors. Therefore the statement was also amended to include children.</p> <p>The GDG therefore developed the statement ‘Healthcare professionals should consider the use of a dynamic support surface for children and young people who have developed pressure ulcers, where this can be tolerated, if pressure on the affected area cannot be relieved by other means (such as repositioning). The support surface should be appropriate for the size and weight of the child’ which was included in Round 2 of the survey, where it was accepted.</p> <p>The GDG discussed the agreed statement and agreed that a recommendation should be made. Qualitative comments received during round 2 of the survey noted that there were some dynamic support surfaces which would be appropriate for use in infants and children. Comments received from panel members generally felt the use of a dynamic support surface may be appropriate where pressure could not be relieved by any other means, for example repositioning. Comments also highlighted that individual patient factors should be taken into account when assessing the potential benefits that use of a dynamic support surface might bring. The GDG therefore felt that on balance, there were potential benefits of using a dynamic support surface for children and young people who have developed pressure ulcers, where pressure cannot be relieved by other means (for example, where a child cannot be repositioning). Any consideration of using a dynamic support surface should account for the individual patient factors and to minimise any potential harms, the size and weight of the child or young person should be carefully</p>

	considered and an appropriate dynamic support surface selected.
Economic considerations	Dynamic support surfaces are more costly than high specification devices, for example the Nimbus paediatric mattress which can be rented for £13.56 per day. Pressure relief is crucial for the treatment of pressure ulcers, and is greatly facilitated by such dynamic devices. Therefore the GDG agreed that the cost of these devices will likely be offset by improvements in quality of life and reduction in further treatment costs. Note that people with pressure ulcers are considered to be at high risk of developing further pressure ulcers, therefore these devices may also help to prevent further pressure ulcers.
Quality of evidence	<p>No RCTs or cohort studies were identified for neonates, infants, children or young people. Formal consensus using a modified Delphi was therefore used to develop the recommendation.</p> <p>To inform the recommendation, the GDG used 1 statement which was included in Round 1 of the Delphi consensus survey, where it reached 12% consensus. The statement was therefore amended for Round 2, where it was accepted at 95% consensus agreement.</p> <p>Further details can be found in Appendix N.</p>
Other considerations	The GDG emphasised that any dynamic support surface used for a child or young person should be appropriate to the size and weight of the child, to prevent safety issues and ensure optimum effectiveness.

1

	<p>22. Consider using specialist support surfaces (including dynamic support surfaces where appropriate) for neonates, infants, children and young people with pressure ulcers, taking into account their current pressure ulcer risk and mobility.</p> <p>23. Tailor the support surface to the location and cause of the pressure ulcer for neonates, infants, children and young people.</p>
Recommendations	
Relative values of different outcomes	The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.
Trade-off between clinical benefits and harms	<p>The GDG used 1 statement from the Delphi consensus panel to develop the recommendation 'Healthcare professionals should not use a standard foam cot/bed mattress for neonates, children, infants or young people who have previously developed pressure ulcers and should use specialist patient support surfaces as clinically indicated.' The statement was not accepted during Round 1 of the Delphi consensus survey and was therefore amended for inclusion in Round 2 of the survey.</p> <p>The GDG discussed comments received during Round 1 which highlighted that this would depend upon the reason for initial pressure ulcer development. The GDG agreed that, given pressure ulcers caused by devices were not included in the current guideline, standard foam mattresses should not be used for those who have developed a pressure ulcer previously, given this would mean that they were at risk of subsequent pressure ulcer development. The GDG therefore amended the statement to reflect that these should not be used routinely, however current risk level should be considered when choosing a specialist support surface for this population. The GDG therefore amended the statement for inclusion in Round 2 of the Delphi consensus to 'Healthcare professionals should not routinely use a standard foam cot/bed mattress for neonates, children, infants or young people who</p>

	<p>have previously developed pressure ulcers and should consider using specialist support surfaces, taking into account current risk level and mobility.’ The statement was accepted.</p> <p>The GDG discussed the agreed statement and agreed that a recommendation should be made. Qualitative comments received during round 2 of the survey generally felt that high specification foam mattresses may be appropriate for this population however, standard foam would not be appropriate for infants, children and young people who had previously had a pressure ulcer. Some panel members noted that some people who had a pressure ulcer were likely to be a lesser risk as their risk was related to an acute situation. The GDG acknowledged this but did not feel that standard foam mattresses should be used for anyone who had previously developed a pressure ulcer, due to the increased risk of developing another pressure ulcer. The GDG also noted that many people in secondary care would be provided with a high specification foam mattress as standard care. The GDG felt that the benefits of providing an alternative foam mattress over a standard foam mattress outweighed any potential harms. A recommendation was therefore developed to reflect this and to highlight that specialist support surfaces, for example, dynamic support surfaces, would be more appropriate for this population.</p> <p>The GDG highlighted that provision of any support surface should take into account current risk level and mobility, as highlighted by comments from the Delphi consensus panel, who noted that a child’s level of pressure ulcer risk may vary, depending on the risk factors.</p> <p>Comments from the Delphi consensus panel also highlighted the importance of ensuring that the support surface chosen was appropriate to the location and cause of the pressure ulcer. For example, the GDG noted that some pressure redistributing devices may increase pressure in at a risk site, whilst decreasing the pressure elsewhere. The GDG therefore felt that it was important to highlight that the choice of pressure redistributing surface should be tailored to the location and cause of the pressure ulcer. It was noted that this was particularly important given the specific sites considered to be at risk in neonates, infants, children and young people, for example, the head and scalp. The GDG therefore chose to develop a recommendation to reflect this.</p>
Economic considerations	<p>Use of high specification and dynamic support surfaces is considered to be cost-effective for individuals with pressure ulcers and for those at significant risk of developing them; therefore standard foam mattresses are not considered to be an efficient use of resources. Furthermore, high specification foam and dynamic surfaces are current best practice and therefore this is not thought to require a substantial increase in resource. Current risk level, mobility, location, and cause of pressure ulcer should be taken into account when selecting the device in order to ensure that an effective device is implemented and clinical and economic benefits are realised as soon as possible.</p>
Quality of evidence	<p>No RCTs or cohort studies were identified for neonates, infants, children or young people. Formal consensus using a modified Delphi was therefore used to develop the recommendation.</p> <p>To inform the recommendation, the GDG used 1 statement which was included in Round 1 of the Delphi consensus survey, where it reached 72% consensus. The statement was therefore amended for Round 2, where it was accepted at 89% consensus agreement.</p> <p>Further details can be found in Appendix N.</p>
Other considerations	<p>There were no other considerations.</p>

7 Adjunctive therapies

7.1 Negative pressure wound therapy (NPWT) - introduction

3 The application of controlled levels of negative pressure for prolonged periods of time to heal
4 wounds has been reported as being used to treat a number of indications, including open fractures,
5 burns, diabetic ulcers, venous ulcers, surgical wound infections and pressure ulcers.

6 The concept is that by applying and maintaining a negative pressure over the wound, healing is
7 encouraged and improved. The technique is considered straightforward and involves placing a piece
8 of gauze or foam with an open cell structure into the wound, over which a drain with multiple
9 perforations is placed. This is then sealed into place with a transparent adhesive membrane placed
10 along the edges of the wound. The tube is connected at the other end to a vacuum source and to a
11 reservoir. When the vacuum is activated fluid is drawn from the wound and discharged into the
12 reservoir. The adhesive membrane helps to maintain the vacuum seal while the gauze and foam
13 ensures that the entire surface of the wound is exposed to the negative pressure, avoiding areas of
14 high and low pressures.

15 The GDG were therefore interested in whether negative pressure wound therapy was clinically or
16 cost effective for the treatment of pressure ulcers.

7.2 Review question: What is the clinical and cost effectiveness of negative pressure wound therapy for the treatment of pressure ulcers?

20 For full details see review protocol in Appendix C.

7.2.1 Clinical evidence (adults)

22 One Cochrane review was identified (Ubbink 2008)¹⁹⁷ for negative pressure wound therapy (NPWT)
23 for treating chronic wounds. This was used as a basis for the review, focusing only on the pressure
24 ulcer studies included.

25 Two studies with pressure ulcers were included in the Cochrane review.^{63, 205} One further study was
26 identified since publication of the 2008 Cochrane review (Ashby 2012).¹³ These studies are
27 summarised in the clinical GRADE evidence profile below (Table 57). See also the full study evidence
28 tables and forest plots in the Appendix G and I.

29 Ford 2002⁶³ included 28 people with grade 3 or 4 ulcers and compared NPWT to modern wound
30 dressings (wound gel products) and followed up for 3 to 10 weeks. Wanner 2003²⁰⁵ included 22
31 paraplegic or tetraplegic people with grade 2 or above pressure ulcers of the pelvic region and
32 compared NPWT to wet-to-dry or wet-to-wet gauze dressings with Ringer's solution. Ashby 2012¹³
33 included 12 participants with grade 3 or 4 pressure ulcers and compared NPWT with spun
34 hydrocolloid dressing, foam dressing or alginate dressing. As the comparators were different, these
35 studies could not be meta-analysed.

36

Summary of included studies

Study	Study type	Intervention/comparison	Population	Outcomes	Length of study/follow-up
Ashby 2012 ¹³	Pilot RCT	Vacuum-assisted wound closure (NPWT) versus standard care (spun hydrocolloid dressing, foam dressing or alginate dressing).	People in acute care and or the community with grade 3 or 4 pressure ulcers.	<ul style="list-style-type: none"> • Time to healing. 	2 to 6 months follow-up.
Ford 2002 ⁶³	RCT	Vacuum-assisted wound closure (NPWT) versus modern wound dressings (wound gel products).	People with 1 to 3 full-thickness pressure ulcers (grade 2 or 4) present for a minimum of 4 weeks.	<ul style="list-style-type: none"> • Proportion of pressure ulcers healed; mean % reduction in pressure ulcer volume. 	6 weeks treatment 3 to 10 weeks follow-up.
Wanner 2003 ²⁰⁵	RCT.	Ulcer debridement followed by: Vacuum-assisted wound closure (NPWT) versus wet-to-dry or wet-to wet technique with gauze soaked in Ringer's solution.	People with a spinal injury (paraplegic or tetraplegic) with grade 3 or 4 pressure ulcers in the pelvic region.	<ul style="list-style-type: none"> • Time to reach 50% of the initial volume; mean pressure ulcer volume (%). 	56 days.

Table 57: Clinical evidence profile: negative pressure wound therapy versus wet-to-dry or wet-to-wet gauze

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	NPWT	Wet-to-dry/wet-to-wet	Relative (95% CI)	Absolute		
Time to 50% of initial wound volume (follow-up 42 days; measured with: photograph of wound and plaster wound impression) – paraplegic or tetraplegic adults²⁰⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	27 (SD 10) days n=11	28 (SD 7) days n=11	-	MD 1 lower (8.21 lower to 6.21 higher)	Very low	Critical
Mean reduction in volume (% change) (follow-up 42 days; measured with: photograph of wound and plaster wound impression) – paraplegic or tetraplegic adults²⁰⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	53%	65%	p=0.9 ^d	MD 12% larger in control group	Very low	Critical
Mean reduction in volume (actual change) (follow-up 42 days; measured with: photograph of wound and plaster wound impression) – paraplegic or tetraplegic adults²⁰⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious directness	Very serious ^c	None	26.5ml	27.3ml	p=0.2?	MD 0.8ml larger in control group	Very low	Critical
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	NPWT	Wet-to-dry/wet-to-wet	Relative (95% CI)	Absolute		
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects (pain, problems with vacuum sealing, reaction of foam)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) No details of sequence generation, allocation concealment or blinding. The mean wound size was larger in the vacuum-assisted than the wet-to-dry/wet-to-wet group.
- (b) The confidence interval crossed one MID point.
- (c) Data taken from graph, no standard deviations given. Very small sample size.
- (d) Wilcoxon rank-sum test result.

Table 58: Clinical evidence profile: negative pressure wound therapy versus modern dressings: wound gel products

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	NPWT	Modern dressings: wound gel products	Relative (95% CI)	Absolute		
Proportion of pressure ulcers completely healed within 6 weeks (follow-up 3-10 months) ⁶³												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/20 (10%)	2/15 (13.3%)	RR 0.75 (0.12 to 4.73)	33 fewer per 1000 (from 117 fewer to 497 more)	Very low	Critical
							-	13.3%		33 fewer per 1000 (from 117		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	NPWT	Modern dressings: wound gel products	Relative (95% CI)	Absolute		
										fewer to 496 more)		
Mean reduction in pressure ulcer volume (% change)^{d63}												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	51.8%	42.1%	p=0.46	MD 9.7% larger in intervention group	Very low	Critical
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects (pain, problems with vacuum sealing, reaction of foam)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No details of allocation concealment were provided. There was a difference in age at baseline.

(b) The confidence interval crossed both MID points.

(c) No standard deviations were given by the authors. The study used a very small sample size.

(d) There were details of reduction in length, width and depth of pressure ulcer (cm). The Cochrane Review (Ubbink 2008) found the figures to be surprisingly large and contacted the author for verification but received no response. No standard deviations were available for this data.

Table 59: Clinical evidence profile: negative pressure wound therapy versus standard care (spun hydrocolloid, alginate or foam dressings)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	NPWT	Spun hydrocolloid, foam or alginate dressings - GRADE III and IV	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed¹³												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	1/6 (16.7%)	0/6 (0%)	Peto OR 7.39 (0.15 to 372.38)	170 more per 1000 (from 190 more to 530 more)	Very low	Critical
							-	0%		170 more per 1000 (from 190 more to 530 more)		
Mortality (all-cause)¹³												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/6 (33.3%)	0/6 (0%)	Peto OR 9.03 (0.49 to 165.19)	330 more per 1000 (from 70 more to 740 more)	Very low	Important
							-	0%		330 more		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	NPWT	Spun hydrocolloid, foam or alginate dressings - GRADE III and IV	Relative (95% CI)	Absolute		
										per 1000 (from 70 more to 740 more)		
Pain (wound-related)¹³												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	1/6 (16.7%)	0/6 (0%)	Peto OR 7.39 (0.15 to 372.38)	170 more per 1000 (from 190 more to 530 more)	Very low	Important
							-	0%		170 more per 1000 (from 190 more to 530 more)		
Time to complete healing												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	NPWT	Spun hydrocolloid, foam or alginate dressings - GRADE III and IV	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects (pain, problems with vacuum sealing, reaction of foam)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No details of blinding of participants or health care providers were reported by the authors. There were a high number of participants who did not continue treatment (all in the NPWT arm).

(b) The confidence interval crossed both MID points and there were a limited number of events.

7.2.2 Economic evidence (adults)

2 Published literature

- 3 One study was identified that included the relevant comparison.¹⁷⁸ This is summarised in the
- 4 economic evidence profile below (Table 60). See also the study selection flow chart in Appendix D
- 5 and study evidence tables in Appendix H.

Table 60: Economic evidence profile: negative pressure wound therapy verses dressings

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
Soares 2013 ¹⁷⁸ (UK)	Directly applicable ^a	Potentially serious Limitations ^b	Decision analytic Markov model based on a network meta-analysis. Negative pressure wound therapy (intervention4) is compared to alginate (intervention 1), spun hydrocolloid (intervention 2), and foam (intervention 3).	Intvn1: £15,249 Intvn2: £15,054 Intvn3: £14,178 Intvn4: £17,521	QALYs Intvn1: 1.2662 Intvn2: 1.2676 Intvn3: 1.2681 Intvn4: 1.2701	Foam dressings had the highest net benefit (£20,000 threshold). NPWT had the lowest expected net benefit.	Probability cost-effective (at £20,000 threshold): Foam 32%, NPWT 22%. When data from existing literature was combined with expert elicited information spun hydrocolloid had the highest net benefit. When data from a pilot trial was also included NPWT dominated all other treatments. ^c
NCGC model	Partially applicable ^d	Minor limitations ^e	A cost comparison which compares negative pressure wound therapy to a standard care dressing regimen in adults with pressure ulcers that are exhibiting high exudate levels that require regular dressing changes.	Small pressure ulcers: £276 Medium pressure ulcers: £230 Large pressure ulcers: £216	N/A	Negative pressure wound therapy is more costly than the standard care dressing regimen.	Deterministic sensitivity analyses included varying the rental cost of the negative pressure wound therapy pump, staff costs, and costs faced in the community. Negative pressure wound therapy remained more costly than standard care dressings in the majority of these analyses.

(a) UK setting; perspective of NHS; QALYs calculated.

(b) The costs of NPWT used in this analysis were not considered to be representative of current costs of this therapy, a limitation which is likely to have a significant impact on the results. In addition, the GDG felt that the comparator should be a dressing regimen rather than individual dressings. Finally, the absolute healing hazard is assumed to be constant over time; this assumption was not considered to be realistic by the GDG. Clinical evidence on the effectiveness of NPWT for the treatment of pressure ulcers is considered to be weak.

(c) The primary purpose of this study was to demonstrate how expert elicited information can be used to supplement existing evidence. The cost-effectiveness of NPWT, and the associated uncertainty are calculated with 3 sets of evidence: 1) existing evidence only, 2) existing evidence + expert elicited evidence, 3) existing evidence + expert elicited evidence + pilot trial data. Base case results are those for scenario 1, as chosen by the GDG.

(d) UK setting and from perspective of UK NHS. Quality of life is not considered.

(e) Health outcomes are not included; no probabilistic analysis of uncertainty.

7.2.2.1 New economic analysis

2 Negative pressure wound therapy (NPWT) was identified by the GDG as a priority for new economic
3 analysis. A model summary is presented here, with full details in Appendix L. This analysis is also
4 summarised in the economic evidence profile (Table 60).

5 The analysis compares the cost of negative pressure wound therapy to a standard dressing regimen
6 for the management of pressure ulcers that exhibit high levels of exudate and require regular
7 dressing changes. A cost comparison was chosen as the most appropriate form of analysis because
8 the clinical data on the comparative effectiveness of NPWT is weak, and was considered not
9 sufficiently reliable on which to base a cost-effectiveness or cost-utility analysis. The GDG therefore
10 decided to focus on NPWT for the on-going management of pressure ulcers which exhibit high
11 exudate levels and require regular dressing changes, rather than to look at differential effects on
12 healing. It was felt that cost-savings could potentially be realised through fewer dressing changes
13 required with NPWT than with a standard dressing regimen. The aim of this analysis is to explore this
14 hypothesis further.

15 **Methods**

16 A cost-comparison was undertaken where costs were considered from a UK NHS and personal social
17 services perspective; health outcomes were not considered. The model was developed in Excel.

18 Two interventions were considered:

- 19 • NPWT (foam or gauze)
- 20 • A standard care dressing regimen.

21 The population considered was adults with pressure ulcers that exhibit high exudate levels that
22 require regular dressing changes. The time horizon of the model was 2 weeks.

23 People in the model were allocated to either NPWT or the standard care dressing regimen. Costs of
24 managing the pressure ulcer using each of these techniques was calculated over the 2 week time
25 horizon. Costs included staff time and materials needed for dressing changes, but did not include
26 adjunct management methods such as pressure relieving devices, as these are assumed constant
27 between the 2 arms of the model.

28 The model considered 3 separate scenarios, management of small pressure ulcers (requiring
29 dressings approximately 10cmx8cm), medium pressure ulcers (requiring dressings approximately
30 18cmx12cm) and large pressure ulcers (requiring dressings approximately 25cmx15cm).

31 Various sensitivity analyses were undertaken to test the robustness of model assumptions and data
32 sources. In these analyses, 1 or more inputs were changed in order to evaluate the impact of these
33 changes on the results of the model. Key parameters for sensitivity analysis were unit costs,
34 frequency of dressing change, and staff time. Probabilistic analysis was not undertaken.

35 **Model Inputs**

36 The standard care dressing regimen was based on advice from the GDG members, and included a
37 combination of alginates, cavity fillers, absorbent dressings and a film membrane in various
38 quantities, depending on size of pressure ulcer. The dressing regimen was chosen to reflect a fairly
39 high cost dressing combination, in order to compare the cost of NPWT against the maximum cost of
40 dressings. Full details are provided in Appendix L.

41 The GDG identified the key NPWT systems which are most commonly used in the UK for inclusion in
42 the model. For these systems, each dressing change requires 1 primary contact dressing, 1

1 foam/gauze dressing, and 1 canister. One pump is also required, per person, for the duration of the
2 therapy. The GDG acknowledged that other dressings and NPWT systems are available, however it
3 was decided that the analysis should focus on the NPWT systems most commonly used in the UK.

4 In the base case it was assumed that the first NPWT dressing change is required after 2 days, and
5 subsequent dressing changes take place every 3 days, while the standard dressing regimen is
6 changed every 2 days throughout the time horizon. It was assumed that half an hour of Band 5 nurse
7 time is required for each dressing change, regardless of the management strategy. 30 minutes of
8 specialist nurse (Band 7) time was also included to account for periodic supervision by a specialist
9 nurse.

10 The cost of staff time was taken from the PSSRU⁴⁷); each dressing change (NPWT and standard care
11 dressing regimen) costs £42.5 in staff costs.

12 All material costs (standard care dressings, primary contact dressings, NPWT dressings and NPWT
13 canisters) were obtained from the NHS drug tariff,¹³⁴ with the exception of the cost of the NPWT
14 pumps which were obtained directly from the manufacturers (full details in Appendix L). NPWT
15 pumps are typically rented rather than purchased, therefore only rental costs are considered in the
16 analysis. The price of the NPWT pump is subject to regional variation, and was therefore varied
17 extensively within the analysis.

18 The total cost per dressing change for the dressing regimen and for NPWT can be found in Table 61.
19 The total cost per dressing change for the dressing regimen includes the cost of the dressing
20 materials and the cost of staff time. The total cost per dressing change for NPWT includes the NPWT
21 dressing materials, primary contact dressings, canisters, and staff time changing the dressing. Note
22 that the cost of the pump and the cost of the fortnightly supervision by the specialist nurse are not
23 included. An unweighted mean of the costs of the various NPWT systems is presented per dressing
24 change; the accompanying range shows the highest and lowest costs per dressing change out of the
25 included NPWT systems.

26 **Table 61: Mean cost per dressing change (range)**

Ulcer size	Standard care dressing regimen	NPWT ^{a,b}
Small	£63	£83 (£81 – £85)
Medium	£74	£90 (£88 – £91)
Large	£88	£106 (£105 – £106)

27 (a) Note these costs do not include the cost of the pump or the fortnightly supervision by the specialist nurse.

28 (b) The range is included in parenthesis to show the minimum and maximum totals based on the different NPWT systems
29 included in this analysis

30 Computations

31 To compute total costs, the cost per dressing change (including staff costs and material costs (see
32 Table 61) was multiplied by the number of dressing changes required over the 2 week time horizon.
33 For the NPWT arm, the total rental cost of the pump (cost per day multiplied by time horizon), and
34 the cost of fortnightly nurse supervision was also added to this.

35 Sensitivity analyses

36 Sensitivity analyses were undertaken to explore the effect of different parameter inputs and
37 assumptions on the results of the model. Sensitivity analyses included extending the time required
38 for a NPWT dressing change to 45 minutes, using a specialist nurse (Band 7) to conduct all dressing
39 changes, removing the requirement for specialist supervision, using community costs, using cost

1 collected by GDG members to capture the effect of regional variation, and altering the frequency of
2 dressing change and rental costs (full details in Appendix L).

3 **Interpreting results**

4 In the absence of reliable evidence to suggest a clear clinical benefit of NPWT, the GDG agreed that
5 NPWT was only likely to represent an efficient use of resources if it was cost-saving (or cost-neutral)
6 for the management of pressure ulcers.

7 The GDG did not look at individual products to make recommendations, but rather looked at the
8 more general comparison of standard care dressings compared to NPWT. The focus on specific
9 dressings and NPWT systems used within this analysis should not be interpreted as a
10 recommendation in favour these particular products.

11 **Results**

12 Table 62 shows the base case results of the analysis; these results include all the costs detailed in the
13 previous sections, over the 2 week time horizon. It is clear from the table that, even though fewer
14 dressing changes are required with NPWT, the standard care dressing regimen is still less costly than
15 all of the included negative pressure wound therapy systems, for small, medium and large pressure
16 ulcers.

17 **Table 62: Mean (range) base case results – costs over 2 week time horizon**

Ulcer size	Standard care dressing regimen	NPWT ^a	Incremental cost
Small	£440	£716 (£706 – £725)	£276
Medium	£520	£751 (£743 – £757)	£230
Large	£614	£830 (£825 – £833)	£216

18 (a) *The range shows the minimum and maximum totals based on the different NPWT systems included in this analysis*

19 In the majority of sensitivity analyses the cost of the dressing regimen remained less than the NPWT
20 systems, including when local costs were used and when NPWT is used in community settings (full
21 details in Appendix L). Threshold sensitivity analyses revealed NPWT would be cost saving for the
22 management of large and medium pressure ulcers if the rental cost per day of the pump reduced to
23 £4, and cost saving for small pressure ulcers if the rental cost per day decreased to £1 (Appendix L).
24 Overall, the sensitivity analyses demonstrated that the results of this analysis were robust to changes
25 in key assumptions, costs, and frequency of dressing change.

26 **Discussion**

27 This analysis found that a standard care dressing regimen is less costly than NPWT for the
28 management of pressure ulcers exhibiting high fluid secretion. This conclusion was robust to a wide
29 range of sensitivity analyses, demonstrating that although uncertainty surrounds model inputs,
30 variation within reasonable ranges does not change the results. As the existing clinical evidence does
31 not identify any clear benefit of NPWT, the GDG agreed that it is unlikely that NPWT is cost-effective
32 compared to standard care dressings for the treatment of pressure ulcers.

33 Note that the standard care dressing regimen included in this analysis is just 1 of many possible
34 dressing combinations. The dressing regimen was chosen to reflect a fairly high cost dressing
35 combination, in order to compare the cost of NPWT against the maximum cost of dressings. As
36 NPWT has been found to be more expensive than the costly dressing regimen, it is clear that it would
37 also be more costly than simpler dressing regimens.

- 1 The conclusions of this analysis fit with those presented by Soares and colleagues,¹⁷⁸ when their
2 analysis was based only on existing data (note that the GDG wished to avoid placing too much
3 reliance on expert elicited data). In this scenario, Soares and colleagues did not find NPWT to be cost-
4 effective compared to dressings.

7.2.3 Clinical evidence (neonates, infants, children and young people)

- 6 No RCTs or cohort studies were identified. Recommendations were developed using a modified
7 Delphi consensus technique. Further details can be found in Appendix N.

7.2.4 Economic evidence (neonates, infants, children and young people)

- 9 No economic evidence was identified. The economic model developed above was not intended to
10 apply to this population.

7.2.5 Evidence statements

7.2.5.1 Clinical (adults)

7.2.5.1.1 Negative pressure wound therapy versus wet-to-dry or wet-to-wet gauze

- 14 • One study (n=22) showed there is potentially no clinical difference between NPWT and wet-to-dry
15 or wet-to-wet gauze for time to reduction of initial wound volume by 50%, but the direction of
16 estimate of effect favoured NPWT (very low quality).
- 17 • One study (n=22) reported no clinical difference between NPWT and wet-to-dry or wet-to-wet
18 gauze for mean reduction in volume (% change, actual change), but the direction of estimate of
19 effect favoured the wet-to-dry or wet-to-wet gauze. The imprecision was unknown (very low
20 quality).
- 21 • No evidence was found for the following outcomes:
- 22 o Time to complete healing (time to event data)
 - 23 o Rate of healing (continuous data)
 - 24 o Rate of change in size of ulcer (absolute and relative) (continuous data)
 - 25 o Proportion of people completely healed within trial period
 - 26 o Pain (wound-related)
 - 27 o Time in hospital or NHS care (continuous data)
 - 28 o Patient acceptability eg measured by compliance and tolerance
 - 29 o Side effects (pain, problems with vacuum sealing, reaction of foam)
 - 30 o Mortality (all cause) (dichotomous)
 - 31 o Health-related quality of life.
- 32

7.2.5.1.2 Negative pressure wound therapy versus modern gel dressings

- 34 • One study (n=35) showed there may be no clinical difference between NPWT versus modern
35 wound gel dressings for the number of ulcers healed within 6 weeks, but the direction of
36 estimate of effect favoured modern wound gel dressings (very low quality).
- 37 • One study (n=35) reported no clinical difference between NPWT versus modern wound gel
38 dressings for the mean reduction in pressure ulcer volume (% change). The imprecision was
39 unknown (very low quality).
- 40 • No evidence was found for the following outcomes:
- 41 o Time to complete healing (time to event data)

- 1 o Rate of healing (continuous data)
- 2 o Rate of change in size of ulcer (absolute and relative) (continuous data)
- 3 o Pain (wound-related)
- 4 o Time in hospital or NHS care (continuous data)
- 5 o Patient acceptability eg measured by compliance and tolerance
- 6 o Side effects (pain, problems with vacuum sealing, reaction to foam)
- 7 o Mortality (all cause) (dichotomous)
- 8 o Health-related quality of life.
- 9

7.2.5.103 Negative pressure wound therapy versus standard care

- 11 • One study (n=12) showed there may be a clinical benefit of NPWT when compared to standard
12 care (spun hydrocolloid, alginate or foam dressings) for proportion of people with pressure
13 ulcers completely healed (very low quality).
- 14 • One study (n=12) showed there may be a clinical harm of NPWT when compared to standard care
15 (spun hydrocolloid, alginate or foam dressings) for increased mortality (very low quality).
- 16 • One study (n=12) showed there may be a clinical harm of NPWT when compared to standard care
17 (spun hydrocolloid, alginate or foam dressings) for increased pain (very low quality).
- 18 • No evidence was found for the following outcomes:
 - 19 o Time to complete healing (time to event data)
 - 20 o Rate of healing (continuous data)
 - 21 o Rate of change in size of ulcer (absolute and relative) (continuous data)
 - 22 o Reduction in size of ulcer and volume of ulcer
 - 23 o Time in hospital or NHS care (continuous data)
 - 24 o Patient acceptability eg measured by compliance and tolerance
 - 25 o Side effects (pain, problems with vacuum sealing, reaction to foam)
 - 26 o Health-related quality of life.

7.2.5.2 Economic (adults)

- 28 • One cost-utility analysis found NPWT is not cost-effective compared to alginate dressings, spun
29 hydrocolloid dressings, or foam dressings (at £20,000 per QALY gained threshold). This study was
30 assessed as directly applicable with potentially serious limitations.
- 31 • One cost-comparison found NPWT to be more costly than standard care dressings for the
32 management of pressure ulcers exhibiting high fluid secretion. This analysis is considered to be
33 partially applicable, with minor limitations.

7.2.5.3 Clinical (neonates, infants, children and young people)

35 No evidence was identified.

7.2.5.4 Economic (neonates, infants, children and young people)

37 No evidence was identified.

38

17.3 Hyperbaric oxygen therapy

2 Hyperbaric oxygen therapy involves administration of 100% oxygen at a pressure of greater than 1
3 atmospheric pressure absolute. The therapy has been posited to treat a number of conditions
4 including the treatment of pressure ulcers, as it has been suggested that an increase in the oxygen
5 supply to the wound bed therefore improves the healing process.

6 Creating the appropriate atmosphere can only be achieved in an environment of elevated
7 atmospheric pressure however, a number of methods of administering hyperbaric oxygen therapy
8 have been developed and it is possible to apply hyperbaric oxygen therapy topically, locally (for
9 example, on an arm) or within a mono or multi-place hyperbaric chamber (for 1 or more people).
10 One of the challenges for treatment is that mono and multi-place chambers are not always available
11 locally, so people often have to travel long distances to achieve necessary treatment.

12 In clinical practice, hyperbaic oxygen therapy has been used with a variety of objectives, generally to
13 facilitate and augment the healing process. The GDG were therefore interested in whether
14 hyperbaric oxygen therapy was clinically or cost effective for the treatment of pressure ulcers.

14 7.4 Review question: What is the clinical and cost-effectiveness of 16 hyperbaric oxygen therapy for the treatment of pressure ulcers?

17 For full details see review protocol in Appendix D.

18.4.1 Clinical evidence (adults)

19 A search was conducted for randomised trials of hyperbaric oxygen therapy for the treatment of
20 pressure ulcers but none were identified. As per the protocol (see Appendix D) a search was then
21 conducted for cohort studies but none relating to pressure ulcers were found. Therefore no studies
22 were included in this review. One Cochrane Review was found (Kranke 2012) which included 9 trials
23 of diabetic or venous ulcers however, no randomised trials were identified focusing on pressure
24 ulcers.⁹⁹

25 As outlined in Chapter 3, the GDG chose to exclude evidence relating to other chronic wounds from
26 the review, as the group considered that the mechanism of pressure ulcer development differed
27 significantly from other wounds and therefore, it was likely that treatment regimens would differ in
28 their effectiveness.

27.4.2 Economic evidence (adults)

30 No relevant economic evaluations assessing the cost-effectiveness of hyperbaric oxygen therapy
31 were identified.

32 In the absence of recent UK cost-effectiveness analysis, relevant unit costs are provided below to aid
33 consideration of cost effectiveness.

34 **Table 63: Example unit costs – hyperbaric oxygen therapy**

Treatment component	Cost	Comment
90 minute HBOT session	£155 – £200 per session	40 sessions required
Consumables (dressings etc)	£383	One-off charge
Total	£6,583 - £8,383	This cost does not include accommodation and transport costs

35 *Source: Treatment components and unit costs are obtained from the HBOT centre in Plymouth and GDG member estimates.*

1 Treatments are usually carried out on consecutive weekdays, thus 40 sessions would be expected to
2 take 8 weeks.

3 Travel costs are likely to be substantial, depending on the mode of transport required and the
4 distance travelled, and are not included in the total above. When people are required to travel a long
5 way there may also be accommodation costs (although these may be partially offset by freeing up
6 hospital beds elsewhere). Distance travelled may be significant, as there are few hyperbaric oxygen
7 chambers in the UK.

7.4.3 Clinical evidence (neonates, infants, children and young people)

9 No RCTs or cohort studies were identified. Recommendations were developed using a modified
10 Delphi consensus technique. Further details can be found in Appendix N.

7.4.4 Economic evidence (neonates, infants, children and young people)

12 No economic evidence was identified. Unit costs are provided in Table 63.

7.5 Electrotherapy

14 Electrotherapy is a non-invasive treatment that has been used for a variety of health conditions,
15 including pressure ulcers and other chronic wounds such as diabetic foot ulcers, venous and arterial
16 leg ulcers. It has been defined as, 'the use of a capacitive coupled electric current to transfer energy
17 to a wound'. Capacitive coupled electrical stimulation of wound healing involves the transference of
18 electric current through an electrode pad applied to moistened skin or wound bed, which form a wet
19 conductive medium. At least 2 electrodes are needed to complete the circuit. The reported rationale
20 for applying electrical stimulation to chronic non-healing wound is that it mimics the natural current
21 of injury and will initiate or accelerate the wound healing process, when other aetiological factors
22 have been both assessed and controlled.

23 Despite its varied use, it is still generally accepted that mechanism by which electrotherapy may work
24 are little understood, with effectiveness and best practice primarily relying on anecdotal evidence.

25 The GDG was therefore interested as to whether the use of electrotherapy could be considered
26 clinically or cost effective in the treatment of pressure ulcers.

7.6 Review question: What is the clinical and cost effectiveness of electrotherapy for the treatment of pressure ulcers?

28 For full details see review protocol in Appendix D.

7.6.1 Clinical evidence (adults)

31 Fourteen studies were included in the review.^{2,3,5,12,14,64,65,67,71,83,84,86,94,208} Evidence from these are
32 summarised in the clinical GRADE evidence profile below (ity

33 Table 5: Clinical). See also the study selection flow chart in Appendix D, forest plots in Appendix I,
34 study evidence tables in Appendix G and exclusion list in Appendix K.

35 A search was conducted for randomised trials comparing the effectiveness of electrotherapy versus
36 placebo or usual care for treatment of people with pressure ulcers. Sixteen randomised trials were
37 identified. Various types of electrical stimulation were included as were different populations. One
38 study was included which compared different types of electrical stimulation (as well as to a control
39 group). Another trial looked at different durations of electrotherapy compared to placebo. Studies

1 that reported pressure ulcers (where each participant could have more than 1 ulcer) were separated
2 from those who reported participants. One study included a mixed population of children and adults
3 (aged 10 to 74) but did not report the results for each population separately. The studies had varying
4 time periods (4 weeks to 5 months) and these were meta-analysed together. No significant
5 heterogeneity was found.

6 Change from baseline scores were used in preference to final values to calculate the reduction in
7 pressure ulcer size. Outcomes such as size of ulcer were reported separately from other outcomes,
8 as the data were continuous and there was a probability that the data was skewed. This was not
9 corrected with log transformation within the studies. It should therefore be emphasised that these
10 data should be interpreted with caution. In addition, it should also be noted that many of the studies
11 had very small sample sizes.

12

Summary of included studies

Study	Intervention/comparison	Population	Outcomes	Length of study
Adegoke 2001 ²	Interrupted direct current versus sham interrupted direct current. Both groups received routine nursing care.	People with a spinal cord injury with grade 4 pressure ulcers in the pelvic region	<ul style="list-style-type: none"> • % reduction in surface area 	4 weeks treatment
Adunsky 2005 ³	Direct current versus sham direct current. Both groups received conservative treatment of wounds.	People receiving geriatric rehabilitation with grade 3 pressure ulcers.	<ul style="list-style-type: none"> • Proportion with complete healing of pressure ulcers; speed of pressure ulcer closure; reduction in absolute pressure ulcer area; reduction in % pressure ulcer size 	Treatment lasted 8 weeks (57 days) and followed up at day 147 Results were also given for 45 days.
Ahmad 2008 ⁵	High-voltage pulsed galvanic stimulation (50µsec, 120 Hz, 100-175 v) (45, 60 and 120 minutes) versus sham treatment and conventional wound therapy, wet dressing and whirlpool therapy. Both groups received debridement before admission to study.	People with an indolent pressure ulcers of grade 2 (Yarkony-Kirk classification) chronic pressure ulcers	<ul style="list-style-type: none"> • Reduction in pressure ulcer surface area (cm²) 	5 weeks treatment
Asbjornsen 1990 ¹²	Transcutaneous electrical nerve stimulation (3Hz, 85 ms, 100Hz, 20-30mA) versus placebo transcutaneous electrical nerve stimulation. Both groups received conventional pressure ulcer treatment including measures to improve general condition, adequate local care and avoidance of pressure.	Geriatric participants with pressure ulcers on the heels or the sacral region.	<ul style="list-style-type: none"> • Proportion with complete healing; proportion of pressure ulcers reduced; proportion of pressure ulcers increased. 	6 weeks treatment
Baker 1996 ¹⁴	Asymmetric biphasic (100usec, 50 pulses/sec) versus symmetric biphasic	People with a spinal cord injury with 1 or more	<ul style="list-style-type: none"> • Rate of healing of pressure ulcers . 	4 weeks treatment

Study	Intervention/comparison	Population	Outcomes	Length of study
	(300Usec, 50 pulses/sec) versus microcurrent (4mA, 10 usec, 1 pulse/sec versus sham electrical stimulation.	pressure ulcers.		
Franek 2011 ⁶⁵	High voltage monophasic stimulation (100us, 100Hz, 100v) versus no stimulation. Both groups received pharmacological agents, including wound cleansing with potassium permanganate. The ulcer base was covered with compresses of fibrolan, colistin, and iruxol and wet dressings of 10% sodium chloride.	People undergoing surgery with grade 1 to 3 pressure ulcers.	<ul style="list-style-type: none"> Proportion of pressure ulcers completely healed; relative change of total surface area of pressure ulcers; relative change in length, relative change in width, relative change in volume, relative change in Gilman Index. 	6 weeks treatment
Franek 2012 ⁶⁴	Standard care plus high voltage electrical stimulation (voltage exceeded 100V, twin monophasic pulses lasting 100us in total and frequency of 100HZ applied). Five 50-minute procedures per week (1 procedure per day) versus no stimulation. Both groups standard care. Pressure redistribution surfaces and devices and pillows as needed; repositioning; standard topical care including cleansing with potassium permanganate followed by dressings; sharp debridement in small number; cleansing; immobilised people received low-molecular-weight heparin (enoxaparin). Antibiotics for those requiring.	People undergoing surgery with grade 2 and 3 pressure ulcers.	<ul style="list-style-type: none"> Change in pressure ulcer surface area (%); change in longest length (%); change in longest width (%); change in cavity volume (%); change in granulation tissue area (%); Gilman parameter. 	6 weeks treatment
Gentzkow 1991 ⁶⁷	Low voltage pulsed direct current (2pps/250 µsec to 128pps/150 µsec) versus placebo low voltage pulsed direct	People with grade 2, 3 or 4 pressure ulcers.	<ul style="list-style-type: none"> Proportion of pressure ulcers healed, rate of healing, mean healing , withdrawals due to 	4 weeks treatment

Study	Intervention/comparison	Population	Outcomes	Length of study
	current .		adverse events, acceptability of treatment	
Griffin 1991 ⁷¹	High-voltage pulsed direct current (100pps, 200v) versus placebo high-voltage pulsed direct current. Both groups received equivalent nursing care - cleansing and application of gel and a dry dressing; wound mechanically debrided. 2 hourly turning.	People with a spinal cord injury and grade 2 to 4 pressure ulcers in the pelvic region.	<ul style="list-style-type: none"> Change in pressure ulcer surface area; proportion of pressure ulcers completed healed. 	20 days treatment
Houghton 2010 ⁸³	Twin peaked high-voltage monophasic pulsed current (50 usec, 50-150v) versus no stimulation. Both groups received a community-based interdisciplinary wound care programme.	People in the community with spinal cord injuries with grade 3 to 4 pressure ulcers.	<ul style="list-style-type: none"> % reduction in pressure ulcer surface area; proportion of pressure ulcers reduced by at least 50%; changes in pressure ulcer appearance (PWAT scores); improved PWAT scores; proportion with increased pressure ulcers; proportion with improved PSST scores; proportion of grade 2 pressure ulcers completely healed; proportion of 3, 4 and 5 pressure ulcers healed; proportion of grade 3, 4 and 5 pressure ulcers reduced by at least 50%; EST compliance; adverse reactions. 	3 months treatment, 4 months follow-up
Jercinovic 1994 ⁸⁴	Low frequency pulsed current (biphasic, asymmetric, charge-balanced pusses 40pps, 205µs, 35mA) versus no stimulation. Both groups received standard wound	People with a spinal cord injury with pressure ulcers.	<ul style="list-style-type: none"> Rate of healing of pressure ulcers. 	4 weeks treatment

Study	Intervention/comparison	Population	Outcomes	Length of study
	care. Debridement; standard dressings; antibiotics in cases of infection; dry-floatation mattresses; repositioning; standard rehabilitation programme.			
Karba 1995 ⁸⁶	4-second trains of biphasic, charge-balanced asymmetrical current stimuli, which alternated with pauses of the same duration (4 seconds) versus sham treatment. Both groups: cleansing; covered with semi-occlusive foam gel dressings.	Males with a spinal cord injury with pressure ulcers.	<ul style="list-style-type: none"> • Rate of healing of pressure ulcers. 	98 days
Kloth 1988 ⁹⁴	High voltage pulsed current (105Hz, 50 µsec, 100-175v) versus sham treatments. Both groups received pressure-relieving devices that reduced exogenous cutaneous pressure; high-protein dietary supplement; manual debridement and with enzymes.	People with grade 4 pressure ulcers	<ul style="list-style-type: none"> • Proportion completely healed; healing rate of pressure ulcers. 	16 weeks treatment
Wood 1993 ²⁰⁸	Pulsed low-intensity direct current (600uA, 0.8Hz) versus placebo pulsed low-intensity direct current plus standard treatment. Standard treatment received wound cleansing, simple moist dressing, whirlpool baths.	People with grade 2 and 3 chronic pressure ulcers.	<ul style="list-style-type: none"> • Proportion of pressure ulcers completely healed; reduction in pressure ulcer area; reduction in pressure ulcer area over 80%, pressure ulcer depth. 	8 weeks treatment

Table 64: Clinical evidence profile: electrotherapy versus control (placebo or usual treatment)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Electrotherapy	Control	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed - end of study (people) people receiving geriatric rehabilitation, grade 3 pressure ulcers (classification system not reported) (Adunsky 2005); geriatric adults, pressure ulcer grade not reported (Asbjornsen 1990); people undergoing surgery, grade 1, 2 and 3 pressure ulcers (classification system not reported, see criteria in evidence table) (Franek 2011); people with a spinal cord injury, grade 2 to 4 pressure ulcers (DeLisa classification system) (Griffin 1991); people with a spinal cord injury in the community, pressure ulcers grade 2 to 4 (NPUAP) (Houghton 2010)^{3, 12, 65, 71, 83}												
5	Randomised trials	Very serious ^a	Serious inconsistency ^b	No serious indirectness	Serious imprecision ^c	None	26/95 (27.4%)	23/93 (24.7%)	RR 1.09 (0.68 to 1.75)	22 more per 1000 (from 79 fewer to 167 more)	Very low	Critical
							-	22.2%				
Proportion of pressure ulcers completely healed - end of study (pressure ulcers) - people with chronic pressure ulcers, grade 2 and 3 (classification system not reported)²⁰⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^e	None	25/43 (58.1%)	1/31 (3.2%)	RR 18.02 (2.58 to 126.01)	549 more per 1000 (from 51 more to 1000 more)	Very low	Critical
							-	3.2%				
More than 80% decrease in ulcer area - ulcers- people with chronic pressure ulcers, grade 2 and 3 (classification system not reported)²⁰⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	31/43 (72.1%)	4/31 (12.9%)	RR 5.59 (2.2 to	592 more per 1000 (from 155	Low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Electrotherapy	Control	Relative (95% CI)	Absolute		
							-	12.9%	14.21)	more to 1000 more)		
										592 more per 1000 (from 155 more to 1000 more)		
Proportion of pressure ulcers that reduced by at least 50% at 3 months (people) – people with a spinal cord injury in the community, pressure ulcers grade 2 to 4 (NPUAP)⁸³												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^c	None	12/15 (80%)	5/14 (35.7%)	RR 2.24 (1.06 to 4.73)	443 more per 1000 (from 21 more to 1000 more)	Low	Important
							-	35.7%		443 more per 1000 (from 21 more to 1000 more)		
Proportion with improved PWAT scores (people) people with a spinal cord injury in the community, pressure ulcers grade 2 to 4 (NPUAP)⁸³												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^c	None	12/16 (75%)	8/18 (44.4%)	RR 1.69 (0.94 to 3.04)	307 more per 1000 (from 27 fewer to 907 more)	Low	Important
							-	44.4%		306 more per 1000 (from 27 fewer to		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Electrotherapy	Control	Relative (95% CI)	Absolute		
											906 more)	
Proportion with improved PSST scores (people) – people with a spinal cord injury in the community, pressure ulcers grade 2 to 4 (NPUAP)⁸³												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious imprecision ^c	None	8/16 (50%)	9/18 (50%)	RR 1.00 (0.51 to 1.96)	0 fewer per 1000 (from 245 fewer to 480 more)	Very low	Important
							-	50%		0 fewer per 1000 (from 245 fewer to 480 more)		
Proportion of people with decreased ulcers - geriatric adults, pressure ulcer grade not reported¹²												
1	Randomised trial	Very serious ^a	No serious	No serious indirectness	Very serious ^{c,e}	None	3/7 (42.9%)	0/9 (0%)	Peto OR 13.98 (1.21 to 162.00)	430 more per 1000 (from 60 fewer to 800 more)	Very low	Important
Proportion of people with increased ulcers - geriatric adults, pressure ulcer grade not reported (Asbjornsen 1990); people with a spinal cord injury in the community, pressure ulcers grade 2 to 4 (NPUAP) (Houghton 2010)^{83, 12}												
2	Randomised trials	Very serious ^a	Very serious ^b	No serious indirectness	Very serious ^{d,e}	None	3/23 (13%)	4/27 (14.8%)	RR 1.05 (0.02 to 68.36)	7 more per 1000 (from 145 fewer to 1000 more)	Very low	Important
							-	11.1%		6 more per 1000 (from 109 fewer to 1000)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Electrotherapy	Control	Relative (95% CI)	Absolute (more)		
Proportion of people with increased ulcers – geriatric adults, pressure ulcer grade not reported ¹²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^{c,e}	None	3/7 (42.9%)	0/9 (0%)	Peto OR 13.98 (1.21 to 162.00)	430 more per 1000 (from 60 fewer to 800 more)	Very low	Important
							-	0%		430 more per 1000 (from 60 fewer to 800 more)		
Proportion of people with increased ulcers – people with a spinal cord injury in the community, pressure ulcers grade 2 to 4 (NPUAP) ⁸³												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	0/16 (0%)	4/18 (22.2%)	Peto OR 0.13 (0.02 to 0.98)	186 fewer per 1000 (from 3 fewer to 217 fewer)	Low	Important
							-	22.2%		186 fewer per 1000 (from 3 fewer to 216 fewer)		
Proportion of ulcers which increased in size - people with chronic pressure ulcers, grade 2 to 3 (classification system not reported) ²⁰⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None	0/43 (0%)	10/31 (32.3%)	Peto OR 0.07 (0.02 to 0.25)	290 fewer per 1000 (from 216 fewer to 313)	Very low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Electrotherapy	Control	Relative (95% CI)	Absolute		
							-	32.3%		fewer) 291 fewer per 1000 (from 1216 fewer to 313 fewer)		
Mortality - geriatric adults, pressure ulcer grade not reported (Asbjornsen 1990); people undergoing surgery, grade 1, 2 and 3 pressure ulcers (classification system not reported, see criteria in evidence table) (Franek 2011); people undergoing surgery with grade 2 and 3 pressure ulcers (Franek 2012); people with a spinal cord injury, grade 2 to 4 pressure ulcers (DeLisa classification system)(Griffin 1991); people with grade 4 pressure ulcers (Kloth 1988); people with chronic pressure ulcers, grade 2 and 3 (classification system not reported) (Wood 1993)^{12,64,65,71,94,208}												
6	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	3/120 (2.5%)	5/108 (4.6%)	RR 0.58 (0.18 to 1.88)	19 fewer per 1000 (from 38 fewer to 41 more)	Very low	Important
Time to- complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Electrotherapy	Control	Relative (95% CI)	Absolute		
Mortality												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) *Adunsky (2005) did not report details of allocation concealment. There was a high drop-out. Per protocol was used but the authors were unclear about the number analysed in the control group. The authors did not provide details of whether outcome assessors were blinded. Asbjornsen (1990) did not report details of sequence generation or allocation concealment or baseline differences. There was a higher drop-out in the treatment group. No statistical tests were mentioned. Franek (2011) did not use blinding (although the authors say it was not possible for EST), but the outcome assessors were not blinded either. Griffin (1991) did not provide details of sequence generation method or allocation concealment. There was a significant difference in groups for duration of spinal cord injury, which was longer in the treatment group. No blinding of outcome assessors. Houghton (2010) did not blind the caregiver or participant however the outcome assessor was blinded. Kloth (1988) did not report details of allocation concealment, baseline differences, blinding of outcome assessors. No statistical tests mentioned. No details of blinding of outcome assessor were given. There were unclear number of participants randomised but 49 were entered into study, and 34 completed. No details of withdrawals were given; measured pressure ulcer by using length and width. Wood (1993) did not provide details of sequence generation method. There were more participants in treatment than control group. There was a high drop-out in control group arm.*
- (b) *There were wide variations in follow-up times.*
- (c) *The confidence interval crossed 1 MID point (0.5 x standard deviation for continuous outcomes and 0.75 to 1.25 for dichotomous outcomes).*
- (d) *The confidence interval crossed both MID points (0.5 x standard deviation for continuous outcomes and 0.75 to 1.25 for dichotomous outcomes).*
- (e) *There was a very wide confidence interval.*
- (f) *Peto odds ratio was used as 1 arm had zero events.*
- (g) *I² = 77%, p=0.04. Asbjornsen, 1990 was a study which included a majority of heel ulcers.*

Table 65: Clinical evidence profile: electrotherapy versus control (placebo or usual treatment)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Electrotherapy	Control	Relative (95% CI)	Absolute		
% mean reduction in wound surface area (people) people undergoing surgery with grade 2 and 3 pressure ulcers (Franek 2012); people with a spinal cord injury in the community, pressure ulcers grade 2 to 4 (NPUAP) (Houghton 2010)^{64,83}												
2	Randomised trials	Serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	Serious ^f	n=42	n=42	-	MD 40.16 higher	Low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Electrotherapy	Control	Relative (95% CI)	Absolute		
										(20.39 to 59.92 higher)		
% mean reduction in wound surface area (pressure ulcers) people with pressure ulcers grade 2, 3 or 4 (classification system not reported but details given – see evidence table)⁶⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^f	49.8 (SD 30.9) n=21	23.4 (SD 47.4) n=19	-	MD 26.4 higher (1.32 to 51.48 higher)	Very low	Important
% median reduction in wound surface area (at 20 days) (people) people with a spinal cord injury, grade 2 to 4 pressure ulcers (DeLis classification system)⁷¹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious imprecision ^e	Serious ^f	Median 80% (range 52 to 100%)	Median 52% (range 14% to 100%)	p=0.05	MD 28%	Very low	Important
Healing rate (%/week) (people) people with grade 4 pressure ulcers (classification system not reported)⁹⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	Serious ^f	44.8 (SD 22.6) n=9	-11.59 (SD 18.6) n=7	-	MD 56.39 higher (36.19 to 76.59 higher)	Very low	Important
Healing rate (%/week) (pressure ulcers) people with a spinal cord injury (classification system not reported (BAKER 1996); patients with pressure ulcers grade 2,3 or 4 (classification system not reported but details given – see evidence table) (Gentzkow 1991)^{14,67}												
2	Randomised trials	Very serious ^a	No serious inconsistency ⁱ	No serious indirectness	Serious imprecision ^b	Serious ^f	n=79	n=44	-	MD 2.99 lower (6.03 lower to 0.05 higher)	Very low	Important
Healing rate (%/day) (people) people with a spinal cord injury (classification system not reported)⁸⁶												
1	Randomised	Very	No serious	No serious	No serious	Serious ^f	7.13 (SD 1.46)	-0.66	-	MD 7.79	Low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Electrotherapy	Control	Relative (95% CI)	Absolute		
	trial	serious ^a	inconsistency	indirectness	imprecision		n=6	(SD 1.16) n=6		higher (6.30 to 9.28 higher)		
Healing rate (%/day) - exponential fitting (pressure ulcers) people with a spinal cord injury (classification system not reported)⁸⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^f	5.7 (SD 7.1) n=61	2.7 (SD 3.6) n=48	-	MD 3 higher (0.95 to 5.05 higher)	Very low	Important
Healing rate (%/day) - linear fitting (pressure ulcers) people with a spinal cord injury (classification system not reported)⁸⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^f	2.2 (SD 2.1) n=61	1.5 (SD 1.7) n=48	-	MD 0.7 higher (0.01 lower to 1.41 higher)	Very low	Important
Healing rate (%/day) - exponential fitting - crossover group (pressure ulcers) people with a spinal cord injury (classification system not reported)⁸⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^f	5 (SD 4.2) n=20	1.2 (SD 2.1) n=20	-	MD 3.8 higher (1.74 to 5.86 higher)	Very low	Important
Healing rate (%/day) - linear fitting - crossover group (pressure ulcers) people with a spinal cord injury (classification system not reported)⁸⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	Serious ^f	2.4 (SD 1.4) n=20	0.6 (SD 1.5) n=20	-	MD 1.8 higher (0.9 to 2.7 higher)	Very low	Important
Time to complete healing (people) geriatric rehabilitation adults, grade 3 pressure ulcers (classification system not reported)³												
1	Randomised trial	Very serious ^a	No serious inconsistency	Serious indirectness	No serious imprecision	Serious ^f	63.4 (SD 15.1) n=9	89.7 (9.2)	-	MD 26.3 lower	Very low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Electrotherapy	Control	Relative (95% CI)	Absolute		
								n=10		(37.69 to 14.91 lower)		
Speed of healing (% change from baseline – days) (people) geriatric rehabilitation adults, grade 3 pressure ulcers (classification system not reported) ³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^f	-0.24 (SD 0.14) n=35	- 0.25 (SD 0.14) n=28	-	MD 0.01 higher (0.06 lower to 0.08 higher)	Very low	Important
Acceptability of treatment – compliance to electrotherapy (hours per day) (people) people with a spinal cord injury in the community, pressure ulcers grade 2 to 4 (NPUAP) ⁸³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	N/A	None	Mean 3.0 (SD 1.5) h/day	-	-	-	Very low	Important
Acceptability of treatment – uncomfortable sensation in the ulcer when current was turned on (pressure ulcers) people with pressure ulcers grade 2, 3 or 4 (classification system not reported but details given – see evidence table) ⁶⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious imprecision ^k	Serious ^f	13.6% n=21	4.2% n= 18	-	MD 9.4%	Very low	Important
Side effects (people) people with a spinal cord injury in the community-, pressure ulcers grade 2 to 4 (NPUAP) ⁸³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	N/A	Serious ^f	See footnote ^h	-	-	-	-	Important
Mean reduction in length (%) – people undergoing surgery with grade 2 and 3 pressure ulcers ⁶⁴												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	Serious ^f	74 (SD 29.6) n=26	36.1 (SD 33.9) n=24	-	MD 37.9 higher (20.2 to 55.6 higher)	Low	Important
Mean reduction in longest width (%) – people undergoing surgery with grade 2 and 3 pressure ulcers ⁶⁴												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	Serious ^f	79 (SD 25.1) n=26	36.3 (41.9)	-	MD 42.7 higher	Low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Electrotherapy	Control	Relative (95% CI)	Absolute		
								n=24		(23.36 to 62.04 higher)		
Mean reduction in cavity volume (%) –people undergoing surgery with grade 2 and 3 pressure ulcers⁶⁴												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	Serious ^f	100 (SD 0.0001) n=26	54 (SD 39.4) n=24	-	46 higher (30.24 to 61.76 higher) ^j	Low	Important
Mean reduction in granulation tissue area (%) people undergoing surgery with grade 2 and 3 pressure ulcers⁶⁴												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious imprecision ^c	Serious ^f	37.66 (SD 76.17) n=26	10.36 (SD 43.46) n=24	-	MD 27.3 higher (6.75 lower to 61.35 higher)	Very low	Important
Gillman parameter – people undergoing surgery, grade 1, 2 and 3 pressure ulcers (classification system not reported, see criteria in evidence table) (Franeck 2011); people undergoing surgery with grade 2 and 3 pressure ulcers (Franeck 2012)^{64,65}												
2	Randomised trials	Serious ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^f	n=26	n=24	-	MD 0.41 higher (0.28 to 0.54 higher)	Very low	Important
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers (time to event data)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Electrotherapy	Control	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) *Adunsky (2005) did not provide details of allocation concealment. There was a high drop-out and per protocol was used by the authors were unclear about the number analysed in the control group. There were no details provided of whether the outcome assessors were blinded. Non-parametric tests were used so the data was possibly skewed but no log transformations were carried out. Adegoke (2001) did not provide details of sequence generation. There was unclear allocation concealment. No details of blinding of outcome assessors were provided. There was 1 drop-out but no details were provided on which arm this was in. There were differences at baseline. No statistical tests were mentioned. Baker (1996) did not provide details of sequence generation or allocation concealment. There was no blinding except of the outcome assessor. There was unclear missing outcome data. Franek (2011) did not blind (although the authors say it was not possible for EST), but the outcome assessors were not blinded either. Non-parametric test were used the data was possibly skewed but no log-transformations were carried out. Franek (2012) did not provide sham treatment and there was no blinding of participants, caregivers or outcome assessors. Gentzkow (1991) did not provide details of sequence generation method; difference at baseline in ulcer size. Pressure ulcers were measured by using length and width. Griffin (1991) did not provide details of sequence generation method or allocation concealment. There was a significant difference in groups for duration of spinal cord injury, which was longer in the treatment group. There was no blinding of outcome assessors. Non-parametric tests used so possibly skewed data but no log transformations. Houghton (2010) did not provide details of blinding of caregiver and participant. Outcome assessor was blinded. Jercinovic (1994) did not provide details of sequence generation or allocation concealment. No blinding was carried out. There was an unclear number randomised and missing outcome data. Kloth (1988) did not provide details of allocation concealment, baseline differences, blinding of outcome assessors. No statistical tests mentioned.*
- (b) *The confidence interval crossed 1 MID point (0.5 x standard deviation for continuous outcomes and 0.75 to 1.25 for dichotomous outcomes).*
- (c) *The confidence interval crossed both MID points (0.5 x standard deviation for continuous outcomes and 0.75 to 1.25 for dichotomous outcomes).*
- (d) *The confidence interval crossed 1 MID point (0.5 x standard deviation for continuous outcomes and 0.75 to 1.25 for dichotomous outcomes) and limited number of events.*
- (e) *Medians given, no standard deviations given.*
- (f) *The data was skewed data and no log transformations were done.*
- (g) *Recommended treatment time 8 hours per day. Proportion using the recommended time: 4/16. Those who healed used the electrotherapy the longest (539 total hours; 2.54h/day); those who did not heal 331 total hours; 2.24h/day; Average for those who healed: 136.4 days (4.5 months).*
- (h) *Red area or burn under the active electrode after EST treatment, area resolved within 48 hours and remedied by turning down the intensity of subsequent electrotherapy treatments. One participant complained of dizziness and delusions while receiving electrotherapy but was evaluated as withdrawal from narcotics after a lapse in prescription.*
- (i) *Baker (1996) included 3 treatments and treatment B (symmetric biphasic 200usec, 50 pulses/sec) was the most similar to Gentzkow (1991) which was pulsed electrical current (2pulses/sec/350usec to 128pulses/sec/150usec).*
- (j) *A standard deviation of 0.001 was used in Revman as the standard deviation of zero showed no result.*
- (k) *No numerator or denominator given so unable to analyse in Revman.*

Table 66: Clinical evidence profile: asymmetric biphasic electrostimulation at 100µs versus control

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Asymmetric biphasic electrostimulation at 100us	Control	Relative (95% CI)	Absolute		
Mean reduction in wound surface area (% per week)— people with a spinal cord injury (classification system not reported)¹⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^c	36.40 (SD 6.2) n=67	32.7 (SD 7) n=25	-	MD 3.7 higher (0.58 to 6.82 higher)	Very low	Important
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) Baker (1996) did not provide details of sequence generation or allocation concealment. No blinding was carried out except for the outcome assessor. There was unclear missing outcome data.
- (b) The confidence interval crossed 1 MID point (0.5 x standard deviation for continuous variables).
- (c) The data were possibly skewed but no log transformation was carried out.

Table 67: Clinical evidence profile: symmetric biphasic electrostimulation 300 µsec versus control

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Symmetric biphasic electrostimulation 300 usec	Control	Relative (95% CI)	Absolute		
Mean reduction in wound surface area (% per week) – people with a spinal cord injury (classification system not reported)¹⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^c	n=58	n=25	-	MD 3 lower (6.04 lower to 0.04 higher)	Very low	Important
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Symmetric biphasic electrostimulation 300 usec	Control	Relative (95% CI)	Absolute		
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Baker (1996) did not report details of sequence generation or allocation concealment. There was no blinding except of the outcome assessor. There was unclear missing outcome data.
 (b) The confidence interval crossed 1 MID point (0.5 x standard deviation for continuous variables).
 (c) The data were possibly skewed but no log transformation was carried out.

Table 68: Clinical evidence profile: microcurrent versus control

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Microcurrent	Control	Relative (95% CI)	Absolute		
Mean reduction in wound surface area (% per week) – people with a spinal cord injury (classification system not reported)¹⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious imprecision ^b	Serious ^c	n=42	n=25	-	MD 9.4 lower (12.5 to 6.3 lower)	Very low	Important
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Microcurrent	Control	Relative (95% CI)	Absolute		
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Baker (1996) did not report details of sequence generation or allocation concealment. No blinding except of outcome assessor. There was unclear missing outcome data.
 (b) Confidence interval crossed 1 MID point (0.5 x standard deviation for continuous variables).
 (c) The data were possibly skewed but no log transformation was carried out.

Table 69: Clinical evidence profile: asymmetric biphasic electrostimulation 100µsec versus 300µsec

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Asymmetric biphasic electrostimulation 100µsec	300 µsec	Relative (95% CI)	Absolute		
Mean reduction in wound surface area (% per week) – people with a spinal cord injury (classification system not reported)¹⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	Serious ^b	36.4 (SD 6.2) n=67	29.7 (SD 5.1) n=5 8	-	MD 6.7 higher (4.72 to 8.68 higher)	Very low	Important
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Asymmetric biphasic electrostimulation 100µsec	300 µsec	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Baker (1996) did not provide details of sequence generation or allocation concealment. There was no blinding except of outcome assessor. There was unclear missing outcome data.

(b) The data were possibly skewed but no log transformation was carried out.

Table 70: Clinical evidence profile: asymmetric biphasic electrostimulation 100µsec versus microcurrent

Quality assessment	No of patients	Effect	Quality	Importance
--------------------	----------------	--------	---------	------------

No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Asymmetric biphasic electrostimulation 100usec	Microcurrent	Relative (95% CI)	Absolute		
Mean reduction in wound surface area (% per week) – people with a spinal cord injury (classification system not reported)¹⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	Serious ^b	36.4 (SD 6.2) n=67	23.3 (SD 4.8) n=42	-	MD 13.1 higher (11.02 to 15.18 higher)	Very low	Important
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Baker (1996) did not provide details of sequence generation or allocation concealment. There was no blinding except of the outcome assessor. There was unclear missing outcome data.

(b) The data were possibly skewed but no log transformation as carried out.

Table 71: Clinical evidence profile: asymmetric biphasic electrostimulation 300µsec versus microcurrent

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Asymmetric biphasic electrostimulation 300µsec	Microcurrent	Relative (95% CI)	Absolute		
Mean reduction in wound surface area (% per week) – people with a spinal cord injury (classification system not reported)¹⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	Serious ^b	29.7 (SD 5.1) n=58	23.3 (SD 4.8) n=42	-	MD 6.4 higher (4.44 to 8.36 higher)	Very low	Important
Proportion of people with complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Baker (1996) did not provide details of sequence generation or allocation concealment. There was no blinding except of the outcome assessor. There was unclear missing outcome data.
 (b) The data were possibly skewed but no log transformation was carried out.

Table 72: Clinical evidence profile: electrotherapy versus control group (grade 3 and 4 pressure ulcers)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Electrotherapy	Control	Relative (95% CI)	Absolute		
Proportion of participants completely healed - at end of study (people) geriatric rehabilitation adults, grade 3 pressure ulcers (classification system not reported) (Adunsky 2005); people with a spinal cord injury, grade 2 to 4 pressure ulcers (DeLisa classification system)(Griffin 1991); people in the community with a spinal cord injury, pressure ulcers grade 2 to 4 (NPUAP) (Houghton 2010)³												
3	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	15/56 (26.8%)	11/49 (22.4%)	RR 1.14 (0.6 to 2.2)	31 more per 1000 (from 90 fewer to 269 more)	Very low	Critical
							-	7.1%		10 more per 1000 (from 28 fewer to 85 more)		
Mortality - people with grade 4 pressure ulcers (classification system not reported) (Kloth 1988)⁹⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/9 (0%)	0/7 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Absolute reduction in size of pressure ulcer (cm) at end of treatment (better indicated by higher values) - geriatric rehabilitation adults, grade 3 pressure ulcers (classification system not reported) (Adunsky 2005)³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision ^b	None	11.15 (SD 1.1) n=21	16.7 (SD 1) n=25	-	MD 5.55 lower (6.16 to 4.94 lower)	Low	Critical
Absolute reduction in size of pressure ulcer (cm) at end of follow-up (better indicated by higher values) - Geriatric rehabilitation adults, grade 3 pressure ulcers (classification system not reported) (Adunsky 2005)³												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Electrotherapy	Control	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	2.53 (SD 2.11) n=21	2.88 (SD 1.92) n=25	-	MD 0.35 lower (1.53 lower to 0.83 higher)	Very low	Critical
Healing rate (%/week) (people) (better indicated by higher values) – people with grade 4 pressure ulcers (Kloth 1988)⁹⁴												
1	Randomised trial	Very serious ^d	No serious inconsistency	No serious indirectness	No serious imprecision	None	44.8 (SD 22.6) n=9	-11.59 (SD 18.6) n=7	-	MD 56.39 higher (36.19 to 76.59 higher)	Low	Critical
Time to complete healing (days) (better indicated by lower values) geriatric rehabilitation adults, grade 3 pressure ulcers (classification system not reported) (Adunsky 2005)												
1	Randomised trial	Very serious ^a	No serious inconsistency	Serious indirectness ^e	No serious imprecision	None	63.4 (SD 15.1) n=9	89.7 (SD 9.2) n=10	-	MD 26.3 lower (37.69 to 14.91 lower)	Very low	Critical
Speed of healing (% change from baseline - days) (better indicated by lower values) geriatric rehabilitation adults, grade 3 pressure ulcers (classification system not reported) (Adunsky 2005)												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	-0.24 (SD 0.14) n=35	-0.25 (SD 0.14) n=28	-	MD 0.01 higher (0.06 lower to 0.08 higher)	Very low	Critical
Time to complete healing of pressure ulcers (time to event data)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Electrotherapy	Control	Relative (95% CI)	Absolute		
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) *Adunsky (2005): no details of allocation concealment were reported by the authors. There was a high drop-out and per protocol was used but was unclear about number analysed in the control group. No details of whether outcome assessors were blinded was reported by the authors. Non-parametric tests were used so the data were possibly skewed but no log transformations were carried out. Adegoke (2001) No details of sequence generation were reported by the authors. There was unclear allocation concealment. No details of blinding of outcome assessors was reported by the authors. There was 1 drop-out but no details of which arm were provided. The groups were different at baseline. No statistical tests were mentioned. Baker (1996): no details of sequence generation or allocation concealment were reported by the authors. No blinding except of outcome assessor was reported. There was unclear missing outcome data. Franek (2011): no blinding (although the authors say it was not possible for EST), but the outcome assessors were not blinded either. Non-parametric test used so possibly skewed data but no log-transformations. Franek (2012) No sham treatment, no blinding of participants, caregivers or outcome assessors. Gentzkow (1991): No details of sequence generation method; difference at baseline in ulcer size; measured pressure ulcer by using length and width. Griffin (1991): no details of sequence generation method or allocation concealment. There was a significant difference in groups for duration of spinal cord injury, which was longer in the treatment group. No blinding of outcome assessors. Non-parametric tests used so possibly skewed data but no log transformations. Houghton (2010): no blinding of caregiver and participant. Outcome assessor was blinded. Jercinovic (1994) No details of sequence generation or allocation concealment. No blinding. Unclear number randomised and missing outcome data. Kloth (1988) No details of allocation concealment, baseline differences, blinding of outcome assessors. No statistical tests mentioned. Ullah (2007): no details of sequence generation or allocation concealment. No details of missing data, how they measured ulcer size, baseline differences or whether outcome assessors were blinded.*
- (b) *Confidence interval crossed both MID points.*
- (c) *Confidence interval crossed 1 MID point.*
- (d) *Kloth (1988) No details of allocation concealment, baseline differences, blinding of outcome assessors. No statistical tests mentioned. No details of blinding of outcome assessor. Unclear number randomised but 49 were entered into study, and 34 completed, no detail of withdrawals; measured pressure ulcer by using length and width.*
- (e) *Time to event data not given as hazard ratio, high risk of bias from mean values.*

7.611 Economic evidence (adults)

2 One study was included with the relevant comparison.¹¹⁸ This is summarised in the economic
3 evidence profile below (Table 73). See also the study selection flow chart in Appendix D and study
4 evidence table in Appendix H.

5

Table 73: Economic evidence profile: Electrotherapy versus standard wound care

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
Mittmann 2011 ¹¹⁸ (Canada)	Partially applicable ^a	Potentially serious limitations ^b	A decision analytic model to calculate the incremental cost per pressure ulcer healed when electrical simulation therapy (ES) plus standard wound care (SWC) is compared to SWC in patients with grade 3-4 pressure ulcers and spinal cord injury.	-£123	0.164 pressure ulcers healed per year	ES+SWC dominates SWC	One-way sensitivity analyses were carried out to identify model drivers; the percentage of pressure ulcers healed was the largest driver of the model. Probabilistic sensitivity analyses revealed a probability that ES+WSC dominates SWC of 61.5%.

- (a) This study is based on the Canadian health care system and does not consider quality of life. The intervention is assessed within a spinal cord injury population thus generalisation to all those with pressure ulcers may not be appropriate.
- (b) The authors have made several assumptions around transition probabilities, for example using a 3 month healing rate taken from Houghton (2010) for 12 month probability of ulcers healing, whereas the rate for relapse was a 9 month rate also assumed to be annual. Estimates of costs and resource use are calculated from the Houghton trial rather than a systematic procedure. The time horizon is only 1 year, thus relevant costs and benefits may not have been accounted for. It is unclear how costs have been calculated.

7.6.2 Clinical evidence (neonates, infants, children and young people)

- 2 No RCTs or cohort studies were identified. Recommendations were developed using a modified
3 Delphi consensus technique. Further details can be found in Appendix N.

7.6.3 Economic evidence (neonates, infants, children and young people)

- 5 No economic evidence was identified.

7.6.4 Evidence statements

7.6.4.1 Clinical evidence (adults)

- 8 • Five studies (n=188) showed there is potentially no clinical difference between electrotherapy and
9 a placebo or usual treatment for the proportion of people with pressure ulcers completely healed,
10 the direction of the estimate of effect favoured the electrotherapy group (very low quality).
- 11 • One study (n=74) showed electrotherapy is potentially more clinically effective than placebo or
12 usual treatment for the proportion of pressure ulcers completely healed (very low quality).
- 13 • One study (n=74) showed electrotherapy is more clinically effective than placebo or usual
14 treatment for the proportion of people with over 80% decrease in pressure ulcer area (low
15 quality).
- 16 • One study (n=29) showed electrotherapy is potentially more clinically effective than placebo or
17 usual treatment for the proportion of pressure ulcers that reduced by at least 50% (low quality).
- 18 • One study (n=34) showed electrotherapy is potentially more clinically effective than placebo or
19 usual treatment for the improvement of PWAT scores (low quality).
- 20 • One study (n=34) showed there may be no clinical difference between electrotherapy and a
21 placebo or usual treatment for improvement of PSST scores (very low quality).
- 22 • One study (n=16) showed electrotherapy may be more clinically effective than placebo or usual
23 treatment for the proportion of people with decreased pressure ulcers (very low quality)
- 24 • Two studies (n=50) showed there may be no clinical difference between electrotherapy and a
25 placebo or usual treatment in a geriatric and spinal cord injured population for the proportion of
26 people with increased pressure ulcers, the direction of the estimate of effect favoured the
27 placebo or usual treatment (very low quality).
- 28 • One study (n=16) showed placebo or usual treatment may be more clinically effective than
29 electrotherapy in a geriatric population for reducing the proportion of people with increased
30 pressure ulcers (very low quality).
- 31 • One study (n=34) showed electrotherapy is possibly more clinically effective than placebo or usual
32 treatment in a spinal cord injured population for reducing the proportion of people with
33 increased pressure ulcers (low quality).
- 34 • One study (n=74) showed electrotherapy is more clinically effective than placebo or usual
35 treatment for the proportion of pressure ulcers which increased in size (very low quality).
- 36 • Six studies (n=228) showed there may be no clinical difference between electrotherapy and
37 placebo or usual treatment for all-cause mortality, the direction of the estimate of effect favoured
38 electrotherapy (very low quality).
- 39 • Two studies (n=84) showed electrotherapy is potentially more clinically effective than placebo or
40 usual treatment for achieving a higher % mean reduction in wound surface area for surgical
41 inpatients and people in the community with spinal cord injuries (very low quality)
- 42 • One study (n=40) showed that electrotherapy may be more clinically effective at achieving higher
43 % mean reduction in wound surface area than placebo or usual treatment (very low quality)

- 1 • One study reported that electrotherapy may be more clinically effective at achieving higher %
2 median reduction in wound surface area than placebo or usual treatment (very low quality).
- 3 • One study (n=16) showed electrotherapy is more clinically effective than placebo or usual
4 treatment for achieving a higher rate of healing (%/week) (very low quality).
- 5 • Two studies (n=123) showed electrotherapy is potentially more clinically effective than placebo or
6 usual treatment for having a higher healing rate (%/week) in people with a spinal cord injury and
7 general participants (very low quality).
- 8 • One study (n=12) showed electrotherapy is more clinically effective than placebo or usual
9 treatment for having a higher healing rate (%/day) for people with a spinal cord injury (low
10 quality).
- 11 • One study (n=109) showed there is potentially no clinical difference between electrotherapy and
12 placebo or usual treatment for % healing rate per day when data were fitted linearly and
13 exponentially for people with a spinal cord injury, but the direction of the estimate of effect
14 favoured electrotherapy (very low quality).
- 15 • One study (n=19) showed electrotherapy is more clinically effective than placebo/usual treatment
16 for delaying time to complete healing (very low quality).
- 17 • One study (n=63) showed there is potentially no clinical difference between electrotherapy and
18 placebo/usual treatment for speed of healing (days, percentage change from baseline), the
19 direction of the estimate of effect favoured either intervention (very low quality).
- 20 • One study (n= 34) reported red area or burn under the active electrode after EST treatment, area
21 resolved within 48 hours and remedied by turning down the intensity of subsequent
22 electrotherapy treatments (very low quality).
- 23 • One study (n=16) reported mean 3.0 (s.d 1.5) hours per day for compliance to electrotherapy
24 treatment but there was no results for the placebo/usual treatment group (very low quality).
- 25 • One study (n=39) reported there may be a clinical harm of electrotherapy when compared to
26 placebo or usual treatment for an uncomfortable sensation in the ulcer when current was turned
27 on (very low quality).
- 28 • One study (n=50) showed electrotherapy may be more clinically effective than placebo or usual
29 treatment for achieving a higher % mean reduction in length (low quality).
- 30 • One study (n=50) showed electrotherapy may be more clinically effective than placebo or usual
31 treatment for achieving a higher % mean reduction in longest width (low quality).
- 32 • One study (n=50) showed electrotherapy may be more clinically effective than placebo or usual
33 treatment for achieving a higher % mean reduction in cavity volume (low quality).
- 34 • One study (n=50) showed electrotherapy is potentially more clinically effective than placebo or
35 usual treatment for achieving a higher % mean reduction in granulation tissue area (low quality).
- 36 • One study (n=50) showed there is potentially no clinical difference between electrotherapy and
37 placebo or usual treatment for reducing the Gilman parameter, the direction of the estimate of
38 effect favoured either intervention (very low quality).
- 39 • One study (n=92) showed there is potentially no clinical difference between asymmetric biphasic
40 electrostimulation at 100 μ s compared to control for mean reduction in % per week mean wound
41 surface area reduction, the direction of the estimate of effect favoured the asymmetric biphasic
42 electrostimulation at 100 μ s (very low quality).
- 43 • One study (n=83) showed there is potentially no clinical difference between symmetric biphasic
44 electrostimulation 300 μ s compared to control for mean reduction in % per week mean wound
45 surface area reduction, the direction of the estimate of effect favoured control (very low quality).
- 46 • One study (n=67) showed there is potentially no clinical difference between microcurrent
47 compared to control for mean reduction in % per week mean wound surface area reduction, the
48 direction of the estimate of effect favoured the control (very low quality).

- 1 • One study (n=125) showed there is potentially no clinical difference between asymmetric biphasic
2 electrostimulation at 100µs compared to 300µs for mean reduction in % per week mean wound
3 surface area reduction, the direction of the estimate of effect favoured the asymmetric biphasic
4 electrostimulation at 100µs (very low quality).
- 5 • One study (n=109) showed there is potentially no clinical difference between asymmetric biphasic
6 electrostimulation at 100µs compared to microcurrent for mean reduction in % per week mean
7 wound surface area reduction, the direction of the estimate of effect favoured the asymmetric
8 biphasic electrostimulation at 100µs (very low quality).
- 9 • One study (n=100) showed there is potentially no clinical difference between asymmetric biphasic
10 electrostimulation at 300µs compared to microcurrent for mean reduction in % per week mean
11 wound surface area reduction, the direction of the estimate of effect favoured the asymmetric
12 biphasic electrostimulation at 300µs (very low quality).
- 13 • Three studies (n=105) showed there may be no clinical difference between electrotherapy and
14 control group for complete healing for grade 3 and above pressure ulcers, the direction of the
15 estimate of effect favours electrotherapy (very low quality).
- 16 • One study (n=16) showed there is no clinical difference between electrotherapy and control
17 group for mortality for those with grade 4 pressure ulcers, the direction of the estimate of effect
18 favours either intervention (low quality).
- 19 • One study (n=46) showed there is no clinical difference between electrotherapy and control
20 group for absolute reduction in size of pressure ulcer (cm) at end of treatment for those with
21 grade 3 pressure ulcers, the direction of the estimate of effect favours the control (very low
22 quality).
- 23 • One study (n=46) showed there is no clinical difference between electrotherapy and control
24 group for absolute reduction in size of pressure ulcer (cm) at end of follow-up for those with
25 grade 4 pressure ulcers, the direction of estimate of effect favoured either intervention (low
26 quality).
- 27 • One study (n=16) showed there is no clinical difference between electrotherapy and control
28 group for % healing rate per week for those with grade 3 pressure ulcers, the direction of
29 estimate of effect favours the control group (very low quality).
- 30 • One study (n=19) showed electrotherapy was more clinically effective than the control group for
31 time to complete healing (days) for those with grade 3 pressure ulcers, the direction of estimate
32 of effect favours the control (very low quality).
- 33 • One study (n=63) showed there is potentially no clinical difference between electrotherapy and
34 control group for speed of healing (% change from baseline, days) for those with grade 3 pressure
35 ulcers, the direction of estimate of effect favours either intervention (very low quality).
- 36 • No evidence was found for the following outcomes:
37 o Pain (wound-related)
38 o Time in hospital or NHS care
39 o Health-related quality of life

7.6.402 Economic evidence (adults)

- 41 • One cost-effectiveness analysis found electrical stimulation in combination with standard wound
42 care to dominate standard wound care, in people with a spinal cord injury with grade 3-4 pressure
43 ulcers. This study was assessed as partially applicable, with potentially serious limitations.

7.6.43 Clinical evidence (neonates, infants, children and young people)

- 45 No RCTs or cohort studies were identified. Recommendations were developed using a modified
46 Delphi consensus technique. Further details can be found in Appendix N.

7.6.414 Economic evidence (neonates, infants, children and young people)

- 2 No economic evidence was identified.

7.7 Recommendations and link to evidence

7.7.1.1 Adults

Recommendations	<p>24. Do not routinely offer adults negative pressure wound therapy to treat a pressure ulcer, unless it is necessary to reduce the number of dressing changes (for example, in a wound with a large amount of exudate).</p> <p>25. Do not offer the following to adults to treat a pressure ulcer:</p> <ul style="list-style-type: none"> • electrotherapy • hyperbaric oxygen therapy.
Relative values of different outcomes	The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.
Trade off between clinical benefits and harms	<p>Electrotherapy</p> <p>Electrotherapy was found to be more clinically beneficial than placebo (or usual treatment) for the proportion of pressure ulcers completely healed in 1 small trial, however it was not found to be clinically beneficial for the proportion of people with pressure ulcers completely healed when 5 trials were meta-analysed. Electrotherapy was clinically beneficial for reducing the size of pressure ulcer area and had a faster healing rate. There were however differing results as to whether electrotherapy also increased the size of ulcers. The GDG considered that electrotherapy was likely to be most beneficial for pressure ulcers of grade 3 and 4, however no clinical benefit was found for the proportion of people completely healed, yet there was a clinical benefit for placebo/usual treatment for the reduction in size of pressure ulcer. There was a clinical benefit for healing rate and time to complete healing. There were no results for electrotherapy compared to other interventions.</p> <p>The GDG felt that any benefit of electrotherapy in clinical practice was likely to be in pressure ulcers of grade 3 and 4. However, the limited and conflicting evidence for these grade mostly demonstrated no clinical benefit of electrotherapy.</p> <p>Hyperbaric oxygen therapy</p> <p>No studies were found for hyperbaric oxygen therapy. The GDG considered that hyperbaric oxygen therapy can cause discomfort and may not be tolerable, therefore in the absence of any evidence of benefit the GDG felt that it should not be used for the treatment of pressure ulcers.</p> <p>Negative pressure wound therapy</p> <p>There was limited evidence for negative pressure wound therapy in pressure ulcers, with only 3 randomised controlled studies found. Two of the studies looked at negative pressure wound therapy compared to gel dressings or gauze dressing, and no clinical benefit was shown either way. One very small study showed clinical benefit of negative pressure wound therapy compared to standard care (spun hydrocolloid, alginate or foam dressings) for pressure ulcers completely healed, however there was more clinical harm from increased pain and mortality in the negative pressure wound therapy group.</p>

	<p>The evidence for the benefit of negative pressure wound therapy was limited and thus could not be recommended for use in routine clinical practice. However, the GDG acknowledged that there were some individuals in which the use of negative pressure wound therapy may have some benefits, most notably in people who require a large number of dressing changes because of a significant amount of exudate. The GDG therefore felt that there may be specific clinical situations in which the negative pressure wound therapy may be used. Finally, the GDG also wished to highlight the need for further high quality research in the area and highlighted in the recommendations that the use of negative pressure wound therapy may be conducted in the context of a clinical trial.</p>
<p>Economic considerations</p>	<p>Electrotherapy</p> <p>One economic study found electrical stimulation in combination with standard pressure ulcer care to dominate standard pressure ulcer care. However, this study was based on clinical effectiveness evidence which showed greater effect than found in the review of the clinical literature, and it also had several other limitations. Given the limitations and the partial applicability of this study, the GDG did not feel that the conclusions of this economic evaluation would apply within a UK NHS setting. The GDG felt that given the absence of any clear evidence to suggest a clinical benefit of electrotherapy for the treatment of pressure ulcers, the substantial additional resource use associated with this therapy could not be justified. Electrotherapy is not considered to be cost-effective.</p> <p>Hyperbaric oxygen therapy</p> <p>In the absence of relevant economic evidence the GDG considered the unit costs of hyperbaric oxygen therapy. The GDG noted that this is an expensive therapy, costing up to £8,383 before accounting for travel and accommodation costs. Given that no evidence of clinical effect was identified, the GDG felt that the high costs of this therapy could not be justified for the management of pressure ulcers. Hyperbaric oxygen therapy is not considered to be cost-effective.</p> <p>Negative pressure wound therapy</p> <p>The GDG considered 1 existing cost-utility analysis; the study found that NPWT dominates dressings (in the base case). However, as no evidence of clinical benefit was found in the clinical review, the GDG were concerned that the economic evidence was based on weak evidence of clinical effectiveness, and for this reason was insufficient on which to base a recommendation.</p> <p>The GDG felt that, in the absence of clinical effectiveness evidence for the healing of pressure ulcers, NPWT may be cost saving for exudate management, as NPWT dressings are changed less frequently. A cost comparison was therefore carried out, looking at NPWT compared to a standard care dressing regime for pressure ulcers with high fluid secretion that require regular dressing changes. This analysis revealed that NPWT was more expensive than standard care dressings in all scenarios (increases of £276, £230, and £216 for small, medium, and large pressure ulcers respectively); therefore NPWT was not cost saving compared to standard care for the management of pressure ulcers.</p> <p>In light of the additional cost of using NPWT, and lack of clear evidence of clinical benefit, the GDG did not feel there was sufficient evidence to suggest that NPWT is cost-effective compared to standard care.</p>
<p>Quality of evidence</p>	<p>For the electrotherapy review the majority of evidence available for the included outcomes was very low or low quality, due to having serious or very serious imprecision and study limitations. There was no evidence for hyperbaric oxygen therapy and limited evidence for negative pressure wound therapy. For the 3 studies available for negative pressure wound therapy there was little clinical benefit found.</p>

	Where there was benefit or harm shown the outcomes had very serious imprecision and were graded very low quality.
Other considerations	<p>The GDG acknowledged that there may be evidence available on the use of adjunctive therapies for chronic wounds, however as per Chapter 3, the GDG decided not to consider indirect evidence.</p> <p>Negative pressure wound therapy</p> <p>There is some suggestion of benefit in reducing the number of dressing changes and therefore reducing consequent pain and discomfort from a patient perspective, therefore NPWT might have some benefit in a subset of people with high pain levels or those with high exudate levels who require very frequent dressing changes. The tolerability of NPWT was discussed. It can be very uncomfortable and noisy and thus not suitable for many people.</p>

7.7.1.2 Neonates, infants, children and young people

Recommendations	<p>26. Do not routinely use negative pressure wound therapy to treat a pressure ulcer in neonates, infants, children and young people.</p> <p>27. Do not use the following to treat a pressure ulcer in neonates, infants, children and young people:</p> <ul style="list-style-type: none"> • electrotherapy • hyperbaric oxygen therapy.
Relative values of different outcomes	The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.
Trade-off between clinical benefits and harms	<p>The GDG used 3 statements from the Delphi consensus to inform the recommendation on the use of adjunctive therapies in neonates, infants, children and young people. These statements were ‘Healthcare professionals should not use negative pressure wound therapy for the treatment of pressure ulcers in neonates, infants, children and young people’, ‘Healthcare professionals should not use hyperbaric oxygen therapy for the treatment of pressure ulcers in neonates, infants, children and young people’ and ‘Healthcare professionals should not routinely use electrotherapy for the treatment of neonates, infants, children and young people with pressure ulcers’. Two statements were then amended for inclusion in Round 2 of the survey. Further detail on the Delphi consensus survey can be found in Appendix N.</p> <p>Negative pressure wound therapy</p> <p>For negative pressure wound therapy, the statement was not accepted by the Delphi consensus panel in Round 1 and the statement was amended for inclusion in Round 2. Comments received during Round 1 of the survey suggested that some healthcare professionals felt that negative pressure wound therapy was helpful to promote healing in some children and young people, with some individuals highlighting that this was particularly helpful for the management of grade 3 and 4 pressure ulcers, or those in hard to reach sites. However, the GDG did not feel that, given the limited evidence to suggest significant benefits of negative pressure wound therapy in adults and the possible harms identified, it was appropriate to amend the statement to promote the use of negative pressure wound therapy. The statement was therefore amended for Round 2 of the survey to reflect that there may be specific situations in which negative pressure wound therapy may be considered however, this should not</p>

	<p>be routinely used ('Healthcare professionals should not routinely use negative pressure wound therapy for the treatment of pressure ulcers in neonates, infants, children and young people.').</p> <p>During Round 2 of the Delphi consensus, this statement was not accepted by the Delphi consensus panel at the 75% level. Comments received during Round 2 of the Delphi consensus panel did however, highlight that negative pressure wound therapy should only be used in these populations with specialist advice and noted again that its role was reserved for hard to heal wounds and those in difficult sites.</p> <p>The GDG therefore accepted that, in the absence of evidence, there may be some situations in which negative pressure wound therapy may have some benefits, particularly for grade 3-4 pressure ulcers and those in difficult sites, with specialist advice. However, given the lack of evidence available to suggest a benefit of negative pressure wound therapy on the management of pressure ulcers in adults, the GDG did not feel that it was appropriate to recommend its use in neonates, infants, children and young people. As such, the GDG extrapolated from the recommendation developed for adults and agreed that the use of negative pressure wound therapy was not routinely recommended in these populations.</p> <p>Hyperbaric oxygen therapy</p> <p>For hyperbaric oxygen therapy, 1 statement was not accepted by the Delphi consensus panel in Round 1 and the statement was amended for inclusion in Round 2, following concerns from the GDG that some members of the Delphi consensus panel may be unclear as to the treatment being considered. The statement was therefore amended for inclusion in Round 2 ('Healthcare professionals should not use hyperbaric oxygen therapy (the use of 'above atmospheric pressure' to increase the oxygen supply to the wound bed) for the treatment of pressure ulcers in neonates, infants, children and young people. '), however, the statement did not reach consensus.</p> <p>However, given the potential risk of adverse events and safety concerns highlighted by the Delphi consensus panel (including the development of retinopathy of prematurity in neonates) and the GDG, the GDG did not feel that it was appropriate to recommend the use of hyperbaric oxygen therapy in these populations. The GDG therefore extrapolated from the recommendation developed for adults and agreed that the use of hyperbaric oxygen therapy was not routinely recommended in neonates, infants, children and young people.</p> <p>Electrotherapy</p> <p>For electrotherapy, the statement was accepted by the Delphi consensus panel in Round 1 of the survey. The GDG therefore agreed that a recommendation should be developed to not routinely use electrotherapy for the treatment of pressure ulcers in neonates, infants, children and young people. Comments received from panel members highlighted that they were unaware of evidence to support the use of electrotherapy. However, some comments suggested that there may be circumstances in which the use of electrotherapy would be beneficial, for example for those with chronic wounds, following holistic assessment and under medical supervision. Therefore, the GDG felt that a recommendation to not routinely use electrotherapy would be appropriate.</p>
Economic considerations	<p>No economic studies on the use of electrotherapy, negative pressure wound therapy or hyperbaric oxygen therapy were identified.</p> <p>The GDG identified that there were significant cost implications in the use of these therapies for the management or treatment of pressure ulcers, and that there were</p>

	safety concerns in these populations. The GDG agreed that use of these therapies in these populations would not be cost-effective.
Quality of evidence	<p>No RCTs or cohort studies were identified for neonates, infants, children or young people. Formal consensus using a modified Delphi was therefore used to develop the recommendation.</p> <p>Negative pressure wound therapy</p> <p>To inform the recommendation, the GDG used 1 statement which was included in Round 1 of the Delphi consensus survey and reached 11% consensus agreement. The statement was therefore amended and included in Round 2 of the Delphi consensus survey, where it reached 67% consensus. The GDG therefore extrapolated from the recommendation developed for adults.</p> <p>Hyperbaric oxygen therapy</p> <p>To inform the recommendation, the GDG used 1 statement which was included in Round 1 of the Delphi consensus survey and reached 43% consensus agreement. The statement was therefore amended and included in Round 2 of the Delphi consensus survey, where it reached 65% consensus.</p> <p>Electrotherapy</p> <p>To inform the recommendation, the GDG used 1 statement which was included in Round 1 of the Delphi consensus survey and reached 77% consensus agreement.</p> <p>Further details can be found in Appendix N.</p>
Other considerations	There were no other considerations.

1

2

8 Debridement

2 Debridement is the removal of necrotic tissue from a wound. Generally, the presence of necrotic or
3 dead tissue is seen as a delaying factor in pressure ulcer healing, preventing the formation of healthy
4 granulation tissue and a good environment to harbour more bacteria, thereby increasing the risk of
5 further sepsis.

6 Necrotic tissue is removed during natural wound healing due to autolytic debridement and this
7 process may be helped by the application of a moist wound dressing. Other forms of debridement
8 include enzymatic (via an agent impregnated in a dressing or applied directly to the pressure ulcer),
9 mechanical (via the physical removal of dead tissue by water either under low or high pressure or by
10 allowing a dressing to stick to the pressure ulcer before removal (wet to dry dressing)) and sharp
11 debridement. Sharp debridement includes debridement of totally dead or necrotic tissue using a
12 scalpel or scissors and the more extensive removal of tissue under anaesthesia (when a surgeon
13 removes enough tissue until tissue with a good bleeding capillary base is found.

14 The choice of debridement method depends upon the nature of the wound, the skill set of the
15 practitioner, access to equipment and dressings, and the condition of the individual. Given the range
16 of debridement options available, the GDG was interested in identifying the most effective method
17 of debridement of non-viable tissue to treat pressure ulcers.

8.1 Review question: What are the most clinically and cost effective 19 methods of debridement of non-viable tissue for the treatment of 20 pressure ulcers?

21 For full details see review protocol in Appendix D.

22 8.1.1 Clinical evidence (adults)

23 Nine randomised trials were identified as meeting the inclusion criteria and were included in this
24 review. All study evidence tables and forest plots are presented in Appendix G and I.

25

Summary of included studies

Study	Intervention/comparator	Population	Outcome	Length of study
Agren,1985 ⁴	Zinc oxide Streptokinase-streptodornase ointment.	Geriatric adults with necrotic pressure ulcer.	<ul style="list-style-type: none"> • Reduction in ulcer area • Side effects 	8 weeks of treatment
Alvarez, 2000 ⁸	Collagenase ointment (Santyl) versus papain/urea ointment (Accuzyme).	People with pressure ulcers requiring debridement, who were stable or improving after a 2 week screening period.	<ul style="list-style-type: none"> • Percent reduction of ulcer size from baseline • Side effects 	2 weeks screening and 4 weeks period of the study
Burgos, 2000 (a) ³⁶	Collagenase ointment (Irujol) versus hydrocolloid dressing (Varihesive).	People of at least 55 years presenting with grade 3 pressure ulcers (skin disruption, tissue damage and exudate and subcutaneous tissue involvement).	<ul style="list-style-type: none"> • Proportion of people with reduction in pressure ulcer area after 12 weeks of treatment • Proportion of people with complete healing of pressure ulcer after 12 weeks of treatment • Mean reduction in ulcer area after 12 weeks of treatment (cm²) • Decrease in pain intensity • Adverse reactions 	12 weeks of treatment or until healing of the pressure ulcer, whichever occurred first.
Burgos, 2000 (b) ³⁵	Collagenase ointment application every 24 hours versus collagenase ointment application every 48 hours.	Hospitalised or institutionalised people aged 55 years or older presenting with grade 3 pressure ulcer for less than 1 year.	<ul style="list-style-type: none"> • Proportion of pressure ulcers that showed complete healing after 8 weeks (intention-to-treat). • Relative risk of non-healing among group 2 (collagenase ointment every 48 hours) as compared with group 1 	Treatment during maximum 8 weeks or until complete healing of the pressure ulcer whatever occurred first.

Study	Intervention/comparator	Population	Outcome	Length of study
			<p>(collagenase ointment every 24 hours)after 8 weeks (intention-to-treat) when granulation tissue covered 11 to 30% of the ulcer surface.</p> <ul style="list-style-type: none"> • Mean reduction of pressure ulcer area (cm²) during 8 weeks (per-protocol). • Decrease in pain intensity after 8 weeks (intention-to-treat). • Decrease in pain intensity after 8 weeks (per-protocol). • Proportion with adverse reactions after 8 weeks. 	
Lee, 1975 ¹⁰³	Collagenase ointment (Santyl) versus preparation of inactivated collagenase.	11 adults with chronic diseases. Four had neoplastic disease; 4 atherosclerotic heart diseases or cerebrovascular accident or both; 2 had Parkinson’s disease and 1 had a femoral neck fracture.	<ul style="list-style-type: none"> • Proportion of pressure ulcers that reduced in volume assessed with the aid of a volume mould • Proportion of pressure ulcers that increased in volume assessed with the aid of a volume mould • Proportion of pressure ulcers with odour at the end of treatment • Side effects 	4 weeks of treatment and follow-up unless complications developed or participant died.
Milne, 2012, 2010 ¹¹⁷	Collagenase ointment (Santyl) versus hydrogel dressing (SoloSite Gel).	People in a long-term care facility.	<ul style="list-style-type: none"> • Proportion of people completely healed; mean reduction in PUSH tool 	84 days

Study	Intervention/comparator	Population	Outcome	Length of study
Müller 2001 ¹²⁵	Hydrocolloid dressing (Duoderm) versus collagenase dressing (Novuxol).	Females with a grade 4 heel pressure ulcers	<p>score; mortality (all-cause).</p> <ul style="list-style-type: none"> • Proportion of people completely healed • Time to healing. 	Maximum 16 weeks
Parish, 1979 ¹⁴⁶	Dextranomer powder (Debrisan) versus collagenase ointment (Santyl) versus sugar and egg white.	People with pressure ulcers in a long-term care institution for the chronically ill and physically disabled.	<ul style="list-style-type: none"> • Proportion of pressure ulcers improved for people treated with dextranomer versus people treated with collagenase (%). • Proportion of pressure ulcers improved for people treated with collagenase versus people treated with sugar and egg white. • Proportion of people with ulcer closure for people treated with dextranomer versus people treated with collagenase. • Proportion of people with ulcers closure for people treated with collagenase versus people treated with sugar and egg white. • Proportion of pressure ulcers closed for people treated with dextranomer versus 	The initial study was to have lasted 4 weeks, but many subjects were treated and observed for up to 4 months or longer.

Study	Intervention/comparator	Population	Outcome	Length of study
			<p>people treated with collagenase.</p> <ul style="list-style-type: none"> • Proportion of pressure ulcers closed for people treated with collagenase versus people treated with sugar and egg white. • Proportion of people improved treated with dextranomer versus people treated with collagenase. • Proportion of pressure ulcer closed treated with dextranomer versus collagenase after 1 week. • Proportion of pressure ulcers closed treated with dextranomer versus collagenase after 1 month. • Proportion of pressure ulcers closed treated with dextranomer versus collagenase after 2 months. • Proportion of pressure ulcers closed treated with dextranomer versus collagenase after more than 2 months. • Proportion of people improved treated with 	

Study	Intervention/comparator	Population	Outcome	Length of study
			<p>collagenase versus people treated with sugar and egg white.</p> <ul style="list-style-type: none"> • Proportion of pressure ulcers closed treated with collagenase versus sugar and egg white after 1 week. • Proportion of pressure ulcers closed treated with collagenase versus sugar and egg white after 1 month. • Proportion of pressure ulcers closed treated with collagenase versus sugar and egg white after 2 months • Proportion of pressure ulcers closed treated with collagenase versus sugar and egg white after more than 2 months • Side effects 	
Püllen, 2002 ¹⁵²	Twice-daily treatment with collagenase ointment (1.2 U/g) (Novuxal) versus twice-daily treatment fibrinolysin/DNAse ointment (1 U Loomis and 666 Christensen/g) (Fibrolan)	Adults with pressure ulcers, Seiler grade 2,3 or 4, in the pelvic region with fibrinous or necrotic slough from 17 hospitals.	<ul style="list-style-type: none"> • Proportion of peoples reporting adverse events • Proportion of serious adverse events reported 	Four weeks of treatment or until complete wound debridement whichever occurred first.

Table 74: Clinical evidence profile: collagenase ointment versus preparation of inactivated collagenase

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase	Preparation of inactivated collagenase	Relative (95% CI)	Absolute		
Proportion of pressure ulcers that decreased in volume – people with chronic diseases- grade not reported- classification system not reported- follow-up 4 weeks¹⁰³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^d	None	8/17 (47.1%)	0/11 (0%)	Peto OR 9.24 (1.78 to 48.04)	470 more per 1000 (from 210 more to 730 more)	Very low	Critical
							-	0%		470 more per 1000 (from 210 more to 730 more)		
Proportion of pressure ulcers that increased in volume – people with chronic diseases- grade not reported- classification system not reported- follow-up 4 weeks¹⁰³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	4/17 (23.5%)	6/11 (54.5%)	RR 0.43 (0.16 to 1.19)	311 fewer per 1000 (from 458 fewer to 104 more)	Very low	Critical
							-	54.6%		311 fewer per 1000 (from 459 fewer to 104 more)		
Proportion of pressure ulcers with odour at the end of treatment– people with chronic diseases- grade not reported- classification system not reported- follow-up 4 weeks¹⁰³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	7/17 (41.2%)	5/11 (45.5%)	RR 0.91 (0.38 to 2.14)	41 fewer per 1000 (from 282 fewer to 518 more)	Very low	Important
							-	45.5%		41 fewer per 1000 (from 282 fewer to 519 more)		
Number of side effects observed– people with chronic diseases- grade not reported- classification system not reported- follow-up 4 weeks¹⁰³												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase	Preparation of inactivated collagenase	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^{c,d}	None	1/17 (5.9%)	0/11 (0%)	Peto OR 5.19 (0.09 to 287.21)	60 more per 1000 (from 11 less to 23 more)	Very low	Important
							-	0%		60 more per 1000 (from 11 less to 23 more)		
Mortality (all-cause)¹⁰³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None	0/17 (0%)	0/11 (0%)	Not pooled	Not pooled	Low	Important
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase	Preparation of inactivated collagenase	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The process for randomisation was unclear. The method of allocation concealment and blinding were unclear.

(b) The confidence interval crossed 1 MID point.

(c) The confidence interval crossed both MID points.

(d) There were a limited number of events.

Table 75: Clinical evidence profile: collagenase ointment versus dextranomer

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase	Dextranomer	Relative (95% CI)	Absolute		
Proportion of pressure ulcers that improved –chronically ill and disabled people- grade not reported – classification system not reported¹⁴⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	5/11 (45.5%)	12/14 (85.7%)	RR 0.53 (0.27 to 1.05)	403 fewer per 1000 (from 626 fewer to 43 more)	Very low	Critical
							-	85.7%		403 fewer per 1000 (from 626 fewer to 43 more)		
Proportion of pressure ulcers completely healed–chronically ill and disabled people- grade not reported – classification system not reported¹⁴⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	1/11 (9.1%)	6/14 (42.9%)	RR 0.21 (0.03 to 1.51)	339 fewer per 1000 (from 416 fewer to 219 more)	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase	Dextranomer	Relative (95% CI)	Absolute		
							-	42.9%		339 fewer per 1000 (from 416 fewer to 219 more)		
Proportion of people with pressure ulcers completely healed –chronically ill and disabled people - grade not reported – classification system not reported¹⁴⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	1/5 (20%)	4/7 (57.1%)	RR 0.35 (0.05 to 2.26)	371 fewer per 1000 (from 543 fewer to 720 more)	Very low	Critical
							-	57.1%		371 fewer per 1000 (from 542 fewer to 719 more)		
Proportion of people that improved–chronically ill and disabled people - grade not reported – classification system not reported¹⁴⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	2/5 (40%)	7/7 (100%)	RR 0.44 (0.17 to 1.16)	560 fewer per 1000 (from 830 fewer to 160 more)	Very low	Critical
							-	100%		560 fewer per 1000 (from 830 fewer to 160 more)		
Proportion of pressure ulcers improved after 1 week–chronically ill and disabled people - grade not reported – classification system not reported¹⁴⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^d	None	0/11 (0%)	6/14 (42.9%)	Peto OR 0.1 (0.02 to	430 fewer per 1000 (from 700	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase	Dextranomer	Relative (95% CI)	Absolute		
									0.64)	fewer to 150 fewer)		
							-	42.9%		430 fewer per 1000 (from 700 fewer to 150 fewer)		
Proportion of pressure ulcers improved after 1 month—chronically ill and disabled people - grade not reported – classification system not reported¹⁴⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	3/11 (27.3%)	8/14 (57.1%)	RR 0.48 (0.16 to 1.39)	297 fewer per 1000 (from 480 fewer to 223 more)	Very low	Critical
							-	57.1%		297 fewer per 1000 (from 480 fewer to 223 more)		
Proportion of pressure ulcers improved after 2 months—chronically ill and disabled people - grade not reported – classification system not reported¹⁴⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	5/11 (45.5%)	8/14 (57.1%)	RR 0.8 (0.36 to 1.75)	114 fewer per 1000 (from 366 fewer to 429 more)	Very low	Critical
							-	57.1%		114 fewer per 1000 (from 365 fewer to 428 more)		
Proportion improved after 2 months—chronically ill and disabled people- grade not reported – classification system not reported¹⁴⁶												
1	Randomised	Very	No serious	No serious	Serious ^b	None	5/11	12/14	RR 0.53	403 fewer	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase	Dextranomer	Relative (95% CI)	Absolute		
	trial	serious ^a	inconsistency	indirectness			(45.5%)	(85.7%)	(0.27 to 1.05)	per 1000 (from 626 fewer to 43 more)		
							-	85.7%		403 fewer per 1000 (from 626 fewer to 43 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The randomisation and concealment methods were not reported by the authors. Blinding failed.

(b) The confidence interval crossed 1 MID point.

(c) The confidence interval crossed both MID points.

(d) There were a limited number of events.

Table 76: Clinical evidence profile: collagenase ointment versus sugar and egg white

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase	Sugar and egg white	Relative (95% CI)	Absolute		
Proportion of pressure ulcers completely healed– chronically ill and disabled people- no grade reported- no classification system reported¹⁴⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^{b,c}	None	1/11 (9.1%)	0/9 (0%)	Peto OR 6.16 (0.12 to 316.67)	90 more per 1000 (from 140 more to 320 more)	Very low	Critical
							-	0%		90 more per 1000 (from 140 more to 320 more)		
Proportion of people with pressure ulcer completely healed– chronically ill and disabled people - no grade reported- no classification system reported¹⁴⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^{b,c}	None	1/5 (20%)	0/5 (0%)	Peto OR 7.39 (0.15 to 372.38)	200 more per 1000 (from 210 less to 610 more)	Very low	Critical
							-	0%		200 more per 1000 (from 210 less to 610 more)		
Proportion of people that improved– chronically ill and disabled people - no grade reported- no classification system reported¹⁴⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^{b,c}	None	2/5 (40%)	0/5 (0%)	Peto OR 9.49 (0.5 to 179.46)	400 more per 1000 (from 50 more to 850 more)	Very low	Critical
							-	0%		400 more per 1000 (from 50 more to 850 more)		
Proportion of pressure ulcers that improved – chronically ill and disabled people - no grade reported- no classification system reported¹⁴⁶												
1	Randomised	Very	No serious	No serious	Serious ^c	None	5/11	0/9	Peto OR	450 more per	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase	Sugar and egg white	Relative (95% CI)	Absolute		
	trial	serious ^a	inconsistency	indirectness			(45.5%)	(0%)	10.00 (1.38 to 146.4)	1000 (from 140 more to 770 more)		
							-	0%		450 more per 1000 (from 140 more to 770 more)		
Proportion of pressure ulcers improved after 1 week– chronically ill and disabled people - no grade reported- no classification system reported¹⁴⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None	0/11 (0%)	0/9 (0%)	Not pooled	Not pooled	Very low	Critical
							-	0%		Not pooled		
Proportion of pressure ulcers improved after 1 month– chronically ill and disabled people - no grade reported- no classification system reported¹⁴⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^{b,c}	None	3/11 (27.3%)	0/9 (0%)	Peto OR 7.63 (0.69 to 84.5)	270 more per 1000 (from 20 fewer to 560 more)	Very low	Critical
							-	0%		270 more per 1000 (from 20 fewer to 560 more)		
Proportion of pressure ulcers improved after 2 months– chronically ill and disabled people - no grade reported- no classification system reported¹⁴⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious ^c	None	5/11 (45.5%)	0/9 (0%)	Peto OR 10.00 (1.38 to 72.67)	450 more per 1000 (from 140 more to 770 more)	Low	Critical
							-	0%		450 more per 1000 (from 140 more to 770 more)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase	Sugar and egg white	Relative (95% CI)	Absolute		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcer												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size and volume of pressure ulcer												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The randomisation and concealment methods were not reported. Blinding failed.

(b) The confidence interval crossed both MID points.

(c) There were a limited number of events.

Table 77: Clinical evidence profile: collagenase ointment versus papainm and urea ointment

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase	papain/ urea	Relative (95% CI)	Absolute		
Percentage reduction in pressure ulcer size after 1 week – people with pressure ulcers- grade 2-4- classification system not reported⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	5.8 (n=10)	1.9 (n=11)	-	MD 3.9 higher (7.78 lower to 15.58 higher)	Very low	Critical
Percentage reduction in pressure ulcer size after 2 weeks (follow-up 4 weeks; better indicated by lower values)⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	19.9 (n=10)	23.7 (n=11)	-	MD 3.8 lower (27.46 lower to 19.86 higher)	Very low	Critical
Percentage reduction in pressure ulcer size after 3 weeks – people with pressure ulcers- grade 2-4- classification system not reported⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	27.3 (n=10)	34.8 (n=11)	-	MD 7.5 lower (30.6 lower to 15.6 higher)	Very low	Critical
Percentage reduction in pressure ulcer size after 4 weeks – people with pressure ulcers- grade 2-4- classification system not reported⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	33.9 (n=10)	55.4 (n=11)	-	MD 21.5 lower (47.09 lower to 4.09 higher)	Very low	Critical
Number of side effects observed (follow-up 4 weeks) – people with pressure ulcers- grade 2-4- classification system not reported⁸												
1	Randomised	Very	No serious	No serious	Very serious ^c	None	1/10	0/11	Peto OR	100 more	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase	papain/urea	Relative (95% CI)	Absolute		
	trial	serious ^a	inconsistency	indirectness			(10%)	(0%)	8.17 (0.16 to 413.39)	per 1000 (from 130 more to 330 more)		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life.												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The methods of concealment and blinding were not reported

(b) There was a small sample. The mean difference is greater or smaller than the standard deviation in control group

(c) The confidence interval crossed both MID points. There were a limited number of events,

Table 78: Clinical evidence profile: collagenase ointment versus fibrinolysis/DNAse ointment

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase	Fibrinolysis /DNAse	Relative (95% CI)	Absolute		
Proportion of people reporting adverse events -elderly people with pressure ulcer in pelvic region- grade 2-4- Seiler classification¹⁵²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	45/66 (68.2%)	34/69 (49.3%)	RR 1.38 (1.03 to 1.85)	187 more per 1000 (from 15 more to 419 more)	Very low	Important
							-	49.3%		187 more per 1000 (from 15 more to 419 more)		
Proportion of people reporting serious adverse events -elderly people with pressure ulcer in pelvic region- grade 2-4- Seiler classification¹⁵²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	54/118 (45.8%)	24/103 (23.3%)	RR 1.96 (1.31 to 2.93)	224 more per 1000 (from 72 more to 450 more)	Low	Important
							-	23.3%		224 more per 1000 (from 72 more to 450 more)		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase	Fibrinolysis /DNAse	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Unclear sequence generation was reported by the authors. There was unclear allocation concealment and a relatively high drop out rate.

(b) Confidece interval crossed 1 MID point.

Table 79: Clinical evidence profile: collagenase ointment versus hydrocolloid dressing

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase	Hydrocolloid dressing	Relative (95% CI)	Absolute		
Proportion of people with reduction in pressure ulcer area – people with pressure ulcer grade 2- classification system not reported³⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	15/18 (83.3%)	14/19 (73.7%)	RR 1.13 (0.81 to 1.59)	96 more per 1000 (from 140 fewer to 435 more)	Very low	Critical
							-	73.7%		96 more per 1000 (from 140 fewer to 435 more)		
Proportion of people with complete healing of pressure ulcers– people with pressure ulcer grade 2 and 4- classification system not reported^{36,125}												
2	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	14/30 (46.7%)	10/30 (33.3%)	RR 1.33 (0.8 to 2.23)	110 more per 1000 (from 67 fewer to 410 more)	Very low	Critical
							-	39.7%		131 more per 1000 (from 79 fewer to 488 more)		
Mean reduction in pressure ulcer area after 12 weeks of treatment – people with pressure ulcer grade 2- classification system not reported³⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	9.1 (n=18)	6.2 (n=19)	-	MD 2.9 higher (4.44 lower to 10.24 higher)	Very low	Critical
Proportion of people reporting adverse events— people with pressure ulcer grade 2- classification system not reported³⁶												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase	Hydrocolloid dressing	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	1/18 (5.6%)	2/19 (10.5%)	RR 0.53 (0.05 to 5.33)	49 fewer per 1000 (from 100 fewer to 456 more)	Very low	Important
							-	10.5%		49 fewer per 1000 (from 100 fewer to 455 more)		
Mean time to healing (weeks) of pressure ulcer- female hospitalised people- grade 4 heel ulcers-classification system not reported¹²⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	12 (n=12)	11 (n=11)	-	MD 4 lower (5.11 to 2.89 lower)	Very low	Critical
Mortality (all-cause)^{36,125}												
2	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^{c,d}	None	3/30 (10%)	1/31 (3.2%)	RR 3.17 (0.36 to 27.72)	70 more per 1000 (from 21 fewer to 862 more)	Very low	Important
							-	2.6%		56 more per 1000 (from 17 fewer to 695 more)		
Rate of reduction in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase	Hydrocolloid dressing	Relative (95% CI)	Absolute		
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The method of allocation concealment was unclear and not all assessors were blinded. There was a relatively high drop-out but no baseline differences were reported.

(b) The confidence interval crossed 1 MID point.

(c) The confidence interval crossed both MID points.

(d) There were a limited number of events.

Table 80: Clinical evidence profile: collagenase ointment application every 24 hours versus every 48 hours

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase ointment application every 24 hours	Collagenase ointment application every 48 hours	Relative (95% CI)	Absolute		
Proportion of pressure ulcers with complete healing after 8 weeks –hospitalised people -grade 3- NPUAP classification³⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	12/43 (27.9%)	9/43 (20.9%)	RR 1.33 (0.63 to 2.83)	69 more per 1000 (from 77 fewer to 383 more)	Very low	Critical
							-	20.9%		69 more per 1000 (from 77 fewer to		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase ointment application every 24 hours	Collagenase ointment application every 48 hours	Relative (95% CI)	Absolute		
										382 more)		
Proportion of people reporting adverse events (rash, necrosis in ulcer bed, ulcer worsening, infection) –hospitalised people -grade 3- NPUAP classification³⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	3/46 (6.5%)	3/46 (6.5%)	RR 1 (0.21 to 4.7)	0 fewer per 1000 (from 52 fewer to 241 more)	Very low	Critical
							-	6.5%		0 fewer per 1000 (from 51 fewer to 240 more)		
Mortality (all-cause)³⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	4/46 (8.7%)	7/46 (15.2%)	RR 0.57 (0.18 to 1.82)	65 fewer per 1000 (from 125 fewer to 125 more)	Very low	Important
							-	15.2%		65 fewer per 1000 (from 125 fewer to 125 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase ointment application every 24 hours	Collagenase ointment application every 48 hours	Relative (95% CI)	Absolute		
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) There were unclear methods of allocation concealment and not all assessors were blinded. There was a relatively high drop out and no baseline differences reported.

(b) The confidence interval crossed both MID points.

Table 81: Clinical evidence profile: collagenase ointment versus hydrogel dressing

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase versus hydrogel	Control	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed¹¹⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	9/13 (69.2%)	3/14 (21.4%)	RR 3.23 (1.11 to 9.39)	478 more per 1000 (from 24 more to 1000)	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase versus hydrogel	Control	Relative (95% CI)	Absolute		
							-	21.4%		more) 477 more per 1000 (from 24 more to 1000 more)		
Mean reduction in PUSH tool score (at day 42) ¹¹⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	5.03 (no s.d) n=13	3.99 (no s.d) n=14	MD 1.04 higher	-	Very low	Critical
Mortality¹¹⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/13 (0%)	0/14 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size and volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagenase versus hydrogel	Control	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No details of sequence generation or allocation concealment were reported. There were baseline differences in pressure ulcer size.

(b) The confidence interval crossed 1 MID point.

(c) No standard deviations were reported so they were calculated from mean initial PUSH tool score and mean at day 42. There was a small sample size.

Table 82: Clinical evidence profile: zinc oxide versus streptokinase-streptodornase ointment⁴

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Zinc oxide	Streptokinase-streptodornase	Relative (95% CI)	Absolute		
Median percentage reduction in ulcer area – elderly people – necrotic pressure ulcers - classification method not reported⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	24 (n=14)	-18.7 (n=14)	-	Not pooled	Very low	Critical
Proportion of people with an infection – elderly people – necrotic pressure ulcers - classification method not reported⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/14 (0%)	1/14 (7.1%)	OR 0.14 (0 to 6.82)	61 fewer per 1000 (from 71 fewer to 273 more)	Very low	Critical
							-	7.1%		60 fewer per 1000 (from 71		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Zinc oxide	Streptokinase-streptodornase	Relative (95% CI)	Absolute		
										fewer to 272 more)		
Proportion of people with skin reaction – elderly people – necrotic pressure ulcers - classification method not reported⁴												
1	Randomised trial	Very serious ^b	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/14 (0%)	1/14 (7.1%)	OR 0.14 (0 to 6.82)	61 fewer per 1000 (from 71 fewer to 273 more)	Very low	Important
							-	7.1%		60 fewer per 1000 (from 71 fewer to 272 more)		
Mortality (all-cause)⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None	0/14 (0%)	0/14 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		-		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Zinc oxide	Streptokinase-streptodornase	Relative (95% CI)	Absolute		
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) Sequence generation was by matched pairs. The authors did not report the method of allocation concealment and there was no blinding of participants or nurses. No log-transformation of data was carried out.
- (b) No standard deviation was reported. There was a small sample size.
- (c) The confidence interval crossed both MID points.
- (d) This comparison was also included in topical agents review (see [Chapter X](#)).

8.11 Economic evidence (adults)

- 2 Five studies were included with relevant comparisons.^{27,36,121,125} These are summarised in the
3 economic evidence profiles below (Table 83- Table 87). See also the study selection flow chart in
4 Appendix C and study evidence tables in Appendix F.
- 5 Two of the included studies^{36,125} compare collagenase ointment to a hydrocolloid dressing (Table
6 190). However, the conclusions of these 2 studies differ; Burgos and colleagues (2000) found
7 collagenase ointment to be more effective and more costly than hydrocolloid dressing, whereas
8 Müller and colleagues (2001) found collagenase to be more effective and less costly than
9 hydrocolloid. This is because a higher proportion of people were healed in the Müller study
10 compared to the Burgos study (Appendix H), and a greater incremental difference in people healed
11 between the trial arms can be seen. This could be partly due to the differences in the populations
12 studied in the trials. The Burgos study was based in Spain (costs are calculated in Spanish pesetas)
13 amongst a group which was 46% male and all of whom had stage 3 pressure ulcers. The Müller study,
14 on the other hand, was conducted in Holland (costs are calculated in Dutch guilders), amongst a
15 population who were all female, and all had stage 4 heel pressure ulcers. Note also that the time
16 horizon of the Müller study was 16 weeks, compared to 12 weeks in the Burgos study.
- 17 Both studies report that collagenase was applied once daily and hydrocolloid every 3 days (or twice a
18 week). Consequently, Burgos and colleagues report higher staff and auxiliary supply costs (per
19 patient) in the collagenase group than in the hydrocolloid group. The higher staff cost and ancillary
20 supplies required for the more frequent dressing changes in the collagenase arm result in this arm
21 being more costly per person than the hydrocolloid arm, despite a lower pharmaceutical cost of
22 collagenase. However, Müller and colleagues report lower personnel costs for collagenase than for
23 hydrocolloid. They attribute this to fewer doctors' appointments required in the collagenase group
24 due to a shorter healing time. Müller and colleagues find personnel costs and material costs to be
25 lower in the collagenase arm, and thus conclude collagenase is cheaper than hydrocolloid.
- 26 One study that met the inclusion criteria was selectively excluded¹⁹¹ – this is summarised in Appendix
27 K, with reasons for exclusion given.

28

1 **Table 83: Economic evidence profile: hydrocolloid dressing versus collagenase dressing**

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Co ef
Burgos 2000 ³⁶ (Spain)	Partially applicable ^a	Potentially serious limitations ^b	Within trial analysis of a collagenase dressing compared to a hydrocolloid dressing, based on analysis of individual level resource use with unit costs applied.	-£46 (p <0.0001)	Pressure ulcers healed: -0.01 (p=0.451)	Co bo ex m th hy
Müller 2001 ¹²⁵ (Netherlands)	Partially applicable ^c	Potentially serious limitations ^d	Within trial analysis of a collagenase dressing compared to a hydrocolloid dressing for heel ulcers, based on analysis of individual level resource use with unit costs applied.	£25	Pressure ulcers healed: -0.29 (p <0.005)	Co do hy

2 (a) Study based in Spain, quality of life not considered, costs based on 1998 values

3 (b) no consideration of quality of life, no analysis of uncertainty reported, unit costs are based on prices faced by patients and could be substantially different to those faced by hospitals

4 (c) Study based in the Netherlands, quality of life not considered, costs based on 1998 values

5 (d) Small study, no unit cost source reported, no consideration of quality of life, no useful analysis of uncertainty reported

6

7

8 **Table 84: Economic evidence profile: hydrogel dressing versus collagenase dressing**

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Co ef
Waycaster 2013 ²⁰⁶ (US)	Partially applicable ^a	Potentially serious limitations ^b	Markov model based on a single RCT. Three states: inflamed wound, healing wound, healed wound. Hydrogel dressings are compared to collagenase dressings.	£2,297	Days spent with non-healed pressure ulcer: 99	Co dr do hy dr co da no pr

9 (c) US healthcare system, quality of life not considered

10 (d) Based on single RCT. The study does not fully describe cost sources or resource usage. No consideration is given to quality of life. Analysis of uncertainty is incomplete.

11

12 **Table 85: Economic evidence profile: gauze versus impregnated gauze versus calcium alginate versus hydroactive wound dressing (with collagenase)**

Study	Applicability	Limitations	Other comments	Costs	Effects	Co ef
Bergemann 1999 ²⁷ (Germany)	Partially applicable ^a	Potentially serious limitations ^b	A model comparing gauze, ointment impregnated gauze, calcium alginate, and a hydroactive wound dressing (in combination with collagenase) in the treatment of four sizes of PU: 5cm x 8 cm, 8cm x 12 cm, 10cm x 15cm, 12cm x 20cm. Cost-comparison only.	Total costs (per patient, median) for 12x20cm ulcer: Intvn 1: £3,813 Intvn 2: £1,501 Intvn 3: £1,677 Intvn 4: £592	None	Ef as th 4 i ef ha co

14 (a) Based in Germany, quality of life not considered, health outcomes not considered (assumed equivalent)

- 1 (b) Unclear whether unit costs are nationally representative, efficacy is assumed the same, it is assumed (not based on
2 evidence) that treatment with hydroactive wound dressing reduces inpatient stay by 10%

3 **Table 86: Economic evidence profile: autolysis versus wet-to-dry dressings versus collagenase**
4 **versus fibrinolysin**

Study	Applicability	Limitations	Other comments	Cost	Incremental effects	Co ef
Mosher 1999 (US) ¹²¹	Partially applicable ^a	Potentially serious limitations ^b	Decision analytic model to calculate the costs of autolytic debridement, wet-to-dry saline dressings, collagenase and fibrinolysin. The key clinical outcomes were the probability of achieving a clean wound bed and the probability of infection.	Autolysis: £591 Wet-to-dry saline dressings: £648 Collagenase: £392 Fibrinolysin: £633	None	Co th of m de

5 (a) Study based in the US, quality of life not considered, costs based on 1995 values

6 (b) Unclear whether unit costs are nationally representative, efficacy is based on expert opinion (small sample of only 9
7 experts), the time horizon is short and therefore the model may not capture the full cost impact between the different
8 strategies.

9 8.1.2 Clinical evidence (neonates, infants, children and young people)

10 No RCTs or cohort studies were identified. Recommendations were developed using a modified
11 Delphi consensus technique. Further details can be found in Appendix N.

12 8.1.3 Economic (neonates, infants, children and young people)

13 No economic evidence was identified.

14 8.1.4 Evidence statements

15 8.1.4.1 Clinical (adults)

16 8.1.4.1.1 Collagenase ointment versus preparation of inactivated collagenase

- 17 • One study (n=28) showed collagenase ointment is potentially more clinically effective for
18 decreasing volume of pressure ulcers compared to a preparation of inactivated collagenase (very
19 low quality).
- 20 • One study (n=28) showed inactivated collagenase is potentially more clinically harmful for
21 increasing the size of volume of pressure ulcers compared to collagenase ointment (very low
22 quality).
- 23 • One study (n=28) showed there may be no clinical difference between collagenase ointment and
24 a preparation of inactivated collagenase for proportion of pressure ulcers with odour at the end
25 of treatment, the direction of the estimate of effect favoured collagenase (very low quality).
- 26 • One study (n=28) showed there may be no clinical difference between collagenase ointment and
27 a preparation of inactivated collagenase for side effects, the direction of the estimate of effect
28 favoured the preparation of inactivated collagenase (very low quality).
- 29 • One study (n=28) showed there is no clinical difference between collagenase ointment and a
30 preparation of inactivated collagenase for mortality (all-cause) (low quality).
- 31 • No evidence was found for the following outcomes:
- 32 o Proportion of people with pressure ulcers completely healed
- 33 o Time to complete healing of pressure ulcers

- 1 o Rate of change in size or volume of pressure ulcers
- 2 o Pain (wound-related)
- 3 o Time in hospital or NHS care
- 4 o Patient acceptability
- 5 o Health-related quality of life
- 6

8.1.4.172 Collagenase ointment versus dextranomer powder

- 8 • One study (n=28) showed dextranomer may be more clinically effective for complete healing of
9 pressure ulcers when compared to collagenase ointment (very low quality).
- 10 • One study (n=25) (chronically ill and disabled people) showed dextranomer may be more clinically
11 effective for proportion of people with complete healing of pressure ulcers when compared to
12 collagenase ointment (very low quality).
- 13 • One study (n=25) showed dextranomer is potentially more clinically effective for proportion of
14 pressure ulcers improved when compared to collagenase ointment (very low quality).
- 15 • One study (n=28) showed dextranomer is potentially more clinically effective for proportion of
16 people with pressure ulcers improved when compared to collagenase ointment (very low quality).
- 17 • One study (n=28) showed dextranomer is potentially more clinically effective for proportion of
18 people with pressure ulcers improved after 1 week when compared to collagenase ointment (very
19 low quality).
- 20 • One study (n=28) showed dextranomer is potentially more clinically effective for proportion of
21 people with pressure ulcers improved after 1 month when compared to collagenase ointment
22 (very low quality).
- 23 • One study (n=28) showed dextranomer may be more clinically effective for proportion of people
24 with pressure ulcers improved after 2 months when compared to collagenase ointment (very low
25 quality).
- 26 • One study (n=28) showed dextranomer is potentially more clinically effective for proportion of
27 people with pressure ulcers improved after over 2 months when compared to collagenase
28 ointment (very low quality).
- 29 • No evidence was found for the following outcomes:
 - 30 o Time to complete healing of pressure ulcers
 - 31 o Rate of change in size or volume of pressure ulcers
 - 32 o Pain (wound-related)
 - 33 o Time in hospital or NHS care
 - 34 o Patient acceptability
 - 35 o Side effects
 - 36 o Mortality (all-cause)
 - 37 o Health-related quality of life
- 38

8.1.4.193 Collagenase ointment versus sugar and egg white

- 40 • One study (n=20) showed collagenase ointment may be more clinically effective for proportion of
41 people with pressure ulcers completely healed when compared to sugar and egg white (very low
42 quality).
- 43 • One study (n=20) showed collagenase ointment may be more clinically effective for complete
44 healing of pressure ulcers when compared to sugar and egg white (very low quality).

- 1 • One study (n=20) showed collagenase ointment may be more clinically effective for improving
2 pressure ulcers when compared to sugar and egg white (very low quality).
- 3 • One study (n=20) showed collagenase ointment no clinical difference between sugar and egg
4 white for improving pressure ulcers at 1 week, the direction of estimate of effect could favour
5 either intervention (low quality).
- 6 • One study (n=20) showed collagenase ointment may be more clinically effective for improving
7 pressure ulcers when compared to sugar and egg white at 1 month (very low quality).
- 8 • One study (n=20) showed collagenase ointment is more clinically effective for improving pressure
9 ulcers when compared to sugar and egg white at 2 months (low quality).
- 10 • One study (n=20) showed collagenase ointment is more clinically effective for reducing proportion
11 of people with pressure ulcers when compared to sugar and egg white (very low quality).
- 12 • No evidence was found for the following outcomes:
 - 13 o Time to complete healing of pressure ulcers
 - 14 o Rate of change in size or volume of pressure ulcers
 - 15 o Pain (wound-related)
 - 16 o Time in hospital or NHS care
 - 17 o Patient acceptability
 - 18 o Side effects
 - 19 o Mortality (all-cause)
 - 20 o Health-related quality of life
- 21

8.1.4.124 Collagenase ointment versus papain/urea ointment

- 23 • One study (n=21) showed there may be no clinical difference between collagenase ointment and
24 papain/urea for reducing pressure ulcers size (%) at 1 week, the direction of estimate of effect
25 favoured papain/urea (very low quality).
- 26 • One study (n=21) showed there may be no clinical difference between collagenase ointment and
27 papain/urea for reducing pressure ulcers size (%) at 2 week², the direction of estimate of effect
28 favoured papain/urea (very low quality).
- 29 • One study (n=21) showed there may be no clinical difference between collagenase ointment and
30 papain/urea for reducing pressure ulcers size (%) at 3 week², the direction of estimate of effect
31 favoured papain/urea (very low quality).
- 32 • One study (n=21) showed there may be no clinical difference between collagenase ointment and
33 papain/urea for reducing pressure ulcers size (%) at 4 weeks, the direction of estimate of effect
34 favoured papain/urea (very low quality).
- 35 • One study (n=21) showed collagenase ointment may be more clinically harmful than papain/urea
36 for adverse events observed (very low quality).
- 37 • No evidence was found for the following outcomes:
 - 38 o Proportion of people with pressure ulcers completely healed
 - 39 o Time to complete healing of pressure ulcers
 - 40 o Rate of change in size or volume of pressure ulcers
 - 41 o Pain (wound-related)
 - 42 o Time in hospital or NHS care
 - 43 o Patient acceptability
 - 44 o Mortality (all-cause)
 - 45 o Health-related quality of life

1

8.1.4.125 Collagenase ointment versus fibrinolysis/DNAse ointment

- 3 • One study (n=135) showed collagenase ointment is potentially more clinically harmful than
4 fibrinolysis/DNAse for adverse events observed (very low quality).
- 5 • One study (n=135) showed collagenase ointment is more clinically harmful than
6 fibrinolysis/DNAse for serious adverse events observed (low quality).
- 7 • No evidence was found for the following outcomes:
- 8 o Proportion of people with pressure ulcers completely healed
- 9 o Time to complete healing of pressure ulcers
- 10 o Rate of change in size or volume of pressure ulcers
- 11 o Reduction in size or volume of pressure ulcers
- 12 o Pain (wound-related)
- 13 o Time in hospital or NHS care
- 14 o Patient acceptability
- 15 o Mortality (all-cause)
- 16 o Health-related quality of life

8.1.4.176 Collagenase dressing versus hydrocolloid dressing

- 18 • One study (n=37) showed no clinical difference between collagenase dressing and hydrocolloid
19 dressing for reducing pressure ulcer area (very low quality).
- 20 • One study (n=37) showed collagenase dressing may be more clinically effective than hydrocolloid
21 dressing for complete healing of pressure ulcers (very low quality).
- 22 • One study (n=37) showed there may be no clinical difference between collagenase dressing and
23 hydrocolloid dressing for mean reduction in pressure ulcer area, the direction of the estimate of
24 effect favoured the collagenase dressing (very low quality).
- 25 • One study (n=37) showed there may be no clinical difference between hydrocolloid dressing and
26 collagenase dressing for adverse events observed, the direction of estimate of effect favoured
27 collagenase (very low quality).
- 28 • One study (n=22) showed collagenase dressing may be more clinically effective than hydrocolloid
29 dressing for delaying time to complete healing of pressure ulcers (very low quality).
- 30 • Two studies (n=61) showed there may be no clinical difference between collagenase dressing and
31 hydrocolloid dressing for mortality, the direction of effect favours the hydrocolloid dressing (very
32 low quality).
- 33 • No evidence was found for the following outcomes:
- 34 o Rate of change in size or volume of pressure ulcers
- 35 o Pain (wound-related)
- 36 o Time in hospital or NHS care
- 37 o Patient acceptability
- 38 o Health-related quality of life
- 39

8.1.4.407 Collagenase ointment 24 hours versus 48 hour application

- 41 • One study (n=86) showed there may be no clinical difference between collagenase ointment
42 applied 24 hours compared to 48 hours for the proportion of pressure ulcers completely healed,
43 the direction of effect favours 24 hours (very low quality).

- 1 • One study (n=92) showed there may be no clinical difference between collagenase ointment
2 applied 24 hours compared to 48 hours for adverse events observed, the direction of effect could
3 favour either application (very low quality).
- 4 • One study (n=86) showed there may be no clinical difference between collagenase ointment
5 applied 24 hours compared to 48 hours for mortality, the direction of effect favours 24 hours
6 (very low quality).
- 7 • No evidence was found for the following outcomes:
- 8 o Time to complete healing of pressure ulcers
- 9 o Rate of change in size or volume of pressure ulcers
- 10 o Reduction in size or volume of pressure ulcers
- 11 o Pain (wound-related)
- 12 o Time in hospital or NHS care
- 13 o Patient acceptability
- 14 o Health-related quality of life
- 15

8.1.4.168 Collagenase ointment versus hydrogel dressing

- 17 • One study (n=27) showed collagenase ointment is potentially more clinically effective than
18 hydrogel for proportion of people with pressure ulcers completely healed (very low quality).
- 19 • One study (n=27) showed there may be no clinical difference between collagenase ointment and
20 hydrogel for reducing mean PUSH tool score, direction of estimate of effect favours collagenase
21 (very low quality).
- 22 • One study (n=27) showed no clinical difference between collagenase ointment and hydrogel for
23 mortality (low quality).
- 24 • No evidence was found for the following outcomes:
- 25 o Time to complete healing of pressure ulcers
- 26 o Rate of change in size or volume of pressure ulcers
- 27 o Reduction in size or volume of pressure ulcers
- 28 o Pain (wound-related)
- 29 o Time in hospital or NHS care
- 30 o Patient acceptability
- 31 o Side effects
- 32 o Mortality (all-cause)
- 33 o Health-related quality of life
- 34

8.1.4.159 Zinc oxide versus streptokinase-streptodornase ointment

- 36 • One study (n=28) reported zinc oxide ointment may be more effective at reducing percentage of
37 ulcer area compared to streptokinase-streptodornase. The clinical importance is unknown (very
38 low quality).
- 39 • One study (n=28) showed that there may be no clinical difference between zinc oxide and
40 streptokinase-streptodornase ointment for proportion of people with an infection, the direction
41 of the estimate of effect favours zinc oxide (very low quality).
- 42 • One study (n=28) showed that there may be no clinical difference between zinc oxide and
43 streptokinase-streptodornase ointment for proportion of people with a skin reaction, the
44 direction of the estimate of effect favours zinc oxide (very low quality).

- 1 • One study (n=28) showed there is no clinical difference between zinc oxide and streptokinase-
2 streptodornase ointment for mortality (all-cause), the direction of the estimate of effect could
3 favour either intervention (low quality).
- 4 • No evidence was found for the following outcomes:
- 5 o Proportion of people with pressure ulcers completely healed
 - 6 o Time to complete healing of pressure ulcers
 - 7 o Rate of change in size or volume of pressure ulcers
 - 8 o Pain (wound-related)
 - 9 o Time in hospital or NHS care
 - 10 o Patient acceptability
 - 11 o Side effects
 - 12 o Mortality (all-cause)
 - 13 o Health-related quality of life

148.1.4.2 Economic (adults)

- 15 • One cost-effectiveness analyses found collagenase is likely to be more expensive and more
16 effective than hydrocolloid for healing people with pressure ulcers; 1 additional cost-effectiveness
17 analysis found that collagen is likely to dominate hydrocolloid (collagen is less costly and more
18 effective) in the treatment of heel pressure ulcers. Both studies were partially applicable with
19 potentially serious limitations.
- 20 • One cost-consequence analysis found collagenase dressings dominate hydrogel dressings, with
21 lower costs and fewer days spent with a pressure ulcer. This study was assessed to be partially
22 applicable with potentially serious limitations.
- 23 • One cost comparison found the combination of a hydroactive wound dressing and collagenase to
24 be less costly than gauze, impregnated gauze and calcium alginate. This study was partially
25 applicable with potentially serious limitations.
- 26 • One cost comparison found collagenase to be less costly than autolysis, wet-to-dry saline
27 dressings and fibrinolysin and desoxyribonuclease combined. This study was partially applicable
28 with potentially serious limitations.

298.1.4.3 Clinical (neonates, infants, children and young people)

30 No evidence was identified.

318.1.4.4 Economic (neonates, infants, children and young people)

32 No relevant economic evaluations were identified.

33 8.2 Maggot (larval) therapy

34 Maggot therapy, also known as larval therapy, is an alternative method of debridement. The maggots
35 used for debridement are from sterile fly larvae of the sheep blowfly *Luciliasericata* (Diptera:
36 Calliphoridae). These maggots are ideal for debridement because the enzymes produced by this
37 species dissolve only dead tissue in human wounds, thus the maggots are unable to damage healthy
38 tissue. Maggot secretions also contain chemicals with inherent antimicrobial properties, which may
39 help to combat infection by having an inhibitory effect on the growth of bacteria. In addition it has
40 been postulated that maggot therapy may result in more rapid debridement and less pain than some
41 other therapies.

- 1 The GDG was interested in identifying the the most clinical and cost effective method of maggot
2 debridement.

**8.3 Review question: What are the most clinically and cost effective
4 methods of maggot debridement of non-viable tissue for treatment
5 of pressure ulcers?**

- 6 For full details see review protocol in Appendix D.

7 8.3.1 Clinical evidence (adults)

- 8 No randomised trials were identified for inclusion of the review, therefore a search for cohort studies
9 was conducted (as per the protocol in Appendix C). Three records were subsequently included in this
10 review. Evidence from these studies is summarised below and the clinical GRADE evidence profiles in
11 Table 74 onwards. All study evidence tables and forest plots are presented in respectively Appendix
12 G and Appendix I.

13

Summary of studies included in the review

Study	Intervention/comparator	Population	Outcome	Length of study
Sherman, 1995 ¹⁷⁵	Maggot therapy administered by disinfected fly larvae of the species <i>Phaenicia sericata</i> versus conventional treatment.	Participants with pressure ulcers stage 3 or 4 for at least 1 month.	<ul style="list-style-type: none"> • Average change in surface area per week 	Participants were followed up for 3 to 4 weeks prior to maggot therapy
Sherman, 2002 ¹⁷⁴	Maggot therapy administered by applying disinfected fly larvae (<i>Phaenicia sericata</i>) to the wound at a density of five to eight per cm ² versus conventional treatment prescribed by their primary care provider or the hospital's wound care team.	People with pressure ulcers.	<ul style="list-style-type: none"> • Change in surface area during treatment (cm²) • Change in surface area per week • Percentage of wounds which decreased in surface area within 4 weeks • Healing rate at 4 weeks • Healing rate at 8 weeks • Percentage of wounds that completely healed • Average time until wounds completely healed (weeks) • Proportion of wounds decreased during treatment 	Wounds were first followed for 2 to 8 weeks (average 4.8 weeks) while still receiving conventional therapy. Then the wounds were treated for 2 weeks or more (average 5.2 weeks) with maggot therapy.
Wang, 2010 ²⁰⁴	Maggot therapy administered by applying disinfected larvae of <i>Lucilia sericata</i> to the wound at a density of 5 to 10 per cm ² versus a dressing applied daily with normal saline only and if necessary surgical debridement.	People with pressure ulcers after spinal cord injury treated in the hospital.	<ul style="list-style-type: none"> • Time to wound healing (days) 	All participants were followed up for 2 to 6 months (mean 3.5 months).

Table 87: Clinical evidence profile: maggot therapy versus conservative treatment

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Maggot therapy	Conservative treatment	Relative (95% CI)	Absolute		
Change in surface area during treatment (cm²) in people with pressure ulcers (grade 3 to 4) -classification system not reported - follow-up mean 5.2 weeks¹⁷⁴												
1	Cohort study	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	-7.3 (n=43)	6.3 (n=49)	-	MD 13.6 lower (15.01 to 12.19 lower)	Very low	Critical
Change in surface area per week in people with pressure ulcers (grade 3 to 4) (classification system not reported)- follow-up mean 5.2 weeks¹⁷⁴												
1	Cohort study	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	-1.5 (n=43)	1.4 (n= 49)	-	MD 2.9 lower (3.25 to 2.55 lower)	Very low	Critical
Proportion wounds decreased in surface area within 4 weeks in people with pressure ulcers (grade 3 to 4) (classification system not reported) - follow-up mean 5.2 weeks¹⁷⁴												
1	Cohort study	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	34/43 (79.1%)	22/49 (44.9%)	RR 1.76 (1.25 to 2.49)	341 more per 1000 (from 112 more to 669 more)	Very low	Critical
							-	44.9%		341 more per 1000 (from 112 more to 669 more)		
Proportion of wounds decreased during treatment in people with pressure ulcers (grade 3 to 4) (classification system not reported) - follow-up mean 5.2 weeks¹⁷⁴												
1	Cohort study	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	36/43 (83.7%)	18/49 (36.7%)	RR 2.28 (1.54 to 3.37)	470 more per 1000 (from 198 more to 871 more)	Very low	Critical
							-	36.7%		470 more per 1000 (from 198 more to 870 more)		
Healing rate at 8 weeks in people with pressure ulcers (grade 3 to 4) (classification system not reported)- follow-up mean 5.2 weeks¹⁷⁴												
1	Cohort study	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0.096 (n=43)	0.027 (n=49)	-	MD 0.12 higher (0.11 to 0.14)	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Maggot therapy	Conservative treatment	Relative (95% CI)	Absolute (higher)		
Proportion of wounds that completely healed in people with pressure ulcers (grade 3 to 4) (classification system not reported)- follow-up mean 5.2 weeks¹⁷⁴												
1	Cohort study	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	17/43 (39.5%)	10/49 (20.4%)	RR 1.94 (1 to 3.77)	192 more per 1000 (from 0 more to 565 more)	Very low	Critical
								20.4%		192 more per 1000 (from 0 more to 565 more)		
Time to wound healing (days) Sherman 2002: in people with pressure ulcers (grade 3 to 4) (classification system not reported - follow-up mean 5.2 weeks; Wang 2010: people with a spinal cord injury with pressure ulcers –follow-up mean 3.5 months^{174,204}												
2	Cohort study	Very serious ^a	Serious ^d	No serious indirectness 4	Serious ^c	None	71.7 (n=53)	85.1 n=57	-	MD 11.27 lower (19.97 to 2.57 lower)	Very low	Critical
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) There was a high risk of selection bias (the method of allocation was potentially related to confounding factors, there were no attempts to balance comparison groups and comparison groups were not comparable at baseline), there was a high risk of performance bias (as both participants and administrators of care were blinded to treatment allocation), there was a high risk of detection bias (investigators were not kept blind for exposure to intervention and other confounding/prognostic factors).*
- (b) The confidence interval crossed both MID points (0.5 x standard deviation for continuous outcomes and 0.75 to 1.25 for dichotomous outcomes).*
- (c) The confidence interval crossed 1e MID point (0.5 x standard deviation for continuous outcomes and 0.75 to 1.25 for dichotomous outcomes).*
- (d) Heterogeneity shows a low p-value.*

1 8.3.2 Economic evidence (adults)

2 Published literature

3 No relevant economic evaluations were identified. One study that met the inclusion criteria was
4 selectively excluded¹⁹¹ – reasons for exclusion are given in Appendix K.

5 Unit costs

6 To aid consideration of cost effectiveness, relevant unit costs were obtained from the UK supplier of
7 maggots (BioMond UK). List prices indicate that a 5x6cm BioBag (without sudocrem) costs £245.
8 Assuming (based on GDG estimate) that each patient has a maximum of 3-4 applications, the cost of
9 debridement with maggots could cost up to £980.

10 8.3.3 Clinical evidence (neonates, infants, children and young people)

11 No RCTs or cohort studies were identified. Recommendations were developed using a modified
12 Delphi consensus technique. Further details can be found in Appendix N.

13 8.3.4 Economic evidence (neonates, infants, children and young people)

14 No relevant economic evaluations were identified.

15 8.3.5 Evidence statements

16 8.3.5.1 Clinical (adults)

- 17 • One study (n=92) reported maggot therapy was more clinically effective than conservative
18 treatment for reducing the surface area of pressure ulcers during treatment (very low quality).
- 19 • One study (n=92) showed that there may be no clinical difference between maggot therapy and
20 conservative treatment for the change in surface area per week. The direction of the effect
21 favoured maggot therapy (very low quality).
- 22 • One study (n=92) showed that maggot therapy was more clinically effective than conservative
23 treatment for decreasing the surface area of pressure ulcers within 4 weeks (very low quality).
- 24 • One study (n=92) showed that there is no clinical difference between maggot therapy and
25 conservative treatment for healing rate at 8 weeks. The direction of the effect favoured maggot
26 therapy (very low quality).
- 27 • One study (n=92) showed that there is potentially no clinical difference between maggot therapy
28 and conservative treatment for the proportion of wounds completely healed. The direction of the
29 effect favoured the maggot therapy (very low quality).
- 30 • Two studies (n=110) showed that maggot therapy is potentially more clinically effective than
31 conservative treatment for time to wound healing (very low quality).
- 32 • No evidence was found for the following outcomes:
- 33 o Pain (wound-related)
 - 34 o Time in hospital or NHS care
 - 35 o Patient acceptability
 - 36 o Side effects
 - 37 o Mortality (all-cause)
 - 38 o Health-related quality of life

398.3.5.2 **Economic (adults)**

40 No economic evidence was identified.

418.3.5.3 **Clinical (neonates, infants, children and young people)**

42 No evidence was identified.

438.3.5.4 **Economic (neonates, infants, children and young people)**

44 No economic evidence was identified.

45 **8.4 Recommendations and link to evidence**

46 **8.4.1 Adults**

Recommendations	<p>28. Assess the need to debride a pressure ulcer in adults, taking into consideration:</p> <ul style="list-style-type: none"> • the amount of necrotic tissue • the grade, size and extent of the pressure ulcer • patient tolerance • any comorbidities <p>29. Offer debridement to adults if identified as needed in the assessment:</p> <ul style="list-style-type: none"> • use autolytic debridement, using an appropriate dressing to support it • consider using sharp debridement if autolytic debridement is likely to take longer and prolong healing time.
Relative values of different outcomes	<p>The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.</p> <p>This recommendation was developed from GDG consensus after reviewing the evidence for debridement, to establish whether debridement is required and what type of debridement would be preferable.</p>
Trade-off between clinical benefits and harms	<p>In order to determine whether debridement should be carried out for the treatment of pressure ulcers, the GDG considered evidence looking at different debridement techniques.</p> <p>There was no evidence comparing different techniques of debridement except for the comparison of enzymatic debridement to autolytic debridement (with the use of hydrogel or hydrocolloid dressings). Enzymatic debridement (collagenase) showed some benefit over autolytic debridement (hydrogel dressing). However the GDG noted that there were certain benefits in allowing debridement to occur naturally, as enzymatic debridement can result in the removal of tissue which might otherwise survive. The GDG felt that the use of collagenase was slower than the use of surgical debridement, and therefore surgical debridement would be preferential over enzymatic debridement.</p> <p>Despite the lack of evidence, the GDG considered that debridement is required</p>

	<p>physiologically for the healing process in some pressure ulcers. Therefore, in order to identify where this would be required, the GDG felt that it was necessary to assess the pressure ulcer. The group therefore used informal consensus to develop a list of considerations to aid an assessment of need for and technique of debridement.</p> <p>The GDG felt that an experienced individual should carry out the debridement. Careful consideration would be needed as to who this should be and in what environment this should be done.</p> <p>The GDG noted that debridement can also be carried out in the community. There is also a need to consider if specialist referral is appropriate. Debridement should be prompt and timely to ensure that there is no delay in initiating treatment.</p> <p>The timing of debridement methods should be dependent upon the individuals clinical need.</p>
<p>Economic considerations</p>	<p>The GDG considered the economic implications of debridement. It was agreed that debridement was necessary to promote healing in some cases, and has long term benefits in the form of improved quality of life and reduced treatment costs.</p> <p>The GDG considered 5 economic evaluations which assessed different methods of debridement, all of which were only partially applicable, and had potentially serious limitations. All 5 analyses indicated that collagenase (enzymatic debridement) is cost-effective (compared to hydrocolloid dressings, hydrogel dressings, gauze, calcium alginate, autolysis, wet-to-dry dressings and fibrinolysin). However, none of these studies were from the UK, and pressure ulcers are not a licensed indication for the use of collagenase in the UK. Due to the limitations of these studies and the limited applicability in a UK NHS setting, the GDG felt that these studies were of little benefit in determining cost-effectiveness, and noted that a more relevant comparison would be sharp debridement compared to enzymatic debridement.</p> <p>The GDG agreed that where debridement was required, it is likely that sharp debridement would be cost effective compared to other methods, as it is a quicker process, thus healing can begin sooner and quality of life improvements realised from an earlier stage. In most cases, sharp debridement does not require anaesthetic as only dead tissue is removed, and can be done at the bedside, meaning it can be achieved quickly and efficiently. The GDG did note however, that in a small number of cases sharp debridement would need to be conducted in an operating theatre which would increase the cost on these occasions. The GDG agreed that the upfront cost of sharp debridement would be offset by future savings from a reduced time to healing and improvements in quality of life.</p> <p>The GDG noted that where autolytic debridement was likely to be sufficient, this method of debridement would be likely to offer a cost-effective solution, as it requires no additional resources over the use of an appropriate dressing (as recommended in Chapter 10. The GDG therefore agreed that where active steps for debridement are required sharp debridement is likely to be the cost-effective strategy, and where autolytic debridement is likely to be sufficient, autolytic debridement is likely to be the cost-effective option.</p> <p>No economic evaluations were included which assessed the cost-effectiveness of larval therapy for debridement; therefore the GDG considered relevant unit costs. The GDG noted that debridement with maggots is substantially more expensive than debridement by other means. As there was limited clinical evidence to suggest a benefit of using larval therapy, the GDG did not think that the additional cost was justified. Larval therapy is not considered to be cost-effective compared to other methods of debridement.</p>

Quality of evidence	<p>This recommendation was based on the GDG’s experience and was developed after reviewing the limited evidence for debridement.</p> <p>Maggot therapy</p> <p>No randomised trials were found, therefore cohort studies were included in the review. The majority of outcomes came from 1 cohort study. The evidence was limited to 3 cohort studies which had very serious limitations and small sample sizes. There was no serious imprecision for the proportion of pressure ulcers decreased in surface area and healing rate. There was serious imprecision for the proportion of pressure ulcers completely healed and time to healing. The conventional treatment involved a variety of treatments including dressings, surgical and enzymatic debridement.</p> <p>Enzymatic debridement</p> <p>The evidence was weak as the studies had small sample sizes and the evidence was downgraded for serious and very serious imprecision for almost all outcomes. All the studies had very serious risk of bias. Therefore there is a lot of uncertainty in the results.</p> <p>The GDG noted that outcomes such as reduction in the area of pressure ulcer were sometimes difficult to interpret as debridement may increase the size of the wound whilst being beneficial to healing.</p>
Other considerations	<p>The GDG noted that debridement methods need to be considered on an individual basis. Such consideration includes patient preference and tolerability. The GDG also identified a concern that people who are involved in the treatment of pressure ulcers do not often have the relevant experience needed to debride. Thus, any such undertaking must be done by a person who is trained and competent to ensure debridement is successful.</p>

47

<p>Recommendations</p>	<p>30. Do not routinely offer adults:</p> <ul style="list-style-type: none"> • larval (maggot) therapy • enzymatic debridement. <p>Consider larval therapy if sharp debridement is contraindicated or if there is associated vascular insufficiency.</p>
Relative values of different outcomes	<p>The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.</p>
Trade off between clinical benefits and harms	<p>Maggot therapy</p> <p>There was limited evidence for maggot debridement, with only 3 small cohort studies comparing maggot treatment to conservative treatment. These studies showed a clinical benefit of maggot debridement for the proportion of pressure ulcers completely healed, shorter time to healing and proportion of pressure ulcers which decreased in surface area. There was no clinical benefit for healing rate and it was unclear for change in surface area.</p> <p>There was no evidence for which method of maggot debridement is more effective (that is maggots in a bag compared to free-roaming maggots). The evidence used maggots that were free-roaming, with dressings to hold them in place.</p> <p>The GDG discussed the high cost associated with maggot debridement and that</p>

	<p>larval therapy was not considered to be cost effective (see Economic considerations). However, it was agreed that some people may benefit from the use of maggot debridement where there are contraindications to other methods of debridement (for example, those with comorbidities, where anaesthetic could be required for sharp debridement but cannot be given or where ulcers are in difficult sites) and that it may be necessary to consider the use of larval therapy in these individuals.</p> <p>Enzymatic debridement</p> <p>The evidence was very limited with a lot of uncertainty in the results. There was only 1 study found per comparison. Collagenase was found to be more clinically beneficial when compared to hydrocolloid or hydrogel dressing for complete healing compared to hydrocolloid dressing. There was no clinical benefit of collagenase for reduction in pressure ulcer size, reduction in adverse events and for time to healing when compared to hydrocolloid dressing and no clinical harm for mortality (all-cause) when compared to hydrogel or hydrocolloid dressing. Collagenase was more clinically beneficial than inactivated collagenase for proportion of ulcers that increased/decreased in size. Collagenase was more effective at improving pressure ulcers and complete healing of pressure ulcers when compared to sugar and egg white. There was no clinical benefit for collagenase compared to inactivated collagenase to reduce the odour at the end of treatment, the number of side effects or mortality. Collagenase was also more clinically beneficial than papain/urea for reduction pressure ulcers size at 4 weeks, although collagenase had higher side effects, as it did when compared to fibrinolysis/DNAse. Frequency of collagenase ointment application did not show a clinical benefit for 24 hours when compared to 48 hours for complete healing, adverse events or reducing all-cause mortality. Dextranomer was clinically more beneficial than collagenase for completely healing and improving pressure ulcers. Zinc oxide showed no clinical difference for infection, skin reaction and mortality when compared to streptokinase-streptodornase.</p> <p>There was no evidence comparing different techniques of debridement except for the comparison of enzymatic debridement to autolytic debridement (with the use of hydrogel or hydrocolloid dressings). Enzymatic debridement (collagenase) showed some benefit over autolytic debridement (hydrogel dressing). However the GDG noted that there were certain benefits in allowing debridement to occur naturally, as enzymatic debridement can result in the removal of tissue which might otherwise survive.</p> <p>The GDG felt that the use of collagenase was slower than the use of surgical debridement, and therefore surgical debridement would be preferential over enzymatic debridement.</p>
<p>Economic considerations</p>	<p>Maggot therapy</p> <p>No economic evaluations were included which assessed the cost-effectiveness of larval therapy for debridement; therefore the GDG considered relevant unit costs. The GDG noted that debridement with maggots is substantially more expensive than debridement by other means. As there was limited clinical evidence to suggest a benefit of using larval therapy, the GDG did not think that the additional cost was justified. Larval therapy is not considered to be cost-effective compared to other methods of debridement.</p> <p>Enzymatic debridement</p> <p>See recommendation 27.</p>
<p>Quality of evidence</p>	<p>Maggot therapy</p> <p>No randomised trials were found, therefore cohort studies were included in the review. The majority of outcomes came from 1 cohort study.</p> <p>The evidence was limited to 3 cohort studies which had very serious limitations and</p>

	<p>small sample sizes. There was no serious imprecision for the proportion of pressure ulcers decreased in surface area and healing rate. There was serious imprecision for the proportion of pressure ulcers completely healed and time to healing. The conventional treatment involved a variety of treatments including dressings, surgical and enzymatic debridement.</p> <p>Enzymatic debridement</p> <p>The evidence was weak as the studies had small sample sizes and the evidence was downgraded for serious and very serious imprecision for almost all outcomes. All the studies had very serious risk of bias. Therefore there is a lot of uncertainty in the results.</p> <p>The GDG noted that outcomes such as reduction in the area of pressure ulcer were sometimes difficult to interpret as debridement may increase the size of the wound whilst being beneficial to healing.</p>
Other considerations	<p>Maggot therapy</p> <p>The GDG noted that there can be some discomfort experienced by the individual when using maggots thus affecting tolerability of the treatment. The GDG stated that maggots were available either in a bagged form so that the maggots are contained or as free roaming maggots. Free roaming maggots are contained in the wound by a dressing put over the top.</p> <p>In addition, it was stated that there is at least a 1 day delay in obtaining the maggots as they cannot be stored as they need to be freshly ordered. This can be particularly problematic when wishing to obtain them over weekends and bank holidays.</p> <p>The GDG felt that the effectiveness of the maggots was also dependent upon the skill of the healthcare professional that uses them.</p> <p>It was acknowledged that the actual time taken to conduct the debridement is faster for maggot debridement than sharp debridement because maggots are quicker to apply and would require less staff time. However, both forms of debridement would require a specialist nurse.</p> <p>Enzymatic debridement</p> <p>The GDG discussed the current use of debriding agents. They informed that collagenase debridement was previously used in the UK and is used throughout the rest of the world, however it is not currently used routinely in most units.</p> <p>The GDG noted that in the NHS, healthcare professionals undertaking surgical debridement need to have suitable qualifications, and thus there are often limited availability for nurses to undertake this. It was therefore felt that this can increase the popularity of using enzymatic debridement methods.</p>

48 8.4.2 Neonates, infants, children and young people

Recommendations	31.Consider autolytic debridement with appropriate dressings for dead tissue in neonates, infants, children and young people. Consider sharp and surgical debridement by trained staff if autolytic debridement is unsuccessful.
Relative values of different outcomes	The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.
Trade-off between clinical benefits and	The GDG used 2 statements from the Delphi consensus survey to help develop the recommendation on debridement in neonates, infants, children and young people.

<p>harms</p>	<p>The statements were: ‘Healthcare professionals should use autolytic debridement, by the use of appropriate dressings, for the debridement of devitalized tissue in neonates, infants, children and young people’ and ‘Healthcare professionals should consider the use of sharp and surgical debridement in neonates, infants, children and young people, where autolytic debridement is insufficient.’</p> <p>The statement on autolytic debridement was accepted by the Delphi consensus panel during Round 1 of the survey. The statement on surgical debridement was amended for Round 2 of the survey on the basis of comments received from the panel. The GDG discussed the comments received during Round 1, which focused on ensuring that a suitably qualified individual carried out any surgical or sharp debridement (for example a member of the surgical team or a trained tissue viability nurse). The GDG amended the statement to highlight this. The GDG felt that the statement should also be amended to highlight that autolytic debridement with appropriate dressings would be used before any sharp or surgical debridement was considered. The statement included in Round 2 of the survey was ‘Healthcare professionals should consider the use of sharp and surgical debridement by appropriately qualified staff, where autolytic debridement via the use of appropriate dressings is insufficient, in neonates, infants, children and young people.’ The statement was accepted during Round 2 of the survey.</p> <p>The GDG discussed the results of the survey and developed a recommendation. The GDG agreed that for some pressure ulcers (for example, those with non-viable tissue), debridement was necessary to ensure that the healing process could be completed. The GDG felt that in the majority of situations, autolytic debridement should be considered the most appropriate method of debridement as this would be achieved naturally, facilitated by the use of a dressing. Comments from the Delphi consensus panel supported this recommendation. However, the GDG acknowledged that there were some situations in which autolytic debridement was likely to be inappropriate or insufficient to remove the non-viable tissue and allow for healing of the pressure ulcer. Comments from the Delphi consensus panel supported this and highlighted that there were situations in which sharp debridement should be considered as an alternative to autolytic debridement, where this is insufficient. The GDG therefore added to the recommendation, to highlight that sharp debridement should be considered where autolytic debridement was insufficient.</p> <p>The GDG and Delphi consensus panel both highlighted that sharp debridement should only be carried out by an appropriate qualified healthcare professional but noted that this may vary by location.</p>
<p>Economic considerations</p>	<p>The GDG noted that autolytic debridement requires no additional resources over the use of an appropriate dressing, as recommended in Chapter 10. Where autolytic debridement is unsuccessful, there may be economic and clinical benefits to sharp debridement. Sharp debridement can speed up the healing process, thus reducing future treatment costs and improving quality of life. The GDG noted that there would be a small upfront cost of sharp debridement, but that this would be offset by future savings from a reduced time to healing and improvements in quality of life.</p>
<p>Quality of evidence</p>	<p>No RCTs or cohort studies were identified for neonates, infants, children or young people. Formal consensus using a modified Delphi was therefore used to develop the recommendation.</p> <p>To inform the recommendation, the GDG used 1 statement which was included in Round 1 of the Delphi consensus survey and reached 84% consensus agreement.</p> <p>A second statement was included in Round 1 of the Delphi consensus, which reached</p>

	<p>63% consensus. This statement was amended for inclusion in Round 2 of the Delphi consensus survey, where it reached 84% consensus agreement.</p> <p>Further details can be found in Appendix N.</p>
Other considerations	<p>The GDG noted that recommendations on assessment to identify need for and techniques of debridement were also likely to be applicable to neonatal, infant, child and young person populations.</p>

9 Systemic antibiotics

51 The role of microorganisms in the aetiology and persistence of chronic wounds, including pressure
52 ulcers, remains poorly understood. All chronic wounds are presumed to be bacterially contaminated,
53 but the point at which this contamination becomes problematic still needs to be determined.

54 Current practice in terms of identifying indications for systemic antimicrobials (largely, antibiotic
55 therapy) is diverse and based on expert opinion. Whilst many healthcare professionals do not feel that it
56 is appropriate to provide systemic antibiotics for pressure ulcers which present only with clinical signs of
57 local infection, others feel that some local infection may also require treatment with systemic
58 antibiotics, especially when the virulence of the organism and the host defences have been taken into
59 account.

60 The GDG was therefore interested in identifying what the most clinically and cost effective antimicrobial
61 agents are in the treatment of pressure ulcers. For the purposes of the review, systemic antibiotics and
62 antifungals were considered.

9.1 Review question: What are the most clinically and cost effective systemic agents for the treatment of pressure ulcers?

64
65 For full details see review protocol in Appendix D.

9.1.1 Clinical evidence (adults)

67 A systematic search for randomised trials identified 6 studies of potential relevance to the review
68 question of which all were subsequently excluded. Reasons for exclusion can be found in Appendix K.

69 A systematic search for cohort studies was subsequently carried out. Eleven studies met the inclusion
70 criteria and were reviewed in detail. All 11 records were excluded. The flow chart and reason for
71 exclusion are presented in Appendix D and J.

9.1.2 Economic evidence (adults)

73 No relevant economic evaluations were identified.

9.1.3 Clinical evidence (neonates, infants, children and young people)

75 No RCTs or cohort studies were identified. Recommendations were developed using a modified
76 Delphi consensus technique. Further details can be found in Appendix N.

9.1.4 Economic evidence (neonates, infants, children and young people)

78 No relevant economic evaluations were identified.

9.1.5 Evidence statements

9.1.5.1 Clinical (adults)

81 No evidence was identified.

9.1.5.2 Economic (adults)

83 No evidence was identified.

9.1.543 Clinical (neonates, infants, children and young people)

85 No evidence was identified.

9.1.564 Economic (neonates, infants, children and young people)

87 No evidence was identified.

9.2.86 Recommendations and link to evidence

9.1.591 Adults

Recommendations	32. Do not offer systemic antibiotics specifically to heal pressure ulcers in adults.
Relative values of different outcomes	The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.
Trade off between clinical benefits and harms	There was no evidence identified on the use of systemic agents for the healing of pressure ulcers, therefore this recommendation was based on GDG informal consensus. The GDG stated that it is not possible to recommend the use of systemic agents for the treatment of pressure ulcers, however these agents may be used for related conditions. The GDG highlighted that there are some systemic agents such as steroids which are detrimental to the healing of pressure ulcers.
Economic considerations	No evidence was identified to suggest that systemic agents were clinically effective in the treatment of pressure ulcers, and the GDG agreed that they are unlikely to promote pressure ulcer healing. Use of systemic agents has a resource implication, thus in the absence of clinical benefit the GDG agreed that the use of systemic agents would not be cost-effective.
Quality of evidence	There were no RCTs or cohort studies identified on the use of systemic agents for the healing of pressure ulcers, therefore the recommendation was developed by GDG informal consensus.
Other considerations	The GDG felt that systemic agents should be reserved for signs and symptoms of systemic sepsis, spreading cellulitis and underlying osteomyelitis. It should be noted that the use of systemic agents should only be prescribed following full assessment of the individual.

90

Recommendations	33. After a skin assessment, offer systemic antibiotics to adults with a pressure ulcer if there are any of the following: <ul style="list-style-type: none"> • signs and symptoms of systemic sepsis • spreading cellulitis • underlying osteomyelitis. 34. Discuss with the local hospital microbiology department which antibiotic to offer adults to ensure that the systemic antibiotic is effective against local strains of infection.
Relative values of different outcomes	The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction

	in size and volume of pressure ulcers were the most critical outcomes to inform decision making.
Trade off between clinical benefits and harms	<p>There was no evidence identified on the use of systemic antibiotics for the healing of pressure ulcers, therefore this recommendation was based on GDG informal consensus.</p> <p>The GDG noted that the use of systemic antibiotics should be reserved for when there are signs and symptoms of systemic sepsis, spreading cellulitis and underlying osteomyelitis. The GDG felt that it would be necessary to have a full assessment of the individual to identify if systemic agents would be required.</p> <p>The GDG therefore used informal consensus to develop a recommendation identifying possible signs of infection which would benefit from treatment using systemic antibiotics.</p> <p>The GDG felt that it was important to highlight that where systemic antibiotics are offered, these should only be offered following discussion with the local microbiology department. The group felt that this was important to ensure that local guidelines on the use of antibiotics were followed and to ensure that the antibiotic being used is effective against local strains of infection. A recommendation was therefore developed using informal consensus to emphasise the importance of this.</p>
Economic considerations	The GDG noted that whilst systemic agents such as antibiotics are unlikely to be cost-effective solely for the treatment of pressure ulcers, there are additional factors to consider when there are signs of systemic sepsis, spreading cellulitis or underlying osteomyelitis. Systemic agents are required to treat these conditions, and are generally inexpensive. The GDG agreed that the small cost of treating these conditions would be outweighed by substantial increases in quality of life, and cost savings would most likely be realised through reductions in further treatment costs.
Quality of evidence	There was no evidence identified on the use of systemic antibiotics for the healing of pressure ulcers, therefore the recommendation was developed by GDG informal consensus.
Other considerations	The GDG stated that it was important to be aware of the unnecessary use of antibiotics as this may lead to the development of antibiotic resistant strains and the group highlighted that there was evidence of the development of drug resistance from other uses of antibiotics. It was also acknowledged that local resistance should be taken into consideration when deciding which antibiotics should be used.

91

Recommendations	35. Do not offer systemic antibiotics to adults based only on positive wound cultures without clinical evidence of infection.
Relative values of different outcomes	The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.
Trade off between clinical benefits and harms	<p>There was no evidence identified on the use of systemic antibiotics for the healing of pressure ulcer, therefore this recommendation was based on GDG informal consensus.</p> <p>The GDG felt that a positive wound culture does not necessarily mean that the wound is infected as it may be due to normal bacteria. Therefore further clinical evidence is required to confirm that the pressure ulcer is infected, via a full assessment.</p>
Economic	The GDG noted that identification of positive wound cultures did not mean systemic

considerations	antibiotics were required. No evidence was identified to suggest that systemic antibiotics were clinically effective in the treatment of pressure ulcers, and the GDG agreed that they are unlikely to promote pressure ulcer healing. Use of systemic antibiotics has a resource implication, thus in the absence of clinical benefit the GDG agreed that the use of systemic agents would not be cost-effective if there was no clinical evidence of infection.
Quality of evidence	There was no evidence identified on the use of systemic agents for the healing of pressure ulcers, therefore the recommendation was developed by GDG informal consensus.
Other considerations	The GDG stated that it was important to be aware of the unnecessary use of antibiotics as this may lead to the development of antibiotic resistant strains and the group highlighted that there was evidence of the development of drug resistance from other uses of antibiotics. It was also acknowledged that local resistance should be taken into consideration when deciding which antibiotics should be used.

9.1.52 Neonates, infants, children and young people

Recommendations	36. Consider systemic antibiotics for neonates, infants, children and young people with pressure ulcers with signs of local or systemic infection.
Relative values of different outcomes	The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.
Trade off between clinical benefits and harms	The GDG used 2 statements from the Delphi consensus panel to develop the recommendation, 'Healthcare professionals should use appropriate systemic antibiotics for the treatment of infected pressure ulcers (ie. advancing cellulitis, osteomyelitis or systemic infection) in neonates, infants, children and young people, as specified in the British National Formulary for Children (BNFc)' and 'Healthcare professionals should only use systemic antibiotic therapy for neonates, infants, children and young people, where clinically indicated (for example a positive wound swab or when 2 or more clinical signs of infection are present at the same time).' Both statements were accepted in Round 1 of the Delphi consensus survey. The GDG agreed that a recommendation should be developed to highlight that systemic antibiotics should be considered for pressure ulcers with signs of local or systemic infection. This was supported by qualitative comments received during Round 1 of the Delphi consensus, which noted that treatment with antibiotics should be carefully considered on an individual basis, accounting for the clinical state and history of the child. The GDG wished to highlight that antibiotics should only be considered where there signs of local or systemic infection, that is where there are signs and symptoms of systemic sepsis, spreading cellulitis or underlying osteomyelitis.
Economic considerations	The GDG noted that systemic antibiotics are often required to treat infection, and are generally inexpensive. The GDG agreed that the small cost of treating infection would be outweighed by substantial increases in quality of life, and cost savings would most likely be realised through reductions in further treatment costs. Systematic antibiotics are only thought to be cost-effective when there are signs of systemic or local infection.
Quality of evidence	No RCTs or cohort studies were identified for neonates, infants, children or young people. Formal consensus using a modified Delphi was therefore used to develop the recommendation.

	<p>To inform the recommendation, the GDG used 2 statements which were included in Round 1 of the Delphi consensus survey and reached 96% and 80% consensus agreement.</p> <p>Further details can be found in Appendix N.</p>
Other considerations	<p>The GDG stated that it was important to be aware of the unnecessary use of antibiotics as this may lead to the development of antibiotic resistant strains. It was also acknowledged that local resistance should be taken into consideration when deciding which antibiotics should be used.</p>

93

Recommendations	<p>37. Discuss with a local hospital microbiology department which antibiotic to offer neonates, infants, children and young people to ensure that t systemic antibiotic is effective against local strains of bacteria.</p>
Relative values of different outcomes	<p>The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.</p>
Trade off between clinical benefits and harms	<p>The GDG used 1 statement from the Delphi consensus panel to develop the recommendation 'Healthcare professionals should account for local sensitivities in antibiotic resistance, in conjunction with the microbiology department of their local hospital'. The statement was agreed in Round 1 of the Delphi consensus survey and a recommendation was therefore developed.</p> <p>The GDG felt that it was important to highlight that the offering of an antibiotic should only be given in conjunction and after discussion with, the local microbiology department. The GDG emphasised the importance of doing so to ensure that the most effective antibiotics are provided to combat local strains. Qualitative comments receiving during Round 1 agreed and noted that there are often local guidelines in place to help guide and advise healthcare professionals on the use of systemic antibiotics and treating infection.</p>
Economic considerations	<p>Discussion with the microbiology department will help promote efficient use of resources, as this will ensure that effective drugs are used, thereby minimising wastage and promoting healing of pressure ulcers.</p>
Quality of evidence	<p>No RCTs or cohort studies were identified for neonates, infants, children or young people. Formal consensus using a modified Delphi was therefore used to develop the recommendation.</p> <p>To inform the recommendation, the GDG used 1 statement which were included in Round 1 of the Delphi consensus survey and reached 95% consensus agreement.</p> <p>Further details can be found in Appendix N.</p>
Other considerations	<p>The GDG stated that it was important to be aware of the unnecessary use of antibiotics as this may lead to the development of antibiotic resistant strains. It was also acknowledged that local resistance should be taken into consideration when deciding which antibiotics should be used.</p>

94

10 Topical antimicrobials and antiseptics

96 A number of topical agents have been used over the years for the treatment of pressure ulcers.
97 These range from antiseptics to antibiotics and newer biological agents such as platelet derived
98 growth factors and nerve growth factors. While many claims have been made for the superiority of
99 individual topical agents, it has been difficult to find and develop the evidence for these. Local
100 cytotoxicity has been an area of concern with a number of agents and the situation is further
101 complicated by the addition of new formulations every year.

102 While topical agents are often grouped together, they are thought to have widely differing
103 mechanisms of action. Reduction in bio burden, antiseptics, disruption of biofilms, prevention of
104 infection and creation of an occlusive barrier have all been proposed as mechanisms by which topical
105 agents can exert a beneficial effect. In addition to aiding pressure ulcer healing, it has been
106 suggested that they reduce the likelihood of systemic antibiotic use, reduce the likelihood of
107 resistant bacterial strains emerging and reduce the local complications associated with pressure
108 ulcers.

109 The GDG were interested in identifying studies that support or negate a role for any of the individual
110 topical agents or a group of agents in the treatment of pressure ulcers.

10.1 Review question: What are the most clinically and cost effective topical agents for the treatment of pressure ulcers?

112

113 For full details see review protocol in Appendix D.

10.1.1 Clinical evidence (adults)

115 A Cochrane review on wound cleansing for pressure ulcer by Moore and Cowman (2011) was
116 identified. A systematic search was undertaken to update the Cochrane review and identify any
117 evidence on other categories of topical agents. Fifty four records were identified as potentially
118 relevant for inclusion and 19 records were excluded. The remaining 35 studies were included in this
119 review.

120 The Cochrane review by Moore and Cowman (2011)¹²⁰ included 3 RCTs,^{23,37,72} of which 2 were
121 excluded because they did not meet the inclusion criteria of this review. One was excluded as it was
122 a study on hydrotherapy³⁷ and was identified as more appropriate for the debridement review. The
123 other study did not report separate outcomes for people with pressure ulcers⁷². The flow chart and
124 reasons for exclusion are presented in Appendix D and K.

125 Thirty-six randomized controlled trials were included in this
126 review^{4,7,23,41,43,68,74,79,81,87,93,95,98,100,101,106,110,119,128,129,133,144,147,148,153,155-159,176,181,190,200,209,211}. Evidence
127 from the included studies is summarised in the clinical GRADE evidence profiles (Table 90). All forest
128 plots and study evidence tables are presented in respectively Appendix D and J.

129 Various types of topical agents are used to treat pressure ulcers. A definition of the different topical
130 agents is provided in Table 89. In this review different types of topical agents are compared to each
131 other or to placebo. The following categories were included in the review:

- 132 • Cleansers: soap, water, detergent, and solvent
- 133 • Moisturisers (emollients): glycerine, oil, cream and ointment
- 134 • Protective agents: for example talc, zinc oxide
- 135 • Antiseptic agents: alcohol, iodine solution, chlorhexidine, chlor oxydantia, peroxide, quaternary
136 ammonium compounds, Oxyquinoline, mercury, gentian violet, silver preparation

- 137 • Antibiotics
- 138 • Anti-inflammatory agents
- 139 • Anti-fungal agents
- 140 • Insulin
- 141 • Growth factors
- 142

Summary of included studies

Study	Intervention/comparator	Population	Outcome	Study length
Agren 1985 ⁴	Zinc oxide Streptokinase-streptodornase ointment	Geriatric adults with necrotic pressure ulcers	<ul style="list-style-type: none"> • Reduction in ulcer area • Side effects 	Eight weeks of treatment
Alm 1989 ⁷	Saline-soaked gauze Hydrocolloid	People in long term care with pressure ulcers	<ul style="list-style-type: none"> • Reduction in ulcer area • Side effects 	Six weeks of treatment and additional 3 and 6 weeks of follow-up
Bellingeri 2004 ²³	Aloe vera, silver chloride and decyl glucoside Isotonic saline	Elderly adults in a home care with a grade 2 to 4 pressure ulcers (NPUAP classification)	<ul style="list-style-type: none"> • Reduction in PSST score 	14 days of treatment
Chang 1998 ⁴¹	Saline-soaked gauze Hydrocolloid	People with a grade 2 or 3 pressure ulcers	<ul style="list-style-type: none"> • Reduction in ulcer area • Side effects 	Eight weeks of treatment or until complete healing
Chuansuwanich 2011 ⁴³	Silver sulfadiazine cream Silver dressing	People in hospital with a grade 3 or 4 pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Rate of healing • Reduction in PUSH score • Side effects 	Eight weeks of treatment
Gerding 1992 ⁶⁸	Oxyquinoline A&D ointment	People in palliative care with a grade 2 or 3 pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Proportion of ulcers completely healed • Proportion of ulcers improved • Proportion of ulcers not changed • Proportion of ulcers worsened • Healing rate 	28 days of treatment or until complete healing
Günes 2007 ⁷⁴	Ethoxydiaminoacridine plus nitrofurazone Honey	Hospitalised adults older than 18 years with a grade 2 or 3 pressure ulcer (AHCPR classification)	<ul style="list-style-type: none"> • Proportion of ulcers completely healed • Reduction in PUSH score • Reduction in ulcer size • Side effects 	Five weeks of treatment or until complete healing

Study	Intervention/comparator	Population	Outcome	Study length
Hirshberg 2003 ⁷⁹	Growth factors Placebo	People in hospital with a grade 3 or 4 pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Proportion of ulcers completely healed • Reduction in ulcer area • Reduction in ulcer volume 	16 weeks or until complete healing
Hollisaz 2004 ⁸¹	Phenytoin cream Saline-soaked gauze Hydrocolloid	People with a spinal cord injury and a grade 1 or 2 pressure ulcer (NPUAP or Shea classification)	<ul style="list-style-type: none"> • Proportion of ulcers completely healed • Proportion of ulcers improved • Proportion of ulcers worsened • Proportion of people completely healed 	Eight weeks of treatment
Kaya 2005 ⁸⁷	Povidone-iodine Hydrogel	Hospitalised adults with a spinal cord injury and a grade 1 to 3 pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Healing rate 	Not reported
Kim 1996 ⁹³	Povidone Hydrocolloid	People with a grade 1 to 2 pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Healing rate • Healing speed • Side effects 	Mean duration of 18.9 days and 24.3 in group 1 and 2 respectively
Knudsen 1982 ⁹⁵	Dialysate Placebo	People with a spinal cord injury and a pressure ulcer.	<ul style="list-style-type: none"> • Decrease in ulcer size • Healing half-time • Side effects 	Three weeks of treatment
Kraft 1993 ⁹⁸	Saline-soaked gauze Foam dressing	Males with a grade 2 or 3 pressure ulcers (Enterstomal Therapy definition)	<ul style="list-style-type: none"> • Proportion of people completely healed 	24 days of treatment
Kuflik 2001 ¹⁰⁰	Ointment (ResurfliX®) Petrolatum	Elderly adults with a grade 1 or 2 pressure ulcer (AHCPR)	<ul style="list-style-type: none"> • Proportion of ulcers completely healed 	Six weeks of treatment

Study	Intervention/comparator	Population	Outcome	Study length
		classification)	<ul style="list-style-type: none"> • Proportion of ulcers improved • Proportion of ulcers not changed • Proportion of ulcers worsened 	
Landi 2003 ¹⁰¹	Nerve growth factor Placebo	Adults in a nursing home with a grade 2 to 5 foot pressure ulcer (Yarkony classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Proportion of people improved in pressure ulcer grade • Reduction in ulcer area • Side effects 	Six weeks of treatment or until complete healing
Ljungberg 2009 ¹⁰⁶	Saline-soaked gauze Dextranomer	Males with a spinal cord injury and exudative pressure ulcers (Eltorai classification)	<ul style="list-style-type: none"> • Proportion of ulcers improved • Side effects 	14 days of treatment
Matzen 1999 ¹¹⁰	Saline-soaked gauze Hydrocolloid dressing	Adults with a grade 3 or 4 pressure ulcer (Lowthian classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Reduction in ulcer volume • Side effects 	12 weeks of treatment or until complete healing
Moberg 1983 ¹¹⁹	Iodine Standard treatment	Hospitalised adults with an deep or superficial pressure ulcer	<ul style="list-style-type: none"> • Proportion of ulcers reduced with 50% • Reduction in ulcer area 	Three weeks of treatment
Mustoe 1994 ¹²⁸	Growth factors Placebo	Adults with a grade 3 or 4 pressure ulcer	<ul style="list-style-type: none"> • Proportion of people completely healed • Ulcer volume 	29 days of treatment and up to five months of follow-up
Nasar 1982 ¹²⁹	Chlorinated lime solution (Eusol) and paraffin Dextranomer	Adults with a deep pressure ulcer	<ul style="list-style-type: none"> • Time to healing (defined as granulation and less than 25% of original) 	Until healing

Study	Intervention/comparator	Population	Outcome	Study length
			ulcer area) • Pain	
Neill 1989 ¹³³	Saline-soaked gauze Hydrocolloid dressing	Adults with a grade 2 or 3 pressure ulcer (Shea classification)	<ul style="list-style-type: none"> • Proportion of ulcers completely healed • Proportion of people worsened • Reduction in ulcer area • Side effects 	Eight weeks of treatment
Oleske 1986 ¹⁴⁴	Saline-soaked gauze Polyurethane dressing	People in hospital with a grade 1 or 2 pressure ulcer (Enis and Sarmiento classification)	<ul style="list-style-type: none"> • Proportion of ulcers completely healed • Proportion of ulcers worsened • Reduction in ulcer area 	10 days of treatment
Payne 2001 ¹⁴⁷	Growth factors Placebo	People in hospital with a grade 3 or 4 pressure ulcer	<ul style="list-style-type: none"> • Proportion of people completely healed • Proportion of people worsened 	35 days of treatment and 1 year of follow-up
Payne 2009 ¹⁴⁸	Saline Foam dressing	People in hospital with a grade 2 pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Time to healing 	Four weeks of treatment or until complete healing
Rees 1999 ¹⁵³	Growth factor Placebo	People with a grade 3 or 4 pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Proportion of people healed ≥ 90% • Reduction in ulcer volume • Side effects 	16 weeks of treatment or until complete healing
Rhodes 2001 ¹⁵⁵	Phenytoin Triple antibiotics Hydrocolloid	People in a nursing home with a grade 2 pressure ulcer (AHCPR classification)	<ul style="list-style-type: none"> • Healing time • Side effects • Pain 	Not reported

Study	Intervention/comparator	Population	Outcome	Study length
Robson 1992a ¹⁵⁸	Growth factors Placebo	People with denervated ulcers and a grade 3 or 4 pressure ulcer	<ul style="list-style-type: none"> • Proportion of people healed > 70% • Reduction in ulcer volume 	30 days of treatment and 5 months of follow-up
Robson 1992 ¹⁵⁹	Growth factors Placebo	People with denervated ulcers and a grade 3 or 4 pressure ulcer	<ul style="list-style-type: none"> • Proportion of people completely healed • Reduction in ulcer depth • Side effects 	Four weeks of treatment and five months of follow-up
Robson 1994 ¹⁵⁶	Growth factors Placebo	People with denervated ulcers and a grade 3 or 4 pressure ulcer	<ul style="list-style-type: none"> • Proportion of people completely healed • Reduction in ulcer area 	28 days of treatment and 3 months of follow-up
Robson 2000 ¹⁵⁷	Growth factors Placebo	People with a grade 3 or 4 pressure ulcer	<ul style="list-style-type: none"> • Reduction in ulcer area 	35 days of treatment
Sipponen 2008 ¹⁷⁶	Resin salve Hydrofibre	Hospitalised people with a grade 2 to 4 pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Proportion of ulcers completely healed • Proportion of ulcers improved • Proportion of ulcers worsened • Reduction in ulcer width and depth • Healing speed • Side effects 	Six months of treatment
Subbanna 2007 ¹⁸¹	Phenytoin Saline-soaked gauze	People with a spinal cord injury and a grade 2 pressure ulcer (NPUAP classification).	<ul style="list-style-type: none"> • Reduction in ulcer size • Reduction in ulcer volume • Reduction in PUSH score • Side effects 	15 days of treatment

Study	Intervention/comparator	Population	Outcome	Study length
Thomas 1998 ¹⁹⁰	Saline-soaked gauze Hydrogel	People with a grade 2, 3 or 4 pressure ulcer.	<ul style="list-style-type: none"> • Proportion of people completely healed • Proportion of people worsened • Reduction in ulcer area • Time to healing 	Ten weeks of treatment or until complete healing
Van Ort 1976 ²⁰⁰	Insulin Standard treatment	People in a nursing home with a pressure ulcer	<ul style="list-style-type: none"> • Healing rate 	Fifteen days of treatment
Xakellis 1992 ²⁰⁹	Saline-soaked gauze Hydrocolloid dressing	People in long term care with a grade 2 or 3 pressure ulcer (Shea classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Time to healing 	Six months of treatment
Yastrub 2004 ²¹¹	Antibiotic ointment Foam dressing	People in long term care with a grade 2 pressure ulcer (AHCPR classification)	<ul style="list-style-type: none"> • Proportion of people improved • PUSH score 	Four weeks of treatment

Table 88: Categories of topical agents

	Saline	Phenytain	Solcoseryl	Aloe vera	Petrolatum	Zinc oxide	A&D ointment	Silver sulfazidine	Ethoxy-diaminoacridine	Oxy-quinoline	Chlorinated lime	Iodophor such as (Povidone)-iodine	Resin salve	Nitrofurazone	Silvadene
Cleanser	X														
Moisturiser		X	X	X	X										
Protecting agent						X	X								
Antiseptic agent (a)								X	X	X	X	X	X	X	
Antibiotic agent (a)													X	X	X
Anti-inflammatory agent (a)												X	X	X	
Antifungal agent (a)												X	X	X	

(a) Antimicrobial agents.

Table 89: Definition topical agents

Topical Agent	Definition
Saline	An isotonic solution of sodium chloride in distilled water.
Phenytoin	Possible mechanisms of action of phenytoin on wound healing are by decreasing serum corticosteroid and by acceleration of assembly and presence of collagen and fibrin in the ulcer area, and stimulation of alkaline phosphatase secretion.
Dialysate (Solcoseryl)	Contains a free protein extract of calf blood that possesses metabolic function in the tissue. Solcoseryl contains a mixture of biologically active substances like aminoacids, irreplaceable microelements, glycolipids, nucleotides, nucleosides.
Petrolatum	Vaseline.
Zinc oxide	A topical astringent and protectant.
Streptokinase-streptodornase	A mixture of enzymes elaborated by hemolytic streptococci; used as a proteolytic and fibrinolytic agent.
Povidone-iodine	An antiseptic that is used for disinfecting skin.
Cadexomer	A dry powder consisting of spherical microbeads that range in diameter from 100 to 315µm. Each microbead is a highly hydrophilic, 3 dimensional network of a modified starch polymer containing iodine, which is physically immobilized within the matrix at a concentration of 0.9%. One gram of powder can absorb as much as 7ml of fluid.
Silver sulfazidine	The cream vehicle consists of white petrolatum, stearyl alcohol, isopropyl myristate, sorbitan monooleate, polyoxyl 40 stearate, propylene glycol, and water, with methylparaben 0.3% as a preservative and sulfa antibiotics.
Resin salve	A pure spruce resin.
Growth factors	Including: <ul style="list-style-type: none"> • Topical growth factor – Beta 3 • Mouse nevre groth factor • Recombinant platelet-derived growth factor-BB • Granulo-macrophage/colony-stimulating factor • Basic fibroblast growth factor • Interleukin 1-beta

Table 90: Clinical evidence profile: saline-soaked gauze versus hydrocolloid dressing

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Saline	Hydro-colloid	Relative (95% CI)	Absolute		
Proportion of people completely healed – general population and people with a spinal cord injury (meta-analysed) – all grade (grade 1 and above) – Lowthian and Shea classification^{m,81,110,209}												
3	Randomised trials	Very serious ^{a,b,c}	Very serious ^h	No serious indirectness	Serious ^d	None	26/63 (41.3 %)	41/63 (65.1%)	RR 0.50 (0.14 to 1.74)	325 fewer per 1000 (from 560 fewer to 482 fewer)	Very low	Critical
							-	71.4%		357 fewer per 1000 (from 614 fewer to 528 fewer)		
Proportion of people completely healed – general population (analysed separately due to population) – all grade (grade 1 and above) – Lowthian and Shea classification^{110,209}												
2	Randomised trials	Very serious ^{a,c}	Very serious ^h	No serious indirectness	Serious ^d	None	18/36 (50%)	21/35 (60%)	RR 0.38 (0.01 to 10.16)	372 fewer per 1000 (from 594 fewer to 1000 more)	Very low	Critical
							-	59.2%		367 fewer per 1000 (from 586 fewer to 1000 more)		
Proportion of people completely healed - people with a spinal cord injury (analysed separately due to population) – all grade (grade 1 and above) – Shea classification⁸¹												
1	Randomised trial	Serious ^b	No serious inconsistency	No serious indirectness	Serious ^d	None	8/27 (29.6 %)	20/28 (71.4%)	RR 0.41 (0.22 to 0.78)	421 fewer per 1000 (from 157 fewer to 557 fewer)	Low	Critical
							-	71.4%		421 fewer per 1000 (from 157 fewer to 557 fewer)		
Proportion of ulcers completely healed (all sites) - general population and people with a spinal cord injury (meta-analysed) – all grade (grade 1 to 3) – Shea classification^{81,133}												
2	Randomised	Very	Serious ^f	No serious	Serious ^d	None	18/75	36/73	RR 0.49	280 fewer	Very low	Critical

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Saline	Hydro-colloid	Relative (95% CI)	Absolute		
	trials	serious ^{b,e}		indirectness			(24%)	(49.3%)	(0.31 to 0.78)	(from 660 fewer to 100 more)		
							-	52.6%		280 fewer (from 660 fewer to 100 more)		
Proportion of ulcers completely healed (all sites) - general population (analysed separately due to population and grade 2 and above only)(grade 2 to 3)– Shea classification¹³³												
1	Randomised trial	Very serious ^e	No serious inconsistency	No serious indirectness	Very serious ^g	None	10/45 (22.2 %)	13/42 (31%)	RR 0.72 (0.35 to 1.46)	87 fewer per 1000 (from 201 fewer to 142 more)	Very low	Critical
							-	31%		87 fewer per 1000 (from 201 fewer to 143 more)		
Proportion of ulcers completely healed (all sites) - people with a spinal cord injury (analysed separately due to population) – grade 1 and above (grade 1 and 2) – Shea classification⁸¹												
1	Randomised trial	Serious ^b	No serious inconsistency	No serious indirectness	No serious imprecision	None	8/30 (26.7 %)	23/31 (74.2%)	RR 0.36 (0.19 to 0.67)	475 fewer per 1000 (from 245 fewer to 601 fewer)	Moderate	Critical
							-	74.2%		475 fewer per 1000 (from 245 fewer to 601 fewer)		
Proportion of ulcers completely healed (all sites) - people with a spinal cord injury (analysed separately due to grade of pressure ulcer) – grade 1 - Shea classification⁸¹												
1	Randomised trial	Serious ^b	No serious inconsistency	No serious indirectness	Serious ^d	None	5/11 (45.5 %)	11/13 (84.6%)	RR 0.54 (0.27 to 1.07)	389 fewer per 1000 (from 618 fewer to 59 more)	Low	Critical
							-	84.6%		389 fewer per		

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Saline	Hydro-colloid	Relative (95% CI)	Absolute		
										1000 (from 618 fewer to 59 more)		
Proportion of ulcers completely healed (all sites) - general population and people with a spinal cord injury (meta-analysed population, analysed grade of pressure ulcer separately) grade 2 - Shea classification^{81,133}												
2	Randomised trials	Very serious ^{b,e}	No serious inconsistency	No serious indirectness	No serious imprecision	None	6/53 (11.3 %)	23/43 (53.5%)	RR 0.22 (0.1 to 0.48)	417 fewer per 1000 (from 278 fewer to 481 fewer)	Low	Critical
							-	55.3%		431 fewer per 1000 (from 288 fewer to 498 fewer)		
Proportion of ulcers completely healed (all sites) - general population (analysed population and grade of ulcer separately) – grade 2 - Shea classification¹³³												
1	Randomised trial	Very serious ^e	No serious inconsistency	No serious indirectness	No serious imprecision	None	3/34 (8.8%)	11/25 (44%)	RR 0.2 (0.06 to 0.64)	352 fewer per 1000 (from 158 fewer to 414 fewer)	Low	Critical
							-	44%		352 fewer per 1000 (from 158 fewer to 414 fewer)		
Proportion of ulcers completely healed (all sites) - people with a spinal cord injury (analysed population separately and grade of pressure ulcer separately) – grade 2 - Shea classification⁸¹												
1	Randomised trial	Serious ^b	No serious inconsistency	No serious indirectness	No serious imprecision	None	3/19 (15.8 %)	12/18 (66.7%)	RR 0.24 (0.08 to 0.7)	507 fewer per 1000 (from 200 fewer to 613 fewer)	Moderate	Critical
							-	66.7%		507 fewer per 1000 (from 200 fewer to 614 fewer)		

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Saline	Hydro-colloid	Relative (95% CI)	Absolute		
Proportion of ulcers completely healed (all sites) - general population (analysed population separately and grade of pressure ulcer separately) – grade 3 - Shea classification ¹³³												
1	Randomised trial	Very serious ^e	No serious inconsistency	No serious indirectness	Very serious ^{d,n}	None	1/11 (9.1%)	2/17 (11.8%)	RR 0.77 (0.08 to 7.54)	27 fewer per 1000 (from 108 fewer to 769 more)	Very low	Critical
							-	11.8%		27 fewer per 1000 (from 109 fewer to 772 more)		
Proportion of ulcers completely healed (sacral area) - people with a spinal cord injury (analysed population and area separately) – grade 1 and above (grade 1 and 2) – Shea classification ⁸¹												
1	Randomised trials	Serious ^b	No serious inconsistency	No serious indirectness	Very serious ^{d,n}	None	4/8 (50%)	0/7 (0%)	OR 10.87 (1.19 to 99.73)	100 fewer (from 650 fewer to 450 more)	Very low	Critical
							-	0%		100 fewer (from 650 fewer to 450 more)		
Proportion of ulcers improved - people with a spinal cord injury (analysed population separately) – grade 1 and above (grade 1 and 2) – Shea classification ⁸¹												
1	Randomised trials	Serious ^b	No serious inconsistency	No serious indirectness	No serious imprecision	None	29/60 (48.3%)	27/31 (87.1%)	RR 0.55 (0.41 to 0.75)	392 fewer per 1000 (from 218 fewer to 514 fewer)	Moderate	Critical
							-	87.1%		392 fewer per 1000 (from 218 fewer to 514 fewer)		
Proportion of ulcers worsened - general population and people with a spinal cord injury (meta-analysed population) – grade 1 and above (grade 1 to 3) – Shea classification ^{81,133}												
2	Randomised	Very	Very serious ^h	No serious	Very	None	24/75	16/73	RR 1.88	193 more per	Very low	Critical

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Saline	Hydro-colloid	Relative (95% CI)	Absolute		
	trials	serious ^{b,e}		indirectness	serious ^g		(32%)	(21.9%)	(0.41 to 8.68)	1000 (from 129 fewer to 1000 more)		
							-	19.9%		175 more per 1000 (from 117 fewer to 1000 more)		
Proportion of ulcers worsened - general population (analysed population and grade 2 and above separately) – grade 2 and above (grade 2 and 3) – Shea classification¹³³												
1	Randomised trial	Very serious ^e	No serious inconsistency	No serious indirectness	Very serious ^g	None	15/45 (33.3%)	14/42 (33.3%)	RR 1 (0.55 to 1.81)	0 fewer per 1000 (from 150 fewer to 270 more)	Very low	Critical
							-	33.3%		0 fewer per 1000 (from 150 fewer to 270 more)		
Proportion of ulcers worsened - people with a spinal cord injury (population analysed separately) – grade 1 and above (grade 1 and 2) – Shea classification⁸¹												
1	Randomised trial	Serious ^b	No serious inconsistency	No serious indirectness	Very serious ^{d,n}	None	9/30 (30%)	2/31 (6.5%)	RR 4.65 (1.09 to 19.78)	235 more per 1000 (from 6 more to 1000 more)	Very low	Critical
							-	6.5%		237 more per 1000 (from 6 more to 1000 more)		
Proportion of ulcers worsened - general population (population analysed separately and grade of pressure ulcer separately) – grade 2 – Shea classification¹³³												
1	Randomised trial	Very serious ^e	No serious inconsistency	No serious indirectness	Very serious ^g	None	11/34 (32.4%)	7/25 (28%)	RR 1.16 (0.52 to 2.56)	45 more per 1000 (from 134 fewer to 437 more)	Very low	Critical
							-	28%		45 more per		

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Saline	Hydro-colloid	Relative (95% CI)	Absolute		
										1000 (from 134 fewer to 437 more)		
Proportion of ulcers worsened - general population (population analysed separately and grade of pressure ulcer separately) – grade 3 – Shea classification¹³³												
1	Randomised trial	Very serious ^e	No serious inconsistency	No serious indirectness	Very serious ^g	None	4/11 (36.4 %)	7/17 (41.2%)	RR 0.88 (0.34 to 2.32)	49 fewer per 1000 (from 272 fewer to 544 more)	Very low	Critical
								41.2%		49 fewer per 1000 (from 272 fewer to 544 more)		
Mean percentage reduction in ulcer area – general population – grade 2 and above (grade 2 and 3) – classification method not reported⁴¹												
1	Randomised trial	Very serious ⁱ	No serious inconsistency	No serious indirectness	Serious ^d	None	-9 (SD 102.45)	34 (SD 102.45)	-	MD 43 lower (111.87 lower to 25.87 higher)	Very low	Critical
Mean percentage reduction in ulcer volume – general population – grade 2 and above (grade 3 and 4) – Lowthian classification¹¹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	64 (SD 16)	26 (SD 20)	-	MD 38 higher (28.61 to 47.39 higher)	Low	Critical
Median percentage reduction in ulcer area – people in long-term care – pressure ulcer grade not reported – classification method not reported⁷												
1	Randomised trial	Very serious ^j	No serious inconsistency	No serious indirectness	Very serious ^k	None	85.7 (n=21)	100 (n=29)	-	Not pooled	Very low	Critical
Median percentage reduction in ulcer size - general population – grade 2– Shea classification¹³³												
1	Randomised trial	Very serious ^e	No serious inconsistency	No serious indirectness	Very serious ^k	None	48 (n=34)	91 (n=25)	p>0.05	Not pooled	Very low	Critical
Median percentage reduction in ulcer size - general population – grade 3 – Shea classification¹³³												
1	Randomised	Very	No serious	No serious	Very	None	30	(0.3)	p>0.05	Not pooled	Very low	Critical

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Saline	Hydro-colloid	Relative (95% CI)	Absolute		
	trial	serious ^e	inconsistency	indirectness	serious ^k		(n=11)	(n=17)				
Median days to healing – people in long-term care – grade 2 and 3 – Shea classification²⁰⁹												
1	Randomised trial	Very serious ^c	No serious inconsistency	No serious indirectness	Very serious ^k	None	11 (n=21)	9 (n=18)	p=0.12	Not pooled	Very low	Critical
Healing distribution function – people in long-term care – pressure ulcer grade not reported – classification method not reported⁷												
1	Randomised trial	Very serious ^j	No serious inconsistency	No serious indirectness	Very serious ^l	None	n=21	n=29	p=0.15 (favours hydrocolloid)	Not pooled	Very low	Critical
Proportion of people with pain at dressing removal – general population –grade 2 and 3– classification method not reported⁴¹												
1	Randomised trial	Very serious ⁱ	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/17 (0%)	7/17 (41.2%)	OR 0.09 (0.02 to 0.45)	352 fewer per 1000 (from 172 fewer to 398 fewer)	Low	Important
							-	41.2%		353 fewer per 1000 (from 172 fewer to 398 fewer)		
Median pain score during treatment (scoring system not reported) – general population – grade 3 and 4 – Lowthian classification¹¹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^k	None	2.0 (range: 1-3) (n=15)	2.0 (range: 1-4) (n=17)	-	Not pooled	Very low	Important
Proportion of people with discomfort at dressing removal – general population – grade 2 and 3 – classification method not reported⁴¹												
1	Randomised trial	Very serious ⁱ	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/17 (0%)	9/17 (52.9%)	OR 0.07 (0.02 to 0.32)	456 fewer per 1000 (from 265 fewer to 507 fewer)	Low	Important
							-	52.9%		456 fewer per 1000 (from 265 fewer to 507 fewer)		

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Saline	Hydro-colloid	Relative (95% CI)	Absolute		
										fewer to 507 fewer)		
Median comfort score during treatment (scoring system not reported) – general population – grade 3 and 4 – Lowthian classification¹¹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^k	None	3.0 (range : 2-4) (n=15)	4.0 (range: 3-4) (n=17)	-	Not pooled	Very low	Important
Proportion of people with an infection – general population – grade 2 and 3 – classification method not reported⁴¹												
1	Randomised trial	Very serious ^l	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/17 (0%)	0/17 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Median smell score during treatment (scoring system not reported) – general population – grade 3 and 4 – Lowthian classification¹¹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^k	None	2.0 (range : 1-4) (n=15)	2.0 (range: 1-3) (n=17)	-	Not pooled	Very low	Important
Proportion of people with skin irritation - general population – grade 2 and 3 – Shea classification¹³³												
1	Randomised trial	Very serious ^e	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/50 (0%)	9/50 (18%)	OR 0.11 (0.03 to 0.44)	156 fewer per 1000 (from 92 fewer to 173 fewer)	Very low	Important
							-	18%		156 fewer per 1000 (from 92 fewer to 173 fewer)		
Mortality (all-cause) – general population and people with a spinal cord injury – all grade (1 and above)^{41,81,110,209}												
4	Randomised trials	Very serious ^{a,b,c,i}	No serious inconsistency	No serious indirectness	Very serious imprecision ^g	None	4/80 (5%)	2/80 (2.5%)	RR 1.79 (0.38 to 8.46)	20 more per 1000 (from 16 fewer to 186 more)	Very low	Important

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Saline	Hydro-colloid	Relative (95% CI)	Absolute		
							-	0%	-	20 more per 1000 (from 16 fewer to 186 more)		
Time to complete healing												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) Matzen (1999) did not report or reported insufficient information on sequence generation, allocation concealment and blinding. No log-transformation of data was carried out.
- (b) Hollisaz (2004) only reported blinding of the outcome assessor.
- (c) Xakellis (1992) did not report on sequence generation and blinding.
- (d) The confidence interval crossed 1 MID point.
- (e) Neill (1989) did not report on sequence generation, allocation concealment and blinding. No ITT analysis or log-transformation of data was carried out.
- (f) The study used different populations and there was high heterogeneity (less than 50%) but p-value > 0.1.
- (g) The confidence interval crossed both MID points.
- (h) The study used different populations and there was high heterogeneity (less than 50%) but p-value > 0.1.
- (i) Chang (1998) did not report on sequence generation, allocation concealment or blinding. No log-transformation of data was carried out.
- (j) Alm (1989) did not report on sequence generation; allocation concealment by stratification according to Norton score; only blinding of outcome assessor; no log-transformation of data
- (k) No standard deviation; unknown if sample size was sufficient
- (l) Only p-value reported
- (m) Matzen (1999): Lowthian classification; Xakellis (1992) and Hollisaz (2004): Shea classification
- (n) Limited number of events.

Table 91: Clinical evidence profile: saline-soaked gauze versus hydrogel dressing

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Saline	Hydrogel	Relative (95% CI)	Absolute		
Proportion of people completely healed – general population – grade 2 to 4 – classification method not reported¹⁹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	9/14 (64.3%)	10/16 (62.5%)	RR 1.03 (0.6 to 1.77)	19 more per 1000 (from 250 fewer to 481 more)	Very low	Critical
							-	62.5%		19 more per 1000 (from 250 fewer to 481 more)		
Proportion of people worsened – general population – grade 2 to 4 – classification method not reported¹⁹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	1/19 (5.3%)	1/22 (4.5%)	RR 1.16 (0.08 to 17.28)	7 more per 1000 (from 42 fewer to 740 more)	Very low	Critical
							-	4.6%		7 more per 1000 (from 42 fewer to 749 more)		
Percentage healing rate – general population – grade 2 to 4 – classification method not reported¹⁹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	64 (n=14)	63 (n=16)	-	Not pooled	Very low	Critical
Mean weeks to healing – general population – grade 2 to 4 – classification method not reported¹⁹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	5.2 (SD 2.4)	5.3 (SD 2.3)	-	MD 0.1 lower (1.79 lower to	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Saline	Hydrogel	Relative (95% CI)	Absolute		
										1.59 higher)		
Mortality (all-cause)¹⁹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	2/19 (10.5%)	4/22 (18.2%)	RR 0.58 (0.12 to 2.82)	76 fewer per 1000 (from 160 fewer to 331 more)	Very low	Important
								25%		76 fewer per 1000 (from 160 fewer to 331 more)		
Time to complete healing (time to event data)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size and volume of pressure ulcer												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(c) The authors did not report on sequence generation, allocation concealment or blinding. No log-transformation of data was carried out.

- (d) The confidence interval crossed both MID points.
 (e) No standard deviation; unknown if sample size was sufficient

Table 92: Clinical evidence profile: saline-soaked gauze versus foam dressing

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Saline	Foam	Relative (95% CI)	Absolute		
Proportion of people completely healed – general population – grade 2 or 3 – Enterostomal Therapy and NPUAP classification^{98,148}												
2	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	9/30 (30%)	20/44 (45.5%)	RR 0.64 (0.34 to 1.22)	164 fewer per 1000 (from 300 fewer to 100 more)	Very low	Critical
							-	45.8%		165 fewer per 1000 (from 302 fewer to 101 more)		
Median days to 50% healing – general population – grade 2 – NPUAP classification¹⁴⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	28 (n=16)	28 (n=20)	-	Not pooled	Very low	Critical
Mortality (all-cause)^{98,148}												
2	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	4/30 (13.3%)	3/44 (6.8%)	RR 1.76 (0.49 to 6.34)	52 more per 1000 (from 35 fewer to 364 more)	Very low	Important
							-	7.5%		57 more per 1000 (from 38 fewer to 401 more)		
Time to complete healing (time to event data)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size and volume of pressure ulcers												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Saline	Foam	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size and volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on sequence generation, allocation concealment or blinding.

(b) The confidence interval crossed 1 MID point.

(c) No standard deviation; unknown if sample size was sufficient.

(d) Kraft (1993): Enterostomal Therapy classification; Payne (2009): NPUAP classification.

Table 93: Clinical evidence profile: saline-soaked gauze versus polyurethane dressing

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Saline	Poly-urethane	Relative (95% CI)	Absolute		
Proportion of ulcers completely healed – general population – grade 1 and 2 – Ernis and Sarmiento classification¹⁴⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	0/10 (0%)	1/9 (11.1%)	OR 0.12 (0 to 6.14)	96 fewer per 1000 (from 111)	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Saline	Poly-urethane	Relative (95% CI)	Absolute		
							-	11.1%		fewer to 323 more) 96 fewer per 1000 (from 111 fewer to 323 more)		
Proportion of ulcers worsened – general population – grade 1 and 2 – Ernis and Sarmiento classification¹⁴⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/10 (20%)	1/9 (11.1%)	RR 1.8 (0.19 to 16.66)	89 more per 1000 (from 90 fewer to 1000 more)	Very low	Critical
							-	11.1%		89 more per 1000 (from 90 fewer to 1000 more)		
Mean percentage reduction in ulcer area – general population – grade 1 and 2 – Ernis and Sarmiento classification¹⁴⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	2.5 (n=10)	42.9 (n=9)	-	Not pooled	Very low	Critical
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Saline	Poly-urethane	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on sequence generation, allocation concealment and blinding; no log-transformation

(b) The confidence interval crossed both MID points

(c) The authors did not report standard deviation. It was unknown if sample size was sufficient

Table 94: Clinical evidence profile: saline-soaked gauze versus dextranomer

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Saline	Dextranomer	Relative (95% CI)	Absolute		
Proportion of ulcers improved – people with a spinal cord injury - grade 2 to 4 – Eltota classification¹⁰⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	2/15 (13.3%)	11/15 (73.3%)	RR 0.18 (0.05 to 0.68)	601 fewer per 1000 (from 235 fewer to 697 fewer)	Low	Critical
							-	73.3%		601 fewer per 1000 (from 235 fewer to 696 fewer)		
Proportion of people with adverse events – people with a spinal cord injury - grade 2 to 4 – Eltota classification¹⁰⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/15 (0%)	0/15 (0%)	Not pooled	Not pooled	Low	Important
								0%		Not pooled		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Saline	Dextranomer	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on sequence generation, allocation concealment or blinding.

Table 95: Clinical evidence profile: phenytoin versus hydrocolloid dressing

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Phenytoin	Hydrocolloid	Relative (95% CI)	Absolute		
Proportion of people completely healed – people with a spinal cord injury – grade 1 and 2 pressure ulcers – NPUAP classification⁸¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	11/28 (39.3%)	20/28 (71.4%)	RR 0.55 (0.33 to 0.92)	321 fewer per 1000 (from 57 fewer to 479 fewer)	Low	Critical
							-	71.4%		321 fewer per 1000		

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Phenytoin	Hydrocolloid	Relative (95% CI)	Absolute		
										(from 57 fewer to 478 fewer)		
Proportion of ulcers completely healed (all sites) – people with a spinal cord injury – grade 1 and 2 pressure ulcers – NPUAP classification⁸¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	12/30 (40%)	23/31 (74.2%)	RR 0.54 (0.33 to 0.88)	341 fewer per 1000 (from 89 fewer to 497 fewer)	Low	Critical
							-	74.2%		341 fewer per 1000 (from 89 fewer to 497 fewer)		
Proportion of ulcers completely healed (all sites) – people with a spinal cord injury - grade 1 – NPUAP classification⁸¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	2/9 (22.2%)	11/13 (84.6%)	RR 0.26 (0.08 to 0.91)	626 fewer per 1000 (from 76 fewer to 778 fewer)	Low	Critical
								84.6%		626 fewer per 1000 (from 76 fewer to 778 fewer)		
Proportion of ulcers completely healed (all sites) – people with a spinal cord injury – grade 2 – NPUAP classification⁸¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	10/21 (47.6%)	12/18 (66.7%)	RR 0.71 (0.41 to 1.24)	193 fewer per 1000 (from 393 fewer to 160 more)	Low	Critical

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Phenytoin	Hydrocolloid	Relative (95% CI)	Absolute		
							-	66.7%		193 fewer per 1000 (from 394 fewer to 160 more)		
Proportion of ulcers completely healed (sacral) – people with a spinal cord injury – grade 1 and 2 pressure ulcers – NPUAP classification⁸¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	4/8 (50%)	4/7 (57.1%)	RR 0.88 (0.34 to 2.25)	69 fewer per 1000 (from 377 fewer to 714 more)	Very low	Critical
							-	57.1%		69 fewer per 1000 (from 377 fewer to 714 more)		
Proportion of ulcers improved – people with a spinal cord injury – grade 1 and 2 pressure ulcers – NPUAP classification⁸¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	16/30 (53.3%)	27/31 (87.1%)	RR 0.61 (0.43 to 0.88)	340 fewer per 1000 (from 105 fewer to 496 fewer)	Low	Critical
							-	87.1%		340 fewer per 1000 (from 105 fewer to 496 fewer)		
Proportion of ulcers worsened– people with a spinal cord injury – grade 1 and 2 pressure ulcers– NPUAP classification⁸¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	2/30 (6.7%)	2/31 (6.5%)	RR 1.03 (0.16 to 6.87)	2 more per 1000 (from 54 fewer to 379 more)	Very low	Critical

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Phenytoin	Hydrocolloid	Relative (95% CI)	Absolute		
							-	6.5%		2 more per 1000 (from 55 fewer to 382 more)		
Mean days to healing -- people in a nursing home -- grade 2 pressure ulcers - (AHCPR classification)¹⁵⁵												
1	Randomised trial	Very serious ^d	No serious inconsistency	No serious indirectness	Serious ^b	None	35.3 (SD 14.3)	51.8 (SD 19.6)	-	MD 16.5 lower (29.38 to 3.62 lower)	Very low	Critical
Proportion of people with pain -- people in a nursing home -- grade 2 pressure ulcers - AHCPR classification¹⁵⁵												
1	Randomised trial	Very serious ^d	No serious inconsistency	No serious indirectness	Very serious ^e	None	-	-	Minimal pain was reported in both groups	Not pooled	Very low	Important
							-	0%				
Proportion of people with treatment related adverse events -- people in a nursing home - grade 2 pressure ulcers -AHCPR classification¹⁵⁵												
1	Randomised trial	Very serious ^d	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/15 (0%)	0/13 (0%)	Not pooled	Not pooled	Low	Important
							-	0%				
Mortality (all-cause)^{81,155}												
2	Randomised trials	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	2/46 (4.3%)	2/44 (4.5%)	RR 0.89 (0.14 to 5.6)	5 fewer per 1000 (from 39 fewer to 209 more)	Very low	Important
							-	6.3%				
Time to complete healing of pressure ulcers (time to event data)												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Phenytoin	Hydrocolloid	Relative (95% CI)	Absolute		
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No blinding of participants or nurses was reported.

(b) The confidence interval crossed 1 MID point.

(c) The confidence interval crossed both MID points.

(d) The authors did not report on allocation concealment, sequence generation or blinding. There was no ITT analysis.

(e) No figures reported, no p-value.

Table 96: Clinical evidence profile: phenytoin versus triple antibiotics

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Phenytoin	Triple antibiotics	Relative (95% CI)	Absolute		
Mean days to healing – people in a nursing home – grade 2 pressure ulcers - AHCPR classification¹⁵⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	35.3 (SD 14.3)	53.8 (SD 8.5)	-	MD 18.5 lower (27.31 to 9.69 lower)	Low	Critical
Proportion of people with pain – people in a nursing home – grade 2 pressure ulcers - AHCPR classification¹⁵⁵												
1	Randomised	Very	No serious	No serious	Very serious ^b	None	-	-	Minimal	Not pooled	Very	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Phenytoin	Triple antibiotics	Relative (95% CI)	Absolute		
	trial	serious ^a	inconsistency	indirectness			-	0%	pain was reported in both groups	Not pooled	low	
Proportion of people with treatment related adverse events – people in a nursing home – grade 2 pressure ulcers - AHCPR classification ¹⁵⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/15 (0%)	0/11 (0%)	Not pooled	Not pooled	Low	Important
								0%		Not pooled		
Mortality (all-cause) ¹⁵⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/16 (12.5%)	1/13 (7.7%)	RR 1.63 (0.17 to 15.99)	48 more per 1000 (from 64 fewer to 1000 more)	Very low	Important
							-	7.7%	-	48 more per 1000 (from 64 fewer to 1000 more)		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing (time to event data)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Phenytoin	Triple antibiotics	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on allocation concealment, sequence generation or blinding. There was no ITT analysis

(b) No figures reported; no p-value

Table 97: Clinical evidence profile: aloe vera, silver chloride and decyl glucoside versus isotonic saline

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Aloe vera	Saline	Relative (95% CI)	Absolute		
Mean percentage reduction in PSST – elderly adults – grade 2 to 4 – NPUAP classification²³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	22.7 (SD 31.3) (n=?)	20.5 (SD 24.1) (n=?)	-	Not pooled	Very low	Critical
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Aloe vera	Saline	Relative (95% CI)	Absolute		
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on allocation concealment, sequence generation or blinding. There was no ITT analysis

(b) No figures reported; no p-value

Table 98: Clinical evidence profile: dialysate versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Dialysate	Placebo	Relative (95% CI)	Absolute		
Mean ml reduction in ulcer area - people with a spinal cord injury – pressure ulcer grade not reported – classification method not reported⁹⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	13.4 (SD 10.02)	6.57 (SD 4.88)	-	MD 6.83 higher (3.54 lower to 17.2 higher)	Very low	Critical
Mean percentage reduction in ulcer area at day 10 - people with a spinal cord injury – pressure ulcer grade not reported – classification method not reported⁹⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	39 (n=5)	28 (n=3)	-	Not pooled	Very low	Critical
Mean percentage reduction in ulcer area at day 20 - people with a spinal cord injury – pressure ulcer grade not reported – classification method not reported⁹⁵												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Dialysate	Placebo	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	80 (n=5)	59 (n=3)	-	Not pooled	Very low	Critical
Mean healing half-time (days) people with a spinal cord injury – pressure ulcer grade not reported – classification method not reported⁹⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	8.52 (2.36)	24 (SD 18.43)	-	MD 15.48 lower (36.44 lower to 5.48 higher)	Very low	Critical
Proportion of people with treatment related adverse events people with a spinal cord injury – pressure ulcer grade not reported – classification method not reported⁹⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/5 (0%)	0/3 (0%)	Not pooled	Not pooled	Low	Important
								0%		Not pooled		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Dialysate	Placebo	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on allocation concealment and sequence generation; double-blinded, but no further information. There was no ITT analysis or log-transformation of data.

(b) Confidence interval crossed 1 MID point

Table 99: Clinical evidence profile: petrolatum ointment versus petrolatum (base component)

Quality assessment							No of ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Topical ointment with petrolatum	Petrolatum (base component)	Relative (95% CI)	Absolute		
Proportion of ulcers completely healed – elderly adult – grade 1 and 2 – AHCPR classification¹⁰⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	5/10 (50%)	2/9 (22.2%)	RR 2.25 (0.57 to 8.86)	358 more per 1000 (from 29 fewer to 751 more)	Very low	Critical
							-	16.7%		269 more per 1000 (from 22 fewer to 564 more)		
Proportion of ulcers completely healed - grade 2– elderly adults – AHCPR classification¹⁰⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	1/5 (20%)	0/3 (0%)	OR 4.95 (0.09 to 283.86)	200 more (from 270 fewer to 670 more)	Very low	Critical

Quality assessment							No of ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Topical ointment with petrolatum	Petrolatum (base component)	Relative (95% CI)	Absolute		
							-	0%		more) 200 more (from 270 fewer to 670 more)		
Proportion of ulcers improved – elderly adults – grade 1 and 2 – AHCPR classification¹⁰⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	4/10 (40%)	0/9 (0%)	OR 9.78 (1.14 to 83.93)	400 more (from 80 more to 720 more)	Very low	Critical
							-	0%		400 more (from 80 more to 720 more)		
Proportion of ulcers improved - Grade 2– elderly adults – AHCPR classification¹⁰⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	3/5 (60%)	0/3 (0%)	OR 9.39 (0.59 to 149.25)	600 more (from 90 fewer to 1110 more)	Very low	Critical
							-	0%		600 more (from 90 fewer to 1110 more)		

Quality assessment							No of ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Topical ointment with petrolatum	Petrolatum (base component)	Relative (95% CI)	Absolute		
Proportion of ulcers worsened - grade 1 and 2 – elderly adults – AHCPR classification¹⁰⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Vno serious	None	0/5 (0%)	3/6 (50%)	OR 0.05 (0.01 to 0.35)	670 fewer (from 990 fewer to 350 fewer)	Low	Critical
							-	50%		670 fewer (from 990 fewer to 350 fewer)		
Proportion of ulcers worsened - grade 2 – elderly adults– AHCPR classification¹⁰⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/5 (0%)	3/3 (100%)	OR 0.02 (0 to 0.38)	1000 fewer per 1000 (from 1390 fewer to 610 fewer)	Low	Critical
							-	100%		1000 fewer per 1000 (from 1390 fewer to		

Quality assessment							No of ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Topical ointment with petrolatum	Petrolatum (base component)	Relative (95% CI)	Absolute		
										610 fewer)		
Mortality (all-cause) ¹⁰⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/10 (0%)	0/9 (0%) 0%	Not pooled -	Not pooled Not pooled	Low	Important
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) There was insufficient information on sequence generation and there was no report on allocation concealment or blinding of outcome assessors.

(b) The confidence interval crossed both MID points.

(c) The confidence interval crossed 1 MID point. Very wide confidence interval.

Table 100: Clinical evidence profile: zinc oxide versus streptokinase-streptodornase^d

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Zinc oxide	Streptokinase-streptodornase	Relative (95% CI)	Absolute		
Median percentage reduction in ulcer area – elderly adults – necrotic pressure ulcer - classification method not reported⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	24 (n=14)	-18.7 (n=14)	-	Not pooled	Very low	Critical
Proportion of people with an infection – elderly adults – necrotic pressure ulcer - classification method not reported⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/14 (0%)	1/14 (7.1%)	OR 0.14 (0 to 6.82)	61 fewer per 1000 (from 71 fewer to 273 more)	Very low	Critical
							-	7.1%		60 fewer per 1000 (from 71 fewer to 272 more)		
Proportion of people with skin reaction – elderly adults – necrotic pressure ulcer - classification method not reported⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/14 (0%)	1/14 (7.1%)	OR 0.14 (0 to 6.82)	61 fewer per 1000 (from 71 fewer to 273 more)	Very low	Important
							-	7.1%		60 fewer per 1000 (from 71 fewer to 272 more)		
Mortality (all-cause)⁴												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Zinc oxide	Streptokinase-streptodornase	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None	0/14 (0%)	0/14 (0%)	Not pooled	Not pooled	Low	Important
							-	0%	-	Not pooled		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Sequence generation was carried out by matched pairs. The authors did not report on allocation concealment and no blinding of participant or nurses. There was no log-transformation of data.

(b) No standard deviation reported. There was a small sample size.

(c) The confidence interval crossed both MID points.

(d) This comparison was also included in debridement review, see Chapter X.

Table 101: Clinical evidence profile: oxyquinoline versus vitamin A&D treatment (cream)

Quality assessment							No of ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Oxyquinoline	A&D treatment	Relative (95% CI)	Absolute		
Proportion of ulcers completely healed (all grades) – people in palliative care – grade 1 and 2 pressure ulcers – NPUAP classification⁶⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	43/86 (50%)	21/51 (41.2%)	RR 1.21 (0.82 to 1.79)	86 more per 1000 (from 74 fewer to 325 more)	Very low	Critical
							-	41.2%		87 more per 1000 (from 74 fewer to 325 more)		
Proportion of ulcers completely healed – people in palliative care – grade 2 pressure ulcers – NPUAP classification⁶⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	20/45 (44.4%)	5/23 (21.7%)	RR 2.04 (0.88 to 4.74)	226 more per 1000 (from 26 fewer to 813 more)	Very low	Critical
							-	21.7%		226 more per 1000 (from 26 fewer to 812 more)		
Proportion of ulcers improved after 15 days – people in palliative care – grade 1 pressure ulcers – NPUAP classification⁶⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	15/41 (36.6%)	6/28 (21.4%)	RR 1.71 (0.76 to	152 more per 1000	Very low	Critical

Quality assessment							No of ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Oxyquinoline	A&D treatment	Relative (95% CI)	Absolute		
									3.86)	(from 51 fewer to 613 more)		
							-	21.4%		152 more per 1000 (from 51 fewer to 612 more)		
Proportion of ulcers improved after 22 days– people in palliative care – grade 2 pressure ulcers – NPUAP classification⁶⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	19/45 (42.2%)	8/23 (34.8%)	RR 1.21 (0.63 to 2.34)	73 more per 1000 (from 129 fewer to 466 more)	Very low	Critical
							-	34.8%		73 more per 1000 (from 129 fewer to 466 more)		
Proportion of ulcers not changed on day 15– people in palliative care – grade 1 pressure ulcers – NPUAP classification⁶⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	4/41 (9.8%)	4/28 (14.3%)	RR 0.68 (0.19 to 2.51)	46 fewer per 1000 (from 116 fewer to 216 more)	Very low	Critical
							-	14.3%		46 fewer		

Quality assessment							No of ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Oxyquinoline	A&D treatment	Relative (95% CI)	Absolute		
										per 1000 (from 116 fewer to 216 more)		
Proportion of ulcers not changed on day 22– people in palliative care – grade 2 pressure ulcers – NPUAP classification⁶⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	5/45 (11.1%)	7/23 (30.4%)	RR 0.37 (0.13 to 1.02)	192 fewer per 1000 (from 265 fewer to 6 more)	Very low	Critical
								30.4%		192 fewer per 1000 (from 264 fewer to 6 more)		
Proportion of ulcers worsened on day 15– people in palliative care – grade 1 pressure ulcers – NPUAP classification⁶⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/41 (0%)	2/28 (7.1%)	OR 0.08 (0 to 1.41)	65 fewer per 1000 (from 71 fewer to 26 more)	Very low	Critical
							-	7.1%		65 fewer per 1000 (from 71 fewer to 26 more)		
Proportion of ulcers worsened on day 22– people in palliative care – grade 2 pressure ulcers – NPUAP classification⁶⁸												

Quality assessment							No of ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Oxyquinoline	A&D treatment	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	1/45 (2.2%)	3/23 (13%)	RR 0.17 (0.02 to 1.55)	108 fewer per 1000 (from 128 fewer to 72 more)	Very low	Critical
							-	13%		108 fewer per 1000 (from 127 fewer to 71 more)		
Mean days to complete healing– people in palliative care – grade 1 and 2 pressure ulcers – NPUAP classification⁶⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	7.23 (SD 4.15)	8.62 (SD 5.16)	-	MD 1.39 lower (3.06 lower to 0.28 higher)	Very low	Critical
Mean days to complete healing– people in palliative care – grade 1 pressure ulcers – NPUAP classification⁶⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	6.75 (SD 3.9)	7.25 (SD 4.8)	-	MD 0.5 lower (2.64 lower to 1.64 higher)	Very low	Critical
Mean days to complete healing– people in palliative care – grade 2 pressure ulcers – NPUAP classification⁶⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	7.8 (SD 4.47)	13 (SD 3.94)	-	MD 5.2 lower (7.27 lower to 3.13)	Low	Critical

Quality assessment							No of ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Oxyquinoline	A&D treatment	Relative (95% CI)	Absolute (lower)		
Time to complete healing (time to event data)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on allocation concealment. Only blinding of outcome assessor was conducted.

(b) The confidence interval crossed 1 MID point.

(c) The confidence interval crossed both MID points.

Table 102: Clinical evidence profile: ethoxy-diaminoacridine plus nitrofuazone versus honey

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Ethoxy-diaminoacridine plus nitrofuazone	Honey	Relative (95% CI)	Absolute		
Proportion of ulcers completely healed – general population – grade 2 and 3 pressure ulcers – AHCPR classification⁷⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/25 (0%)	5/25 (33.3%)	OR 0.11 (0.02 to 0.71)	173 fewer per 1000 (from 49 fewer to 195 fewer)	Low	Critical
							-	33.3%		272 fewer per 1000 (from 28 fewer to 323 fewer)		
Mean percentage reduction in PUSH score – general population – grade 2 and 3 pressure ulcers – AHCPR classification⁷⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	12.9 (SD 28.92)	56.3 (SD 28.92)	-	MD 43.4 lower (59.43 to 27.37 lower)	Low	Critical
Mean percentage reduction in ulcer size – general population – grade 2 and 3 pressure ulcers – AHCPR classification⁷⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	13 (SD 29.39)	56 (SD 29.39)	-	MD 43 lower (59.29 to 26.71 lower)	Low	Critical
Proportion of people with treatment related adverse events – general population grade 2 and 3 pressure ulcers – AHCPR classification⁷⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/11 (0%)	0/15 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Mortality (all-cause)⁷⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	1/12 (8.3%)	0/15 (0%)	OR 9.49 (0.18 to	80 more per 1000 (from	Low	Important

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Ethoxy-diaminoacridine plus nitrofuazone	Honey	Relative (95% CI)	Absolute		
							-	0%	489.97)	110 fewer to 280 more)		
										80 more per 1000 (from 110 fewer to 280 more)		
Time to complete healing												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on allocation concealment, sequence generation or blinding. There was no ITT analysis or log-transformation of data.

Table 103: Clinical evidence profile: povidone-iodine versus hydrocolloid

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Povidone-iodine	Hydrocolloid	Relative (95% CI)	Absolute		
Proportion of people completely healed – general population – grade 1 and 2 pressure ulcers – NPUAP classification⁹³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	14/18 (77.8%)	21/26 (80.8%)	RR 0.96 (0.71 to 1.31)	32 fewer per 1000 (from 234 fewer to 250 more)	Very low	Critical
							-	80.8%		32 fewer per 1000 (from 234 fewer to 250 more)		
Percentage rate of healing – general population – grade 1 and 2 pressure ulcers – NPUAP classification⁹³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	77.8 (n=18)	80.8 (n=26)	-	Not pooled	Very low	Critical
Mean speed of healing (mm²/day) – general population – grade 1 and 2 pressure ulcers – NPUAP classification⁹³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^d	None	7.9 (SD 4.7)	9.1 (SD 5.4)	-	MD 1.2 lower (4.2 lower to 1.8 higher)	Very low	Critical
Proportion of people with hypergranulation – general population – grade 1 and 2 pressure ulcers – NPUAP classification⁹³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	0/18 (0%)	3/26 (11.5%)	OR 0.17 (0.02 to 1.79)	94 fewer per 1000 (from 113 fewer to 74 more)	Very low	Important
								11.5%		93 fewer per 1000 (from 112 fewer to 74 more)		
Mortality (all-cause)⁹³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None	0/18 (0%)	0/26 (0%)	Not pooled	Not pooled	Low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Povidone-iodine	Hydrocolloid	Relative (95% CI)	Absolute		
								0%		Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on allocation concealment, sequence generation or blinding. There was no log-transformation of data.

(b) The confidence interval crossed both MID points.

(c) No standard deviation reported; unclear if sample size was sufficient

(d) The confidence interval crossed 1 MID point.

Table 104: Clinical evidence profile: povidone-iodine versus hydrogel dressing

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Povidone-iodine	Hydrogel	Relative (95% CI)	Absolute		
Mean cm²/day to healing – people with a spinal cord injury – grade 1 to 3 – NPUAP classification⁸⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	0.09 (SD 0.05)	0.12 (SD 0.16)	-	MD 0.03 lower (0.1 lower to	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Povidone-iodine	Hydrogel	Relative (95% CI)	Absolute (0.04 higher)		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on allocation concealment, sequence generation or blinding. There was no ITT analysis or log-transformation of data.

(b) Confidence interval crossed 1 MID point

Table 105: Clinical evidence profile: cadexomer iodine versus standard treatment

Quality assessment							No of ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Cadexomer iodine	Standard treatment	Relative (95% CI)	Absolute		
Proportion of ulcers reduced with 50% - general population – superficial or deep pressure ulcer – classification method not reported¹¹⁹												
1	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	8/16 (50%)	1/18 (5.6%)	RR 9 (1.26 to 64.33)	444 more per 1000 (from 14 more to 1000 more)	Low	Critical
							-	5.6%		448 more per 1000 (from 15 more to 1000 more)		
Mean cm² reduction in ulcer area - general population – superficial or deep pressure ulcer – classification method not reported¹¹⁹												
1	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	2.9 (SD 5.2)	2.5 (SD 4.67)	-	MD 0.4 higher (2.94 lower to 3.74 higher)	Low	Critical
Mean percentage reduction in ulcer area - general population – superficial or deep pressure ulcer – classification method not reported¹¹⁹												
1	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	30.9 (SD 46)	19.6 (SD 83.16)	-	MD 11.3 higher (33.24 lower to 55.84 higher)	Low	Critical
Mortality (all-cause)¹¹⁹												
1	Randomised	Very	No serious	No serious	No serious	None	0/19	0/19	Not	Not	Low	Important

Quality assessment							No of ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Cadexomer iodine	Standard treatment	Relative (95% CI)	Absolute		
	trials	serious ^a	inconsistency	indirectness	imprecision		(0%)	(0%)	pooled	pooled		
							-	0%		Not pooled		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on allocation concealment or blinding. No ITT analysis or log-transformation of data was carried out.

Table 106: Clinical evidence profile: silver sulfazidine cream versus silver dressing

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Silver sulfazidine	Silver dressing	Relative (95% CI)	Absolute		
Mean percentage reduction in ulcer area – in- and outpatients – grade 4 – NPUAP classification⁴³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	25.06 (SD 56.13)	36.95 (SD 56.13)	-	MD 11.89 lower (46.68 lower to 22.9 higher)	Very low	Critical
Percentage reduction in PUSH score – in- and outpatients – grade 4 – NPUAP classification⁴³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	34.51 (n=20)	28.15 (SD 20)	p=0.473	Not pooled	Very low	Critical
Proportion of people with adverse events – in- and outpatients – grade 4 – NPUAP classification⁴³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/20 (0%)	0/20 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Mortality (all-cause)⁴³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/17 (0%)	0/17 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Silver sulfazidine	Silver dressing	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on sequence generation, allocation concealment or blinding. There was no log-transformation of data.

(b) The confidence interval crossed both MID points.

(c) No standard deviation; unknown if sample size was sufficient

Table 107: Clinical evidence profile: resin salve versus hydrofibre

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Resin salve	Hydrofibre	Relative (95% CI)	Absolute		
Proportion of people completely healed – general population – grade 2 to 4 pressure ulcers – NPUAP classification¹⁷⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	12/13 (92.3%)	4/9 (44.4%)	RR 2.08 (0.98 to 4.38)	480 more per 1000 (from 9 fewer to 1000 more)	Very low	Critical
								44.4%		480 more per 1000 (from 9 fewer to 1000 more)		

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Resin salve	Hydrofibre	Relative (95% CI)	Absolute		
Proportion of ulcers completely healed – general population – grade 2 to 4 pressure ulcers – NPUAP classification¹⁷⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	17/18 (94.4%)	4/11 (36.4%)	RR 2.6 (1.18 to 5.72)	582 more per 1000 (from 65 more to 1000 more)	Very low	Critical
								36.4%		582 more per 1000 (from 66 more to 1000 more)		
Proportion of ulcers improved – general population – grade 2 to 4 pressure ulcers – NPUAP classification¹⁷⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	18/18 (100%)	10/11 (90.9%)	RR 1.11 (0.89 to 1.4)	100 more per 1000 (from 100 fewer to 364 more)	Very low	Critical
								90.9%		100 more per 1000 (from 100 fewer to 364 more)		
Proportion of ulcers worsened – general population – grade 2 to 4 pressure ulcers – NPUAP classification¹⁷⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/18 (0%)	1/11 (9.1%)	OR 0.07 (0.00 to	84 fewer per 1000 (from 91	Very low	Critical

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Resin salve	Hydrofibre	Relative (95% CI)	Absolute		
									4.07)	fewer to 198 more)		
								9.1%		84 fewer per 1000 (from 91 fewer to 198 more)		
Mean percentage reduction in ulcer width – general population – grade 2 to 4 pressure ulcers – NPUAP classification¹⁷⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	93.75 (n=18)	57.14 (n=11)	-	Not pooled	Very low	Critical
Mean percentage reduction in ulcer depth – general population – grade 2 to 4 pressure ulcers – NPUAP classification¹⁷⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	88.46 (n=18)	-1.89 (n=11)	-	Not pooled	Very low	Critical
Speed of healing (days) – general population – grade 2 to 4 pressure ulcers – NPUAP classification¹⁷⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^e	None	(n=18)	(n=11)	p=0.013 (log-rank-test) (favour resin salve)	Not pooled	Very low	Critical
Proportion of people with allergic skin reactions – general population – grade 2 to 4 pressure ulcers – NPUAP classification¹⁷⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	1/21 (4.8%)	0/16 (0%)	OR 5.82 (0.11 to 304.33)	50 more (from 80 fewer to 180 more)	Very low	Important
								0%		50 more		

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Resin salve	Hydrofibre	Relative (95% CI)	Absolute (from 80 fewer to 180 more)		
Mortality (all-cause) ¹⁷⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	3/21 (14.3%)	4/16 (25%)	RR 0.57 (0.15 to 2.2)	108 fewer per 1000 (from 213 fewer to 300 more)	Very low	Important
								25%		108 fewer per 1000 (from 213 fewer to 300 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Resin salve	Hydrofibre	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report blinding. There was no ITT analysis or log-transformation of data.

(b) Confidence interval crossed 1 MID point.

(c) Confidence interval crossed both MID points.

(d) No standard deviation reported; small sample size.

(e) Only p-value reported.

Table 108: Clinical evidence profile: antibiotic ointment versus foam dressing

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Antibiotic	Foam dressing	Relative (95% CI)	Absolute		
Proportion of people completely healed – institutionalised elderly adults – grade 2 pressure ulcers – NPUAP classification ²¹¹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	15/23 (65.2%)	18/21 (85.7%)	RR 0.76 (0.54 to 1.08)	206 fewer per 1000 (from 394 fewer to 69 more)	Very low	Critical
							-	85.7%		206 fewer per 1000 (from 394 fewer to 69 more)		
Mean PUSH score at end of treatment – institutionalised elderly adults – grade 2 pressure ulcers – NPUAP classification ²¹¹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	1.61 (n=19)	3.24 (n=23)	p>0.05	Not pooled	Very low	Critical
Time to complete healing of pressure ulcers												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Antibiotic	Foam dressing	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on sequence generation, allocation concealment or blinding.

(b) Confidence interval crossed 1 MID point.

(c) No standard deviation; unknown if sample size was sufficient.

Table 109: Clinical evidence profile: insulin versus standard treatment

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Insulin	Placebo	Relative (95% CI)	Absolute		
Mean rate of healing – people in a nursing home – grade not reported – pressure ulcer definition was reported^{c200}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	n=6	n=8	p=0.05 (favour insulin group)	Not pooled	Very low	Critical
Mortality (all-cause)²⁰⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None	0/6 (0%)	0/6 (0%)	Not pooled	Not pooled	Low	Important
								0%	Not pooled			
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on allocation concealment and blinding.

(b) Only p-value reported.

(c) Pressure ulcers were defined as a break in skin continuity as evidenced by epidermal or dermal injury involving erythema, pallor, cyanosis, and superficial erosion.

Table 110: Clinical evidence profile: different growth factors versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Growth factors	Placebo	Relative (95% CI)	Absolute		
Proportion of people completely healed – general population and denervated adults – grade 2 and above – NPUAP and Yarkony classification ^{i79,101,128,147,153,156,159}												
6	Randomised trials	Very serious ^a	Very serious ^b	No serious indirectness	Very serious ^d	None	54/222 (24.3%)	12/94 (12.8%)	RR 2.33 (0.54 to 10.02)	170 more per 1000 (from 59 more to 1000 more)	Very low	Critical
							-	0%		170 more per 1000 (from 59 more to 1000 more)		
Proportion of people completely healed - TGF-β3j versus placebo – inpatients – grade 3 and 4 – NPUAP classification ⁷⁹												
1	Randomised trial	Very serious ^c	No serious inconsistency	No serious indirectness	Very serious ^d	None	1/9 (11.1%)	0/5 (0%)	OR 4.74 (0.08 to 283.15)	200 fewer per 1000 (from 200 fewer to 420 more)	Very low	Critical
							-	0%		200 fewer per 1000 (from 200 fewer to 200 fewer)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Growth factors	Placebo	Relative (95% CI)	Absolute		
										fewer to 420 more)		
Proportion of people completely healed (foot ulcers) - mNGF j versus placebo – people in a nursing home– grade 2 and above - Yarkony classification¹⁰¹												
1	Randomised trial	Serious ^e	No serious inconsistency	No serious indirectness	No serious imprecision	None	8/18 (44.4%)	1/18 (5.6%)	RR 8.00 (1.11 to 57.57)	389 more per 1000 (from 6 more to 1000 more)	Moderate	Critical
							-	5.6%		392 more per 1000 (from 6 more to 1000 more)		
Proportion of people completely healed - rPDGF-BB j versus placebo – general population and denervated people – grade 3 and 4 – NPUAP classification^{128,153,159}												
3	Randomised trials	Very serious ^f	No serious inconsistency	No serious indirectness	Very serious ^d	None	18/136 (13.2%)	1/52 (1.9%)	RR 2.55 (0.56 to 11.65)	30 more per 1000 (from 8 more to 205 more)	Very low	Critical
								0%		30 more per 1000 (from 8 more to 205 more)		
Proportion of people completely healed - bFGF or GM-CSF j versus placebo – inpatients – grade 3 and 4 – classification system not reported¹⁴⁷												
1	Randomised	Very	No serious	No serious	Very	None	27/41	10/13	RR 0.86 (0.59 to	108 fewer	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Growth factors	Placebo	Relative (95% CI)	Absolute		
	trial	serious ^g	inconsistency	indirectness	serious ^d		(65.9%)	(76.9%)	1.24)	per 1000 (from 315 fewer to 185 more)		
							-	76.9%		108 fewer per 1000 (from 315 fewer to 185 more)		
Proportion of people completely healed - rIL-1β j versus placebo – denervated people – grade 3 and 4 – classification system not reported¹⁵⁶												
1	Randomised trial	Very serious ^h	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/18 (0%)	0/6 (0%)	not pooled	not pooled	Low	Critical
							-	0%		not pooled		
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Growth factors	Placebo	Relative (95% CI)	Absolute		
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) Hirshberg (2003): no report on sequence generation and allocation concealment and report of blinding, but no further information; Landi (2003): allocation according to age, group, sex and ulcer area and blinding of nurses and outcome assessor, but no blinding of participants; Mustoe (1994), Payne (2001) and Robson (1994): no report on sequence generation, allocation concealment and report of double blinding, but no further information; Rees (1999): no report on sequence generation, allocation concealment and blinding; Robson (1992b): no report on sequence generation, unequal allocation and only blinding of outcome assessor
- (b) Heterogeneity: p -value < 0.1 and I^2 > 50%
- (c) Hirshberg (2003): no report on sequence generation and allocation concealment and report of blinding, but no further information
- (d) Confidence interval crossed both MID points
- (e) Landi (2003): allocation according to age, group, sex and ulcer area and blinding of nurses and outcome assessor, but no blinding of participant
- (f) No explanation was provided
- (g) Payne (2001): no report on sequence generation, allocation concealment and report of double blinding, but no further information
- (h) Robson (1994): no report on sequence generation, allocation concealment and report of double blinding, but no further information
- (i) Hirshberg (2003) and Rees (1999): NPUAP classification; Landi (2003): Yarkony classification; Mustoe (1994), Robson (1992b and 1994), and Payne (2001): classification system not reported
- (j) TGF- μ 3: topical growth factor; mNGF: S murine nerve growth factor; rPDGF-BB: recombinant platelet-derived growth factor –BB; bFGF: basic fibroblast growth factor; GM-CSF: granulocyte-macrophage/colony-stimulating factor; rIL-1 α : rhu- interleukin

Table 111: Clinical evidence profile: topical growth factor – beta 3 (1.0µg/cm²) versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	TGF-β3 (1.0µg/cm ²)	Placebo	Relative (95% CI)	Absolute		
Proportion of people completely healed – inpatients – grade 3 and 4 – NPUAP classification⁷⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/4 (0%)	0/5 (0%)	Not pooled	Not pooled	Low	Critical
							-	0%		Not pooled		
Mean percentage reduction in ulcer area – inpatients – grade 3 and 4 – NPUAP classification⁷⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	70 (n=4)	30 (n=5)	-	Not pooled	Very low	Critical
Mean percentage reduction in ulcer volume – inpatients – grade 3 and 4 – NPUAP classification⁷⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	75 (n=4)	20 (n=5)	-	Not pooled	Very low	Critical
Mortality (all-cause)⁷⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^{c,d}	None	1/4 (25%)	0/5 (0%)	OR 9.49 (0.18 to 489.97)	250 more per 1000 (from 210 fewer to 710 more)	Very low	Important
							-	0%		250 more per 1000 (from 210 fewer to 710 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	TGF-β3 (1.0µg/cm ²)	Placebo	Relative (95% CI)	Absolute		
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) Hirshberg (2003): no report on sequence generation and allocation concealment and report of blinding, but no further information; no log-transformation of data
- (b) No standard deviation; small sample size
- (c) Confidence interval crossed both MID points
- (d) Limited number of events.

Table 112: Clinical evidence profile: topical growth factor – beta 3 (1.0µg/cm²) versus topical growth factor – beta 3 (2.5µg/cm²)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	TGF-β3 (1.0µg/cm ²)	TGF-β3 (2.5µg/cm ²)	Relative (95% CI)	Absolute		
Proportion of people completely healed – inpatients – grade 3 and 4 – NPUAP classification⁷⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	0/4 (0%)	1/5 (20%)	OR 0.17 (0 to 8.54)	159 fewer per 1000 (from 200 fewer to	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	TGF-β3 (1.0µg/cm ²)	TGF-β3 (2.5µg/cm ²)	Relative (95% CI)	Absolute		
							-	20%		481 more) 159 fewer per 1000 (from 200 fewer to 481 more)		
Mean percentage reduction in ulcer area – inpatients – grade 3 and 4 – NPUAP classification⁷⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	70 (n=4)	60 (n=5)	-	Not pooled	Very low	Critical
Mean percentage reduction in ulcer volume – inpatients – grade 3 and 4 – NPUAP classification⁷⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	75 (n=4)	60 (n=5)	-	Not pooled	Very low	Critical
Mortality (all-cause)⁷⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^{b,d}	None	1/4 (25%)	0/5 (0%)	OR 9.49 (0.18 to 489.97)	250 more per 1000 (from 210 fewer to 710 more)	Very low	Critical
							-	0%		250 more per 1000 (from 210 fewer to 710 more)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	TGF-β3 (1.0µg/cm ²)	TGF-β3 (2.5µg/cm ²)	Relative (95% CI)	Absolute		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) Hirshberg (2003): no report on sequence generation and allocation concealment and report of blinding, but no further information; no log-transformation of data
- (b) Confidence interval crossed both MID points
- (c) No standard deviation; small sample size
- (d) Limited number of events.

Table 113: Clinical evidence profile: topical growth factor – beta 3 (2.5µg/cm²) versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	TGF-β3 (2.5µg/cm ²)	Placebo	Relative (95% CI)	Absolute		
Proportion of people completely healed – inpatients – grade 3 and 4 – NPUAP classification⁷⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	1/5 (20%)	0/5 (0%)	OR 7.39 (0.15 to 372.38)	200 more per 1000 (from 210 fewer to 610 more)	Very low	Critical
							-	0%		200 more per 1000 (from 210 fewer to 610 more)		
Mean percentage reduction in ulcer area – inpatients – grade 3 and 4 – NPUAP classification⁷⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	60 (n=5)	30 (n=5)	-	Not pooled	Very low	Critical
Mean percentage reduction in ulcer volume – inpatients – grade 3 and 4 – NPUAP classification⁷⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	60 (n=5)	20 (n=5)	-	Not pooled	Very low	Critical
Mortality (all-cause)⁷⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/5 (0%)	1/4 (25%)	OR 0.11 (0 to 5.44)	215 fewer per 1000 (from 250 fewer to 395 more)	Very low	Important
							-	25%		215 fewer per 1000 (from 250		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	TGF-β3 (2.5µg/cm ²)	Placebo	Relative (95% CI)	Absolute (fewer to 395 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Hirshberg (2003): no report on sequence generation and allocation concealment and report of blinding, but no further information; no log-transformation of data
 (b) Confidence interval crossed both MID points
 (c) No standard deviation; small sample size

Table 114: Clinical evidence profile: nerve growth factor (2.5 S murine) versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	NGF	Placebo	Relative (95% CI)	Absolute		
Proportion of people completely healed (foot ulcers) – people in a nursing home – grade 2 and above - Yarkony classification¹⁰¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	8/18 (44.4%)	1/18 (5.6%)	RR 8 (1.11 to 57.57)	389 more per 1000 (from 6 more to 1000 more)	Low	Critical
								5.6%		392 more per 1000 (from 6 more to 1000 more)		
Proportion of people improved by 3 or more grade (foot ulcers) – people in a nursing home – grade 2 and above - Yarkony classification¹⁰¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	5/18 (27.8%)	0/18 (0%)	OR 9.56 (1.48 to 61.61)	280 more (from 60 more to 490 more)	Moderate	Critical
								0%		280 more (from 60 more to 490 more)		
Proportion of peoples improved by 2 grade (foot ulcers) – people in a nursing home – grade 2 and above - Yarkony classification¹⁰¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	14/18 (77.8%)	2/18 (11.1%)	RR 7 (1.85 to 26.46)	667 more per 1000 (from 94 more to 1000 more)	Moderate	Critical
								11.1%		666 more		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	NGF	Placebo	Relative (95% CI)	Absolute		
										per 1000 (from 94 more to 1000 more)		
Proportion of people improved by 1 grade (foot ulcers) – nursing home patients – grade II and above - Yarkony classification¹⁰¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	18/18 (100%)	8/18 (44.4%)	RR 2.18 (1.31 to 3.61)	524 more per 1000 (from 138 more to 1000 more)	Moderate	Critical
								44.4%		524 more per 1000 (from 138 more to 1000 more)		
Mean mm² reduction in ulcer area (foot ulcers) – people in a nursing home – grade 2 and above - Yarkony classification¹⁰¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	738 (SD 393)	485 (SD 384)	-	MD 253 higher (0.83 lower to 506.83 higher)	Low	Critical
Mean mm² reduction in ulcer (foot ulcers) – people in a nursing home – grade 2 and above - Yarkony classification¹⁰¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	6.5 (SD 0.3)	5.9 (SD 0.3)	-	MD 0.6 higher (0.4 to 0.8 higher) (adjusted for	Moderate	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	NGF	Placebo	Relative (95% CI)	Absolute baseline ulcer area, location and duration)		
Proportion of people with adverse events (foot ulcers) – people in a nursing home – grade 2 and above - Yarkony classification¹⁰¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/18 (0%)	0/18 (0%)	Not pooled	Not pooled	Moderate	Critical
								0%	Not pooled			
Mortality (all-cause)¹⁰¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	1/19 (5.3%)	0/19 (0%)	OR 7.39 (0.15 to 372.38)	50 more per 1000 (from 80 fewer to 190 more)	Very low	Important
								0%	50 more per 1000 (from 80 fewer to 190 more)			
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	NGF	Placebo	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Landi (2003): allocation according to age, group, sex and ulcer area and blinding of nurses and outcome assessor, but no blinding of participant

(b) The confidence interval crossed 1 MID point

(c) The confidence interval crossed both MID points. There were a limited number of events.

Table 115: Clinical evidence profile: recombinant platelet-derived growth factor-BB (100µg/ml) versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (100µg/ml)	Placebo	Relative (95% CI)	Absolute		
Proportion of people completely healed – general population and denervated people – grade 3 and 4 – NPUAP classification^{e128,153,159}												
2	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	8/29 (27.6%)	2/21 (9.5%)	RR 2.68 (0.74 to 9.74)	160 more per 1000 (from 25 fewer to 832 more)	Very low	Critical
							-	7.1%		119 more per 1000 (from 18 fewer to 621 more)		
Ulcer volume^g at end of treatment – general population – grade 3 and 4 – classification system not reported¹²⁸												
1	Randomised	Very	No serious	No serious	Very	None	1.75	3.5	-	Not	Very	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (100µg/ml)	Placebo	Relative (95% CI)	Absolute		
	trial	serious ^c	inconsistency	indirectness	serious ^d		(n=16)	(n=14)		pooled (adjusted for initial volume)	low	
Mortality (all-cause)¹⁵⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/35 (0%)	0/15 (0%)	Not pooled	Not pooled	Very low	Important
							-	0%		Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Mustoe (1994) did not report on sequence generation, allocation concealment and report of double blinding, but no further information; Robson (1992b) did not report on sequence generation, unequal allocation and only the outcome assessor was blinded.

- (b) The confidence interval crossed 1 MID point
- (c) Mustoe (1994) did not report on sequence generation, allocation concealment and report of double blinding, but no further information
- (d) No standard deviation was reported and there was a small sample size.
- (e) Mustoe (1994) did not report the classification system used; Robson (1992b): NPUAP classification.

Table 116: Clinical evidence profile: recombinant platelet-derived growth factor-BB (100µg/ml) versus recombinant platelet-derived growth factor-BB (300mg/ml)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (100µg/ml)	rPDGF-BB (300ug/ml)	Relative (95% CI)	Absolute		
Proportion of people completely healed – general population – grade 3 and 4 – classification system not reported¹²⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	6/16 (37.5%)	3/12 (25%)	RR 1.5 (0.47 to 4.82)	125 more per 1000 (from 132 fewer to 955 more)	Very low	Critical
							-	25%		125 more per 1000 (from 132 fewer to 955 more)		
Ulcer volume^e at end of treatment – general population – grade 3 and 4 – classification system not reported¹²⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	1.75 (n=16)	2.0 (n=12)	-	Not pooled (adjusted for initial volume)	Very low	Critical
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (100µg/ml)	rPDGF-BB (300ug/ml)	Relative (95% CI)	Absolute		
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Mustoe (1994) did not report on sequence generation, allocation concealment and report of double blinding, but no further information was provided.

(b) The confidence interval crossed both MID points.

(c) There was no standard deviation reported and the study used a small sample size.

Table 117: Clinical evidence profile: recombinant platelet-derived growth factor-BB (300µg/ml) versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (300µg/ml)	Placebo	Relative (95% CI)	Absolute		
Proportion of people completely healed – general population – grade 3 and 4 – classification system not reported¹²⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	3/12 (25%)	2/14 (14.3%)	RR 1.75 (0.35 to 8.79)	107 more per 1000 (from 93 fewer to 1000 more)	Very low	Critical
							-	14.3%		107 more per		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (300µg/ml)	Placebo	Relative (95% CI)	Absolute		
										1000 (from 93 fewer to 1000 more)		
Ulcer volume^g at end of treatment – general population – grade 3 and 4 – classification system not reported¹²⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	2.0 (n=12)	3.5 (n=14)	-	Not pooled (adjusted for initial volume)	Very low	Critical
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Mustoe (1994) did not report on sequence generation, allocation concealment and report of double blinding, but no further information was provided.

(b) The confidence interval crossed both MID points.

(c) There was no standard deviation reported and the study used a small sample size.

Table 118: Clinical evidence profile: granulo-macrophage/colony-stimulating factor (2.0µg/cm²) versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rGM-CSF (2.0µg/cm ²)	Placebo	Relative (95% CI)	Absolute		
Proportion of people completely healed (after 1 year) – inpatients – grade 3 and 4 – classification not reported¹⁴⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	8/14 (57.1%)	10/13 (76.9%)	RR 0.74 (0.43 to 1.28)	200 fewer per 1000 (from 438 fewer to 215 more)	Very low	Critical
							-	76.9%		200 fewer per 1000 (from 438 fewer to 215 more)		
Proportion of people worsened (after 1 year) – inpatients – grade 3 and 4 – classification not reported¹⁴⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/14 (14.3%)	0/13 (0%)	OR 7.43 (0.44 to 125.76)	140 more (from 70 fewer to 360 more)	Very low	Critical
							-	0%		140 more (from 70 fewer to 360 more)		
Mean percentage reduction in ulcer area – inpatients – grade 3 and 4 – classification not reported¹⁵⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	67 (SD 24)	71 (SD 11)	-	MD 4 lower (17.36 lower to 9.36 higher)	Very low	Critical
Median percentage reduction in ulcer area – inpatients – grade 3 and 4 – classification not reported¹⁵⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	70 (range: 3-93) (n=15)	72 (range: 39-84) (n=15)	-	Not pooled	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rGM-CSF (2.0µg/cm ²)	Placebo	Relative (95% CI)	Absolute		
Mortality (all-cause)¹⁵⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/15 (0%)	0/15 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) There was no report on sequence generation, allocation concealment and report of double blinding, but no further information was provided.

(b) The confidence interval crossed both MID points.

(c) There was no standard deviation reported and the study used a small sample size.

(d) No log-transformation of data was carried out.

Table 119: Clinical evidence profile: granulo-macrophage/colony-stimulating factor (2.0µg/cm²) versus basic fibroblast growth factor (5.0µ/cm²)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rGM-CSF (2.0ug/cm ²)	rBFGF (5.0ug/cm ²)	Relative (95% CI)	Absolute		
Proportion of people completely healed (after 1 year) – inpatients – grade 3 and 4 – classification not reported¹⁴⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	8/14 (57.1%)	10/14 (71.4%)	RR 0.8 (0.46 to 1.4)	143 fewer per 1000 (from 386 fewer to 286 more)	Very low	Critical
								71.4%		143 fewer per 1000 (from 386 fewer to 286 more)		
Proportion of people worsened (after 1 year) – inpatients – grade 3 and 4 – classification not reported¹⁴⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/14 (14.3%)	4/14 (28.6%)	RR 0.5 (0.11 to 2.3)	143 fewer per 1000 (from 254 fewer to 371 more)	Very low	Critical
							-	28.6%		143 fewer per 1000 (from 255		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rGM-CSF (2.0ug/cm ²)	rBFGF (5.0ug/cm ²)	Relative (95% CI)	Absolute		
										fewer to 372 more)		
Mean percentage reduction in ulcer area – inpatients – grade 3 and 4 – classification not reported¹⁵⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	67 (SD 24)	75 (SD 19)	-	MD 8 lower (23.49 lower to 7.49 higher)	Very low	Critical
Median percentage reduction in ulcer area – inpatients – grade 3 and 4 – classification not reported¹⁵⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	70 (range:3-93) (n=15)	79 (range:42-99) (n=15)	-	Not pooled	Very low	Critical
Mortality (all-cause)¹⁵⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None	0/15 (0%)	0/15 (0%)	Not pooled	Not pooled	Low	Important
							-	0%	-	Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rGM-CSF (2.0ug/cm ²)	rBFGF (5.0ug/cm ²)	Relative (95% CI)	Absolute		
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) There was no report on sequence generation, allocation concealment and report of double blinding, but no further information was provided.
- (b) The confidence interval crossed both MID points.
- (c) The confidence interval crossed 1 MID point.
- (d) There was no standard deviation reported and the study used a small sample size.
- (e) No log-transformation of data was conducted.

Table 120: Clinical evidence profile: granulo-macrophage/colony-stimulating factor (2.0µg/cm²) versus granulo-macrophage/colony-stimulating factor (2.0mg/cm²) and basic fibroblast growth factor (5.0µg/cm²)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rGM-CSF	rGM-CSF/rBFGF	Relative (95% CI)	Absolute		
Proportion of people completely healed (after 1 year) – inpatients – grade 3 and 4 – classification not reported¹⁴⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	8/14 (57.1%)	9/13 (69.2%)	RR 0.83 (0.46 to 1.48)	118 fewer per 1000 (from 374 fewer to 332 more)	Very low	Critical
							-	69.2%		118 fewer per 1000 (from 374 fewer to 332 more)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rGM-CSF	rGM-CSF/rBFGF	Relative (95% CI)	Absolute		
Proportion of people worsened (after 1 year) – inpatients – grade 3 and 4 – classification not reported¹⁴⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/14 (14.3%)	1/13 (7.7%)	RR 1.86 (0.19 to 18.13)	66 more per 1000 (from 62 fewer to 1000 more)	Very low	Critical
							-	7.7%		66 more per 1000 (from 62 fewer to 1000 more)		
Mean percentage reduction in ulcer area – inpatients – grade 3 and 4 – classification not reported¹⁵⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	67 (SD 24)	68 (SD 21)	-	MD 1 lower (16.92 lower to 14.92 higher)	Very low	Critical
Median percentage reduction in ulcer area – inpatients – grade 3 and 4 – classification not reported¹⁵⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	70 (range: 3-93) (n=15)	73 (range:29-98) (n=16)	-	Not pooled	Very low	Critical
Mortality (all-cause)¹⁵⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None	0/15 (0%)	0/16 (0%)	Not pooled	Not pooled	Low	Important
							-	-		-		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rGM-CSF	rGM-CSF/rBFGF	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) There was no report on sequence generation, allocation concealment and report of double blinding, but no further information was provided.

(b) The confidence interval crossed both MID points.

(c) There was no standard deviation reported and the study used a small sample size.

Table 121: Clinical evidence profile: basic fibroblast growth factor (5.0µg/cm²) versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rBFGF	Placebo	Relative (95% CI)	Absolute		
Proportion of people completely healed (after 1 year) – inpatients – grade 3 and 4 – classification not reported¹⁴⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	10/14 (71.4%)	10/13 (76.9%)	RR 0.93 (0.59 to 1.45)	54 fewer per 1000 (from 315 fewer to 346 more)	Very low	Critical
							-	76.9%		54 fewer per 1000 (from 315 fewer to 346 more)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rBFGF	Placebo	Relative (95% CI)	Absolute		
Proportion of people worsened (after 1 year) – inpatients – grade 3 and 4 – classification not reported¹⁴⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	4/14 (28.6%)	0/13 (0%)	OR 8.85 (1.1 to 71.2)	290 more (from 30 fewer to 540 more)	Very low	Critical
								0%		290 more (from 30 fewer to 540 more)		
Mean percentage reduction in ulcer area – inpatients – grade 3 and 4 – classification not reported¹⁵⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	79 (SD 19)	71 (SD 11)	-	MD 4 higher (7.11 lower to 15.11 higher)	Very low	Critical
Median percentage reduction in ulcer area – inpatients – grade 3 and 4 – classification not reported¹⁵⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	79 (range:4 2-99) (n=15)	72 (range:3 9-84) (n=15)	-	Not pooled	Very low	Critical
Mortality (all-cause)¹⁵⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None	0/15 (0%)	0/15 (0%)	Not pooled	Not pooled	Low	Important
							-	0%	-	Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rBFGF	Placebo	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) There was no report on sequence generation, allocation concealment and report of double blinding, but no further information was provided.

(b) The confidence interval crossed both MID points.

(c) The confidence interval crossed 1 MID point.

(d) There was no standard deviation reported and the study used a small sample size.

(e) No log-transformation of data was conducted.

Table 122: Clinical evidence profile: basic fibroblast growth factor (5.0µg/cm²) versus granulo-macrophage/colony-stimulating factor (2.0µg/cm²) and basic fibroblast growth factor (5.0mg/cm²)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rBFGF	rGM-CSF/rBFGF	Relative (95% CI)	Absolute		
Proportion of people completely healed (after 1 year) – inpatients – grade 3 and 4 – classification not reported¹⁴⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	10/14 (71.4%)	9/13 (69.2%)	RR 1.03 (0.63 to 1.69)	21 more per 1000 (from 256 fewer to 478 more)	Very low	Critical
							-	69.2%		21 more per 1000 (from 256 fewer to 477 more)		
Proportion of people worsened (after 1 year) – inpatients – grade 3 and 4 – classification not reported¹⁴⁷												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rBFGF	rGM-CSF/rBFGF	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	4/14 (28.6%)	1/13 (7.7%)	RR 3.71 (0.47 to 29.06)	208 more per 1000 (from 41 fewer to 1000 more)	Very low	Critical
							-	7.7%		209 more per 1000 (from 41 fewer to 1000 more)		
Mean percentage reduction in ulcer area – inpatients – grade 3 and 4 – classification not reported¹⁵⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	75 (SD 19)	68 (SD 21)	-	MD 7 higher (7.08 lower to 21.08 higher)	Very low	Critical
Median percentage reduction in ulcer area – inpatients – grade 3 and 4 – classification not reported¹⁵⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	79 (range: 42-99) (n=15)	73 (range: 29-98) (n=16)	-	Not pooled	Very low	Critical
Mortality (all-cause)¹⁵⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None	0/15 (0%)	0/16 (0%)	Not pooled	Not pooled	Low	Important
							-	-				
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rBFGF	rGM-CSF/rBFGF	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) There was no report on sequence generation, allocation concealment and report of double blinding, but no further information was provided.

(b) The confidence interval crossed both MID points.

(c) The confidence interval crossed 1 MID point.

(d) There was no standard deviation and the study used a small sample size.

(e) No log-transformation of data was conducted.

Table 123: Clinical evidence profile: granulo-macrophage/colony-stimulating factor (2.0µg/cm²) and basic fibroblast growth factor (5.0µg/cm²) versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rGM-CSF/rBFGF	Placebo	Relative (95% CI)	Absolute		
Proportion of people completely healed (after 1 year) – inpatients – grade 3 and 4 – classification not reported¹⁴⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	9/13 (69.2%)	10/13 (76.9%)	RR 0.9 (0.56 to 1.44)	77 fewer per 1000 (from 338 fewer to 338 more)	Very low	Critical
							-	76.9%		77 fewer per 1000 (from		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rGM-CSF/rBFGF	Placebo	Relative (95% CI)	Absolute		
										338 fewer to 338 more)		
Proportion of people worsened (after 1 year) – inpatients – grade 3 and 4 – classification not reported¹⁴⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	1/13 (7.7%)	0/13 (0%)	OR 7.39 (0.15 to 372.38)	80 more (from 110 fewer to 270 more)	Very low	Critical
							-	0%		80 more (from 110 fewer to 270 more)		
Mean percentage reduction in ulcer area – inpatients – grade 3 and 4 – classification not reported¹⁵⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	168 (SD 21)	71 (SD 11)	-	MD 3 lower (14.7 lower to 8.7 higher)	Very low	Critical
Median percentage reduction in ulcer area – inpatients – grade 3 and 4 – classification not reported¹⁵⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	73 (range:29-98) (n=16)	72 (range:39-84) (n=15)	-	Not pooled	Very low	Critical
Mortality (all-cause)¹⁵⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	no serious	None	0/16 (0%)	0/15 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		-		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rGM-CSF/rBFGF	Placebo	Relative (95% CI)	Absolute		
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) There was no report on sequence generation, allocation concealment and report of double blinding, but no further information was provided.

(b) The confidence interval crossed both MID points.

(c) No standard deviation was reported and the study used a small sample size.

(d) No log-transformation of data was conducted.

Table 124: Clinical evidence profile: recombinant platelet-derived growth factor-BB (100.0µg/g) versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB	Placebo	Relative (95% CI)	Absolute		
Proportion of people completely healed – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	7/31 (22.6%)	0/31 (0%)	OR 9.19 (1.93 to 43.75)	230 more (from 70 more to 380 more)	Low	Critical
							-	0%		230 more (from 70 more to 380 more)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB	Placebo	Relative (95% CI)	Absolute (more)		
Proportion of people healed 90% or higher – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	18/31 (58.1%)	9/31 (29%)	RR 2 (1.07 to 3.74)	290 more per 1000 (from 20 more to 795 more)	Very low	Critical
							-	29%		290 more per 1000 (from 20 more to 795 more)		
Median percentage reduction in ulcer volume – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	99.6 (n=31)	99.1 (n=31)	p=0.013	Not pooled	Very low	Critical
Proportion of people with osteomyelitis – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	2/31 (6.5%)	1/31 (3.2%)	RR 2 (0.19 to 20.93)	32 more per 1000 (from 26 fewer to 643 more)	Very low	Important
							-	3.2%		32 more per 1000 (from 26 fewer to 638 more)		
Proportion of peoples with infection – general population – grade 3 and 4 – NPUAP classification¹⁵³												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB	Placebo	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	0/31 (0%)	1/31 (3.2%)	OR 0.14 (0 to 6.82)	28 fewer per 1000 (from 32 fewer to 153 more)	Very low	Important
							-	3.2%		27 fewer per 1000 (from 32 fewer to 152 more)		
Proportion of people with sepsis – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/31 (0%)	0/31 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Proportion of people with adverse events other than osteomyelitis, infection and sepsis – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	2/31 (6.5%)	2/31 (6.5%)	RR 1 (0.15 to 6.66)	0 fewer per 1000 (from 55 fewer to 365 more)	Very low	Important
								6.5%		0 fewer per 1000 (from 55 fewer to 368 more)		
Mortality (all-cause)¹⁵³												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB	Placebo	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/31 (0%)	0/31 (0%)	Not pooled	Not pooled	Low	Important
							-	0%	-	Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate or reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Rees (1999) did not report on sequence generation, allocation concealment and blinding; no log-transformation of data was conducted.

(b) The confidence interval crossed 1 MID point.

(c) No standard deviation was reported. It was unknown if sample size was sufficient.

(d) The confidence interval crossed both MID points.

Table 125: Clinical evidence profile: recombinant platelet-derived growth factor-BB (100.0mg/g) versus recombinant platelet-derived growth factor-BB (300.0mg/g) alternated with placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (100µg/g)	rPDGF-BB (300µg/g) alternated with placebo	Relative (95% CI)	Absolute		
Proportion of people completely healed – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	7/31 (22.6%)	6/32 (18.8%)	RR 1.2 (0.46 to 3.18)	38 more per 1000 (from 101 fewer to 409 more)	Very low	Critical
							-	18.8%		38 more per 1000 (from 102 fewer to 410 more)		
Proportion of people healed 90% or higher – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	18/31 (58.1%)	19/32 (59.4%)	RR 0.98 (0.65 to 1.48)	12 fewer per 1000 (from 208 fewer to 285 more)	Very low	Critical
							-	59.4%		12 fewer per 1000 (from 208 fewer to 285 more)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (100µg/g)	rPDGF-BB (300µg/g) alternated with placebo	Relative (95% CI)	Absolute		
Median percentage reduction in ulcer volume – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	99.6 (n=31)	99.7 (n=32)	-	Not pooled	Very low	Critical
Proportion of people with osteomyelitis – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/31 (6.5%)	1/32 (3.1%)	RR 2.06 (0.2 to 21.63)	33 more per 1000 (from 25 fewer to 645 more)	Very low	Important
							-	3.1%		33 more per 1000 (from 25 fewer to 640 more)		
Proportion of people with infection – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/31 (0%)	0/32 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Proportion of people with sepsis – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	0/31 (0%)	1/32 (3.1%)	OR 0.14 (0 to 7.04)	27 fewer per 1000 (from 31 fewer to 154 more)	Very low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (100µg/g)	rPDGF-BB (300µg/g) alternated with placebo	Relative (95% CI)	Absolute		
							-	3.1%		27 fewer per 1000 (from 31 fewer to 153 more)		
Proportion of people with adverse events other than osteomyelitis, infection and sepsis – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/31 (6.5%)	3/32 (9.4%)	RR 0.69 (0.12 to 3.84)	29 fewer per 1000 (from 83 fewer to 266 more)	Very low	Important
							-	9.4%		29 fewer per 1000 (from 83 fewer to 267 more)		
Mortality (all-cause)¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/31 (0%)	0/32 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		-		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (100µg/g)	rPDGF-BB (300µg/g) alternated with placebo	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Rees (1999): no report on sequence generation, allocation concealment and blinding; ; no log-transformation of data;

(b) Confidence interval crossed both MID points

(c) No standard deviation; unknown if sample size was sufficient

Table 126: Clinical evidence profile: recombinant platelet-derived growth factor-BB (100.0µg/g) versus recombinant platelet-derived growth factor-BB (300.0µg/g)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (100ug/g)	rPDGF-BB (300ug/g)	Relative (95% CI)	Absolute		
Proportion of people completely healed – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	7/31 (22.6%)	1/30 (3.3%)	RR 6.77 (0.89 to 51.8)	192 more per 1000 (from 4 fewer to 1000)	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (100ug/g)	rPDGF-BB (300ug/g)	Relative (95% CI)	Absolute		
							-	3.3%		more) 190 more per 1000 (from 4 fewer to 1000 more)		
Proportion of peoples healed 90% or higher – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	18/31 (58.1%)	12/30 (40%)	RR 1.45 (0.85 to 2.47)	180 more per 1000 (from 60 fewer to 588 more)	Very low	Critical
							-	40%		180 more per 1000 (from 60 fewer to 588 more)		
Median percentage reduction in ulcer volume – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	99.6 (n=31)	98.6 (n=30)	-	Not pooled	Very low	Critical
Proportion of people with osteomyelitis – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	2/31 (6.5%)	0/30 (0%)	OR 7.4 (0.45 to 121.11)	60 more (from 40 fewer to 170 more)	Very low	Important
							-	0%		60 more (from 40		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (100ug/g)	rPDGF-BB (300ug/g)	Relative (95% CI)	Absolute		
										fewer to 170 more)		
Proportion of people with infection – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	0/31 (0%)	1/30 (3.3%)	OR 0.13 (0 to 6.6)	29 fewer per 1000 (from 33 fewer to 152 more)	Very low	Important
							-	3.3%		29 fewer per 1000 (from 33 fewer to 151 more)		
Proportion of people with sepsis – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None	0/31 (0%)	0/30 (0%)	Not pooled	Not pooled	Very low	Important
							-	0%		Not pooled		
Proportion of people with adverse events other than osteomyelitis, infection and sepsis – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	2/31 (6.5%)	2/30 (6.7%)	RR 0.97 (0.15 to 6.44)	2 fewer per 1000 (from 57 fewer to 363 more)	Very low	Important
							-	6.7%		2 fewer per 1000 (from 57		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (100ug/g)	rPDGF-BB (300ug/g)	Relative (95% CI)	Absolute (fewer to 364 more)		
Mortality (all-cause)¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/31 (0%)	0/30 (0%)	Not pooled	Not pooled	Low	Important
							-	-	-	Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Rees (1999) did not report on sequence generation, allocation concealment and blinding; no log-transformation of data was conducted.

(b) The confidence interval crossed 1 MID point.

(c) No standard deviation was reported and it was unknown if sample size was sufficient.

(d) The confidence interval crossed both MID points.

Table 127: Clinical evidence profile: recombinant platelet-derived growth factor-BB (300.0µg/g) alternated with placebo versus placebo

Quality assessment	No of patients	Effect	Quality	Importance
--------------------	----------------	--------	---------	------------

No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (300µg/g) alternated with placebo	Placebo	Relative (95% CI)	Absolute		
Proportion of people completely healed – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	6/32 (18.8%)	0/31 (0%)	OR 8.51 (1.6 to 45.18)	190 more (from 50 more to 330 more)	Low	Critical
							-	0%		190 more (from 50 more to 330 more)		
Proportion of people healed 90% or higher – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	19/32 (59.4%)	9/31 (29%)	RR 2.05 (1.1 to 3.8)	305 more per 1000 (from 29 more to 813 more)	Very low	Critical
							-	29%		304 more per 1000 (from 29 more to 812 more)		
Median percentage reduction in ulcer volume – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	99.7 (n=32)	99.1 (n=31)	p=0.011	Not pooled	Very low	Critical
Proportion of people with osteomyelitis – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised	Very	No serious	No serious	Very serious ^d	None	2/31	1/31	RR 2	32 more	Very	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (300µg/g) alternated with placebo	Placebo	Relative (95% CI)	Absolute		
	trial	serious ^a	inconsistency	indirectness			(6.5%)	(3.2%)	(0.19 to 20.93)	per 1000 (from 26 fewer to 643 more)	low	
							-	3.2%		32 more per 1000 (from 26 fewer to 638 more)		
Proportion of people with infection – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	0/32 (0%)	1/31 (3.2%)	OR 0.13 (0 to 6.61)	28 fewer per 1000 (from 32 fewer to 148 more)	Very low	Important
							-	3.2%		28 fewer per 1000 (from 32 fewer to 147 more)		
Proportion of people with sepsis – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	1/32 (3.1%)	0/31 (0%)	OR 7.16 (0.14 to	30 more (from 50 fewer to	Very low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (300µg/g) alternated with placebo	Placebo	Relative (95% CI)	Absolute		
									361.11)	110 more)-		
							-	0%		-		
Proportion of people with adverse events other than osteomyelitis, infection and sepsis – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	3/32 (9.4%)	2/31 (6.5%)	RR 1.45 (0.26 to 8.11)	29 more per 1000 (from 48 fewer to 459 more)	Very low	Important
							-	6.5%		29 more per 1000 (from 48 fewer to 462 more)		
Mortality (all-cause)¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/32 (0%)	0/31 (0%)	Not pooled	Not pooled	Low	Important
							-	0%	-	Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate or reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (300µg/g) alternated with placebo	Placebo	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) Rees (1999) did not report on sequence generation, allocation concealment and blinding. There was no log-transformation of data.
- (b) The confidence interval crossed 1 MID point.
- (c) No standard deviation was reported and it was unknown if sample size was sufficient.
- (d) The confidence interval crossed both MID points.

Table 128: Clinical evidence profile: recombinant platelet-derived growth factor-BB (300.0µg/g) alternated with placebo versus recombinant platelet-derived growth factor-BB (300.0µg/g)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (300µg/g) alternated with placebo	rPDGF-BB (300µg/g)	Relative (95% CI)	Absolute		
Proportion of people completely healed – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	6/32 (18.8%)	1/30 (3.3%)	RR 5.63 (0.72 to 44.03)	154 more per 1000 (from 9 fewer to	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (300µg/g) alternated with placebo	rPDGF-BB (300µg/g)	Relative (95% CI)	Absolute		
							-	3.3%		1000 more 152 more per 1000 (from 9 fewer to 1000 more)		
Proportion of people healed 90% or higher – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	19/32 (59.4%)	12/30 (40%)	RR 1.48 (0.88 to 2.51)	192 more per 1000 (from 48 fewer to 604 more)	Very low	Critical
							-	40%		192 more per 1000 (from 48 fewer to 604 more)		
Median percentage reduction in ulcer volume – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	99.7 (n=32)	98.6 (n=30)	-	Not pooled	Very low	Critical
Proportion of people with osteomyelitis – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	1/32 (3.1%)	0/30 (0%)	OR 6.94 (0.14 to	30 more (from 50	Very low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (300µg/g) alternated with placebo	rPDGF-BB (300µg/g)	Relative (95% CI)	Absolute		
							-	0%	350.54)	fewer to 120 more)		
Proportion of people with infection – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	0/32 (0%)	1/30 (3.3%)	OR 0.13 (0 to 6.39)	29 fewer per 1000 (from 33 fewer to 147 more)	Very low	Important
							-	3.3%		29 fewer per 1000 (from 33 fewer to 146 more)		
Proportion of people with sepsis – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	1/32 (3.1%)	0/30 (0%)	OR 6.94 (0.14 to 350.54)	30 more (from 50 fewer to 120 more)	Very low	Important
							-	0%		30 more (from 50 fewer to 120 more)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (300µg/g) alternated with placebo	rPDGF-BB (300µg/g)	Relative (95% CI)	Absolute		
Proportion of people with adverse events other than osteomyelitis, infection and sepsis – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	3/32 (9.4%)	2/30 (6.7%)	RR 1.41 (0.25 to 7.84)	27 more per 1000 (from 50 fewer to 456 more)	Very low	Important
							-	6.7%		27 more per 1000 (from 50 fewer to 458 more)		
Mortality (all-cause)¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/32 (0%)	0/30 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (300µg/g) alternated with placebo	rPDGF-BB (300µg/g)	Relative (95% CI)	Absolute		
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Rees (1999) did not report on sequence generation, allocation concealment and blinding; no log-transformation of data was conducted.

(b) The confidence interval crossed both MID points.

(c) The confidence interval crossed 1 MID point.

(d) No standard deviation was reported; unknown if sample size was sufficient.

Table 129: Clinical evidence profile: recombinant platelet-derived growth factor-BB (300.0µg/g) versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (300µg/g)	Placebo	Relative (95% CI)	Absolute		
Proportion of people completely healed – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	1/30 (3.3%)	0/31 (0%)	OR 7.64 (0.15 to 385.21)	30 more (from 50 fewer to 120 more)	Very low	Critical
							-	0%		30 more (from 50 fewer to 120 more)		
Proportion of people healed 90% or higher – general population – grade 3 and 4 – NPUAP classification¹⁵³												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (300µg/g)	Placebo	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	12/30 (40%)	9/31 (29%)	RR 1.38 (0.68 to 2.78)	110 more per 1000 (from 93 fewer to 517 more)	Very low	Critical
							-	29%		110 more per 1000 (from 93 fewer to 516 more)		
Median percentage reduction in ulcer volume – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	98.6 (n=30)	99.1 (n=31)	-	Not pooled	Very low	Critical
Proportion of people with osteomyelitis – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	0/30 (0%)	1/31 (3.2%)	OR 0.14 (0 to 7.05)	28 fewer per 1000 (from 32 fewer to 158 more)	Very low	Important
							-	3.2%		27 fewer per 1000 (from 32 fewer to 157 more)		
Proportion of people with infection – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised	Very	No serious	No serious	Very serious ^b	None	1/30	1/31	RR 1.03	1 more	Very	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (300µg/g)	Placebo	Relative (95% CI)	Absolute		
	trial	serious ^a	inconsistency	indirectness			(3.3%)	(3.2%)	(0.07 to 15.78)	per 1000 (from 30 fewer to 477 more)	low	
							-	3.2%		1 more per 1000 (from 30 fewer to 473 more)		
Proportion of peoples with sepsis – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/30 (0%)	0/31 (0%)	Not pooled	Not pooled	Low	Important
								0%		Not pooled		
Proportion of people with adverse events other than osteomyelitis, infection and sepsis – general population – grade 3 and 4 – NPUAP classification¹⁵³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/30 (6.7%)	2/31 (6.5%)	RR 1.03 (0.16 to 6.87)	2 more per 1000 (from 54 fewer to 379 more)	Very low	Important
							-	6.5%		2 more per 1000 (from 55 fewer to 382 more)		
Mortality (all-cause)¹⁵³												
1	Randomisd	Very	No serious	No serious	No serious	None	0/30	0/31	Not	Not	Low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (300µg/g)	Placebo	Relative (95% CI)	Absolute		
	trials	serious ^a	inconsistency	indirectness	imprecision		(0%)	(0%)	pooled	pooled		
							-	0%		Not pooled		
Time to complete healing of pressure ulcers¹⁵³												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers¹⁵³												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)¹⁵³												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital¹⁵³												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment¹⁵³												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life¹⁵³												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Rees (1999) did not report on sequence generation, allocation concealment and blinding; no log-transformation of data was conducted.

(b) The confidence interval crossed both MID points.

(c) No standard deviation was reported. It was unknown if sample size was sufficient.

Table 130: Clinical evidence profile: recombinant platelet-derived growth factor-BB (1.0µg/g) versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	RPDGF-BB (1.0µg/ml)	Placebo	Relative (95% CI)	Absolute		
Proportion of peoples completely healed – denervated people – grade 3 and 4 – classification not reported¹⁵⁹												
1	Randomised	Very	No serious	No serious	No serious	None	0/4	0/7	Not pooled	Not pooled	Low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	RPDGF-BB (1.0µg/ml)	Placebo	Relative (95% CI)	Absolute		
	trial	serious ^a	inconsistency	indirectness	imprecision		(0%)	(0%)				
							-	0%		Not pooled		
Proportion of people with infection – denervated people – grade 3 and 4 – classification not reported¹⁵⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/4 (0%)	0/7 (0%)	Not pooled	Not pooled	Low	Important
							--	0%		Not pooled		
Mortality (all-cause)¹⁵⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/4 (0%)	0/7 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate or reduction in size or volume of pressure ulcers												
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Robson (1992b) did not report on sequence generation, unequal allocation and only blinding of outcome assessor was carried out.

Table 131: Clinical evidence profile: recombinant platelet-derived growth factor-BB (1.0µg/g) versus. recombinant platelet-derived growth factor-BB (10.0µg/g)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (1.0µg/ml)	rPDGF-BB (10.0µg/ml)	Relative (95% CI)	Absolute		
Proportion of people completely healed – denervated people – grade 3 and 4 – classification not reported¹⁵⁹												
1	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/4 (0%)	0/4 (0%)	Not pooled	Not pooled	Low	Critical
							-	0%		Not pooled		
Proportion of people with infection – denervated people – grade 3 and 4 – classification not reported¹⁵⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/4 (0%)	0/4 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Mortality (all-cause)¹⁵⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/4 (0%)	0/4 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate or reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (1.0µg/ml)	rPDGF-BB (10.0µg/ml)	Relative (95% CI)	Absolute		
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Robson (1992b) did not report on sequence generation, unequal allocation and only blinding of outcome assessor was carried out.

Table 132: Recombinant platelet-derived growth factor-BB (1.0µg/g) versus recombinant platelet-derived growth factor-BB (100.0µg/g)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	RPDGF-BB (1.0µg/ml)	rPDGF-BB (100µg/ml)	Relative (95% CI)	Absolute		
Proportion of people completely healed – denervated people – grade 3 and 4 – classification not reported												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	0/4 (0%)	2/5 (40%)	OR 0.13 (0.01 to 2.52)	320 fewer per 1000 (from 393 fewer to 227 more)	Very low	Critical
							-	40%		320 fewer per 1000 (from 393 fewer to 227 more)		
Proportion of people with infection – denervated people – grade 3 and 4 – classification not reported												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/4 (0%)	0/5 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	RPDGF-BB (1.0µg/ml)	rPDGF-BB (100µg/ml)	Relative (95% CI)	Absolute		
										pooled		
Mortality (all-cause)												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/4 (0%)	0/5 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate or reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Robson (1992b) did not report on sequence generation, unequal allocation and only blinding of outcome assessor was carried out.

(b) The confidence interval crossed both MID points.

Table 133: Clinical evidence profile: recombinant platelet-derived growth factor-BB (10.0µg/g) versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (10.0µg/ml)	Placebo	Relative (95% CI)	Absolute		
Proportion of people completely healed – denervated people – grade 3 and 4 – classification not reported¹⁵⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/4 (0%)	0/7 (0%)	Not pooled	Not pooled	Low	Critical
							-	0%		Not pooled		
Proportion of people with infection – denervated people – grade 3 and 4 – classification not reported¹⁵⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/4 (0%)	0/7 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Mortality (all-cause)¹⁵⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/4 (0%)	0/7 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (10.0µg/ml)	Placebo	Relative (95% CI)	Absolute		
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Robson (1992b) did no report on sequence generation, unequal allocation and only blinding of outcome assessor was carried out.

Table 134: Clinical evidence profile: recombinant platelet-derived growth factor-BB (10.0µg/g) versus recombinant platelet-derived growth factor-BB (100.0µg/g)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (10.0µg/ml)	rPDGF-BB (100µg/ml)	Relative (95% CI)	Absolute		
Proportion of people completely healed – denervated people – grade 3 and 4 – classification not reported ¹⁵⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	0/4 (0%)	2/5 (40%)	OR 0.13 (0.01 to 2.52)	320 fewer per 1000 (from 393 fewer to 227 more)	Very low	Critical
								40%		320 fewer per 1000 (from 393 fewer to 227 more)		
Proportion of people with infection – denervated people – grade 3 and 4 – classification not reported												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (10.0µg/ml)	rPDGF-BB (100µg/ml)	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/4 (0%)	0/5 (0%)	Not pooled	Not pooled	Low	Important
								0%		Not pooled		
Mortality (all-cause)												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/4 (0%)	0/5 (0%)	Not pooled	Not pooled	Low	Important
								0%		Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Robson (1992b) did not report on sequence generation, unequal allocation and only blinding of outcome assessor was carried out.

(b) The confidence interval crossed both MID points.

Table 135: Clinical evidence profile: recombinant platelet-derived growth factor-BB (100.0µg/g) versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rPDGF-BB (100µg/ml)	Placebo	Relative (95% CI)	Absolute		
Proportion of people completely healed – denervated people – grade 3 and 4 – classification not reported¹⁵⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/5 (40%)	0/7 (0%)	OR 14.01 (0.73 to 267.29)	400 more (from 30 fewer to 830 more)	Very low	Critical
								0%		400 more (from 30 fewer to 830 more)		
Mean percentage reduction in ulcer depth – denervated people – grade 3 and 4 – classification not reported¹⁵⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	85.9 (SD 14.8)	65.1 (SD 13.4)	-	MD 20.8 higher (4.47 to 37.13 higher)	Low	Critical
Mean percentage reduction in ulcer volume – denervated people – grade 3 and 4 – classification not reported¹⁵⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	93.6 (SD 4)	78.2 (SD 5.6)	-	MD 15.4 higher (4.54 to 26.26 higher)	Low	Critical
Proportion of people with infection – denervated people – grade 3 and 4 – classification not reported¹⁵⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/5 (0%)	0/7 (0%)	Not pooled	Not pooled	Low	Important
								0%		not pooled		

Mortality (all-cause) ¹⁵⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/5 (0%)	0/7 (0%)	Not pooled	Not pooled	Low	Important
								0%		Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Robson (1992b) did not report on sequence generation, unequal allocation and only blinding of outcome assessor; no log-transformation of data was conducted.

(b) The confidence interval crossed both MID points.

Table 136: Clinical evidence profile: basic fibroblast growth factor (different schedules and doses) versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	bFGF	Placebo	Relative (95% CI)	Absolute		
Proportion of people healed 70% or more – denervated people – grade 3 and 4 – classification not reported ¹⁵⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	21/35 (60%)	4/14 (28.6%)	RR 2.1 (0.88 to 5.02)	314 more per 1000 (from 34 fewer to 1000 more)	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	bFGF	Placebo	Relative (95% CI)	Absolute		
								28.6%		315 more per 1000 (from 34 fewer to 1000 more)		
Mean percentage reduction in volume – denervated people – grade 3 and 4 – classification not reported¹⁵⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	69 (n=35)	59 (n=14)	-	Not pooled	Very low	Critical
Mortality (all-cause)¹⁵⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None	0/35 (0%)	0/15 (0%)	Not pooled	Not pooled	Low	Important
								0%		Not pooled		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-relate)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	bFGF	Placebo	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Robson (1992a) did not report on sequence generation, unequal allocation and only blinding of outcome assessor; no log-transformation of data was conducted.

(b) The confidence interval crossed 1 MID point.

(c) No standard deviation was reported and the study used a small sample size.

Table 137: Clinical evidence profile: interleukin 1-beta (0.01µg/cm²) versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rIL-1beta (0.01µg/cm ²)	Placebo	Relative (95% CI)	Absolute		
Proportion of people completely healed – denervated people – grade 3 and 4– classification not reported¹⁵⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/6 (0%)	0/6 (0%)	Not pooled	Not pooled	Low	Critical
								0%		Not pooled		
Mortality (all-cause)¹⁵⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/6 (0%)	0/6 (0%)	Not pooled	Not pooled	Low	Important
								0%		Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rIL-1beta (0.01µg/cm ²)	Placebo	Relative (95% CI)	Absolute		
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												

(a) Robson (1994) did not report on sequence generation, allocation concealment and report of double blinding, but no further information was provided.

Table 138: Clinical evidence profile: interleukin 1-beta (0.01µg/cm²) versus interleukin 1-beta (0.1µg/cm²)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rIL-1beta (0.01µg/cm ²)	rIL-1beta (0.1µg/cm ²)	Relative (95% CI)	Absolute		
Proportion of people completely healed – denervated people – grade 3 and 4 – classification not reported												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/6 (0%)	0/6 (0%)	Not pooled	Not pooled	Low	Critical
							-	0%		Not pooled		
Mortality (all-cause)												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/6 (0%)	0/6 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Time to complete healing of pressure ulcers												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rIL-1beta (0.01µg/cm ²)	rIL-1beta (0.1µg/cm ²)	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Robson (1994) did not report on sequence generation, allocation concealment and report of double blinding, but no further information was provided.

Table 139: Clinical evidence profile: interleukin 1-beta (0.01µg/cm²) versus interleukin 1-beta (1.0µg/cm²)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rIL-1beta (0.01µg/cm ²)	rIL-1beta (1.0µg/cm ²)	Relative (95% CI)	Absolute		
Proportion of people completely healed – denervated people – grade 3 and 4 – classification not reported¹⁵⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/6 (0%)	0/6 (0%)	Not pooled	Not pooled	Low	Critical
							-	0%		Not		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rIL-1beta (0.01µg/cm ²)	rIL-1beta (1.0µg/cm ²)	Relative (95% CI)	Absolute pooled		
Mortality (all-cause)¹⁵⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/6 (0%)	0/6 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Robson (1994) did not report on sequence generation, allocation concealment and report of double blinding, but no further information was provided.

Table 140: Clinical evidence profile: interleukin 1-beta (0.1µg/cm²) versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rIL-1beta (0.1µg/cm ²)	Placebo	Relative (95% CI)	Absolute		
Proportion of people completely healed – denervated people – grade 3 and 4 – classification not reported¹⁵⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/6 (0%)	0/6 (0%)	Not pooled	Not pooled	Low	Critical
							-	0%		Not pooled		
Mortality (all-cause)¹⁵⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/6 (0%)	0/6 (0%)	Not pooled	Not pooled	Low	Important
							-	0%	-	Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rIL-1beta (0.1µg/cm ²)	Placebo	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Robson (1994) did not report on sequence generation, allocation concealment and report of double blinding, but no further information was provided.

Table 141: Clinical evidence profile: interleukin 1-beta (0.1µg/cm²) versus interleukin 1-beta (1.0µg/cm²)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rIL-1beta (0.1µg/cm ²)	rIL-1beta (1.0µg/cm ²)	Relative (95% CI)	Absolute		
Proportion of people completely healed – denervated people – grade 3 and 4 – classification not reported¹⁵⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/6 (0%)	0/6 (0%)	Not pooled	Not pooled	Low	Critical
							-	0%		Not pooled		
Mortality (all-cause)¹⁵⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/6 (0%)	0/6 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rIL-1beta (0.1µg/cm ²)	rIL-1beta (1.0µg/cm ²)	Relative (95% CI)	Absolute		
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Robson (1994) did not report on sequence generation, allocation concealment and report of double blinding, but no further information was provided.

Table 142: Clinical evidence profile: interleukin 1-beta (1.0µg/cm²) versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rIL-1beta (1.0µg/cm ²)	Placebo	Relative (95% CI)	Absolute		
Proportion of people completely healed – denervated people – grade 3 and 4 – classification not reported¹⁵⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/6 (0%)	0/6 (0%)	Not pooled	Not pooled	Low	Critical
							-	0%		Not pooled		
Mortality (all-cause)¹⁵⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/6 (0%)	0/6 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	rIL-1beta (1.0µg/cm ²)	Placebo	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Robson (1994) did not report on sequence generation, allocation concealment and report of double blinding, but no further information was provided.

Table 143: Clinical evidence profile: chlorinated lime solution versus dextranomer

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Chlorinated lime solution	Dextranomer	Relative (95% CI)	Absolute		
Time to healing (defined as granulation and less than 25% of original ulcer area) (days) – elderly adults – grade not reported – classification system not reported¹²⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	61.8 (SD 13.86)	39.3 (SD 17.67)	-	MD 22.5 higher (3.86 to 41.14 higher)	Very low	Critical

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Chlorinated lime solution	Dextranomer	Relative (95% CI)	Absolute		
Proportion of people with pain – elderly adults– grade not reported – classification system not reported¹²⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	3/?	1/?	Not pooled	Not pooled	Very low	Important
							-	-		Not pooled		
Mortality¹²⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/8 (0%)	1/8 (12.5%)	OR 0.14 (0 to 6.82)	105 fewer per 1000 (from 125 fewer to 368 more)	Very low	Important
							-	12.5%		-		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing (time to event data)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Chlorinated lime solution	Dextranomer	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No report on allocation concealment, sequence generation, blinding; no ITT analysis.

(b) The confidence interval crossed 1 MID point.

(c) It was unclear how many people were included in each group

10.12 Economic evidence (adults)

2 Published literature

3 One study was included which compared saline soaked gauze to a polyurethane self-adhesive foam
4 dressing.¹⁴⁸ This is summarised in the economic evidence profile below (Table 144). See also the
5 study selection flow chart in Appendix D and study evidence tables in Appendix H.

6 One study that met the inclusion criteria was selectively excluded due to methodological
7 limitations¹⁵⁷ – this is summarised in Appendix K, with reasons for exclusion given.

8

Table 144: Economic evidence profile: saline soaked gauze versus polyurethane self-adhesive foam dressing

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
Payne 2009 ¹⁴⁸ (US)	Partially applicable ^a	Minor limitations ^b	Within trial analysis with analysis of individual level resource use. Patients randomised to receive saline soaked gauze or polyurethane self-adhesive foam dressing.	-£301	Pressure ulcer free days: 2.4 Ulcers healed by day 28: 12%	Polyurethane self-adhesive foam dressing dominates saline soaked gauze	Costs for patients who dropped out were included only up until the point of withdrawal in a deterministic sensitivity analysis. ^c The foam dressing remained dominant compared to saline soaked gauze.

(a) The analysis is based in the US; quality of life is not considered

(b) All resource use and health outcomes are obtained from within the trial rather than via a systematic procedure. The cost of the saline soaked gauze is calculated to be the same cost as the foam dressing. Exploration of uncertainty is inadequate. There is also a potential conflict of interest as the study is carried out by manufacturer of the foam dressing.

(c) In the base case analysis, per day treatment costs were continued until the 28 day time horizon even if the patient withdrew from the trial

10.1.13 Clinical evidence (neonates, infants, children and young people)

- 2 No RCTs or cohort studies were identified. Recommendations were developed using a modified
3 Delphi consensus technique. Further details can be found in Appendix N.

10.1.14 Economic evidence (neonates, infants, children and young people)

- 5 No relevant economic evidence was identified.

10.1.15 Evidence statements

10.1.5.71 Clinical (adults)

10.1.5.181 *Saline-soaked gauze versus hydrocolloid dressing*

- 9 • Three studies (n=126) (general population and people with a spinal cord injury) showed that
10 hydrocolloid dressing is potentially more clinically effective than saline-soaked gauze for complete
11 healing of (grade 1 and above pressure ulcers) (very low quality).
- 12 • Two studies (n=71) (general population) showed that hydrocolloid is potentially more clinically
13 effective compared to saline for complete healing of (grade 1 and above pressure ulcers) (very
14 low quality).
- 15 • One study (n=55) (people with a spinal cord injury) showed that hydrocolloid is potentially
16 clinically more effective than saline for complete healing of pressure ulcers (grade 1 and 2) (low
17 quality).
- 18 • Two studies (n=148) (general population and people with a spinal cord injury) showed that a
19 hydrocolloid is potentially more effective compared to saline for complete healing of pressure
20 ulcers (grade 1 to 3) (very low quality).
- 21 • One study (n=87) (general population) showed that a hydrocolloid may be more clinically effective
22 compared to saline for complete healing of pressure ulcers (grade 2 to 3) (very low quality).
- 23 • One study (n=61) (people with a spinal cord injury) showed that a hydrocolloid is clinically more
24 effective compared to saline for complete healing of pressure ulcers (grade 1 to 2) (moderate
25 quality).
- 26 • One study (n=24) (people with a spinal cord injury) showed that a hydrocolloid is potentially more
27 clinically effective compared to saline for complete healing of pressure ulcers (grade 1) (low
28 quality).
- 29 • Two studies (n=96) (general population and people with a spinal cord injury) showed that a
30 hydrocolloid is more clinically effective compared to saline for complete healing of pressure ulcers
31 (grade 2) (low quality).
- 32 • One study (n=59) (general population) showed that that a hydrocolloid is more clinically effective
33 compared to saline for complete healing of pressure ulcers (grade 2) (low quality).
- 34 • One study (n=37) (people with a spinal cord injury) showed that that a hydrocolloid is more
35 clinically effective compared to saline for complete healing of pressure ulcers (grade 2) (moderate
36 quality).
- 37 • One study (n=28) (general population) showed that there may be no clinical difference between
38 saline and a hydrocolloid for complete healing of pressure ulcers (grade 3), the direction of the
39 estimate of the effect favoured the hydrocolloid dressing (very low quality).
- 40 • One study (n=15) (people with a spinal cord injury) showed that a hydrocolloid is potentially more
41 clinically effective compared to saline for complete healing of pressure ulcers (grade 1 and 2)
42 (sacral area) (very low quality).

- 1 • One study (n=91) (people with a spinal cord injury) showed that a hydrocolloid is more clinically
2 effective compared to saline to improve healing of pressure ulcers (grade 1 and 2) (moderate
3 quality).
- 4 • Two studies (n=148) (general population and people with a spinal cord injury) showed saline may
5 be more clinically harmful than a hydrocolloid dressing for worsening of pressure ulcers (grade 1
6 to 3) (all sites) (very low quality).
- 7 • One study (n=87) (general population) showed that there may be no difference between saline
8 and a hydrocolloid for worsening of pressure ulcers (grade 2 and 3), the direction of the estimate
9 of the effect could favour either intervention (very low quality).
- 10 • One study (n=61) (people with a spinal cord injury) showed that a hydrocolloid is potentially more
11 clinically effective compared to saline to reduce pressure ulcers worsening (grade 1 and 2) (all
12 sites) (very low quality).
- 13 • One study (n=59) (general population) showed that there may be no clinical difference between
14 saline and a hydrocolloid for worsening of pressure ulcers (grade 2), the direction of the estimate
15 of the effect favoured the hydrocolloid dressing (very low quality).
- 16 • One study (n=28) (general population) showed that there may be no clinical difference between
17 saline and a hydrocolloid for worsening of pressure ulcers (grade 3) , the direction of the estimate
18 of the effect favoured the hydrocolloid dressing (very low quality).
- 19 • One study (n=34) (general population) showed that there is potentially no clinical difference
20 between saline and a hydrocolloid for mean percentage reduction in pressure ulcer area (grade 2
21 and 3), the direction of the estimate of the effect favoured the hydrocolloid dressing (very low
22 quality).
- 23 • One study (n=32) (general population) showed that saline is more clinically effective for mean
24 percentage reduction in pressure ulcer volume (grade 3 and 4) (low quality).
- 25 • One study (n=50) (people in long-term care) reported a median percentage reduction in pressure
26 ulcer area (grade not reported) for saline and a hydrocolloid. The median for saline was 85.7% and
27 100% for hydrocolloid. No estimate of effect or precision could be derived (very low quality).
- 28 • One study (n=59) (general population) reported a median percentage reduction in ulcer size
29 (grade 2) for saline and a hydrocolloid. The median for saline was 48% and 91% for hydrocolloid. A
30 p-value > 0.05 was reported (very low quality).
- 31 • One study (n=28) (general population) reported a median percentage reduction in pressure ulcer
32 size (grade 3) for saline and a hydrocolloid. The median for saline was 30% and 0.3% for
33 hydrocolloid. A p-value > 0.05 was reported (very low quality).
- 34 • One study (n=39) (people in long-term care) reported median days to healing of pressure ulcers
35 (grade 2 and 3) for saline and a hydrocolloid. The median for saline was 11 days and 9 days for
36 hydrocolloid. A p-value of 0.12 was reported (very low quality).
- 37 • One study (n=50) (people in long-term care) reported a healing distribution function (grade not
38 reported) for saline and a hydrocolloid. A p-value of 0.15 was reported (very low quality).
- 39 • One study (n=34) (general population) showed that saline is more clinically effective compared to
40 a hydrocolloid in terms of pain at dressing removal (low quality).
- 41 • One study (n=32) (general population) reported a median pain score during treatment (grade 3
42 and 4) for saline and a hydrocolloid. The median for saline was 2.0 (range 1-3) and 2.0 (range 1-4)
43 for hydrocolloid. No estimate of effect or precision could be derived (very low quality).
- 44 • One study (n=34) (general population) showed that saline is more clinically effective compared to
45 a hydrocolloid in terms of discomfort at dressing removal (low quality).
- 46 • One study (n=32) (general population) reported a median comfort score during treatment (grade
47 3 and 4) for saline and a hydrocolloid. The median for saline was 3.0 (range 2-4) and 4.0 (range 3-
48 4) for hydrocolloid. No estimate of effect or precision could be derived (very low quality).

- 1 • One study (n=34) (general population) showed no clinical difference between saline and a
2 hydrocolloid to reduce the incidence of infections (grade 2 and 3) (low quality).
- 3 • One study (n=32) (general population) reported a median comfort score during treatment (grade
4 3 and 4) for saline and a hydrocolloid. The median for saline was 2.0 (range 1-4) and 2.0 (range 1-
5 3) for hydrocolloid. No estimate of effect or precision could be derived (very low quality).
- 6 • One study (n=100) (general population) showed that saline is more clinically effective compared
7 to hydrocolloid to reduce the incidence of skin irritation (very low quality).
- 8 • One study (n=160) (general and spinal cord injured population) showed that there may be no
9 clinical difference between saline and hydrocolloid for mortality (all-cause)(grade 1 and above
10 pressure ulcers) (very low quality).
- 11 • No evidence was found for the outcomes:
 - 12 o Time to complete healing
 - 13 o Time in hospital

10.1.5.142 Saline-soaked gauze versus hydrogel dressing

- 15 • One study (n=30) (general population) showed that there may be no clinical difference between
16 saline and hydrogel for complete healing of pressure ulcers (grade 2 to 4), the direction of the
17 estimate of the effect favoured the saline (very low quality).
- 18 • One study (n=41) (general population) showed that there may be no clinical difference between
19 saline and hydrogel for worsening of pressure ulcers (grade 2 to 4 pressure ulcers), the direction
20 of the estimate of the effect favoured the hydrogel (very low quality).
- 21 • One study (n=30) (general population) reported a percentage healing rate of pressure ulcers
22 (grade 2 to 4) for saline and hydrogel. The rate for saline was 64% and 63% for hydrogel. No
23 estimate of effect or precision could be derived (very low quality).
- 24 • One study (n=30) (general population) showed that there may be no clinical difference between
25 saline and hydrogel for mean weeks to healing of pressure ulcers (grade 2 to 4), the direction of
26 the estimate of the effect favoured the hydrogel (very low quality).
- 27 • One study (n=41) (general population) showed there may be no clinical difference between saline
28 and hydrogel for mortality (all-cause) (grade 2 to 4 pressure ulcers) (very low quality).
- 29 • No evidence was found for the following outcomes:
 - 30 o Time to complete healing (time to event data)
 - 31 o Pain (wound-related)
 - 32 o Time in hospital
 - 33 o Acceptability of treatment
 - 34 o Side effects
 - 35 o Health-related quality of life

10.1.5.173 Saline-soaked gauze versus foam dressing

- 38 • Two studies (n=74) (general population) showed that a foam dressing is potentially more clinically
39 effective compared to saline for complete healing of pressure ulcers (grade 2 and 3) (very low
40 quality).
- 41 • One study (n=36) (general population) reported a median days to healing of 50% of the patients
42 (grade II) for saline and a foam. The median for both saline and hydrogel of 28 days. No estimate
43 of effect or precision could be derived (very low quality).
- 44 • Two studies (n=74) (general population) showed there is potentially no clinical difference
45 between a foam dressing and saline for mortality (grade 2 and 3 pressure ulcers) (very low
46 quality).

- 1 • No evidence was found for the following outcomes:
- 2 o Time to complete healing (time to event data)
- 3 o Rate of reduction in size and volume of pressure ulcers
- 4 o Reduction in size and volume of pressure ulcers
- 5 o Pain (wound-related)
- 6 o Time in hospital
- 7 o Acceptability of treatment
- 8 o Side effects
- 9 o Health-related quality of life
- 10

10.1.5.114 Saline-soaked gauze versus polyurethane dressing

- 12 • One study (n=19) (general population) showed that a polyurethane dressing may be more clinically effective compared to saline at complete healing of pressure ulcers (grade 1 and 2)(very low quality).
- 13
- 14
- 15 • One study (n=19) (general population) showed that a polyurethane dressing may be more clinically effective compared to saline to reduce pressure ulcers worsening (grade 1 and 2 pressure ulcers) (very low quality).
- 16
- 17
- 18 • One study (n=19) (general population) reported a mean percentage reduction in pressure ulcer area (grade 1 and 2) for saline and polyurethane. The mean for saline was 2.5% and 42.9% for polyurethane. No estimate of effect or precision could be derived (very low quality).
- 19
- 20
- 21 • No evidence was found for the following outcomes:
- 22 o Time to complete healing of pressure ulcers
- 23 o Rate of reduction in size or volume of pressure ulcers
- 24 o Pain (wound-related)
- 25 o Time in hospital
- 26 o Acceptability of treatment
- 27 o Side effects
- 28 o Mortality (all-cause)
- 29 o Health-related quality of life
- 30

10.1.5.115 Saline-soaked gauze versus dextranomer

- 32 • One study (n=30) (people with a spinal cord injury) showed that dextranomer is more clinically effective to improve healing of pressure ulcers (grade 2 to 4) (low quality).
- 33
- 34 • One study (n=30) (people with a spinal cord injury) showed no clinical difference for incidence of adverse events between saline and dextranomer (low quality).
- 35
- 36 • No evidence was found for the following outcomes:
- 37 o Proportion of people with pressure ulcers completely healed
- 38 o Time to complete healing of pressure ulcers
- 39 o Rate of reduction in size or volume of pressure ulcers
- 40 o Reduction in size or volume of pressure ulcers
- 41 o Pain (wound-related)
- 42 o Time in hospital
- 43 o Acceptability of treatment

- 1 o Side effects
- 2 o Mortality (all-cause)
- 3

10.1.5.146 Phenytoin versus saline-soaked gauze

- 5 • One study (n=55) (people with a spinal cord injury) showed that phenytoin may be more clinically
6 effective compared to saline for proportion of people with complete healing of pressure ulcers
7 (grade 1 and 2) (very low quality).
- 8 • One study (n=60) (people with a spinal cord injury) showed that phenytoin may be more clinically
9 effective compared to saline for complete healing of pressure ulcers (grade 1 and 2) (very low
10 quality).
- 11 • One study (n=40) (people with a spinal cord injury) showed that phenytoin is potentially more
12 clinically effective compared to saline for complete healing of pressure ulcers (grade 2) (very low
13 quality).
- 14 • One study (n=60) (people with a spinal cord injury) showed that phenytoin may be more clinically
15 effective than saline for improved healing of pressure ulcers (grade 1 and 2) (very low quality).
- 16 • One study (n=60) (people with a spinal cord injury) showed that phenytoin is potentially more
17 clinically effective compared to saline to reduce pressure ulcer worsening (grade 1 and 2) (very
18 low quality).
- 19 • One study (n=26) (people with a spinal cord injury) showed that phenytoin is potentially more
20 clinically effective compared to saline for mean percentage reduction in pressure ulcer size (grade
21 2) (very low quality).
- 22 • One study (n=26) (people with a spinal cord injury) showed that there may be no clinical
23 difference between phenytoin and saline for mean percentage reduction in pressure ulcer volume
24 (grade 2) (very low quality).
- 25 • One study (n=26) (people with a spinal cord injury) showed that phenytoin may be more clinically
26 effective compared to saline for mean percentage reduction in PUSH score (grade 2) (very low
27 quality).
- 28 • One study (n=30) (people with a spinal cord injury) showed no clinical difference for incidence of
29 adverse events between saline and phenytoin, the direction of the estimate of effect favoured
30 (low quality).
- 31 • Two studies (n=84) showed no clinical difference between phenytoin and saline for mortality (all-
32 cause), the direction of the estimate of effect favoured either intervention (moderate quality).
- 33 • No evidence was found for the following outcomes:
 - 34 o Time to complete healing of pressure ulcers
 - 35 o Rate of reduction in size or volume of pressure ulcers
 - 36 o Pain (wound-related)
 - 37 o Time in hospital
 - 38 o Acceptability of treatment
 - 39 o Side effects
 - 40 o Health-related quality of life
 - 41

10.1.5.427 Phenytoin versus hydrocolloid dressing

- 43 • One study (n=56) (people with a spinal cord injury) showed that a hydrocolloid is potentially more
44 clinically effective compared to phenytoin for proportion of people with complete healing of
45 pressure ulcers (grade 1 and 2) (low quality).

- 1 • One study (n=61) (people with a spinal cord injury) showed that a hydrocolloid is potentially more
2 clinically effective compared to phenytoin for pressure ulcers completely healed (grade 1 and 2
3 pressure ulcers) (low quality).
- 4 • One study (n=22) (people with a spinal cord injury) showed that a hydrocolloid is potentially more
5 clinically effective compared to phenytoin for pressure ulcers completely healed (grade 1) (low
6 quality).
- 7 • One study (n=39) (people with a spinal cord injury) showed that a hydrocolloid is potentially more
8 clinically effective compared to phenytoin for pressure ulcers completely healed (grade 2) (low
9 quality).
- 10 • One study (n=15) (people with a spinal cord injury) showed that there may be no clinical
11 difference between phenytoin and a hydrocolloid for complete healing of pressure ulcers (grade 1
12 and 2) in the sacral area (very low quality).
- 13 • One study (n=61) (people with a spinal cord injury) showed that a hydrocolloid is potentially more
14 clinically effective compared to phenytoin to improve healing pressure ulcers (grade 1 and 2) (low
15 quality).
- 16 • One study (n=61) (people with a spinal cord injury) showed that there may be no clinical
17 difference between phenytoin and a hydrocolloid for pressure ulcer worsening (grade 1 and 2
18 pressure ulcers) (very low quality).
- 19 • One study (n=28) (people in a nursing home) showed that phenytoin is potentially more clinically
20 effective compared to a hydrocolloid for mean days to healing (grade 2 pressure ulcers) (low
21 quality).
- 22 • One study (n=28) (people in a nursing home) reported minimal pain in people receiving phenytoin
23 and a hydrocolloid dressing (grade 2 pressure ulcers). No estimate of effect or precision could be
24 derived (very low quality).
- 25 • One study (n=28) (people in a nursing home) showed no clinical difference between phenytoin
26 and a hydrocolloid to reduce the incidence of adverse events (grade 2 pressure ulcers) (low
27 quality).
- 28 • Two studies (n=90) (people in a nursing home) showed there may be no clinical difference
29 between phenytoin and a hydrocolloid for mortality (all-cause) (grade 2 pressure ulcers), the
30 direction of the estimate of effect could favoured phenytoin (low quality).
- 31 • No evidence was found for the following outcomes:
- 32 o Time to complete healing of pressure ulcers (time to event data)
- 33 o Rate of reduction in size or volume of pressure ulcers
- 34 o Reduction in size or volume of pressure ulcers
- 35 o Time in hospital
- 36 o Acceptability of treatment
- 37 o Health-related quality of life
- 38

10.1.5.398 Phenytoin versus triple antibiotics

- 40 • One study (n=26) (people in a nursing home) showed that phenytoin is clinically more effective
41 compared to triple antibiotics for mean days to healing (grade 2) (low quality).
- 42 • One study (n=26) (people in a nursing home) reported minimal pain in people receiving phenytoin
43 and triple antibiotics. No estimate of effect or precision could be derived (very low quality).
- 44 • One study (n=26) (people in a nursing home) showed no clinical difference between phenytoin
45 and triple antibiotics to reduce the incidence of adverse events (low quality).
- 46 • One study (n=26) (people in a nursing home) showed there may be no clinical difference between
47 phenytoin and triple antibiotics for mortality (all-cause) (very low quality).

- 1 • No evidence was found for the following outcomes:
- 2 o Proportion of people with pressure ulcers completely healed
- 3 o Time to complete healing of pressure ulcers
- 4 o Time to complete healing (time to event data)
- 5 o Rate of reduction in size or volume of pressure ulcers
- 6 o Reduction in size or volume of pressure ulcers
- 7 o Time in hospital
- 8 o Acceptability of treatment
- 9 o Health-related quality of life
- 10

10.1.5.119 Aloe vera, silver chloride and decyl glucoside versus saline

- 12 • One study (number of participants) (elderly adults) reported a mean percentage reduction in PSST
- 13 score (grade 2 to 4 pressure ulcers) for aloe vera, silver chloride and decyl glucoside versus saline.
- 14 The mean for aloe vera was 22.7% and 20.5% for saline. No estimate of effect or precision could
- 15 be derived (very low quality).
- 16 • No evidence was found for the following outcomes:
- 17 o Proportion of people with pressure ulcers completely healed
- 18 o Time to complete healing of pressure ulcers
- 19 o Rate of reduction in size or volume of pressure ulcers
- 20 o Reduction in size or volume of pressure ulcers
- 21 o Pain (wound-related)
- 22 o Time in hospital
- 23 o Acceptability of treatment
- 24 o Side effects
- 25 o Mortality (all-cause)
- 26 o Health-related quality of life
- 27

10.1.5.120 Dialysate versus placebo

- 29 • One study (n=8) (people with a spinal cord injury) showed that dialysate is potentially more
- 30 clinically effective compared to placebo for reducing mean ml in pressure ulcer area (very low
- 31 quality).
- 32 • One study (n=8) (people with a spinal cord injury) reported mean percentage reduction in
- 33 pressure ulcer area at day 10 for dialysate and placebo. The mean for dialysate was 39% and 28%
- 34 for placebo. No estimate of effect or precision could be derived (very low quality).
- 35 • One study (n=8) (people with a spinal cord injury) reported mean percentage reduction in
- 36 pressure ulcer area at day 20 for dialysate and placebo. The mean for dialysate was 80% and 59%
- 37 for placebo. No estimate of effect or precision could be derived (very low quality).
- 38 • One study (n=8) (people with a spinal cord injury) showed that dialysate is potentially more
- 39 clinically effective compared to placebo for mean healing half-time (very low quality).
- 40 • One study (n=8) (people with a spinal cord injury) showed no clinical difference between dialysate
- 41 and placebo for treatment-related adverse events (low quality).
- 42 • No evidence was found for the following outcomes:
- 43 o Proportion of people with pressure ulcers completely healed
- 44 o Time to complete healing of pressure ulcers

- 1 o Rate of reduction in size or volume of pressure ulcers
- 2 o Pain (wound-related)
- 3 o Time in hospital
- 4 o Acceptability of treatment
- 5 o Mortality (all-cause)
- 6 o Health-related quality of life
- 7

10.1.5.1.1 ~~1~~ Petrolatum ointment versus petrolatum (base component)

- 9 • One study (n=19) (elderly people) showed that petrolatum ointment may be more clinically
10 effective compared to petrolatum (base component) for pressure ulcers completely healed (grade
11 1 and 2 pressure ulcers) (very low quality).
- 12 • One study (n=8) (elderly people) showed that petrolatum ointment may be more clinically
13 effective compared to petrolatum (base component) for pressure ulcers completely healed (grade
14 2 pressure ulcers) (very low quality).
- 15 • One study (n=19) (elderly people) showed that petrolatum ointment may be more clinically
16 effective compared to petrolatum (base component) to improve healing of pressure ulcers (grade
17 1 and 2) (very low quality).
- 18 • One study (n=8) (elderly people) showed that petrolatum ointment may be more clinically
19 effective compared to petrolatum (base component) to improve healing of pressure ulcers (grade
20 2) (very low quality).
- 21 • One study (n=19) (elderly people) showed that petrolatum ointment is clinically more clinically
22 effective compared to petrolatum (base component) to reduce pressure ulcers (grade 1 and 2)
23 worsening (low quality).
- 24 • One study (n=8) (elderly people) showed that petrolatum ointment is clinically more effective
25 compared to petrolatum (base component) to reduce pressure ulcers (grade 2) worsening (low
26 quality).
- 27 • One study (n=19) (elderly people) showed no clinical difference between petrolatum ointment
28 and petrolatum (base component) for mortality (grade 2 pressure ulcers) (low quality).
- 29 • No evidence was found for the following outcomes:
 - 30 o Time to complete healing of pressure ulcers
 - 31 o Rate of reduction in size or volume of pressure ulcers
 - 32 o Reduction in size or volume of pressure ulcers
 - 33 o Pain (wound-related)
 - 34 o Time in hospital
 - 35 o Acceptability of treatment
 - 36 o Side effects
 - 37 o Health-related quality of life
- 38

10.1.5.1.3 ~~2~~ Zinc oxide versus streptokinase-streptodornase

- 40 • One study (n=28) (elderly people) reported a median percentage reduction in pressure ulcer area
41 (necrotic PUs) for zinc oxide and streptokinase-streptodornase. The median for zinc oxide was
42 24% and -18.7% for streptokinase-streptodornase. No estimate of effect or precision could be
43 derived (very low quality).

- 1 • One study (n=28) (elderly people) showed that there may be no clinical difference between zinc
2 oxide and streptokinase-streptodornase for reducing the incidence of infections, the direction of
3 effect favoured zinc oxide (very low quality).
- 4 • One study (n=28) (elderly people) showed that there may be no clinical difference between zinc
5 oxide and streptokinase-streptodornase for reducing the incidence of skin reactions, the direction
6 of effect favoured zinc oxide (very low quality).
- 7 • One study (n=28) (elderly people) showed no clinical difference between zinc oxide and
8 streptokinase-streptodornase for mortality (all-cause), the direction of the estimate of effect
9 favoured either direction (low quality).
- 10 • No evidence was found for the following outcomes:
 - 11 o Proportion of people with pressure ulcers completely healed
 - 12 o Time to complete healing of pressure ulcers
 - 13 o Rate of reduction in size or volume of pressure ulcers
 - 14 o Pain (wound-related)
 - 15 o Time in hospital
 - 16 o Acceptability of treatment
 - 17 o Side effects
 - 18 o Health-related quality of life
- 19

10.1.5.1213 Oxyquinoline versus vitamin A&D treatment (cream)

- 21 • One study (n=137) (people receiving palliative care) showed that oxyquinoline is potentially more
22 clinically effective compared to Vitamin A&D treatment (cream) for pressure ulcers completely
23 healed (grade 1 and 2) (very low quality).
- 24 • One study (n=68) (people receiving palliative care) showed that oxyquinoline is potentially more
25 clinically effective compared to Vitamin A&D treatment (cream) for pressure ulcers completely
26 healed (grade 2) (very low quality).
- 27 • One study (n=69) (people receiving palliative care) showed that oxyquinoline is potentially more
28 clinically effective compared to Vitamin A&D treatment (cream) to improve healing of pressure
29 ulcers (grade 1) (very low quality).
- 30 • One study (n=68) (people receiving palliative care) showed that there may be no clinical
31 difference between oxyquinoline and Vitamin A&D treatment (cream) to improve healing of
32 pressure ulcers (grade 2), the direction of the estimate of the effect favoured the oxyquinoline
33 (very low quality).
- 34 • One study (n=68) (people receiving palliative care) showed that oxyquinoline may be more
35 clinically effective compared to Vitamin A&D treatment (cream) to reduce the incidence of
36 pressure ulcers (grade 2) not changed (very low quality).
- 37 • One study (n=69) (people receiving palliative care) showed no clinical difference between
38 oxyquinoline and Vitamin A&D treatment (cream) to reduce the incidence of pressure ulcers
39 (grade 1) worsened (very low quality).
- 40 • One study (n=68) (people receiving palliative care) showed that oxyquinoline may be more
41 clinically effective compared to Vitamin A&D treatment (cream) to reduce the incidence of
42 pressure ulcers (grade 2) worsening (very low quality).
- 43 • One study (n=137) (people receiving palliative care) showed that there is potentially no clinical
44 difference between oxyquinoline and Vitamin A&D treatment (cream) for mean days to complete
45 healing of pressure ulcers (grade 1 and 2), the direction of the estimate of the effect favoured the
46 oxyquinoline (very low quality).

- 1 • One study (n=69) (people receiving palliative care) showed that there is potentially no clinical
2 difference between oxyquinoline and Vitamin A&D treatment (cream) for mean days to complete
3 healing of pressure ulcers (grade 1), the direction of the estimate of the effect favoured the
4 oxyquinoline (very low quality).
- 5 • One study (n=68) (people receiving palliative care) showed that oxyquinoline is more clinically
6 effective compared to Vitamin A&D treatment (cream) for mean days to complete healing of
7 pressure ulcers (grade 2) (low quality).
- 8 • No evidence was found for the following outcomes:
- 9 o Time to complete healing (time to event data)
- 10 o Rate of reduction in size or volume of pressure ulcers
- 11 o Reduction in size or volume of pressure ulcers
- 12 o Pain (wound-related)
- 13 o Time in hospital
- 14 o Acceptability of treatment
- 15 o Side effects
- 16 o Mortality (all-cause)
- 17 o Health-related quality of life
- 18

10.1.5.1194 Ethoxy-diaminoacridine plus nitrofuazone versus honey

- 20 • One study (n=50) (general populations) showed that honey is clinically more clinically effective
21 compared to ethoxy-diaminoacridine plus nitrofuazone for pressure ulcers completely healed
22 (grade 2 and 3) (low quality).
- 23 • One study (n=50) (general populations) showed that honey is clinically more clinically effective
24 compared to ethoxy-diaminoacridine plus nitrofuazone for mean percentage reduction in PUSH
25 score (grade 2 and 3 pressure ulcers) (low quality).
- 26 • One study (n=50) (general populations) showed that honey is clinically more clinically effective
27 compared to ethoxy-diaminoacridine plus nitrofuazone for mean percentage reduction in ulcer
28 size (grade 2 and 3 pressure ulcers) (low quality).
- 29 • One study (n=50) (general populations) showed that there is no clinical difference between honey
30 and ethoxy-diaminoacridine plus nitrofuazone to reduce the incidence of treatment-related
31 adverse events, the direction of the estimate of effect could favour either intervention (low
32 quality).
- 33 • One study (n=50) (general populations) showed that there is no clinical difference between honey
34 and ethoxy-diaminoacridine plus nitrofuazone for mortality (all-cause), the direction of the
35 estimate of effect favours honey (low quality).
- 36 • No evidence was found for the following outcomes:
- 37 o Time to complete healing
- 38 o Rate or reduction n in size or volume of pressure ulcers
- 39 o Pain (wound-related)
- 40 o Time in hospital
- 41 o Acceptability of treatment
- 42 o Health-related quality of life
- 43

10.1.5.1.15 Povidone-iodine versus hydrocolloid dressing

- 2 • One study (n=44) (general populations) showed that there may be no clinical difference between
3 povidone-iodine and hydrocolloid for proportion of people with pressure ulcers completely
4 healed (grade 1 and 2), the direction of the estimate of the effect favoured the hydrocolloid (very
5 low quality).
- 6 • One study (n=44) (general populations) reported percentage healing rate for povidone-iodine and
7 hydrocolloid. The healing rate for povidone-iodine was 77.8% and 80.8% for hydrocolloid
8 dressing. No estimate of effect or precision could be derived (very low quality).
- 9 • One study (n=44) (general populations) showed that a hydrocolloid is potentially more clinically
10 effective compared to povidone-iodine for mean speed of healing of pressure ulcers (grade 1 and
11 2) (very low quality).
- 12 • One study (n=44) (general populations) showed that a hydrocolloid dressing may be more
13 clinically effective for increasing hypergranulation than povidone-iodine (grade 1 and 2 pressure
14 ulcers) (very low quality).
- 15 • One study (n=44) (general populations) showed that there may be no clinical difference between
16 povidone-iodine and hydrocolloid for mortality (all-cause) (grade 1 and 2 pressure ulcers), the
17 direction of the estimate of effect could favour either direction (very low quality).
- 18 • No evidence was found for the following outcomes:
 - 19 o Time to complete healing of pressure ulcers
 - 20 o Reduction in size or volume of pressure ulcers
 - 21 o Pain (wound-related)
 - 22 o Time in hospital
 - 23 o Acceptability of treatment
 - 24 o Health-related quality of life
- 25

10.1.5.1266 Povidone-iodine versus hydrogel dressing

- 27 One study (n=49) (general populations) showed that there is potentially no clinical difference
28 between hydrogel and povidone-iodine for mean speed of healing of pressure ulcers, the
29 direction of the estimate of effect favours hydrogel (grade 1 to 3 pressure ulcers) (very low
30 quality).
- 31 • No evidence was found for the following outcomes:
 - 32 o Proportion of people with pressure ulcers completely healed
 - 33 o Time to complete healing of pressure ulcers
 - 34 o Reduction in size or volume of pressure ulcers
 - 35 o Pain (wound-related)
 - 36 o Time in hospital
 - 37 o Acceptability of treatment
 - 38 o Side effects
 - 39 o Mortality (all-cause)
 - 40 o Health-related quality of life

10.1.5.1417 Cadexomer iodine versus standard treatment

- 42 • One study (n=34) (general populations) showed that cadexomer iodine is more clinically effective
43 compared to standard treatment to reduce the proportion of deep and superficial pressure ulcers
44 healed by 50% (low quality).

- 1 • One study (n=34) (general populations) showed there is no clinical difference between cadexomer
2 iodine and standard treatment for mean cm² reduction in pressure ulcer area, the direction of the
3 estimate of effect favours cadexomer iodine (low quality).
- 4 • One study (n=34) (general populations) showed that there is no clinical difference between
5 cadexomer iodine and standard treatment for mean percentage reduction in pressure ulcer area,
6 the direction of the estimate of effect favoured cadexomer iodine (low quality).
- 7 • One study (n=34) (general populations) showed there is no clinical difference between cadexomer
8 iodine and standard treatment for mortality (all-cause) (low quality).
- 9 • No evidence was found for the following outcomes:
- 10 o Proportion of people with pressure ulcers completely healed
- 11 o Time to complete healing of pressure ulcers
- 12 o Rate of reduction in size or volume of pressure ulcers
- 13 o Pain (wound-related)
- 14 o Time in hospital
- 15 o Acceptability of treatment
- 16 o Side effects
- 17 o Health-related quality of life
- 18

10.1.5.11~~18~~ Silver sulfazidine cream versus silver dressing

- 20 • One study (n=40) (general populations) showed that there may be no clinical difference between
21 silver sulfazidine cream and a silver dressing for mean percentage reduction in pressure ulcer area
22 (grade 4 pressure ulcers) (very low quality).
- 23 • One study (n=40) (general populations) reported percentage reduction in PUSH score (grade IV
24 PUs) for silver sulfazidine cream and a silver dressing. The mean for silver sulfazidine cream was
25 34.51% and 28.15% for silver dressing. A p-value of p=0.473 was reported (very low quality).
- 26 • One study (n=40) (general populations) showed no difference between silver sulfazidine cream
27 and a silver dressing to reduce the incidence of adverse events, the direction of the estimate of
28 effect favours either intervention (low quality).
- 29 • One study (n=40) (general populations) showed no difference between silver sulfazidine cream
30 and a silver dressing for mortality (all-cause) (low quality).
- 31 • No evidence was found for the following outcomes:
- 32 o Proportion of people with pressure ulcers completely healed
- 33 o Time to complete healing of pressure ulcers
- 34 o Rate of reduction in size or volume of pressure ulcers
- 35 o Pain (wound-related)
- 36 o Time in hospital
- 37 o Acceptability of treatment
- 38 o Health-related quality of life
- 39

10.1.5.14~~19~~ Resin salve versus hydrofibre

- 41 • One study (n=22) (general populations) showed that resin salve is potentially more clinically
42 effective compared to a hydrofibre for proportion of people with pressure ulcers completely
43 healed (grade 2 to 4) (very low quality).

- 1 • One study (n=29) (general populations) showed that resin salve is potentially more clinically
2 effective compared to a hydrofibre for pressure ulcers completely healed (grade 2 to 4) (very low
3 quality).
- 4 • One study (n=29) (general populations) showed that there is potentially no clinical difference
5 between resin salve and a hydrofibre to improve healing of pressure ulcers (grade 2 to 4), the
6 direction of the estimate of the effect favoured the resin salve (very low quality).
- 7 • One study (n=29) (general populations) showed there may be no clinical difference between resin
8 salve and hydrofibre to reduce pressure ulcers (grade 2 to 4) worsening (very low quality).
- 9 • One study (n=29) (general populations) reported mean percentage reduction in ulcer width for
10 resin salve and hydrofibre. The mean for resin salve was 93.75% and 57.14% for hydrofibre. No
11 estimate of effect or precision could be derived (very low quality).
- 12 • One study (n=29) (general populations) reported mean percentage reduction in ulcer depth for
13 resin salve and hydrofibre. The mean for resin salve was 88.46% and -1.89% for hydrofibre. No
14 estimate of effect or precision could be derived (very low quality).
- 15 • One study (n=29) (general populations) reported speed of healing for resin salve and hydrofibre.
16 The log-rank-test revealed a p-value 0.013, which favoured resin salve (very low quality).
- 17 • One study (n=22) (general populations) showed there may be no clinical difference between
18 hydrofibre and resin salve to reduce the incidence of skin reactions, the direction of the estimate
19 of effect favours hydrofibre (very low quality).
- 20 • One study (n=29) (general populations) showed hydrofibre may be more clinically harmful than
21 resin salve for mortality (all-cause) (very low quality).
- 22 • No evidence was found for the following outcomes:
23 o Time to complete healing of pressure ulcers
24 o Pain (wound-related)
25 o Time in hospital
26 o Acceptability of treatment
27 o Side effects
28 o Health-related quality of life
29

10.1.5.1320 Antibiotic ointment versus foam dressing

- 31 • One study (n=44) (institutionalised elderly adults) showed that a foam dressing may be more
32 clinically effective compared to antibiotic ointment for proportion of people with pressure ulcers
33 completely healed (grade 2) (very low quality).
- 34 • One study (n=44) (institutionalized elderly adults) reported mean PUSH score for antibiotic
35 ointment and a foam dressing. The mean score was 1.61 for the antibiotic ointment and 3.24 for
36 foam dressing. A p-value > 0.05 was reported (very low quality).
- 37 • No evidence was found for the following outcomes:
38 o Time to complete healing of pressure ulcers
39 o Rate of reduction in size or volume of pressure ulcers
40 o Reduction in size or volume of pressure ulcers
41 o Pain (wound-related)
42 o Time in hospital
43 o Acceptability of treatment
44 o Side effects
45 o Mortality (all-cause)

1

10.1.5.1.21 Insulin versus standard treatment

- 3 • One study (n=14) (people in a nursing home) reported mean healing rate for insulin and standard
4 treatment. A p-value of 0.05 in favour of insulin was reported (very low quality).
- 5 • One study (n=12) showed there is no clinical difference between insulin and standard treatment
6 for mortality (all-cause), the direction of the estimate of effect could favour either intervention
7 (low quality).
- 8 • No evidence was found for the following outcomes:
- 9 o Proportion of people with pressure ulcers completely healed
- 10 o Time to complete healing
- 11 o Reduction in size or volume of pressure ulcers
- 12 o Pain (wound-related)
- 13 o Time in hospital
- 14 o Acceptability of treatment
- 15 o Side effects
- 16 o Health-related quality of life
- 17

10.1.5.1.22 Growth factor versus placebo

- 19 • Six studies (n=316) (general population and denervated people) showed that different types of
20 growth factors may be more clinically effective compared to placebo for proportion of people
21 with pressure ulcers completely healed (grade 2 and above) (very low quality).
- 22 • One study (n=14) showed that TGF β 3 may be more clinically effective compared to placebo for
23 proportion of people completely healed (grade 3 to 4) (very low quality).
- 24 • One study (n=36) (people in a nursing home with foot ulcers) showed that mNGF is more clinically
25 effective than placebo for proportion of people with pressure ulcers completely healed (grade 2
26 and above) (moderate quality).
- 27 • One study (n=188) showed that there may be no clinical difference between rPDFG-BB compared
28 to placebo for the proportion of people completely healed (grade 3 and 4) (very low quality).
- 29 • One study (n=54) showed that there may be no clinical difference between bFGF or GM-CSF
30 compared to placebo for proportion of people completely healed (grade 3 and 4) (very low
31 quality).
- 32 • One study (n=24) showed that there is no clinical difference between rIL-1 β compared to placebo
33 for proportion of people completely healed (grade 3 and 4) (low quality).
- 34 • No evidence was found for the following outcomes:
- 35 o Mortality (all-cause)
- 36 o Time to complete healing of pressure ulcers
- 37 o Rate of reduction in size or volume of pressure ulcers
- 38 o Reduction in size or volume of pressure ulcers
- 39 o Pain (wound-related)
- 40 o Time in hospital
- 41 o Acceptability of treatment
- 42 o Side effects
- 43 o Health-related quality of life
- 44

10.1.5.1.23 Transforming growth factor-beta 3 (1.0µg/cm) versus placebo

- 2 • One study (n=9) (inpatients) showed that there is no clinical difference between transforming
3 growth factor-beta 3 (1.0µg/cm) and placebo for proportion of people with pressure ulcers
4 completely healed (grade 3 and 4) (low quality).
- 5 • One study (n=9) (inpatients) reported mean percentage reduction in pressure ulcer area for
6 transforming growth factor-beta 3 (1.0µg/cm) and placebo. The mean for transforming growth
7 factor-beta 3 (1.0µg/cm) was 70% and 30% for placebo. No estimate of effect or precision could
8 be derived (very low quality).
- 9 • One study (n=9) (inpatients) reported mean percentage reduction in ulcer volume for
10 transforming growth factor-beta 3 (1.0µg/cm) and placebo. The mean for transforming growth
11 factor-beta 3 (1.0µg/cm) was 75% and 20% for placebo. No estimate of effect or precision could
12 be derived (very low quality)
- 13 One study (n=14) (inpatients) showed that transforming growth factor-beta 3 (1.0µg/cm) may be
14 more clinically effective when compared to placebo for reduction in mortality (all-cause) (grade 3
15 and 4) (very low quality)
- 16 • No evidence was found for the following outcomes:
 - 17 o Time to complete healing of pressure ulcers
 - 18 o Rate of reduction in size or volume of pressure ulcers
 - 19 o Pain (wound-related)
 - 20 o Time in hospital
 - 21 o Acceptability of treatment
 - 22 o Side effects
 - 23 o Health-related quality of life
- 24

10.1.5.1.24 Transforming growth factor-beta 3 (2.5µg/cm) versus transforming growth factor- beta 3 (1.0µg/cm)

- 27 • One study (n=9) (inpatients) showed that transforming growth factor-beta 3 (2.5µg/cm) may be
28 more clinically effective compared to transforming growth factor-beta 3 (1.0µg/cm) for
29 proportion of people with pressure ulcers completely healed (grade 3 and 4) (very low quality).
- 30 • One study (n=9) (inpatients) reported mean percentage reduction in ulcer area for transforming
31 growth factor-beta 3 (1.0µg/cm) and transforming growth factor-beta 3 (2.5µg/cm). The mean for
32 transforming growth factor-beta 3 (1.0µg/cm) was 70% and 60% for transforming growth factor-
33 beta 3 (2.5µg/cm). No estimate of effect or precision could be derived (very low quality).
- 34 • One study (n=9) (inpatients) reported mean percentage reduction in ulcer volume for
35 transforming growth factor-beta 3 (1.0µg/cm) and transforming growth factor-beta 3 (2.5µg/cm).
36 The mean for transforming growth factor-beta 3 (1.0µg/cm) was 75% and 60% for transforming
37 growth factor-beta 3 (2.5µg/cm). No estimate of effect or precision could be derived (very low
38 quality).
- 39 • One study (n=9) (inpatients) showed that transforming growth factor-beta 3 (2.5µg/cm) may be
40 more clinically effective compared to transforming growth factor-beta 3 (1.0µg/cm) for mortality
41 (all-cause)(very low quality).
- 42 • No evidence was found for the following outcomes:
 - 43 o Time to complete healing of pressure ulcers
 - 44 o Rate of reduction in size or volume of pressure ulcers
 - 45 o Pain (wound-related)
 - 46 o Time in hospital

- 1 o Acceptability of treatment
- 2 o Side effects
- 3 o Health-related quality of life
- 4

10.1.5.1.25 Transforming growth factor-beta 3 (2.5µg/cm) versus placebo

- 6 • One study (n=10) (inpatients) showed that transforming growth factor-beta 3 (2.5µg/cm) may be
7 more clinically effective compared to placebo for proportion of people with pressure ulcers
8 completely healed (grade 3 and 4) (low quality).
- 9 • One study (n=10) (inpatients) reported mean percentage reduction in ulcer area for transforming
10 growth factor-beta 3 (2.5µg/cm) and placebo. The mean for transforming growth factor-beta 3
11 (2.5µg/cm) was 60% and 30% for placebo. No estimate of effect or precision could be derived
12 (very low quality).
- 13 • One study (n=10) (inpatients) reported mean percentage reduction in ulcer volume for
14 transforming growth factor-beta 3 (2.5µg/cm) and placebo. The mean for transforming growth
15 factor-beta 3 (2.5µg/cm) was 60% and 20% for placebo. No estimate of effect or precision could
16 be derived (very low quality).
- 17 • One study (n=10) (inpatients) showed that transforming growth factor-beta 3 (2.5µg/cm) may be
18 more clinically effective compared to placebo for mortality (all-cause) (very low quality).
- 19 • No evidence was found for the following outcomes:
 - 20 o Time to complete healing of pressure ulcers
 - 21 o Rate of reduction in size or volume of pressure ulcers
 - 22 o Pain (wound-related)
 - 23 o Time in hospital
 - 24 o Acceptability of treatment
 - 25 o Side effects
 - 26 o Health-related quality of life
 - 27

10.1.5.1.26 Mouse nerve growth factor (2.5 S murine) versus placebo

- 29 • One study (n=36) (people in a nursing home) showed that mouse nerve growth factors is
30 potentially more clinically effective compared to placebo for proportion of people with pressure
31 ulcers completely healed (grade 2 and above) (foot ulcers) (moderate quality).
- 32 • One study (n=36) (people in a nursing home) showed that mouse nerve growth factors is more
33 clinically effective compared to placebo to improve healing by 3 or more grade of pressure ulcers
34 (grade 2 and above) (foot ulcers) (moderate quality).
- 35 • One study (n=36) (people in a nursing home) showed that mouse nerve growth factors is more
36 clinically effective compared to placebo to improve healing by 2 grade of pressure ulcers (grade 2
37 and above) (foot ulcers) (moderate quality).
- 38 • One study (n=36) (people in a nursing home) showed that mouse nerve growth factors is more
39 clinically effective compared to placebo to improve healing by 1 grade of pressure ulcers (grade 2
40 and above) (foot ulcers) (moderate quality).
- 41 • One study (n=36) (people in a nursing home) showed that there may be no clinical difference
42 between mouse nerve growth factors and placebo for mean mm² reduction in pressure ulcer area
43 (grade 2 and above pressure ulcers)(foot ulcers), the direction of the estimate of the effect
44 favoured the nerve growth factors (low quality).
- 45 • One study (n=36) (people in a nursing home) showed that mouse nerve growth factors is more
46 clinically effective compared to placebo for mean mm² reduction in pressure ulcer area (adjusted

- 1 for baseline ulcer area, location and duration) (grade 2 and above pressure ulcers) (foot ulcers)
2 (moderate quality).
- 3 • One study (n=36) (people in a nursing home) showed that no clinical difference between mouse
4 nerve growth factors and placebo for the incidence of adverse events (moderate quality).
- 5 • One study (n=36) (people in a nursing home) showed that there may be no clinical difference
6 between mouse nerve growth factors and placebo for the mortality (all-cause), the direction of
7 the estimate of effect could favour the mouse nerve growth factors (moderate quality).
- 8 • No evidence was found for the following outcomes:
- 9 o Time to complete healing of pressure ulcers
- 10 o Rate of reduction in size or volume of pressure ulcers
- 11 o Pain (wound-related)
- 12 o Time in hospital
- 13 o Acceptability of treatment
- 14 o Health-related quality of life
- 15

10.1.5.11 ~~17~~ Recombinant platelet-derived growth factor 100µ/ml versus placebo

- 17 • Two studies (n=50) (general population and denervated people) showed that recombinant
18 platelet-derived growth factor (100µg/ml) may be more clinically effective compared to placebo
19 for proportion of people with pressure ulcers completely healed (grade 3 and 4) (very low
20 quality).
- 21 • One study (n=30) (general population) reported ulcer volume at end of treatment (adjusted for
22 initial volume) for recombinant platelet-derived growth factor (100µg/ml) and placebo. The
23 volume was 1.75g for the recombinant platelet-derived growth factor (100µg/ml) and 3.5 g for
24 placebo. No estimate of effect or precision could be derived (very low quality).
- 25 • One study (n=50) (general population and denervated people) showed there is no clinical
26 difference between recombinant platelet-derived growth factor and placebo for mortality (all-
27 cause) (very low quality).
- 28 • No evidence was found for the following outcomes:
- 29 o Time to complete healing of pressure ulcers
- 30 o Rate of reduction in size or volume of pressure ulcers
- 31 o Reduction in size or volume of pressure ulcers
- 32 o Pain (wound-related)
- 33 o Time in hospital
- 34 o Acceptability of treatment
- 35 o Side effects
- 36 o Health-related quality of life
- 37

10.1.5.12 ~~28~~ Recombinant platelet-derived growth factor 100µg/ml versus recombinant platelet-derived growth factor 300µg/ml

- 39 • One study (n=28) (general population) showed that recombinant platelet-derived growth factor
40 (100µg/ml) may be more clinically effective compared to recombinant platelet-derived growth
41 factor (300µg/ml) for proportion of people with pressure ulcers completely healed (grade 3 and 4)
42 (very low quality).
- 43 • One study (n=28) (general population) reported ulcer volume at end of treatment (adjusted for
44 initial volume) for recombinant platelet-derived growth factor (100µg/ml) and recombinant
45

1 platelet-derived growth factor (300µg/ml). The volume was 1.75g for the recombinant platelet-
2 derived growth factor (100µg/ml) and 2.0g for recombinant platelet-derived growth factor
3 (300µg/ml). No estimate of effect or precision could be derived (very low quality).

10.1.5.1.29 Recombinant platelet-derived growth factor 300µg/ml versus placebo

- 5 • One study (n=26) (general population) showed that recombinant platelet-derived growth factor
6 (300µg/ml) may be more clinically effective compared to placebo for proportion of people with
7 pressure ulcers completely healed (grade 3 and 4) (very low quality).
- 8 • One study (n=30) (general population) reported ulcer volume at end of treatment (adjusted for
9 initial volume) for recombinant platelet-derived growth factor (300µg/ml) and placebo. The
10 volume was 2.0g for the recombinant platelet-derived growth factor (300µg/ml) and 3.5g for
11 placebo. No estimate of effect or precision could be derived (very low quality).
- 12

10.1.5.1.30 Basic fibroblast growth factor or granulocyte-macrophage colony-stimulating factor versus placebo

- 14 • One study (n=54) (inpatients) showed that there is potentially no clinical difference between basic
15 fibroblast growth factor or granulocyte-macrophage colony-stimulating factor and placebo for
16 complete healing of pressure ulcers (grade 3 and 4) (very low quality).
- 17

10.1.5.1.31 Granulocyte-macrophage colony-stimulating factor 2.0µg/cm² versus placebo

- 19 • One study (n=27) (inpatients) showed that placebo may be more clinically effective compared to
20 granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) for proportion of people with
21 pressure ulcers completely healed (grade 3 and 4) (very low quality).
- 22 • One study (n=27) (inpatients) showed that placebo may be more clinically effective compared to
23 granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) to reduce pressure ulcers (grade 3
24 and 4) worsening (very low quality).
- 25 • One study (n=30) (inpatients) showed that there is potentially no clinical difference between
26 granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) and placebo for mean percentage
27 reduction in pressure ulcer area (grade 3 and 4 pressure ulcers) (very low quality).
- 28 • One study (n=30) (inpatients) reported median percentage reduction in ulcer area for
29 granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) and placebo. The median for
30 granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) was 70% and 72% for placebo. No
31 estimate of effect or precision could be derived (very low quality).
- 32 • One study (n=30) (inpatients) reported no clinical difference between granulocyte-macrophage
33 colony-stimulating factor (2.0 µg/cm²) and placebo for mortality (all-cause) (low quality).
- 34 • No evidence was found for the following outcomes:
- 35 o Time to complete healing of pressure ulcers
- 36 o Rate of reduction in size or volume of pressure ulcers
- 37 o Reduction in size or volume of pressure ulcers
- 38 o Pain (wound-related)
- 39 o Time in hospital
- 40 o Acceptability of treatment
- 41 o Side effects
- 42 o Health-related quality of life
- 43

10.1.5.1.32 Basic fibroblast growth factor (5.0µg/cm²) versus granulocyte-macrophage colony-stimulating factor (2.0µg/cm²)

- One study (n=28) (inpatients) showed that there basic fibroblast growth factor (5.0µg/cm²) may be more clinically effective for the proportion of people with pressure ulcers completely healed compared to granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) (grade 3 and 4), (very low quality).
- One study (n=28) (inpatients) showed that granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) may be more clinically effective compared to basic fibroblast growth factor (5.0µg/cm²) to reduce pressure ulcers (grade 3 and 4) worsening (very low quality).
- One study (n=30) (inpatients) showed that basic fibroblast growth factor (5.0µg/cm²) is potentially more clinically effective compared to granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) for mean percentage reduction in pressure ulcer area (grade 3 and 4 pressure ulcers) (very low quality).
- One study (n=30) (inpatients) reported median percentage reduction in ulcer area for granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) and basic fibroblast growth factor (5.0µg/cm²). The median for granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) was 70% and 79% for basic fibroblast growth factor (5.0µg/cm²). No estimate of effect or precision could be derived (very low quality).
- One study (n=28) (inpatients) showed that there is no clinical difference between granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) and basic fibroblast growth factor (5.0µg/cm²) for mortality (all-cause) (low quality).
- No evidence was found for the following outcomes:
 - o Time to complete healing of pressure ulcers
 - o Rate of reduction in size or volume of pressure ulcers
 - o Reduction in size or volume of pressure ulcers
 - o Pain (wound-related)
 - o Time in hospital
 - o Acceptability of treatment
 - o Side effects
 - o Mortality
 - o Health-related quality of life

10.1.5.1.33 Granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) and basic fibroblast growth factor (5.0µg/cm²) versus granulocyte-macrophage colony-stimulating factor (2.0µg/cm²)

- One study (n=27) (inpatients) showed that granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) and basic fibroblast growth factor (5.0µg/cm²) may be more clinically effective for proportion of people with pressure ulcers completely healed compared to granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) (grade 3 and 4), the direction of the estimate of the effect favoured the granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) and basic fibroblast growth factor (5.0µg/cm²) (very low quality).
- One study (n=27) (inpatients) showed that granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) and basic fibroblast growth factor (5.0µg/cm²) may be more clinically effective compared to granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) to reduce pressure ulcers (grade 3 and 4) worsening (very low quality).
- One study (n=30) (inpatients) showed there may be no clinical difference between granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) and basic fibroblast growth factor (5.0µg/cm²) compared to granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) for mean percentage

- 1 reduction in pressure ulcer area (grade 3 and 4 pressure ulcers), the direction of the estimate of
2 effect could favour either granulocyte-macrophage colony-stimulating factor ($2.0\mu\text{g}/\text{cm}^2$) (very
3 low quality).
- 4 • One study ($n=30$) (inpatients) reported median percentage reduction in ulcer area for
5 granulocyte-macrophage colony-stimulating factor ($2.0\mu\text{g}/\text{cm}^2$) versus granulocyte-macrophage
6 colony-stimulating factor ($2.0\mu\text{g}/\text{cm}^2$) and basic fibroblast growth factor ($5.0\mu\text{g}/\text{cm}^2$). The median
7 for granulocyte-macrophage colony-stimulating factor ($2.0\mu\text{g}/\text{cm}^2$) was 70% and 73% granulocyte-
8 macrophage colony-stimulating factor ($2.0\mu\text{g}/\text{cm}^2$) and basic fibroblast growth factor ($5.0\mu\text{g}/\text{cm}^2$).
9 No estimate of effect or precision could be derived (very low quality).
- 10 • One study ($n=30$) (inpatients) showed there is no clinical difference between granulocyte-
11 macrophage colony-stimulating factor ($2.0\mu\text{g}/\text{cm}^2$) and basic fibroblast growth factor ($5.0\mu\text{g}/\text{cm}^2$)
12 compared to granulocyte-macrophage colony-stimulating factor ($2.0\mu\text{g}/\text{cm}^2$) for mortality (all-
13 cause), the direction of the estimate of effect could favour either intervention (very low quality).
- 14 • No evidence was found for the following outcomes:
- 15 o Time to complete healing of pressure ulcers
- 16 o Rate of reduction in size or volume of pressure ulcers
- 17 o Pain (wound-related)
- 18 o Time in hospital
- 19 o Acceptability of treatment
- 20 o Side effects
- 21 o Health-related quality of life
- 22

10.1.5.1234 Basic fibroblast growth factor ($5.0\mu\text{g}/\text{cm}^2$) versus placebo

- 24 • One study ($n=27$) (inpatients) showed that there may be no clinical difference between basic
25 fibroblast growth factor ($5.0\mu\text{g}/\text{cm}^2$) and placebo for proportion of people with pressure ulcers
26 completely healed (grade 3 and 4), the direction of the estimate of the effect favoured placebo
27 (very low quality).
- 28 • One study ($n=27$) (inpatients) showed that placebo is potentially more clinically effective
29 compared to basic fibroblast growth factor ($5.0\mu\text{g}/\text{cm}^2$) to reduce pressure ulcer (grade 3 and 4)
30 worsening (very low quality).
- 31 • One study ($n=30$) (inpatients) showed that there is potentially no clinical difference between basic
32 fibroblast growth factor ($5.0\mu\text{g}/\text{cm}^2$) and placebo for mean percentage reduction in pressure ulcer
33 area (grade 3 and 4 pressure ulcers), the direction of the estimate of the effect favoured the basic
34 fibroblast growth factor ($5.0\mu\text{g}/\text{cm}^2$) (very low quality).
- 35 • One study ($n=30$) (inpatients) reported median percentage reduction in ulcer area for basic
36 fibroblast growth factor ($5.0\mu\text{g}/\text{cm}^2$) and placebo. The median for basic fibroblast growth factor
37 ($5.0\mu\text{g}/\text{cm}^2$) was 79% and 72% placebo. No estimate of effect or precision could be derived (very
38 low quality).
- 39 • One study ($n=30$) (inpatients) showed that there is no clinical difference between basic fibroblast
40 growth factor ($5.0\mu\text{g}/\text{cm}^2$) and placebo for mortality (all-cause), the direction of the estimate of
41 the effect could favour either intervention (low quality).
- 42 • No evidence was found for the following outcomes:
- 43 o Time to complete healing of pressure ulcers
- 44 o Rate of reduction in size or volume of pressure ulcers
- 45 o Pain (wound-related)
- 46 o Time in hospital
- 47 o Acceptability of treatment

- 1 o Side effects
- 2 o Health-related quality of life
- 3

10.1.5.1.35 Basic fibroblast growth factor (5.0µg/cm²) versus granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) and basic fibroblast growth factor (5.0µg/cm²)

- 6 • One study (n=27) (inpatients) showed that there may be no clinical difference between basic
7 fibroblast growth factor (5.0µg/cm²) versus granulocyte-macrophage colony-stimulating factor
8 (2.0µg/cm²) and basic fibroblast growth factor (5.0µg/cm²) for proportion of people with pressure
9 ulcers completely healed (grade 3 and 4), the direction of the estimate of the effect favoured
10 basic fibroblast growth factor (5.0µg/cm²) (very low quality).
- 11 • One study (n=27) (inpatients) showed that granulocyte-macrophage colony-stimulating factor
12 (2.0µg/cm²) and basic fibroblast growth factor (5.0µg/cm²) may be more clinically effective
13 compared to basic fibroblast growth factor (5.0µg/cm²) to reduce pressure ulcers (grade 3 and 4)
14 worsening (very low quality).
- 15 • One study (n=31) (inpatients) showed that there is potentially no clinical difference between basic
16 fibroblast growth factor (5.0µg/cm²) versus granulocyte-macrophage colony-stimulating factor
17 (2.0µg/cm²) and basic fibroblast growth factor (5.0µg/cm²) for mean percentage reduction in
18 pressure ulcer area (grade 3 and 4 pressure ulcers), the direction of the estimate of the effect
19 favoured the basic fibroblast growth factor (5.0µg/cm²) (very low quality).
- 20 • One study (n=31) (inpatients) reported median percentage reduction in ulcer area for basic
21 fibroblast growth factor (5.0µg/cm²) versus granulocyte-macrophage colony-stimulating factor
22 (2.0µg/cm²) and basic fibroblast growth factor (5.0µg/cm²). The median for basic fibroblast
23 growth factor (5.0µg/cm²) was 79% and 73% granulocyte-macrophage colony-stimulating factor
24 (2.0µg/cm²) and basic fibroblast growth factor (5.0µg/cm²). No estimate of effect or precision
25 could be derived (very low quality).
- 26 • One study (n=31) (inpatients) showed no clinical difference between basic fibroblast growth
27 factor (5.0µg/cm²) versus granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) and
28 basic fibroblast growth factor (5.0µg/cm²) for mortality (all-cause) (low quality).
- 29 • No evidence was found for the following outcomes:
 - 30 o Time to complete healing of pressure ulcers
 - 31 o Rate of reduction in size or volume of pressure ulcers
 - 32 o Pain (wound-related)
 - 33 o Time in hospital
 - 34 o Acceptability of treatment
 - 35 o Side effects
 - 36 o Health-related quality of life
- 37

10.1.5.1.36 Basic fibroblast growth factor (5.0µg/cm²) and granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) versus placebo

- 40 • One study (n=26) (inpatients) showed that there may be no clinical difference between basic
41 fibroblast growth factor (5.0µg/cm²) and granulocyte-macrophage colony-stimulating factor
42 (2.0µg/cm²) versus placebo for proportion of people with pressure ulcers completely healed
43 (grade 3 and 4), the direction of the estimate of the effect favoured placebo (very low quality).
- 44 • One study (n=26) (inpatients) showed that placebo may be more clinically effective compared to
45 granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) and basic fibroblast growth factor
46 (5.0µg/cm²) to reduce pressure ulcers (grade 3 and 4) worsening (very low quality).

- 1 • One study (n=31) (inpatients) showed that there may be no clinical difference between basic
2 fibroblast growth factor (5.0µg/cm²) and granulocyte-macrophage colony-stimulating factor
3 (2.0µg/cm²) versus placebo for mean percentage reduction in pressure ulcer area (grade 3 and 4
4 pressure ulcers), the direction of the estimate of the effect favoured the basic fibroblast growth
5 factor (5.0µg/cm²) and granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) (very low
6 quality).
- 7 • One study (n=31) (inpatients) reported median percentage reduction in ulcer area for basic
8 fibroblast growth factor (5.0µg/cm²) and granulocyte-macrophage colony-stimulating factor
9 (2.0µg/cm²) versus placebo. The median for basic fibroblast growth factor (5.0µg/cm²) and
10 granulocyte-macrophage colony-stimulating factor (2.0µg/cm²) was 73% and 72% for placebo. No
11 estimate of effect or precision could be derived (very low quality).
- 12 • One study (n=31) (inpatients) showed that there may be no clinical difference between basic
13 fibroblast growth factor (5.0µg/cm²) and granulocyte-macrophage colony-stimulating factor
14 (2.0µg/cm²) versus placebo for mortality (all-cause) (low quality).
- 15 • No evidence was found for the following outcomes:
 - 16 o Time to complete healing of pressure ulcers
 - 17 o Rate of reduction in size or volume of pressure ulcers
 - 18 o Pain (wound-related)
 - 19 o Time in hospital
 - 20 o Acceptability of treatment
 - 21 o Side effects
 - 22 o Health-related quality of life
- 23

10.1.5.1237 Recombinant platelet-derived growth factor-BB (100µg/g) versus placebo

- 25 • One study (n=62) (general population) showed that recombinant platelet-derived growth factor-
26 BB (100µg/g) is more clinically effective compared to placebo for proportion of people with
27 pressure ulcers completely healed (grade 3 and 4) (low quality).
- 28 • One study (n=62) (general population) showed that recombinant platelet-derived growth factor-
29 BB (100µg/g) is potentially more clinically effective compared to placebo to improve healing ?90%
30 pressure ulcers (grade 3 and 4) (very low quality).
- 31 • One study (n=62) (general population) reported median percentage reduction in ulcer volume for
32 recombinant platelet-derived growth factor-BB (100µg/g) and placebo. The median for
33 recombinant platelet-derived growth factor-BB (100µg/g) was 99.6% and 99.1% for placebo. A p-
34 value of 0.013 was reported (very low quality).
- 35 • One study (n=62) (general population) showed that there may be no clinical difference between
36 recombinant platelet-derived growth factor-BB (100µg/g) and placebo to reduce the incidence of
37 osteomyelitis (grade 3 and 4 pressure ulcers) (very low quality).
- 38 • One study (n=62) (general population) showed that there may be no clinical difference between
39 recombinant platelet-derived growth factor-BB (100µg/g) and placebo to reduce the incidence of
40 infections (grade 3 and 4 pressure ulcers) (very low quality).
- 41 • One study (n=62) (general population) showed that there is no clinical difference between
42 recombinant platelet-derived growth factor-BB (100µg/g) and placebo for reduction of incidence
43 of sepsis (grade 3 and 4 pressure ulcers) (low quality).
- 44 • One study (n=62) (general population) showed that there may be no clinical difference between
45 recombinant platelet-derived growth factor-BB (100µg/g) and placebo for reduction of incidence
46 of adverse events other than osteomyelitis, sepsis and infections, the direction of the estimate of
47 the effect could favour either intervention (grade 3 and 4 pressure ulcers) (very low quality).

- 1 • One study (n=62) (general population) showed no clinical difference between platelet-derived
2 growth factor-BB (100µg/g) and placebo for mortality (all-cause) (low quality).
- 3 • No evidence was found for the following outcomes:
- 4 o Time to complete healing of pressure ulcers
- 5 o Rate of reduction in size or volume of pressure ulcers
- 6 o Pain (wound-related)
- 7 o Time in hospital
- 8 o Acceptability of treatment
- 9 o Side effects
- 10 o Health-related quality of life
- 11

**10.1.5.1128 Recombinant platelet-derived growth factor-BB (100µg/g) versus recombinant platelet-derived
13 growth factor-BB (300µg/g) alternated with placebo**

- 14 • One study (n=63) (general population) showed that there may be no clinical difference between
15 recombinant platelet-derived growth factor-BB (100µg/g) and recombinant platelet-derived
16 growth factor-BB (300µg/g) alternated with placebo for proportion of people with pressure ulcers
17 completely healed (grade 3 and 4 pressure ulcers), the direction of the estimate of the effect
18 favoured recombinant platelet-derived growth factor-BB (100µg/g) (very low quality).
- 19 • One study (n=63) (general population) showed that there may be no clinical difference between
20 recombinant platelet-derived growth factor-BB (100µg/g) and recombinant platelet-derived
21 growth factor-BB (300µg/g) alternated with placebo to improve healing of 90% of pressure ulcers
22 grade III and IV, the direction of the estimate of the effect favoured recombinant platelet-derived
23 growth factor-BB (300µg/g) alternated with placebo (very low quality).
- 24 • One study (n=63) (general population) reported median percentage reduction in ulcer volume for
25 recombinant platelet-derived growth factor-BB (100µg/g) and recombinant platelet-derived
26 growth factor-BB (300µg/g) alternated with placebo. The median for recombinant platelet-
27 derived growth factor-BB (100µg/g) was 99.6% and 99.7% for recombinant platelet-derived
28 growth factor-BB (300µg/g) alternated with placebo. No estimate of effect or precision could be
29 derived (very low quality).
- 30 • One study (n=63) (general population) showed that there may be no clinical difference between
31 recombinant platelet-derived growth factor-BB (100µg/g) and recombinant platelet-derived
32 growth factor-BB (300µg/g) alternated with placebo to reduce the incidence of osteomyelitis
33 (grade 3 and 4 pressure ulcers) (very low quality).
- 34 • One study (n=63) (general population) showed that there is no clinical difference between
35 recombinant platelet-derived growth factor-BB (100µg/g) and recombinant platelet-derived
36 growth factor-BB (300µg/g) alternated with placebo to reduce the incidence of infections (grade 3
37 and 4 pressure ulcers) (low quality).
- 38 • One study (n=63) (general population) showed that there may be no clinical difference between
39 recombinant platelet-derived growth factor-BB (100µg/g) and recombinant platelet-derived
40 growth factor-BB (300µg/g) alternated with placebo for reduction of incidence of sepsis (grade 3
41 and 4 pressure ulcers) (very low quality).
- 42 • One study (n=63) (general population) showed there may be no clinical difference between
43 recombinant platelet-derived growth factor-BB (100µg/g) and recombinant platelet-derived
44 growth factor-BB (300µg/g) alternated with placebo for reduction of incidence of adverse events
45 other than osteomyelitis, sepsis and infections (grade 3 and 4 pressure ulcers), the direction of
46 the estimate of effect favours recombinant platelet-derived growth factor-BB (100µg/g) and
47 recombinant platelet-derived growth factor-BB (300µg/g) (very low quality).

- 1 • One study (n=63) (general population) showed that there is no difference between recombinant
2 platelet-derived growth factor-BB (100µg/g) and recombinant platelet-derived growth factor-BB
3 (300µg/g) alternated with placebo for mortality (all-cause) (low quality).
- 4 • No evidence was found for the following outcomes:
- 5 o Time to complete healing of pressure ulcers
- 6 o Rate of reduction in size or volume of pressure ulcers
- 7 o Pain (wound-related)
- 8 o Time in hospital
- 9 o Acceptability of treatment
- 10 o Side effects
- 11 o Health-related quality of life
- 12

**10.1.5.1139 Recombinant platelet-derived growth factor-BB (100µg/g) versus recombinant platelet-derived
14 growth factor-BB (300µg/g)**

- 15 • One study (n=61) (general population) showed that recombinant platelet-derived growth factor-
16 BB (100µg/g) is potentially more clinically effective compared to recombinant platelet-derived
17 growth factor-BB (300µg/g) for proportion of people with pressure ulcers completely healed
18 (grade 3 and 4) (very low quality).
- 19 • One study (n=61) (general population) showed that recombinant platelet-derived growth factor-
20 BB (100µg/g) is potentially more clinically effective than recombinant platelet-derived growth
21 factor-BB (300µg/g) to improve healing of 90% of pressure ulcers (grade 3 and 4) (very low
22 quality).
- 23 • One study (n=61) (general population) reported median percentage reduction in ulcer volume for
24 recombinant platelet-derived growth factor-BB (100µg/g) and recombinant platelet-derived
25 growth factor-BB (300µg/g). The median for recombinant platelet-derived growth factor-BB
26 (100µg/g) was 99.6% and 98.6% for recombinant platelet-derived growth factor-BB (300µg/g). No
27 estimate of effect or precision could be derived (very low quality).
- 28 • One study (n=61) (general population) showed there may be no clinical difference between
29 recombinant platelet-derived growth factor-BB (300µg/g) and recombinant platelet-derived
30 growth factor-BB (100µg/g) to reduce the incidence of osteomyelitis (grade 3 and 4 pressure
31 ulcers) (very low quality).
- 32 • One study (n=61) (general population) showed that there may be no clinical difference between
33 recombinant platelet-derived growth factor-BB (100µg/g) compared to recombinant platelet-
34 derived growth factor-BB (300µg/g) to reduce the incidence of infections (grade 3 and 4 pressure
35 ulcers) (very low quality).
- 36 • One study (n=61) (general population) showed that there is no clinical difference between
37 recombinant platelet-derived growth factor-BB (100µg/g) and recombinant platelet-derived
38 growth factor-BB (300µg/g) for reduction of incidence of sepsis (grade 3 and 4 pressure ulcers)
39 (very low quality).
- 40 • One study (n=61) (general population) showed that there may be no clinical difference between
41 recombinant platelet-derived growth factor-BB (100µg/g) and recombinant platelet-derived
42 growth factor-BB (300µg/g) for reduction of incidence of adverse events other than osteomyelitis,
43 sepsis and infections (grade III and IV pressure ulcers), the direction of the estimate of the effect
44 favoured recombinant platelet-derived growth factor-BB (100µg/g) (very low quality).
- 45 • One study (n=61) (general population) showed no clinical difference between recombinant
46 platelet-derived growth factor-BB (100µg/g) and recombinant platelet-derived growth factor-BB
47 (300µg/g) for mortality (all-cause), the direction of the estimate of effect could favour either
48 intervention (low quality).

- 1 • No evidence was found for the following outcomes:
- 2 o Time to complete healing of pressure ulcers
- 3 o Rate of reduction in size or volume of pressure ulcers
- 4 o Pain (wound-related)
- 5 o Time in hospital
- 6 o Acceptability of treatment
- 7 o Health-related quality of life
- 8

10.1.5.1.40 Recombinant platelet-derived growth factor-BB (300µg/g) alternated with placebo versus placebo

- 10 • One study (n=63) (general population) showed that recombinant platelet-derived growth factor-
11 BB (300µg/g) alternated with placebo is more clinically effective compared to placebo for
12 proportion of people with pressure ulcers completely healed (grade 3 and 4) (low quality).
- 13 • One study (n=63) (general population) showed that recombinant platelet-derived growth factor-
14 BB (300µg/g) alternated with placebo is potentially more clinically effective compared placebo to
15 improve healing of 90% of pressure ulcers (grade 3 and 4) (very low quality).
- 16 • One study (n=63) (general population) reported median percentage reduction in ulcer volume for
17 recombinant platelet-derived growth factor-BB (300µg/g) alternated with placebo and placebo.
18 The median for recombinant platelet-derived growth factor-BB (300µg/g) alternated with placebo
19 was 99.7% and 99.1% for placebo. A p-value of 0.011 was reported (very low quality).
- 20 • One study (n=63) (general population) showed there may be no clinical difference between
21 recombinant platelet-derived growth factor-BB (300µg/g) alternated with placebo compared to
22 placebo to reduce the incidence of osteomyelitis (grade 3 and 4 pressure ulcers) (very low
23 quality).
- 24 • One study (n=63) (general population) showed there may be no clinical difference between
25 recombinant platelet-derived growth factor-BB (300µg/g) alternated with placebo compared to
26 placebo to reduce the incidence of infections (grade 3 and 4 pressure ulcers) (very low quality).
- 27 • One study (n=63) (general population) showed there may be no clinical difference between
28 recombinant platelet-derived growth factor-BB (300µg/g) alternated with placebo and placebo for
29 reduction of incidence of sepsis (grade 3 and 4 pressure ulcers) (very low quality).
- 30 • One study (n=63) (general population) showed there may be no clinical difference between
31 recombinant platelet-derived growth factor-BB (300µg/g) alternated with placebo compared to
32 placebo for reduction of incidence of adverse events other than osteomyelitis, sepsis and
33 infections (grade 3 and 4 pressure ulcers) (very low quality).
- 34 • One study (n=63) (general population) showed no clinical difference between recombinant
35 platelet-derived growth factor-BB (300µg/g) and placebo for mortality (all-cause), the direction of
36 the estimate of effect could favour either intervention (low quality).
- 37 • No evidence was found for the following outcomes:
- 38 o Time to complete healing of pressure ulcers
- 39 o Rate of reduction in size or volume of pressure ulcers
- 40 o Pain (wound-related)
- 41 o Time in hospital
- 42 o Acceptability of treatment
- 43 o Health-related quality of life
- 44

10.1.5.1.41 *Recombinant platelet-derived growth factor-BB (300µg/g) alternated with placebo versus recombinant platelet-derived growth factor-BB (300µg/g)*

- One study (n=62) (general population) showed that recombinant platelet-derived growth factor-BB (300µg/g) alternated with placebo may be more clinically effective compared to recombinant platelet-derived growth factor-BB (300µg/g) for proportion of people with pressure ulcers completely healed (grade 3 and 4) (very low quality).
- One study (n=62) (general population) showed that recombinant platelet-derived growth factor-BB (300µg/g) alternated with placebo is potentially more clinically effective compared to recombinant platelet-derived growth factor-BB (300µg/g) to improve healing of 90% of pressure ulcers (grade 3 and 4) (very low quality).
- One study (n=62) (general population) reported median percentage reduction in ulcer volume for recombinant platelet-derived growth factor-BB (300µg/g) alternated with placebo and recombinant platelet-derived growth factor-BB (300µg/g). The median for recombinant platelet-derived growth factor-BB (300µg/g) alternated with placebo was 99.7% and 98.6% for recombinant platelet-derived growth factor-BB (300µg/g). No estimate of effect or precision could be derived (very low quality).
- One study (n=62) (general population) showed there may be no clinical difference between recombinant platelet-derived growth factor-BB (300µg/g) compared to recombinant platelet-derived growth factor-BB (300µg/g) alternated with placebo to reduce the incidence of osteomyelitis (grade 3 and 4 pressure ulcers) (very low quality).
- One study (n=62) (general population) showed there may be no clinical difference between recombinant platelet-derived growth factor-BB (300µg/g) alternated with placebo compared to placebo to reduce the incidence of infections (grade 3 and 4 pressure ulcers) (very low quality).
- One study (n=62) (general population) showed there may be no clinical difference between that recombinant platelet-derived growth factor-BB (300µg/g) alternated with placebo compared to recombinant platelet-derived growth factor-BB (300µg/g) for reduction of incidence of sepsis (grade 3 and 4 pressure ulcers) (very low quality).
- One study (n=62) (general population) showed there may be no clinical difference between recombinant platelet-derived growth factor-BB (300µg/g) compared to recombinant platelet-derived growth factor-BB (300µg/g) alternated with placebo for reduction of incidence of adverse events other than osteomyelitis, sepsis and infections (grade 3 and 4 pressure ulcers) (very low quality).
- One study (n=62) (general population) showed no clinical difference between recombinant platelet-derived growth factor-BB (300µg/g) and recombinant platelet-derived growth factor-BB (300µg/g) for mortality (all-cause), the direction of the estimate of effect could favour either intervention (low quality).
- No evidence was found for the following outcomes:
 - o Time to complete healing of pressure ulcers
 - o Rate of reduction in size or volume of pressure ulcers
 - o Pain (wound-related)
 - o Time in hospital
 - o Acceptability of treatment
 - o Health-related quality of life

10.1.5.1.42 *Recombinant platelet-derived growth factor-BB (300µg/g) versus placebo*

- One study (n=61) (general population) showed there may be no clinical difference between recombinant platelet-derived growth factor-BB (300µg/g) compared to placebo for proportion of people with pressure ulcers completely healed (grade 3 and 4) (very low quality).

- 1 • One study (n=61) (general population) showed that recombinant platelet-derived growth factor-
2 BB (300µg/g) may be more clinically effective compared to placebo to improve healing of 90% of
3 pressure ulcers (grade 3 and 4) (very low quality).
- 4 • One study (n=61) (general population) reported median percentage reduction in ulcer volume for
5 recombinant platelet-derived growth factor-BB (300µg/g) and placebo. The median for
6 recombinant platelet-derived growth factor-BB (300µg/g) was 98.6% and 99.1% for placebo. No
7 estimate of effect or precision could be derived (very low quality).
- 8 • One study (n=61) (general population) showed there may be no clinical difference between
9 recombinant platelet-derived growth factor-BB (300µg/g) compared to placebo to reduce the
10 incidence of osteomyelitis (grade 3 and 4 pressure ulcers) (very low quality).
- 11 • One study (n=61) (general population) showed that there may be no clinical difference between
12 recombinant platelet-derived growth factor-BB (300µg/g) and recombinant platelet-derived
13 growth factor-BB (300µg/g) for reduction of incidence of infections (grade 3 and 4 pressure
14 ulcers), the direction of the estimate of effect favours placebo (very low quality).
- 15 • One study (n=61) (general population) showed that there is no clinical difference between
16 recombinant platelet-derived growth factor-BB (300µg/g) and recombinant platelet-derived
17 growth factor-BB (300µg/g) for reduction of incidence of sepsis (grade 3 and 4 pressure ulcers)
18 (low quality).
- 19 • One study (n=61) (general population) showed there may be no clinical difference between
20 recombinant platelet-derived growth factor-BB (300µg/g) and placebo for reduction of incidence
21 of adverse events other than osteomyelitis, sepsis and infections (grade 3 and 4 pressure ulcers),
22 the direction of the estimate of effect favours placebo (very low quality).
- 23 • One study (n=61) (general population) showed there may be no clinical difference between
24 recombinant platelet-derived growth factor-BB (300µg/g) and placebo for mortality (all-cause)
25 (low quality).
- 26 • No evidence was found for the following outcomes:
- 27 o Time to complete healing of pressure ulcers
- 28 o Rate of reduction in size or volume of pressure ulcers
- 29 o Pain (wound-related)
- 30 o Time in hospital
- 31 o Acceptability of treatment
- 32 o Health-related quality of life
- 33

10.1.5.1343 Recombinant platelet-derived growth factor-BB (1.0µg/g) versus placebo

- 35 • One study (n=11) (denervated people) showed that there is no clinical difference between
36 recombinant platelet-derived growth factor-BB (1.0µg/g) and placebo for proportion of people
37 with pressure ulcers completely healed (grade 3 and 4) (low quality).
- 38 • One study (n=11) (denervated people) showed that there is no clinical difference between
39 recombinant platelet-derived growth factor-BB (1.0µg/g) and placebo at reducing the incidence of
40 infections (grade 3 and 4 pressure ulcers) (low quality).
- 41 • One study (n=11) (denervated people) showed that there is no clinical difference between
42 recombinant platelet-derived growth factor-BB (1.0µg/g) and placebo for mortality (all-cause), the
43 direction of the estimate of effect could favour either intervention (low quality).
- 44

10.1.5.1.44 *Recombinant platelet-derived growth factor-BB (1.0µg/g) versus recombinant platelet-derived growth factor-BB (10.0µg/g)*

- One study (n=8) (denervated people) showed that there is no clinical difference between recombinant platelet-derived growth factor-BB (1.0µg/g) and recombinant platelet-derived growth factor-BB (10.0µg/g) for the proportion of people with pressure ulcers completely healed (grade 3 and 4) , the direction of the estimate of effect could favour either intervention (low quality).
- One study (n=8) (denervated people) showed that there is no clinical difference between recombinant platelet-derived growth factor-BB (1.0µg/g) and recombinant platelet-derived growth factor-BB (10.0µg/g) at reducing the incidence of infections (grade 3 and 4 pressure ulcers) , the direction of the estimate of effect could favour either intervention (low quality).
- One study (n=8) (denervated people) showed that there is no clinical difference between recombinant platelet-derived growth factor-BB (1.0µg/g) and recombinant platelet-derived growth factor-BB (10.0µg/g) for mortality (all-cause) , the direction of the estimate of effect could favour either intervention (low quality).
- No evidence was found for the following outcomes:
 - o Time to complete healing of pressure ulcers
 - o Rate of reduction in size or volume of pressure ulcers
 - o Pain (wound-related)
 - o Time in hospital
 - o Acceptability of treatment
 - o Health-related quality of life

10.1.5.1.45 *Recombinant platelet-derived growth factor-BB (100.0µg/g) versus recombinant platelet-derived growth factor-BB (1.0µg/g)*

- One study (n=9) (denervated people) showed that recombinant platelet-derived growth factor-BB (100.0µg/g) may be more clinically effective compared to recombinant platelet-derived growth factor-BB (1.0µg/g) for proportion of people with pressure ulcers completely healed (grade 3 and 4) (very low quality).
- One study (n=9) (denervated people) showed that there is no clinical difference between recombinant platelet-derived growth factor-BB (1.0µg/g) and recombinant platelet-derived growth factor-BB (100.0µg/g) at reducing the incidence of infections (grade 3 and 4 pressure ulcers) , the direction of the estimate of effect could favour either intervention (low quality).
- One study (n=9) (denervated people) showed that there is no clinical difference between recombinant platelet-derived growth factor-BB (1.0µg/g) and recombinant platelet-derived growth factor-BB (100.0µg/g) for mortality (all-cause) , the direction of the estimate of effect could favour either intervention (low quality).
- No evidence was found for the following outcomes:
 - o Time to complete healing of pressure ulcers
 - o Rate of reduction in size or volume of pressure ulcers
 - o Pain (wound-related)
 - o Time in hospital
 - o Acceptability of treatment
 - o Health-related quality of life

10.1.5.1.46 Recombinant platelet-derived growth factor-BB (10.0µg/g) versus placebo

- 2 • One study (n=11) (denervated people) showed that there is no clinical difference between
3 recombinant platelet-derived growth factor-BB (10.0µg/g) and placebo for the proportion of
4 people with pressure ulcers completely healed (grade 3 and 4), the direction of the estimate of
5 effect could favour either intervention (low quality).
- 6 • One study (n=11) (denervated people) showed that there is no clinical difference between
7 recombinant platelet-derived growth factor-BB (10.0µg/g) and placebo at reducing the incidence
8 of infections (grade 3 and 4 pressure ulcers), the direction of the estimate of effect could favour
9 either intervention (low quality).
- 10 • One study (n=11) (denervated people) showed that there is no clinical difference between
11 recombinant platelet-derived growth factor-BB (10.0µg/g) and placebo for mortality (all-cause) ,
12 the direction of the estimate of effect could favour either intervention (low quality).
- 13 • No evidence was found for the following outcomes:
 - 14 o Time to complete healing of pressure ulcers
 - 15 o Rate of reduction in size or volume of pressure ulcers
 - 16 o Reduction in size or volume of pressure ulcers
 - 17 o Pain (wound-related)
 - 18 o Time in hospital
 - 19 o Acceptability of treatment
 - 20 o Health-related quality of life
- 21

10.1.5.1.47 Recombinant platelet-derived growth factor-BB (100.0µg/g) versus recombinant platelet-derived growth factor-BB (10.0µg/g)

- 24 • One study (n=9) (denervated people) showed that recombinant platelet-derived growth factor-BB
25 (100.0µg/g) may be more clinically effective compared to recombinant platelet-derived growth
26 factor-BB (10.0µg/g) for the proportion of people with pressure ulcers completely healed (grade 3
27 and 4) (very low quality).
- 28 • One study (n=9) (denervated people) showed that there is no clinical difference between
29 recombinant platelet-derived growth factor-BB (10.0µg/g) and recombinant platelet-derived
30 growth factor-BB (100.0µg/g) at reducing the incidence of infections (grade 3 and 4 pressure
31 ulcers), the direction of the estimate of effect could favour either intervention (low quality).
- 32 • One study (n=9) (denervated people) showed that there is no clinical difference between
33 recombinant platelet-derived growth factor-BB (10.0µg/g) and recombinant platelet-derived
34 growth factor-BB (100.0µg/g) for mortality (all-cause), the direction of the estimate of effect
35 could favour either intervention (low quality).
- 36 • No evidence was found for the following outcomes:
 - 37 o Time to complete healing of pressure ulcers
 - 38 o Rate of reduction in size or volume of pressure ulcers
 - 39 o Reduction in size or volume of pressure ulcers
 - 40 o Pain (wound-related)
 - 41 o Time in hospital
 - 42 o Acceptability of treatment
 - 43 o Health-related quality of life
- 44

10.1.5.1.48 Recombinant platelet-derived growth factor-BB (100.0µg/g) versus placebo

- 2 • One study (n=12) (denervated people) showed that recombinant platelet-derived growth factor-
3 BB (100.0µg/g) may be more effective compared to placebo for the proportion of people with
4 pressure ulcers completely healed (grade 3 and 4) (very low quality).
- 5 • One study (n=12) (denervated people) showed that recombinant platelet-derived growth factor-
6 BB (100.0µg/g) is clinically more effective compared to placebo for mean percentage reduction in
7 pressure ulcer depth (grade 3 and 4 pressure ulcers) (low quality).
- 8 • One study (n=12) (denervated people) showed that recombinant platelet-derived growth factor-
9 BB (100.0µg/g) is clinically more effective compared to placebo for mean percentage reduction in
10 pressure ulcer volume (grade 3 and 4 pressure ulcers) (low quality).
- 11 • One study (n=12) (denervated people) showed that there is no clinical difference between
12 recombinant platelet-derived growth factor-BB (100.0µg/g) and placebo at reducing the incidence
13 of infections (grade 3 and 4 pressure ulcers), the direction of the estimate of effect could favour
14 either intervention (low quality).
- 15 • One study (n=12) (denervated people) showed that there is no clinical difference between
16 recombinant platelet-derived growth factor-BB (100.0µg/g) and placebo for mortality (all-cause),
17 the direction of the estimate of effect could favour either intervention (low quality).
- 18 • No evidence was found for the following outcomes:
 - 19 o Time to complete healing of pressure ulcers
 - 20 o Rate of reduction in size or volume of pressure ulcers
 - 21 o Reduction in size or volume of pressure ulcers
 - 22 o Pain (wound-related)
 - 23 o Time in hospital
 - 24 o Acceptability of treatment
 - 25 o Health-related quality of life
- 26

10.1.5.1249 Basic fibroblast growth factors (different schedules and doses) versus placebo

- 28 • One study (n=49) (denervated people) showed that basic fibroblast growth factors (different
29 schedules and doses) is potentially more effective compared to placebo to improve >70% healing
30 of pressure ulcers (grade 3 and 4) (very low quality).
- 31 • One study (n=49) (denervated people) reported mean percentage reduction in ulcer volume for
32 basic fibroblast growth factors (different schedules and doses) and placebo. The mean was 69%
33 for basic fibroblast growth factors (different schedules and doses) and 59% for placebo. No
34 estimate of effect or precision could be derived (very low quality).
- 35 • One study (n=49) (denervated people) showed no clinical difference between basic fibroblast
36 growth factors (different schedules and doses) and placebo for mortality (all-cause), the direction
37 of the estimate of effect could favour either intervention (low quality).
- 38 • No evidence was found for the following outcomes:
 - 39 o Time to complete healing of pressure ulcers
 - 40 o Rate of reduction in size or volume of pressure ulcers
 - 41 o Reduction in size or volume of pressure ulcers
 - 42 o Pain (wound-related)
 - 43 o Time in hospital
 - 44 o Acceptability of treatment
 - 45 o Health-related quality of life
- 46

10.1.5.1.50 Interleukin 1 beta versus placebo

- 2 • One study (n=24) (denervated people) showed no clinical difference between interleukin 1 beta
3 and placebo for the proportion of people with pressure ulcers completely healed (grade 3 and 4),
4 the direction of the estimate of effect could favour either intervention (low quality).
- 5 • One study (n=24) (denervated people) showed no clinical difference between interleukin 1 beta
6 and placebo for mortality (all-cause), the direction of the estimate of effect could favour either
7 intervention (low quality).
- 8 • No evidence was found for the following outcomes:
 - 9 o Time to complete healing of pressure ulcers
 - 10 o Rate of reduction in size or volume of pressure ulcers
 - 11 o Reduction in size or volume of pressure ulcers
 - 12 o Pain (wound-related)
 - 13 o Time in hospital
 - 14 o Acceptability of treatment
 - 15 o Health-related quality of life

10.1.5.1151 Interleukin 1 beta (0.01µg/cm²) versus placebo

- 18 • One study (n=12) (denervated people) showed no clinical difference between interleukin 1 beta
19 (0.01µg/cm²) and placebo for the proportion of people with pressure ulcers completely healed
20 (grade 3 and 4), the direction of the estimate of effect could favour either intervention (low
21 quality).
- 22 • One study (n=12) (denervated people) showed no clinical difference between interleukin 1 beta
23 (0.01µg/cm²) and placebo for mortality (all-cause), the direction of the estimate of effect could
24 favour either intervention (low quality).
- 25 • No evidence was found for the following outcomes:
 - 26 o Time to complete healing of pressure ulcers
 - 27 o Rate of reduction in size or volume of pressure ulcers
 - 28 o Pain (wound-related)
 - 29 o Time in hospital
 - 30 o Acceptability of treatment
 - 31 o Health-related quality of life

10.1.5.1352 Interleukin 1 beta (0.01µg/cm²) versus interleukin 1 beta (0.1µg/cm²)

- 34 • One study (n=12) (denervated people) showed no clinical difference between interleukin 1 beta
35 (0.01µg/cm²) and interleukin 1 beta (0.1µg/cm²) for the proportion of people with pressure ulcers
36 completely healed (grade 3 and 4), the direction of the estimate of effect could favour either
37 intervention (low quality).
- 38 • One study (n=12) (denervated people) showed no clinical difference between interleukin 1 beta
39 (0.01µg/cm²) and interleukin 1 beta (0.1µg/cm²) for mortality (all-cause) , the direction of the
40 estimate of effect could favour either intervention (low quality).
- 41 • No evidence was found for the following outcomes:
 - 42 o Proportion of people with pressure ulcers completely healed
 - 43 o Time to complete healing of pressure ulcers
 - 44 o Rate of reduction in size or volume of pressure ulcers
 - 45 o Pain (wound-related)

- 1 o Time in hospital
- 2 o Acceptability of treatment
- 3 o Side effects
- 4 o Health-related quality of life
- 5

10.1.5.1.53 Interleukin 1 beta (0.01µg/cm²) versus interleukin 1 beta (1.0µg/cm²)

- 7 • One study (n=12) (denervated people) showed no clinical difference between interleukin 1 beta
8 (0.01µg/cm²) and interleukin 1 beta (1.0µg/cm²) for the proportion of people with pressure ulcers
9 completely healed (grade 3 and 4), the direction of the estimate of effect could favour either
10 intervention (low quality).
- 11 • One study (n=12) (denervated people) showed no clinical difference between interleukin 1 beta
12 (0.01µg/cm²) and interleukin 1 beta (1.0µg/cm²) for mortality (all-cause), the direction of the
13 estimate of effect could favour either intervention (low quality).
- 14 • No evidence was found for the following outcomes:
 - 15 o Time to complete healing of pressure ulcers
 - 16 o Rate of reduction in size or volume of pressure ulcers
 - 17 o Reduction in size or volume of pressure ulcers
 - 18 o Pain (wound-related)
 - 19 o Time in hospital
 - 20 o Acceptability of treatment
 - 21 o Side effects
 - 22 o Health-related quality of life
- 23

10.1.5.1.54 Interleukin 1 beta (0.1µg/cm²) versus placebo

- 25 • One study (n=12) (denervated people) showed no clinical difference between interleukin 1 beta
26 (0.1µg/cm²) and placebo for the proportion of people with pressure ulcers completely healed
27 (grade 3 and 4), the direction of the estimate of effect could favour either intervention (low
28 quality).
- 29 • One study (n=12) (denervated people) showed no clinical difference between interleukin 1 beta
30 (0.1µg/cm²) and placebo for mortality (all-cause), the direction of the estimate of effect could
31 favour either intervention (low quality).
- 32 • No evidence was found for the following outcomes:
 - 33 o Time to complete healing of pressure ulcers
 - 34 o Rate of reduction in size or volume of pressure ulcers
 - 35 o Reduction in size or volume of pressure ulcers
 - 36 o Pain (wound-related)
 - 37 o Time in hospital
 - 38 o Acceptability of treatment
 - 39 o Side effects
 - 40 o Health-related quality of life
- 41

10.1.5.1.55 Interleukin 1 beta (0.1µg/cm²) versus interleukin 1 beta (1.0µg/cm²)

- 43 • One study (n=12) (denervated people) showed no clinical difference between interleukin 1 beta
44 (0.1µg/cm²) and interleukin 1 beta (1.0µg/cm²) for the proportion of people with pressure ulcers

- 1 completely healed (grade 3 and 4), the direction of the estimate of effect could favour either
2 intervention (low quality).
- 3 • One study (n=12) (denervated people) showed no clinical difference between interleukin 1 beta
4 (0.1µg/cm²) and interleukin 1 beta (1.0µg/cm²) for mortality (all-cause), the direction of the
5 estimate of effect could favour either intervention (low quality).
- 6 • No evidence was found for the following outcomes:
- 7 o Time to complete healing of pressure ulcers
- 8 o Rate of reduction in size or volume of pressure ulcers
- 9 o Reduction in size or volume of pressure ulcers
- 10 o Pain (wound-related)
- 11 o Time in hospital
- 12 o Acceptability of treatment
- 13 o Side effects
- 14 o Health-related quality of life
- 15

10.1.5.1156 Interleukin 1 beta (1.0µg/cm²) versus placebo

- 17 • One study (n=12) (denervated people) showed no clinical difference between interleukin 1 beta
18 (1.0µg/cm²) and placebo for the proportion of people with pressure ulcers completely healed
19 (grade 3 and 4), the direction of the estimate of effect could favour either intervention (low
20 quality).
- 21 • One study (n=12) (denervated people) showed no clinical difference between interleukin 1 beta
22 (1.0µg/cm²) and placebo for mortality (all-cause), the direction of the estimate of effect could
23 favour either intervention (low quality).
- 24 • No evidence was found for the following outcomes:
- 25 o Time to complete healing of pressure ulcers
- 26 o Rate of reduction in size or volume of pressure ulcers
- 27 o Reduction in size or volume of pressure ulcers
- 28 o Pain (wound-related)
- 29 o Time in hospital
- 30 o Acceptability of treatment
- 31 o Side effects
- 32 o Health-related quality of life

10.1.32 Economic (adults)

- 34 • One cost-effectiveness analysis found that polyurethane self-adhesive foam dressing dominated
35 saline soaked gauze, providing an increase in pressure ulcer free days, and ulcers healed at day
36 28, at a lower cost. This study was partially applicable with minor limitations.

10.1.373 Clinical (neonates, infants, children and young people)

38 No evidence was identified.

10.1.394 Economic (neonates, infants, children and young people)

40 No evidence was identified.

10.2 Recommendations and link to evidence

10.2.1 Adults

Recommendations	38. Do not routinely use topical antiseptics and antimicrobials to treat a pressure ulcer in adults.
Relative values of different outcomes	<p>The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.</p> <p>It was also recognised that it was important to consider quality of life for this question.</p>
Trade off between clinical benefits and harms	<p>The evidence does not support the use of saline-soaked gauze. Some evidence suggested a benefit of hydrocolloid dressing on grade 1-2 pressure ulcers when compared to saline-soaked gauze, and no difference or a possible benefit of saline-soaked gauze for grade 3-4. The GDG felt this mirrored clinical practice and that people often use hydrocolloid dressings on grade 1 and 2 pressure ulcers. It was not necessarily appropriate to use hydrocolloid dressings on more severe pressure ulcers as the dressing would not cover the wound. The GDG also noted that saline-soaked gauze was not used within the UK regularly but is used in Europe and the US. The group who had the hydrocolloid dressing experienced more pain and discomfort on removal of dressing and greater skin irritation. There was no difference in infection rates.</p> <p>Saline-soaked gauze was also not clinically beneficial when compared to other dressings. There was no clinical difference between hydrogel dressings and saline-soaked gauze for the proportion of people completely healed, people worsened and mean weeks to healing. There was however higher mortality in this group. Foam dressing was more clinically beneficial than saline-soaked gauze for the proportion of people complete healing of pressure ulcers. Polyurethane dressing was more clinically beneficial than saline-soaked gauze for the proportion of pressure ulcers completely healed, reduction of pressure ulcers worsened, mean percentage reduction in pressure ulcer area. Dextranomer powder was of clinical benefit when compared to saline-soaked gauze for the proportion of pressure ulcers improved but there was no difference in the number of adverse events. There was no clinically important benefit for isotonic saline solution when compared to aloe vera, silver chloride and decyl glucoside for mean percentage Pressure Sore Status Tool (PSST). The GDG expressed concern as to whether this outcome represented healing.</p> <p>The evidence was favourable for phenytoin ointment when compared to other topical agents (saline solution and triple antibiotics ointment), but was not as favourable when compared to a hydrocolloid dressing. Phenytoin cream was clinically beneficial when compared to saline-soaked gauze for the proportion of pressure ulcers completely healed, proportion of pressure ulcers improved and reduction in the number of pressure ulcers worsened. There was no difference for the proportion of people with treatment-related adverse events. Phenytoin was of benefit when compared to triple antibiotic ointment for mean days to healing but there was no difference for pain and treatment-related adverse events. There was a clinical benefit for foam dressing compared to phenytoin cream for the proportion of people completely healed (yet unsure of clinical benefit for mean Pressure ulcer Scale for Healing (PUSH) score) when compared to antibiotic ointment. Hydrocolloid dressing was of clinical benefit for the proportion of people completely healed when compared to phenytoin cream. There was no difference for pain, treatment-related adverse events and proportion of people whose pressure ulcers had worsened. Overall however, the GDG did not consider that there was sufficient evidence to</p>

demonstrate a benefit of the use of phenytoin and therefore, chose not to make a recommendation on its use for the treatment of pressure ulcers.

Resin salve was favourable in comparison to hydrofibre dressings. There was a clinical benefit for resin salve for the proportion of people completely healed, improved, reduction in pressure ulcers worsened, mean percentage reduction in pressure ulcer width, depth, speed of healing and for less allergic skin reaction.

There was no strong evidence to favour iodine solutions (povidone-iodine and cadexomer iodine solutions). Povidone-iodine solution was not as beneficial as hydrocolloid dressing. There was no clinical benefit of povidone-iodine when compared to hydrogel dressings and cadexomer iodine showed unclear results when compared to standard treatment (which was a range of different comparators including saline dressings, enzyme-based debriding agents, and nonadhesive dressing). There was no clinical benefit for hydrocolloid dressing compared to povidone-iodone for people completely healed and no clinical benefit of povidone-iodone for mean speed of healing. There was a clinical benefit for the proportion of pressure ulcers reduced by 50 percent, which is an uncommon outcome. There was also a mean percentage reduction in pressure ulcer area but there was no clinical benefit for the mean cm² reduction in pressure ulcer area for cadexomer iodine compared to standard treatment. Standard treatment was individualised to each person and included saline dressings, enzyme-based debriding agents, and non-adhesive dressings. Povidone-iodine had no clinical benefit when compared to hydrogel dressings.

Some benefits were shown for dialysate versus placebo (jelly and ointment) but this study was extremely small (under 10 participants) and was compared to placebo. There was no clinical difference found between insulin and standard treatment but this was also a small study with few relevant outcomes which was compared to standard treatment.

Oxyquinoline ointment was of clinical benefit for the proportion of pressure ulcers completely healed, improved and for reducing the amount of pressure ulcers worsened for people in palliative care with grade 2 and 3 pressure ulcers when compared to vitamin A and D cream. The GDG were unsure as to whether vitamin A and D cream was a valid comparator. Petrolatum ointment compared to base component was deemed not relevant by the GDG as it contained products which were unlicensed in the UK. One study compared honey to ethoxy-diaminoacridine and nitrofurzaone dressing but the GDG stated that ethoxy-diaminoacridine and nitrofurzaone dressing is not used in clinical practice in the UK and could not be found in the BNF. There was no strong evidence to recommend silver sulfazidine cream over silver dressing. In addition the GDG did not regard this as a relevant comparison.

The GDG considered the evidence on growth factors. There was some evidence to suggest their benefit but the GDG felt that more information was needed and therefore further research was required. The GDG noted that most growth factors are used for research but are not generally used in clinical practice. It was noted that it is likely that growth factors have a greater effect on highly debrided wounds but they are very expensive.

No evidence was identified on skin protectants, cleansers and moisturisers.

The GDG felt that there was no convincing evidence to support a recommendation to suggest the use of 1 topical agent over another or against placebo. The evidence was not strong enough to suggest the effectiveness of topical agents and therefore the choice of agent would be down to local resources and cost. There was no conclusive

	<p>evidence towards saline-soaked gauze or hydrocolloid dressing. There is some cross-over to the dressings review but the topical agents review focuses on the topical agent which is applied or in gauze. In addition the GDG recognised that there were many confounders and biases. The GDG noted that phenytoin cream is used topically for venous leg ulcers, and although it is not routinely used for pressure ulcers, it could be effective.</p> <p>The GDG felt that there was limited evidence available across a broad range of products and as such, it was not appropriate to develop a recommendation in favour of using 1 product. Furthermore, the GDG did not feel that topical agents were likely to be significant additional benefits to the use of topical agents compared to the use of dressings, which were likely to have further benefits for example, in promoting autolytic debridement. Additionally, it is likely that topical agents would need to be used in combination with a dressing. The GDG did not think that the addition of a topical agent to a dressing would provide any further clinical benefit.</p> <p>The GDG therefore developed a recommendation that topical antiseptics and antibiotics should not be routinely used to treat pressure ulcers, acknowledging that there may be specific situations in which the use of these agents may be beneficial.</p>
<p>Economic considerations</p>	<p>One economic evaluation was included which compared saline soaked gauze to polyurethane self-adhesive foam dressing. The polyurethane self-adhesive foam dressing was found to dominate saline soaked gauze. This study was based in the US, therefore applicability to the UK is limited. No economic evaluations were found which compared topical agents to no topical agents, or to dressings.</p> <p>The GDG felt that there was no convincing clinical evidence for the use of topical agents, and noted that use of such topical agents will have resource implications. Therefore, based on current evidence, the use of topical agents is considered unlikely to be cost-effective.</p>
<p>Quality of evidence</p>	<p>Overall the evidence was limited. Most studies looked at different interventions and comparisons and studies were small. Most of the studies had very serious risk of bias, and a few had serious risk of bias. Most of the results where there was an event had serious to very serious limitations. Therefore the overall grading was very low or low.</p> <p>The comparison which had the most studies was saline-soaked gauze compared to hydrocolloid dressing, however when this was meta-analysed there was a lot of heterogeneity and thus the results were analysed separately. This was done according to pre-defined subgroups, such as people with spinal cord injury. Imprecision was serious to very serious for all outcomes except for people with spinal cord injuries. The results for people with spinal cord injury had no imprecision or slight imprecision (just crossed the minimally important difference) therefore we have more confidence in these results. The proportion of pressure ulcers completely healed, opposed to the proportion of people with pressure ulcers completely healed, had no imprecision for grade 2 pressure ulcers. The proportion of people with pain, discomfort or skin irritation at dressing removal had no imprecision.</p> <p>The other comparisons were all small studies. Where there was an event there was serious to very serious imprecision and in most cases a very serious risk of bias. In the study of phenytoin versus saline-soaked gauze in people with spinal cord injury there was a serious risk of bias. Saline versus dextranomer had no serious imprecision and very serious risk of bias even though it was a very small study. Cadexomer iodine showed a benefit compared to standard treatment. There was no serious imprecision but there was a very wide confidence interval that nearly crossed the minimally important difference and a very serious risk of bias.</p>

	<p>Phenytoin did not show benefits compared to hydrocolloid and this study had serious to very serious imprecision where there was an event and had a serious risk of bias for the majority of outcomes.</p> <p>Resin salve showed a benefit compared to hydrofibre for complete healing of pressure ulcers, speed of healing and reduction in mortality but no clinical difference for improvement or worsening of pressure ulcers and skin reactions.</p> <p>Antibiotic ointment compared to foam dressing outcomes showed foam dressing more clinically effective than the antibiotic ointment for complete healing of pressure ulcers and reduction in PUSH score.</p> <p>The type of support surface was not reported in many of the studies. In order for there to be an accurate account of the benefit of the topical agent the surfaces need to be comparable. In addition the application of a topical agent can result in the patient being repositioned which may bias the benefits shown in studies for topical agents.</p>
Other considerations	<p>There is some overlap between the dressings review and the topical agents review as many of the comparators were dressings. Some consideration should be given to the number and frequency of dressing changes, as the topical creams will not require this. Dressings which include iodine may have evidence, this will be considered in the dressings review as this review is focused on the use of solutions.</p> <p>Studies looking at saline were included in the topical agent review as well as the dressings review. Although cleansing of pressure ulcers has not been included in the guideline, saline was included in this review as the studies were focused on treatment as opposed to cleansing.</p>

10.2.12 Neonates, infants, children and young people

Recommendations	39. Do not routinely use topical antiseptics and antimicrobials to treat a pressure ulcer in neonates, infants, children and young people.
Relative values of different outcomes	<p>The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.</p> <p>It was also recognised that it was important to consider quality of life for this question.</p>
Trade off between clinical benefits and harms	<p>The GDG used 1 statement from the Delphi consensus panel to develop the recommendation 'Healthcare professionals should not routinely use topical antimicrobial dressings (for example, silver or iodine) for the treatment of pressure ulcers in infants, children and young people.' The statement was included in Round 1 of the Delphi consensus survey and did not reach consensus.</p> <p>Qualitative responses gathered during Round 1 of the survey noted that the treatment of a pressure ulcer should be tailored to the needs of the individual. Comments suggested that topical antiseptics and antimicrobials may have a role in some pressure ulcers showing signs of infection.</p> <p>The GDG discussed the comments received on this statement and amended it to reflect that, although topical antimicrobials may be used in some situations for the treatment of infected pressure ulcers, it was likely that systemic antibiotics would be used for the majority of these situations. However, there may be instances where infected pressure ulcers are treated topically and the statement has been clarified to reflect this.</p> <p>The GDG also noted that certain antimicrobials (for example, iodine) were not</p>

	<p>necessarily appropriate for use in these populations and this would be highlighted when developing the recommendation.</p> <p>The amended statement ‘Healthcare professionals should not routinely use topical antimicrobials for infected pressure ulcers in neonates, infants, children and young people.’ was therefore developed and included in Round 2 of the survey, where it reached consensus agreement. The GDG subsequently discussed the agreed statement and developed a recommendation to reflect this.</p>
Economic considerations	<p>The GDG felt that there was limited clinical benefit to be gained from the use of topical agents in most cases, and noted that use of topical agents will have resource implications. Therefore, based on current evidence, use of topical agents is considered unlikely to be cost-effective for treatment of the majority of pressure ulcers.</p>
Quality of evidence	<p>No RCTs or cohort studies were identified for neonates, infants, children or young people. Formal consensus using a modified Delphi was therefore used to develop the recommendation.</p> <p>To inform the recommendation, the GDG used 1 statement which was included in Round 1 of the Delphi consensus survey and reached 64% consensus agreement. The latter statement was therefore included in Round 2 of the survey, where it reached 86% consensus agreement.</p> <p>Further details can be found in Appendix N.</p>
Other considerations	<p>The GDG noted that Chapter 10 covers the use of iodine dressings in neonates.</p>

11 Dressings

2 For the promotion of pressure ulcer healing, it is recognised that a moist healing environment is
3 needed which can be stimulated by the use of an appropriate dressing. In order for healing to take
4 place at an optimum rate, all dressing materials used should ensure that the pressure ulcer remains
5 moist with exudate but does not become macerated. It also needs to be free from clinical infection,
6 excessive slough or devitalised tissue, toxic chemical and fibres. To achieve this, there are a number
7 of dressings which fall broadly into 3 groups:

- 8 • passive materials which may cover and simply protect the pressure ulcer
- 9 • interactive materials, that have the ability to both create and maintain a moist healing
10 environment if used as per manufacturer's instructions
- 11 • active materials that because of their mechanism of action have the ability to facilitate a change
12 in composition of the pressure ulcer healing fluid whilst the product is in use. (Thomas 2010).

13 A number of considerations are also needed when choosing the most appropriate dressing such as
14 the anatomical location of the pressure ulcer, its condition and that of the surrounding skin, the aim
15 of treatment and influence of any relevant aetiological factors.

16 The choice of dressings is vast and thus the GDG were interested in identifying the most clinically and
17 cost effective dressings for the management of pressure ulcers.

11.1 Review question: What are the most clinically and cost effective dressings for the treatment of pressure ulcers?

19 For full details see review protocol in [Appendix A](#).

11.1.1 Clinical evidence (adults)

22 Sixty-two randomised trials were included in this review.<sup>4,7,10,16-
23 19,24,28,31,32,35,41,43,45,46,49,50,58,69,74,81,82,87,90,93,96,98,106,110,115,116,122,124,125,127</sup> Evidence from the included studies
24 is summarised in the clinical GRADE evidence profiles (Table 146). All forest plots and study evidence
25 tables are presented in Appendix D and Appendix G.

26 Various types of dressings are used to treat pressure ulcers. A definition of the different dressings is
27 provided in Table 145.

28 In this review different types of dressings are compared to each other, or to placebo. The following
29 categories were considered, with further information provided in Table 145:

- 30 • Passive dressings
- 31 • Gauze dressings
- 32 • Impregnated gauze dressings
- 33 • Charcoal dressings
- 34 • Active dressings
- 35 • Hydrocolloid dressings
- 36 • Foam dressings
- 37 • Polyurethane dressings
- 38 • Hydrogel
- 39 • Alginate dressings

- 1 • Hydrofibre dressings
- 2 • Capillary dressings
- 3 • Collagen dressing
- 4 • Hyaluronic dressing
- 5 • Copolymer dressing
- 6 • Antibacterial dressings
- 7 • Silver dressings
- 8 • Dextranomer
- 9 • Sugar
- 10 • Honey
- 11 • Other dressings
- 12 • Skin replacement
- 13 • Growth factors
- 14 • Platelet gel
- 15 No randomised trials were identified for capillary dressing in the treatment of pressure ulcers.

Summary of included studies

Study	Intervention	Population	Outcome	Follow-up
Agren 1985 ⁴	Gauze dressing premedicated with zinc Streptokinase-streptodornase ointment	Geriatric adults with necrotic pressure ulcers	<ul style="list-style-type: none"> • Reduction in ulcer area • Side effects 	8 weeks of treatment
Alm 1989 ⁷	Hydrocolloid dressing Wet saline gauze dressing	People in long-term care with pressure ulcers	<ul style="list-style-type: none"> • Reduction in ulcer area • Side effects 	6 weeks of treatment and additional 3 and 6 weeks of follow-up
Amione 2005 ¹⁰	Foam dressing (Allevyn) Foam dressing (Biatain)	People with a grade 2 or 3 pressure ulcer (EPUAP classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Reduction in ulcer area • Side effects 	7 dressings with a maximum of 6 weeks of treatment
Bale 1997 ¹⁷	Hydrocolloid dressing Foam dressing	People with a stage 2 or 3 pressure ulcer (Stirling classification)	<ul style="list-style-type: none"> • Proportion of people completely healed 	30 days of treatment or until complete healing
Bale 1998 ¹⁶	Hydrogel (Sterigel) Hydrogel (Intrasite)	People with necrotic pressure ulcers	<ul style="list-style-type: none"> • Wound pain • Side effects 	4 weeks of treatment or until complete debridement
Banks 1994a ¹⁸	Hydrocolloid dressing Polyurethane dressing	Inpatients with a grade 2 or 3 pressure ulcer.	<ul style="list-style-type: none"> • Proportion of people completely healed • Proportion of people improved • Time to healing • Side effects 	6 weeks of treatment or until complete healing
Banks 1994b ¹⁹	Hydrocolloid dressing Polyurethane dressing	People in the community with a grade 2 or 3 pressure ulcer.	<ul style="list-style-type: none"> • Proportion of people completely healed • Proportion of people improved • Side effects 	6 weeks of treatment or until complete healing
Belmin 2002 ²⁴	Hydrocolloid dressing Alginate dressing	Inpatients aged 65 years and older with a grade 3 or 4 pressure ulcer (Yarkony's classification)	<ul style="list-style-type: none"> • Proportion of people with at least 40% healing • Reduction in ulcer area • Side effects 	8 weeks of treatment

Study	Intervention	Population	Outcome	Follow-up
Bito 2012 ²⁸	Wrap therapy (polyurethane dressing) Standard care	Inpatients aged 50 years and older with a stage 2 or 3 pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Time to healing • Difference in PUSH score • Side effects 	12 weeks of treatment or until complete healing
Brod 1990 ³¹	Hydrocolloid dressing Poly-hema	Elderly people with a grade 2 or 3 pressure ulcer	<ul style="list-style-type: none"> • Proportion of people completely healed • Time to healing • Rate of healing • Side effects 	6 weeks of treatment
Brown-Etris 2006 ³²	Hydrocolloid dressing Polyurethane dressing	People with a stage 3 or shallow 3 pressure ulcer	<ul style="list-style-type: none"> • Proportion of people completely healed • Reduction in ulcer area • Rate of healing • Side effects 	56 days of treatment or until complete healing
Burgos 2000 ³⁵	Hydrocolloid dressing Collagenase ointment	Inpatients with a stage 3 pressure ulcer	<ul style="list-style-type: none"> • Proportion of people completely healed • Reduction in ulcer area • Side effects 	12 weeks of treatment or until complete healing
Chang 1998 ⁴¹	Hydrocolloid dressing Wet saline gauze dressing	Inpatients with a stage 2 or 3 pressure ulcer	<ul style="list-style-type: none"> • Reduction in ulcer area • Side effects 	8 weeks of treatment or until complete healing
Chuansuanich 2011 ⁴³	Silver dressing Silver sulfadiazine cream	In- and outpatients with a stage 3 or 4 pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Rate of healing • Reduction in PUSH score • Side effects 	8 weeks of treatment
Colin 1996 ⁴⁵	Hydrogel Dextranomer	People with a grade 1, 2, 3 or 4 pressure ulcer (according to AHCRO and International Association of Enterostomal Therapy)	<ul style="list-style-type: none"> • Reduction in ulcer area • Side effects 	21 days of treatment or until complete healing
Colwell 1993 ⁴⁶	Hydrocolloid dressing Moist gauze dressing	Inpatients with a stage 2 or 3 pressure ulcer	<ul style="list-style-type: none"> • Proportion of people completely healed 	Minimum 8 days of treatment (range: 6-56 days)

Study	Intervention	Population	Outcome	Follow-up
			<ul style="list-style-type: none"> • Reduction in ulcer area 	
Darkovich 1990 ⁴⁹	Hydrocolloid dressing Hydrogel	People with a stage 1 or 2 pressure ulcer (Enis and Sarmienti classification - equivalent to stage 2 or 3 in the NPUAP system)	<ul style="list-style-type: none"> • Proportion of ulcers completely healed • Proportion of ulcers improved • Proportion of ulcers not changed • Proportion of ulcers worsened • Reduction in ulcer area • Rate of healing 	60 days of treatment or until complete healing, discharge or no change based on clinical judgement
Day 1995 ⁵⁰	Hydrocolloid dressing: triangular shape versus oval shape	Inpatients with a stage 2 or 3 sacral pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Proportion of people improved • Proportion of people not changed • Proportion of people worsened • Reduction in ulcer length • Side effects 	6 dressings or until complete healing
Felzani 2011 ⁵⁸	Hyaluronic acid Sodium hyaluronate	Inpatients with a stage 1, 2 or 3 pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Reduction in ulcer area • Time to 50% healing 	15 days of treatment
Graumlich 2003 ⁶⁹	Hydrocolloid dressing Collagen dressing	People with a stage 2 or 3 pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Time to healing • Reduction in ulcer area • Side effects 	8 weeks of treatment with a median follow-up of 35 days
Günes 2007 ⁷⁴	Honey dressing Ethoxydiaminoacridine and nitrofurazone dressing	Inpatients with a stage 2 or 3 pressure ulcer (AHCRC classification)	<ul style="list-style-type: none"> • Proportion of ulcers completely healed • Reduction in ulcer area • Reduction in PUSH score • Side effects 	5 weeks or until complete healing
Hollisaz	Hydrocolloid dressing	People with a spinal cord injury	<ul style="list-style-type: none"> • Proportion of ulcers completely 	8 weeks of treatment

Study	Intervention	Population	Outcome	Follow-up
2004 ⁸¹	Gauze dressing Phenytoin cream	and a stage 1 or 2 pressure ulcer (Shea classification)	healed <ul style="list-style-type: none"> • Proportion of ulcers improved • Proportion of ulcers worsened • Proportion of people completely healed 	
Hondé 2004 ⁸²	Hydrocolloid dressing Amino acid copolymer dressing	Inpatients aged 65 years or older with a grade 2, 3 or 4 pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Time to healing • Side effects 	8 weeks of treatment or until complete healing
Kaya 2005 ⁸⁷	Hydrogel Povidone-iodine gauze dressing	Inpatients with a spinal cord injury and grade 1, 2 or 3 pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Rate of healing 	Not reported
Kerihuel 2010 ⁹⁰	Hydrocolloid dressing Charcoal dressing	Inpatients with a stage 2c or 4 pressure ulcer (Yarkoni classification)	<ul style="list-style-type: none"> • Proportion of people worsened • Reduction in ulcer area • Wound pain • Side effects 	4 weeks of treatment
Kim 1996 ⁹³	Hydrocolloid dressing Povidone gauze dressing	People with a stage 1 or 2 pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Rate of healing • Side effects 	Mean duration was 18.9 (8.2) days in group 1 and 24.3 (11.2) days in group 2
Kordestani 2008 ⁹⁶	Hydrocolloid dressing Gauze dressing	Inpatients with a pressure ulcer (NPUAP classification) – no stage reported	<ul style="list-style-type: none"> • Proportion of ulcers completely healed • Side effects 	21 days of treatment and 3 months of follow-up
Kraft 1993 ⁹⁸	Foam dressing Saline moistened gauze dressing	Male veterans with a stage 2 or 3 pressure ulcer (Enterstomal Therapy definition)	<ul style="list-style-type: none"> • Proportion of people completely healed 	24 days of treatment
Ljungberg 2009 ¹⁰⁶	Saline gauze dressing Dextranomer	Male adults with a spinal cord injury and exudative pressure ulcers (Eltorai classification)	<ul style="list-style-type: none"> • Proportion of ulcers improved • Side effects 	14 days of treatment

Study	Intervention	Population	Outcome	Follow-up
Matzen 1999 ¹¹⁰	Hydrocolloid dressing Saline gauze dressing	People with a stage 3 or 4 pressure ulcer (Lowthian classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Reduction in ulcer volume • Side effects 	12 weeks of treatment or until complete healing
Meaume 2003 ¹¹⁶	Foam dressing (Mepilex®) Foam dressing (Tielle®)	People aged 65 years or older with a stage 2 pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Proportion of people improved • Proportion of people worsened • Side effects 	8 weeks of treatment or until complete healing
Meaume 2005 ¹¹⁵	Alginate dressing Silver alginate dressing	People aged 65 years or older with a stage III or IV pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • People aged 65 years or older with a stage 3 or 4 pressure ulcer (NPUAP classification) 	4 weeks of treatment
Motta 1999 ¹²²	Hydrocolloid dressing Hydrogel	People receiving home care with a stage 2 or 3 pressure ulcer	<ul style="list-style-type: none"> • Proportion of people completely healed • Rate of healing • Reduction in ulcer area • Side effects 	8 weeks of treatment
Mulder 1993 ¹²⁴	Hydrocolloid dressing Hydrogel	In- and outpatients with a stage 2 or 3 pressure ulcer	<ul style="list-style-type: none"> • Reduction in ulcer area • Side effects 	8 weeks of treatment or until complete healing
Müller 2001 ¹²⁵	Hydrocolloid dressing Collagenase ointment	Female inpatients with a grade 4 heel pressure ulcer	<ul style="list-style-type: none"> • Proportion of people completely healed • Time to healing 	Maximum 16 weeks
Münter 2006 ¹²⁷	Silver foam dressing Different types of dressings	People with a grade 2 or 3 pressure ulcer (EPUAP classification)	<ul style="list-style-type: none"> • People with a grade 2 or 3 pressure ulcer (EPUAP classification) 	4 weeks of treatment
Nasar 1982 ¹²⁹	Dextranomer Chlorinated lime solution	Elderly people with a deep pressure ulcer	<ul style="list-style-type: none"> • Time to healing (defined as granulation and less than 25% of original ulcer area) • Pain 	Until healing

Study	Intervention	Population	Outcome	Follow-up
Neill 1989 ¹³³	Hydrocolloid dressing Saline gauze dressing	People with a grade 2 or 3 pressure ulcer (Shea classification)	<ul style="list-style-type: none"> • Proportion of ulcers completely healed • Proportion of people worsened • Reduction in ulcer area • Side effects 	8 weeks of treatment
Nisi 2005 ¹³⁵	Protease modulating matrix Vaseline soaked gauze dressing	Inpatients with a stage 2, 3 or 4 pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Time to healing • Side effects 	Treatment time not reported. 6 months of follow-up.
Oleske 1986 ¹⁴⁴	Polyurethane dressing Saline gauze dressing	Inpatients with a stage 1 or 2 pressure ulcer (Enis and Sarmiento classification)	<ul style="list-style-type: none"> • Proportion of ulcers completely healed • Proportion of ulcers worsened • Reduction in ulcer area 	10 days of treatment
Parish 1979 ¹⁴⁶	Dextranomer Sugar and eggs white	Long-term care people with a pressure ulcer	<ul style="list-style-type: none"> • Proportion of ulcers completely healed • Proportion of people completely healed • Proportion of ulcers improved • Proportion of people improved • Side effects 	4 weeks of treatment. Some patients were treated longer.
Payne 2004 ¹⁴⁹	Skin replacement Saline moistened gauze dressing	People with a grade 3 pressure ulcer	<ul style="list-style-type: none"> • Proportion of people completely healed • Reduction in ulcer area • Reduction in ulcer volume • Side effects 	Maximum 24 weeks of treatment and up to 2 weeks of follow-up
Payne 2009 ¹⁴⁸	Collagen and foam dressing Foam dressing	People with a stage 2 pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Time to healing 	4 weeks of treatment or until complete healing
Piatkowski	Collagen and foam dressing	People with stagnating pressure	<ul style="list-style-type: none"> • Proportion of people completely 	3 weeks.

Study	Intervention	Population	Outcome	Follow-up
2012	Foam dressing	ulcers, of at least 4 weeks' duration	healed	
Rhodes 1979 ¹⁵⁴	Sugar Different types of topical agents	Geriatric adults with a pressure ulcer – stage not reported	<ul style="list-style-type: none"> • Proportion of ulcers completely healed • Mean healing index 	Not reported
Rhodes 2001 ¹⁵⁵	Hydrocolloid dressing Phenytoin ointment Antibiotic ointment	People in a nursing home with a stage 2 pressure ulcer (AH CPR classification)	<ul style="list-style-type: none"> • Time to healing • Side effects 	Not reported
Sayag 1996 ¹⁶⁵	Alginate dressing Dextranomer	People with a grade 3 or 4 pressure ulcer (Yarkony classification)	<ul style="list-style-type: none"> • Proportion of people healed more than 75% • Proportion of people healed more than 40% • Proportion of people stagnated or worsened • Reduction in ulcer area • Side effects 	Maximum 8 weeks
Scevola 2010 ¹⁶⁶	Allogeneic platelet gel Different types of dressings	People with a spinal cord injury and a grade 3 or 4 pressure ulcer (NPUAP classification)	<ul style="list-style-type: none"> • Proportion of ulcers completely healed • Proportion of ulcers improved • Reduction in ulcer area 	8 weeks of treatment and up to 4 weeks of follow-up
Seaman 2000 ¹⁷⁰	Hydrocolloid dressing (SignaDress®) Hydrocolloid dressing (Comfeel®Plus)	People in a nursing home with a stage 2, 3 or 4 pressure ulcer (AH CPR classification)	<ul style="list-style-type: none"> • People in a nursing home with a stage 2, 3 or 4 pressure ulcer (AH CPR classification) 	5 dressing changes or until complete healing
Sebern 1989 ¹⁷¹	Polyurethane dressing Gauze dressing	People receiving home care with a grade 2 or 3 pressure ulcer (Shea classification)	<ul style="list-style-type: none"> • Proportion of ulcers completely healed • Proportion of ulcers not changed • Proportion of ulcers worsened • Proportion of ulcers decreased in pressure ulcer grade • Proportion of ulcers increased in pressure ulcer grade 	5 dressing changes or until complete healing

Study	Intervention	Population	Outcome	Follow-up
			<ul style="list-style-type: none"> • Reduction in ulcer area 	
Seeley 1999 ¹⁷²	Hydrocolloid dressing Foam dressing	People with a stage 2 or 3 pressure ulcer (AHCPR classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Reduction in ulcer area • Side effects 	8 weeks of treatment
Sipponen 2008 ¹⁷⁶	Hydrofibre dressing Resin salve	People in hospital with a grade 2 to 4 pressure ulcer (EPUAP classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Proportion of ulcers completely healed • Proportion of ulcers improved • Proportion of ulcers worsened • Mean percentage reduction in ulcer width • Mean percentage reduction in ulcer depth • Speed of healing (days) • Side effects 	6 months
Small 2002 ¹⁷⁷	Hydrogel Different types of dressings	People in the community with a stage 2, 3 or 4 pressure ulcer (Stirling classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Reduction in ulcer area • Side effects 	6 weeks of treatment or until complete healing, withdrawal or occurrence of adverse events
Sopata 2002 ¹⁷⁹	Foam dressing Hydrogel	People receiving palliative care with a grade 2 or 3 pressure ulcer (Torrance classification)	<ul style="list-style-type: none"> • Proportion of ulcers completely healed • Proportion of ulcers improved • Rate of healing 	8 weeks of treatment or until complete healing
Thomas 1997 ¹⁹²	Hydrocolloid dressing Foam dressing	People in the community with a grade 2 or 3 pressure ulcer (Stirling classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Proportion of people improved • Proportion of people not changed 	6 weeks of treatment

Study	Intervention	Population	Outcome	Follow-up
			<ul style="list-style-type: none"> • Proportion of people worsened • Reduction in ulcer area • Side effects 	
Thomas 1998 ¹⁹⁰	Hydrogel Saline soaked gauze dressing	People with a stage 2, 3 or 4 pressure ulcer	<ul style="list-style-type: none"> • Proportion of people completely healed • Proportion of people worsened • Reduction in ulcer area • Time to healing 	10 weeks of treatment or until complete healing
Thomas 2005 ^{189,195}	Hydrocolloid dressing Radiant heat dressing	People with a stage 3 or 4 pressure ulcer	<ul style="list-style-type: none"> • Proportion of people completely healed 	12 weeks of treatment
Trial 2010	Alginate dressing Silver alginate dressing	People with a pressure ulcer – stage not reported	<ul style="list-style-type: none"> • Decrease in infection score 	15 days of treatment
Winter 1990 ²⁰⁷	Hydrocolloid dressing Paraffin gauze dressing	People with a pressure ulcer – stage not reported	<ul style="list-style-type: none"> • Proportion of people completely healed • Proportion of people improved • Proportion of people not changed 	12 weeks of treatment
Xakellis 1992 ²⁰⁹	Hydrocolloid dressing Saline wet-to-moist gauze dressing	People in long term care with a stage 2 or 3 (Shea classification)	<ul style="list-style-type: none"> • Proportion of people completely healed • Time to healing 	6 months of treatment
Yastrub 2004 ²¹¹	Foam dressing Antibiotic ointment	People in long term care with a stage 2 pressure ulcer (AHCPR classification)	<ul style="list-style-type: none"> • Proportion of people improved • PUSH score 	4 weeks of treatment

Table 145: Types of dressings

Dressing type	Usual Presentation	Prime Treatment Objectives
Hydrocolloid dressing	Hydrocolloid layer bonded to a film membrane or foam pad, Semi-permeable to water vapour and oxygen	<ul style="list-style-type: none"> • Protection • Rehydration of tissues • Promote autolysis • Absorption (moderate) • Optimise the local wound healing environment
Gauze dressing	Cotton - plain weave Ideally should be non-filamented	<ul style="list-style-type: none"> • Temporary covering • Absorption (minimal) • Padding agent
Foam dressing	Hydrophillic polyurethane foam with or without a plastic film backing. Adhesive and non- adhesive versions	<ul style="list-style-type: none"> • Protection • Absorption (moderate) • Optimise the local wound healing environment
Polyurethane film membrane dressing	Vapour permeable (to water vapour and oxygen but impermeable to water and micro- organisms) sheets with or without a combined central island pad	<ul style="list-style-type: none"> • Protection • Minimise risk of infection (Barrier to micro-organisms) • Optimise the local wound healing environment (superficial wounds) • Can also be used as a secondary dressing to secure another interactive dressing in place for example alginates
Collagen dressing	Collagen, silver and oxidised regenerated cellulose matrix sheets (needs to be covered by a secondary dressing)	<ul style="list-style-type: none"> • Rebalancing the wound environment • Protease modulating matrix dressings used to control the activity of proteolytic enzymes such as MMP's • Stimulate healing
Hydrogel	Amorphous hydrogel (water donating) available in tubes or sheets of a fixed structure	<ul style="list-style-type: none"> • Rehydration of tissues • Promote autolysis

Dressing type	Usual Presentation	Prime Treatment Objectives
		<ul style="list-style-type: none"> • Stimulate healing
Alginate	<p>Non-woven or fibrous, non-occlusive, made up of calcium alginate or a combination of calcium alginate and sodium alginate – derived from brown seaweed</p> <p>If has no integral backing sheet, needs to be covered by a secondary dressing</p>	<ul style="list-style-type: none"> • Fill lesions – sinus or cavity • Absorption • Removal of slough and /or cellular debris from the wound bed • Assists with Haemostasis (should not be prime reason for use) • Stimulate healing
Charcoal dressing	Activated charcoal contained with another dressing material such as viscose rayon / foam / alginate	<ul style="list-style-type: none"> • Odour absorbing • Fluid absorption • (minimal)
Silver alginate	An alginate (see above) impregnated with Silver	<ul style="list-style-type: none"> • Anti-microbial effect • Fill lesions – sinus or cavity • Absorption • Removal of slough and /or cellular debris from the wound bed • Assists with Haemostasis (should not be prime reason for use) • Stimulate healing
Silver dressing	Three layer dressing consisting of a polyester core between low adherent silver coated high density polyethylene mesh	<ul style="list-style-type: none"> • Anti-microbial effect • Minimise risk of infection (Barrier to micro-organisms) • Absorption (moderate) • Stimulate healing
Sugar	Needs to be made up as a paste (usually in pharmacy). Always requires a secondary dressing	<ul style="list-style-type: none"> • Increase osmolarity of wound bed • Antimicrobial effect • Stimulate healing
Hydrofibre dressing	Soft non-woven pad containing hydrocolloid fibres, resemble alginate dressings	<ul style="list-style-type: none"> • Fill lesions – sinus or cavity • Absorption (moderate)

Dressing type	Usual Presentation	Prime Treatment Objectives
		<ul style="list-style-type: none">• Removal of slough and /or cellular debris from the wound bed• Assists with Haemostasis (should not be prime reason for use)• Stimulate healing

Table 146: Clinical evidence profile: hydrocolloid dressing versus gauze dressing

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Gauze dressing	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – general population and people with a spinal cord injury (meta-analysed) – all grade (grade 1 and above) – NPUAP, Shea, Lowthian classification^{m81,93,110,209}												
4	Randomised trials	Very serious ^{a,b}	Very serious ^c	No serious indirectness	Serious ^d	None	62/89 (69.7%)	40/81 (49.4%)	RR 1.38 (0.81 to 2.35)	188 more per 1000 (from 94 more to 667 more)	Very low	Critical
							-	53.7%		204 more per 1000 (from 102 more to 725 more)		
Proportion of people with pressure ulcers completely healed - general population (analysed separately by population due to heterogeneity) – all grade (grade 1 and above) - NPUAP, Shea, Lowthian classification^{m 93,110,209}												
3	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^d	None	42/61 (68.9%)	32/54 (59.3%)	RR 1.07 (0.77 to 1.48)	41 more per 1000 (from 136 fewer to 284 more)	Very low	Critical
							-	77.8%		54 more per 1000 (from 179 fewer to 373 more)		
Proportion of people with pressure ulcers completely healed - people s with spinal cord injury (analysed separately by population due to heterogeneity) – all grade (grade 1 and above) – Shea classification⁸¹												
1	Randomised trial	Serious ^b	No serious inconsistency	No serious indirectness	No serious imprecision	None	20/28 (71.4%)	8/27 (29.6%)	RR 2.41 (1.29 to 4.51)	418 more per 1000 (from 86 more to 1000)	Moderate	Critical

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Gauze dressing	Relative (95% CI)	Absolute (more)		
							-	29.6%		417 more per 1000 (from 86 more to 1000 more)		
Proportion of pressure ulcers completely healed (all sites) - general population and people with a spinal cord injury (meta-analysed) – all grade (grade 1 and above) – NPUAP, Shea classification^{n 46,81,96,133}												
4	Randomised trials	Very serious ^{a,b}	No serious inconsistency	No serious indirectness	No serious imprecision	None	61/137 (44.5%)	23/136 (16.9%)	RR 2.53 (1.7 to 3.78)	259 more per 1000 (from 118 more to 470 more)	Low	Critical
							-	24.4%		373 more per 1000 (from 171 more to 678 more)		
Proportion of pressure ulcers completely healed (all sites) - general population (analysed separately by grade due to heterogeneity) – all grade (grade 1 and above) - NPUAP, Shea classification^{n 46,96,133}												
3	Randomised trials	Very serious ^a	Serious ^e	No serious indirectness	Serious ^d	None	38/106 (35.8%)	15/106 (14.2%)	RR 2.46 (1.01 to 5.96)	207 more per 1000 (from 1 more to 702 more)	Very low	Critical
							-	22.2%		324 more per 1000 (from 2 more to 1000 more)		

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Gauze dressing	Relative (95% CI)	Absolute		
Proportion of pressure ulcers completely healed (all sites) - people with a spinal cord injury (analysed separately by grade due to heterogeneity) –all grade (grade 1 and 2)- Shea classification⁸¹												
1	Randomised trial	Serious ^b	No serious inconsistency	No serious indirectness	No serious imprecision	None	23/31 (74.2%)	8/30 (26.7%)	RR 2.78 (1.48 to 5.22)	475 more per 1000 (from 128 more to 1000 more)	Moderate	Critical
							-	26.7%		475 more per 1000 (from 128 more to 1000 more)		
Proportion of pressure ulcers completely healed (all sites) – general population and people with a spinal cord injury (meta-analysed grade 2 and above) – (grade 2 and 3) – Shea classification^{81,133}												
2	Randomised trials	Very serious ^{a,b}	Serious ^f	No serious indirectness	Serious ^d	None	23/43 (53.5%)	12/53 (22.6%)	RR 2.42 (0.97 to 6.00)	322 more per 1000 (from 7 fewer to 1000 more)	Very low	Critical
							-	21.1%		300 more per 1000 (from 6 fewer to 1000 more)		
Proportion of pressure ulcers completely healed (all sites) - people with a spinal cord injury (analysed separately due to heterogeneity) – grade 2 and above – Shea classification⁸¹												
1	Randomised	Serious ^b	No serious	No serious	No serious	None	12/18	3/19	RR 4.22	508 more	Moderate	Critical

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Gauze dressing	Relative (95% CI)	Absolute		
	trial		inconsistency	indirectness	imprecision		(66.7%)	(15.8%)	(1.42 to 12.54)	per 1000 (from 66 more to 1000 more)		
							-	15.8%		509 more per 1000 (from 66 more to 1000 more)		
Proportion of pressure ulcers completely healed (all sites) - general population (analysed seperately due to heterogeneity) – grade 2 and above (analysed separately due to heterogeneity) – Shea classification¹³³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^d	None	11/25 (44%)	9/34 (26.5%)	RR 1.66 (0.81 to 3.39)	175 more per 1000 (from 50 fewer to 633 more)	Very low	Critical
							-	26.5%		175 more per 1000 (from 50 fewer to 633 more)		
Proportion of pressure ulcers completely healed (all sites) - general population (analysed separately due to heterogeneity) – grade 3 (analysed separately due to heterogeneity) – Shea classification¹³³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/17 (11.8%)	1/11 (9.1%)	RR 1.29 (0.13 to 12.62)	26 more per 1000 (from 79 fewer to 1000 more)	Very low	Critical
							-	9.1%		26 more		

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Gauze dressing	Relative (95% CI)	Absolute per 1000 (from 79 fewer to 1000 more)		
Proportion of pressure ulcers completely healed (sacral) - people with a spinal cord injury – grade 1 and 2 (analysed separately due to heterogeneity) – Shea classification¹³³												
1	Randomised trial	Serious ^b	No serious inconsistency	No serious indirectness	Serious ^d	None	0/7 (0%)	4/8 (50%)	Peto OR 0.09 (0.01 to 0.84)	417 fewer per 1000 (from 43 fewer to 490 fewer)	Low	Critical
							-	50%		417 fewer per 1000 (from 43 fewer to 490 fewer)		
Proportion of pressure ulcers improved - people with a spinal cord injury – all grade (grade 1 and 2) – Shea classification¹³³												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	27/31 (87.1%)	29/60 (48.3%)	RR 1.8 (1.34 to 2.42)	387 more per 1000 (from 164 more to 686 more)	Moderate	Critical
							-	48.3%		386 more per 1000 (from 164 more to 686 more)		
Proportion of pressure ulcers worsened– general pressure ulceration and people with a spinal cord injury (meta-analysed) – all grade (grade 1 to 3) - Shea classification^{81,133}												
2	Randomised	Very	Very serious ^c	No serious	Very	None	16/73	24/75	RR 0.53 (0.12 to	150 fewer per 1000	Very low	Critical

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Gauze dressing	Relative (95% CI)	Absolute		
	trials	serious ^{a,b}		indirectness	serious ^g		(21.9%)	(32%)	2.46)	(from 282 fewer to 467 more)		
							-	31.7%		149 fewer per 1000 (from 279 fewer to 463 more)		
Proportion of pressure ulcers worsened - people with a spinal cord injury (analysed separately due to pressure ulceration)– all grade (grade 1 and 2) - Shea classification⁸¹												
1	Randomised trial	Serious ^b	No serious inconsistency	No serious indirectness	Serious ^d	None	2/31 (6.5%)	9/30 (30%)	RR 0.22 (0.05 to 0.91)	234 fewer per 1000 (from 27 fewer to 285 fewer)	Low	Critical
							-	30%		234 fewer per 1000 (from 27 fewer to 285 fewer)		
Proportion of pressure ulcers worsened - general pressure ulceration (analysed separately due to pressure ulceration) – all grade (grade 2 and 3) - Shea classification¹³³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^g	None	14/42 (33.3%)	15/45 (33.3%)	RR 1 (0.55 to 1.81)	0 fewer per 1000 (from 150 fewer to 270 more)	Very low	Critical
							-	33.3%		0 fewer per 1000 (from 150 fewer to 270 more)		

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Gauze dressing	Relative (95% CI)	Absolute		
										fewer to 270 more)		
Proportion of pressure ulcers worsened - general pressure ulceration – grade 2 (analysed separately due to heterogeneity)- Shea classification¹³³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	7/25 (28%)	11/34 (32.4%)	RR 0.87 (0.39 to 1.92)	42 fewer per 1000 (from 197 fewer to 298 more)	Very low	Critical
							-	32.4%		42 fewer per 1000 (from 198 fewer to 298 more)		
Proportion of pressure ulcers worsened - general pressure ulceration – grade 3 (analysed separately due to heterogeneity) - Shea classification¹³³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	7/17 (41.2%)	4/11 (36.4%)	RR 1.13 (0.43 to 2.98)	47 more per 1000 (from 207 fewer to 720 more)	Very low	Critical
							-	36.4%		47 more per 1000 (from 207 fewer to 721 more)		
Mean percentage reduction in pressure ulcer area – general pressure ulceration – all grade (grade 2 and 3) – classification system not reported^{41,123}												
2	Randomised trials	Very serious ^{a,h,0}	No serious inconsistency	No serious indirectness	Serious ^d	None	18.65 (n=38)	46.73 (n=37)	-	MD 0.34 higher (14.71 lower to 15.38 higher)	Very low	Critical

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Gauze dressing	Relative (95% CI)	Absolute		
Mean cm² reduction in pressure ulcer area – inpatients – all grade (grade 2 and 3) – classification system not reported⁴⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^j	None	0.73 (n=48)	-0.67 (n=49)	-	Not pooled	Very low	Critical
Median percentage reduction in pressure ulcer area– people in long-term care– all grade – classification system not reported⁷												
1	Randomised trial	Very serious ^k	No serious inconsistency	No serious indirectness	Very serious ^l	None	100 (n=28)	85.7 (n=21)	-	Not pooled	Very low	Critical
Median percentage reduction in pressure ulcer area– in-and out patients – grade 2 and 3 - classification system not reported¹²⁴												
1	Randomised trial	Very serious ^h	No serious inconsistency	No serious indirectness	Very serious ^j	None	7.4 (n=21)	7.0 (n=20)	-	Not pooled	Very low	Critical
Median percentage reduction in pressure ulcer area - general pressure ulceration – grade 2 – Shea classification¹³³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^j	None	91 (n=25)	48 (n=34)	p>0.05	Not pooled	Very low	Critical
Median percentage reduction in pressure ulcer area - general pressure ulceration – grade 3 – Shea classification¹³³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ⁱ	None	0.3 (n=17)	30 (n=11)	p>0.05	Not pooled	Very low	Critical
Mean percentage reduction in pressure ulcer volume – general pressure ulceration – all grade (grade 3 and 4) – Lowthian classification¹¹⁰												
1	Randomised trial	Very serious ^{a,p}	No serious inconsistency	No serious indirectness	No serious imprecision	None	26 (SD 20)	64 (SD 16)	-	MD 38 higher (50.49 to 25.51 lower)	Low	Critical
Mean healing speed of pressure ulcers (mm²/day) – general pressure ulceration – all grade (grade 1 and 2) - NPUAP classification⁹³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^d	None	9.1 (SD 5.4)	7.9 (SD 4.7)	-	MD 1.2 higher (1.8 lower to 4.2 higher)	Very low	Critical

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Gauze dressing	Relative (95% CI)	Absolute		
Median time to healing of pressure ulcers (days) – people in long-term care– all grade (grade 2 and 3) – Shea classification²⁰⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ⁱ	None	9 (n=18)	11 (n=21)	-	Not pooled	Very low	Critical
Proportion of people with an infection – inpatients – all grade (grade 2 and 3) – no classification reported⁴¹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^g	None	0/17 (0%)	1/17 (0%)	OR 0.14 (0.00 to 6.82)	50 fewer per 1000 (from 59 fewer to 240 more)	Very low	Important
							-	0%		50 fewer per 1000 (from 59 fewer to 240 more)		
Proportion of infected pressure ulcers – inpatients – no grade reported – NPUAP classification⁹⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/16 (0%)	0/12 (0%)	not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Proportion of people with hypergranulation - general pressure ulceration – all grade (grade 1 and 2) - NPUAPclassification⁹³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^g	None	3/26 (11.5%)	0/18 (0%)	OR 5.9 (0.56 to 62.29)	120 more (from 30 fewer to 260 more)	Very low	Important
							-	0%		120 more (from 30 fewer to 260 more)		
Proportion of people with skin irritation – general pressure ulceration – all grade (grade 2 and 3) – Shea classification¹³³												
1	Randomised	Very	No serious	No serious	No serious	None	0/50	9/50	OR 0.11	156 fewer	Low	Important

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Gauze dressing	Relative (95% CI)	Absolute		
	trial	serious ^a	inconsistency	indirectness	imprecision		(0%)	(18%)	(0.03 to 0.44)	per 1000 (from 92 fewer to 173 fewer)		
							-	18%		156 fewer per 1000 (from 92 fewer to 173 fewer)		
Proportion of people with pain at dressing removal - inpatients – all grade (grade 2 and 3) – classification system not reported⁴¹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/17 (0%)	7/17 (41.2%)	OR 0.09 (0.02 to 0.45)	352 fewer per 1000 (from 172 fewer to 398 fewer)	Low	Important
							-	41.2%		353 fewer per 1000 (from 172 fewer to 398 fewer)		
Median pain score during treatment (scoring system not reported) - general pressure ulceration – all grade (grade 3 and 4) – Lowthian classification¹¹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ⁱ	None	2.0 (range: 1-3) (n=17)	2.0 (range: 1-3) (n=15)	-	Not pooled	Very low	Important
Median odour score during treatment (scoring system not reported) - general pressure ulceration – all grade (grade 3 and 4) – Lowthian classification¹¹⁰												
1	Randomised	Very	No serious	No serious	Very	None	2.0	2.0	-	Not	Very low	Important

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Gauze dressing	Relative (95% CI)	Absolute		
	trial	serious ^a	inconsistency	indirectness	serious ⁱ		(range: 1-4) (n=17)	(range: 1-3) (n=15)		pooled		
Proportion of people with discomfort - inpatients – all grade (grade 2 and 3) – classification system not reported⁴¹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/17 (0%)	9/17 (52.9%)	Peto OR 0.07 (0.02 to 0.32)	456 fewer per 1000 (from 265 fewer to 507 fewer)	Low	Important
							-	52.9%		456 fewer per 1000 (from 265 fewer to 507 fewer)		
Median comfort score during treatment (scoring system not reported) – general pressure ulceration – all grade (grade 3 and 4) – Lowthian classification¹¹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ⁱ	None	4.0 (range: 3-4) (n=17)	3.0 (range: 2-4) (n=15)	-	Not pooled	Very low	Important
Mortality (all cause)^{96,110,209}												
6	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^d	None	2/119 (1.7%)	14/150 (9.3%)	RR 0.24 (0.07 to 0.89)	71 fewer per 1000 (from 10 fewer to 87 more)	Very low	Important
							-	3.3%		25 fewer per 1000 (from 4 fewer to		

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Gauze dressing	Relative (95% CI)	Absolute		
										31 fewer)		
Time to complete healing of pressure ulcers												
0	-	-	-	-	-	-	-	-	-	-	-	-
Rate of healing of pressure ulcers												
0	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
0	-	-	-	-	-	-	-	-	-	-	-	-

(a) Kim (1996), Matzen (1999), Xakellis (1992), Colwell (1993), Kordestani (2008), Neill (1989), Chang (1998)^{41,46,93,96,110,133,209} did not report or there was insufficient information on sequence generation, allocation concealment and no blinding. Matzen (1999)¹¹⁰: drop out 10% differential or higher than event rate for proportion completely healed. Colwell (1993):⁴⁶ Drop out is more than 10% higher than event rate for proportion completely healed. Kordestani (2008):⁹⁶ Drop out is more than 10% higher than event rate for proportion completely healed for proportion of infected ulcers.

(b) Hollisaz (2004):⁸¹ only blinding of outcome assessor.

(c) Different pressure ulcerations and high heterogeneity (> 50%) and p-value < 0.1.

(d) The confidence interval crossed 1 MID point.

(e) Heterogeneity > 50%.

(f) Different pressure ulcerations and high heterogeneity (> 50%) but p-value > 0.1.

(g) The confidence interval crossed both MID points.

(h) Mulder (1993):¹²⁴ no report on allocation concealment or blinding.

(i) No standard deviations were reported and the study used a small sample size.

(j) No standard deviation was reported and it was unknown if sample size was sufficient.

(k) Alm (1989):⁷ no report on sequence generation; allocation concealment by stratification according to Norton score; only blinding of outcome assessor.

(l) No standard deviation was reported and the number of participants completed per group was unclear.

(m) Kim (1996):⁹³ NPUAP classification; Matzen (1999):¹¹⁰ Lowthian classificatio.; Xakellis (1992) and Hollisaz (2004):^{81,209} Shea classification.

(n) Kordestani (2008)⁹⁶: NPUAP classification; Colwell (1993):⁴⁶ no classification reported; Neill (1989) and Hollisaz (2004):⁸¹ Shea classification.

(o) Chang (1998)⁴¹: standard deviation was calculated based on the available raw data. Mulder (1993): no transformation of data.

(p) Matzen (1999):¹¹⁰ no log-transformation of data was carried out.

Table 147: Clinical evidence profile: hydrocolloid dressing versus foam dressing

Quality assessment	No of patients	Effect	Quality	Importance
--------------------	----------------	--------	---------	------------

No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Foam dressing	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – general pressure ulceration – all grade (grade 2 and 3) – Stirling and AHCPR classification^{g 17,172,192}												
3	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	29/77 (37.7%)	25/80 (31.3%)	RR 1.24 (0.81 to 1.9)	75 more per 1000 (from 59 fewer to 281 more)	Very low	Critical
								40%		96 more per 1000 (from 76 fewer to 360 more)		
Proportion of people with pressure ulcers improved – people in the community – all grade (grade 2 and 3) – Stirling classification¹⁹²												
1	Randomised trial	Very serious ^c	No serious inconsistency	No serious indirectness	No serious imprecision	None	39/48 (81.3%)	39/48 (81.3%)	RR 1 (0.83 to 1.21)	0 fewer per 1000 (from 138 fewer to 171 more)	Low	Critical
								81.3%		0 fewer per 1000 (from 138 fewer to 171 more)		
Proportion of people with pressure ulcers not changed - general pressure ulceration – all grade (grade 2 and 3) – Stirling classification^{17,192}												
2	Randomised trials	Very serious ^{a,c}	No serious inconsistency	No serious indirectness	Very serious ^d	None	5/79 (6.3%)	2/77 (2.6%)	RR 2.17 (0.50 to 9.33)	30 more per 1000 (from 13 fewer to 216 more)	Very low	Critical
								4.2%		49 more per 1000 (from 21 fewer to 350 more)		
Proportion of people with pressure ulcers worsened - general pressure ulceration – all grade (grade 2 and 3) – Stirling classification^{17,192}												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Foam dressing	Relative (95% CI)	Absolute		
2	Randomised trials	Very serious ^{a,c}	No serious inconsistency	No serious indirectness	Very serious ^d	None	9/79 (11.4%)	6/77 (7.8%)	RR 1.48 (0.56 to 3.94)	37 more per 1000 (from 34 fewer to 229 more)	Very low	Critical
								10.4%		50 more per 1000 (from 46 fewer to 306 more)		
Mean percentage reduction in pressure ulcer area – general pressure ulceration – all grade (grade 2 and 3) - AHCP R classification¹⁷²												
1	Randomised trial	Very serious ^{c,h}	No serious inconsistency	No serious indirectness	Serious ^b	None	52 (SD 6.06)	50 (SD 6.06)	-	MD 2.0 higher (1.81 lower to 5.81 higher)	Very low	Critical
Proportion of people with hypergranulation – people in the community – all grade (grade 2 and 3) – Stirling classification¹⁹²												
1	Randomised trial	Very serious ^c	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/49 (0%)	0/50 (0%)	not pooled	0 more (from 4 fewer to 4 more)	Low	Important
								0%		0 more (from 4 fewer to 4 more)		
Proportion of people with bleeding - people in the community – all grade (grade 2 and 3) – Stirling classification¹⁹²												
1	Randomised	Very	No serious	No serious	Very serious ^d	None	2/49	0/50	Peto OR	4 more	Very	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Foam dressing	Relative (95% CI)	Absolute		
	trial	serious ^c	inconsistency	indirectness			(4.1%)	(0%)	7.7 (0.47 to 124.89)	(from 3 fewer to 11 more)	low	
								0%		4 more (from 3 fewer to 11 more)		
Proportion of people with maceration - people in the community – all grade (grade 2 and 3) – Stirling classification¹⁹²												
1	Randomised trial	Very serious ^c	No serious inconsistency	No serious indirectness	Serious ^b	None	4/49 (8.2%)	0/50 (0%)	Peto OR 8.04 (1.1 to 58.85)	8 more (from 0 fewer to 170 more)	Very low	Important
								0%		8 more (from 0 fewer to 170 more)		
Proportion of people with inflammation or maceration – general population – all grade (grade 2 and 3) - AHCP classification¹⁷²												
1	Randomised trial	Very serious ^e	No serious inconsistency	No serious indirectness	Serious ^b	None	6/19 (31.6%)	12/20 (60%)	RR 0.53 (0.25 to 1.12)	282 fewer per 1000 (from 450 fewer to 72 more)	Very low	Important
								60%		282 fewer per 1000 (from 450 fewer to 72 more)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Foam dressing	Relative (95% CI)	Absolute		
Mean pain score at end of treatment (scale 0 no pain - 3 severe pain) – general population – all grade (grade 2 and 3) - AHCPR classification¹⁷²												
1	Randomised trial	Very serious ^e	No serious inconsistency	No serious indirectness	Serious ^b	None	0.47 (SD 0.9)	0.15 (SD 0.8)	-	MD 0.32 higher (0.22 lower to 0.86 higher)	Very low	Important
Mean odour score at end of treatment (scale 0 no odour - 3 severe odour) – general population – all grade (grade 2 and 3) - AHCPR classification¹⁷²												
1	Randomised trial	Very serious ^e	No serious inconsistency	No serious indirectness	Serious ^b	None	0.47 (SD 0.8)	0.16 (SD 0.5)	-	MD 0.31 higher (0.11 lower to 0.73 higher)	Very low	Important
Proportion of people with adverse events (unknown if dressing related) – general population – all grade (grade 2 and 3) – Stirling and AHCPR classification^{g17,172}												
2	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	5/51 (9.8%)	8/49 (16.3%)	RR 0.61 (0.22 to 1.71)	64 fewer per 1000 (from 127 fewer to 116 more)	Very low	Important
								17.7%		69 fewer per 1000 (from 138 fewer to 126 more)		
Mortality (all-cause)¹⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	2/31 (6.5%)	6/29 (20.7%)	RR 0.31 (0.07 to 1.42)	143 fewer per 1000 (from 192 fewer to 87 more)	Very low	Important

Time in hospital or NHS care

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Foam dressing	Relative (95% CI)	Absolute		
								20.7%		143 fewer per 1000 (from 193 fewer to 87 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) Bale (1997):¹⁷ did not report on sequence generation, allocation concealment and blinding; Seeley (1999) did not report allocation concealment by stratification according to initial ulcer size and no blinding; Thomas (1997):¹⁹² did not report on sequence generation and there was no blinding.
- (b) The confidence interval crossed 1 MID point.
- (c) Thomas (1997):¹⁹² did not report on sequence generation and there was no blinding.
- (d) The confidence interval crossed both MID points.
- (e) Seeley (1999):¹⁷² allocation concealment by stratification according to initial ulcer size and no blinding.
- (f) No standard deviation was reported and the study used a small sample size.
- (g) Bale (1997) and Thomas (1997):¹⁹² Stirling classification; Seeley (1999):¹⁷² AHCP classification.
- (h) Seeley (1999):¹⁷² no log-transformation of data was carried out.

Table 148: Clinical evidence profile profile: hydrocolloid dressing versus polyurethane dressing

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Polyurethane dressing	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – general population (meta-analysed) – all grade (grade 2 and 3) – classification system not reported^{18,19,32}												
3	Randomised trials	Very serious ^a	Serious ^b	No serious indirectness	Serious ^c	None	43/59 (72.9%)	43/63 (68.3%)	RR 1.07 (0.87 to 1.33)	48 more per 1000 (from 89 fewer to 225 more)	Very low	Critical
							-	66.7%		47 more per 1000 (from 87 fewer to 220 more)		
Proportion of people with pressure ulcers improved – people in the community (analysed separately due to heterogeneity)– all grade (grade 2 and 3) – classification system not reported¹⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	10/10 (100%)	18/18 (100%)	RR 1 (0.86 to 1.16)	0 fewer per 1000 (from 140 fewer to 160 more)	Low	Critical
							-	100%		0 fewer per 1000 (from 140 fewer to 160 more)		
Mean percentage reduction in pressure ulcer area - general population (analysed separately due to heterogeneity) – all grade (grade 2 and 3) – classification system not reported³²												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Polyurethane dressing	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	23.8 (n=37)	26.7 (n=35)	-	Not pooled	Very low	Critical
Median time to healing of pressure ulcers (days) – inpatients - all grade (grade 2 and 3) – classification system not reported¹⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^e	None	12.69 (n=12)	13.36 (n=10)	p > 0.05	Not pooled	Very low	Critical
Linear healing rate of pressure ulcers (cm/week) - general population – all grade (grade 2 and 3) – classification system not reported³²												
1	Randomised trial	Very serious ^{a,h}	No serious inconsistency	No serious indirectness	Serious ^c	None	0.12 (n=37)	0.10 (n=35)	-	MD 0.02 higher (0.06 lower to 0.1 higher)	Very low	Critical
Mean odour score (1 very poor - 5 very good) - general population – all grade (grade 2 and 3) – classification system not reported³²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	4.8 (SD 0.39)	5 (SD 0.14)	-	MD 0.2 lower (0.33 to 0.07 lower)	Very low	Important
Mean comfort score (1 very poor - 5 very good) - general population – all grade (grade 2 and 3) – classification system not reported³²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	4.4 (SD 0.66)	4.8 (SD 0.34)	-	MD 0.4 lower (0.64 to 0.16 lower)	Very low	Important
Proportion of people with adverse events - general population – all grade (grade 2 and 3) – classification system not reported³²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/37 (0%)	0/35 (0%)	Not pooled	Not pooled	Low	Important
							-	0%		Not		

Quality assessment							No of patients		Effect		Quality	Importance	
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Polyurethane dressing	Relative (95% CI)	Absolute			
											pooled		
Proportion of people with pain at dressing removal - general population – all grades (grade 2 and 3) – classification system not reported^{18,19}													
2	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^f	None	-	-	p < 0.005	Not pooled	Very low	Important	
							-	0%		Not pooled			
Proportion of people with discomfort at dressing removal – general population – all grades (grade 2 and 3) – classification system not reported^{18,19}													
2	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^g	None	-	-	p > 0.05	Not pooled	Very low	Important	
							-	0%		Not pooled			
Mortality (all-cause)^{18,19}													
2	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ⁱ	None	2/36 (5.6%)	1/33 (3% ¹⁹)	RR 2 (0.2 to 20.33)	30 more per 1000 (from 24 fewer to 586 more)	Very low	Important	
							-	2.5%		25 more per 1000 (from 20 fewer to 483 more)			
Time to complete healing of pressure ulcers													
-	-	-	-	-	-	-	-	-	-	-	-	-	
Time in hospital or NHS care													

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Polyurethane dressing	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No report on sequence generation, allocation concealment and no blinding.

(b) Heterogeneity > 50%; p-value of 0.1.

(c) Confidence interval crossed 1MID point.

(d) No standard deviation; unknown if sample size was sufficient.

(e) No standard deviation; small sample size.

(f) Only p-values and a figure are reported. Both studies showed more pain in the hydrocolloid group compared to the polyurethane group.

(g) Only p-values and a figure are reported. Both studies showed more discomfort in the hydrocolloid group compared to the polyurethane group.

(h) Brown-Etris (2006):³² no log-transformation of data.

(i) Confidence interval crossed both MID points.

Table 149: Clinical evidence profile: hydrocolloid dressing versus collagenase ointment

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Collagenase	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – general population – all grades (grade 2 and above) – no system classification reported ^{35,125}												
2	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	10/30 (33.3%)	14/30 (46.7%)	RR 0.75 (0.45 to 1.26)	117 fewer per 1000 (from 257 fewer to 121 more)	Very low	Critical
							-	54.2%		135 fewer per 1000 (from 298 fewer to 141 more)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Collagenase	Relative (95% CI)	Absolute		
Mean percentage reduction in pressure ulcer area – inpatients – all grades (grade 3) - classification system not reported³⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	73.7 (SD=92.4)	83.3 (SD=92.4)	-	MD 9.6 lower (69.17 lower to 49.97 higher)	Very low	Critical
Mean cm² reduction in pressure ulcer area – inpatients – all grades (grade 3) - classification system not reported³⁵												
1	Randomised trial	Very serious ^{a,d}	No serious inconsistency	No serious indirectness	Serious ^c	None	6.2 (SD 9.8)	9.1 (SD 12.7)	-	MD 2.9 lower (10.24 lower to 4.44 higher)	Very low	Critical
Mean time to pressure ulcer healing (weeks) – general population - all grades (grade 4) – classification system not reported¹²⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	14 (SD 4.6)	10 (SD 4.6)	-	MD 4 higher (0.24 to 7.76 higher)	Very low	Critical
Proportion of people with adverse events^e – inpatients – all grades (grade 3) - classification system not reported³⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/19 (10.5%)	1/18 (5.6%)	RR 1.89 (0.19 to 19.13)	49 more per 1000 (from 45 fewer to 1000 more)	Very low	Important
							-	5.6%		50 more per 1000 (from 45 fewer to 1000 more)		
Mortality (all-cause)^{35,125}												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	1/31 (3.2%)	3/30 (10%)	RR 0.32 (0.04 to 2.76)	68 fewer per 1000 (from 96 fewer to 176 more)	Very low	Important
								8.3%		56 fewer per 1000 (from 80		

Rate of reduction in size of pressure ulcers

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Collagenase	Relative (95% CI)	Absolute fewer to 146 more)		
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) Burgos (2000a): no allocation concealment and only blinding of assessor; Müller (2001): no report on sequence generation, allocation concealment and no blinding.
 (b) Confidence interval crossed both MID points.
 (c) Confidence interval crossed 1 MID point.
 (d) Burgos (2000a): no allocation concealment and only blinding of assessor; no log-transformation of data.
 (e) Hydrocolloid group: 1 participant had erythema and exudate and 1 participant had exudate and intense odour. Collagenase group: 1 participant had dermatitis.

Table 150: Clinical evidence profile: hydrocolloid dressing versus collagen

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Collagen	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – inpatients – all grades (grade 2 and 3) - NPUAP classification⁶⁹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	15/30 (50%)	18/35 (51.4%)	RR 0.97 (0.6 to	15 fewer per 1000 (from	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Collagen	Relative (95% CI)	Absolute		
									1.57)	206 fewer to 293 more)		
							-	51.4%		15 fewer per 1000 (from 206 fewer to 293 more)		
Mean percentage reduction in pressure ulcer area – inpatients – all grades (grade 2 and 3) - NPUAP classification⁶⁹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	9 (SD=73.98)	33 (SD=73.98)	-	MD 24 lower (60.08 lower to 12.08 higher)	Low	Critical
Mean healing speed of pressure ulcers (mm²/day) – inpatients – all grades (grade 2 and 3) - NPUAP classification⁶⁹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	6 (SD 16)	6 (SD 19)	-	MD 0 higher (8.23 lower to 8.23 higher)	Moderate	Critical
Mean time to healing of pressure ulcers (weeks) – inpatients – all grades (grade 2 and 3) - NPUAP classification⁶⁹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	6 (SD 2.68)	6 (SD 2.68)	-	MD 1 higher (0.36 lower to	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Collagen	Relative (95% CI)	Absolute		
										2.36 higher)		
Proportion of people with adverse events – inpatients – all grades (grade 2 and 3) - NPUAP classification⁶⁹												
1	Randomised trial	Very serious ^d	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/30 (0%)	0/35 (0%)	not pooled	Not pooled	Low	Important
							-	0%		Not pooled		
Mortality (all-cause)⁶⁹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very Serious ^b	None	2/30 (6.7%)	3/35 (8.6%)	RR 0.78 (0.14 to 4.35)	19 fewer per 1000 (from 74 fewer to 287 more)	Very low	Important
							-	8.6%		19 fewer per 1000 (from 74 fewer to 288 more)		
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Collagen	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) Only blinding of outcome assessor.
- (b) Confidence interval crossed both MID points.
- (c) Confidence interval crossed 1 MID point.
- (d) Only blinding of outcome assessor; drop out is more than 10% higher than event rate.

Table 151: Clinical evidence profile: hydrocolloid dressing versus hydrogel

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Hydrogel	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – people in the community – all grades (grade 2 and 3) – classification system not reported (but described as partial thickness wounds which is equivalent to stage II and III in the NPUAP classification system)¹²²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^{c,b}	None	2/5 (40%)	2/5 (40%)	RR 1 (0.22 to 4.56)	0 fewer per 1000 (from 312 fewer to 1000 more)	Very low	Critical
							-	40%		0 fewer per 1000 (from 312 fewer to 1000 more)		
Proportion of pressure ulcers completely healed (all sites) – general population - all grades (grade 1 and 2) – Enis and Sarmienti classification (equivalent to grade 2 and 3 in the NPUAP classification system)⁴⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	12/67 (17.9%)	24/62 (38.7%)	RR 0.46 (0.25 to	209 fewer per 1000 (from 62	Very low	Critical

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Hydrogel	Relative (95% CI)	Absolute		
							-	38.7%	0.84)	fewer to 290 fewer)		
										209 fewer per 1000 (from 62 fewer to 290 fewer)		
Proportion of pressure ulcers not changed – general population - all grades (grade 1 and 2) – Enis and Sarmienti classification (equivalent to stage II and III in the NPUAP classification system)⁴⁹												
1	Randomised trial	Very serious ^b	No serious inconsistency	No serious indirectness	Very serious ^b	None	8/67 (11.9%)	5/62 (8.1%)	RR 1.48 (0.51 to 4.28)	39 more per 1000 (from 40 fewer to 265 more)	Very low	Critical
							-	8.1%		39 more per 1000 (from 40 fewer to 266 more)		
Proportion of pressure ulcers worsened– general population - all grades (grade 1 and 2) – Enis and Sarmienti classification (equivalent to stage II and III in the NPUAP classification system)⁴⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	7/67 (10.4%)	1/62 (1.6%)	RR 6.48 (0.82 to 51.16)	88 more per 1000 (from 3 fewer to 809 more)	Very low	Critical
							-	1.6%		88 more per 1000 (from 3 fewer to 803 more)		
Mean percentage reduction in pressure ulcer area– general population – grade 1 - Enis and Sarmienti classification (equivalent to stage II and III in the NPUAP classification system)⁴⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	44 (n=31)	72 (n=27)	p > 0.05	Not pooled	Very low	Critical
Mean percentage reduction in pressure ulcer area– general population – grade 2 - Enis and Sarmienti classification (equivalent to stage II and III in the NPUAP classification system)⁴⁹												

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Hydrogel	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^{a,i}	No serious inconsistency	No serious indirectness	Very serious ^{c,e}	None	34 (SD 47.7)	64 (SD 47.7)	-	MD 30 lower (52.19 to 7.81 lower)	Very low	Critical
Median percentage reduction in pressure ulcer area– in –and outpatients – all grades (grade 2 and 3) – classification system not reported¹²⁴												
1	Randomised trial	Very serious ^f	No serious inconsistency	No serious indirectness	Very serious ^d	None	7.4 (n=21)	5.6 (n=20)	-	Not pooled	Very low	Critical
Mean healing rate of pressure ulcers (cm/day) – people in the community – all grades (grade 2 and 3) – classification system not reported¹²²												
1	Randomised trial	Very serious ^{a,i}	No serious inconsistency	No serious indirectness	Very serious ^b	None	0.35 (SD 0.43)	0.15 (SD 0.22)	-	MD 0.2 higher (0.22 lower to 0.62 higher)	Very low	Critical
Healing rate of pressure ulcers (%/day) – general population - all grades (grade 1 and 2) – Enis and Sarmienti classification⁴⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^e	None	3.1 (n=?)	8.1 (n=?)	-	Not pooled	Very low	Critical
Median odour score during treatment – people in the community – all grades (grade 2 and 3) – classification system not reported¹²²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^h	None	2 (n=5)	2 (n=5)	-	Not pooled	Very low	Important
Median comfort score during treatment – people in the community – all grades (grade 2 and 3) – classification system not reported¹²²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^h	None	3 (n=5)	4 (n=5)	-	Not pooled	Very low	Important
Mortality (all-cause)¹²²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None	0/5 (0%)	0/5 (0%)	Not pooled	Not pooled	Low	Important
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Hydrogel	Relative (95% CI)	Absolute		
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) No report on sequence generation, allocation concealment and no blinding.
- (b) The confidence interval crossed both MID points.
- (c) The confidence interval crossed 1 MID point.
- (d) No standard deviation was reported; unknown if sample size was insufficient.
- (e) The standard deviation was calculated on a p-value <0.01 (less precise).
- (f) Mulder (1993) did not report on allocation concealment and no blinding was reported.
- (g) No standard deviation was reported and it is unknown how many ulcers were included in analysis.
- (h) No standard deviation was reported and the study used a very small sample size.
- (i) No log-transformation of data was carried out.

Table 152: Clinical evidence profile: hydrocolloid dressing versus impregnated gauze

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Impregnated gauze	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – general population – grade and classification system not reported²⁰⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	5/6 (83.3%)	3/5 (60%)	RR 1.39 (0.62 to 3.09)	234 more per 1000 (from 228 fewer to 1000)	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Impregnated gauze	Relative (95% CI)	Absolute		
							-	60%		more) 234 more per 1000 (from 228 fewer to 1000 more)		
Proportion of people with pressure ulcers improved – general population – grade and classification system not reported²⁰⁷												
1	Randomised trial	Very serious ^{a,c}	No serious inconsistency	No serious indirectness	Very serious ^b	None	6/6 (100%)	5/5 (100%)	RR 1 (0.73 to 1.37)	0 fewer per 1000 (from 270 fewer to 370 more)	Very low	Critical
							-	100%		0 fewer per 1000 (from 270 fewer to 370 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Impregnated gauze	Relative (95% CI)	Absolute		
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No report on sequence generation, allocation concealment and no blinding was reported.

(b) The confidence interval crossed both MID points.

(c) The drop out is more than 10% higher than event rate.

Table 153: Clinical evidence profile: hydrocolloid dressing versus poly-hema dressing

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Poly-hema dressing	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – elderly people – all grades (grade 2 and 3) – classification system not reported³¹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	10/16 (62.5%)	14/27 (51.9%)	RR 1.21 (0.71 to 2.04)	109 more per 1000 (from 150)	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Poly-hema dressing	Relative (95% CI)	Absolute		
							-	51.9%		fewer to 539 more) 109 more per 1000 (from 151 fewer to 540 more)		
Median time to healing of pressure ulcers (days) – elderly people – all grades (grade 2 and 3) – classification system not reported³¹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	42 (n=16)	32 (n=27)	p=0.56	Not pooled	Very low	Critical
Absolute rate of healing of pressure ulcers (cm²/week) – elderly people – all grades (grade 2 and 3) – classification system not reported³¹												
1	Randomised trial	Very serious ^{a, g}	No serious inconsistency	No serious indirectness	Serious ^d	None	0.10 (SD 0.085)	0.18 (SD 0.085)	-	MD 0.08 lower (0.13 to 0.03 lower)	Very low	Critical
Proportion of people with adverse events – elderly people – all grades (grade 2 and 3) – classification system not reported³¹												
1	Randomised trial	Very serious ^{a, f}	No serious inconsistency	No serious indirectness	Very serious ^b	None	1/16 (6.3%)	0/27 (0%)	Peto OR 14.69 (0.25 to 847.55)	6 more (from 8 fewer to 210 more)	Very low	Important
							-	0%		6 more (from 8 fewer to 210)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Poly-hema dressing	Relative (95% CI)	Absolute (more)		
Mortality (all-cause)³¹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	1/16 (6.3%)	2/27 (7.4%)	RR 0.84 (0.08 to 8.58)	12 fewer per 1000 (from 68 fewer to 561 more)	Very low	Important
							-	-				
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Allocation concealment was stratified according to lesion stage and only blinding of the outcome assessor was reported.

(b) The confidence interval crossed both MID points.

(c) No standard deviation was reported and the study used a small sample size.

(d) The confidence interval crossed 1 MID point.

(e) It was unknown if adverse events were dressing related.

(f) The drop out is more than 10% higher than event rate.

(g) No log-transformation of data was carried out.

Table 154: Clinical evidence profile: hydrocolloid dressing versus co-polymer (amino acid) dressing

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Copolymer (amino acid)	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – inpatients – all grades (grade 2, 3 or 4) – NPUAP classification⁸²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	23/88 (26.1%)	31/80 (38.8%)	RR 0.67 (0.43 to 1.05)	128 fewer per 1000 (from 221 fewer to 19 more)	Very low	Critical
							-	38.8%		128 fewer per 1000 (from 221 fewer to 19 more)		
Median time to pressure ulcer healing (days) – inpatients – all grades (grade 2, 3 or 4) – NPUAP classification⁸²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	38 (range: 13-59) (n=88)	32 (range:11-63) (n=80)	p=0.044 (adjusted for wound depth)	Not pooled	Very low	Critical
Proportion of people with an infection – inpatients – all grades (grade 2, 3 or 4) – NPUAP classification⁸²												
1	Randomised trial	Very serious ^{a,e}	No serious inconsistency	No serious indirectness	Very serious ^d	None	6/88 (6.8%)	6/80 (7.5%)	RR 0.91 (0.31 to 2.7)	7 fewer per 1000 (from 52 fewer to 128 more)	Very low	Important
							-	7.5%		7 fewer		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Copolymer (amino acid)	Relative (95% CI)	Absolute		
										per 1000 (from 52 fewer to 128 more)		
Rate of change in size in pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) No report on allocation concealment or blinding.
- (b) The confidence interval crossed 1 MID point.
- (c) No standard deviation was reported.
- (d) The confidence interval crossed both MID points.
- (e) The drop out is more than 10% higher than event rate.

Table 155: Clinical evidence profile: hydrocolloid dressing versus phenytoin cream

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Phenytoin cream	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – people with a spinal cord injury – all grades (grade 1 and 2) – Shea classification⁸¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	20/28 (71.4%)	8/27 (29.6%)	RR 2.41 (1.29 to 4.51)	418 more per 1000 (from 86 more to 1000 more)	Moderate	Critical
							-	29.6%		417 more per 1000 (from 86 more to 1000 more)		
Proportion of pressure ulcers completely healed – people with a spinal cord injury – all grades (grade 1 and 2) – Shea classification⁸¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	23/31 (74.2%)	12/30 (40%)	RR 1.85 (1.14 to 3.01)	340 more per 1000 (from 56 more to 804 more)	Low	Critical
							-	40%		340 more per 1000 (from 56 more to 804 more)		
Proportion of pressure ulcers improved – people with a spinal cord injury – all grades (grade 1 and 2) – Shea classification⁸¹												

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Phenytoin cream	Relative (95% CI)	Absolute		
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	27/31 (87.1%)	16/30 (53.3%)	RR 1.63 (1.14 to 2.34)	336 more per 1000 (from 75 more to 715 more)	Low	Critical
							-	53.3%		336 more per 1000 (from 75 more to 714 more)		
Proportion of pressure ulcers worsened– people with a spinal cord injury – all grades (grade 1 and 2) – Shea classification⁸¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	2/31 (6.5%)	2/30 (6.7%)	RR 0.97 (0.15 to 6.44)	2 fewer per 1000 (from 57 fewer to 363 more)	Very low	Critical
							-	6.7%		2 fewer per 1000 (from 57 fewer to 364 more)		
Mortality (all-cause)⁸¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	No serious	None	0/28 (0%)	0/28 (0%)	Not pooled	Not pooled	Moderate	Important
Time to complete healing of pressure ulcers												

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Phenytoin cream	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Only blinding of outcome assessor was reported.

(b) The confidence interval crossed 1 MID point.

(c) The confidence interval crossed both MID points.

Table 156: Clinical evidence profile: hydrocolloid dressing versus alginate dressing

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Alginate dressing	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers partially (40%) healed – older inpatients – all grades (grade 3 and 4) – Yarkony classification²⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	31/53 (58.5%)	43/57 (75.4%)	RR 0.78 (0.59 to 1.02)	166 fewer per 1000 (from 309 fewer to 15 more)	Very low	Critical
							-	75.4%		166 fewer per 1000 (from 309 fewer to 15 more)		
Mean percentage reduction in pressure ulcer area – older inpatients – all grades (grade 3 and 4) – Yarkony classification²⁴												
1	Randomised trial	Very serious ^{a,e}	No serious inconsistency	No serious indirectness	No serious imprecision	None	42.6 (SD 49.1)	69.1 (SD 33.9)	-	MD 26.5 lower (42.38 to 10.62 lower)	Low	Critical
Mean cm² reduction in pressure ulcer area – older inpatients – all grades (grade 3 and 4) – Yarkony classification²⁴												
1	Randomised trial	Very serious ^{a,e}	No serious inconsistency	No serious indirectness	No serious imprecision	None	5.2 (SD 7.2)	9.7 (SD 7.1)	-	MD 4.5 lower (7.17 to 1.83 lower)	Very low	Critical
Proportion of people with an infection – older inpatients – all grades (grade 3 and 4) – Yarkony classification²⁴												
1	Randomised trial	Very serious ^{a,d}	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/53 (0%)	1/57 (1.8%)	Peto OR 0.15 (0	15 fewer per 1000	Very low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Alginate dressing	Relative (95% CI)	Absolute		
									to 7.34)	(from 18 fewer to 98 more)		
							-	1.8%		15 fewer per 1000 (from 18 fewer to 101 more)		
Proportion of people with skin irritation – older inpatients – all grades (grade 3 and 4) – Yarkony classification²⁴												
1	Randomised trial	Very serious ^{a,d}	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/53 (0%)	2/57 (3.5%)	Peto OR 0.14 (0.01 to 2.31)	30 fewer per 1000 (from 35 fewer to 46 more)	Very low	Important
							-	3.5%		30 fewer per 1000 (from 35 fewer to 46 more)		
Proportion of people with hypergranulation – older inpatients – all grades (grade 3 and 4) – Yarkony classification²⁴												
1	Randomised trial	Very serious ^{a,d}	No serious inconsistency	No serious indirectness	Very serious ^c	None	5/53 (9.4%)	1/57 (1.8%)	RR 5.38 (0.65 to 44.54)	77 more per 1000 (from 6 fewer to 764 more)	Very low	Important
							-	1.8%		79 more per 1000 (from 6 fewer to 784 more)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Alginate dressing	Relative (95% CI)	Absolute (more)		
Proportion of people with maceration – older inpatients – all grades (grade 3 and 4) – Yarkony classification²⁴												
1	Randomised trial	Very serious ^{a,d}	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/53 (0%)	1/57 (1.8%)	Peto OR 0.15 (0 to 7.34)	15 fewer per 1000 (from 18 fewer to 98 more)	Very low	Important
							-	1.8%		15 fewer per 1000 (from 18 fewer to 101 more)		
Proportion of people with bleeding – older inpatients – all grades (grade 3 and 4) – Yarkony classification²⁴												
1	Randomised trial	Very serious ^{a,d}	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/53 (0%)	1/57 (1.8%)	Peto OR 0.15 (0 to 7.34)	15 fewer per 1000 (from 18 fewer to 98 more)	Very low	Important
							-	1.8%		15 fewer per 1000 (from 18 fewer to 101 more)		
Incidence of pain at dressing removal – older inpatients – all grades (grade 3 and 4) – Yarkony classification²⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	411/1314 (31.3%)	316/887 (35.6%)	RR 0.88 (0.78 to 0.99)	43 fewer per 1000 (from 4 fewer to 78 fewer)	Very low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Alginate dressing	Relative (95% CI)	Absolute		
							-	35.6%		43 fewer per 1000 (from 4 fewer to 78 fewer)		
Incidence of strong odour at dressing removal – older inpatients – all grades (grade 3 and 4) – Yarkony classification²⁴												
1	Randomised trials	Very serious ^{a,d}	No serious inconsistency	No serious indirectness	Serious ^b	None	173/1314 (13.2%)	178/887 (20.1%)	RR 0.66 (0.54 to 0.79)	68 fewer per 1000 (from 42 fewer to 92 fewer)	Very low	Important
							-	20.1%		68 fewer per 1000 (from 42 fewer to 92 fewer)		
Incidence of mild odour at dressing removal – older inpatients – all grades (grade 3 and 4) – Yarkony classification²⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	382/1314 (40.7%)	361/887 (40.7%)	RR 0.71 (0.64 to 0.80)	118 fewer per 1000 (from 81 fewer to 147 fewer)	Very low	Important
								40.7%		118 fewer per 1000 (from 81 fewer to 147 fewer)		
Mortality (all-cause)²⁴												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Alginate dressing	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	11/57 (19.3%)	8/53 (15.1%)	RR 1.28 (0.56 to 2.93)	42 more per 1000 (from 66 fewer to 291 more)	Very low	Important
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Sequence generation was by block of 4 participants; allocation was balanced by centre; only blinding of outcome assessor.

(b) The confidence interval crossed 1 MID point.

(c) The confidence interval crossed both MID points.

(d) The drop out is more than 10% higher than event rate.

(e) No log-transformation of data was carried out.

Table 157: Clinical evidence profile: hydrocolloid dressing versus charcoal dressing

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Charcoal dressing	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers worsened – inpatients – all grades (grade 2c and 4) – Yarkoni classification⁹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	1/30 (3.3%)	0/29 (0%)	Peto OR 7.15 (0.14 to 360.38)	3 more (from 6 fewer to 120 more)	Very low	Critical
							-	0%		3 more (from 6 fewer to 120 more)		
Median percentage reduction in pressure ulcer area– inpatients – all grades (grade 2c and 4) – Yarkoni classification⁹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	18.5 (range:100 to -260.9) (n=31)	26.9 (range: 82 to -97.9) (n=29)	-	Not pooled	Very low	Critical
Median cm² reduction in pressure ulcer area – inpatients – all grades (grade 2c and 4) – Yarkoni classification⁹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	3.1 (range: 24.1 to -46.0) (n=31)	4.3 (range: 31.2 to -13.8) (n=29)	-	Not pooled	Very low	Critical
Proportion of people with maceration – inpatients – all grades (grade 2c and 4) – Yarkoni classification⁹⁰												
1	Randomised trial	Very serious ^{a,e}	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/30 (6.7%)	0/29 (0%)	Peto OR 7.4 (0.45 to	7 more (from 4 fewer to	Very low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Charcoal dressing	Relative (95% CI)	Absolute		
									121.22)	170 more)		
							-	0%		7 more (from 4 fewer to 170 more)		
Proportion of people with an infection – inpatients – all grades (grade 2c and 4) – Yarkoni classification⁹⁰												
1	Randomised trial	Very serious ^{a,e}	No serious inconsistency	No serious indirectness	Very serious ^d	None	2/30 (6.7%)	1/29 (3.4%)	RR 1.93 (0.19 to 20.18)	32 more per 1000 (from 28 fewer to 661 more)	Very low	Important
							-	3.5%		33 more per 1000 (from 28 fewer to 671 more)		
Proportion of people with hypergranulation – inpatients – all grades (grade 2c and 4) – Yarkoni classification⁹⁰												
1	Randomised trial	Very serious ^{a,e}	No serious inconsistency	No serious indirectness	Very serious ^d	None	1/30 (3.3%)	0/29 (0%)	Peto OR 7.15 (0.14 to 360.38)	3 more (from 6 fewer to 120 more)	Very low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Charcoal dressing	Relative (95% CI)	Absolute		
							-	0%		3 more (from 6 fewer to 120 more)		
Proportion of people with skin irritation and eczema – inpatients – all grades (grade 2c and 4) – Yarkoni classification⁹⁰												
1	Randomised trial	Very serious ^{a,e}	No serious inconsistency	No serious indirectness	Very serious ^d	None	1/30 (3.3%)	0/29 (0%)	Peto OR 7.15 (0.14 to 360.38)	3 more (from 6 fewer to 120 more)	Very low	Important
							-	0%		3 more (from 6 fewer to 120 more)		
Proportion of people with bleeding – inpatients – all grades (grade 2c and 4) – Yarkoni classification⁹⁰												
1	Randomised trial	Very serious ^{a,e}	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/30 (0%)	0/29 (0%)	not pooled	0 more (from 6 fewer to 6 more)	Low	Important
							-	0%		0 more (from 6 fewer to 6 more)		
Proportion of people with pruritus – inpatients – all grades (grade 2c and 4) – Yarkoni classification⁹⁰												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Charcoal dressing	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^{a,e}	No serious inconsistency	No serious indirectness	Very serious ^d	None	0/30 (0%)	1/29 (3.4%)	Peto OR 0.13 (0 to 6.59)	30 fewer per 1000 (from 34 fewer to 156 more)	Very low	Important
							-	3.5%		30 fewer per 1000 (from 35 fewer to 158 more)		
Proportion of people with wound pain – inpatients – all grades (grade 2c and 4) – Yarkoni classification⁹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/30 (0%)	0/29 (0%)	Not pooled	0 more (from 6 fewer to 6 more)	Low	Important
							-	0%		0 more (from 6 fewer to 6 more)		
Proportion of people with pain at dressing removal – inpatients – all grades (grade 2c and 4) – Yarkoni classification⁹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	19/30 (63.3%)	19/29 (65.5%)	RR 0.97 (0.66 to 1.41)	20 fewer per 1000 (from 223 fewer to 269 more)	Very low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Charcoal dressing	Relative (95% CI)	Absolute		
							-	65.5%		20 fewer per 1000 (from 223 fewer to 269 more)		
Mortality (all-cause)⁹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious imprecision ^d	None	2/31 (6.5%)	1/29 (3.4%)	RR 1.87 (0.18 to 19.55)	30 more per 1000 (from 28 fewer to 640 more)	Very low	Important
							-	3.5%		30 more per 1000 (from 29 fewer to 649 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) No report on sequence generation and only blinding of outcome assessor.
- (b) The confidence interval crossed both MID points.
- (c) No standard deviation was reported and it was unknown if sample size was sufficient.
- (d) The confidence interval crossed both MID points.
- (e) The drop out is more than 10% higher than event rate.

Table 158: Clinical evidence profile: hydrocolloid dressing versus phenytoin ointment

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Phenytoin ointment	Relative (95% CI)	Absolute		
Mean time to healing of pressure ulcers (days) – people in a nursing home – all grades (grade 2) – AHCPR classification¹⁵⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	51.8 (SD 19.6)	35.3 (SD 14.3)	-	MD 16.5 higher (3.62 to 29.38 higher)	Very low	Critical
Proportion of people with adverse events – people in a nursing home – all grades (grade 2) – AHCPR classification¹⁵⁵												
1	Randomised trial	Very serious ^{a,c}	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/13 (0%)	0/15 (0%)	Not pooled	0 more (from 130 fewer to 130 more)	Low	Important
							-	0%		0 more (from 130 fewer to 130 more)		
Mortality (all-cause)¹⁵⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	2/16 (12.5%)	2/18 (11.1%)	RR 1.13 (0.18 to 7.09)	13 more per 1000 (from 91 fewer to 677)	Very low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Phenytoln ointment	Relative (95% CI)	Absolute (more)		
							-	11.1%		13 more per 1000 (from 91 fewer to 676 more)		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size and volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) No report on sequence generation, allocation concealment or blinding.
- (b) The confidence interval crossed 1 MID point.
- (c) The drop out is more than 10% higher than event rate.
- (d) The confidence interval crossed both MID points.

Table 159: Clinical evidence profile: hydrocolloid dressing versus antibiotic ointment

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Antibiotic ointment	Relative (95% CI)	Absolute		
Mean time to healing of pressure ulcers (days) – people in a nursing home – all grades (grade 2) – AHCPR classification¹⁵⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	51.8 (SD 19.6)	53.8 (SD 8.5)	-	MD 2 lower (13.78 lower to 9.78 higher)	Very low	Critical
Proportion of people with adverse events – people in a nursing home – all grades (grade 2) – AHCPR classification¹⁵⁵												
1	Randomised trial	Very serious ^{a,c}	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/13 (0%)	0/11 (0%)	Not pooled	0 more (from 150 fewer to 150 more)	Low	Important
							-	0%		0 more (from 150 fewer to 150 more)		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcer												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size and volume of pressure ulcer												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Antibiotic ointment	Relative (95% CI)	Absolute		
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No report on sequence generation, allocation concealment or blinding.
 (b) The confidence interval crossed both MID points.
 (c) The drop out is more than 10% higher than event rate.

Table 160: Clinical evidence profile: hydrocolloid dressing: triangular shape versus oval shape

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing: triangular shape	Hydrocolloid dressing: oval shape	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – inpatients – all grades (grade 2 and 3) – NPUAP classification⁵⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	17/47 (36.2%)	11/49 (22.4%)	RR 1.61 (0.85 to 3.07)	137 more per 1000 (from 34 fewer to 465 more)	Very low	Critical
							-	22.5%		137 more per 1000 (from 34 fewer to 465 more)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing: triangular shape	Hydrocolloid dressing: oval shape	Relative (95% CI)	Absolute		
										fewer to 466 more)		
Proportion of people with pressure ulcers improved – inpatients – all grades (grade 2 and 3) – NPUAP classification⁵⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	41/47 (87.2%)	31/49 (63.3%)	RR 1.38 (1.08 to 1.75)	240 more per 1000 (from 51 more to 474 more)	Very low	Critical
							-	63.3%		241 more per 1000 (from 51 more to 475 more)		
Proportion of people with pressure ulcers not changed – inpatients – all grades (grade 2 and 3) – NPUAP classification⁵⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	4/47 (8.5%)	3/49 (6.1%)	RR 1.39 (0.33 to 5.88)	24 more per 1000 (from 41 fewer to 299 more)	Very low	Critical
							-	6.1%		24 more per 1000 (from 41 fewer to 298 more)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing: triangular shape	Hydrocolloid dressing: oval shape	Relative (95% CI)	Absolute (more)		
Proportion of people with pressure ulcers worsened – inpatients – all grades (grade 2 and 3) – NPUAP classification⁵⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	2/47 (4.3%)	15/49 (30.6%)	RR 0.14 (0.03 to 0.58)	263 fewer per 1000 (from 129 fewer to 297 fewer)	Low	Critical
							-	91.8%		789 fewer per 1000 (from 386 fewer to 890 fewer)		
Mean percentage reduction in pressure ulcer length – inpatients – all grades (grade 2 and 3) – NPUAP classification⁵⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	32 (SD 34.15)	17 (SD 34.15)	-	MD 15 higher (1.33 to 28.67 higher)	Low	Critical
Mean percentage reduction in pressure ulcer width – inpatients – all grades (grade 2 and 3) – NPUAP classification⁵⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	28 (n=47)	24 (n=49)	p > 0.05	Not pooled	Very low	Critical
Mean pain at dressing change – inpatients – all grades (grade 2 and 3) – NPUAP classification⁵⁰												
1	Randomised	Very	No serious	No serious	No serious	None	2.1	4.3	-	MD 2.2	Low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing: triangular shape	Hydrocolloid dressing: oval shape	Relative (95% CI)	Absolute		
	trial	serious ^a	inconsistency	indirectness	imprecision		(SD 2.1)	(SD 1.75)		lower (2.97 to 1.43 lower)		
Proportion of people with ulcer pain – inpatients – all grades (grade 2 and 3) – NPUAP classification⁵⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	8/47 (17%)	15/49 (30.6%)	RR 0.56 (0.26 to 1.19)	135 fewer per 1000 (from 227 fewer to 58 more)	Very low	Important
							-	30.6%		135 fewer per 1000 (from 226 fewer to 58 more)		
Proportion of people with adverse events – inpatients – all grades (grade 2 and 3) – NPUAP classification⁵⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	0/47 (0%)	4/49 (8.2%)	OR 0.13 (0.02 to 0.97)	70 fewer per 1000 (from 2 fewer to 80 fewer)	Very low	Important
							-	8.2%		71 fewer per 1000 (from 2 fewer to		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing: triangular shape	Hydrocolloid dressing: oval shape	Relative (95% CI)	Absolute		
										80 fewer)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) Randomised schedule and no report on allocation concealment and no blinding was reported. no log-transformation of data was carried out.
- (b) The confidence interval crossed 1 MID point.
- (c) The confidence interval crossed both MID points.
- (d) No standard deviation was reported and it was unknown if sample size was sufficient.
- (e) Oval group: increase in necrotic tissue, wound size and depth, inflammation of surrounding skin, severe pain upon dressing removal, and bleeding.

Table 161: Clinical evidence profile: hydrocolloid dressing (SignaDress) versus hydrocolloid dressing (ComfeelPlus)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloids : SingaDress	Hydrocolloids : ComfeelPlus	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – people in a nursing home – all grades (grade 2 to 4) – AHCPR classification¹⁷⁰												
1	Randomised trial	Very serious ^{a, d}	No serious inconsistency	No serious indirectness	Serious ^b	None	6/17 (35.3%)	1/18 (5.6%)	RR 6.35 (0.85 to 47.44)	297 more per 1000 (from 8 fewer to 1000 more)	Very low	Critical
							-	5.6%		300 more per 1000 (from 8 fewer to 1000 more)		
Percentage reduction in pressure ulcer area – people in a nursing home – all grades (grade 2 to 4) – AHCPR classification¹⁷⁰												
1	Randomised trial	Very serious ^{a, e}	No serious inconsistency	No serious indirectness	Very serious ^c	None	60 (n=17)	22 (n=18)	p=0.01	Not pooled	Very low	Critical
Healing rate of pressure ulcers (%/week) – people in a nursing home – all grades (grade 2 to 4) – AHCPR classification¹⁷⁰												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	33.8 (n=17)	7.0 (n=18)	-	Not pooled	Very low	Critical
Proportion of people with adverse events – people in a nursing home – all grades (grade 2 to 4) – AHCPR classification¹⁷⁰												
1	Randomised trial	Very serious ^{a, d}	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/17 (0%)	0/18 (0%)	Not pooled	0 (from 100 fewer to 100 more)	Low	Important
							-	0%		0 (from 100 fewer to 100)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloids : SingaDress	Hydrocolloids : ComfeelPlus	Relative (95% CI)	Absolute (more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) The authors did not report on blinding.
- (b) The confidence interval crossed 1 MID point.
- (c) No standard deviation was reported and the study used a small sample size.
- (d) The drop out is more than 10% higher than event rate.
- (e) No log-transformation of data was carried out.

Table 162: Clinical evidence profile: gauze dressing versus foam dressing

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Gauze dressing	Foam dressing	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – general population – all grades (grade 2 and 3) – Enterostomal Therapy and NPUAP classification^{d98,148}												
2	Randomised trials	Very serious ^{a,e}	No serious inconsistency	No serious indirectness	Serious ^b	None	9/30 (30%)	20/44 (45.5%)	RR 0.64 (0.34 to 1.22)	164 fewer per 1000 (from 300 fewer to 100 more)	Very low	Critical
							-	45.8%		165 fewer per 1000 (from 302 fewer to 101 more)		
Median time to 50% healing of pressure ulcers (days) – general population – grade 2 – NPUAP classification¹⁴⁸												
1	Randomised trials ¹	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	28 (n=16)	28 (n=20)	-	Not pooled	Very low	Critical
Mortality (all-cause)^{98,148}												
2	Randomised trials	Very serious ^{a,e}	No serious inconsistency	No serious indirectness	Very serious ^c	None	4/30 (13.3%)	3/44 (6.8%)	RR 1.76 (0.49 to 6.34)	52 more per 1000 (from 35 fewer to 364 more)	Very low	Important
							-	7.5%		57 more per 1000 (from 38 fewer to 401 more)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Gauze dressing	Foam dressing	Relative (95% CI)	Absolute (more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size and volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No report on sequence generation, allocation concealment or blinding

(b) The confidence interval crossed 1 MID point

(c) No standard deviation was reported and the study used a ; small sample size

(d) Kraft (2003): Enterostomal therapy classification; Payne (2009): NPUAP classification

(e) Kraft (1993): Drop out is more than 10% higher than event rate

Table 163: Clinical evidence profile: gauze dressing versus polyurethane dressing

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Gauze dressing	Polyurethane dressing	Relative (95% CI)	Absolute		
Proportion of pressure ulcers completely healed – general population – all grades – Enis and Sarmiento and Shea classification^{f 144,171}												
2	Randomised trials	Very serious ^{a,b}	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/22 (0%)	15/31 (48.4%)	Peto OR 0.08 (0.02 to 0.31)	414 fewer per 1000 (from 259 fewer to 465 fewer)	Low	Critical
							-	37.4%		328 fewer per 1000 (from 218 fewer to 362 fewer)		
Proportion of pressure ulcers completely healed – people in the community – grade 2 – Shea classification¹⁷¹												
1	Randomised trial	Very serious ^b	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/12 (0%)	14/22 (63.6%)	Peto OR 0.08 (0.02 to 0.32)	514 fewer per 1000 (from 277 fewer to 603 fewer)	Low	Critical
							-	63.6%		513 fewer per 1000 (from 277 fewer)		

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Gauze dressing	Polyurethane dressing	Relative (95% CI)	Absolute		
										fewer to 02 fewer)		
Proportion of pressure ulcers worsened – general population – Enis and Sarmiento and Shea classification^{f144,171}												
2	Randomised trials	Very serious ^{a,b}	No serious inconsistency	No serious indirectness	No serious imprecision	None	9/22 (40.9%)	4/31 (12.9%)	RR 3.46 (1.26 to 9.49)	317 more per 1000 (from 34 more to 1000 more)	Low	Critical
							-	12.4%		305 more per 1000 (from 32 more to 1000 more)		
Proportion of pressure ulcers decreased in ulcer stage– people in the community– grade 2 – Shea classification¹⁷¹												
1	Randomised trial	Very serious ^b	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/12 (0%)	16/22 (72.7%)	Peto OR 0.06 (0.01 to 0.24)	589 fewer per 1000 (from 337 fewer to 701 fewer)	Low	Critical
							-	72.7%		589 fewer per 1000 (from 337 fewer to 701 fewer)		

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Gauze dressing	Polyurethane dressing	Relative (95% CI)	Absolute		
Proportion of pressure ulcers increased in ulcer stage – people in the community –grade 2 – Shea classification¹⁷¹												
1	Randomised trial	Very serious ^b	No serious inconsistency	No serious indirectness	Serious ^c	None	5/12 (41.7%)	1/22 (4.5%)	RR 9.17 (1.21 to 69.69)	371 more per 1000 (from 10 more to 1000 more)	Very low	Critical
							-	4.6%		376 more per 1000 (from 10 more to 1000 more)		
Mean percentage reduction in pressure ulcer area – inpatients – all grades (grade 1 and 2) – Enis and Sarmiento classification¹⁴⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	2.5 (n=10)	42.9 (n=9)	-	Not pooled	Very low	Critical
Median percentage reduction in pressure ulcer area– people in the community – grade 2 – Shea classification¹⁷¹												
1	Randomised trial	Very serious ^b	No serious inconsistency	No serious indirectness	Very serious ^e	None	52 (n=22)	100 (n=22)	-	Not pooled	Very low	Critical
Median percentage reduction in pressure ulcer area– people in the community – grade 3 – Shea classification¹⁷¹												
1	Randomised trial	Very serious ^b	No serious inconsistency	No serious indirectness	Very serious ^d	None	44 (n=15)	67 (n=15)	-	Not pooled	Very low	Critical
Proportion of people with maceration – people in the community – Shea classification¹⁷¹												
1	Randomised trial	Very serious ^b	No serious inconsistency	No serious indirectness	Serious ^c	None	10/12 (83.3%)	17/22 (77.3%)	RR 1.08 (0.77 to 1.51)	62 more per 1000 (from 178 fewer to 394)	Very low	Important

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Gauze dressing	Polyurethane dressing	Relative (95% CI)	Absolute (more)		
							-	77.3%		62 more per 1000 (from 178 fewer to 394 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcer												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Oleske (1986) did not report on sequence generation, allocation concealment or blinding. No log-transformation of data was carried out.

(b) Sebern (1989) did not report on allocation concealment or blinding.

(c) The confidence interval crossed 1 MID point

(d) No standard deviation was reported and there was a small sample size.

(e) No standard deviation was reported and it was unknown if sample size was sufficient.

(f) Oleske (1986): Enis and Sarmiento classification; Sebern (1989): Shea classification

Table 164: Clinical evidence profile: gauze dressing versus hydrogel

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Gauze dressing	Hydrogel dressing	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – general pressure ulceration – all grades (grade 2 to 4) – classification system not reported¹⁹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	9/14 (64.3%)	10/16 (62.5%)	RR 1.03 (0.6 to 1.77)	19 more per 1000 (from 250 fewer to 481 more)	Very low	Critical
							-	62.5%		19 more per 1000 (from 250 fewer to 481 more)		
Proportion of people with pressure ulcers worsened – general pressure ulceration – all grades (grade 2 to 4) – classification system not reported¹⁹⁰												
1	Randomised trial	Very serious ^{a,f}	No serious inconsistency	No serious indirectness	Very serious ^b	None	1/19 (5.3%)	1/22 (4.5%)	RR 1.16 (0.08 to 17.28)	7 more per 1000 (from 42 fewer to 740 more)	Very low	Critical
							-	4.6%		7 more per 1000 (from 42 fewer to 749 more)		
Mean percentage reduction in pressure ulcer area – In- and outpatients – grade 2 and 3 – classification system not reported¹²⁴												
1	Randomised trial	Very serious ^c	No serious inconsistency	No serious indirectness	Serious ^d	None	5.1 (SD 14.8)	8 (SD 14.8)	-	MD 2.9 lower (12.07 lower to 6.27 higher)	Very low	Critical
Mean healing rate of pressure ulcers (cm²/day) – people with a spinal cord injury – all grades (grade 2 to 4) – NPUAP classification⁸⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	0.12 (SD 0.16)	0.09 (SD 0.05)	-	MD 3 higher (5.58 lower to 11.58 higher)	Very low	Critical
Mean time to healing of pressure ulcers (weeks) – general population – all grades (grade 2 to 4) – classification system not reported¹⁹⁰												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Gauze dressing	Hydrogel dressing	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	5.2 (SD 2.4)	5.3 (SD 2.3)	-	MD 0.1 lower (1.79 lower to 1.59 higher)	Very low	Critical
Mortality (all-cause)¹⁹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/14 (14.3%)	4/16 (25%)	RR 0.57 (0.12 to 2.66)	108 fewer per 1000 (from 220 fewer to 415 more)	Very low	Critical
							-	25%		108 fewer per 1000 (from 220 fewer to 415 more)		
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No report on sequence generation, allocation concealment or blinding. No log-transformation of data was carried out.

(b) The confidence interval crossed both MID points.

(c) Mulder (1993) did not report on allocation concealment or blinding.

(d) The confidence interval crossed 1 MID point.

(e) No standard deviation was reported and the study used a small sample size.

(f) The drop out is more than 10% higher than event rate

Table 165: Clinical evidence profile: gauze dressing versus dextranomer

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Gauze dressing	Dextranomer dressing	Relative (95% CI)	Absolute		
Proportion of pressure ulcers improved – people with a spinal cord injury – all grades (grade 2 to 4) – Eltorai classification¹⁰⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	2/15 (13.3%)	11/15 (73.3%)	RR 0.18 (0.05 to 0.68)	601 fewer per 1000 (from 235 fewer to 697 fewer)	Low	Critical
							-	73.3%		601 fewer per 1000 (from 235 fewer to 696 fewer)		
Proportion of people with adverse events - people with a spinal cord injury – all grades (grade 2 to 4) – Eltorai classification¹⁰⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/15 (0%)	0/15 (0%)	Not pooled	0 more (from 120 fewer to 120 more)	Low	Important
							-	0%		0 more (from 120 fewer to 120 more)		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Gauze dressing	Dextranome r dressing	Relative (95% CI)	Absolute		
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Ljungberg (2009) did not report on sequence generation, allocation concealment or blinding.

(b) Sebern (2009) did not report on sequence generation, allocation concealment or blinding.

Table 166: Clinical evidence profile: gauze dressing versus phenytoin cream

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Gauze dressing	Phenytoin cream	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – people with a spinal cord injury – all grades (grade 1 and 2) – NPUAP classification⁸¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	8/27 (29.6%)	11/28 (39.3%)	RR 0.75 (0.36 to 1.58)	98 fewer per 1000 (from 251 fewer to 228 more)	Very low	Critical
							-	39.3%		98 fewer per 1000 (from 252 fewer to		

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Gauze dressing	Phenytoin cream	Relative (95% CI)	Absolute		
										228 more)		
Proportion of pressure ulcers completely healed (all sites) – people with a spinal cord injury – all grades (grade 1 and 2) – NPUAP classification⁸¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	8/30 (26.7%)	12/30 (40%)	RR 0.67 (0.32 to 1.39)	132 fewer per 1000 (from 272 fewer to 156 more)	Very low	Critical
							-	40%		132 fewer per 1000 (from 272 fewer to 156 more)		
Proportion of pressure ulcers improved – people with a spinal cord injury – all grades (grade 1 and 2) – NPUAP classification⁸¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	13/30 (43.3%)	16/30 (53.3%)	RR 0.81 (0.48 to 1.38)	101 fewer per 1000 (from 277 fewer to 203 more)	Very low	Critical
							-	53.3%		101 fewer per 1000 (from 277 fewer to 203 more)		
Proportion of pressure ulcers worsened – people with a spinal cord injury – all grades (grade 1 and 2) – NPUAP classification⁸¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	9/30 (30%)	2/30 (6.7%)	RR 4.5 (1.06 to 19.11)	233 more per 1000 (from 4 more to 1000 more)	Low	Critical
							-	6.7%		235 more per 1000		

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Gauze dressing	Phenytoin cream	Relative (95% CI)	Absolute (from 4 more to 1000 more)		
Mortality (all-cause) ⁸¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/27 (0%)	0/28 (0%)	Not pooled	Not pooled	Moderate	Important
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Only blinding of outcome assessor was conducted.

(b) The confidence interval crossed both MID points.

(c) The confidence interval crossed 1 MID point.

Table 167: Clinical evidence profile: foam dressing versus skin replacement

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Foam dressing	skin replacement	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – general pressure ulceration – all grades (grade 3) – classification system not reported¹⁴⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/16 (12.5%)	2/18 (11.1%)	RR 1.13 (0.18 to 7.09)	13 more per 1000 (from 91 fewer to 677 more)	Very low	Critical
							-	11.1%		13 more per 1000 (from 91 fewer to 676 more)		
Median percentage reduction in pressure ulcer area (closed ulcers) – general pressure ulceration – all grades (grade 3) – classification system not reported¹⁴⁹												
1	Randomised trial	Very serious ^{a,e}	No serious inconsistency	No serious indirectness	Very serious ^c	None	33.5 (range:-77.5-100) (n=16)	49.5 (range: -81.7-100) (n=18)	-	Not pooled	Very low	Critical
Median percentage reduction in pressure ulcer area (unclosed ulcers) – general pressure ulceration – all grades (grade 3) – classification system not reported¹⁴⁹												
1	Randomised trial	Very serious ^{a,e}	No serious inconsistency	No serious indirectness	Very serious ^c	None	17.4 (range: -434.5-100) (n=16)	38.8 (range:-201.7-100) (n=18)	-	Not pooled	Very low	Critical
Mean percentage reduction in pressure ulcer volume – general pressure ulceration – all grades (grade 3) – classification system not reported¹⁴⁹												
1	Randomised trial	Very serious ^{a,e}	No serious inconsistency	No serious indirectness	Very serious ^c	None	4.1 (n=16)	18.7 (n=18)	-	Not pooled	Very low	Critical
Median percentage reduction in pressure ulcer volume – general pressure ulceration – all grades (grade 3) – classification system not reported¹⁴⁹												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Foam dressing	skin replacement	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^{a,e}	No serious inconsistency	No serious indirectness	Very serious ^c	None	17.4 (n=16)	41.2 (n=18)	-	Not pooled	Very low	Critical
Proportion of people with infection – general pressure ulceration – all grades (grade 3) – classification system not reported¹⁴⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	3/16 (18.8%)	3/18 (16.7%)	RR 1.13 (0.26 to 4.8)	22 more per 1000 (from 123 fewer to 633 more)	Very low	Important
							-	16.7%		22 more per 1000 (from 124 fewer to 635 more)		
Proportion of people with adverse events – general pressure ulceration – all grades (grade 3) – classification system not reported¹⁴⁹												
1	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/16 (0%)	0/18 (0%)	Not pooled	0 more (from 110 fewer to 110 more)	Low	Important
							-	0%		0 more (from 110 fewer to 110 more)		
Time to complete healing of pressure ulcers												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Foam dressing	skin replacement	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) Single blinding (no additional information) was carried out.
- (b) The confidence interval crossed both MID points.
- (c) No standard deviation was reported and the study used a small sample size.
- (d) The drop out is more than 10% higher than event rate.
- (e) No log-transformation of data was carried out.

Table 168: Clinical evidence profile: foam dressing versus antibiotic ointment

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Foam dressing	Antibiotic ointment	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – people in long term care – all grades (grade 2) – AHCPR classification²¹¹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	18/21 (85.7%)	15/23 (65.2%)	RR 1.31 (0.93 to 1.86)	202 more per 1000 (from 46 fewer to 561 more)	Very low	Critical
							-	65.2%		202 more per 1000 (from 46 fewer to 561 more)		
Mean PUSH score at end of treatment – people in long term care – all grades (grade 2) – AHCPR classification²¹¹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	3.24 (n=19)	1.61 (n=23)	p > 0.05	Not pooled	Very low	Critical
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Foam dressing	Antibiotic ointment	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No report on sequence generation, allocation concealment or blinding; no log-transformation of data was carried out.

(b) The confidence interval crossed 1 MID point.

(c) No standard deviation was reported and there was a small sample size.

Table 169: Clinical evidence profile: foam dressing: Allevyn® versus Biatain®

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Allevyn	Biatain	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcer completely healed – general pressure ulceration – all grades (grade 2 and 3) – NPUAP classification ¹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	11/14 (78.6%)	5/18 (27.8%)	RR 2.83 (1.28 to 6.25)	508 more per 1000 (from 78 more to 1000 more)	Low	Critical
							-	27.8%		509 more per 1000 (from 78 more to 1000 more)		
Median percentage reduction in pressure ulcer area – general pressure ulceration – all grades (grade 2 and 3) – NPUAP classification ¹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	38.2 (range: - 97.6- 99.4) (n=14)	45.8 (range: - 56.9- 90.0) (n=18)	p > 0.05	Not pooled	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Allevyn	Biatain	Relative (95% CI)	Absolute		
Mean pain score at dressing removal (1: none - 4 severe) – general pressure ulceration – all grades (grade 2 and 3) – NPUAP classification¹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	1.01 (range: 1.00-1.17) (n=14)	1.10 (range: 1.00-2.17) (n=18)	p > 0.05	Not pooled	Very low	Important
Mean comfort score at dressing removal (1: none - 4 severe) – general pressure ulceration – all grades (grade 2 and 3) – NPUAP classification¹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	1.84 (SD 0.26)	2.11 (SD 0.26)	-	MD 0.27 lower (0.45 to 0.09 lower)	Very low	Important
Proportion of people with dressing related adverse events – general pressure ulceration – all grades (grade 2 and 3) – NPUAP classification¹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	1/14 (7.1%)	4/18 (22.2%)	RR 0.32 (0.04 to 2.57)	151 fewer per 1000 (from 213 fewer to 349 more)	Very low	Important
							-	22.2%		151 fewer per 1000 (from 213 fewer to 349 more)		
Mortality (all-cause)¹⁰												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	0/14 (0%)	1/18 (5.6%)	Peto OR 0.17 (0 to 8.79)	46 fewer per 1000 (from 56 fewer to 285 more)	Very low	Important
							-	5.6%		46 fewer per 1000 (from 56		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Allevyn	Biatain	Relative (95% CI)	Absolute		
										fewer to 287 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No report on sequence generation or blinding. Allocation according to baseline exudate level and treatment centre; no log-transformation of data was carried out.

(b) No standard deviation was reported and the study used a small sample size.

(c) The confidence interval crossed 1 MID point.

(d) The confidence interval crossed both MID points

Table 170: Clinical evidence profile: foam dressing (Mepilex) versus foam dressing (Tielle)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Mepilex	Tielle	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – elderly people – all grades (grade 2) – NPUAP classification¹¹⁶												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	8/18 (44.4%)	10/20 (50%)	RR 0.89 (0.45 to 1.75)	55 fewer per 1000 (from 275 fewer to 375 more)	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Mepilex	Tielle	Relative (95% CI)	Absolute		
							-	50%		55 fewer per 1000 (from 275 fewer to 375 more)		
Proportion of people with pressure ulcers improved – elderly people – all grades (grade 2) – NPUAP classification¹¹⁶												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	15/18 (83.3%)	19/20 (95%)	RR 0.88 (0.7 to 1.1)	114 fewer per 1000 (from 285 fewer to 95 more)	Low	Critical
							-	95%		114 fewer per 1000 (from 285 fewer to 95 more)		
Proportion of people with pressure ulcers worsened – elderly people – all grades (grade 2) – NPUAP classification¹¹⁶												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/18 (11.1%)	1/20 (5%)	RR 2.22 (0.22 to 22.49)	61 more per 1000 (from 39 fewer to 1000 more)	Very low	Critical
							-	5%		61 more per 1000 (from 39 fewer to 1000 more)		
Proportion of people with maceration – elderly people – all grades (grade 2) – NPUAP classification¹¹⁶												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	0/18 (0%)	3/20 (15%)	OR 0.13 (0.01 to 1.38)	128 fewer per 1000 (from 148 fewer to 46 more)	Very low	Important
							-	15%		128 fewer per 1000 (from 148 fewer to 46 more)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Mepilex	Tielle	Relative (95% CI)	Absolute		
Proportion of people reporting odour – elderly people – all grades (grade 2) – NPUAP classification¹¹⁶												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	0/18 (0%)	3/20 (15%)	OR 0.13 (0.01 to 1.38)	128 fewer per 1000 (from 148 fewer to 46 more)	Very low	Important
							-	15%		128 fewer per 1000 (from 148 fewer to 46 more)		
Proportion of people with adverse events^d – elderly people – all grades (grade 2) – NPUAP classification¹¹⁶												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	1/18 (5.6%)	3/20 (15%)	RR 0.37 (0.04 to 3.25)	95 fewer per 1000 (from 144 fewer to 338 more)	Very low	Important
							-	15%		95 fewer per 1000 (from 144 fewer to 338 more)		
Mortality (all-cause)¹¹⁶												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	1/18 (5.6%)	1/20 (5%)	RR 1.11 (0.07 to 16.49)	6 more per 1000 (from 47 fewer to 775 more)	Very low	Important
							-	5%		6 more per 1000 (from 47 fewer to 775 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of healing												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Mepilex	Tielle	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of ulcer												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No blinding reported.

(b) The confidence interval crossed both MID points.

(c) The confidence interval crossed 1 MID point.

(d) Mepilex group: hypergranulation; Tielle group: hypergranulation, new ulcer, and redness and irritation.

Table 171: Clinical evidence profile: hydrogel (aquagel) versus polyurethane foam (lyofoam) dressing

Quality assessment							No of ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrogel dressing	Foam dressing	Relative (95% CI)	Absolute		
Proportion of pressure ulcers completely healed – people in palliative care– all grades (grade 2 and 3) – Torrance classification¹⁷⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	15/20 (75%)	15/18 (83.3%)	RR 0.9 (0.65 to 1.25)	83 fewer per 1000 (from 292 fewer to 208 more)	Very low	Critical
							-	83.3%		83 fewer per		

Quality assessment							No of ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrogel dressing	Foam dressing	Relative (95% CI)	Absolute		
										1000 (from 292 fewer to 208 more)		
Proportion of pressure ulcers improved - people in palliative care – all grades (grade 2 and 3) – Torrance classification¹⁷⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	19/20 (95%)	18/18 (100%)	RR 0.95 (0.83 to 1.1)	50 fewer per 1000 (from 170 fewer to 100 more)	Low	Critical
							-	100%		50 fewer per 1000 (from 170 fewer to 100 more)		
Mean healing rate healed pressure ulcers (cm²/day) - people in palliative care – grade 2 – Torrance classification¹⁷⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	0.67 (SD 0.37)	1.23 (SD 1.33)	-	MD 0.56 lower (1.66 lower to 0.54 higher)	Very low	Critical
Mean healing rate healed pressure ulcers (cm²/day) - people in palliative care – grade 3 – Torrance classification¹⁷⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	0.31 (SD 0.21)	0.44 (SD 0.27)	-	MD 0.13 lower (0.32 lower to 0.06 higher)	Very low	Critical
Mean healing rate improved ulcers (cm²/day) - people in palliative care – grade 3 – Torrance classification¹⁷⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	0.27 (SD 0.11)	0.7 (SD 0.63)	-	MD 0.43 lower (0.79 to 0.07 lower)	Very low	Critical
Mortality (all-cause)¹⁷⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	3/17 (17.6%)	2/17 (11.8%)	RR 1.5 (0.29 to	59 more per 1000 (from 84 fewer to 808	Very low	Important

Quality assessment							No of ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrogel dressing	Foam dressing	Relative (95% CI)	Absolute		
							-	11.8%	7.87)	more) 59 more per 1000 (from 84 fewer to 811 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No report on allocation concealment and no blinding; no log-transformation of data.

(b) The confidence interval crossed 1 MID point

(c) The confidence interval crossed both MID points.

Table 172: Clinical evidence profile: hydrogel versus dextranomer

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrogel dressing	Dextranomer	Relative (95% CI)	Absolute		
Median percentage reduction in pressure ulcer area – general pressure ulceration – all grades (grade 1 to 4) – AHCPR and International Association of Enterostomal Therapy classification⁴⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	35 (n=67)	7 (n=68)	p=0.03	Not pooled	Very low	Critical
Proportion of people with pain at dressing application – general pressure ulceration - all grades (grade 1 to 4) – AHCPR and International Association of Enterostomal Therapy classification⁴⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/67 (0%)	1/68 (1.5%)	Peto OR 0.14 (0 to 6.92)	13 fewer per 1000 (from 15 fewer to 79 more)	Very low	Important
							-	1.5%		13 fewer per 1000 (from 15 fewer to 80 more)		
Mortality (all-cause)⁴⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	2/67 (3%)	2/68 (2.9%)	RR 1.01 (0.15 to 7)	0 more per 1000 (from 25 fewer to 176 more)	Very low	Important
							-	2.9%		0 more per 1000 (from 25 fewer to 174 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrogel dressing	Dextranomer	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size and volume of pressure ulcer												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on sequence generation, allocation concealment or blinding.

(b) No standard deviation was reported.

(c) The confidence interval crossed both MID points

Table 173: Clinical evidence profile: hydrogel, foam dressing or transparent film versus different types of dressings

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrogel dressings	Different types of dressings	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – people in the community – all grades (grade 2 to 4) – Stirling classification¹⁷⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	15/23 (65.2%)	9/18 (50%)	RR 1.3 (0.75 to	150 more per 1000	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrogel dressings	Different types of dressings	Relative (95% CI)	Absolute		
							-	50%	2.26)	(from 125 fewer to 630 more)		
										150 more per 1000 (from 125 fewer to 630 more)		
Percentage healed per week – people in the community – all grades (grade 2 to 4) – Stirling classification¹⁷⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	n=28	n=30	p=0.15 (log-rank test)		Very low	Critical
Proportion of people reporting the application of the dressing as comfortable – people in the community – all grades (grade 2 to 4) – Stirling classification¹⁷⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	14/14 (100%)	6/7 (85.7%)	RR 1.19 (0.84 to 1.68)	163 more per 1000 (from 137 fewer to 583 more)	Very low	Important
							-	85.7%		163 more per 1000 (from 137 fewer to 583 more)		
Proportion of people reporting discomfort at dressing removal – people in the community – all grades (grade 2 to 4) – Stirling classification¹⁷⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/14 (0%)	1/7 (14.3%)	Peto OR 0.05 (0.00 to 3.18)	135 fewer per 1000 (143 fewer to 204 more)	Very low	Important
							-	14.3%		135 fewer		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrogel dressings	Different types of dressings	Relative (95% CI)	Absolute		
										per 1000 (143 fewer to 204 more)		
Proportion of people with adverse events – people in the community – all grades (grade 2 to 4) – Stirling classification¹⁷⁷												
1	Randomised trial	Very serious ^{a, d}	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/28 (0%)	0/30 (0%)	Not pooled	0 more (from 6 fewer to 6 more)	Low	Important
							-	0%		0 more (from 6 fewer to 6 more)		
Mortality (all-cause)¹⁷⁷												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	3/28 (10.7%)	7/30 (23.3%)	RR 0.46 (0.13 to 1.6)	126 fewer per 1000 (from 203 fewer to 140 more)	Very low	Important
							-	23.3%		126 fewer per 1000 (from 203 fewer to 140 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrogel dressings	Different types of dressings	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Allocation according to pressure ulcer stage and blinding was not reported.

(b) The confidence interval crossed 1 MID point.

(c) The confidence interval crossed both MID points.

(d) The drop out is more than 10% higher than event rate.

Table 174: Clinical evidence profile: hydrogel (Sterigel) versus hydrogel (Intrasite)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Sterigel	Intrasite	Relative (95% CI)	Absolute		
Mean percentage reduction in pressure ulcer area – general pressure ulceration – necrotic pressure ulcers – classification not reported¹⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^d	None	-82.3	7.45	Not pooled	Not pooled	Very low	Critical
Proportion of people with intermittent pressure ulcer pain at end of study^e – general pressure ulceration – necrotic pressure ulcers – classification not reported¹⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	13/24 (54.2%)	16/23 (69.6%)	RR 0.78 (0.49 to 1.23)	153 fewer per 1000 (from 355 fewer to 160 more)	Very low	Important
							-	69.6%				

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Sterigel	Intrasite	Relative (95% CI)	Absolute		
										per 1000 (from 355 fewer to 160 more)		
Proportion of people with continuous pressure ulcer pain at end of study^f – general pressure ulceration – necrotic pressure ulcers – classification not reported¹⁵												
1	Randomised trial	Very serious ^{a,g}	No serious inconsistency	No serious indirectness	Very serious ^c	None	1/24 (4.2%)	2/23 (8.7%)	RR 0.48 (0.05 to 4.93)	45 fewer per 1000 (from 83 fewer to 342 more)	Very low	Important
							-	8.7%		45 fewer per 1000 (from 83 fewer to 342 more)		
Proportion of people with slight pain at dressing removal – general pressure ulceration – necrotic pressure ulcers – classification not reported¹⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	5/22 (22.7%)	6/20 (30%)	RR 0.76 (0.27 to 2.1)	72 fewer per 1000 (from 219 fewer to 330 more)	Very low	Important
							-	30%		72 fewer per 1000 (from 219 fewer to 330 more)		
Proportion of people with severe pain at dressing removal – general pressure ulceration – necrotic pressure ulcers – classification not reported¹⁵												
1	Randomised trial	Very serious ^{a,g}	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/22 (0%)	1/20 (5%)	Peto OR 0.12 (0 to 6.2)	44 fewer per 1000 (from 50 fewer to	Very low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Sterigel	Intrasite	Relative (95% CI)	Absolute		
							-	5%		196 more) 44 fewer per 1000 (from 50 fewer to 196 more)		
Proportion of people with discomfort – general pressure ulceration – necrotic pressure ulcers – classification not reported¹⁵												
1	Randomised trial	Very serious ^{a,g}	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/22 (0%)	1/20 (5%)	Peto OR 0.12 (0 to 6.2)	44 fewer per 1000 (from 50 fewer to 196 more)	Very low	Important
							-	5%		44 fewer per 1000 (from 50 fewer to 196 more)		
Proportion of people with maceration – general pressure ulceration – necrotic pressure ulcers – classification not reported¹⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	8/21 (38.1%)	9/17 (52.9%)	RR 0.72 (0.36 to 1.46)	148 fewer per 1000 (from 339 fewer to 244 more)	Very low	Important
							-	52.9%		148 fewer per 1000 (from 339 fewer to 243 more)		
Mortality (all-cause)¹⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	3/26 (11.5%)	4/24 (16.7%)	RR 0.69 (0.17 to	52 fewer per 1000	Very low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Sterigel	Intrasite	Relative (95% CI)	Absolute		
									2.78)	(from 138 fewer to 297 more)		
							-	16.7%		52 fewer per 1000 (from 139 fewer to 297 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Proportion of people with complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on allocation concealment and only blinding of outcome assessor; no log-transformation of data was carried out.

(b) The confidence interval crossed 1 MID point.

(c) The confidence interval crossed both MID points.

(d) Reduction was calculated based on reported baseline value and value at 14 days. No p-value or SD could be derived.

(e) At start of the study 17/24 and 18/23 reported intermittent pain.

(f) At start of the study 3/24 and 2/23 reported continuous pain

(g) The drop out is more than 10% higher than event rate.

Table 175: Clinical evidence profile: protease modulating matrix versus impregnated gauze dressing

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagen dressing	Impregnated gauze dressing	Relative (95% CI)	Absolute		
Proportion of people completely healed – inpatients – all grades (grade 2 to 4) – NPUAP classification¹³⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	36/40 (90%)	28/40 (70%)	RR 1.29 (1.02 to 1.61)	203 more per 1000 (from 14 more to 427 more)	Very low	Critical
							-	70%		203 more per 1000 (from 14 more to 427 more)		
Time to complete healing of pressure ulcers (days) – inpatients – all grades (grade 2 to 4) – NPUAP classification¹³⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	6-15 (n=40)	14-52 (n=40)	-	Not pooled	Very low	Critical
Proportion of people with adverse events – inpatients – all grades (grade 2 to 4) – NPUAP classification¹³⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/40 (0%)	0/40 (0%)	Not pooled	Not pooled	Low	Important
Mortality (all-cause)¹³⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/40 (0%)	0/40 (0%)	Not pooled	Not pooled	Low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagen dressing	Impregnated gauze dressing	Relative (95% CI)	Absolute		
Rate of change in size of pressure ulcer												
0	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcer												
0	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
0	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
0	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
0	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
0	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on sequence generation, allocation concealment or blinding.
 (b) The confidence interval crossed 1 MID point.
 (c) Only range values were reported.

Table 176: Clinical evidence profile: polyurethane dressing versus different types of dressing

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Polyurethane dressing	Different types of dressings	Relative (95% CI)	Absolute		
Mean time to healing of pressure ulcers (days)– inpatients – all grades (grade 2 and 3) – NPUAP classification²⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	59.8 (SD 29.4)	57.5 (SD 33.5)	-	MD 2.3 higher	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Polyurethane dressing	Different types of dressings	Relative (95% CI)	Absolute		
										(13.31 lower to 17.91 higher)		
Mean difference in PUSH score – inpatients – all grades (grade 2 and 3) – NPUAP classification²⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0.9 (SD 1.3)	1.1 (SD 2.1)	-	MD 0.2 lower (1.08 lower to 0.68 higher)	Low	Critical
Proportion of people with systemic worsening – inpatients – all grades (grade 2 and 3) – NPUAP classification²⁸												
1	Randomised trial	Very serious ^{a, d}	No serious inconsistency	No serious indirectness	Very serious ^c	None	4/35 (11.4%)	3/29 (10.3%)	RR 1.1 (0.27 to 4.54)	10 more per 1000 (from 76 fewer to 366 more)	Very low	Important
							-	10.3%		10 more per 1000 (from 75 fewer to 365 more)		
Proportion of people with localized adverse events – inpatients – all grades (grade 2 and 3) – NPUAP classification²⁸												
1	Randomised trial	Very serious ^{a, d}	No serious inconsistency	No serious indirectness	Very serious ^c	None	6/35 (17.1%)	7/29 (24.1%)	RR 0.71 (0.27 to 1.88)	70 fewer per 1000 (from 176 fewer to 212 more)	Very low	Important
							-	24.1%		70 fewer		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Polyurethane dressing	Different types of dressings	Relative (95% CI)	Absolute		
										per 1000 (from 176 fewer to 212 more)		
Mortality (all-cause)²⁸												
1	Randomised trial	Very serious ^{a, d}	No serious inconsistency	No serious indirectness	Very serious ^c	None	2/35 (5.7%)	2/31 (6.5%)	RR 0.89 (0.13 to 5.92)	7 fewer per 1000 (from 56 fewer to 317 more)	Very low	Important
							-	6.5%		7 fewer per 1000 (from 57 fewer to 320 more)		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcer												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patent acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No report on sequence generation and only blinding of outcome assessor was reported; no log-transformation of data was carried out.

(b) The confidence interval crossed 1 MID point.

(c) The confidence interval crossed both MID points.

(d) The drop out is more than 10% higher than event rate.

Table 177: Clinical evidence profile: alginate dressing versus silver alginate dressing

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alginate dressing	Silver alginate dressing	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers worsened – elderly people – all grades (grade 3 and 4) – NPUAP classification¹¹²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	4/15 (26.7%)	2/13 (15.4%)	RR 1.73 (0.38 to 7.98)	112 more per 1000 (from 95 fewer to 1000 more)	Very low	Critical
							-	15.4%		112 more per 1000 (from 95 fewer to 1000 more)		
Mean percentage reduction in pressure ulcer area – elderly people – all grades (grade 3 and 4) – NPUAP classification¹¹²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	13.9 (SD 50.3)	31.6 (SD 38.1)	-	MD 17.7 lower (50.52 lower to 15.12 higher)	Very low	Critical
Absolute cm² decrease in pressure ulcer area – elderly people – all grades (grade 3 and 4) – NPUAP classification¹¹²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	0.8 (SD 10)	7.2 (SD 9)	-	MD 6.4 lower (13.44 lower to 0.64 higher)	Very low	Critical
Mean rate of healing of pressure ulcers (cm²/day) – elderly people – all grades (grade 3 and 4) – NPUAP classification¹¹²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	0.03 (SD 0.36)	0.26 (SD 0.32)	-	MD 0.23 lower (0.48 lower to 0.02)	Very low	Critical

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alginate dressing	Silver alginate dressing	Relative (95% CI)	Absolute		
											higher)	
Proportion of people with infection – elderly people – all grades (grade 3 and 4) – NPUAP classification¹¹²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2/15 (13.3%)	1/13 (7.7%)	RR 1.73 (0.18 to 16.99)	56 more per 1000 (from 63 fewer to 1000 more)	Very low	Important
							-	7.7%		56 more per 1000 (from 63 fewer to 1000 more)		
Percentage reduction in infection score – general pressure ulceration – grade and classification system not reported¹⁹⁵												
1	Randomised trial	Very serious ^d	No serious inconsistency	No serious indirectness	Very serious ^e	None	50 (n=13)	52 (n=11)	-	Not pooled	Very low	Important
Mean mASEPSIS index at end of treatment – elderly people – grade 3 and 4 – NPUAP classification¹¹²												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^c	None	115.3 (SD 80.2)	81.8 (SD 45.1)	-	MD 33.5 higher (13.92 lower to 80.92 higher)	Very low	Important
Proportion of people with poor acceptability and/or tolerability – elderly people – grade 3 and 4 – NPUAP classification¹¹²												
1	Randomised trial	Very serious ^{a,f}	No serious inconsistency	No serious indirectness	Very serious ^b	None	0/15 (0%)	1/13 (7.7%)	OR 0.12 (0 to 5.91)	67 fewer per 1000 (from 77 fewer to 253 more)	Very low	Important
							-	7.7%		67 fewer per 1000 (from 77 fewer to 253 more)		
Mortality (all-cause)¹¹²												
1	Randomised	Very	No serious	No serious	No serious	None	0/48	0/51	Not pooled	Not pooled	Low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alginate dressing	Silver alginate dressing	Relative (95% CI)	Absolute		
	trial	serious ^a	inconsistency	indirectness			(0%)	(0%)				
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Proportion of people with complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Meaume (2006) did not report allocation according to wound type and no report on blinding was reported.

(b) The confidence interval crossed both MID points

(c) The confidence interval crossed 1 MID point.

(d) Trial (2010) did not report on sequence generation and blinding.

(e) No standard deviation was reported and the study had a small sample size.

(f) The drop out is more than 10% higher than event rate.

Table 178: Clinical evidence profile: alginate dressing versus dextranomer

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alginate dressing	Dextranomer	Relative (95% CI)	Absolute		
Proportion of people with more than 75% reduction in pressure ulcer area – general pressure ulceration – all grades (grade 3 and 4) – Yarkony classification¹⁶⁵												
1	Randomised trial	Very serious ^{a, d}	No serious inconsistency	No serious indirectness	Serious ^b	None	15/47 (31.9%)	6/45 (13.3%)	RR 2.39 (1.02 to 5.62)	185 more per 1000 (from 3 more to 616 more)	Very low	Critical
							-	13.3%		185 more per 1000 (from 3 more to 614 more)		
Proportion of people with more than 40% reduction in pressure ulcer area – general pressure ulceration – all grades (grade 3 and 4) – Yarkony classification¹⁶⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	35/47 (74.5%)	19/45 (42.2%)	RR 1.76 (1.21 to 2.58)	321 more per 1000 (from 89 more to 667 more)	Very low	Critical
							-	42.2%		321 more per 1000 (from 89 more to 667 more)		
Proportion of people with pressure ulcers worsened or stagnated – general pressure ulceration – all grades (grade 3 and 4) – Yarkony classification¹⁶⁵												
1	Randomised trial	Very serious ^{a, d}	No serious inconsistency	No serious indirectness	No serious imprecision	None	2/47 (4.3%)	15/45 (33.3%)	RR 0.13 (0.03 to 0.53)	290 fewer per 1000 (from 157 fewer to 323 fewer)	Low	Critical
							-	33.3%		290 fewer per 1000		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alginate dressing	Detraxomer	Relative (95% CI)	Absolute (from 157 fewer to 323 fewer)		
Mean rate of healing in people improved more than 40% (cm²/week) – general pressure ulceration – all grades (grade 3 and 4) – Yarkony classification¹⁶⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	3.55 (SD 2.18)	2.15 (SD 3.6)	-	MD 1.4 higher (0.18 to 2.62 higher)	Very low	Critical
Mean rate of healing of pressure ulcers (cm²/week) – general pressure ulceration – all grades (grade 3 and 4) – Yarkony classification¹⁶⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	2.39 (SD 3.54)	0.27 (SD 3.21)	-	MD 2.12 higher (0.74 to 3.5 higher)	Very low	Critical
Proportion of people with infection – general pressure ulceration – all grades (grade 3 and 4) – Yarkony classification¹⁶⁵												
1	Randomised trial	Very serious ^{a, d}	No serious inconsistency	No serious indirectness	Very serious ^c	None	2/47 (4.3%)	2/45 (4.4%)	RR 0.96 (0.14 to 6.51)	2 fewer per 1000 (from 38 fewer to 245 more)	Very low	Important
							-	4.4%		2 fewer per 1000 (from 38 fewer to 242 more)		
Proportion of people with hypergranulation – general pressure ulceration – all grades (grade 3 and 4) – Yarkony classification¹⁶⁵												
1	Randomised trial	Very serious ^{a, d}	No serious inconsistency	No serious indirectness	Very serious ^c	None	1/47 (2.1%)	3/45 (6.7%)	RR 0.32 (0.03 to 2.96)	45 fewer per 1000 (from 65 fewer to 131 more)	Very low	Important
							-	6.7%		46 fewer per 1000 (from 65		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alginate dressing	Detraxomer	Relative (95% CI)	Absolute		
										fewer to 131 more)		
Proportion of people with skin irritation – general pressure ulceration – all grades (grade 3 and 4) – Yarkony classification¹⁶⁵												
1	Randomised trial	Very serious ^{a, d}	No serious inconsistency	No serious indirectness	Very serious ^c	None	1/47 (2.1%)	1/45 (2.2%)	RR 0.96 (0.06 to 14.85)	1 fewer per 1000 (from 21 fewer to 308 more)	Very low	Important
								2.2%		1 fewer per 1000 (from 21 fewer to 305 more)		
Proportion of people with bleeding – general pressure ulceration – all grades (grade 3 and 4) – Yarkony classification¹⁶⁵												
1	Randomised trial	Very serious ^{a, d}	No serious inconsistency	No serious indirectness	Serious ^b	None	0/47 (0%)	3/45 (6.7%)	Peto OR 0.12 (0.01 to 1.22)	58 fewer per 1000 (from 66 fewer to 13 more)	Very low	Important
							-	6.7%		58 fewer per 1000 (from 66 fewer to 14 more)		
Proportion of people with pain – general pressure ulceration – all grades (grade 3 and 4) – Yarkony classification¹⁶⁵												
1	Randomised trial	Very serious ^{a, d}	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/47 (0%)	5/45 (11.1%)	Peto OR 0.12 (0.02 to 0.71)	96 fewer per 1000 (from 30 fewer to 109 fewer)	Low	Important
							-	11.1%		96 fewer per 1000		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alginate dressing	Detraxomer	Relative (95% CI)	Absolute (from 30 fewer to 109 fewer)		
Proportion of people with pruritus – general pressure ulceration – all grades (grade 3 and 4) – Yarkony classification¹⁶⁵												
1	Randomised trial	Very serious ^{a, d}	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/47 (0%)	1/45 (2.2%)	Peto OR 0.13 (0 to 6.53)	19 fewer per 1000 (from 22 fewer to 107 more)	Very low	Important
							-	2.2%		19 fewer per 1000 (from 22 fewer to 106 more)		
Mortality (all-cause)¹⁶⁵												
1	Randomised trial	Very serious ^{a, d}	No serious inconsistency	No serious indirectness	Very serious ^c	None	5/47 (10.6%)	6/45 (13.3%)	RR 0.8 (0.26 to 2.43)	27 fewer per 1000 (from 99 fewer to 191 more)	Very low	Important
							-	13.3%		27 fewer per 1000 (from 98 fewer to 190 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Proportion of patients with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Alginate dressing	Detraxomer	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Sayag (1996) did not report sequence generation and blinding; no log-transformation of data was carried out.

(b) The confidence interval crossed 1 MID point.

(c) The confidence interval crossed both MID points.

(d) The drop out is more than 10% higher than event rate.

Table 179: Clinical evidence profile: silver dressing versus different types of dressings

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Silver dressing	Different types of dressings	Relative (95% CI)	Absolute		
Mean percentage reduction in pressure ulcer area – general pressure ulceration – all grades (grade 2 and 3) – NPUAP classification¹²⁷												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	58.5 (n=24)	33.3 (n=24)	-	Not pooled	Very low	Critical
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Proportion of people with complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Silver dressing	Different types of dressings	Relative (95% CI)	Absolute		
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on blinding.

(b) No standard deviation was reported and it was unknown if sample size was sufficient as sample size calculation was based on the inclusion of different types of wounds..

Table 180: Clinical evidence profile: silver dressing versus silver cream

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Silver dressing	Silver cream	Relative (95% CI)	Absolute		
Mean percentage reduction in pressure ulcer area – in- and outpatients – all grades (grade 4) – NPUAP classification⁴³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	36.95 (SD 56.13)	25.06 (SD 56.13)	-	MD 11.89 higher (22.9 lower to 46.68 higher)	Very low	Critical
Percentage reduction in PUSH score – in- and outpatients – all grades (grade 4) – NPUAP classification⁴³												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Silver dressing	Silver cream	Relative (95% CI)	Absolute		
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	28.15 (n=20)	34.51 (n=20)	p=0.473	Not pooled	Very low	Critical
Proportion of people with adverse events – in- and outpatients – all grades (grade 4) – NPUAP classification⁴³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/20 (0%)	0/20 (0%)	Not pooled	0 more (from 9 fewer to 9 more)	Low	Important
Mortality (all-cause)⁴³												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/20 (0%)	0/20 (0%)	Not pooled	0 more (from 9 fewer to 9 more)	Low	Important
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Proportion of people with complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on allocation concealment or blinding.

(b) The confidence interval crossed both MID points.

(c) No standard deviation was reported and there was a small sample size.

Table 181: Clinical evidence profile: sugar versus dextranomer

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Sugar	Dextranomer	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – people in long term care – grade and classification system not reported¹⁴⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	0/5 (0%)	4/7 (57.1%)	Peto OR 0.09 (0.01 to 0.97)	464 fewer per 1000 (from 7 fewer to 558 fewer)	Very low	Critical
							-	57.1%		464 fewer per 1000 (from 7 fewer to 558 fewer)		
Proportion of pressure ulcers completely healed – people in long term care – grade and classification system not reported¹⁴⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	0/9 (0%)	6/14 (42.9%)	Peto OR 0.12 (0.02 to 0.77)	346 fewer per 1000 (from 62 fewer to 414 fewer)	Very low	Critical
							-	42.9%		346 fewer per 1000 (from 63 fewer to 414 fewer)		
Proportion of people with pressure ulcers improved – people in long term care – grade and classification system not reported¹⁴⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/5 (0%)	7/7 (100%)	Peto OR 0.02 (0 to 0.21)	2 more (from 0 more to 210 more)	Low	Critical
							-	100%		2 more		

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Sugar	Dextranomer	Relative (95% CI)	Absolute (from 0 more to 210 more)		
Proportion of pressure ulcers improved — people in long term care – grade and classification system not reported¹⁴⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/9 (0%)	12/14 (85.7%)	Peto OR 0.04 (0.01 to 0.19)	664 fewer per 1000 (from 324 fewer to 801 fewer)	Low	Critical
							-	85.7%		664 fewer per 1000 (from 325 fewer to 800 fewer)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcer												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Sugar	Dextranomer	Relative (95% CI)	Absolute		
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No sequence generation or allocation concealment was reported and blinding failed.

(b) The confidence interval crossed 1MID point.

Table 182: Clinical evidence profile: sugar versus different types of topical agents

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Sugar	Different types of topical agents	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – geriatric adults – grade and classification system not reported¹⁵⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	16/17 (94.1%)	9/21 (42.9%)	RR 2.2 (1.32 to 3.65)	514 more per 1000 (from 137 more to 1000 more)	Low	Critical
							-	42.9%		515 more per 1000 (from 137 more to 1000 more)		
Mean healing index – geriatric adults – grade and classification system not reported¹⁵⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	16.8 (SD 39.65)	-3.8 (SD 39.65)	-	MD 20.6 higher (4.75 lower to 45.95 higher)	Very low	Critical
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Sugar	Different types of topical agents	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on allocation concealment or blinding.

(b) The confidence interval crossed 1 MID point.

Table 183: Clinical evidence profile: honey versus ethoxydiaminoacridine and nitrofurazone

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Honey	Ethoxydiamin o-acridine and nitrofurazone	Relative (95% CI)	Absolute		
Proportion of pressure ulcers completely healed – inpatients – all grades (grade 2 and 3) – AHCPR classification⁷⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	5/25 (33.3%)	0/25 (0%)	Peto OR 8.83 (1.42 to 54.99)	200 more per 1000 (from 30 more to 370 more)	Low	Critical
								0%		200 more per 1000 (from 30 more to 370 more)		
Mean percentage reduction in pressure ulcer area – inpatients – all grades (grade 2 and 3) – AHCPR classification⁷⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	56 (SD 28.92)	13 (SD 28.92)	-	MD 43 higher (24.49 to 61.51 higher)	Very low	Critical
Mean percentage decrease in PUSH score – inpatients – all grades (grade 2 and 3) – AHCPR classification⁷⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	12.62 (SD 2.15)	6.55 (SD 2.14)	-	MD 6.07 higher (4.40 to 7.74 higher)	Low	Critical
Proportion of people with adverse events – inpatients – all grades (grade 2 and 3) – AHCPR classification⁷⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/15 (0%)	0/11 (0%)	Not pooled	0 more (from 140 fewer to 140 more)	Low	Important

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Honey	Ethoxydiamin o-acridine and nitrofurazone	Relative (95% CI)	Absolute		
							-	0%		0 more (from 140 fewer to 140 more)		
Mortality (all-cause) ⁷⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/15 (0%)	1/12 (8.3%)	OR 0.11 (0 to 5.44)	73 fewer per 1000 (from 83 fewer to 248 more)	Very low	Important
							-	8.3%		73 fewer per 1000 (from 83 fewer to 247 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcer												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on sequence generation, allocation concealment and no blinding; no log-transformation of data was carried out.
 (b) SD calculated on a p-value < 0.001 (less precise).
 (c) The confidence interval crossed both MID points.

Table 184: Clinical evidence profile: platelet gel versus other treatment

Quality assessment							No of ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Platelet gel	Other treatment	Relative (95% CI)	Absolute		
Proportion of pressure ulcers completely healed – people with a spinal cord injury – all grades (grade 3 and 4) – NPUAP classification¹⁶⁶												
1	Randomised trial	Very serious ^{a,c}	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/8 (0%)	0/8 (0%)	Not pooled	0 more (from 210 fewer to 210 more)	Low	Critical
							-	0%		0 more (from 210 fewer to 210 more)		
Proportion of pressure ulcers improved – people with a spinal cord injury – all grades (grade 3 and 4) – NPUAP classification¹⁶⁶												
1	Randomised trial	Very serious ^{a,c}	No serious inconsistency	No serious indirectness	Serious ^b	None	8/8 (100%)	7/8 (87.5%)	RR 1.13 (0.81 to 1.58)	114 more per 1000 (from 166 fewer to 508 more)	Very low	Critical
							-	87.5%		114 more per 1000 (from 166 fewer to 508 more)		
Mean percentage reduction in pressure ulcer volume – people with a spinal cord injury – all grades (grade 3 and 4) – NPUAP classification¹⁶⁶												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	55 (SD 22.9)	17.2 (SD 98.1)	-	MD 37.8 higher (32.01 lower to 107.61 higher)	Very low	Critical
Time to complete healing of pressure ulcers												

Quality assessment							No of ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Platelet gel	Other treatment	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on sequence generation, allocation concealment or blinding.

(b) The confidence interval crossed 1 MID point.

(c) The drop out is more than 10% higher than event rate.

Table 185: Clinical evidence profile: hyaluronic acid versus sodium hyaluronic

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hyaluronic acid	Sodium hyaluronate	Relative (95% CI)	Absolute		
Mean percentage reduction in pressure ulcer area– inpatients – grade 1– NPUAP classification⁵⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	90 (SD 21.29)	70 (SD 21.29)	-	MD 20 higher (1.34 to 38.66 higher)	Very low	Critical
Mean percentage reduction in pressure ulcer area– inpatients – grade 2 – NPUAP classification⁵⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	70 (SD 26.28)	40 (SD 26.28)	-	MD 30 higher (6.96 to 53.04 higher)	Very low	Critical
Mean percentage reduction in pressure ulcer area– inpatients – grade 3 – NPUAP classification⁵⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	(n=7)	(n=7)	p<0.01	Not pooled	Very low	Critical
Time to 50% reduction in pressure ulcer diameter (days)– inpatients – grade 1– NPUAP classification⁵⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	9 (SD 6.39)	15 (SD 6.39)	-	MD 6 lower (11.6 to 0.4 lower)	Very low	Critical
Time to 50% reduction in pressure ulcer diameter (days)– inpatients – grade 2 – NPUAP classification⁵⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	9.5 (SD 5.85)	15 (SD 5.85)	-	MD 5.5 lower (10.63 to 0.37 lower)	Very low	Critical
Time to 50% reduction in pressure ulcer diameter (days)– inpatients – grade 3 – NPUAP classification⁵⁸												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	12.9 (SD 6.71)	19.2 (SD 6.71)	-	MD 6.3 lower (13.33 lower to 0.73 higher)	Very low	Critical
Time to complete healing of pressure ulcers												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hyaluronic acid	Sodium hyaluronate	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality (all-cause)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on sequence generation and allocation concealment and blinding of nurse, outcome assessor and statistician, blinding of participant not reported; no log-transformation of data.

(b) The confidence interval crossed 1 MID point; SD calculated on a p-value < 0.05 (less precise).

(c) The confidence interval crossed 1 MID point; SD calculated on a p-value < 0.02 (less precise).

(d) Only p-value were reported.

Table 186: Clinical evidence profile: zinc gauze dressing versus streptokinase-streptodornase ointment

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Zinc gauze	Streptokinase-streptodornase (ointment)	Relative (95% CI)	Absolute		
Median percentage reduction in pressure ulcer area – geriatric adults – necrotic pressure ulcers – classification system not reported⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	2.4 (n=14)	-18.7 (n=14)	-	Not pooled	Very low	Critical
Proportion of people with skin reaction – geriatric adults– necrotic pressure ulcers – classification system not reported⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/14 (0%)	1/14 (7.1%)	OR 0.14 (0 to 6.82)	61 fewer per 1000 (from 71 fewer to 273 more)	Very low	Important
							-	7.1%		60 fewer per 1000 (from 71 fewer to 272 more)		
Proportion of people with infection – geriatric adults – necrotic pressure ulcers – classification system not reported⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/14 (0%)	1/14 (7.1%)	OR 0.14 (0 to 6.82)	61 fewer per 1000 (from 71 fewer to 273 more)	Very low	Important
							-	7.1%		60 fewer per 1000 (from 71 fewer to 272 more)		
Mortality (all-cause)⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None	0/14 (0%)	0/14 (0%)	Not pooled	Not pooled	Low	Important

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Zinc gauze	Streptokinase-streptodornase (ointment)	Relative (95% CI)	Absolute		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Sequence generation by pairs, no report on allocation concealment and only blinding of outcome assessor; no log-transformation of data was carried out.

(b) No standard deviation was reported and the study used a small sample size.

(c) The confidence interval crossed both MID points.

Table 187: Clinical evidence profile: hydrofibre dressing versus resin salve

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrofibre	Resin salve	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed – people in hospital – all grades (grade 2 to 4) – EPUAP classification¹⁷⁶												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	4/9 (44.4%)	12/13 (92.3%)	RR 0.48 (0.23 to 1.02)	480 fewer per 1000 (from 711 fewer to 18 more)	Low	Critical
							-	92.3%		480 fewer per 1000 (from 711 fewer to 18 more)		
Proportion of pressure ulcers completely healed – people in hospital – all grades (grade 2 to 4) – EPUAP classification¹⁷⁶												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	4/11 (36.4%)	17/18 (94.4%)	RR 0.39 (0.17 to 0.85)	576 fewer per 1000 (from 142 fewer to 784 fewer)	Low	Critical
							-	94.4%		576 fewer per 1000 (from 142 fewer to 784 fewer)		
Proportion of pressure ulcers improved – people in hospital – all grades (grade 2 to 4) – EPUAP classification¹⁷⁶												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	10/11 (90.9%)	18/18 (100%)	RR 0.9 (0.72 to 1.13)	100 fewer per 1000 (from 280 fewer to 130 more)	Low	Critical
							-	100%		100 fewer per 1000		

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrofibre	Resin salve	Relative (95% CI)	Absolute (from 280 fewer to 130 more)		
Proportion of pressure ulcers worsened – people in hospital – all grades (grade 2 to 4) – EPUAP classification¹⁷⁶												
1	Randomised trial	Very serious ^{a,f}	No serious inconsistency	No serious indirectness	Very serious ^c	None	1/11 (9.1%)	0/18 (0%)	OR 13.96 (0.25 to 792.93)	90 more per 1000 (from 110 fewer to 290 more)	Very low	Critical
							-	0%		90 more per 1000 (from 110 fewer to 290 more)		
Mean percentage reduction in pressure ulcer width – people in hospital – all grades (grade 2 to 4) – EPUAP classification¹⁷⁶												
1	Randomised trial	Very serious ^{a,g}	No serious inconsistency	No serious indirectness	Very serious ^d	None	57.14 (n=11)	93.75 (n=18)	-	Not pooled	Very low	Critical
Mean percentage reduction in pressure ulcer depth – people in hospital – all grades (grade 2 to 4) – EPUAP classification¹⁷⁶												
1	Randomised trial	Very serious ^{a,g}	No serious inconsistency	No serious indirectness	Very serious ^d	None	-1.89 (n=11)	88.46 (n=18)	-	Not pooled	Very low	Critical
Speed of healing of pressure ulcers (days) (log-rank-test) – people in hospital – all grades (grade 2 to 4) – EPUAP classification¹⁷⁶												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Very serious ^e	None	(n=11)	n=18)	p=0.013 (favour resin salve)	Not pooled	Very low	Critical
Proportion of people with allergic skin reaction – people in hospital – all grades (grade 2 to 4) – EPUAP classification¹⁷⁶												
1	Randomised trial	Very serious ^{a,f}	No serious inconsistency	No serious indirectness	Very serious ^c	None	0/16 (0%)	1/21 (4.8%)	Peto OR 0.17 (0 to 8.97)	39 fewer per 1000 (from 48 fewer to	Very low	Important

Quality assessment							No of patients/ulcers		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrofibre	Resin salve	Relative (95% CI)	Absolute		
							-	4.8%		262 more 40 fewer per 1000 (from 48 fewer to 263 more)		
Mortality (all-cause) ¹⁷⁶												
1	Randomised trial	Very serious ^{a,f}	No serious inconsistency	No serious indirectness	Very serious ^c	None	4/16 (25%)	3/21 (14.3%)	RR 1.75 (0.45 to 6.74)	107 more per 1000 (from 79 fewer to 820 more)	Very low	Important
							-	14.3%		107 more per 1000 (from 79 fewer to 821 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report blinding; no intention-to-treat analysis was carried out.

(b) The confidence interval crossed 1 MID point.

- (c) The confidence interval crossed both MID points.
- (d) No standard deviation was reported and the study used a small sample size.
- (e) No values, only p-value and the study used a small sample size.
- (f) The drop out is more than 10% higher than event rate.
- (g) No log-transformation was carried out.

Table 188: Clinical evidence profile: dextranomer versus chlorinated lime solution

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Dextranomer	Chlorinated lime solution	Relative (95% CI)	Absolute		
Time to healing (defined as granulating and less than 25% of original ulcer area) (days) – elderly adults – grade not reported – classification system not reported¹²⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	39.3 (SD 17.67)	61.8 (SD 13.86)	-	MD 22.5 lower (41.14 to 3.86 lower)	Very low	Critical
Proportion of people with pain¹²⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	1/?	3/?	Not pooled	Not pooled	Very low	Important
							-	-		Not pooled		
Mortality (all-cause)¹²⁹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^d	None	1/8 (12.5%)	0/8 (0%)	Peto OR 7.39 (0.15 to 372.38)	1/8 (12.5%)	Very low	Important
							-	0%		-		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Dextranomer	Chlorinated lime solution	Relative (95% CI)	Absolute		
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) The authors did not report on allocation concealment, sequence generation, and no blinding; no intention to treat analysis was carried out.

(b) The confidence interval crossed 1 MID point.

(c) It was unclear how many participants were included in each group.

(d) The confidence interval crossed both MID points. There were a limited number of events.

Table 189: Clinical evidence profile: collagen and foam versus foam dressing

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagen and foam	Foam	Relative (95% CI)	Absolute		
Proportion of people with pressure ulcers completely healed - stagnating pressure ulcers, of at least 4 weeks duration - classification system not reported¹⁵¹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^b	None	4/5 (80%)	5/5 (100%)	RR 0.82 (0.49 to 1.38)	180 fewer per 1000 (from 510 fewer to 380 more)	Very low	Critical
							-	100%		180 fewer per 1000 (from 510 fewer to		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Collagen and foam	Foam	Relative (95% CI)	Absolute		
										380 more)		
Mortality (all-cause) ¹⁵¹												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious imprecision	None	0/5 (0%)	0/5 (0%)	Not pooled	Not pooled	Low	Important
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of change in size of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital or NHS care												
-	-	-	-	-	-	-	-	-	-	-	-	-
Patient acceptability												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) There was a very small sample size. The author did not report details of allocation concealment or blinding.

(b) The confidence interval crossed both MID points.

11.12 Economic evidence (adults)

2 Published literature

3 Eleven studies were included with relevant comparisons.^{27,36,62,69,92,113,122,125,143,148,206} These are
4 summarised in the economic evidence profiles below (Table 190 - Table 196). See also the study
5 selection flow chart in Appendix D and study evidence tables in Appendix H.

6 Two studies that met the inclusion criteria were selectively excluded^{75,91} – these are summarised in
7 Appendix H, with reasons for exclusion given.

8 Unit costs

9 Relevant unit costs were provided to aid consideration of cost effectiveness. See Appendix P..

Table 190: Economic evidence profile: hydrocolloid dressing versus. collagen dressing

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
Burgos 2000 ³⁶ (Spain)	Partially applicable ^a	Potentially serious limitations ^b	Within trial analysis of a collagen dressing compared to a hydrocolloid dressing, based on analysis of individual level resource use with unit costs applied.	-£46	<p>Patients healed: RR 0.95 (CI 0.22-4.10)</p> <p>Mean percentage reduction in ulcer area MD: -9.6 (CI -69.17-49.97)</p> <p>Mean cm2 reduction in ulcer area MD: -2.9 (CI -10.24 – 4.44)</p>	Collagen is both more expensive and more effective than hydrocolloid	None reported
Graumlich 2003 ⁶⁹ (US)	Partially applicable ^c	Potentially serious limitations ^d	Within trial analysis of a collagen dressing compared to a hydrocolloid dressing, based on analysis of individual level resource use with unit costs applied.	-£260	<p>Patients healed: RR 0.97 (CI 0.60-1.57)</p> <p>Mean percentage reduction in ulcer area MD: -24.00 (CI -60.08-</p>	Collagen is both more expensive and more effective than hydrocolloid	It is stated that sensitivity analyses did not reveal likely conditions under which collagen would be cheaper than hydrocolloid; results are not presented.

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
					12.08) Mean time to healing (weeks) MD 1.00 (CI -0.36-2.36) Mean healing speed (mm ² /day) MD: 0.00 (CI -8.23-8.23)		
Müller 2001 ¹²⁵ (Netherlands)	Partially applicable ^e	Potentially serious limitations ^f	Within trial analysis of a collagen dressing compared to a hydrocolloid dressing for heel ulcers, based on analysis of individual level resource use with unit costs applied.	£25	Proportion of patients healed: -29% (p <0.005)	Collagen dominates hydrocolloid	No useful sensitivity analyses reported.

(a) Study based in Spain, quality of life not considered, costs based on 1998 values

(b) no analysis of uncertainty reported, unit costs are based on prices faced by patients and could be substantially different to those faced by hospitals, differential costs past 12 weeks not included due to time horizon

(c) Study based in US, quality of life not considered, costs year not reported

(d) No consideration of quality of life, analysis of uncertainty results are not reported, it is not clear whether unit costs are nationally representative, differential costs past 8 weeks not included due to time horizon

(e) Study based in the Netherlands, quality of life not considered, costs based on 1998 values

(f) Small study, no unit cost source reported, no consideration of quality of life, no useful analysis of uncertainty reported

Table 191: Economic evidence profile: hydrocolloid dressings versus saline gauze

Study	Applicability	Limitations	Other comments	Costs	Effects	Cost effectiveness	Uncertainty
Kerstein	Partially	Potentially	Decision analytic model to	Intvn 1: £703	Patients	DuoDERM	None reported

Study	Applicability	Limitations	Other comments	Costs	Effects	Cost effectiveness	Uncertainty
2001 ⁹² (US)	applicable ^a	serious limitations ^b	compare saline gauze (intvn 1), Comfeel dressing (intvn 2), and DuoDERM dressing (intvn 3). The model is based on proportion of patients healed, and takes into account the probability of debridement and infection.	Intvn 2: £384 Intvn 3: £353	healed at 12 weeks: Intvn 1: 51% Intvn 2: 48% Intvn 3: 61%	dressing dominates Comfeel dressing and saline gauze.	
Meaume 2002 ¹¹³ (Europe)	Partially applicable ^c	Potentially serious limitations ^d	Decision analytic model to compare saline gauze (intvn 1), Comfeel dressing (intvn 2), and DuoDERM dressing (intvn 3). The model is based on proportion of patients healed, and takes into account the probability of debridement and infection.	Intvn 1: £1,651 Intvn 2: £516 Intvn 3: £500	Patients healed at 12 weeks: Intvn 1: 51% Intvn 2: 48% Intvn 3: 61%	DuoDERM dressing dominates Comfeel dressing and saline gauze.	None reported

(a) The analysis is based in the US; quality of life is not considered

(b) No analysis of uncertainty reported, average ratios presented, no cohort characteristics provided. There is also a potential conflict of interest as the study is carried out by manufacturer of the DuoDERM dressing. Differential costs past 12 weeks not included due to time horizon

(c) The analysis is based in Europe (based a variety of countries, costs calculated in Euros); quality of life is not considered.

(d) No analysis of uncertainty reported, average ratios presented, no cohort characteristics provided. Source of funding not reported. Differential costs past 12 weeks not included due to time horizon.

Table 192: Economic evidence profile: hydrocolloid dressing versus hydrogel dressing

Study	Applicability	Limitations	Other comments	Incremental cost	Effects	Cost effectiveness	Uncertainty
Motta 1999 ¹²² (US)	Partially applicable ^a	Potentially serious limitations ^b	Within trial analysis of a hydrocolloid dressing compared to a polymer hydrogel dressing, based on analysis of individual level resource use with unit costs applied	-£22	Patients healed: RR 1 (CI 0.22-4.56) Mean healing rate (cm/day)	Number of patients healed equal, so lower cost of hydrogel indicates hydrogel is cost-effective.	None reported

Study	Applicability	Limitations	Other comments	Incremental cost	Effects	Cost effectiveness	Uncertainty
					MD: 0.2 (CI - 0.22-0.62)		

(a) US healthcare system, quality of life not considered, cost year not reported

(b) Small pilot study with only ten patients, no unit cost source reported, no analysis of uncertainty reported. Differential costs past 8 weeks not included due to time horizon restriction.

Table 193: Economic evidence profile: hydrogel dressing versus collagenase dressing

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
Waycaster 2013 ²⁰⁶ (US)	Partially applicable ^a	Potentially serious limitations ^b	Markov model based on a single RCT. Three states: inflamed wound, healing wound, healed wound. Hydrogel dressings are compared to collagenase dressings.	£2,297	Days spent with pressure ulcer: 99	Collagenase dressings dominate hydrogel dressings: lower costs and fewer days spent with pressure ulcer.	Parameters were varied by +/- 20%. Collagenase dressings remained dominant in all scenarios. Frequency of dressing change was varied from twice daily to every 3 days – this variable had the greatest influence on the results.

(a) US healthcare system, quality of life not considered

(b) Based on single RCT. The study does not fully describe cost sources or resource usage. No consideration is given to quality of life. Analysis of uncertainty is incomplete.

Table 194: Economic evidence profile: gauze versus impregnated gauze versus calcium alginate versus hydroactive wound dressing

Study	Applicability	Limitations	Other comments	Costs	Effects	Cost effectiveness	Uncertainty
Bergermann 1999 ²⁷ (Germany)	Partially applicable ^a	Potentially serious limitations ^b	A model comparing gauze, ointment impregnated gauze, calcium alginate, and a hydroactive wound dressing (in combination with enzymatic wound cleaning) in the treatment of four sizes of PU: 5cm x 8 cm, 8cm x 12 cm, 10cm x	Total costs (per patient, median) for 12x20cm ulcer: Intvn 1: £3,813 Intvn 2: £1,501 Intvn 3: £1,677	None	Intervention 4 has the lowest cost.	Results were not sensitive to changes in personnel cost per minute, time required for changing a wound dressing or total number of wound dressing changes.

Study	Applicability	Limitations	Other comments	Costs	Effects	Cost effectiveness	Uncertainty
			15cm, 12cm x 20cm. Cost-comparison only.	Intvn 4: £592			

(a) Based in Germany, quality of life not considered, health outcomes not considered (assumed equivalent)

(b) Unclear whether unit costs are nationally representative, efficacy is assumed the same, it is assumed (not based on evidence) that treatment with hydroactive wound dressing reduces inpatient stay by 10%

Table 195: Economic evidence profile: advanced dressings versus traditional/simple dressings

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
Ohura 2004 ¹⁴³ (Japan)	Partially applicable ^a	Potentially serious limitations ^b	Within study analysis (prospective cohort study) of a variety of modern wound dressings compared to a traditional dressing, based on analysis of individual level resource use with unit costs applied	-£0.32	Reduction in PSST score: 4.2	Modern dressings dominate traditional wound care, with reduced costs and greater reduction in PSST score	No sensitivity analysis reported
Foglia 2012 ⁶² (Italy)	Partially applicable ^c	Potentially serious limitations ^d	Within trial analysis with analysis of individual level resource use. Observational study in which advanced dressings were compared to simple saline dressings.	-£78	Reduction in ulcer size 6%	Advanced dressings dominated simple dressings, with a reduction in cost and greater reduction in ulcer size.	Deterministic analyses revealed that when using min and max values for personnel costs, transport expenses and material costs, the cost savings from the use of advanced dressings were between 27-29%. Bootstrapping methods and Monte Carlo simulation were also carried out; the use of advanced dressings was cost

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
							saving in all scenarios.

- (a) Japanese healthcare system, quality of life not considered
- (b) No analysis of uncertainty reported, unclear whether unit costs are nationally representative, differential costs past 12 weeks not included due to time horizon (healing is not recorded and effectiveness is based on PSST score only), not a randomised study (no significant differences in age, size of ulcer or PSST score at baseline).
- (c) The analysis is based in Italy; quality of life is not considered
- (d) Based on single observational study. The study does not fully describe the relevant comparators, or the cost sources. Only the costs were subject to sensitivity analysis. Differential costs past 30 days not included due to time horizon restriction.

Table 196: Economic evidence profile: saline soaked gauze versus polyurethane self-adhesive foam dressing

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
Payne 2009 ¹⁴⁸ (US)	Partially applicable ^a	Minor limitations ^b	Within trial analysis with analysis of individual level resource use. Patients randomised to receive saline soaked gauze or polyurethane self-adhesive foam dressing.	-£301	Pressure ulcer free days: 2.4 Ulcers healed by day 28: 12%	Polyurethane self-adhesive foam dressing dominates saline soaked gauze	Costs for patients who dropped out were included only up until the point of withdrawal in a deterministic sensitivity analysis (in the base case analysis costs were included up until the 28 day horizon even if the patient withdrew). The foam dressing remained dominant compared to saline soaked gauze.

- (a) The analysis is based in the US; quality of life is not considered

All resource use and health outcomes are obtained from within the trial rather than via a systematic procedure. The cost of the saline soaked gauze is calculated to be the same cost as the foam dressing. Exploration of uncertainty is inadequate. Differential costs past 28 days not included due to time horizon.

11.1.13 Clinical evidence (neonates, infants, children and young people)

- 2 No RCTs or cohort studies were identified. Recommendations were developed using a modified
3 Delphi consensus technique. Further details can be found in Appendix N.

11.1.14 Economic evidence (neonates, infants, children and young people)

- 5 No relevant economic evaluations were identified. The GDG considered relevant unit costs (see
6 Appendix P).

11.1.15 Evidence statements

11.1.15.1 Clinical (adults)

11.1.15.1.1 *Hydrocolloid dressing versus gauze dressing*

- 10 • Four studies (n=170) (general population and people with spinal cord injury) showed a
11 hydrocolloid dressing is potentially more clinically effective at increasing the proportion of people
12 with pressure ulcers completely healed (all grades) when compared to a gauze dressing (very low
13 quality).
- 14 • Three studies (n=115) (general population) showed there is potentially no clinical difference
15 between a hydrocolloid dressing and gauze dressing for increasing the proportion of people with
16 pressure ulcers completely healed (all grades) (very low quality).
- 17 • One study (n=55) (people with spinal cord injury) showed a hydrocolloid dressing is more clinically
18 effective at increasing the proportion of people with pressure ulcers completely healed (all
19 grades) when compared to a gauze dressing (moderate quality).
- 20 • Four studies (n=273) (general population and people with spinal cord injury) showed a
21 hydrocolloid dressing is more clinically effective at increasing the proportion of pressure ulcers
22 completely healed (all sites, all grades) when compared to a gauze dressing (low quality).
- 23 • Three studies (n=212) (general population) showed a hydrocolloid dressing is potentially more
24 clinically effective at increasing the proportion of pressure ulcers completely healed (all sites, all
25 grades) when compared to a gauze dressing (very low quality).
- 26 • One study (n=61) (people with spinal cord injury) showed a hydrocolloid dressing is more clinically
27 effective at increasing the proportion of pressure ulcers completely healed (all sites, all grades)
28 when compared to a gauze dressing (moderate quality).
- 29 • Two studies (n=96) (general population and people with spinal cord injury) showed a hydrocolloid
30 dressing is potentially more clinically effective at increasing the proportion of people with
31 pressure ulcers completely healed (all sites, grade 2 and above) when compared to a gauze
32 dressing (very low quality).
- 33 • One study (n=37) (people with spinal cord injury) showed a hydrocolloid dressing is more clinically
34 effective at increasing the proportion of people with pressure ulcers completely healed (all sites,
35 grade 2 and above) when compared to a gauze dressing (moderate quality).
- 36 • One study (n=59) (general population) showed a hydrocolloid dressing is potentially more
37 clinically effective at increasing the proportion of people with pressure ulcers completely healed
38 (all sites, grade 2 and above) when compared to a gauze dressing (very low quality).
- 39 • One study (n=28) (general population) showed there may be no clinical difference between a
40 hydrocolloid dressing and a gauze dressing for the proportion of people with pressure ulcers
41 completely healed (all sites, grade 3), but the direction of the estimate of effect favoured the
42 hydrocolloid dressing (very low quality).

- 1 • One study (n=15) (people with spinal cord injury) showed a gauze dressing is potentially more
2 clinically effective at increasing the proportion of people with pressure ulcers completely healed
3 (sacral, grade 1 and 2) when compared to a hydrocolloid dressing (low quality).
- 4 • One study (n=91) (people with spinal cord injury) showed a hydrocolloid dressing is more clinically
5 effective at increasing the proportion of people with pressure ulcers improved (all grades) when
6 compared to a gauze dressing (moderate quality).
- 7 • Two studies (n=148) (general population and people with spinal cord injury) showed there may be
8 a clinical benefit for a hydrocolloid dressing compared to a gauze dressing at reducing the
9 proportion of people with pressure ulcers worsened (all grades) (very low quality).
- 10 • One study (n=61) (people with spinal cord injury) showed a hydrocolloid dressing is potentially
11 more clinically effective at reducing the proportion of people with pressure ulcers worsened (all
12 grades) when compared to a gauze dressing (low quality).
- 13 • One study (n=87) (general population) showed there may be no clinical difference between a
14 hydrocolloid dressing and a gauze dressing for the proportion of people with pressure ulcers
15 worsened (all grades), but the direction of the estimate of effect could favour either intervention
16 (very low quality).
- 17 • One study (n=59) (general population) showed there may be no clinical difference between a
18 hydrocolloid dressing and a gauze dressing for the proportion of people with pressure ulcers
19 worsened (grade 2) but the direction of the estimate of effect favoured the hydrocolloid dressing
20 (very low quality).
- 21 • One study (n=28) (general population) showed there may be no clinical difference between a
22 hydrocolloid dressing and a gauze dressing for the proportion of people with pressure ulcers
23 worsened (grade 3) but the direction of the estimate of effect favoured the gauze dressing (very
24 low quality).
- 25 • Two studies (n=75) (general population) showed there is potentially no clinical difference
26 between a hydrocolloid dressing and a gauze dressing for mean percentage reduction in ulcer
27 area (all grades), the direction of the estimate of effect favoured the gauze dressing (very low
28 quality).
- 29 • One study (n=97) (in-patients) showed there may be a clinical benefit for a gauze dressing
30 compared to a hydrocolloid dressing for the mean cm² reduction in ulcer area (all grades). No
31 estimate of precision could be derived (very low quality).
- 32 • One study (n=49) (people in long term care) reported medians for a hydrocolloid dressing and a
33 gauze dressing for percentage reduction in pressure ulcer area (all grades). The median reduction
34 for the hydrocolloid dressing was 100% and 85.7% for the gauze dressing. No estimate of effect or
35 precision could be derived (very low quality).
- 36 • One study (n=41) (in- and out-patients) reported medians for a hydrocolloid dressing and a gauze
37 dressing for percentage reduction in pressure ulcer area (grade 2 and 3). The median reduction
38 for the hydrocolloid dressing was 7.4% and 7.0% for the gauze dressing. No estimate of effect or
39 precision could be derived (very low quality).
- 40 • One study (n=59) (general population) reported medians for a hydrocolloid dressing and a gauze
41 dressing for percentage reduction in pressure ulcer area (grade 2). The median reduction for the
42 hydrocolloid dressing was 91% and 48% for the gauze dressing. No estimate of effect or precision
43 could be derived (very low quality).
- 44 • One study (n=28) (general population) reported medians for a hydrocolloid dressing and a gauze
45 dressing for percentage reduction in pressure ulcer area (grade 3). The median reduction for the
46 hydrocolloid dressing was 0.3% and 30% for the gauze dressing. No estimate of effect or precision
47 could be derived (very low quality).

- 1 • One study (n=32) (general population) showed a gauze dressing is more clinically effective for
2 mean percentage reduction in pressure ulcer volume (all grades) when compared to a
3 hydrocolloid dressing (low quality).
- 4 • One study (n=32) (general population) showed there is potentially no clinical difference between
5 a hydrocolloid dressing and a gauze dressing for mean healing speed of pressure ulcers (all
6 grades), the direction of the estimate of effect favoured the hydrocolloid dressing (very low
7 quality).
- 8 • One study (n=39) (people in long term care) reported medians for a hydrocolloid dressing and a
9 gauze dressing for time to healing of pressure ulcer area (all grades). The median reduction for
10 the hydrocolloid dressing was 9 days and 11 days for the gauze dressing. No estimate of effect or
11 precision could be derived (very low quality).
- 12 • One study (n=34) (in-patients) showed there may be no clinical difference between a hydrocolloid
13 dressing and a gauze dressing for the proportion of people with an infection, but the direction of
14 the estimate of effect favoured hydrocolloid dressing (very low quality).
- 15 • One study (n=28) (general population) showed there is no clinical difference between a
16 hydrocolloid dressing and a gauze dressing for the proportion of people with infected pressure
17 ulcers, the estimate of effect could favour either intervention (low quality).
- 18 • One study (n=44) (general population) showed there may be a clinical benefit for a hydrocolloid
19 dressing compared to a gauze dressing for a higher proportion of people with hypergranulation
20 (very low quality).
- 21 • One study (n=100) (general population) showed a hydrocolloid dressing is more clinically effective
22 for reducing the proportion of people with skin irritation when compared to a gauze dressing (low
23 quality).
- 24 • One study (n=34) (in-patients) showed a hydrocolloid dressing is more clinically effective for
25 reducing the proportion of people with pain at dressing removal when compared to a gauze
26 dressing (low quality).
- 27 • One study (n=32) (general population) showed there may be no clinical difference between a
28 hydrocolloid dressing and a gauze dressing for median pain score during treatment, but the
29 direction of the estimate of effect could favour either intervention. No estimate of precision could
30 be derived (very low quality).
- 31 • One study (n=32) (general population) showed there may be no clinical difference between a
32 hydrocolloid dressing and a gauze dressing for median odour score during treatment, but the
33 direction of the estimate of effect could favour either intervention. No estimate of precision could
34 be derived (very low quality).
- 35 • One study (n=34) (in-patients) showed there is potentially a clinical benefit for a hydrocolloid
36 dressing compared to a gauze dressing for reducing the proportion of people with discomfort (low
37 quality).
- 38 • One study (n=32) (general population) reported medians comfort score during treatment for a
39 hydrocolloid dressing and a gauze dressing. The median for the hydrocolloid dressing was 4.0
40 (range 3-4) and 3.0 (range 2-4) for the gauze dressing. No estimate of effect or precision could be
41 derived (very low quality).
- 42 • Six studies (n=269) showed there is potentially no clinical difference between a hydrocolloid
43 dressing and gauze dressing for reducing all-cause mortality, the estimate of effect favours the
44 hydrocolloid dressing (very low quality).
- 45 • No evidence was found for the following outcomes:
 - 46 o Time to complete healing
 - 47 o Time in hospital or NHS care
 - 48 o Health-related quality of life

11.1.5.112 Hydrocolloid dressing versus foam dressing

- 2 • Three studies (n=157) (general population) showed a hydrocolloid dressing is potentially more
3 clinically effective at increasing the proportion of people with pressure ulcers completely healed
4 (all grades) when compared to a foam dressing (very low quality).
- 5 • One study (n=96) (community patients) showed there is no clinical difference of a hydrocolloid
6 dressing for proportion of people with pressure ulcers improved (all grades) when compared with
7 a foam dressing, the estimate of effect favoured either intervention (very low quality).
- 8 • Two studies (n=156) (general population) showed there may be no clinical difference between a
9 hydrocolloid dressing and a foam dressing for proportion of people with pressure ulcers not
10 changed (all grades), but the direction of the estimate of effect favoured the foam dressing (very
11 low quality).
- 12 • Two studies (n=156) (general population) showed there may be no clinical difference between a
13 hydrocolloid dressing and a foam dressing for proportion of people with pressure ulcers worsened
14 (all grades), but the direction of the estimate of effect favoured the foam dressing (very low
15 quality).
- 16 • One study (n=39) (general population) showed there is potentially no clinical difference between
17 a hydrocolloid dressing and a foam dressing for mean reduction in pressure ulcer area, the
18 direction of the estimate of effect favoured the hydrocolloid dressing (very low quality).
- 19 • One study (n=99) (people in the community) showed there is no clinical difference between a
20 hydrocolloid dressing and a foam dressing for proportion of people with hypergranulation, the
21 direction of the estimate of effect could favour either intervention (low quality).
- 22 • One study (n=99) (people in the community) showed there may be no clinical difference between
23 a hydrocolloid dressing and a foam dressing for proportion of people with bleeding, but the
24 direction of the estimate of effect could favour either intervention (very low quality).
- 25 • One study (n=99) (people in the community) showed there is potentially no clinical difference
26 between a foam dressing and a hydrocolloid dressing for lower proportion of people with
27 maceration, the direction of the estimate of effect favours either intervention (very low quality).
- 28 • One study (n=39) (general population) showed a hydrocolloid dressing is potentially more
29 clinically effective at reducing the proportion of people with inflammation or maceration when
30 compared to a foam dressing (very low quality).
- 31 • One study (n = 39) (general population) showed there is potentially no clinical difference between
32 a hydrocolloid dressing and a foam dressing for mean pain score at the end of treatment, the
33 direction of the estimate of effect favoured the foam dressing (very low quality).
- 34 • One study (n = 39) (general population) showed there is potentially no clinical difference between
35 a hydrocolloid dressing and a foam dressing for mean odour score at the end of treatment, the
36 direction of the estimate of effect favoured the foam dressing (very low quality).
- 37 • Two studies (n=100) (general population) showed there may be no clinical difference between a
38 hydrocolloid dressing and a foam dressing for reducing the proportion of people with adverse
39 events, the direction of the estimate of effect favoured the hydrocolloid dressing (very low
40 quality).
- 41 • One study (n=60) showed there may be a clinical benefit for a hydrocolloid dressing compared to
42 a foam dressing for reducing all-cause mortality (very low quality).
- 43 • No evidence was found for the following outcomes:
 - 44 o Time to complete healing
 - 45 o Rate of reduction in size of ulcers
 - 46 o Time in hospital or NHS care
 - 47 o Patient acceptability
 - 48 o Health-related quality of life

11.1.5.113 *Hydrocolloid dressing versus polyurethane dressing*

- 2 • One study (n=122) (general population) showed there is potentially no clinical difference between
3 a hydrocolloid dressing and a polyurethane dressing for increasing the proportion of people with
4 pressure ulcers completely healed (all grades), the direction of the estimate of effect favoured the
5 hydrocolloid dressing (very low quality).
- 6 • One study (n=28) (people in the community) showed there is no clinical difference between a
7 hydrocolloid dressing and a polyurethane dressing for increasing the proportion of people with
8 pressure ulcers improved (all grades), the direction of the estimate of effect favoured the
9 hydrocolloid dressing (low quality).
- 10 • One study (n=72) (general population) reported mean percentage reduction in pressure ulcer area
11 (all grades) for a hydrocolloid dressing and a polyurethane dressing. The mean for the
12 hydrocolloid dressing was 23.8% and 26.7% for the polyurethane dressing. No estimate of effect
13 or precision could be derived (very low quality).
- 14 • One study (n=22) (in-patients) reported median time to healing of pressure ulcers (all grades) for
15 a hydrocolloid dressing and a polyurethane dressing. The median for the hydrocolloid dressing
16 was 12.69 days and 13.36 days for the polyurethane dressing. No estimate of effect or precision
17 could be derived (very low quality).
- 18 • One study (n=72) (general population) showed there is potentially no clinical difference between
19 a hydrocolloid dressing and a polyurethane dressing for linear healing rate of pressure ulcer (all
20 grades), the direction of the estimate of effect favoured the hydrocolloid dressing (very low
21 quality).
- 22 • One study (n=72) (general population) showed there is potentially no clinical difference between
23 a hydrocolloid dressing and a polyurethane dressing for mean odour score, the direction of the
24 estimate of effect favoured the polyurethane dressing (very low quality).
- 25 • One study (n=72) (general population) showed there is potentially no clinical difference between
26 a hydrocolloid dressing and a polyurethane dressing for mean comfort score, the direction of the
27 estimate of effect favoured the polyurethane dressing (very low quality).
- 28 • One study (n=72) (general population) showed there is no clinical difference between a
29 hydrocolloid dressing and a polyurethane dressing for proportion of people with adverse events,
30 the direction of the estimate of effect could have favoured either intervention (low quality).
- 31 • One study (n=69) (general population) reported a significant difference between a hydrocolloid
32 dressing and a polyurethane dressing for proportion of people with pain at dressing removal. The
33 clinical importance is unknown (very low quality).
- 34 • One study (n=69) (general population) reported no significant difference between a hydrocolloid
35 dressing and a polyurethane dressing for proportion of people with discomfort at dressing
36 removal. The clinical importance is unknown (very low quality).
- 37 One study (n=69) (general population) showed there may be no clinical difference between a
38 polyurethane dressing and a hydrocolloid dressing for reducing all-cause mortality (very low
39 quality).
- 40 • No evidence was found for the following outcomes:
 - 41 o Time to complete healing
 - 42 o Time in hospital or NHS care
 - 43 o Health-related quality of life
 - 44 o Patient acceptability
- 45

11.1.5.114 Hydrocolloid dressing versus collagenase ointment

- 2 • Two studies (n=60) (general population) showed a collagenase ointment may be more clinically
3 effective at increasing the proportion of people with pressure ulcers (grade 2 and above)
4 completely healed when compared to a hydrocolloid dressing (very low quality).
- 5 • One study (n=60) (in-patients) showed there may be a clinical benefit for a collagenase ointment
6 compared to a hydrocolloid dressing for mean percentage reduction in pressure ulcer area (very
7 low quality).
- 8 • One study (n=60) (in-patients) showed there is potentially a clinical benefit for a collagenase
9 ointment compared to a hydrocolloid dressing for mean cm² reduction in pressure ulcer area
10 (very low quality).
- 11 • One study (n=33) (general population) showed there may be a clinical benefit for a collagenase
12 ointment compared to a hydrocolloid dressing for reducing the mean time to pressure ulcer
13 healing (grade 4) (very low quality).
- 14 • One study (n=37) (in-patients) showed there may be no clinical difference between a collagenase
15 ointment and a hydrocolloid dressing for proportion of people with adverse events, but the
16 direction of the estimate of effect favoured collagenase (very low quality).
- 17 • Two studies (n=88) (general population) showed a collagenase ointment is potentially more
18 clinically effective for reducing the mean time to pressure ulcer healing (grade 2 and above) when
19 compared to a hydrocolloid dressing (very low quality).
- 20 • One study (n=61) (population) showed there may be a clinical benefit for a hydrocolloid dressing
21 compared to a collagenase ointment for reducing all-cause mortality (very low quality).
- 22 • No evidence was found for the following outcomes:
 - 23 o Rate of reduction in size of ulcers
 - 24 o Pain (wound-related)
 - 25 o Time in hospital or NHS care
 - 26 o Patient acceptability
 - 27 o Health-related quality of life
- 28

11.1.5.115 Hydrocolloid dressing versus collagen

- 30 • One study (n=65) (in-patients) showed there may be no clinical difference between collagen and a
31 hydrocolloid dressing for increasing the proportion of people with pressure ulcers completely
32 healed (grade 2 and 3), the direction of the estimate of effect favoured collagen (very low
33 quality).
- 34 • One study (n=65) (in-patients) showed collagen is potentially more clinically effective at increasing
35 the mean percentage reduction in pressure ulcer area (grade 2 and 3) when compared to a
36 hydrocolloid dressing (low quality).
- 37 • One study (n=65) (in-patients) showed there is no clinical difference between collagen and
38 hydrocolloid dressing for mean healing speed of pressure ulcers , the direction of the estimate of
39 effect favoured either intervention(moderate quality).
- 40 • One study (n=65) (in-patients) showed there may be no clinical difference between collagen and a
41 hydrocolloid dressing for reducing the mean time to pressure ulcer healing (grade 2 and 3), the
42 direction of the estimate of effect favoured either intervention (very low quality).
- 43 • One study (n=65) (in-patients) showed there is no clinical difference between a hydrocolloid
44 dressing and collagen for the proportion of people with adverse events, the direction of the
45 estimate of effect favoured either intervention (low quality).

- 1 • One study (n=65) (in-patients) showed there may be no clinical difference between a hydrocolloid
- 2 dressing and collagen for all-cause mortality, but the direction of the estimate of effect favoured
- 3 the hydrocolloid dressing (very low quality).
- 4 • No evidence was found for the following outcomes:
- 5 o Pain (wound-related)
- 6 o Time in hospital or NHS care
- 7 o Patient acceptability
- 8 o Health-related quality of life
- 9

11.1.5.106 Hydrocolloid dressing versus hydrogel

- 11 • One study (n=10) (people in the community) showed there may be no clinical difference between
- 12 a hydrocolloid dressing and hydrogel for increasing the proportion of people with pressure ulcers
- 13 completely healed (grade 2 and 3), but the direction of the estimate of effect could favour either
- 14 intervention (very low quality).
- 15 • One study (n=129) (general population) showed hydrogel is potentially more clinically effective at
- 16 increasing the proportion of people with pressure ulcers completely healed (grade 2 and 3) when
- 17 compared to a hydrocolloid dressing (very low quality).
- 18 • One study (n=129) (general population) showed there may be a clinical benefit of hydrogel
- 19 dressing for proportion of people with pressure ulcers not changed (grade 2 and 3) when
- 20 compared to hydrocolloid dressing (very low quality).
- 21 • One study (n=129) (general population) showed hydrogel is potentially more clinically effective at
- 22 reducing the proportion of people with pressure ulcers worsened (grade 2 and 3) when compared
- 23 to a hydrocolloid dressing (very low quality).
- 24 • One study (n=58) (general population) showed there may be a clinical benefit for hydrogel
- 25 compared to a hydrocolloid dressing for increasing the mean percentage reduction in pressure
- 26 ulcer area (grade 1). No estimate of precision could be derived (very low quality).
- 27 • One study (n=71) (general population) showed there may be a clinical benefit for hydrogel
- 28 compared to a hydrocolloid dressing for increasing the mean percentage reduction in pressure
- 29 ulcer area (grade 2) (very low quality).
- 30 • One study (n=41) (in- and out-patients) reported median percentage reduction in pressure ulcer
- 31 area for a hydrocolloid dressing and hydrogel. The median for the hydrocolloid dressing was 7.4%
- 32 and 5.6 for hydrogel. No estimate of effect or precision could be derived (very low quality).
- 33 • One study (n=10) (people in the community) showed there may be no clinical difference between
- 34 a hydrocolloid dressing and hydrogel for mean healing rate of pressure ulcers (grade 2 and 3), but
- 35 the direction of the estimate of effect favoured hydrogel (very low quality).
- 36 • One study (n=129) (general population) reported healing rate of pressure ulcers (grade 2 and 3)
- 37 for a hydrocolloid dressing and hydrogel. The rate for the hydrocolloid dressing was 3.1%/day and
- 38 8.1%/day for hydrogel. No estimate of effect or precision could be derived (very low quality).
- 39 • One study (n=10) (people in the community) reported median odour score during treatment for a
- 40 hydrocolloid dressing and hydrogel. The median for the hydrocolloid dressing was 2 and 2 for
- 41 hydrogel. No estimate of effect or precision could be derived (very low quality).
- 42 • One study (n=10) (people in the community) reported median comfort score during treatment for
- 43 a hydrocolloid dressing and hydrogel. The median for the hydrocolloid dressing was 3 and 4 for
- 44 hydrogel. No estimate of effect or precision could be derived (very low quality).
- 45 • One study (n=10) (people in the community) showed there is no clinical difference between a
- 46 hydrocolloid dressing and hydrogel for all-cause mortality (low quality).
- 47 • No evidence was found for the following outcomes:

- 1 o Time to complete healing
- 2 o Pain (wound-related)
- 3 o Time in hospital or NHS care
- 4 o Health-related quality of life

11.1.5.157 Hydrocolloid dressing versus impregnated gauze

- 6 • One study (n=11) (general population) showed there may be a clinical benefit for a hydrocolloid
7 dressing compared to impregnated gauze for increasing the proportion of people with pressure
8 ulcers completely healed (grade unknown) (very low quality).
- 9 • One study (n=11) (general population) showed there may be no clinical difference between a
10 hydrocolloid dressing and impregnated gauze for increasing the proportion of people with
11 pressure ulcers improved (grade unknown), but the direction of the estimate of effect could
12 favour either intervention (very low quality).
- 13 • No evidence was found for the following outcomes:
 - 14 o Time to complete healing
 - 15 o Rate of reduction in size of ulcers
 - 16 o Reduction in size and/or volume of ulcer.
 - 17 o Pain (wound-related)
 - 18 o Time in hospital or NHS care
 - 19 o Patient acceptability
 - 20 o Side effects
 - 21 o Mortality (all cause)
 - 22 o Health-related quality of life
- 23

11.1.5.148 Hydrocolloid dressing versus poly-hema dressing

- 25 • One study (n=43) (elderly people) showed there may be a clinical benefit for a hydrocolloid
26 dressing compared to a poly-hema dressing for increasing the proportion of people with pressure
27 ulcers completely healed (grade 2 and 3) (very low quality).
- 28 • One study (n=42) (elderly people) reported median time to healing of pressure ulcers (grade 2 and
29 3) for a hydrocolloid dressing and a poly-hema dressing. The median for the hydrocolloid dressing
30 was 42 days and 32 days for a poly-hema dressing. No estimate of effect or precision could be
31 derived (very low quality).
- 32 • One study (n=42) (elderly people) showed there is potentially no clinical difference between a
33 hydrocolloid dressing and a poly-hema dressing for absolute rate of healing of pressure ulcers
34 (grade 2 and 3), the direction of the estimate of effect favoured the poly-hema dressing (very low
35 quality).
- 36 • One study (n=42) (elderly population) showed there may be no clinical difference between a
37 hydrocolloid dressing and a poly-hema dressing for proportion of people with adverse events, but
38 the direction of the estimate of effect favoured poly-hema dressing (very low quality).
- 39 • One study (n=42) (elderly population) showed there may be no clinical difference between a
40 hydrocolloid dressing and a poly-hema dressing for all-cause mortality, but the direction of the
41 estimate of effect favoured the hydrocolloid dressing (very low quality).
- 42 • No evidence was found for the following outcomes:
 - 43 o Reduction in size and/or volume of ulcer.
 - 44 o Pain (wound-related)
 - 45 o Time in hospital or NHS care

- 1 o Patient acceptability
- 2 o Mortality (all cause)
- 3 o Health-related quality of life
- 4

11.1.5.159 Hydrocolloid dressing versus co-polymer (amino acid) dressing

- 6 • One study (n=168) (in-patients) showed a co-polymer (amino acid) dressing is potentially more
7 clinically effective at increasing the proportion of people with pressure ulcers completely healed
8 (grade 2 and above) when compared to a hydrocolloid dressing (very low quality).
- 9 • One study (n=168) (in-patients) reported median time to pressure ulcer healing (grade 2 and
10 above) for a hydrocolloid dressing and a co-polymer (amino acid) dressing. The median for the
11 hydrocolloid dressing was 38 days (range 13-59 days) and 32 days (range 11-63 days) for a co-
12 polymer (amino acid) dressing. No estimate of effect or precision could be derived (very low
13 quality).
- 14 • One study (n=168) (in-patients) showed there may be no clinical difference between a
15 hydrocolloid dressing and a co-polymer (amino acid) dressing for the proportion of people with an
16 infection, but the direction of the estimate of effect favoured the hydrocolloid dressing (very low
17 quality).
- 18 • No evidence was found for the following outcomes:
 - 19 o Rate of reduction in size of ulcers
 - 20 o Reduction in size and/or volume of ulcer.
 - 21 o Pain (wound-related)
 - 22 o Time in hospital or NHS care
 - 23 o Patient acceptability
 - 24 o Mortality (all cause)
 - 25 o Health-related quality of life
- 26

11.1.5.1270 Hydrocolloid dressing versus phenytoin cream

- 28 • One study (n=55) (people with a spinal cord injury) showed a hydrocolloid dressing is more
29 clinically effective at increasing the proportion of people with pressure ulcers completely healed
30 (grade 1 and 2) when compared to phenytoin cream (moderate quality).
- 31 • One study (n=61) (people with a spinal cord injury) showed a hydrocolloid dressing is potentially
32 more clinically effective at increasing the proportion of pressure ulcers completely healed (grade
33 1 and 2) when compared to phenytoin cream (low quality).
- 34 • One study (n=61) (people with a spinal cord injury) showed a hydrocolloid dressing is potentially
35 more clinically effective at increasing the proportion of pressure ulcers completely healed (grade
36 2) when compared to phenytoin cream (low quality).
- 37 • One study (n=61) (people with a spinal cord injury) showed a hydrocolloid dressing is potentially
38 more clinically effective at increasing the proportion of pressure ulcers improved (grade 1 and 2)
39 when compared to phenytoin cream (low quality).
- 40 • One study (n=61) (people with a spinal cord injury) showed there may be no clinical difference
41 between a hydrocolloid dressing and phenytoin cream at reducing the proportion of people with
42 pressure ulcers worsened (grade 1 and 2), but the direction of the estimate of effect favoured
43 phenytoin cream (very low quality).
- 44 • One study (n=56) (people with a spinal cord injury) showed there is no clinical difference between
45 a hydrocolloid dressing and phenytoin cream for all-cause mortality (moderate quality).
- 46 • No evidence was found for the following outcomes:

- 1 o Time to complete healing
- 2 o Rate of reduction in size of ulcers
- 3 o Reduction in size and/or volume of ulcer.
- 4 o Pain (wound-related)
- 5 o Time in hospital or NHS care
- 6 o Patient acceptability
- 7 o Side effects
- 8 o Health-related quality of life

11.1.5.1.1 ~~11~~ Hydrocolloid dressing versus alginate dressing

- 10 • One study (n=110) (older in-patients) showed an alginate dressing is potentially more clinically
11 effective at increasing the proportion of people with pressure ulcers partially (40%) healed (grade
12 3 and 4) when compared to a hydrocolloid dressing (very low quality).
- 13 • One study (n=110) (older in-patients) showed an alginate dressing is more clinically effective for
14 reducing the mean percentage pressure ulcer area (grade 3 and 4) when compared to a
15 hydrocolloid dressing (low quality).
- 16 • One study (n=110) (older in-patients) showed an alginate dressing is more clinically effective for
17 reducing the mean cm² pressure ulcer area (grade 3 and 4) when compared to a hydrocolloid
18 dressing (very low quality).
- 19 • One study (n=110) (older in-patients) showed there may be no clinical difference between an
20 alginate dressing and a hydrocolloid dressing for proportion of people with an infection, but the
21 direction of the estimate of effect favoured the hydrocolloid dressing (very low quality).
- 22 • One study (n=110) (older in-patients) showed there may be no clinical difference between an
23 alginate dressing and a hydrocolloid dressing for proportion of people with skin irritation, but the
24 direction of the estimate of effect favoured the hydrocolloid dressing (very low quality).
- 25 • One study (n=110) (older in-patients) showed there may be no clinical difference between
26 alginate dressing and hydrocolloid for hypergranulation (very low quality).
- 27 • One study (n=110) (older in-patients) showed there may be no clinical difference between an
28 alginate dressing and a hydrocolloid dressing for proportion of people with maceration, but the
29 direction of the estimate of effect favoured the hydrocolloid dressing (very low quality).
- 30 • One study (n=110) (older in-patients) showed there may be no clinical difference between an
31 alginate dressing and a hydrocolloid dressing for proportion of people with bleeding, but the
32 direction of the estimate of effect favoured the hydrocolloid dressing (very low quality).
- 33 • One study (n=2201) (older in-patients) showed no clinical difference between a hydrocolloid
34 dressing and alginate dressing for pain at dressing removal, but the estimate of effect favoured
35 the hydrocolloid dressing(very low quality).
- 36 • One study (n=2201) (older in-patients) showed there is potentially no clinical difference between
37 a hydrocolloid dressing and alginate dressing for lower proportion of people with strong odour,
38 but the direction of estimate of effect favoured the hydrocolloid dressing(very low quality).
- 39 • One study (n=2201) (older in-patients) showed a hydrocolloid dressing is potentially more
40 clinically effective for lower proportion of people with mild odour at dressing removal when
41 compared to an alginate dressing (very low quality).
- 42 • One study (n=110) (older in-patients) showed there may no clinical difference between an
43 alginate dressing and a hydrocolloid dressing for reducing all-cause mortality, but the direction of
44 estimate of effect favoured the alginate dressing (very low quality).
- 45 • No evidence was found for the following outcomes:
46 o Time to complete healing

- 1 o Rate of reduction in size of ulcers
- 2 o Proportion of completely healed within trial period
- 3 o Pain (wound-related)
- 4 o Time in hospital or NHS care
- 5 o Patient acceptability
- 6 o Health-related quality of life

11.1.5.1.12 Hydrocolloid dressing versus charcoal dressing

- 8 • One study (n=59) (in-patients) showed there may be no clinical difference between a hydrocolloid
9 dressing and a charcoal dressing for proportion of people with pressures ulcers worsened (grade
10 2c and 4), but the direction of the estimate of effect favoured the charcoal dressing (very low
11 quality).
- 12 • One study (n=60) (in-patients) reported median percentage reduction in pressure ulcer area for a
13 hydrocolloid dressing and a charcoal dressing. The median for a hydrocolloid dressing was 18.5%
14 (range 100% to -260.9%) and 26.9% (range 82% to -97.9%) for a charcoal dressing. No estimate of
15 effect or precision could be derived (very low quality).
- 16 • One study (n=60) (in-patients) reported median reduction in pressure ulcer area (cm²) for a
17 hydrocolloid dressing and a charcoal dressing. The median for a hydrocolloid dressing was 3.1cm²
18 (range 24cm² to -46.0cm²) and 4.3cm² (range 31.2 cm² to -13.8cm²) for a charcoal dressing. No
19 estimate of effect or precision could be derived (very low quality).
- 20 • One study (n=59) (in-patients) showed there may be no clinical difference between a charcoal
21 dressing and a hydrocolloid dressing for lowering the proportion of people with maceration, but
22 the direction of the estimate of effect favoured the charcoal dressing (very low quality).
- 23 • One study (n=59) (in-patients) showed there may be no clinical difference between a charcoal
24 dressing and a hydrocolloid dressing for proportion of people with an infection, but the direction
25 of the estimate of effect favoured the charcoal dressing (very low quality).
- 26 • One study (n=59) (in-patients) showed there may be no clinical difference between a charcoal
27 dressing and a hydrocolloid dressing for proportion of people with hypergranulation, but the
28 direction of the estimate of effect favoured the charcoal dressing (very low quality).
- 29 • One study (n=59) (in-patients) showed there may be no clinical difference between a charcoal
30 dressing and a hydrocolloid dressing for proportion of people with skin irritation and eczema, but
31 the direction of the estimate of effect could favour either intervention (very low quality).
- 32 • One study (n=59) (in-patients) showed there is no clinical difference between a charcoal dressing
33 and a hydrocolloid dressing for proportion of people with bleeding (low quality).
- 34 • One study (n=59) (in-patients) showed there may be no clinical difference between a charcoal
35 dressing and a hydrocolloid dressing for proportion of people with pruritus, but the direction of
36 the estimate of effect favoured the charcoal dressing (very low quality).
- 37 • One study (n=59) (in-patients) showed there is no clinical difference between a charcoal dressing
38 and a hydrocolloid dressing for proportion of people with wound pain (low quality).
- 39 • One study (n=59) (in-patients) showed there may be no clinical difference between a charcoal
40 dressing and a hydrocolloid dressing for proportion of people with pain at dressing removal, but
41 the direction of the estimate of effect favoured the charcoal dressing (very low quality).
- 42 • One study (n=60) (in-patients) showed there may be no clinical difference between a charcoal
43 dressing and a hydrocolloid dressing for all-cause mortality, but the direction of the estimate of
44 effect favoured the charcoal dressing (very low quality).
- 45 • No evidence was found for the following outcomes:
46 o Time to complete healing
47 o Rate of reduction in size of ulcers

- 1 o Proportion of completely healed within trial period
- 2 o Time in hospital or NHS care
- 3 o Patient acceptability
- 4 o Health-related quality of life

11.1.5.1.13 Hydrocolloid dressing versus phenytoin ointment

- 6 • One study (n=28) (people in a nursing home) showed phenytoin ointment is potentially more clinically effective at reducing the mean time to healing of pressure ulcers (grade 2) when compared to a hydrocolloid dressing (very low quality).
- 7
- 8
- 9 • One study (n=28) (people in a nursing home) showed there is no clinical difference between a hydrocolloid dressing and phenytoin ointment for proportion of people with adverse events (low quality).
- 10
- 11
- 12 • One study (n=34) (people in a nursing home) showed there may be no clinical difference between a hydrocolloid dressing and phenytoin ointment for all-cause mortality, but the direction of the estimate of effect favoured phenytoin ointment (very low quality).
- 13
- 14
- 15 • No evidence was found for the following outcomes:
- 16 o Rate of reduction in size of ulcers
- 17 o Reduction in size and/or volume of ulcer.
- 18 o Proportion of completely healed within trial period
- 19 o Pain (wound-related)
- 20 o Time in hospital or NHS care
- 21 o Patient acceptability
- 22 o Health-related quality of life

11.1.5.1.14 Hydrocolloid dressing versus antibiotic ointment

- 24 • One study (n=24) (people in a nursing home) showed there may be no clinical difference between a hydrocolloid dressing and antibiotic ointment for mean time to healing of pressure ulcers, but the direction of the estimate of effect favoured hydrocolloid dressing (very low quality).
- 25
- 26
- 27 • One study (n=24) (people in a nursing home) showed there is no clinical difference between a hydrocolloid dressing and antibiotic ointment for proportion of people with adverse events (low quality).
- 28
- 29
- 30 • No evidence was found for the following outcomes:
- 31 o Rate of reduction in size of ulcers
- 32 o Reduction in size and/or volume of ulcer.
- 33 o Proportion of completely healed within trial period
- 34 o Pain (wound-related)
- 35 o Time in hospital or NHS care
- 36 o Patient acceptability
- 37 o Health-related quality of life
- 38 o All-cause mortality
- 39

11.1.5.1.15 Hydrocolloid dressing: triangular shape versus oval shape

- 41 • One study (n=96) (in-patients) showed a triangular shaped hydrocolloid dressing is potentially more clinically effective at increasing the proportion of people with pressure ulcers completely healed (grade 2 and 3) when compared to an oval shaped hydrocolloid dressing (very low quality).
- 42
- 43

- 1 • One study (n=96) (in-patients) showed a triangular shaped hydrocolloid dressing is potentially
2 more clinically effective at increasing the proportion of people with pressure ulcers improved
3 (grade 2 and 3) when compared to an oval shaped hydrocolloid dressing (very low quality).
- 4 • One study (n=96) (in-patients) showed there may be no clinical difference between a triangular
5 shaped hydrocolloid dressing and an oval shaped hydrocolloid dressing for the proportion of
6 people with pressure ulcers unchanged (grade 2 and 3), but the direction of the estimate of effect
7 could favour either intervention (very low quality).
- 8 • One study (n=96) (in-patients) showed a triangular shaped hydrocolloid dressing is more clinically
9 effective at reducing the proportion of people with pressure ulcers worsened (grade 2 and 3)
10 when compared to an oval shaped hydrocolloid dressing (low quality).
- 11 • One study (n=96) (in-patients) showed a triangular shaped hydrocolloid dressing is more clinically
12 effective for mean percentage reduction in pressure ulcer length when compared to an oval
13 shaped hydrocolloid dressing (low quality).
- 14 • One study (n=96) (in-patients) showed there may be no clinical difference between a triangular
15 shaped hydrocolloid dressing and an oval shaped hydrocolloid dressing for mean percentage
16 reduction in pressure ulcer width. No estimate of precision could be derived (very low quality).
- 17 • One study (n=96) (in-patients) reported mean pain at dressing change for a triangular shaped
18 hydrocolloid dressing a triangular shaped hydrocolloid dressing (2.1 SD 2.1) and an oval shaped
19 hydrocolloid dressing (4.3 SD 1.75). The clinical importance is unknown (low quality).
- 20 • One study (n=96) (in-patients) showed a triangular shaped hydrocolloid dressing is potentially
21 more clinically effective for a lower proportion of people with ulcer pain when compared to an
22 oval shaped hydrocolloid dressing (very low quality).
- 23 • One study (n=96) (in-patients) showed there is potentially no clinical difference between a
24 triangular shaped hydrocolloid dressing and an oval shaped hydrocolloid dressing for lowering the
25 proportion of people with adverse events (very low quality).
- 26 • No evidence was found for the following outcomes:
- 27 o Time to complete healing
- 28 o Rate of reduction in size of ulcers
- 29 o Time in hospital or NHS care
- 30 o Patient acceptability
- 31 o Mortality (all cause)
- 32 o Health-related quality of life
- 33

11.1.5.1316 Hydrocolloid dressing: Comfeel versus ComfeelPlus

- 35 • One study (n=61) (general population with necrotic pressure ulcers) showed there may be no
36 clinical difference between a Comfeel hydrocolloid dressing and a Comfeel Plus hydrocolloid
37 dressing for percentage reduction in pressure ulcer area, but the direction of the estimate of
38 effect could favour either intervention (very low quality).
- 39 • One study (n=61) (general population with necrotic pressure ulcers) showed there may be no
40 clinical difference between a Comfeel hydrocolloid dressing and a Comfeel Plus hydrocolloid
41 dressing for proportion of people with dressing intolerance, but the direction of the estimate of
42 effect could favour either intervention (very low quality).
- 43 • One study (n=333) (general population with necrotic pressure ulcers) showed there is no clinical
44 difference between a Comfeel Plus hydrocolloid dressing and a Comfeel hydrocolloid dressing for
45 proportion of people reporting the dressing as good to excellent for comfort at dressing change,
46 the direction of the estimate of effect favoured the Comfeel®Plus hydrocolloid dressing (low
47 quality).

- 1 • One study (n=61) (general population with necrotic pressure ulcers) showed there is no clinical
2 difference between a ComfeelPlus hydrocolloid dressing and a Comfeel hydrocolloid dressing for
3 all-cause mortality (low quality).
- 4 • No evidence was found for the following outcomes:
- 5 o Time to complete healing
- 6 o Rate of reduction in size of ulcers
- 7 o Proportion of completely healed within trial period
- 8 o Pain (wound-related)
- 9 o Time in hospital or NHS care
- 10 o Side effects
- 11 o Health-related quality of life
- 12

11.1.5.117 Hydrocolloid dressing: SignaDress versus Comfeel®Plus

- 14 • One study (n=35) (people in a nursing home) showed a SignaDress hydrocolloid dressing is
15 potentially more clinically effective at increasing the proportion of people with pressure ulcers
16 completely healed (grade 2 to 4) when compared to a Comfeel Plus hydrocolloid dressing (low
17 quality).
- 18 • One study (n=35) (people in a nursing home) showed there may be a clinical benefit for a
19 SignaDress hydrocolloid dressing compared to a Comfeel Plus hydrocolloid dressing for
20 percentage reduction in pressure ulcer area (grade 2 to 4). No estimate of precision could be
21 derived (very low quality).
- 22 • One study (n=35) (people in a nursing home) showed there may be a clinical benefit for a
23 SignaDress hydrocolloid dressing compared to a Comfeel Plus hydrocolloid dressing for increasing
24 the healing rate of pressure ulcers (grade 2 to 4). No estimate of precision could be derived (very
25 low quality).
- 26 • One study (n=35) (people in a nursing home) showed there is no clinical difference between a
27 SignaDress hydrocolloid dressing and a Comfeel Plus hydrocolloid dressing for proportion of
28 people with adverse events (low quality).
- 29 • No evidence was found for the following outcomes:
- 30 o Time to complete healing
- 31 o Pain (wound-related)
- 32 o Time in hospital or NHS care
- 33 o Patient acceptability
- 34 o Mortality (all cause)
- 35 o Health-related quality of life
- 36

11.1.5.118 Gauze dressing versus foam dressing

- 38 • Two studies (n=74) (general population) showed a foam dressing is potentially more clinically
39 effective at reducing the proportion of people with pressure ulcers completely healed (grade 2 and
40 3) when compared to a gauze dressing (very low quality).
- 41 • One study (n=36) (general population) showed there may be no clinical difference between a
42 foam dressing and a gauze dressing for median time to 50% healing of pressure ulcers. No
43 estimate of precision could be derived (very low quality).
- 44 • Two studies (n=74) (general population) showed there may be a clinical benefit for a foam
45 dressing compared to a gauze dressing for reducing all-cause mortality (very low quality).

- 1 • No evidence was found for the following outcomes:
- 2 o Time to complete healing
- 3 o Rate of reduction in size of ulcers
- 4 o Reduction in size and/or volume of ulcer.
- 5 o Pain (wound-related)
- 6 o Time in hospital or NHS care
- 7 o Patient acceptability
- 8 o Side effects
- 9 o Health-related quality of life
- 10

11.1.5.1119 Gauze dressing versus polyurethane dressing

- 12 • Two studies (n=53) (general population) showed a polyurethane dressing is more clinically
13 effective at increasing the proportion of pressure ulcers completely healed (all grades) when
14 compared to a gauze dressing (low quality).
- 15 • One study (n=34) (people in the community) showed a polyurethane dressing is more clinically
16 effective at increasing the proportion of pressure ulcers completely healed (grade 2) when
17 compared to a gauze dressing (low quality).
- 18 • Two studies (n=53) (general population) showed a polyurethane dressing is more clinically
19 effective at reducing the proportion of pressure ulcers worsened (all grades) when compared to a
20 gauze dressing (low quality).
- 21 • One study (n=34) (people in the community) showed a polyurethane dressing is more clinically
22 effective at increasing the proportion of pressure ulcers decreased in ulcer stage when compared
23 to a gauze dressing (low quality).
- 24 • One study (n=34) (people in the community) showed a polyurethane dressing is potentially more
25 clinically effective at reducing the proportion of ulcers increased in ulcer stage when compared to
26 a gauze dressing (very low quality).
- 27 • One study (n=19) (in-patients) showed there may be a clinical benefit for a polyurethane dressing
28 compared to a gauze dressing for mean percentage reduction in pressure ulcer area (grade 1 and
29 2). No estimate of precision could be derived (very low quality).
- 30 • One study (n=44) (people in the community) showed there may be a clinical benefit for a
31 polyurethane dressing compared to a gauze dressing for median percentage reduction in pressure
32 ulcer area (grade 2). No estimate of precision could be derived (very low quality).
- 33 • One study (n=30) (people in the community) showed there may be a clinical benefit for a
34 polyurethane dressing compared to a gauze dressing for median percentage reduction in pressure
35 ulcer area (grade 3). No estimate of precision could be derived (very low quality).
- 36 • One study (n=34) (people in the community) showed there is potentially no clinical difference
37 between a polyurethane dressing and a gauze dressing for proportion of people with maceration,
38 the direction of the estimate of effect favoured the polyurethane dressing (very low quality).
- 39 • No evidence was found for the following outcomes:
- 40 o Time to complete healing
- 41 o Rate of reduction in size of ulcers
- 42 o Pain (wound-related)
- 43 o Time in hospital or NHS care
- 44 o Patient acceptability
- 45 o Mortality (all cause)
- 46 o Health-related quality of life

1

11.1.5.1.20 Gauze dressing versus hydrogel

- 3 • One study (n=30) (general population) showed there is potentially no clinical difference between
4 a gauze dressing and hydrogel for increasing the proportion of people with pressure ulcers
5 completely healed (grade 2 to 4), the direction of the estimate of effect favoured the gauze
6 dressing (very low quality).
- 7 • One study (n=41) (general population) showed there may be no clinical difference between a
8 gauze dressing and hydrogel for reducing the proportion of people with pressure ulcers worsened
9 (grade 2 to 4), but the direction of the estimate of effect favoured hydrogel dressing (very low
10 quality).
- 11 • One study (n=40) (in- and out-patients) showed there is potentially no clinical difference between
12 a gauze dressing and hydrogel for mean percentage reduction in pressure ulcer area (grade 2 and
13 3), the direction of the estimate of effect favoured the hydrogel (very low quality).
- 14 • One study (n=30) (general population) showed there may be no clinical difference between a
15 gauze dressing and hydrogel for increasing the percentage rate of pressure ulcer healing, but the
16 direction of the estimate of effect favoured hydrogel dressing (very low quality).
- 17 • One study (n=27) (people with a spinal cord injury) showed there may be no clinical difference
18 between a gauze dressing and hydrogel for mean healing rate of pressure ulcers (grade 2 to 4),
19 but the direction of the estimate of effect favoured gauze dressing (very low quality).
- 20 • One study (n=30) (general population) showed there may be no clinical difference between a
21 gauze dressing and hydrogel for increasing the mean time to healing of pressure ulcers (grade 2 to
22 4), but the direction of the estimate of effect favoured either intervention (very low quality).
- 23 • One study (n=30) (general population) showed there may be a clinical benefit for a gauze dressing
24 compared to hydrogel for reducing all-cause mortality (very low quality).
- 25 • No evidence was found for the following outcomes:
- 26 o Pain (wound-related)
- 27 o Time in hospital or NHS care
- 28 o Patient acceptability
- 29 o Side effects
- 30 o Health-related quality of life
- 31

11.1.5.1.21 Gauze dressing versus dextranomer

- 33 • One study (n=30) (people with a spinal cord injury) showed dextranomer is more clinically
34 effective at increasing the proportion of pressure ulcers improved (grade 2 to 4) when compared
35 to a gauze dressing (low quality).
- 36 • One study (n=30) (people with a spinal cord injury) showed there is no clinical difference between
37 a gauze dressing and dextranomer for proportion of people with adverse events (low quality).
- 38 • No evidence was found for the following outcomes:
- 39 o Time to complete healing
- 40 o Rate of reduction in size of ulcers
- 41 o Proportion of completely healed within trial period
- 42 o Pain (wound-related)
- 43 o Time in hospital or NHS care
- 44 o Patient acceptability
- 45 o Mortality (all cause)

- 1 o Health-related quality of life
- 2

11.1.5.1.22 Gauze dressing versus phenytoin cream

- 4 • One study (n=55) (people with a spinal cord injury) showed there may be a clinical benefit for
5 phenytoin cream compared to a gauze dressing for increasing the proportion of people with
6 pressure ulcers completely healed (grade 1 and 2)(very low quality).
- 7 • One study (n=60) (people with a spinal cord injury) showed there may be a clinical benefit for
8 phenytoin cream compared to a gauze dressing for increasing the proportion of pressure ulcers
9 completely healed (grade 1 and 2) (very low quality).
- 10 • One study (n=60) (people with a spinal cord injury) showed phenytoin cream is potentially more
11 clinically effective for increasing the proportion of pressure ulcers completely healed when
12 compared to a gauze dressing (grade 2) (low quality).
- 13 • One study (n=60) (people with a spinal cord injury) showed there may be a clinical benefit for
14 phenytoin cream compared to a gauze dressing for increasing the proportion of pressure ulcers
15 improved (grade 1 and 2) (very low quality).
- 16 • One study (n=60) (people with a spinal cord injury) showed there is potentially a clinical benefit
17 for phenytoin cream compared to a gauze dressing for reducing the proportion of pressure ulcers
18 worsened (grade 1 and 2) (low quality).
- 19 • One study (n=55) (people with a spinal cord injury) showed there is no clinical difference between
20 phenytoin cream and a gauze dressing for all-cause mortality (moderate quality).
- 21 • No evidence was found for the following outcomes:
 - 22 o Time to complete healing
 - 23 o Rate of reduction in size of ulcers
 - 24 o Pain (wound-related)
 - 25 o Time in hospital or NHS care
 - 26 o Patient acceptability
 - 27 o Side effects
 - 28 o Health-related quality of life
 - 29

11.1.5.1.23 Foam dressing versus skin replacement

- 31 • One study (n=34) (general population) showed there may be no clinical difference between a
32 foam dressing and skin replacement for increasing the proportion of people with pressure ulcers
33 completely healed (grade 3), but the direction of the estimate of effect favoured the foam
34 dressing (very low quality).
- 35 • One study (n=34) (general population) reported medians for percentage reduction in pressure
36 ulcer area (closed ulcers). The median for a foam dressing was 33.5% (range -77.5 to 100%) and
37 49.5% (range -81.7 to 100%) for the skin replacement. No estimate of effect or precision could be
38 derived (very low quality).
- 39 • One study (n=34) (general population) reported medians for percentage reduction in pressure
40 ulcer area (unclosed ulcers). The median for a foam dressing was 17.4.5% (range -434.5 to 100%)
41 and 38.8% (range -201.7 to 100%) for the skin replacement. No estimate of effect or precision
42 could be derived (very low quality).
- 43 • One study (n=34) (general population) showed there may be a clinical benefit for skin
44 replacement compared to a foam dressing for mean percentage reduction in pressure ulcer
45 volume. No estimate of precision could be derived (very low quality).

- 1 • One study (n=34) (general population) reported medians for percentage reduction in pressure
2 ulcer volume. The median for a foam dressing was 17.4% and 41.2% for the skin replacement. No
3 estimate of effect or precision could be derived (very low quality).
- 4 • One study (n=34) (general population) showed there may be no clinical difference between skin
5 replacement and a foam dressing for proportion of people with infection, but the direction of the
6 estimate of effect favoured skin replacement (very low quality).
- 7 • One study (n=34) (general population) showed there is no clinical difference between a foam
8 dressing and skin replacement for proportion of people with adverse events (low quality).
- 9 • No evidence was found for the following outcomes:
 - 10 o Time to complete healing
 - 11 o Rate of reduction in size of ulcers
 - 12 o Pain (wound-related)
 - 13 o Time in hospital or NHS care
 - 14 o Patient acceptability
 - 15 o Mortality (all cause)
 - 16 o Health-related quality of life

11.1.5.1174 Foam dressing versus antibiotic ointment

- 18 • One study (n=44) (people in long term care) showed a foam dressing is potentially more clinically
19 effective at increasing the proportion of people with pressure ulcers completely healed when
20 compared to antibiotic ointment (very low quality).
- 21 • One study (n=42) (people in long-term care) reported means for PUSH score at end of treatment
22 for a foam dressing and antibiotic ointment. The mean for a foam dressing was 3.24 and 1.61 for
23 antibiotic ointment. No estimate of effect or precision could be derived (very low quality).
- 24 • No evidence was found for the following outcomes:
 - 25 o Time to complete healing
 - 26 o Rate of reduction in size of ulcers
 - 27 o Pain (wound-related)
 - 28 o Time in hospital or NHS care
 - 29 o Patient acceptability
 - 30 o Side effects
 - 31 o Mortality (all cause)
 - 32 o Health-related quality of life

11.1.5.1325 Foam dressing: Allevyn versus Biatain®

- 35 • One study (n=32) (general population) showed Allevyn is more clinically effective at increasing the
36 proportion of people with pressure ulcers completely healed (grade 2 and 3) when compared to
37 Biatain® (low quality).
- 38 • One study (n=32) (general population) reported median percentage reduction in pressure ulcer
39 area for Allevyn and Biatain. The median for Allevyn was 38.2% (range -97.6 to 99.4%) and 45.8%
40 (range -56.9-90.0%) for Biatain. No estimate of effect or precision could be derived (very low
41 quality).
- 42 • One study (n=32) (general population) showed there may be no clinical difference between
43 Allevyn and Biatain for mean pain score at dressing removal, but the direction of the estimate of
44 effect favoured Allevyn (very low quality).

- 1 • One study (n=32) (general population) showed there is potentially no clinical difference between
2 Allevyn and Biatain for mean comfort score at dressing removal, the direction of the estimate of
3 effect favoured Biatain (very low quality).
- 4 • One study (n=32) (general population) showed there may be a clinical benefit for Allevyn
5 compared to Biatain for reducing the proportion of people with dressing related adverse events
6 (very low quality).
- 7 • One study (n=32) (general population) showed there may be no clinical difference between
8 Allevyn and Biatain for all-cause mortality, but the direction of the estimate of effect favoured
9 Allevyn (very low quality).
- 10 • No evidence was found for the following outcomes:
- 11 o Time to complete healing
- 12 o Rate of reduction in size of ulcers
- 13 o Time in hospital or NHS care
- 14 o Patient acceptability
- 15 o Health-related quality of life
- 16

11.1.5.1126 Foam dressing: Mepilex versus Tielle

- 18 • One study (n=38) (elderly adults) showed there may be no clinical difference between Mepilex
19 and Tielle® for increasing the proportion of people with pressure ulcers completely healed (grade
20 2), but the direction of the estimate of effect favoured Tielle (very low quality).
- 21 • One study (n=38) (elderly adults) showed Tielle is potentially more clinically effective at increasing
22 the proportion of people with pressure ulcers improved (grade 2) when compared to Mepilex
23 (low quality).
- 24 • One study (n=38) (elderly adults) showed there may be no clinical difference between Tielle and
25 Mepilex for reducing the proportion of people with pressure ulcers worsened (grade 2), the
26 direction of the estimate of effect favoured Tielle (very low quality).
- 27 • One study (n=38) (elderly adults) showed there may be a clinical benefit for Mepilex compared to
28 Tielle for a lower proportion of people with maceration (very low quality).
- 29 • One study (n=38) (elderly adults) showed there may be a clinical benefit for Mepilex compared to
30 Tielle for a lower proportion of people reporting odour (very low quality).
- 31 • One study (n=38) (elderly adults) showed there may be a clinical benefit for Mepilex compared to
32 Tielle for a lower proportion of people with adverse events (very low quALITY).
- 33 • One study (n=38) (elderly adults) showed there may be no clinical difference between Mepilex
34 and Tielle for all-cause mortality, but the direction of the estimate of effect could favour either
35 Tielle (very low quality).
- 36 • No evidence was found for the following outcomes:
- 37 o Time to complete healing of pressure ulcers
- 38 o Rate of healing of pressure ulcers
- 39 o Rate of reduction in size or volume of pressure ulcers
- 40 o Time in hospital or NHS care
- 41 o Patient acceptability
- 42 o Health-related quality of life

11.1.5.1.27 Hydrogel (aquagel) versus polyurethane foam (lyofoam) dressing

- 2 • One study (n=38) (people in palliative care) showed a polyurethane foam dressing is potentially
3 more clinically effective for increasing the proportion of pressure ulcers completely healed (grade
4 2 and 3) when compared to a hydrogel dressing (very low quality).
- 5 • One study (n=38) (people in palliative care) showed no clinical difference between a polyurethane
6 foam dressing and a hydrogel dressing for the proportion of pressure ulcers improved (grade 2
7 and 3) (low quality).
- 8 • One study (n=12) (people in palliative care) showed there may be no clinical difference between a
9 polyurethane foam dressing and hydrogel for mean healing rate for healed pressure ulcers (grade
10 2), but the direction of the estimate of effect favoured the foam dressing (very low quality).
- 11 • One study (n=26) (people in palliative care) showed there is potentially no clinical difference
12 between a polyurethane foam dressing and hydrogel for mean healing rate for healed pressure
13 ulcers (grade 3), the direction of the estimate of effect favoured the polyurethane foam dressing
14 (very low quality).
- 15 • One study (n=26) (people in palliative care) showed there is potentially no clinical difference
16 between a polyurethane foam dressing and hydrogel for mean healing rate for improved pressure
17 ulcers (grade3), the direction of the estimate of effect favoured the polyurethane foam dressing
18 (very low quality).
- 19 • One study (n=34) (people in palliative care) showed there may be no clinical difference between a
20 polyurethane foam dressing and hydrogel for all-cause mortality, but the direction of the estimate
21 of effect favoured the foam dressing (very low quality).
- 22 • No evidence was found for the following outcomes:
 - 23 o Time to complete healing
 - 24 o Pain (wound-related)
 - 25 o Time in hospital or NHS care
 - 26 o Patient acceptability
 - 27 o Side effects
 - 28 o Health-related quality of life

11.1.5.1.28 Hydrogel dressing versus dextranomer dressing

- 30 • One study (n=135) (general population) reported medians for percentage reduction in pressure
31 ulcer area for a hydrogel dressing and a dextranomer dressing. The median for hydrogel dressing
32 was 35% and 7% for dextranomer dressing. No estimate of effect or precision could be derived
33 (very low quality).
- 34 • One study (n=135) (general population) showed there may be no clinical difference between
35 hydrogel dressing and dextranomer dressing for proportion of people with pain at dressing
36 application, but the direction of the estimate of effect favoured the hydrogel dressing (very low
37 quality).
- 38 • One study (n=34) (people in palliative care) showed there may be no clinical difference between
39 polyurethane foam dressing and hydrogel dressing for all-cause mortality, but the direction of the
40 estimate of effect could favour either intervention (very low quality).
- 41 • No evidence was found for the following outcomes:
 - 42 o Time to complete healing
 - 43 o Rate of reduction in size or volume of pressure ulcers
 - 44 o Proportion of completely healed within trial period
 - 45 o Time in hospital or NHS care
 - 46 o Patient acceptability

- 1 o Side effects

2 **Hydrogel, foam dressing or transparent film versus different types of dressings**

- 3 • One study (n=41) (people in the community) showed there is potentially a clinical benefit of
4 hydrogel, foam dressing or transparent film for proportion of people with pressure ulcers
5 completely healed (grade 2 to 4) when compared to different types of dressing (very low quality).
- 6 • One study (n=58) (people in the community) reported that there was no significant difference in
7 the percentage of pressure ulcers healed per week (grade 2 to 4) when hydrogel, foam dressing or
8 transparent film was compared with different types of dressing. No estimate of effect or precision
9 could be derived (very low quality).
- 10 • One study (n=21) (people in the community) showed there is potentially a clinical benefit of
11 hydrogel, foam dressing or transparent film for proportion of people reporting the application of
12 the dressing as comfortable when compared to different types of dressings (very low quality).
- 13 • One study (n=21) (people in the community) showed there may be a difference in clinical benefit of
14 hydrogel, foam or transparent film for proportion of people reporting discomfort at dressing
15 removal when compared to different types of dressings (very low quality).
- 16 • One study (n=58) (people in the community) showed there is no clinical difference between
17 hydrogel, foam or transparent film and different types of dressing for proportion of people with
18 adverse events (low quality).
- 19 • One study (n=58) (people in the community) showed there may be a clinical benefit for hydrogel,
20 foam or transparent film compared to different types of dressing for reducing all-cause mortality
21 (very low quality).
- 22 • No evidence was found for the following outcomes:
 - 23 o Time to complete healing
 - 24 o Rate of reduction in size of ulcers
 - 25 o Pain (wound-related)
 - 26 o Time in hospital or NHS care
 - 27 o Patient acceptability
 - 28 o Health-related quality of life

11.1.5.129 **Hydrogel: Sterigel versus Intrasite**

- 30 • One study (n=47) (general population with necrotic pressure ulcers) showed Intrasite is
31 potentially more clinically effective for mean percentage reduction in pressure ulcer area when
32 compared to Sterigel. No estimate of precision could be derived (very low quality).
- 33 • One study (n=47) (general population with necrotic pressure ulcers) showed Sterigel is potentially
34 more clinically effective at for reducing the proportion of people with intermittent pressure ulcer
35 pain at the end of the study when compared to Intrasite (very low quality).
- 36 • One study (n=47) (general population with necrotic pressure ulcers) showed there may be no
37 clinical difference between Sterigel and Intrasite for reducing the proportion of people with
38 continuous pressure ulcer pain at the end of the study, but the direction of the estimate of effect
39 could favour Sterigel (very low quality).
- 40 • One study (n=42) (general population with necrotic pressure ulcers) showed there may be no clinical
41 difference between Sterigel and Intrasite® for a lower proportion of people with slight pain at
42 dressing removal, the direction of the estimate of effect favoured Sterigel® (very low quality).
- 43 • One study (n=42) (general population with necrotic pressure ulcers) showed there may be no
44 clinical difference between Sterigel and Intrasite for a lower proportion of people with severe
45 pain at dressing removal, but the direction of the estimate of effect could favour Sterigel (very
46 low quality).

- 1 • One study (n=42) (general population with necrotic pressure ulcers) showed there may be no
2 clinical difference between Sterigel and Intrasite for a lower proportion of people with
3 discomfort, but the direction of the estimate of effect could favour Sterigel (very low quality).
- 4 • One study (n=42) (general population with necrotic pressure ulcers) showed there may be a
5 clinical benefit of Sterigel for a lower proportion of people with maceration when compared to
6 Intrasite® (very low quality).
- 7 • One study (n=50) (general population with necrotic pressure ulcers) showed there may be no
8 clinical difference between Sterigel and Intrasite for reducing all-cause mortality, the direction of
9 the estimate of effect favoured Sterigel® (very low quality).
- 10 • No evidence was found for the following outcomes:
 - 11 o Time to complete healing
 - 12 o Rate of reduction in size or volume of pressure ulcers
 - 13 o Proportion of pressure ulcers completely healed
 - 14 o Pain (wound-related)
 - 15 o Time in hospital or NHS care
 - 16 o Patient acceptability
 - 17 o Health-related quality of life

11.1.5.130 *Protease modulating matrix versus impregnated gauze dressing*

- 19 • One study (n=80) (in-patients) showed a protease modulating matrix is potentially more clinically
20 effective at increasing the proportion of people completely healed (grade 2 to 4) when compared
21 to an impregnated gauze dressing (very low quality).
22 One study (n=80) (in-patients) reported time to complete healing of pressure ulcers (grade 2 to 4)
23 for a protease modulating matrix and an impregnated gauze dressing. The time to complete
24 healing for the protease modulating matrix was 6-15 days and 14-52 days for the an impregnated
25 gauze dressing. No estimate of effect or precision could be derived (very low quality).
- 26 • One study (n=80) (in-patients) showed there is no clinical difference between a protease
27 modulating matrix and an impregnated gauze dressing for proportion of people with adverse
28 events (low quality).
- 29 • One study (n=80) (in-patients) showed there is no clinical difference between a protease
30 modulating matrix and an impregnated gauze dressing for all-cause mortality (low quality).
- 31 • No evidence was found for the following outcomes:
 - 32 o Rate of reduction in size of ulcers
 - 33 o Reduction in size and/or volume of ulcer.
 - 34 o Pain (wound-related)
 - 35 o Time in hospital or NHS care
 - 36 o Patient acceptability
 - 37 o Health-related quality of life

11.1.5.131 *Polyurethane dressing versus different types of dressing*

- 39 • One study (n=64) (in-patients) showed there is potentially no clinical difference between a
40 polyurethane dressing and different types of dressings for mean time to healing of pressure ulcers
41 (grade 2 and 3), the direction of the estimate of effect favoured different types of dressings (very
42 low quality).
- 43 • One study (n=64) (in-patients) showed there is no clinical difference between a polyurethane
44 dressing and different types of dressing for reduction in PUSH tool, the direction of the estimate
45 of effect favoured the polyurethane dressing (low quality).

- 1 • One study (n=64) (in-patients) showed there may be no clinical difference between a
2 polyurethane dressing and different types of dressings for proportion of people with systematic
3 worsening, but the direction of the estimate of effect favoured the different types of dressing
4 (very low quality).
- 5 • One study (n=64) (in-patients) showed there may be no clinical difference between a
6 polyurethane dressing and different types of dressing for reducing the proportion of people with
7 localised adverse events, the direction of the estimate of effect favoured the polyurethane
8 dressing (very low quality).
- 9 • One study (n=64) (in-patients) showed there may be no clinical difference between a
10 polyurethane dressing and different types of dressings for all-cause mortality, but the direction of
11 the estimate of effect favoured the polyurethane dressing (very low quality).
- 12 • No evidence was found for the following outcomes:
 - 13 o Rate of reduction in size of ulcers
 - 14 o Proportion of completely healed within trial period
 - 15 o Pain (wound-related)
 - 16 o Time in hospital or NHS care
 - 17 o Patient acceptability
 - 18 o Health-related quality of life

11.1.5.1132 Alginate dressing versus silver alginate dressing

- 20 • One study (n=28) (elderly people) showed there may be a clinical benefit for a silver alginate
21 dressing compared to an alginate dressing for reducing the proportion of people with pressure
22 ulcers worsened (grade 3 and 4) (very low quality).
- 23 • One study (n=28) (elderly people) showed there may be a clinical benefit for a silver alginate
24 dressing compared to an alginate dressing for mean percentage reduction in pressure ulcer area
25 (grade 3 and 4) (very low quality).
- 26 • One study (n=28) (elderly people) showed a silver alginate dressing is potentially more clinically
27 effective for absolute decrease in pressure ulcer area (grade 3 and 4) when compared to an
28 alginate dressing (very low quality).
- 29 • One study (n=28) (elderly people) showed there is potentially no clinical difference between a
30 silver alginate dressing and an alginate dressing for mean rate of healing of pressure ulcers, the
31 direction of the estimate of effect favoured the silver alginate dressing (very low quality).
- 32 • One study (n=28) (elderly people) showed there may be no clinical difference between a silver
33 alginate dressing and an alginate dressing for proportion of people with infection, but the
34 direction of the estimate of effect favoured the silver alginate dressing (very low quality).
- 35 • One study (n=24) (elderly people) showed there may be no clinical difference between a silver
36 alginate dressing and an alginate dressing for percentage reduction in infection score, but the
37 direction of the estimate of effect could favour either intervention. No estimate of precision could
38 be derived (very low quality).
- 39 • One study (n=28) (elderly people) reported mean mASEPSIS index at the end of treatment for a
40 silver alginate dressing and an alginate dressing. The index for a silver alginate dressing was 115.3
41 and 81.8 for an alginate dressing. The clinical importance is unknown (very low quality).
- 42 • One study (n=28) (elderly people) showed there may be no clinical difference between a silver
43 alginate dressing and (grade 3 and 4) an alginate dressing for proportion of people with poor
44 acceptability and/or tolerability, but the direction of the estimate of effect favoured the silver
45 alginate dressing (very low quality).
- 46 • One study (n=99) (elderly people) showed there is no clinical difference between a silver alginate
47 dressing and an alginate dressing for all-cause mortality (low quality).

- 1 • No evidence was found for the following outcomes:
- 2 o Proportion of completely healed within trial period
- 3 o Time to complete healing
- 4 o Pain (wound-related)
- 5 o Time in hospital or NHS care
- 6 o Health-related quality of life
- 7

11.1.5.1.33 Alginate dressing versus dextranomer

- 9 • One study (n=92) (general population) showed an alginate dressing is potentially more clinically
10 effective for increasing the proportion of people with more than 75% reducing in pressure ulcer
11 area (grade 3 and 4) when compared to dextranomer (very low quality).
- 12 • One study (n=92) (general population) showed an alginate dressing is potentially more clinically
13 effective for increasing the proportion of people with more than 40% reducing in pressure ulcer
14 area (grade 3 and 4) when compared to dextranomer (very low quality).
- 15 • One study (n=92) (general population) showed an alginate dressing is more clinically effective at
16 reducing the proportion of people with pressure ulcers worsened or stagnated (grade 3 and 4)
17 when compared to dextranomer (low quality).
- 18 • One study (n=92) (general population) showed an alginate dressing is potentially more clinically
19 effective for increasing the mean rate of healing of pressure ulcers in people improved more than
20 40% (grade 3 and 4) when compared to dextranomer (very low quality).
- 21 • One study (n=92) (general population) showed an alginate dressing is potentially more clinically
22 effective for increasing the mean rate of healing of pressure ulcers (grade 3 and 4) when
23 compared to dextranomer (very low quality).
- 24 • One study (n=92) (general population) showed there may be no clinical difference between an
25 alginate dressing and dextranomer for the proportion of people with infection, but the direction
26 of the estimate of effect favoured the alginate dressing (very low quality).
- 27 • One study (n=92) (general population) showed there may be no clinical difference between an
28 alginate dressing and dextranomer for the proportion of people with hypergranulation, but the
29 direction of the estimate of effect favoured the dextranomer dressing (very low quality).
- 30 • One study (n=92) (general population) showed there may be no clinical difference between an
31 alginate dressing and dextranomer for the proportion of people with skin irritation, but the
32 direction of the estimate of effect favoured the alginate dressing (very low quality).
- 33 • One study (n=92) (general population) showed there is potentially no clinical difference between
34 an alginate dressing and dextranomer for the proportion of people with bleeding, the direction of
35 the estimate of effect favoured the alginate dressing (very low quality).
- 36 • One study (n=92) (general population) showed an alginate dressing is more clinically effective for
37 a lower proportion of people with pain when compared to dextranomer (low quality).
- 38 • One study (n=92) (general population) showed there may be no clinical difference between an
39 alginate dressing and dextranomer for the proportion of people with pruritus, but the direction of
40 the estimate of effect favoured the alginate dressing (very low quality).
- 41 • One study (n=92) (general population) showed there may be no clinical difference between an
42 alginate dressing and dextranomer for all-cause mortality, but the direction of the estimate of
43 effect could favoured the alginate dressing (very low quality).
- 44 • No evidence was found for the following outcomes:
- 45 o Time to complete healing
- 46 o Proportion of completely healed within trial period

- 1 o Time in hospital or NHS care
- 2 o Patient acceptability
- 3 o Health-related quality of life
- 4

11.1.5.1.34 Silver dressing versus different types of dressings

- 6 • One study (n=48) (general population) showed there may be a clinical benefit for a silver dressing compared to different types of dressings for mean percentage reduction in pressure ulcer area.
- 7
- 8 No estimate of precision could be derived (very low quality).
- 9

11.1.5.1.35 Silver dressing versus silver cream

- 11 • One study (n=40) (in- and out-patients) showed there may be a clinical benefit for a silver dressing compared to a silver cream for mean percentage reduction in pressure ulcer area (very low quality).
- 12
- 13
- 14 • One study (n=40) (in- and out-patients) showed there may be a clinical benefit for a silver cream compared to a silver dressing for percentage reduction in PUSH score. No estimate of precision could be derived (very low quality).
- 15
- 16
- 17 • One study (n=40) (in- and out-patients) showed there is no clinical difference of a silver dressing and a silver cream for proportion of people with adverse events (low quality).
- 18
- 19 • One study (n=40) (in- and out-patients) showed there is no clinical difference between a silver dressing and a silver cream for all-cause mortality (low quality).
- 20
- 21 • No evidence was found for the following outcomes:
- 22 o Time to complete healing
- 23 o Rate of reduction in size of ulcers
- 24 o Proportion of completely healed within trial period
- 25 o Pain (wound-related)
- 26 o Time in hospital or NHS care
- 27 o Patient acceptability
- 28 o Health-related quality of life
- 29

11.1.5.1.36 Sugar versus dextranomer

- 31 • One study (n=12) (people in long term care) showed dextranomer is potentially more clinically effective for increasing the proportion of people with pressure ulcers completely healed (grade unknown) when compared to sugar (very low quality).
- 32
- 33
- 34 • One study (n=12) (people in long term care) showed no clinical difference between dextranomer and sugar for increasing the proportion of people with pressure ulcers improved, the direction of the estimate of effect favoured sugar (low quality).
- 35
- 36
- 37 • One study (n=23) (people in long term care) showed dextranomer is potentially more clinically effective for increasing the proportion of pressure ulcers completely healed (grade unknown) when compared to sugar (very low quality).
- 38
- 39
- 40 • One study (n=23) (people in long term care) showed dextranomer is more clinically effective for increasing the proportion of pressure ulcers improved when compared to sugar (low quality).
- 41
- 42 • No evidence was found for the following outcomes:
- 43 o Time to complete healing
- 44 o Rate of reduction in size of ulcers

- 1 o Pain (wound-related)
- 2 o Time in hospital or NHS care
- 3 o Patient acceptability
- 4 o Side effects
- 5 o Mortality (all cause)
- 6 o Health-related quality of life

11.1.5.1.37 Sugar versus different types of topical agents

- 8 • One study (n=38) (geriatric adults) showed sugar is more clinically effective at increasing the
9 proportion of people with pressure ulcers completely healed (grade not reported) when
10 compared to different types of topical agents (low quality).
- 11 • One study (n=38) (geriatric adults) showed sugar is potentially more clinically effective at
12 improving mean healing index when compared to different types of topical agents (very low
13 quality).
- 14 • No evidence was found for the following outcomes:
 - 15 o Time to complete healing
 - 16 o Rate of reduction in size of ulcers
 - 17 o Reduction in size and/or volume of ulcer.
 - 18 o Pain (wound-related)
 - 19 o Time in hospital or NHS care
 - 20 o Patient acceptability
 - 21 o Side effects
 - 22 o Mortality (all cause)
 - 23 o Health-related quality of life
- 24

11.1.5.1.38 Honey versus ethoxydiaminoacridine and nitrofurazone

- 26 • One study (n=50) (in-patients) showed honey is more clinically effective at increasing the
27 proportion of pressure ulcers completely healed (grade 2 and 3) when compared to
28 ethoxydiaminoacridine and nitrofurazone (low quality).
- 29 • One study (n=26) (in-patients) showed honey is potentially more clinically effective for mean
30 percentage reduction in pressure ulcer area (grade 2 and 3) when compared to
31 ethoxydiaminoacridine and nitrofurazone (very low quality).
- 32 • One study (n=26) (in-patients) showed honey is more clinically effective for mean percentage
33 decrease in PUSH score when compared to ethoxydiaminoacridine and nitrofurazone ((grade 2
34 and 3) (grade 2 and 3) (grade 2 and 3) (low quality).
- 35 • One study (n=26) (in-patients) showed there is no clinical difference between honey and
36 ethoxydiaminoacridine and nitrofurazone for proportion of people with adverse events (low
37 quality).
- 38 • One study (n=27) (in-patients) showed there may be no clinical difference between honey and
39 ethoxydiaminoacridine and nitrofurazone for all-cause mortality, but the direction of the estimate
40 of effect favoured honey (very low quality).
- 41 • No evidence was found for the following outcomes:
 - 42 o Time to complete healing
 - 43 o Rate of reduction in size of ulcers
 - 44 o Pain (wound-related)
 - 45 o Time in hospital or NHS care

- 1 o Patient acceptability
- 2 o Health-related quality of life
- 3

11.1.5.1.39 Platelet gel versus other treatment

- 5 • One study (n=16) (people with a spinal cord injury) showed there is no clinical difference between
6 platelet gel and other treatment for proportion of pressure ulcers completely healed (grade 3 and
7 4) (low quality).
- 8 • One study (n=16) (people with a spinal cord injury) showed there is potentially no clinical
9 difference between platelet gel and other treatment for proportion of pressure ulcers improved
10 (grade 3 and 4), the direction of the estimate of effect favoured platelet gel (very low quality).
- 11 • One study (n=16) (people with a spinal cord injury) showed platelet gel is potentially more
12 clinically effective at mean percentage reduction in pressure ulcer volume (grade 3 and 4) when
13 compared to other treatment (very low quality).
- 14 • No evidence was found for the following outcomes:
 - 15 o Time to complete healing
 - 16 o Rate of reduction in size of ulcers
 - 17 o Pain (wound-related)
 - 18 o Time in hospital or NHS care
 - 19 o Patient acceptability
 - 20 o Side effects
 - 21 o Mortality (all cause)
 - 22 o Health-related quality of life
 - 23

11.1.5.1.40 Hyaluronic acid versus sodium hyaluronic

- 25 • One study (n=20) (in-patients) showed there may be a clinical benefit for hyaluronic acid
26 compared to sodium hyaluronic for mean percentage reduction in pressure ulcer area (grade 1)
27 (very low quality).
- 28 • One study (n=20) (in-patients) showed there may be a clinical benefit for hyaluronic acid
29 compared to sodium hyaluronic for mean percentage reduction in pressure ulcer area (grade 2)
30 (very low quality).
- 31 • One study (n=14) (in-patients) showed there may be a clinical benefit for hyaluronic acid
32 compared to sodium hyaluronic for mean percentage reduction in pressure ulcer area (grade 3)
33 No estimate of precision could be derived (very low quality).
- 34 • One study (n=20) (in-patients) showed there may be a clinical benefit for hyaluronic acid
35 compared to sodium hyaluronic for time to 50% reduction in pressure ulcer diameter (grade 1)
36 (very low quality).
- 37 • One study (n=20) (in-patients) showed there may be a clinical benefit for hyaluronic acid
38 compared to sodium hyaluronic for time to 50% reduction in pressure ulcer diameter (grade 2)
39 (very low quality).
- 40 • One study (n=14) (in-patients) showed there may be a clinical benefit for hyaluronic acid
41 compared to sodium hyaluronic for time to 50% reduction in pressure ulcer diameter (grade 3)
42 (very low quality).
- 43 • No evidence was found for the following outcomes:
 - 44 o Time to complete healing
 - 45 o Rate of reduction in size of ulcers

- 1 o Proportion of completely healed within trial period
- 2 o Pain (wound-related)
- 3 o Time in hospital or NHS care
- 4 o Patient acceptability
- 5 o Side effects
- 6 o Mortality (all cause)
- 7 o Health-related quality of life

11.1.5.1.41 Zinc gauze dressing versus streptokinase-streptodornase ointment

- 9 • One study (n=28) (geriatric adults with necrotic pressure ulcers) reported medians for percentage
10 reduction in pressure ulcer area for a zinc gauze dressing and a streptokinase-streptodornase
11 ointment. The median for a zinc gauze dressing was 2.4% and -18.7% for a streptokinase-
12 streptodornase ointment. No estimate of effect or precision could be derived (very low quality).
- 13 • One study (n=28) (geriatric adults with necrotic pressure ulcers) showed there may be no clinical
14 difference between a zinc gauze dressing and a streptokinase-streptodornase ointment for
15 proportion of people with skin reaction, but the direction of the estimate of effect favoured the
16 zinc gauze dressing (very low quality).
- 17 • One study (n=28) (geriatric adults with necrotic pressure ulcers) showed there may be no clinical
18 difference between a zinc gauze dressing and a streptokinase-streptodornase ointment for
19 proportion of people with infection, but the direction of the estimate of effect favoured the zinc
20 gauze dressing (very low quality).
- 21 • One study (n=28) (geriatric adults with necrotic pressure ulcers) showed there is no clinical
22 difference between a zinc gauze dressing and a streptokinase-streptodornase ointment for all-
23 cause mortality (low quality).
- 24 • No evidence was found for the following outcomes:
 - 25 o Time to complete healing
 - 26 o Rate of reduction in size of ulcers
 - 27 o Proportion of completely healed within trial period
 - 28 o Pain (wound-related)
 - 29 o Time in hospital or NHS care
 - 30 o Patient acceptability
 - 31 o Health-related quality of life

11.1.5.1.42 Hydrofibre dressing versus resin salve

- 33 • One study (n=22) (people in hospital) showed a resin salve is potentially more clinically effective
34 at increasing the proportion of people with pressure ulcers completely healed (grade 2 to 4) when
35 compared to a hydrofibre dressing (low quality).
- 36 • One study (n=29) (people in hospital) showed a resin salve is potentially more clinically effective
37 at increasing the proportion of pressure ulcers completely healed (grade 2 to 4) when compared
38 to a hydrofibre dressing (low quality).
- 39 • One study (n=29) (people in hospital) showed a resin salve is potentially more clinically effective
40 at increasing the proportion of pressure ulcers improved (grade 2 to 4) when compared to a
41 hydrofibre dressing (low quality).
- 42 • One study (n=29) (people in hospital) showed there may be clinical harm for a hydrofibre dressing
43 for the proportion of pressure ulcers worsened when compared to resin salve (very low quality).
- 44 • One study (n=29) (people in hospital) showed there may be a clinical benefit for a resin salve
45 compared to a hydrofibre dressing for mean percentage reduction in pressure ulcer width (grade
46 2 to 4). No estimate of precision could be derived (very low quality).

- 1 • One study (n=29) (people in hospital) showed there may be a clinical benefit for a resin salve
2 compared to a hydrofibre dressing for mean percentage reduction in pressure ulcer depth (grade
3 2 to 4). No estimate of precision could be derived (very low quality).
- 4 • One study (n=29) (people in hospital) reported that the speed of healing of pressure ulcers was
5 significantly faster with a resin salve when compared with a hydrofibre dressing. No estimate of
6 effect or precision could be derived (very low quality).
- 7 • One study (n=37) (people in hospital) showed there may be no clinical difference between a resin
8 salve and a hydrofibre dressing for proportion of people with allergic skin reaction, but the
9 direction of the estimate of effect favoured the hydrofibre dressing (very low quality).
- 10 • One study (n=37) (people in hospital) showed there may be a clinical benefit of resin salve for the
11 for all-cause mortality, when compared to a hydrofibre dressing (very low quality).
- 12 • No evidence was found for the following outcomes:
- 13 o Time to complete healing
- 14 o Pain (wound-related)
- 15 o Time in hospital or NHS care
- 16 o Patient acceptability
- 17 o Health-related quality of life
- 18

11.1.5.1143 Dextranomer versus chlorinated lime solution

- 20 • One study (n=16) (elderly adults) showed dextranomer is potentially more clinically effective at
21 reducing the time to healing (defined as granulating and less than 25% of original ulcer area)
22 when compared to a chlorinated lime solution (very low quality).
- 23 • One study (n=16) (elderly adults) showed there may be no clinical difference between a
24 dextranomer and a chlorinated lime solution for all-cause mortality, the direction of the estimate
25 of effect favoured the intervention (very low quality).
- 26 • No evidence was found for the following outcomes:
- 27 o Rate of reduction in size of ulcers
- 28 o Reduction in size and/or volume of ulcer.
- 29 o Proportion of completely healed within trial period
- 30 o Pain (wound-related)
- 31 o Time in hospital or NHS care
- 32 o Patient acceptability
- 33 o Side effects
- 34 o Health-related quality of life
- 35

11.1.5.1344 Collagen and foam versus foam dressing

- 37 • One study (n=10) (stagnating pressure ulcers of at least 4 weeks duration) showed there may be
38 no clinical difference between collagen and foam, and a foam dressing for increasing the
39 proportion of people with pressure ulcers completely healed, but the direction of the estimate of
40 effect could favour the foam dressing (very low quality).
- 41 • One study (n=10) (stagnating pressure ulcers of at least 4 weeks duration) showed there is no
42 clinical difference between collagen and foam, and a foam dressing for all-cause mortality (low
43 quality).
- 44 • No evidence was found for the following outcomes:
- 45 o Time to complete healing

- 1 o Rate of reduction in size of ulcers
- 2 o Reduction in size and/or volume of ulcer.
- 3 o Pain (wound-related)
- 4 o Time in hospital or NHS care
- 5 o Patient acceptability
- 6 o Side effects
- 7 o Health-related quality of life

11.1.52 Economic (adults)

- 9 • Two cost-consequence analyses found collagen is likely to be more expensive and more effective
10 than hydrocolloid for healing people with pressure ulcers; 1 additional cost-effectiveness analysis
11 found that collagen is likely to dominate hydrocolloid (collagen is less costly and more effective) in
12 the treatment of heel pressure ulcers. All 3 studies were partially applicable with potentially
13 serious limitations.
- 14 • Two cost-effectiveness analyses found DuoDERM hydrocolloid dressings are likely to dominate
15 Comfeel hydrocolloid dressings and saline gauze; both studies reported the Comfeel dressing to
16 be less effective and less costly than the saline gauze. Both studies were partially applicable with
17 potentially serious limitations.
- 18 • One cost-consequence analysis found that hydrogel dressings are likely to be less costly than
19 hydrocolloid dressings (effectiveness was assumed equal). This study was assessed to be partially
20 applicable with potentially serious limitations.
- 21 • One cost-consequence analysis found collagenase dressings dominate hydrogel dressings, with
22 lower costs and fewer days spent with a pressure ulcer. This study was assessed to be partially
23 applicable with potentially serious limitations.
- 24 • One cost comparison found a hydroactive wound dressing, in combination with enzymatic wound
25 cleaning, to be less costly than gauze, impregnated gauze, and calcium alginate. This study was
26 assessed to be partially applicable with potentially serious limitations.
- 27 • One cost-effectiveness analysis found modern dressings are likely to dominate traditional wound
28 care (modern dressings are less costly and more effective than traditional care); an additional
29 cost-effectiveness analysis found advanced dressings are likely to dominate simple dressings. Both
30 studies were assessed as partially applicable with potentially serious limitations.
- 31 • One cost-consequence analysis found that polyurethane self-adhesive foam dressing is likely to
32 dominate saline soaked gauze. This analysis was partially applicable and had minor limitations.

11.1.53 Clinical (neonates, infants, children and young people)

34 No evidence was identified.

11.1.54 Economic (neonates, infants, children and young people)

36 No relevant evidence was identified.

37

11.1.16 Recommendations and link to evidence

11.1.621 Adults

Recommendations	<p>40. Consider using a dressing for adults that promotes a warm, moist wound healing environment to treat grade 2, 3 and 4 pressure ulcers.</p> <p>41. Discuss with the adult what type of dressing should be used, taking into account:</p> <ul style="list-style-type: none"> • pain and tolerance • position of the ulcer • amount of exudate • frequency of dressing change
Relative values of different outcomes	<p>The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.</p> <p>It was acknowledged that pain experienced during dressing change was important from a patient perspective and that the frequency of dressing change should be considered.</p>
Trade off between clinical benefits and harms	<p>The majority of studies were compared against hydrocolloid dressing, as the GDG felt this is often considered the gold standard and that it has been available for a long time. The results were mixed for the benefits of hydrocolloid. There was a clinical benefit of hydrocolloid dressing over foam dressing and phenytoin cream for proportion of people completely healed, also for improvement in pressure ulcers when compared to phenytoin cream. However there was no difference for pressure ulcers worsened. When hydrocolloid dressing was compared to phenytoin ointment in a small study the phenytoin ointment was more clinically beneficial for reducing the mean time to healing but there was no difference for adverse events and mortality.</p> <p>There was no clinical difference between a collagen dressing when compared to a hydrocolloid dressing for people completely healed, mean healing speed, time to healing, adverse events or mortality but there was a clinical benefit of collagen for the mean percentage reduction in ulcer area. Hydrogel dressings were more clinically beneficial than hydrocolloid dressings for the proportion of people with pressure ulcers completely healed in 1 study (Darkovich 1990) but no difference in proportion of pressure ulcers completely healed in another very small (Motta, 1999)¹²² study (grade 2 and 3). For reduction in size and for reduction of worsened pressures ulcers, hydrogel was more beneficial but there was uncertainty in any difference in healing rate. There was no clinical difference in odour score, comfort or mortality rate. The GDG discussed that in clinical practice hydrogel dressings and hydrocolloid dressings were not necessarily an appropriate comparison as there would be different clinical indications for each dressing. It would also be determined by what form the dressing takes for example, sheet or film.</p> <p>Alginate dressing was more clinically beneficial than hydrocolloid dressing for the proportion of people partially healed (40%) and reduction in pressure ulcer area. There was no clinical difference in infection, skin irritation, maceration, bleeding, pain at dressing removal, odour, hypergranulation and mortality. The GDG thought that alginate dressings and hydrocolloid dressings was not a relevant comparison as they are used in clinical practice for different clinical indications.</p>

	<p>There was no clinical benefit of hydrocolloid dressing for time to healing or for adverse events when compared to antibiotic ointment, nor for any outcomes for hydrocolloid dressing compared to polyurethane dressing. The GDG noted that this may be due to the fact that the results would be dependent upon the grade of pressure ulcer.</p> <p>There was a clinical benefit for resin salve dressing compared to hydrofibre dressing for the proportion of people completely healed, improved, worsened, mean percentage reduction in ulcer width and depth and mortality. There was an unclear benefit for speed of healing but it favoured the hydrofibre dressing.</p> <p>There was a clinical benefit of foam dressing for the proportion of ulcers completely healed in a palliative care setting when compared to a hydrogel dressing. There were no other clinical differences between foam dressings and hydrogel dressings. More pressure ulcers worsened with an alginate dressing than with a silver alginate dressing and there was a clinical benefit for silver alginate dressing for reduction in pressure ulcer area. There were no clinical differences for rate of healing of pressure ulcers, poor acceptability and/or tolerability, infection and mortality between alginate and silver alginate dressings.</p> <p>Dextranomer, sugar, hyaluronic acid and poly-hema were judged to have little relevance by the GDG as they are not in use in current clinical practice in the UK. Furthermore, the GDG thought that the comparison of silver dressing compared to silver cream was not relevant to the review as silver is the same constituent and this was therefore not a comparison of dressings. Where different hydrocolloid dressings were compared this was not regarded as relevant to the review as again it was not comparing different types of dressing (with different functions). This also applied to different foam dressings. The GDG felt that where interventions were compared to a variety of dressings or other treatments this was not useful to informing the recommendation. Where comparisons included debriding or topical agents these studies were included in the debridement and topical agent reviews.</p> <p>Charcoal dressing was compared to hydrocolloid dressing but the GDG suggested that charcoal dressings are mainly used for odour control and that this comparison was therefore not appropriate, particularly given that odour was not an outcome considered by the study. One study compared honey to ethocyclidiaminoacridine and nitrofurzaone but the GDG noted that ethocyclidiaminoacridine and nitrofurazone is not used in clinical practice and is not listed in the BNF.</p> <p>The GDG did not feel that the evidence allowed for a recommendation to be made about the use of a specific type of dressing. This was due to the lack and quality of evidence, as well as the importance of considering the function of the dressing and specific patient factors. The GDG emphasised that the effectiveness of each dressing would be dependent upon the type of pressure ulcer.</p> <p>The GDG therefore chose to recommend a dressing which promotes the optimum healing environment, rather than a specific type of dressing. To inform this decision, a second recommendation was developed to highlight the patient factors which should be considered in choosing the most appropriate dressing.</p>
Economic considerations	<p>Eleven economic studies were included, however the majority of these provided only pairwise comparisons, and none were conducted inside the UK. The existing economic evidence was considered to be only partially informative in determining the cost-effectiveness of various dressings. The GDG did not feel that the evidence was strong enough to identify a cost-effective type of dressing.</p>

	<p>The GDG considered UK relevant unit costs, but noted that the major resource implications come from the frequency that each dressing requires changing. This is likely to be dependent on a range of factors, such as location of the ulcer, the amount of exudate, and patient acceptability. The frequency of dressing change can also have a substantial impact on quality of life. The GDG therefore agreed that the dressing which was deemed more effective when taking these factors into account would be most likely to be cost-effective.</p>
Quality of evidence	<p>Overall, the quality of evidence was graded low to very low. Most of the studies had very serious limitations. In the studies where a clinical effect was found most of the results had serious to very serious imprecision, thus indicating a lot of uncertainty in the results. The GDG noted that there were some problems with the comparisons in studies, such as non-clinically relevant comparisons and dressings not used in current clinical practice. Therefore these comparisons have not been focused upon. Having reviewed the evidence and taken into consideration the above listed limiting factors the recommendation was developed by informal consensus of the GDG.</p>
Other considerations	<p>The GDG felt it was important to consider the following factors when choosing a dressing. Such factors include; the adhesiveness of a dressing (ease of removal), the nature of the wound, ease of use of the dressing, amount of exudate, amount of pain at dressing change, protection of surrounding skin, irritation caused by the adhesive, infection, odour, and absorption. In addition, it was noted that the wound can deteriorate because of dressing changes and this is specific issue with regards to sacral ulcers that are likely to become frequently soiled. The frequency of dressing changes was also noted as have an impact on the healing of a wound and can be detrimental to the effectiveness of the dressing. The patient members of the GDG stated that tolerability of the dressing and dressing change were important factors, as were odour and skin irritation.</p> <p>Discussion also focused on the need to consider who has the responsibility for choosing the type of dressing used, and who is responsible for dressing changes. It was felt that this should be a healthcare professional with appropriate knowledge and experience of the use of dressings.</p> <p>The GDG highlighted that when a pressure ulcer is not improving it was important to consider other factors such as pressure relief and nutrition to facilitate healing. It was also important to recognise when a certain dressing is not appropriate and consideration should be given to using a different type of dressing.</p> <p>The GDG felt that different shapes of dressing may be needed for different pressure ulcer sites.</p>

1

Recommendations	42. Do not offer gauze dressings to treat pressure ulcers in adults.
Relative values of different outcomes	<p>The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.</p> <p>It was acknowledged that pain at dressing change was important from a patient perspective and that the frequency of dressing change should be considered.</p>
Trade off between clinical benefits and harms	<p>Evidence showed there was a clinical benefit for hydrocolloid dressing compared to gauze dressing for the proportion of people with pressure ulcers completely healed, and improved. There was heterogeneity in the results so the results were analysed in their pre-defined subgroups, which showed a more profound benefit for those with</p>

	<p>spinal cord injury than the general population, although most results showing hydrocolloid to be more beneficial. There was no difference for the proportion of pressure ulcers which worsened for the general population but hydrocolloid dressing was more clinically beneficial than gauze dressing for reducing pressure ulcers worsened. There was a clinical benefit for gauze dressing for the reduction in size and volume of pressure ulcers. There was a clinical harm for gauze dressing for skin irritation, pain at dressing removal and discomfort. There was also a clinical benefit of hydrocolloid dressing compared to impregnated gauze dressing for proportion of completely healed, but there was no difference for people improved.</p> <p>There was a clinical benefit for hydrocolloid dressing compared to foam dressing for the proportion of people completely healed. Foam dressing showed more harm for the proportion of people with inflammation or maceration but other outcomes showed no clinically beneficial results.</p> <p>There was a clinical benefit of foam dressing when compared to gauze dressing for the proportion of people completely healed and reduced mortality. Polyurethane dressing was clinically beneficial when compared to gauze dressing for: the proportion of pressure ulcers completely healed, worsened, decreased in size, increased in ulcer grade. There was no clinical benefit for polyurethane dressing for proportion with maceration. There was a clinical benefit of phenytoin cream when compared to gauze dressing for people completely healed, for the proportion of ulcers improved and for a lower proportion of people with worsening of pressure ulcers. There was no clinical benefit for hydrogel dressing or gauze dressing for any outcomes except there may be a benefit for gauze dressing for reducing all-cause mortality.</p> <p>Dextranomer dressing was more clinically beneficial than gauze dressing but the GDG judged it to have little relevance as it is not used in current clinical practice in the UK. The GDG did not think that this was a relevant comparison.</p> <p>Overall there was little clinical benefit of gauze dressing. There are adverse events associated with gauze dressings which the GDG identified as important such as increased pain at dressing removal, skin irritation and discomfort. The GDG stated that gauze is rarely used in clinical practice due to the fact that there are more effective dressings available. It is for these reasons that the above recommendation has been made.</p>
Economic considerations	The GDG considered 3 economic analyses which included gauze dressing as a comparator. None of these studies found gauze dressing to be cost effective (comparators included calcium alginate, hydroactive wound dressings, and hydrocolloid dressings).
Quality of evidence	Overall, the quality of evidence was graded low to very low. Most of the studies had very serious limitations. Where there was a clinical effect, most of the results had serious to very serious imprecision indicating a lot of uncertainty in these results. No serious imprecision was found for gauze versus hydrocolloid dressings or gauze versus polyurethane dressings. The GDG noted that there were some problems with the studies, such as non-clinically relevant comparisons and dressings not used in current clinical practice. Therefore these comparisons have not been focused upon.
Other considerations	The GDG were concerned about the use of gauze dressings as they often dry out and on removal can remove healing skin. Such removal can also cause pain to the individual.

11.1.612 Neonates, infants, children and young people

Recommendations	43. Do not use iodine dressings to treat pressure ulcers in neonates.
------------------------	--

Relative values of different outcomes	<p>The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.</p> <p>It was acknowledged that pain at dressing change was important from a patient perspective and that the frequency of dressing change should be considered.</p>
Trade-off between clinical benefits and harms	<p>The GDG used 1 statement from the Delphi consensus panel to develop the recommendation. The statement was ‘Healthcare professionals should not use iodine dressings for the treatment of pressure ulcers in neonates.’ The statement was accepted by the Delphi consensus panel in Round 1 of the survey. Further detail on the Delphi consensus survey can be found in Appendix N.</p> <p>The statement was included in Round 1 of the Delphi consensus. Qualitative responses gathered from panel members suggested that there was a risk of toxicity from the use of iodine in neonates. The GDG discussed the statement and agreed that a recommendation should be made. The GDG agreed that the risk of toxicity from the use of iodine dressings in neonates meant that these dressings should not be used in this population and a recommendation was developed to reflect this.</p>
Economic considerations	<p>The primary concern is safety for the neonates; iodine dressings are not advised in this population, therefore cost-effectiveness is not considered.</p>
Quality of evidence	<p>No RCTs or cohort studies were identified for neonates, infants, children or young people. Formal consensus using a modified Delphi was therefore used to develop the recommendation.</p> <p>To inform the recommendation, the GDG used 1 statement which was included in Round 1 of the Delphi consensus survey and reached 86% consensus agreement.</p> <p>Further details can be found in Appendix N.</p>
Other considerations	<p>Comments from the Delphi consensus panel suggested that iodine dressings should be used only with extreme caution in infants and children, where other dressings were not appropriate.</p>

1

Recommendations	<p>44. Consider using a dressing which promotes a warm, moist healing environment to treat grade 2, 3 and 4 pressure ulcers in neonates, infants, children and young people.</p>
Relative values of different outcomes	<p>The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.</p> <p>It was acknowledged that pain at dressing change was important from an individual perspective and that the frequency of dressing change should be considered.</p>
Trade-off between clinical benefits and harms	<p>The GDG used 1 statement from the Delphi consensus panel to develop the recommendation. The statement ‘Healthcare professionals should treat all pressure ulcers with wound dressings which promote a warm, moist wound healing environment’ was not accepted during Round 1 of the Delphi consensus survey and was therefore amended for Round 2 of the survey. The GDG discussed comments from panel members which suggested that the use of such dressings would not be appropriate for Grade 1 ulcers and only for some Grade 2 ulcers. Comments also highlighted that different dressings would be required depending upon the clinical condition of the neonate, infant, child or young person. As such, the statement was amended to reflect that such a dressing should be considered, rather than used for all ulcers. The statement was also amended to reflect that this may be used for</p>

	<p>Grade 2, 3 or 4 ulcers only. The statement was accepted by the Delphi consensus panel in Round 2 of the survey. Further detail on the Delphi consensus survey can be found in Appendix N.</p> <p>The GDG discussed the comments and agreed that a recommendation should be developed to support the use of a dressing which promotes a warm, moist healing environment, rather than a specific type of dressing. Comments gathered from the panel in Round 2 of the Delphi consensus survey suggested that the use of any dressings should be part of an individualised management plan.</p>
Economic considerations	<p>The GDG considered UK relevant unit costs, but noted that the major resource implications come from the frequency that each dressing requires changing. This is likely to be dependent on a range of factors, such as location of the ulcer, the amount of exudate, and patient acceptability. The frequency of dressing change can also have a substantial impact on quality of life. In the absence of evidence the GDG did not feel that 1 cost-effective type of dressing could be identified, but agreed that the dressing which was deemed more effective when taking these factors (for example, location of the ulcer, the amount of exudate, and patient acceptability) into account would be most likely to be cost-effective.</p>
Quality of evidence	<p>No RCTs or cohort studies were identified for neonates, infants, children or young people. Formal consensus using a modified Delphi was therefore used to develop the recommendation.</p> <p>To inform the recommendation, the GDG used 1 statement which was included in Round 1 of the Delphi consensus survey and reached 74% consensus agreement. The statement was therefore amended and included in Round 2 of the Delphi consensus survey where it reached 87% consensus.</p> <p>Further details can be found in Appendix N.</p>
Other considerations	<p>There were no other considerations.</p>

1

Recommendations	<p>45. Consider using topical antimicrobial dressings to treat pressure ulcers where clinically indicated in neonates, infants, children and young people, for example, where there is spreading cellulitis</p> <p>46. Do not offer gauze dressings to treat pressure ulcers in neonates, infants, children and young people.</p>
Relative values of different outcomes	<p>The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.</p> <p>It was acknowledged that pain at dressing change was important from a patient perspective and that the frequency of dressing change should be considered.</p>
Trade-off between clinical benefits and harms	<p>The GDG used 1 statement from the Delphi consensus survey to develop the recommendation on topical antimicrobial dressings. The statement 'Healthcare professionals should not routinely use topical antimicrobial dressings (for example silver or iodine) for the treatment of pressure ulcers in infants, children and young people.' was included in Round 1 of the Delphi consensus process and was not accepted. The statement was subsequently amended by the GDG for inclusion in Round 2 of the survey. The GDG noted that the majority of comments received during Round 1 were based upon the use of silver and iodine dressings. The statement was therefore amended to remove these examples, as it was agreed that they were not appropriate examples. The statement was also amended to suggest</p>

	<p>that there may be situations in which topical antimicrobial dressings are appropriate and that these may be considered when treating neonates, infants, children and young people, depending upon the clinical condition.</p> <p>The amended statement ‘Healthcare professionals should consider using topical antimicrobial dressings for the treatment of pressure ulcers in infants, children and young people, where clinically indicated’ was therefore included in Round 2 of the Delphi consensus survey, where it was accepted.</p> <p>The GDG agreed that a recommendation should be developed to highlighted that topical antimicrobial dressings should be considered in these populations where clinically indicated. Comments from the Delphi consensus panel highlighted that the choice of topical antimicrobial should be considered carefully in neonates, infants and children and that silver and iodine dressings were unlikely to be appropriate in people of these ages. Comments also emphasised that of topical antimicrobials should not be used routinely and the GDG therefore felt that a recommendation to ‘consider’ using these dressings would be appropriate.</p>
Economic considerations	<p>The GDG noted that in some scenarios topical antimicrobials will be required for the treatment of pressure ulcers. In such cases they are required for healing, therefore the small upfront cost is expected to be off-set by reductions in future treatment costs and improvements in quality of life. These dressings will not require substantial additional resource over the use of a dressing which promotes a warm, moist healing environment, as recommended in Chapter 10. The GDG agreed that the use of topical antimicrobial dressings is highly likely to be cost-effective, but only where clinically indicated.</p>
Quality of evidence	<p>No RCTs or cohort studies were identified for neonates, infants, children or young people. Formal consensus using a modified Delphi was therefore used to develop the recommendation.</p> <p>To inform the recommendation, the GDG used 1 statement which was included in Round 1 of the Delphi consensus survey and reached 65% consensus agreement. An amended statement was therefore included in Round 2 of the survey where it reached 79% consensus and was accepted.</p> <p>Further details can be found in Appendix N.</p>
Other considerations	<p>Recommendation X covers the use of iodine dressings in neonates.</p>

1

Recommendations	<p>47. Do not offer gauze dressings to treat pressure ulcers in neonates, infants, children and young people.</p>
Relative values of different outcomes	<p>The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.</p> <p>It was acknowledged that pain at dressing change was important from an individual perspective and that the frequency of dressing change should be considered.</p>
Trade-off between clinical benefits and harms	<p>During discussion of the Delphi consensus survey and development of the recommendations, the GDG highlighted that it was inappropriate to use gauze dressings to treat pressure ulcers and subsequently developed a corresponding recommendation using informal consensus.</p>
Economic considerations	<p>Gauze dressings are not considered to be effective in the treatment of pressure ulcers, therefore they are not considered to be cost-effective.</p>

Quality of evidence	No RCTs or cohort studies were identified for neonates, infants, children or young people. Formal consensus using a modified Delphi was therefore used to develop the recommendation. The recommendation was based upon informal consensus of the GDG.
Other considerations	There were no other considerations.

12 Management of heel pressure ulcers

2 Heel pressure ulcers are localised injury to the heel as result of pressure sometimes in association
3 with other factors. The heel is at the back of the foot, extending from the Achilles tendon around the
4 plantar surface, it covers the apex of the calcaneum bone. It is a common site for pressure ulcer
5 development, particularly in people who are supine or semi-recumbent with immobility. In this
6 position, bone and tendon can be involved as there is little underlying connective tissue.

7 The lower limb can be subject to disease processes such as ischaemia, oedema, structural changes
8 (due to fractures or bone disorders) and neuropathy, all of which affect the development and healing
9 of heel pressure ulcers.

10 In light of these anatomical and pathological differences of the heel, the GDG wished to consider
11 whether there are specific management considerations for heel pressure ulcers.

12.1 Review question: What is the most clinically and cost-effective method for management of pressure ulcers of the heel?

14 For full details see review protocol in Appendix C.

12.1.1 Clinical evidence (adults)

16 Five studies were included in the review and 1 Cochrane Review was found.^{101,111,114,125,161} Evidence
17 from these are summarised in the clinical GRADE evidence profile below (Table 197). See also the
18 study selection flow chart in Appendix D, forest plots in Appendix I, study evidence tables in
19 Appendix G and exclusion list in Appendix J.

20 A Cochrane Review (McGinnis 2011)¹¹¹ was found for pressure-relieving devices for treating heel
21 pressure ulcers, 1 study was found (Russell 2000)¹⁶¹ which looked at 2 different types of mattress.
22 One study looked at topical agents – nerve growth factors compared to placebo (Landi 2003), this is
23 reported in the topical agents review and reported feet and heel ulcers. As this present review
24 focuses on heel ulcers, only 1 outcome was extricable from the study (reduction in ulcer area) as all
25 other outcomes related to foot and heel ulcers. One study (Muller 2001) looked at collagenase-
26 containing ointment compared to hydrocolloid dressing to treat pressure ulcers. Meaume (2009)
27 looked at ornithine alpha-ketoglutarate, an amino acid salt, compared to placebo as a supplement to
28 treat heel pressure ulcers.

29 No randomised trials were identified regarding repositioning, electrotherapy, NPWT, HBOT,
30 debridement, antimicrobials, antibiotics, skin massage or rubbing.

31

Summary of included studies

Study	Intervention/comparator	Population	Outcome	Study length
Landi 2003 ¹⁰¹	Nerve growth factor Placebo	People in a nursing home with a stage 2 to 5 foot pressure ulcer (Yarkony classification)	<ul style="list-style-type: none"> • Reduction in ulcer area 	Six weeks of treatment or until complete healing
Meaume 2009 ¹¹⁴	10g sachet of ornithine alpha-ketoglutarate versus 1 sachet of placebo	Elderly people (geriatrics, internal medicine, physical medicine and rehabilitation, trauma, plastic surgery, cardiology, neurology and dermatology settings) who had pressure ulcers of the heel of stage 2 or 3 (NPUAP classification)	<ul style="list-style-type: none"> • % reduction in pressure ulcer surface area; more than 90% reduction by week 6; rate of complete healing (cm²/day); all-cause mortality 	6 weeks
Muller 2001 ¹²⁵	Hydrocolloid dressing Collagen dressing	Female inpatients with a grade 4 heel pressure ulcer	<ul style="list-style-type: none"> • Proportion of people completely healed • Time to healing 	Maximum 16 weeks
Russell 2000 ¹⁶¹	2 types of alternating cell mattress systems with pressure-relieving cushions: Huntleigh Nimbus 3 with Aura cushion and 4-hourly turning versus Pegasus Cairwave Therapy System with Proactive 2 seating cushion and 8-hourly turning.	People from care of the elderly units with pressure ulcer of grade 2 or above (Torrance classification system). Average age 83.9 and 84.6 years in the 2 groups.	<ul style="list-style-type: none"> • Ulcer healing at 12 and 18 months 	18-month follow-up

Table 197: Clinical evidence profile: Nimbus system versus Cairwave system

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Nimbus system	Cairwave system	Relative (95% CI)	Absolute		
Proportion of people with heel pressure ulcers completely healed – grade 2 and above heel pressure ulcers (Torrance)¹⁶¹												
1	Randomised trial	Serious ^a	No serious inconsistency	no serious indirectness	Serious ^b	None	24/55 (43.6%)	17/58 (29.3%)	RR 1.49 (0.9 to 2.45)	144 more per 1000 (from 29 fewer to 425 more)	Low	Critical
							-	29.3%		144 more per 1000 (from 29 fewer to 425 more)		
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality												
-	-	-	-	-	-	-	-	-	-	-	-	-

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Nimbus system	Cairwave system	Relative (95% CI)	Absolute		
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) No details of randomisation method were provided by the authors and there were unclear methods of allocation concealment.

(b) The confidence interval crossed 1 MID point.

Table 198: Clinical evidence profile: nerve growth factor versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Nerve growth factor	Placebo	Relative (95% CI)	Absolute		
Reduction in heel ulcer area (mm²) (better indicated by higher values) – grade 2-4 heel pressure ulcers (Yarkony)¹⁰¹												
1	Randomised trial	Serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	623 (SD 451) n=18	485 (SD 384) n=18	-	MD 138 higher (135.64 lower to 411.64 higher)	Low	Critical
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Nerve growth factor	Placebo	Relative (95% CI)	Absolute		
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

(a) Allocation according to age group, sex and ulcer area and blinding of nurses and outcome assessor but no blinding of patient.

(b) The confidence interval crosses 1 MID point.

Table 199: Clinical evidence profile: hydrocolloid dressing versus collagen dressing

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Collagen dressing	Relative (95% CI)	Absolute		
Proportion of people with heel pressure ulcers completely healed – general population – grade 4 heel pressure ulcers – classification system not reported¹²⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	7/11 (63.6%)	11/12 (91.7%)	RR 0.69 (0.43 to 1.12)	284 fewer per 1000 (from 522 fewer to 110 more)	Very low	Critical
							-	91.7%		284 fewer per 1000 (from 523 fewer to 110 more)		

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Hydrocolloid dressing	Collagen dressing	Relative (95% CI)	Absolute		
										110 more)		
Mean time to healing of heel pressure ulcers (weeks) – general population – grade 4 heel pressure ulcers – classification system not reported¹²⁵												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	14 (SD 4.6)	10 (SD 4.6)	-	MD 4 higher (0.24 to 7.76 higher)	Very low	Critical
Time to complete healing of pressure ulcers (time to event data)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Rate of reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in size or volume of pressure ulcers												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-												
Mortality												
-												
Health-related quality of life												
-												

(a) Müller (2001) did not report on sequence generation, allocation concealment or blinding.
 (b) The confidence interval crossed 1 MID point.

(c) The confidence interval crossed both MID points.

Table 200: Clinical evidence profile: ornithine alpha-ketoglutarate versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	10g Ornithine alpha-ketoglutarate	Placebo	Relative (95% CI)	Absolute		
Rate of complete healing of heel pressure ulcers (cm²/day) – elderly people – grade 2 or 3 heel pressure ulcers (NPUAP) (unclear if nutritionally deficient)¹¹⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	0.07 (s.d 0.11) n= 85	0.04 (s.d 0.08) n= 75	MD 0.03 higher (0 to 0.06 higher)	-	Very low	Critical
Mean % reduction in heel pressure ulcer size – elderly people – grade 2 or 3 heel pressure ulcers (NPUAP) (unclear if nutritionally deficient)¹¹⁴												
1	Randomised trial	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None ^f	59.5 (s.d 71.4) n= 85	54 (s.d 69) n= 75	MD 5.5 higher (16.28 lower to 27.28 higher)	-	Low	Critical
Mean surface area reduction (cm²) – elderly people – grade 2 or 3 heel pressure ulcers (NPUAP) (unclear if nutritionally deficient)¹¹⁴												
1	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	No serious	None ^f	2.3 (s.d 4.2) n= 85	1.7 (s.d 1.7) n= 75	MD 0.6 higher (0.37 lower to 1.57 higher)	-	Low	Critical
90% reduction by week 6 – elderly people – grade 2 or 3 heel pressure ulcers (NPUAP) (unclear if nutritionally deficient)¹¹⁴												
1	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	Serious ^b	None	23.4% n=85	13% n=75	OR 0.49 (CI 0.16 to 14.6) ^e	-	Very low	Critical
All-cause mortality – elderly people – grade 2 or 3 heel pressure ulcers (NPUAP) (unclear if nutritionally deficient)¹¹⁴												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	10g Ornithine alpha-ketoglutarate	Placebo	Relative (95% CI)	Absolute		
1	Randomised trials	Very serious ^a	No serious inconsistency	No serious indirectness	Very serious ^c	None	5/89 (5.6%)	3/76 (3.9%)	RR 1.42 (0.35 to 5.76)	17 more per 1000 (from 26 fewer to 188 more)	Very low	Important
							-	4%		17 more per 1000 (from 26 fewer to 190 more)		
Proportion of people with pressure ulcers completely healed												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time to complete healing												
-	-	-	-	-	-	-	-	-	-	-	-	-
Pain (wound-related)												
-	-	-	-	-	-	-	-	-	-	-	-	-
Time in hospital												
-	-	-	-	-	-	-	-	-	-	-	-	-
Acceptability of treatment												
-	-	-	-	-	-	-	-	-	-	-	-	-
Side effects												
-	-	-	-	-	-	-	-	-	-	-	-	-
Mortality												
-	-	-	-	-	-	-	-	-	-	-	-	-
Health-related quality of life												
-	-	-	-	-	-	-	-	-	-	-	-	-

- (a) *There was a very high drop-out in both arms. Due to problems in recruitment the study was opened up to other centres so some centres had 2 participants and randomisation was balanced by blocks of four. There were baseline differences. The missing data were higher than the event rate.*
- (b) *The confidence interval crossed 1 MID point.*
- (c) *The confidence interval crossed both MID points.*
- (d) *Value reported by study*
- (e) *Odds ratio reported by study.*

ANCOVA used. Non-parametric tests detected between-group differences ($p=0.044$) which were confirmed by parametric tests after log-transformation to normalise distribution ($p=0.027$ for group comparisons).

12.1.12 Economic evidence (adults)

2 Published literature

3 One study was included with a relevant comparison.¹²⁵ This is summarised in the economic evidence
4 profiles below (Table 201). See also the study selection flow chart in Appendix D and study evidence
5 tables in Appendix H.

6

Table 201: Economic evidence profile: hydrocolloid dressing versus collagen dressing

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost effectiveness	Uncertainty
Müller 2001 ¹²⁵ (Netherlands)	Partially applicable ^a	Potentially serious limitations ^b	Within trial analysis of a collagen dressing compared to a hydrocolloid dressing for heel ulcers, based on analysis of individual level resource use with unit costs applied.	£25	Pressure ulcers healed: -0.29 (p < 0.005)	Collagen dominates hydrocolloid	No useful sensitivity analyses reported.

(a) Study based in the Netherlands, quality of life not considered, costs based on 1998 values

(b) Small study, no unit cost source reported, no consideration of quality of life, no useful analysis of uncertainty reported

12.1.13 Clinical evidence (neonates, infants, children and young people)

- 2 No RCTs or cohort studies were identified. Recommendations were developed using a modified
3 Delphi consensus technique. Further details can be found in Appendix N.

12.1.14 Economic evidence (neonates, infants, children and young people)

- 5 No economic evidence was identified.

12.1.15 Evidence statements

12.1.5.71 Clinical (adults)

12.1.5.181 *Alternating pressure mattress (Nimbus system) versus alternating pressure mattress (Cairwave system)*

- 9
- 10 • One study (n=113) showed the nimbus system is potentially more clinically effective than the
11 cairwave system for complete healing of heel pressure ulcers (grade 2 and above pressure ulcers)
12 (low quality).
- 13 • No evidence was found for the following outcomes:
- 14 o Time to complete healing (time to event data)
- 15 o Rate of healing
- 16 o Rate of change in size of ulcer
- 17 o Reduction in size of ulcer and volume of ulcer
- 18 o Pain (wound-related)
- 19 o Time in hospital or NHS care
- 20 o Patient acceptability
- 21 o Side effects
- 22 o Mortality (all cause)
- 23 o Health-related quality of life
- 24

12.1.5.152 *Nerve growth factor versus placebo*

- 26 • One study (n=36) showed that nerve growth factor is potentially more clinically effective at
27 reducing the size of the heel ulcer area when compared to placebo (low quality).
- 28 • No evidence was found for the following outcomes:
- 29 o Time to complete healing (time to event data)
- 30 o Rate of healing
- 31 o Rate of change in size of ulcer
- 32 o Proportion of people completely healed
- 33 o Pain (wound-related)
- 34 o Time in hospital or NHS care
- 35 o Patient acceptability
- 36 o Side effects
- 37 o Mortality (all cause)
- 38 o Health-related quality of life
- 39

12.1.5.113 Hydrocolloid dressing versus collagen dressing

- 2 • One study (n= 23) showed that a collagen dressing is potentially more clinically effective than a
3 hydrocolloid dressing for complete healing of heel pressure ulcers (grade 4 pressure ulcers) (very
4 low quality).
- 5 • One study (n=24) showed a collagen dressing may be more clinically effective than a hydrocolloid
6 dressing for reducing the time to healing of heel pressure ulcers (grade 4 pressure ulcers) (very
7 low quality).
- 8 • No evidence was found for the following outcomes:
 - 9 o Time to complete healing (time to event data)
 - 10 o Rate of healing
 - 11 o Rate of change in size of ulcer
 - 12 o Reduction in size of ulcer and volume of ulcer.
 - 13 o Pain (wound-related)
 - 14 o Time in hospital or NHS care (continuous data)
 - 15 o Patient acceptability
 - 16 o Side effects
 - 17 o Mortality (all cause)
 - 18 o Health-related quality of life
 - 19

12.1.5.204 Ornithine alpha-ketoglutarate versus placebo

- 21 • One study (n=160) showed there is potentially no clinical difference between ornithine alpha-
22 ketoglutarate and placebo for rate of complete healing of heel pressure ulcers (grade 2 or 3
23 pressure ulcers), but the direction of the estimate of effect favoured ornithine alpha-
24 ketoglutarate (very low quality).
- 25 • One study (n=160) showed a clinical benefit of ornithine alpha-ketoglutarate mean reduction in
26 size (%) when compared to placebo (low quality).
- 27 • One study (n=160) showed no clinical difference between ornithine alpha-ketoglutarate and
28 placebo for mean reduction in size (cm²) but the direction of the estimate of effect favoured
29 ornithine alpha-ketoglutarate (low quality).
- 30 • One study (n=160) showed a clinical benefit of ornithine alpha-ketoglutarate for 90% reduction in
31 heel pressure ulcers compared to placebo (very low quality).
- 32 • One study (n=165) showed there may be no clinical difference between ornithine alpha-
33 ketoglutarate and placebo for mortality, but the direction of the estimate of effect favoured the
34 placebo (very low quality).
- 35 • No evidence was found for the following outcomes:
 - 36 o Time to complete healing (time to event data)
 - 37 o Rate of change in size of ulcer
 - 38 o Proportion of people completely healed
 - 39 o Pain (wound-related)
 - 40 o Time in hospital or NHS care (continuous data)
 - 41 o Patient acceptability
 - 42 o Side effects
 - 43 o Health-related quality of life
 - 44

12.1.512 Economic (adults)

- 2 • One cost-effectiveness analysis found that collagen is likely to dominate hydrocolloid (collagen is
3 less costly and more effective) in the treatment of heel pressure ulcers. This study was assessed
4 to be partially applicable with potentially serious limitations.

12.1.553 Clinical (neonates, infants, children and young people)

6 No evidence was identified.

12.1.574 Economic (neonates, infants, children and young people)

8 No evidence was identified.

12.2 Recommendations and link to evidence

12.2.01 Adults

Recommendations	48. Discuss with adults with a heel pressure ulcer a strategy to offload heel pressure as part of their individualised care plan.
Relative values of different outcomes	The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.
Trade off between clinical benefits and harms	<p>There was limited evidence from 4 studies, which included widely varying management techniques for the management of heel pressure ulcers. One study included 2 types of alternating pressure mattresses with pressure-relieving cushions and found 1 alternating pressure mattress (NIMBUS system) was more clinically beneficial than another alternating pressure mattress (CAREWAVE system) for complete healing of grade 2 and above heel pressure ulcers. There was, however, a difference in repositioning between the 2 arms which could confound results.</p> <p>One study looked at topical nerve growth factor (2.5S murine nerve growth factor) which was more clinically beneficial than placebo for the reduction in heel pressure ulcer area for grade 2 and above heel pressure ulcers.</p> <p>Another study on dressings identified that collagen dressing was more clinically beneficial for complete healing of heel pressure ulcers than hydrocolloid dressing. A final study found that a nutritional supplement, ornithine alpha-ketoglutarate, was clinically more beneficial than placebo for the percentage reduction in heel pressure ulcer size and 90% reduction in heel pressure ulcers.</p> <p>The GDG considered this information and noted that the management of heel ulcers had not been excluded from the other recommendations which had been drafted on ulcer management. Therefore it was decided that no individual recommendations relating to the management of heel ulcers using the interventions included in the guideline were needed.</p> <p>However, the GDG felt that it was important to highlight that people who had a heel pressure ulcer should be provided with a heel elevation strategy to ensure that pressure is relieved from the heel. No evidence to support a specific strategy was identified.</p>
Economic considerations	<p>One economic analysis was identified for this question however this looked at dressings rather than heel elevation strategies.</p> <p>Once a heel pressure ulcer has developed, pressure must be relieved from the heels.</p>

	The GDG acknowledged that there may be resource implications associated with a heel elevation strategy, but asserted that pressure must be relieved immediately to prevent further pressure damage. Further pressure damage would lead to reductions in quality of life and escalated treatment costs.
Quality of evidence	There was little evidence on the management of heel pressure ulcers. The evidence available was graded low to very low due to serious or very serious imprecision and study limitations. There were no interventions specifically aimed at managing heel pressure ulcers.
Other considerations	Heel ulcers are often found in association with peripheral arterial disease and recommendations on the management of peripheral arterial disease can be found in NICE clinical guideline ¹⁴⁷ 'Lower limb peripheral arterial disease'. For recommendations on the prevention of heel pressure ulcers please see part 1 'Prevention of pressure ulcers'.

12.2.12 Neonates, infants, children and young people

Recommendations	49. Discuss with parents or carers of neonates and infants and with children and young people, a strategy to offload heel pressure as part of their individualised care plan, taking into account differences in size, mobility, pain and tolerance.
Relative values of different outcomes	The GDG identified that the proportion of people with pressure ulcers completely healed, time to complete healing, reduction in size and volume and rate of reduction in size and volume of pressure ulcers were the most critical outcomes to inform decision making.
Trade off between clinical benefits and harms	The GDG used 1 statement from the Delphi consensus panel to develop the recommendation, 'Healthcare professionals should treat heel pressure ulcers in neonates, infants, children and young people in line with treatments for adults.' The statement was not accepted during Round 1 of the Delphi consensus survey. The GDG therefore discussed treatment of heel pressure ulcers. Comments received during Round 1 had highlighted that although treatment in children was likely to be similar to adults, there may be differences arising from variation in size, mobility and tolerability and the statement was amended to reflect this. The statement 'Healthcare professionals should treat heel pressure ulcers in neonates, infants, children and young people in line with treatment for adults, taking in account differences in size, mobility and tolerability.' was therefore included in round 2 of the survey. The statement was accepted. Qualitative responses gathered during round 2 of the survey highlighted that there was limited evidence relating to neonates, infants, children and young people and supported the statement. The GDG therefore chose to develop a recommendation highlighting that the treatment of heel pressure ulcers in neonates, infants, children and young people was likely to be similar to adults and was likely to focus on pressure redistribution using appropriate strategies.
Economic considerations	The GDG agreed that the cost-effective strategies for the treatment of heel pressure ulcers were likely to be similar to those identified for adults. Additional considerations of size, mobility and pain tolerance will allow more effective, efficient treatment, and mean economic and clinical benefits can be realised as early as possible.
Quality of evidence	No RCTs or cohort studies were identified for neonates, infants, children or young

	<p>people. Formal consensus using a modified Delphi was therefore used to develop the recommendation.</p> <p>To inform the recommendation, the GDG used 1 statement which was included in Round 1 of the Delphi consensus survey and reached 43% consensus agreement. The latter statement was therefore included in Round 2 of the survey, where it reached 84% consensus agreement.</p> <p>Further details can be found in Appendix N.</p>
Other considerations	<p>The GDG noted that in neonates, infants, children and young people there were specific at risk sites which should be considered, for example the head and scalp, in addition to heels.</p>

1

2

13 References

- 2 1 NHS Supply Chain Catalogue. NHS Supply Chain, 2013 Available from:
3 <http://www.supplychain.nhs.uk/>
- 4 2 Adegoke BO, Badmos KA. Acceleration of pressure ulcer healing in spinal cord injured patients
5 using interrupted direct current. *African Journal of Medicine and Medical Sciences*. 2001;
6 30(3):195-197
- 7 3 Adunsky A, Ohry A, DDCT Group. Decubitus direct current treatment (DDCT) of pressure ulcers:
8 results of a randomized double-blinded placebo controlled study. *Archives of Gerontology and*
9 *Geriatrics*. 2005; 41(3):261-269
- 10 4 Agren MS, Stromberg HE. Topical treatment of pressure ulcers. A randomized comparative trial
11 of Varidase and zinc oxide. *Scandinavian Journal of Plastic and Reconstructive Surgery*. 1985;
12 19(1):97-100
- 13 5 Ahmad ET. High-voltage pulsed galvanic stimulation: effect of treatment duration on healing of
14 chronic pressure ulcers. *Annals of Burns and Fire Disasters*. 2008; 21(3):124-128
- 15 6 Allman RM, Walker JM, Hart MK, Laprade CA, Noel LB, Smith CR. Air-fluidized beds or
16 conventional therapy for pressure sores. A randomized trial. *Annals of Internal Medicine*. 1987;
17 107(5):641-648
- 18 7 Alm A, Hornmark AM, Fall PA, Linder L, Bergstrand B, Ehrnebo M et al. Care of pressure sores: a
19 controlled study of the use of a hydrocolloid dressing compared with wet saline gauze
20 compresses. *Acta Dermato-Venereologica*. 1989; 149:1-10
- 21 8 Alvarez OM, Fernandez-Obregon A, Rogers RS, Bergamo L, Masso J, Black M. Chemical
22 debridement of pressure ulcers: a prospective, randomized, comparative trial of collagenase
23 and papain/urea formulations. *Wounds: A Compendium of Clinical Research and Practice*.
24 2000; 12(2):15-25
- 25 9 Alvey B, Hennen N, Heard H. Improving accuracy of pressure ulcer staging and documentation
26 using a computerized clinical decision support system. *Journal of Wound, Ostomy and*
27 *Continence Nursing*. 2012; 39(6):607-612
- 28 10 Amione P, Ricci E, Topo F, Izzo L, Pirovano R, Rega V et al. Comparison of Allevyn Adhesive and
29 Biatain Adhesive in the management of pressure ulcers. *Journal of Wound Care*. 2005;
30 14(8):365-370
- 31 11 Anthony D. Measuring pressure sores. *Nursing Times*. 1985; 81(22):57-61
- 32 12 Asbjornsen G, Hernaes B, Molvaer G. The effect of transcutaneous electrical nerve stimulation
33 on pressure sores in geriatric patients. *Journal of Clinical and Experimental Gerontology*. 1990;
34 12(4):209-214
- 35 13 Ashby RL, Dumville JC, Soares MO, McGinnis E, Stubbs N, Torgerson DJ et al. A pilot
36 randomised controlled trial of negative pressure wound therapy to treat grade III/IV pressure
37 ulcers [ISRCTN69032034]. *Trials*. 2012; 13:119

- 1 14 Baker LL, Rubayi S, Villar F, Demuth SK. Effect of electrical stimulation waveform on healing of
2 ulcers in human beings with spinal cord injury. *Wound Repair and Regeneration*. 1996; 4(1):21-
3 28
- 4 15 Bale S, Banks V, Haglestein S, Harding KG. A comparison of two amorphous hydrogels in the
5 debridement of pressure sores. *Journal of Wound Care*. 1998; 7(2):65-68
- 6 16 Bale S, Haglestein S, Banks V, Harding KG. Costs of dressings in the community. *Journal of*
7 *Wound Care*. 1998; 7(7):327-330
- 8 17 Bale S, Squires D, Varnon T, Walker A, Benbow M, Harding KG. A comparison of two dressings
9 in pressure sore management. *Journal of Wound Care*. 1997; 6(10):463-466
- 10 18 Banks V, Bale S, Harding K. Comparing two dressings for exuding pressure sores in community
11 patients. *Journal of Wound Care*. 1994; 3(4):175-178
- 12 19 Banks V, Bale S, Harding K. The use of two dressings for moderately exuding pressure sores.
13 *Journal of Wound Care*. 1994; 3(3):132-134
- 14 20 Beeckman D, Schoonhoven L, Boucque H, Van Maele G, Defloor T. Pressure ulcers: e-learning
15 to improve classification by nurses and nursing students. *Journal of Clinical Nursing*. 2008;
16 17(13):1697-1707
- 17 21 Beeckman D, Schoonhoven L, Fletcher J, Furtado K, Gunningberg L, Heyman H et al. EPUAP
18 classification system for pressure ulcers: European reliability study. *Journal of Advanced*
19 *Nursing*. 2007; 60(6):682-691
- 20 22 Beeckman D, Schoonhoven L, Fletcher J, Furtado K, Heyman H, Paquay L et al. Pressure ulcers
21 and incontinence-associated dermatitis: effectiveness of the Pressure Ulcer Classification
22 education tool on classification by nurses. *Quality and Safety in Health Care*. 2010; 19(5):e3
- 23 23 Bellingeri A., Attolini R., Fioretti C, Scalise A., Forma O., Trapedini P. et al. Evaluation of the
24 efficacy of a preparation for the cleansing of cutaneous injuries. *Minerva Medica*. 2004; 95
25 (suppl):1-9
- 26 24 Belmin J, Meaume S, Rabus MT, Bohbot S. Sequential treatment with calcium alginate
27 dressings and hydrocolloid dressings accelerates pressure ulcer healing in older subjects: A
28 multicenter randomized trial of sequential versus nonsequential treatment with hydrocolloid
29 dressings alone. *Journal of the American Geriatrics Society*. 2002; 50(2):269-274
- 30 25 Benati G, Delvecchio S, Cilla D, Pedone V. Impact on pressure ulcer healing of an arginine-
31 enriched nutritional solution in patients with severe cognitive impairment. *Archives of*
32 *Gerontology and Geriatrics Supplement*. 2001; 7:43-47
- 33 26 Berg W, Traneroth C, Gunnarsson A, Lossing C. A method for measuring pressure sores. *Lancet*.
34 1990; 335(8703):1445-1446
- 35 27 Bergemann R, Lauterbach KW, Vanscheidt W, Neander K, Engst R. Economic evaluation of the
36 treatment of chronic wounds: hydroactive wound dressings in combination with enzymatic
37 ointment versus gauze dressings in patients with pressure ulcer and venous leg ulcer in
38 Germany. *Pharmacoeconomics*. 1999; 16(4):367-377

- 1 28 Bito S, Mizuhara A, Oonishi S, Takeuchi K, Suzuki M, Akiyama K et al. Randomised controlled
2 trial evaluating the efficacy of wrap therapy for wound healing acceleration in patients with
3 NPUAP stage II and III pressure ulcer. *BMJ*. 2012; 2:1-8
- 4 29 Branom R, Rappl LM. "Constant force technology" versus low-air-loss therapy in the treatment
5 of pressure ulcers. *Ostomy/Wound Management*. 2001; 47(9):38-46
- 6 30 Brewer RD, Jr., Mihaldzic N, Dietz A. The effect of oral zinc sulfate on the healing of decubitus
7 ulcers in spinal cord injured patients. *Proceedings of the Annual Clinical Spinal Cord Injury*
8 *Conference*. 1967; 16:70-72
- 9 31 Brod M, McHenry E, Plasse TF, Fedorczyk D, Trout JR. A randomized comparison of poly-hema
10 and hydrocolloid dressings for treatment of pressure sores. *Archives of Dermatology*. 1990;
11 126(7):969-970
- 12 32 Brown-Etris M, Punchello M, O'Connor T, Milne C, Orsted H, Couture N et al. A randomized
13 comparative clinical evaluation of a transparent absorbent acrylic dressing and a hydrocolloid
14 dressing on stage II and III pressure ulcers. *Journal of Wound, Ostomy and Continence Nursing*.
15 2006; 33(3S):Supplement
- 16 33 Buckley KM, Tran BQ, Adelson LK, Agazio JG, Halstead L. The use of digital images in evaluating
17 homecare nurses' knowledge of wound assessment. *Journal of Wound, Ostomy and*
18 *Continence Nursing*. 2005; 32(5):307-316
- 19 34 Buntinx F, Beckers H, De Keyser G, Flour M, Nissen G, Raskin T et al. Inter-observer variation in
20 the assessment of skin ulceration. *Journal of Wound Care*. 1996; 5(4):166-170
- 21 35 Burgos A, Gimenez J, Moreno E, Campos J, Ardanaz J, Talaero C et al. Collagenase ointment
22 application at 24- versus 48-hour intervals in the treatment of pressure ulcers. A randomised
23 multicentre study. *Clinical Drug Investigation*. 2000; 19(6):399-407
- 24 36 Burgos A, Gimenez J, Moreno E, Lamberto E, Utrera M, Urraca EM et al. Cost, efficacy,
25 efficiency and tolerability of collagenase ointment versus hydrocolloid occlusive dressing in the
26 treatment of pressure ulcers: a comparative, randomised, multicentre study. *Clinical Drug*
27 *Investigation*. 2000; 19(5):357-365
- 28 37 Burke DT, Ho CHK, Saucier MA, Stewart G. Effects of hydrotherapy on pressure ulcer healing.
29 *American Journal of Physical Medicine and Rehabilitation*. 1998; 77(5):394-398
- 30 38 Caley L, Jones S, Freer J. Randomized Prospective Trial: Treatment Outcomes and Cost-
31 Effectiveness of Two Types of Low-Air-Loss Therapy. 9th Annual Clinical Symposium on
32 Pressure Ulcer and Wound Management Nashville, TN. 1994;1-2
- 33 39 Cassino R, Ippolito AM, Cuffaro C, Corsi A, Ricci E. A controlled, randomised study on the
34 efficacy of two overlays in the treatment of decubitus ulcers. *Minerva Chirurgica*. 2013;
35 68(1):105-116
- 36 40 Cereda E, Gini A, Pedrolli C, Vanotti A. Disease-specific, versus standard, nutritional support for
37 the treatment of pressure ulcers in institutionalized older adults: a randomized controlled trial.
38 *Journal of the American Geriatrics Society*. 2009; 57(8):1395-1402
- 39 41 Chang KW, Alsagoff S, Ong KT, Sim PH. Pressure ulcers--randomised controlled trial comparing
40 hydrocolloid and saline gauze dressings. *Medical Journal of Malaysia*. 1998; 53(4):428-431

- 1 42 Chernoff RS, Milton KY, Lipschitz DA. The effect of a very high-protein liquid formula on
2 decubitus ulcers healing in long-term tube-fed institutionalized patients. *Journal of the*
3 *American Dietetic Association*. 1990; 90:A-130
- 4 43 Chuangsuwanich A, Charnsanti O, Lohsiriwat V, Kangwanpoom C, Thong-In N. The efficacy of
5 silver mesh dressing compared with silver sulfadiazine cream for the treatment of pressure
6 ulcers. *Journal of the Medical Association of Thailand*. 2011; 94(5):559-565
- 7 44 Clark M. A randomised controlled trial comparing the healing of pressure sores upon two
8 pressure-redistributing seat cushions. *Proceedings of the 7th European Conference on*
9 *Advances in Wound Management*. Harrogate, UK 1998;122-125
- 10 45 Colin D, Kurring PA, Quinlan D, Yvon C. The clinical investigation of an amorphous hydrogel
11 compared with a dextranomer paste dressing in the management of sloughy pressure sores.
12 *Proceedings of the 5th European Conference on Advances in Wound Management*. London
13 1996;22-25
- 14 46 Colwell J, Foreman M, Trotter J. A comparison of the efficacy and cost-effectiveness of two
15 methods of managing pressure ulcers. *Decubitus*. 1993; 6:28-36
- 16 47 Curtis L. Unit costs of health and social care 2012. Canterbury: Personal Social Services Reseach
17 Unit, University of Kent; 2012. Available from:
18 <http://www.pssru.ac.uk/archive/pdf/uc/uc2012/full-with-covers.pdf>
- 19 48 Cutler NR, George R, Seifert RD, Brunelle R, Sramek JJ, McNeill K et al. Comparison of
20 quantitative methodologies to define chronic pressure ulcer measurements. *Decubitus*. 1993;
21 6(6):22-30
- 22 49 Darkovich SL, Brown-Etris M, Spencer M. Biofilm hydrogel dressing: a clinical evaluation in the
23 treatment of pressure sores. *Ostomy/Wound Management*. 1990; 29:47-60
- 24 50 Day A, Dombranski S, Farkas C, Foster C, Godin J, Moody M et al. Managing sacral pressure
25 ulcers with hydrocolloid dressings: results of a controlled, clinical study. *Ostomy/Wound*
26 *Management*. 1995; 41(2):52-65
- 27 51 Day A, Leonard F. Seeking quality care for patients with pressure ulcers. *Decubitus*. 1993;
28 6(1):32-43
- 29 52 Defloor T, Schoonhoven L, Katrien V, Weststrate J, Myny D. Reliability of the European Pressure
30 Ulcer Advisory Panel classification system. *Journal of Advanced Nursing*. 2006; 54(2):189-198
- 31 53 Defloor T, Schoonhoven L. Inter-rater reliability of the EPUAP pressure ulcer classification
32 system using photographs. *Journal of Clinical Nursing*. 2004; 13(8):952-959
- 33 54 Desneves KJ, Todorovic BE, Cassar A, Crowe TC. Treatment with supplementary arginine,
34 vitamin C and zinc in patients with pressure ulcers: a randomised controlled trial. *Clinical*
35 *Nutrition*. 2005; 24(6):979-987
- 36 55 Devine B. Alternating pressure air mattresses in the management of established pressure
37 sores. *Journal of Tissue Viability*. 1995; 5(3):94-98
- 38 56 Evans D, Land L, Geary A. A clinical evaluation of the Nimbus 3 alternating pressure mattress
39 replacement system. *Journal of Wound Care*. 2000; 9(4):181-186

- 1 57 Ewing MR, Garrow C, Presley TA, Ashley C, Kisella NM. Further experiences in the use of sheep
2 skins as an aid in nursing. *Australian Nurses' Journal*. 1964;215-219
- 3 58 Felzani G, Spoletini I, Convento A, Di LB, Rossi P, Miceli M et al. Effect of lysine hyaluronate on
4 the healing of decubitus ulcers in rehabilitation patients. *Advances in Therapy*. 2011;
5 28(5):439-445
- 6 59 Ferrell BA, Osterweil D, Christenson P. A randomized trial of low-air-loss beds for treatment of
7 pressure ulcers. *JAMA*. 1993; 269(4):494-497
- 8 60 Feuchtinger J, de BR, Dassen T, Halfens R. A 4-cm thermoactive viscoelastic foam pad on the
9 operating room table to prevent pressure ulcer during cardiac surgery. *Journal of Clinical
10 Nursing*. 2006; 15(2):162-167
- 11 61 Fleurence RL. Cost-effectiveness of pressure-relieving devices for the prevention and treatment
12 of pressure ulcers. *International Journal of Technology Assessment in Health Care*. 2005;
13 21(3):334-341
- 14 62 Foglia E, Restelli U, Napoletano AM, Coclite D, Porazzi E, Bonfanti M et al. Pressure ulcers
15 management: an economic evaluation. *Journal of Preventive Medicine and Hygiene*. 2012;
16 53(1):30-36
- 17 63 Ford CN, Reinhard ER, Yeh D, Syrek D, De Las Morenas A, Bergman SB et al. Interim analysis of
18 a prospective, randomized trial of vacuum-assisted closure versus the healthpoint system in
19 the management of pressure ulcers. *Annals of Plastic Surgery*. 2002; 49(1):55-61
- 20 64 Franek A, Kostur R, Polak A, Taradaj J, Szlachta Z, Blaszczyk E et al. Using high-voltage electrical
21 stimulation in the treatment of recalcitrant pressure ulcers: results of a randomized, controlled
22 clinical study. *Ostomy/Wound Management*. 2012; 58(3):30-44
- 23 65 Franek A, Kostur R, Taradaj J, Blaszczyk E, Szlachta Z, Dolibog P. Effect of high voltage
24 monophasic stimulation on pressure ulcer healing: results from a randomized controlled trial.
25 *Wounds: A Compendium of Clinical Research and Practice*. 2011; 23(1):15-23
- 26 66 Frantz RA, Johnson DA. Stereophotography and computerized image analysis: a three-
27 dimensional method of measuring wound healing. *Wounds*. 1992; 4:58-64
- 28 67 Gentzkow GD, Pollack VP, Kloth LC, Stubbs HA. Improved healing of pressure ulcers using
29 Dermapulse, a new electrical stimulation device. *Wounds: A Compendium of Clinical Research
30 and Practice*. 1991; 3(5):158-170
- 31 68 Gerding GA, Browning JS, Gerding GA, Browning JS. Oxyquinoline-containing ointment vs.
32 standard therapy for stage I and stage II skin lesions. *Dermatology Nursing*. 1992; 4(5):389-398
- 33 69 Graumlich JF, Blough LS, McLaughlin RG, Milbrandt JC, Calderon CL, Agha SA et al. Healing
34 pressure ulcers with collagen or hydrocolloid: a randomized, controlled trial. *Journal of the
35 American Geriatrics Society*. 2003; 51(2):147-154
- 36 70 Griffin JW, Tolley EA, Tooms RE, Reyes RA, Clift JK. A comparison of photographic and
37 transparency-based methods for measuring wound surface area. *Physical Therapy*. 1993;
38 73(2):117-122

- 1 71 Griffin JW, Tooms RE, Mendius RA, Clifft JK, Vander Zwaag R, el-Zeky F. Efficacy of high voltage
2 pulsed current for healing of pressure ulcers in patients with spinal cord injury. *Physical*
3 *Therapy*. 1991; 71(6):433-434
- 4 72 Griffiths RD, Fernandez RS, Ussia CA. Is tap water a safe alternative to normal saline for wound
5 irrigation in the community setting? *Journal of Wound Care*. 2001; 10(10):407-411
- 6 73 Groen HW, Groenier KH, Schuling J. Comparative study of a foam mattress and a water
7 mattress. *Journal of Wound Care*. 1999; 8(7):333-335
- 8 74 Gunes UY, Eser I. Effectiveness of a honey dressing for healing pressure ulcers. *Journal of*
9 *Wound, Ostomy and Continence Nursing*. 2007; 34(2):184-190
- 10 75 Harding K, Cutting K, Price P. The cost-effectiveness of wound management protocols of care.
11 *British Journal of Nursing*. 2000; 9(19 Tissue Viability Supplement):S6, S8, S10-S6, S8, S20
- 12 76 Hart S, Bergquist S, Gajewski B, Dunton N. Reliability testing of the National Database of
13 Nursing Quality Indicators pressure ulcer indicator. *Journal of Nursing Administration*. 2010;
14 40(10 Suppl):S16-S25
- 15 77 Hayward PG, Hillman GR, Quast MJ, Robson MC. Surface area measurement of pressure sores
16 using wound molds and computerized imaging. *Journal of the American Geriatrics Society*.
17 1993; 41(3):238-240
- 18 78 Healey F. The reliability and utility of pressure sore grading scales. *Journal of Tissue Viability*.
19 1995; 5:111-114
- 20 79 Hirshberg J, Coleman J, Marchant B, Rees RS. TGF-beta3 in the treatment of pressure ulcers: a
21 preliminary report. *Advances in Skin and Wound Care*. 2001; 14(2):91-95
- 22 80 Hisashige A, Ohura T. Cost-effectiveness of nutritional intervention on healing of pressure
23 ulcers. *Clinical Nutrition*. 2012; 31(6):868-874
- 24 81 Hollisaz MT, Khedmat H, Yari F. A randomized clinical trial comparing hydrocolloid, phenytoin
25 and simple dressings for the treatment of pressure ulcers [ISRCTN33429693]. *BMC*
26 *Dermatology*. 2004; 4(1):18-26
- 27 82 Honde C, Derks C, Tudor D. Local treatment of pressure sores in the elderly: Amino acid
28 copolymer membrane versus hydrocolloid dressing. *Journal of the American Geriatrics Society*.
29 1994; 42(11):1180-1183
- 30 83 Houghton PE, Campbell KE, Fraser CH, Harris C, Keast DH, Potter PJ et al. Electrical stimulation
31 therapy increases rate of healing of pressure ulcers in community-dwelling people with spinal
32 cord injury. *Archives of Physical Medicine and Rehabilitation*. 2010; 91(5):669-678
- 33 84 Jercinovic A, Karba R, Vodovnik L, Stefanovska A, Kroselj P, Turk R et al. Low frequency pulsed
34 current and pressure ulcer healing. *IEEE Transactions on Rehabilitation Engineering*. 1994;
35 2(4):225-233
- 36 85 Joint Formulary Committee. British national formulary. 61st edition. London: British Medical
37 Association and Royal Pharmaceutical Society; 2011. Available from: <http://www.bnf.org.uk>

- 1 86 Karba R, Semrov D, Vodovnik L, Benko H, Savrin R. DC electrical stimulation for chronic wound
2 healing enhancement. Part 1. Clinical study and determination of electrical field distribution in
3 the numerical wound model. *Bioelectrochemistry and Bioenergetics*. 1997; 43(2):265-270
- 4 87 Kaya AZ, Turani N, Akyuz M. The effectiveness of a hydrogel dressing compared with standard
5 management of pressure ulcers. *Journal of Wound Care*. 2005; 14(1):42-44
- 6 88 Kelly J, Isted M. Assessing nurses' ability to classify pressure ulcers correctly. *Nursing Standard*.
7 2011; 26(7):62-66
- 8 89 Keogh A, Dealey C. Profiling beds versus standard hospital beds: effects on pressure ulcer
9 incidence outcomes. *Journal of Wound Care*. 2001; 10(2):15-19
- 10 90 Kerihuel JC. Effect of activated charcoal dressings on healing outcomes of chronic wounds.
11 *Journal of Wound Care*. 2010; 19(5):208-215
- 12 91 Kerstein MD. Unexpected economics of ulcer care protocols. *Southern Medical Journal*. 2004;
13 97(2):135-136
- 14 92 Kerstein MD, Gemmen E, van RL, Lyder CH, Phillips T, Xakellis G et al. Cost and cost
15 effectiveness of venous and pressure ulcer protocols of care. *Disease Management and Health
16 Outcomes*. 2001; 9(11):651-663
- 17 93 Kim YC, Shin JC, Park CI, Oh SH, Choi SM, Kim YS. Efficacy of hydrocolloid occlusive dressing
18 technique in decubitus ulcer treatment: a comparative study. *Yonsei Medical Journal*. 1996;
19 37(3):181-185
- 20 94 Kloth LC, Feedar JA. Acceleration of wound healing with high voltage, monophasic, pulsed
21 current *Phys Ther* 1989 Aug;69(8):702. *Physical Therapy*. 1988; 68(4):503-508
- 22 95 Knudsen L, Solvhoj L, Christensen B. The use of a haemodialysate in the treatment of decubital
23 ulcer: A double-blind randomized clinical study. *Current Therapeutic Research - Clinical and
24 Experimental*. 1982; 32(3):498-504
- 25 96 Kordestani S, Shahrezaee M, Tahmasebi MN, Hajimahmodi H, Haji GD, Abyaneh MS. A
26 randomised controlled trial on the effectiveness of an advanced wound dressing used in Iran.
27 *Journal of Wound Care*. 2008; 17(7):323-327
- 28 97 Kottner J, Halfens R, Dassen T. An interrater reliability study of the assessment of pressure
29 ulcer risk using the Braden scale and the classification of pressure ulcers in a home care setting.
30 *International Journal of Nursing Studies*. 2009; 46(10):1307-1312
- 31 98 Kraft MR, Lawson LL, Pohlmann B, Reid-Lokos C, Barder L. A comparison of epi-lock and saline
32 dressings in the treatment of pressure ulcers. *Decubitus*. 1993; 6(6):42-48
- 33 99 Kranke P, Bennett MH, Martyn-St JM, Schnabel A, Debus SE. Hyperbaric oxygen therapy for
34 chronic wounds. *Cochrane Database of Systematic Reviews*. 2012; Issue 4:CD004123.
35 DOI:10.1002/14651858.CD004123.pub3
- 36 100 Kuflik A, Stillo JV, Sanders D, Roland K, Sweeney T, Lemke PM. Petrolatum versus Resurfix
37 ointment in the treatment of pressure ulcers. *Ostomy/Wound Management*. 2001; 47(2):52-56

- 1 101 Landi F, Aloe L, Russo A, Cesari M, Onder G, Bonini S et al. Topical Treatment of Pressure Ulcers
2 with Nerve Growth Factor: A Randomized Clinical Trial. *Annals of Internal Medicine*. 2003;
3 139(8):635-642
- 4 102 Langer G, Schloemer G, Knerr A, Kuss O, Behrens J. Nutritional interventions for preventing and
5 treating pressure ulcers. *Cochrane Database of Systematic Reviews*. 2003; Issue 4:CD003216.
6 DOI:10.1002/14651858.CD003216
- 7 103 Lee JK, Ambrus JL. Collagenous therapy for decubitus ulcers. *Geriatrics*. 1975; 30(5):91-98
- 8 104 Lee SK, Posthauer ME, Dorner B, Redovian V, Maloney MJ. Pressure ulcer healing with a
9 concentrated, fortified, collagen protein hydrolysate supplement: a randomized controlled
10 trial. *Advances in Skin and Wound Care*. 2006; 19(2):92-96
- 11 105 Leigh B, Desneves K, Rafferty J, Pearce L, King S, Woodward MC et al. The effect of different
12 doses of an arginine-containing supplement on the healing of pressure ulcers. *Journal of*
13 *Wound Care*. 2012; 21(3):150-156
- 14 106 Ljungberg S. Comparison of dextranomer paste and saline dressings for management of
15 decubital ulcers. *Clinical Therapeutics*. 1998; 20(4):737-743
- 16 107 Lucas C, Classen J, Harrison D, De H. Pressure ulcer surface area measurement using instant
17 full-scale photography and transparency tracings. *Advances in Skin and Wound Care*. 2002;
18 15(1):17-23
- 19 108 Makhsous M, Lin F, Knaus E, Zeigler M, Rowles DM, Gittler M et al. Promote pressure ulcer
20 healing in individuals with spinal cord injury using an individualized cyclic pressure-relief
21 protocol. *Advances in Skin and Wound Care*. 2009; 22(11):514-521
- 22 109 Marrie RA, Ross JB, Rockwood K. Pressure Ulcers: Prevalence, Staging, and Assessment of Risk.
23 *Geriatrics Today*. 2003; 6(3):134-140
- 24 110 Matzen S, Peschardt A, Alsbjorn B. A new amorphous hydrocolloid for the treatment of
25 pressure sores: A randomised controlled study. *Scandinavian Journal of Plastic and*
26 *Reconstructive Surgery and Hand Surgery*. 1999; 33(1):13-15
- 27 111 McGinnis E, Stubbs N. Pressure-relieving devices for treating heel pressure ulcers. *Cochrane*
28 *Database of Systematic Reviews*. 2011; Issue 9:CD005485.
29 DOI:10.1002/14651858.CD005485.pub2
- 30 112 Meaume, -D-Vallet, MN M, -L-Teot. [Evaluation of a silverf__releasing hydroalginate dressing in
31 chronic wounds with signs of local infection]. *Zeitschrift Fur Wundheilung*. 2006; 11:236f
- 32 113 Meaume S, Gemmen E. Cost-effectiveness of wound management in France: pressure ulcers
33 and venous leg ulcers. *Journal of Wound Care*. 2002; 11(6):219-224
- 34 114 Meaume S, Kerihuel JC, Constans T, Teot L, Lerebours E, Kern J et al. Efficacy and safety of
35 ornithine alpha-ketoglutarate in heel pressure ulcers in elderly patients: results of a
36 randomized controlled trial. *Journal of Nutrition, Health and Aging*. 2009; 13(7):623-630
- 37 115 Meaume S, Vallet D, Morere MN, Teot L. Evaluation of a silver-releasing hydroalginate dressing
38 in chronic wounds with signs of local infection. *Journal of Wound Care*. 2005; 14(9):411-419

- 1 116 Meaume S, Van De Looverbosch D, Heyman H, Romanelli M, Ciangherotti A, Charpin S. A study
2 to compare a new self-adherent soft silicone dressing with a self-adherent polymer dressing in
3 stage II pressure ulcers. *Ostomy/Wound Management*. 2003; 49(9):44-51
- 4 117 Milne C, Ciccarelli A, Lassy M. A comparison of collagenase to hydrogel dressings in
5 maintenance debridement and wound closure. *Wounds: A Compendium of Clinical Research
6 and Practice*. 2012; 24(11):317-322
- 7 118 Mittmann N, Chan BC, Craven BC, Isogai PK, Houghton P. Evaluation of the cost-effectiveness
8 of electrical stimulation therapy for pressure ulcers in spinal cord injury. *Archives of Physical
9 Medicine and Rehabilitation*. 2011; 92(6):866-872
- 10 119 Moberg S, Hoffman L, Grennert ML, Holst A. A randomized trial of cadexomer iodine in
11 decubitus ulcers. *Journal of the American Geriatrics Society*. 1983; 31(8):462-465
- 12 120 Moore ZEH, Cowman S. Wound cleansing for pressure ulcers. *Cochrane Database of Systematic
13 Reviews*. 2013; Issue 3:CD004983. DOI:10.1002/14651858.CD004983.pub3
- 14 121 Mosher BA, Cuddigan J, Thomas DR, Boudreau DM. Outcomes of 4 methods of debridement
15 using a decision analysis methodology. *Advances in Wound Care*. 1999; 12(2):81-88
- 16 122 Motta G, Dunham L, Dye T, Mentz J, O'Connell-Gifford E, Smith E. Clinical efficacy and cost-
17 effectiveness of a new synthetic polymer sheet wound dressing. *Ostomy/Wound Management*.
18 1999; 45(10):41-49
- 19 123 Mulder GD, Taro N, Seeley J, Andrews K. A study of pressure ulcer response to low air loss beds
20 vs. conventional treatment. *Journal of Geriatric Dermatology*. 1994; 2(3):87-91
- 21 124 Mulder GD, Altman M, Seeley JE, Tintle T. Prospective randomized study of the efficacy of
22 hydrogel, hydrocolloid, and saline solution-moistened dressings on the management of
23 pressure ulcers. *Wound Repair and Regeneration*. 1993; 1(4):213-218
- 24 125 Muller E, van Leen MWF, Bergemann R. Economic evaluation of collagenase-containing
25 ointment and hydrocolloid dressing in the treatment of pressure ulcers. *Pharmacoeconomics*.
26 2001; 19(12):1209-1216
- 27 126 Munro BH, Brown L, Heitman BB. Pressure ulcers: one bed or another? *Geriatric Nursing*. 1989;
28 10(4):190-192
- 29 127 Münter KC, Beele H, Russell L, Crespi A, Gröchenig E, Basse P et al. Effect of a sustained silver-
30 releasing dressing on ulcers with delayed healing: the CONTOP study. *Journal of Wound Care*.
31 2006; 15(5):199-206
- 32 128 Mustoe TA, Cutler NR, Allman RM, Goode PS, Deuel TF, Prause JA et al. A phase II study to
33 evaluate recombinant platelet-derived growth factor- BB in the treatment of stage 3 and 4
34 pressure ulcers. *Archives of Surgery*. 1994; 129(2):213-219
- 35 129 Nasar MA, Morley R. Cost effectiveness in treating deep pressure sores and ulcers. *Practitioner*.
36 1982; 226(1364):307-310
- 37 130 National Collaborating Centre for Acute Care. Nutrition support in adults: oral nutrition
38 support, enteral tube feeding and parenteral nutrition. NICE clinical guideline 32. London.
39 Royal College of Surgeons of England, 2006 Available from: <http://guidance.nice.org.uk/CG32>

- 1 131 National Institute for Health and Clinical Excellence. The guidelines manual. London: National
 2 Institute for Health and Clinical Excellence; 2012. Available from:
 3 <http://publications.nice.org.uk/the-guidelines-manual-pmg6/>
- 4 132 National Pressure Ulcer Advisory Panel (NPUAP) and European Pressure Ulcer Advisory Panel
 5 (EPUAP). Treatment of pressure ulcers. Quick reference guide. Washington, D.C.. National
 6 Pressure Ulcer Advisory Panel, 2009
- 7 133 Neill KM, Conforti C, Kedas A, Burris JF. Pressure sore response to a new hydrocolloid dressing.
 8 *Wounds: A Compendium of Clinical Research and Practice*. 1989; 1:173-185
- 9 134 NHS Business Services Authority. NHS electronic drug tariff. 2013. Available from:
 10 http://www.ppa.org.uk/ppa/edt_intro.htm [Last accessed: 16 July 2013]
- 11 135 Nisi G, Brandi C, Grimaldi L, Calabro M, D'Aniello C. Use of a protease-modulating matrix in the
 12 treatment of pressure sores. *Chirurgia Italiana*. 2005; 57(4):465-468
- 13 136 Nixon J, Cranny G, Iglesias C, Nelson EA, Hawkins K, Phillips A et al. Randomised, controlled trial
 14 of alternating pressure mattresses compared with alternating pressure overlays for the
 15 prevention of pressure ulcers: PRESSURE (pressure relieving support surfaces) trial. *BMJ*. 2006;
 16 332(7555):1413
- 17 137 Nixon J, McElvenny D, Mason S, Brown J, Bond S. A sequential randomised controlled trial
 18 comparing a dry visco-elastic polymer pad and standard operating table mattress in the
 19 prevention of post-operative pressure sores. *International Journal of Nursing Studies*. 1998;
 20 35(4):193-203
- 21 138 Nixon J, Nelson EA, Cranny G, Iglesias CP, Hawkins K, Cullum NA et al. Pressure relieving
 22 support surfaces: a randomised evaluation. *Health Technology Assessment*. 2006; 10(22):1-163
- 23 139 Nixon J, Thorpe H, Barrow H, Phillips A, Andrea NE, Mason SA et al. Reliability of pressure ulcer
 24 classification and diagnosis. *Journal of Advanced Nursing*. 2005; 50(6):613-623
- 25 140 Norris J, Reynolds R. The effect of oral zinc sulphate therapy on decubitus ulcers. *Journal of the*
 26 *American Geriatrics Society*. 1971; 19(9):793-797
- 27 141 O'Meara SM, Bland JM, Dumville JC, Cullum NA. A systematic review of the performance of
 28 instruments designed to measure the dimensions of pressure ulcers. *Wound Repair and*
 29 *Regeneration*. 2012; 20(3):263-276
- 30 142 Ohura T, Nakajo T, Okada S, Omura K, Adachi K. Evaluation of effects of nutrition intervention
 31 on healing of pressure ulcers and nutritional states (randomized controlled trial). *Wound*
 32 *Repair and Regeneration*. 2011; 19(3):330-336
- 33 143 Ohura T, Sanada H, Mino Y. Clinical activity-based cost effectiveness of traditional versus
 34 modern wound management in patients with pressure ulcers. *Wounds*. 2004; 16(5):157-163
- 35 144 Oleske DM, Smith XP, White P, Pottage J, Donovan MI. A randomized clinical trial of two
 36 dressing methods for the treatment of low-grade pressure ulcers. *Journal of Enterostomal*
 37 *Therapy*. 1986; 13(3):90-98
- 38 145 Osterbrink J, Mayer H, Schroder G. Clinical evaluation of the effectiveness of a multimodal
 39 static pressure relieving device. European Wound Management Association Conference.
 40 Stuttgart, Germany 2005; Thur14:00-15:30;V26-6:73

- 1 146 Parish LC, Collins E. Decubitus ulcers: a comparative study. *Cutis*. 1979; 23(1):106-110
- 2 147 Payne WG, Ochs DE, Meltzer DD, Hill DP, Mannari RJ, Robson LE et al. Long-term outcome
3 study of growth factor-treated pressure ulcers. *American Journal of Surgery*. 2001; 181(1):81-
4 86
- 5 148 Payne WG, Posnett J, Alvarez O, Brown-Etris M, Jameson G, Wolcott R et al. A prospective,
6 randomized clinical trial to assess the cost-effectiveness of a modern foam dressing versus a
7 traditional saline gauze dressing in the treatment of stage II pressure ulcers. *Ostomy/Wound
8 Management*. 2009; 55(2):50-55
- 9 149 Payne WG, Wright TE, Ochs D, Mannari RJ, Robson MC, Edington H et al. An exploratory study
10 of dermal replacement therapy in the treatment of stage III pressure ulcers. *Journal of Applied
11 Research*. 2004; 4(1):12-23
- 12 150 Pedley GE. Comparison of pressure ulcer grading scales: a study of clinical utility and inter-rater
13 reliability. *International Journal of Nursing Studies*. 2004; 41(2):129-140
- 14 151 Piatkowski A, Ulrich D, Seidel D, Abel M, Pallua N, Andriessen A. Randomised, controlled pilot
15 to compare collagen and foam in stagnating pressure ulcers. *Journal of Wound Care*. 2012;
16 21(10):505-511
- 17 152 Pullen R, Popp R, Volkens P, Fusgen I. Prospective randomized double-blind study of the
18 wound-debriding effects of collagenase and fibrinolysin/deoxyribonuclease in pressure ulcers.
19 *Age and Ageing*. 2002; 31(2):126-130
- 20 153 Rees RS, Robson MC, Smiell JM, Perry BH. Becaplermin gel in the treatment of pressure ulcers:
21 A phase II randomized, double-blind, placebo-controlled study. *Wound Repair and
22 Regeneration*. 1999; 7(3):141-147
- 23 154 Rhodes B, Daltrey D, Chattwood JG. The treatment of pressure sores in geriatric patients: a trial
24 of sterculia powder. *Nursing Times*. ENGLAND 1979; 75(9):365-368
- 25 155 Rhodes RS, Heyneman CA, Culbertson VL, Wilson SE, Phatak HM. Topical phenytoin treatment
26 of stage II decubitus ulcers in the elderly. *Annals of Pharmacotherapy*. 2001; 35(6):675-681
- 27 156 Robson MC, Abdullah A, Burns BF, Phillips LG, Garrison L, Cowan W et al. Safety and effect of
28 topical recombinant human interleukin-1 beta in the management of pressure sores. *Wound
29 Repair and Regeneration*. 1994; 2(3):177-181
- 30 157 Robson MC, Hill DP, Smith PD, Wang X, Meyer-Siegler K, Ko F et al. Sequential cytokine therapy
31 for pressure ulcers: clinical and mechanistic response. *Annals of Surgery*. 2000; 231(4):600-611
- 32 158 Robson MC, Phillips LG, Thomason A, Altrock BW, Pence PC, Heggors JP et al. Recombinant
33 human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers. *Annals
34 of Plastic Surgery*. 1992; 29(3):193-201
- 35 159 Robson MC, Phillips LG, Thomason A, Robson LE, Pierce GF. Platelet-derived growth factor BB
36 for the treatment of chronic pressure ulcers. *Lancet*. 1992; 339(8784):23-25
- 37 160 Russell JA, Lichtenstein SL. Randomized controlled trial to determine the safety and efficacy of
38 a multi-cell pulsating dynamic mattress system in the prevention of pressure ulcers in patients
39 undergoing cardiovascular surgery. *Ostomy/Wound Management*. 2000; 46(2):46-5

- 1 161 Russell L, Reynolds TM, Carr J, Evans A, Holmes M. Randomised controlled trial of two
2 pressure-relieving systems. *Journal of Wound Care*. 2000; 9(2):52-55
- 3 162 Russell L, Reynolds TM, Towns A, Worth W, Greenman A, Turner R. Randomized comparison
4 trial of the RIK and the Nimbus 3 mattresses. *British Journal of Nursing*. 2003; 12(4):254, 256-
5 254, 259
- 6 163 Russell LJ, Reynolds TM. How accurate are pressure ulcer grades? An image-based survey of
7 nurse performance. *Journal of Tissue Viability*. 2001; 11(2):67, 70-67, 75
- 8 164 Sarhan F, Weatherburn G, Graham A, Thiyagarajan C. Use of digital images in the assessment
9 and treatment of pressure ulcers in patients with spinal injuries in community settings. *Journal*
10 *of Telemedicine and Telecare*. 2010; 16(4):207-210
- 11 165 Sayag J, Meaume S, Bohbot S. Healing properties of calcium alginate dressings. *Journal of*
12 *Wound Care*. 1996; 5(8):357-362
- 13 166 Scevola S, Nicoletti G, Brenta F, Isernia P, Maestri M, Faga A. Allogenic platelet gel in the
14 treatment of pressure sores: A pilot study. *International Wound Journal*. 2010; 7(3):184-190
- 15 167 Schoonhoven L, Bousema MT, Buskens E. The prevalence and incidence of pressure ulcers in
16 hospitalised patients in the Netherlands: a prospective inception cohort study. *International*
17 *Journal of Nursing Studies*. 2007; 44(6):927-935
- 18 168 Schubert V. Measuring the area of chronic ulcers for consistent documentation in clinical
19 practice. *Wounds: A Compendium of Clinical Research and Practice*. 1997; 9(5):153-159
- 20 169 Schubert V, Zander M. Analysis of the measurement of four wound variables in elderly patients
21 with pressure ulcers. *Advances in Wound Care*. 1996; 9(4):29-36
- 22 170 Seaman S, Herbster S, Muglia J, Murray M, Rick C. Simplifying modern wound management for
23 nonprofessional caregivers. *Ostomy/Wound Management*. 2000; 46(8):18-27
- 24 171 Sebern MD. Pressure ulcer management in home health care: efficacy and cost-effectiveness of
25 moisture vapor permeable dressing. *Archives of Physical Medicine and Rehabilitation*. 1986;
26 67(10):726-729
- 27 172 Seeley J, Jensen JL, Hutcherson J. A randomized clinical study comparing a hydrocellular
28 dressing to a hydrocolloid dressing in the management of pressure ulcers. *Ostomy/Wound*
29 *Management*. 1999; 45(6):39-47
- 30 173 Shea JD. Pressure sores: classification and management. *Clinical Orthopaedics and Related*
31 *Research*. 1975;(112):89-100
- 32 174 Sherman RA. Maggot versus conservative debridement therapy for the treatment of pressure
33 ulcers. *Wound Repair and Regeneration*. 2002; 10(4):208-214
- 34 175 Sherman RA, Wyle F, Vulpe M. Maggot therapy for treating pressure ulcers in spinal cord injury
35 patients. *Journal of Spinal Cord Medicine*. 1995; 18(2):71-74
- 36 176 Sipponen A, Jokinen JJ, Sipponen P, Papp A, Sarna S, Lohi J. Beneficial effect of resin salve in
37 treatment of severe pressure ulcers: A prospective, randomized and controlled multicentre
38 trial. *British Journal of Dermatology*. 2008; 158(5):1055-1062

- 1 177 Small N, Mulder M, Mackenzie MJ, Nel M. A comparative analysis of pressure sore treatment
2 modalities in community settings. *Curationis*. 2002; 25(1):74-82
- 3 178 Soares MO, Dumville JC, Ashby RL, Iglesias CP, Bojke L, Adderley U et al. Methods to assess
4 cost-effectiveness and value of further research when data are sparse: negative-pressure
5 wound therapy for severe pressure ulcers. *Medical Decision Making*. 2013; 33(3):415-436
- 6 179 Sopata M, Luczak J, Ciupinska M. Effect of bacteriological status on pressure ulcer healing in
7 patients with advanced cancer. *Journal of Wound Care*. 2002; 11(3):107-110
- 8 180 Strauss MJ, Gong J, Gary BD, Kalsbeek WD, Spear S. The cost of home air-fluidized therapy for
9 pressure sores. A randomized controlled trial. *Journal of Family Practice*. 1991; 33(1):52-59
- 10 181 Subbanna PK, Margaret Shanti FX, George J, Tharion G, Neelakantan N, Durai S et al. Topical
11 phenytoin solution for treating pressure ulcers: a prospective, randomized, double-blind
12 clinical trial. *Spinal Cord*. 2007; 45(11):739-743
- 13 182 Sugama J, Matsui Y, Sanada H, Konya C, Okuwa M, Kitagawa A. A study of the efficiency and
14 convenience of an advanced portable Wound Measurement System (VISITRAK). *Journal of
15 Clinical Nursing*. 2007; 16(7):1265-1269
- 16 183 Taylor TV, Rimmer S, Day B, Butcher J, Dymock IW. Ascorbic acid supplementation in the
17 treatment of pressure-sores. *Lancet*. 1974; 2(7880):544-546
- 18 184 ter Riet G, Kessels AG, Knipschild PG. Randomized clinical trial of ascorbic acid in the treatment
19 of pressure ulcers. *Journal of Clinical Epidemiology*. 1995; 48(12):1453-1460
- 20 185 Terris DD, Woo C, Jarczok MN, Ho CH. Comparison of in-person and digital photograph
21 assessment of stage III and IV pressure ulcers among veterans with spinal cord injuries. *Journal
22 of Rehabilitation Research and Development*. 2011; 48(3):215-224
- 23 186 Theilla M, Schwartz B, Cohen J, Shapiro H, Anbar R, Singer P. Impact of a nutritional formula
24 enriched in fish oil and micronutrients on pressure ulcers in critical care patients. *American
25 Journal of Critical Care*. 2012; 21(4):e102-e109
- 26 187 Theilla M, Schwartz B, Zimra Y, Shapiro H, Anbar R, Rabizadeh E et al. Enteral n-3 fatty acids
27 and micronutrients enhance percentage of positive neutrophil and lymphocyte adhesion
28 molecules: a potential mediator of pressure ulcer healing in critically ill patients. *British Journal
29 of Nutrition*. 2012; 107(7):1056-1061
- 30 188 Thomas AC, Wysocki AB. The healing wound: a comparison of three clinically useful methods of
31 measurement. *Decubitus*. 1990; 3:18-25
- 32 189 Thomas DR, Diebold MR, Eggemeyer LM. A controlled, randomized, comparative study of a
33 radiant heat bandage on the healing of stage 3-4 pressure ulcers: A pilot study. *Journal of
34 American Medical Directors Association*. 2005; 6(1):46-49
- 35 190 Thomas DR, Goode PS, LaMaster K, Tennyson T. Acemannan hydrogel dressing versus saline
36 dressing for pressure ulcers. A randomized, controlled trial. *Advances in Wound Care*. 1998;
37 11(6):273-276
- 38 191 Thomas S. Cost of managing chronic wounds in the UK, with particular emphasis on maggot
39 debridement therapy. *Journal of Wound Care*. 2006; 15(10):465-469

- 1 192 Thomas S, Banks V, Bale S, Fear-Price M, Hagelstein S, Harding KG et al. Evaluation. A
2 comparison of two dressings in the management of chronic wounds. *Journal of Wound Care*.
3 1997; 6(8):383-386
- 4 193 Thomson JS, Brooks RG. The economics of preventing and treating pressure ulcers: a pilot
5 study. *Journal of Wound Care*. 1999; 8(6):312-316
- 6 194 Torrance C. *Pressure sores: aetiology, treatment and prevention*. London: Groom Helm; 1983
- 7 195 Trial C, Darbas H, Lavigne JP, Sotto A, Simoneau G, Tillet Y et al. Assessment of the
8 antimicrobial effectiveness of a new silver alginate wound dressing: a RCT. *Journal of Wound*
9 *Care*. 2010; 19(1):20-26
- 10 196 Trueman P, Whitehead SJ. The economics of pressure relieving surfaces: an illustrative case
11 study of the impact of high-specification surfaces on hospital finances. *International Wound*
12 *Journal*. 2010; 7(1):48-54
- 13 197 Ubbink DT, Westerbos SJ, Evans D, Land L, Vermeulen H. Topical negative pressure for treating
14 chronic wounds. *Cochrane Database of Systematic Reviews*. 2008; Issue 3:CD001898.
15 DOI:10.1002/14651858.CD001898.pub2
- 16 198 Van Anholt RD, Sobotka L, Meijer EP, Heyman H, Groen HW, Topinkov E et al. Specific
17 nutritional support accelerates pressure ulcer healing and reduces wound care intensity in non-
18 malnourished patients. *Nutrition*. 2010; 26(9):867-872
- 19 199 Van Anholt RD, Sobotka L, Meijer EP, Schols JM. An arginine- and micronutrient-enriched
20 nutritional supplement accelerates pressure ulcer healing and reduces wound care in non-
21 malnourished patients. *EWMA Journal*. 2010; 10(2):45, Abstract
- 22 200 Van Ort SR, Gerber RM. Topical application of insulin in the treatment of decubitus ulcers: a
23 pilot study. *Nursing Research*. 1976; 25(1):9-12
- 24 201 Vanderwee K, Clark M, Dealey C, Gunningberg L, Defloor T. Pressure ulcer prevalence in
25 Europe: a pilot study. *Journal of Evaluation in Clinical Practice*. 2007; 13(2):227-235
- 26 202 Vanderwee K, Grypdonck MH, De BD, Defloor T. The reliability of two observation methods of
27 nonblanchable erythema, Grade 1 pressure ulcer. *Applied Nursing Research*. 2006; 19(3):156-
28 162
- 29 203 Vanderwee K, Grypdonck MHF, De Bacquer D, Defloor T. Effectiveness of turning with unequal
30 time intervals on the incidence of pressure ulcer lesions. *Journal of Advanced Nursing*. 2007;
31 57(1):59-68
- 32 204 Wang SY, Wang JN, Lv DC, Diao YP, Zhang Z. Clinical research on the bio-debridement effect of
33 maggot therapy for treatment of chronically infected lesions. *Orthopaedic Surgery*. 2010;
34 2(3):201-206
- 35 205 Wanner MB, Schwarzl F, Strub B, Zaech GA, Pierer G. Vacuum-assisted wound closure for
36 cheaper and more comfortable healing of pressure sores: a prospective study. *Scandinavian*
37 *Journal of Plastic and Reconstructive Surgery and Hand Surgery*. 2003; 37(1):28-33
- 38 206 Waycaster C, Milne CT. Clinical and economic benefit of enzymatic debridement of pressure
39 ulcers compared to autolytic debridement with a hydrogel dressing. *Journal of Medical*
40 *Economics*. 2013; 16(7):976-986

- 1 207 Winter A, Hewitt H. Testing a hydrocolloid. *Nursing Times*. 1990; 86(50):59-62
- 2 208 Wood JM, Evans PE, Schallreuter KU, Jacobson WE, Sufit R, Newman J et al. A multicenter study
3 on the use of pulsed low-intensity direct current for healing chronic stage II and stage III
4 decubitus ulcers. *Archives of Dermatology*. 1993; 129(8):999-1009
- 5 209 Xakellis GC, Chrischilles EA. Hydrocolloid versus saline-gauze dressings in treating pressure
6 ulcers: a cost-effectiveness analysis. *Archives of Physical Medicine and Rehabilitation*. 1992;
7 73(5):463
- 8 210 Yarkony GM, Kirk PM, Carlson C, Roth EJ, Lovell L, Heinemann A et al. Classification of pressure
9 ulcers. *Archives of Dermatology*. 1990; 126(9):1218-1219
- 10 211 Yastrub DJ. Relationship between type of treatment and degree of wound healing among
11 institutionalized geriatric patients with stage II pressure ulcers. *Care Management Journals*.
12 2004; 5(4):213-218
- 13
- 14

14 Acronyms and abbreviations

ACA	Available case analysis
APAM	Alternative pressure air mattress
AUC	Area under the curve
CBA	Cost benefit analysis
CCA	Cost consequences analysis
CEA	Cost effectiveness analysis
CUA	Cost utility analysis
CI	Confidence interval
CLP	Continuous low pressure
CLP	Continuous low pressure
DMSO	Dimethyl sulfoxide
EPUAP	European pressure ulcer advisory panel
GDG	Guideline Development Group
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HBOT	Hyperbaric oxygen therapy
HR	Hazard ratio
ICER	Incremental cost effectiveness ratio
ICU	Intensive care unit
IDL	Indentation load deflection
INB	Incremental net benefit
IQR	Inter quartile range
ISO	Inflated static overlay
ITT	Intention to treat
LALDM	Low air loss dynamic mattress
MID	Minimal important difference
MSO	Microfluid static overlay
NBE	Non-blanchable erythema
NCGC	National Clinical Guideline Centre
NHS	National health service
NICE	National Institute for Health and Care Excellence
NNT	Number needed to treat
NPV	Negative predictive value
NPWT	Negative pressure wound therapy
OR	Odds ratio
PPV	Positive predictive value
PUM	Poly-urethane mattress
QALY	Quality adjusted life year
RCT	Randomised controlled trial
ROC	Receiver operator curve
RR	Relative risk
SD	Standard deviation
SFC	Standard foam cushion

SFM	Standard foam mattress
SHM	Standard hospital mattress

15 Glossary

Abstract	Summary of a study, which may be published alone or as an introduction to a full scientific paper.
Algorithm (in guidelines)	A flow chart of the clinical decision pathway described in the guideline, where decision points are represented with boxes, linked with arrows.
Allocation concealment	The process used to prevent advance knowledge of group assignment in an RCT. The allocation process should be impervious to any influence by the individual making the allocation, by being administered by someone who is not responsible for recruiting participants.
Applicability	How well the results of a study or NICE evidence review can answer a clinical question or be applied to the population being considered.
Arm (of a clinical study)	Subsection of individuals within a study who receive 1 particular intervention, for example placebo arm
Association	Statistical relationship between two or more events, characteristics or other variables. The relationship may or may not be causal.
Autolysis	Autolysis is the disintegration of devitalised cells or tissues by natural enzymes. During autolytic debridement, the process may be facilitated by the use of a dressing.
Baseline	The initial set of measurements at the beginning of a study (after run-in period where applicable), with which subsequent results are compared.
Bias	Influences on a study that can make the results look better or worse than they really are. (Bias can even make it look as if a treatment works when it does not.) Bias can occur by chance, deliberately or as a result of systematic errors in the design and execution of a study. It can also occur at different stages in the research process, for example, during the collection, analysis, interpretation, publication or review of research data. For examples see selection bias, performance bias, information bias, confounding factor, and publication bias.
Blanchable erythema	See erythema
Blinding	A way to prevent researchers, doctors and patients in a clinical trial from knowing which study group each patient is in so they cannot influence the results. The best way to do this is by sorting patients into study groups randomly. The purpose of 'blinding' or 'masking' is to protect against bias. A single-blinded study is 1 in which patients do not know which study group they are in (for example whether they are taking the experimental drug or a placebo). A double-blinded study is 1 in which neither patients nor the researchers/doctors know which study group the patients are in. A triple blind study is 1 in which neither the patients, clinicians or the people carrying out the statistical analysis know which treatment patients received.
Carer (caregiver)	Someone who looks after family, partners or friends in need of help because they are ill, frail or have a disability.
Categorisation	The process of determining the severity of the pressure ulcer in order to guide management.
Child	Person aged between 1 to 13 years
Clinical efficacy	The extent to which an intervention is active when studied under controlled research conditions.
Clinical effectiveness	How well a specific test or treatment works when used in the 'real world' (for example, when used by a doctor with a patient at home), rather than in a carefully controlled clinical trial. Trials that assess clinical effectiveness are sometimes called management trials. Clinical effectiveness is not the same as efficacy.

Clinician	A healthcare professional who provides patient care. For example, a doctor, nurse or physiotherapist.
Cochrane Review	The Cochrane Library consists of a regularly updated collection of evidence-based medicine databases including the Cochrane Database of Systematic Reviews (reviews of randomised trials prepared by the Cochrane Collaboration).
Cohort study	A study with two or more groups of people - cohorts - with similar characteristics. One group receives a treatment, is exposed to a risk factor or has a particular symptom and the other group does not. The study follows their progress over time and records what happens. See also observational study.
Comorbidity	A disease or condition that someone has in addition to the health problem being studied or treated.
Comparability	Similarity of the groups in characteristics likely to affect the study results (such as health status or age).
Confidence interval (CI)	<p>There is always some uncertainty in research. This is because a small group of patients is studied to predict the effects of a treatment on the wider population. The confidence interval is a way of expressing how certain we are about the findings from a study, using statistics. It gives a range of results that is likely to include the 'true' value for the population.</p> <p>The CI is usually stated as '95% CI', which means that the range of values has a 95 in a 100 chance of including the 'true' value. For example, a study may state that 'based on our sample findings, we are 95% certain that the 'true' population blood pressure is not higher than 150 and not lower than 110'. In such a case the 95% CI would be 110 to 150.</p> <p>A wide confidence interval indicates a lack of certainty about the true effect of the test or treatment - often because a small group of patients has been studied. A narrow confidence interval indicates a more precise estimate (for example, if a large number of patients have been studied).</p>
Confounding factor	<p>Something that influences a study and can result in misleading findings if it is not understood or appropriately dealt with.</p> <p>For example, a study of heart disease may look at a group of people that exercises regularly and a group that does not exercise. If the ages of the people in the two groups are different, then any difference in heart disease rates between the two groups could be because of age rather than exercise. Therefore age is a confounding factor.</p>
Consensus methods	Techniques used to reach agreement on a particular issue. Consensus methods may be used to develop NICE guidance if there is not enough good quality research evidence to give a clear answer to a question. Formal consensus methods include Delphi and nominal group techniques.
Control group	<p>A group of people in a study who do not receive the treatment or test being studied. Instead, they may receive the standard treatment (sometimes called 'usual care') or a dummy treatment (placebo). The results for the control group are compared with those for a group receiving the treatment being tested. The aim is to check for any differences.</p> <p>Ideally, the people in the control group should be as similar as possible to those in the treatment group, to make it as easy as possible to detect any effects due to the treatment.</p>
Cost–benefit analysis (CBA)	Cost-benefit analysis is 1 of the tools used to carry out an economic evaluation. The costs and benefits are measured using the same monetary units (for example, pounds sterling) to see whether the benefits exceed the costs.
Cost–consequences analysis	Cost-consequence analysis is 1 of the tools used to carry out an economic

(CCA)	evaluation. This compares the costs (such as treatment and hospital care) and the consequences (such as health outcomes) of a test or treatment with a suitable alternative. Unlike cost-benefit analysis or cost-effectiveness analysis, it does not attempt to summarise outcomes in a single measure (like the quality-adjusted life year) or in financial terms. Instead, outcomes are shown in their natural units (some of which may be monetary) and it is left to decision-makers to determine whether, overall, the treatment is worth carrying out.
Cost-effectiveness analysis (CEA)	Cost-effectiveness analysis is 1 of the tools used to carry out an economic evaluation. The benefits are expressed in non-monetary terms related to health, such as symptom-free days, heart attacks avoided, deaths avoided or life years gained (that is, the number of years by which life is extended as a result of the intervention).
Cost-effectiveness model	An explicit mathematical framework, which is used to represent clinical decision problems and incorporate evidence from a variety of sources in order to estimate the costs and health outcomes.
Cost-utility analysis (CUA)	Cost-utility analysis is 1 of the tools used to carry out an economic evaluation. The benefits are assessed in terms of both quality and duration of life, and expressed as quality-adjusted life years (QALYs). See also utility.
Debridement	The process of removal of devitalised (dead or dying) tissue from an ulcer. Types of debridement include: Autolytic: the removal of devitalised tissue by the body's own mechanisms Mechanical: the removal of devitalised tissue by physical forces such as with scissors or scalpels. Larval: the use of maggots to remove devitalised tissue
Decision analysis	An explicit quantitative approach to decision-making under uncertainty, based on evidence from research. This evidence is translated into probabilities, and then into diagrams or decision trees which direct the clinician through a succession of possible scenarios, actions and outcomes.
Diascopy	A test, used to identify non-blanchable erythema, by putting pressure on the surface of the skin and observing colour changes. Pressure may be placed on the skin using a transparent disk or a finger.
Discounting	Costs and perhaps benefits incurred today have a higher value than costs and benefits occurring in the future. Discounting health benefits reflects individual preference for benefits to be experienced in the present rather than the future. Discounting costs reflects individual preference for costs to be experienced in the future rather than the present.
Dominance	A health economics term. When comparing tests or treatments, an option that is both less effective and costs more is said to be 'dominated' by the alternative.
Dressings	Materials applied to a wound for a variety of reasons, including protection, absorption, and hydration.
Drop-out	A participant who withdraws from a trial before the end.
Economic evaluation	An economic evaluation is used to assess the cost effectiveness of healthcare interventions (that is, to compare the costs and benefits of a healthcare intervention to assess whether it is worth doing). The aim of an economic evaluation is to maximise the level of benefits - health effects - relative to the resources available. It should be used to inform and support the decision-making process; it is not supposed to replace the judgement of healthcare professionals. There are several types of economic evaluation: cost-benefit analysis, cost-consequence analysis, cost-effectiveness analysis, cost-minimisation analysis and cost-utility analysis. They use similar methods to define and evaluate costs, but differ in the way they estimate the benefits of a

	particular drug, programme or intervention.
Effect (as in effect measure, treatment effect, estimate of effect, effect size)	<p>A measure that shows the magnitude of the outcome in 1 group compared with that in a control group.</p> <p>For example, if the absolute risk reduction is shown to be 5% and it is the outcome of interest, the effect size is 5%.</p> <p>The effect size is usually tested, using statistics, to find out how likely it is that the effect is a result of the treatment and has not just happened by chance (that is, to see if it is statistically significant).</p>
Effectiveness	How beneficial a test or treatment is under usual or everyday conditions, compared with doing nothing or opting for another type of care.
Efficacy	How beneficial a test, treatment or public health intervention is under ideal conditions (for example, in a laboratory), compared with doing nothing or opting for another type of care.
Electrotherapy	The use of an electrical current, delivered in various ways, to stimulate wound healing.
Elevated risk	Neonates, infants, children and young people considered to be at elevated risk of developing a pressure ulcer will usually have more than 1 risk factor (for example, significantly limited mobility, risk of nutritional deficiency, inability to reposition themselves, a neurological condition, significant cognitive impairment) identified during risk assessment with or without a validated scale. Those with a history of pressure ulcers are also considered to be at elevated risk.
Epidemiological study	The study of a disease within a population, defining its incidence and prevalence and examining the roles of external influences (for example, infection, diet) and interventions.
Erythema	Redness of the skin due to dilation of superficial capillaries. Erythema is blanchable when the area turns white or pale temporarily with the application of pressure. Non-blanchable erythema retains redness on the application of pressure.
EQ-5D (EuroQol 5 dimensions)	A standardised instrument used to measure health-related quality of life. It provides a single index value for health status.
Evidence	Information on which a decision or guidance is based. Evidence is obtained from a range of sources including randomised trials, observational studies, expert opinion (of clinical professionals or patients).
Exclusion criteria (literature review)	Explicit standards used to decide which studies should be excluded from consideration as potential sources of evidence.
Exclusion criteria (clinical study)	Criteria that define who is not eligible to participate in a clinical study.
Extended dominance	If Option A is both more clinically effective than Option B and has a lower cost per unit of effect, when both are compared with a do-nothing alternative then Option A is said to have extended dominance over Option B. Option A is therefore more cost effective and should be preferred, other things remaining equal.
Extrapolation	An assumption that the results of studies of a specific population will also hold true for another population with similar characteristics.
Follow-up	Observation over a period of time of an individual, group or initially defined population whose appropriate characteristics have been assessed in order to observe changes in health status or health-related variables.
Generalisability	The extent to which the results of a study hold true for groups that did not participate in the research. See also external validity.
Gold standard	A method, procedure or measurement that is widely accepted as being the best available to test for or treat a disease.

GRADE, GRADE Profile	A system developed by the GRADE (Grading of Recommendations Assessment, Development and Evaluation) Working Group to address the shortcomings of present grading systems in healthcare. The GRADE system uses a common, sensible and transparent approach to grading the quality of evidence. The results of applying the GRADE system to clinical trial data are displayed in a table known as a GRADE profile.
Harms	Adverse effects of an intervention.
Health economics	Study or analysis of the cost of using and distributing healthcare resources.
Health-related quality of life (HRQoL)	A measure of the effects of an illness to see how it affects someone's day-to-day life.
Heel devices	Equipment or materials with known pressure redistributing/alleviating properties to minimise the effects of pressure on the heel.
Heterogeneity or Lack of homogeneity	The term is used in meta-analyses and systematic reviews to describe when the results of a test or treatment (or estimates of its effect) differ significantly in different studies. Such differences may occur as a result of differences in the populations studied, the outcome measures used or because of different definitions of the variables involved. It is the opposite of homogeneity.
High specification foam mattress	Mattresses made of high density foam or visco-elastic foam which conforms to the body contours resulting in superior pressure reduction to the standard hospital foam mattress.
Hydration	The provision of an adequate fluid intake to meet all bodily needs and replace any losses.
Hyperbaric oxygen therapy	The use of above atmospheric pressure to increase the oxygen supply to the wound bed and possibly promote wound healing.
Imprecision	Results are imprecise when studies include relatively few patients and few events and thus have wide confidence intervals around the estimate of effect.
Inclusion criteria (literature review)	Explicit criteria used to decide which studies should be considered as potential sources of evidence.
Infant	Person under 1 year of age
Incremental analysis	The analysis of additional costs and additional clinical outcomes with different interventions.
Incremental cost	The extra cost linked to using 1 test or treatment rather than another. Or the additional cost of doing a test or providing a treatment more frequently.
Incremental cost-effectiveness ratio (ICER)	The difference in the mean costs in the population of interest divided by the differences in the mean outcomes in the population of interest for 1 treatment compared with another.
Incremental net benefit (INB)	The value (usually in monetary terms) of an intervention net of its cost compared with a comparator intervention. The INB can be calculated for a given cost-effectiveness (willingness to pay) threshold. If the threshold is £20,000 per QALY gained then the INB is calculated as: (£20,000 x QALYs gained) – Incremental cost.
Indirectness	The available evidence is different to the review question being addressed, in terms of PICO (population, intervention, comparison and outcome).
Intention to treat analysis (ITT)	An assessment of the people taking part in a clinical trial, based on the group they were initially (and randomly) allocated to. This is regardless of whether or not they dropped out, fully complied with the treatment or switched to an alternative treatment. Intention-to-treat analyses are often used to assess clinical effectiveness because they mirror actual practice: that is, not everyone complies with treatment and the treatment people receive may be changed according to how they respond to it.

Intervention	In medical terms this could be a drug treatment, surgical procedure, diagnostic or psychological therapy. Examples of public health interventions could include action to help someone to be physically active or to eat a more healthy diet.
Intraoperative	The period of time during a surgical procedure.
Kappa statistic	A statistical measure of inter-rater agreement that takes into account the agreement occurring by chance.
Length of stay	The total number of days a participant stays in hospital.
Licence	See 'Product licence'.
Life years gained	Mean average years of life gained per person as a result of the intervention compared with an alternative intervention.
Likelihood ratio	The likelihood ratio combines information about the sensitivity and specificity. It tells you how much a positive or negative result changes the likelihood that a patient would have the disease. The likelihood ratio of a positive test result (LR+) is sensitivity divided by (1 minus specificity).
Long-term care	Residential care in a home that may include skilled nursing care and help with everyday activities. This includes nursing homes and residential homes.
Markov model	A method for estimating long-term costs and effects for recurrent or chronic conditions, based on health states and the probability of transition between them within a given time period (cycle).
Mattress overlay	An overlay which lies on top of the base mattress and may have pressure reducing, pressure redistributing or pressure relieving properties.
Meta-analysis	A method often used in systematic reviews. Results from several studies of the same test or treatment are combined to estimate the overall effect of the treatment.
Moisture lesion	A moisture lesion can be defined as localised injury to the skin initiated by the effects of moisture.
Multivariate model	A statistical model for analysis of the relationship between two or more predictor (independent) variables and the outcome (dependent) variable.
Negative predictive value (NPV)	In screening or diagnostic tests: A measure of the usefulness of a screening or diagnostic test. It is the proportion of those with a negative test result who do not have the disease, and can be interpreted as the probability that a negative test result is correct.
Negative pressure wound therapy (NPWT)	The use of negative pressure with the aim of promoting wound healing by enhancing nutrient and oxygen delivery, removal of wound exudate, promotion of granulation tissue, promotion of angiogenesis, and the removal of wound inhibitory factors.
Neonate	A baby under 4 weeks of age
Non-blanchable erythema	See erythema
Number needed to treat (NNT)	The average number of patients who need to be treated to get a positive outcome. For example, if the NNT is four, then 4 patients would have to be treated to ensure 1 of them gets better. The closer the NNT is to 1, the better the treatment. For example, if you give a stroke prevention drug to 20 people before 1 stroke is prevented, the number needed to treat is 20. See also number needed to harm, absolute risk reduction.
Nutrition	The provision of all essential food components (including macro and micro nutrients) to maintain current body function and growth whilst also meeting any additional needs associated with promoting pressure ulcer healing and other metabolic stresses.
Observational study	Individuals or groups are observed or certain factors are measured. No attempt is made to affect the outcome. For example, an observational study

	<p>of a disease or treatment would allow 'nature' or usual medical care to take its course. Changes or differences in 1 characteristic (for example, whether or not people received a specific treatment or intervention) are studied without intervening.</p> <p>There is a greater risk of selection bias than in experimental studies.</p>
Odds ratio	<p>Odds are a way to represent how likely it is that something will happen (the probability). An odds ratio compares the probability of something in 1 group with the probability of the same thing in another.</p> <p>An odds ratio of 1 between two groups would show that the probability of the event (for example a person developing a disease, or a treatment working) is the same for both. An odds ratio greater than 1 means the event is more likely in the first group. An odds ratio less than 1 means that the event is less likely in the first group.</p> <p>Sometimes probability can be compared across more than two groups - in this case, 1 of the groups is chosen as the 'reference category', and the odds ratio is calculated for each group compared with the reference category. For example, to compare the risk of dying from lung cancer for non-smokers, occasional smokers and regular smokers, non-smokers could be used as the reference category. Odds ratios would be worked out for occasional smokers compared with non-smokers and for regular smokers compared with non-smokers. See also confidence interval, relative risk, risk ratio.</p>
Opportunity cost	<p>The loss of other health care programmes displaced by investment in or introduction of another intervention. This may be best measured by the health benefits that could have been achieved had the money been spent on the next best alternative healthcare intervention.</p>
Outcome	<p>The impact that a test, treatment, policy, programme or other intervention has on a person, group or population. Outcomes from interventions to improve the public's health could include changes in knowledge and behaviour related to health, societal changes (for example, a reduction in crime rates) and a change in people's health and wellbeing or health status. In clinical terms, outcomes could include the number of patients who fully recover from an illness or the number of hospital admissions, and an improvement or deterioration in someone's health, functional ability, symptoms or situation. Researchers should decide what outcomes to measure before a study begins.</p>
P-value	<p>The p value is a statistical measure that indicates whether or not an effect is statistically significant.</p> <p>For example, if a study comparing two treatments found that 1 seems more effective than the other, the p value is the probability of obtaining these results by chance. By convention, if the p value is below 0.05 (that is, there is less than a 5% probability that the results occurred by chance) it is considered that there probably is a real difference between treatments. If the p value is 0.001 or less (less than a 1% probability that the results occurred by chance), the result is seen as highly significant.</p> <p>If the p value shows that there is likely to be a difference between treatments, the confidence interval describes how big the difference in effect might be.</p>
Perioperative	<p>The period from admission through surgery until discharge, encompassing the pre-operative and post-operative periods.</p>
Placebo	<p>A fake (or dummy) treatment given to participants in the control group of a clinical trial. It is indistinguishable from the actual treatment (which is given to participants in the experimental group). The aim is to determine what effect the experimental treatment has had - over and above any placebo effect caused because someone has received (or thinks they have received) care or attention.</p>

Polypharmacy	The use or prescription of multiple medications.
Positive predictive value (PPV)	In screening or diagnostic tests: A measure of the usefulness of a screening or diagnostic test. It is the proportion of those with a positive test result who have the disease, and can be interpreted as the probability that a positive test result is correct.
Postoperative	Pertaining to the period after patients leave the operating theatre, following surgery.
Power (statistical)	The ability to demonstrate an association when 1 exists. Power is related to sample size; the larger the sample size, the greater the power and the lower the risk that a possible association could be missed.
Preoperative	The period before surgery commences.
Pressure redistributing devices	The use of a support surface to distribute weight over the contact areas of the human body. This term replaces prior terminology of pressure reduction and pressure relief surfaces.
Pressure ulcer	A pressure ulcer is a localized injury to the skin and/or underlying tissue usually over a bony prominence, as a result of pressure, or pressure in combination with shear. A number of contributing or confounding factors are also associated with pressure ulcers; the significance of these factors is yet to be elucidated. This term replaces prior terminology pressure sore or bed sore.
Prevention	To keep something from happening. Interventions before the initial onset of a condition through the reduction of risk factors and the enhancement of protective factors in a targeted population
Primary care	Healthcare delivered outside hospitals. It includes a range of services provided by GPs, nurses, health visitors, midwives and other healthcare professionals and allied health professionals such as dentists, pharmacists and opticians.
Primary outcome	The outcome of greatest importance, usually the 1 in a study that the power calculation is based on.
Prognosis	A probable course or outcome of a disease. Prognostic factors are patient or disease characteristics that influence the course. Good prognosis is associated with low rate of undesirable outcomes; poor prognosis is associated with a high rate of undesirable outcomes.
Prospective study	A research study in which the health or other characteristic of participants is monitored (or 'followed up') for a period of time, with events recorded as they happen. This contrasts with retrospective studies.
Publication bias	Publication bias occurs when researchers publish the results of studies showing that a treatment works well and don't publish those showing it did not have any effect. If this happens, analysis of the published results will not give an accurate idea of how well the treatment works. This type of bias can be assessed by a funnel plot.
Quality of life	See 'Health-related quality of life'.
Quality-adjusted life year (QALY)	A measure of the state of health of a person or group in which the benefits, in terms of length of life, are adjusted to reflect the quality of life. One QALY is equal to 1 year of life in perfect health. QALYS are calculated by estimating the years of life remaining for a patient following a particular treatment or intervention and weighting each year with a quality of life score (on a zero to 1 scale). It is often measured in terms of the person's ability to perform the activities of daily life, freedom from pain and mental disturbance.
Randomisation	Assigning participants in a research study to different groups without taking any similarities or differences between them into account. For example, it could involve using a random numbers table or a computer-generated

	random sequence. It means that each individual (or each group in the case of cluster randomisation) has the same chance of receiving each intervention.
Randomised controlled trial (RCT)	A study in which a number of similar people are randomly assigned to two (or more) groups to test a specific drug or treatment. One group (the experimental group) receives the treatment being tested, the other (the comparison or control group) receives an alternative treatment, a dummy treatment (placebo) or no treatment at all. The groups are followed up to see how effective the experimental treatment was. Outcomes are measured at specific times and any difference in response between the groups is assessed statistically. This method is also used to reduce bias.
RCT	See 'Randomised controlled trial'.
Receiver operated characteristic (ROC) curve	A graphical method of assessing the accuracy of a diagnostic test. Sensitivity is plotted against 1 minus specificity. A perfect test will have a positive, vertical linear slope starting at the origin. A good test will be somewhere close to this ideal.
Reference standard	The test that is considered to be the best available method to establish the presence or absence of the outcome – this may not be the 1 that is routinely used in practice.
Relative risk (RR)	The ratio of the risk of disease or death among those exposed to certain conditions compared with the risk for those who are not exposed to the same conditions (for example, the risk of people who smoke getting lung cancer compared with the risk for people who do not smoke). If both groups face the same level of risk, the relative risk is 1. If the first group had a relative risk of 2, subjects in that group would be twice as likely to have the event happen. A relative risk of less than 1 means the outcome is less likely in the first group. Relative risk is sometimes referred to as risk ratio.
Reporting bias	See 'Publication bias'.
Resource implication	The likely impact in terms of finance, workforce or other NHS resources.
Retrospective study	A research study that focuses on the past and present. The study examines past exposure to suspected risk factors for the disease or condition. Unlike prospective studies, it does not cover events that occur after the study group is selected.
Review question	In guideline development, this term refers to the questions about treatment and care that are formulated to guide the development of evidence-based recommendations.
Risk assessment	A method of assessing the likelihood of developing pressure ulcers.
Risk assessment tools	Tools used to assess the likelihood of developing pressure ulcers, which can be used in combination with clinical judgement.
Secondary outcome	An outcome used to evaluate additional effects of the intervention deemed a priori as being less important than the primary outcomes.
Selection bias	Selection bias occurs if: a) The characteristics of the people selected for a study differ from the wider population from which they have been drawn, or b) There are differences between groups of participants in a study in terms of how likely they are to get better.
Sensitivity	How well a test detects the thing it is testing for. If a diagnostic test for a disease has high sensitivity, it is likely to pick up all cases of the disease in people who have it (that is, give a 'true positive' result). But if a test is too sensitive it will sometimes also give a positive result in people who don't have the disease (that is, give a 'false positive').

	<p>For example, if a test were developed to detect if a woman is 6 months pregnant, a very sensitive test would detect everyone who was 6 months pregnant, but would probably also include those who are 5 and 7 months pregnant.</p> <p>If the same test were more specific (sometimes referred to as having higher specificity), it would detect only those who are 6 months pregnant, and someone who was 5 months pregnant would get a negative result (a 'true negative'). But it would probably also miss some people who were 6 months pregnant (that is, give a 'false negative').</p> <p>Breast screening is a 'real-life' example. The number of women who are recalled for a second breast screening test is relatively high because the test is very sensitive. If it were made more specific, people who don't have the disease would be less likely to be called back for a second test but more women who have the disease would be missed.</p>
Sensitivity analysis	<p>A means of representing uncertainty in the results of economic evaluations. Uncertainty may arise from missing data, imprecise estimates or methodological controversy. Sensitivity analysis also allows for exploring the generalisability of results to other settings. The analysis is repeated using different assumptions to examine the effect on the results.</p> <p>One-way simple sensitivity analysis (univariate analysis): each parameter is varied individually in order to isolate the consequences of each parameter on the results of the study.</p> <p>Multi-way simple sensitivity analysis (scenario analysis): two or more parameters are varied at the same time and the overall effect on the results is evaluated.</p> <p>Threshold sensitivity analysis: the critical value of parameters above or below which the conclusions of the study will change are identified.</p> <p>Probabilistic sensitivity analysis: probability distributions are assigned to the uncertain parameters and are incorporated into evaluation models based on decision analytical techniques (for example, Monte Carlo simulation).</p>
Shear	<p>The pressure caused when layers of skin are caused to slide over 1 another. This can happen when a person slides down a bed or is pulled up in bed. Stress caused by shear can contribute to the development of a pressure ulcer.</p>
Significance (statistical)	<p>A result is deemed statistically significant if the probability of the result occurring by chance is less than 1 in 20 ($p < 0.05$).</p>
Skin assessment	<p>Methods used to assess skin status to identify potential risk of pressure ulcer development, or early signs of pressure damage. This may include the use of diascopy or the measurement of skin temperature.</p>
Skin massage	<p>Rubbing or kneading of parts of the skin, with the aim of reducing pressure ulceration.</p>
Specificity	<p>The proportion of true negatives that are correctly identified as such. For example in diagnostic testing the specificity is the proportion of non-cases correctly diagnosed as non-cases.</p> <p>See related term 'Sensitivity'.</p> <p>In terms of literature searching a highly specific search is generally narrow and aimed at picking up the key papers in a field and avoiding a wide range of papers.</p>
Stakeholder	<p>An organisation with an interest in a topic that NICE is developing a clinical guideline or piece of public health guidance on. Organisations that register as stakeholders can comment on the draft scope and the draft guidance. Stakeholders may be:</p> <ul style="list-style-type: none"> • manufacturers of drugs or equipment • national patient and carer organisations

	<ul style="list-style-type: none"> • NHS organisations • organisations representing healthcare professionals.
Systematic review	A review in which evidence from scientific studies has been identified, appraised and synthesised in a methodical way according to predetermined criteria. It may include a meta-analysis.
Systemic antimicrobials	An agent, that acts directly on a microorganism to destroy bacteria and prevent the development of new bacteria, viruses and fungi colonies, that is ingested by an individual as a means of treatment. These may include antiseptics, antiviral, antibiotic and antibacterial agents.
Time horizon	The time span over which costs and health outcomes are considered in a decision analysis or economic evaluation.
Topical antimicrobials	An agent, that acts directly on a microorganism to destroy the bacteria, viruses or fungi and prevent the development of new bacterial colonies, that is applied to the body's surface as a means of prevention/treatment of infection. These may include antiseptics, antibiotics and antibacterial agents.
Treatment allocation	Assigning a participant to a particular arm of a trial.
Ulcer assessment	Methods used to determine the area, depth and volume of a pressure ulcer.
Univariate	Analysis which separately explores each variable in a data set.
Utility	In health economics, a 'utility' is the measure of the preference or value that an individual or society places upon a particular health state. It is generally a number between zero (representing death) and 1 (perfect health). The most widely used measure of benefit in cost-utility analysis is the quality-adjusted life year, but other measures include disability-adjusted life years (DALYs) and healthy year equivalents (HYEs).
Young person	Person aged 13-18.

1

1 **Appendices**

2 **Appendices A-O can be found in separate documents.**